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Hypothyroidism is the most common thyroid disorder and it is significantly more 
frequent than presented - millions of people suffer from this disease without knowing 
it. People with this condition will have symptoms associated with slow metabolism. 
Estimates of subclinical hypothyroidism range between 3 to 8 %, increasing with 
age, whereas it more likely affects women than men. About 10% of women may 
have some degree of thyroid hormone deficiency. Hypothyroidism may affect lipid 
metabolism, neurological diseases or other clinical conditions. The book includes 
studies on advancements in diagnosis, regulation and replacement therapy, thyroid 
ultrasonography and radioiodine therapy for hypothyroidism. “Hypothyroidism 
- Influences and Treatments” contains many important specifications, results of 
scientific studies and innovations for endocrine practice.
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Preface 
This book provides both the most up-to-date information on the clinical aspect of
hypothyroidism. This second part offers elaborated view on the hypothyroidism in 
conjunction with other diseases, diagnose, regulation and therapy of hypothyroidism
and moreover conclusion from some weighty study.
Researchers and clinicians experts provide results of their long time experience and
results of their own scientific work. This information may be helpful for all of
physician not only endocrine specialization.
In this book are chapters summarizing the hypothyroidism in conjunction with lipid 
metabolism, thalassemia, neurological diseases or other clinical conditions; following 
chapters describe replacement therapy, thyroid ultrasonography and radioiodine 
therapy. 
This second part contains many important specifications, results of scientific study and
innovations for endocrine practice.
I would like to thank all of authors who had helped in the preparation of this book.
We hope it would be useful as a current resource for endocrine specialists.
Drahomira Springer 
Institute of Clinical Biochemistry and Laboratory Diagnostics, 
General University Hospital, Prague, 
Czech Republic
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Hypothyroidism on Lipid Metabolism 
J. Coria Mariela*, V. Carmona Yamila*, 
B. Oliveros Liliana** and S. Giménez Maria**  
Instituto Multidisciplinario de Investigaciones  
Biológicas-CONICET, San Luis. Universidad Nacional de San Luis. 
Argentina  
1. Introduction 
The thyroid gland is important in the human body because of its ability to produce the 
hormones triiodothyronine (T3) and tetraiodothyronine (T4), necessaries for appropriate 
energy levels and an active life. It has long been known that thyroid hormones are of vital 
importance in maintaining the initial level of phospholipids in cell membranes and fatty 
acids composition of the lipids (Prasad & Kumar, 2005). T3 plays a critical role in lipid 
metabolism by regulating genes involved in lipogenesis and lipolysis (Zhu & Chang, 2010). 
The underlying mechanisms, however, have only begun to be unraveled in recent years. 
Hypothyroidism, characterized by low serum thyroid hormone levels, is associated with 
reduced metabolism, reduced lipolysis, weight gain, reduced cholesterol clearance, and 
elevated serum cholesterol. It is known that thyroid hormone has genomic and nongenomic 
effects (Davis et al., 2008). Thyroid hormones exert their effects by stimulation of thyroid 
hormone receptors (TRs) that have different tissue distribution and metabolic targets. 
Thyroid hormone receptors possess two isoforms, TRα and TRβ (Nr1a1 and Nr1a2) encoded 
by the TRα (NR1A1) and TRβ (NR1A2) genes, and each isoform exists as two or three 
subtypes, respectively (α1, α 2, β1, β2, and β3). TRα plays a key role in postnatal 
development, adipose tissue and cardiac metabolism, whereas TRβ regulates multiple steps 
in hepatic metabolism as well as thyroid hormone levels (Oetting & Yen, 2007). Nuclear 
mechanisms of thyroid hormone action have been extensively described but an increasing 
number of nongenomic effects of the hormone at the cellular level have been recognized in 
the past 10 years (Cheng et al. 2010). Nongenomic actions of thyroid hormone are by 
definition independent on nuclear receptors for the hormone and have been described at the 
plasma membrane, various organelles, the cytoskeleton, and in cytoplasm. The actions 
include alterations in the transport of solutes like Ca++, Na+ and glucose, changes in 
activities of several kinases, including protein kinase C, cAMP-dependent protein kinase 
and mitogen-activated protein kinase. Iodothyronines also can regulate nongenomically 
through a protein kinase C activation of neutral lipids, phospholipids and 
phosphatidylinositol 4, 5-bisphosphate [PtdIns (4, 5) P2] (Axelband et al., 2011). 
                                                 
* Both authors contributed equally to this work 
** Corresponding Authors 
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The objective of this review is to provide a current overview of the impact of 
hypothyroidism on lipid content, distribution and metabolism in serum, erytrocytes and 
different tissues of human and experimental animals. The molecular mechanisms involved 
in lipids regulation, with emphasis on the effect of hypothyroidism on liver, which is a 
fundamental organ responsible for controlling cholesterol metabolism, and on adipose 
tissue, where the role of thyroid hormone in regulating adipogenesis and lipolysis is 
complex and controversial, are discused. Finally, an overview of hipothyroidism and its 
correlation with lipid homeostasis in the liver and mammary gland during pregnancy and 
lactation is also given.  
2. Hypothyroidism and circulating lipids 
Thyroid dysfunctions are frequent (Benseñor  et al., 2001). Abnormal serum thyrotropin 
(TSH) values and thyroid dysfunction are more prevalent in women than men and increase 
with age (Valeix et al., 2004). Hypothyroidism has been defined as those conditions which 
result from suboptimal circulating levels of thyroid hormones (Castieiras Lacambra et al., 
1998). It affects 0.5-2.4% of the general population (Sawin et al., 1985). The term myxedema 
was formerly used as a synonym for hypothyroidism. It is now well kown that 
hypothyroidism is a graded phenomenon, including presentations with clinical 
manifestations (overt hypothyroidism) to asymptomatic states known as subclinical 
hypothyroidism (Evered & Hall, 1972). Subclinical thyroid dysfunction may be defined as 
an elevated TSH concentration in an asymptomatic patient with a normal serum free 
thyroxine concentration (Woeber, 1997). It is a common condition affecting 6-17% of the 
general population (Helfand, 2004). Moreover, subclinical hypothyroidism may progress to 
overt hypothyroidism. The rate of progression is higher with the concomitant presence of 
thyroperoxidase antibodies or higher levels of TSH (Vanderpump et al., 1995). 
In 1952, Robertson & Kirkpatrick showed very high level of cholesterol in serum of patients 
with overt hypothyroidism which decreased after adequate hypothyroidism treatment. In 
1972, Nikkilä & Kekki observed a moderate increase of serum triglycerides in hypothyroid 
patients, associated with a decrease in efficiency of triglyceride removal from plasma, which 
was attributed to a low lipoprotein lipase (LPL) activity. Fowler, in 1973, mentioned that 
serum cholesterol and triglycerides were increased in patients with “preclinical” 
hypothyroidism, condition equivalent to the actual subclinical hypothyroidism. 
Furthermore the author also suggested that the abnormal lipid pattern is the first change to 
occur as hypothyroidism develops and the last to disappear after treatment. It is now widely 
recognized that hypothyroidism is one of the most common causes of secondary 
dyslipidemia. The most common abnormalities of lipoprotein metabolism associated with 
hypothyroidism are elevated levels of total cholesterol and low-density-lipoprotein 
cholesterol (LDL-C), which are attributable to the effect of thyroid hormone on lipoprotein 
lipase activity (Lithell et al., 1981) and the expression of the LDL- receptor (Staels et al., 
1990). These changes probably play an important role in atherogenesis.  
2.1 Lipid profile in overt hypothyroidism 
It is known that overt hypothyroidism is associated with increased fasting plasma 
cholesterol and triglyceride levels (Tulloch, 1974). Hypothyroid patients also usually have 
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increased lipoprotein a, Lp(a), levels (Tzotzas et al., 2000),  a low-density lipoprotein (LDL)-
like particle synthesized by the liver that has been reported to promote thrombosis, 
inflammation, and foam cell formation (Erqou et al., 2009). Trials evaluating the effects of 
overt hypothyroidism on LDL subfractions have shown conflicting results. A study in 
newly-diagnosed hypothyroid patients (n=60) showed that hypothyroidism was associated 
with higher prevalence of atherogenic small and dense LDL (sdLDL) (Abbas et al., 2008). By 
contrast, Roscini et al. (1999) found no significant differences between overt hypothyroid 
patients and healthy controls regarding sdLDL levels. In addition, Pearce et al. (2008) has 
evaluated the effects of short-term overt hypothyroidism on LDL subfractions. Patients 
exhibited an increase in LDL-C that was found to be primarily due to increases in the large 
LDL particles, while sdLDL did not significantly change (Pearce et al., 2008). A possible 
explanation for these dissimilar results could be the different methodology used for the 
measurement of LDL subparticles. Hypothyroid patients may also exhibit elevated levels of 
high-density lipoprotein cholesterol (HDL-C), mainly due to increased concentration of 
cholesterol- and phospholipid-enriched HDL-2 particles (Pearce et al., 2008). A decreased 
HDL2 catabolism and cholesteryl ester transfer protein activity has been observed. This 
decrease leads to a reduced transfer of cholesteryl esters from HDL to very-low-density 
lipoprotein (VLDL), thus increasing HDL-C levels (Dullaart et al., 1990). 
Hypothyroidism correction results in a decrease of serum total cholesterol, LDL-C, 
apolipoprotein (apo) A1, apo B and apo E. Hypothyroidism treatment may also decrease 
serum triglycerides (Stockigt, 2002). The apoB/apoA-1 ratio is highly valuable for detecting 
atherogenic risk (Millán et al., 2009). In addition, elevated levels of LDL-C have been 
consistently associated with an increased risk for development of cardiovascular disease 
(Pekkanen et al., 1990). Recently, non-HDL-C, a measure of total cholesterol minus HDL-C, 
has emerged as a predictor of cardiovascular disease. After levo-thyroxine replacement, a 
decrease in non-HDL-C has been observed in patients with overt hypothyroidism (Ito et al., 
2007). The altered serum concentrations of non-HDL-C in hypothyroidism may be related to 
the disturbed metabolism of LDL, remnant lipoprotein, and Apo B (Ito et al., 2007).  
2.2 Lipid profile in subclinical hypothyroidism 
Unlike the relationship established between overt hypothyroidism and lipid alterations, the 
relationship between subclinical hypothyroidism and dyslipidemia is still controversial. 
Despite the fact that the Colorado study of over 25.000 subjects (Caneris et al., 2000) showed 
a continuous graded increase in serum cholesterol over a range of serum TSH values from 
<0.3 to >60mU/l, there is no consensus whether mild thyroid failure has an adverse effect 
on plasma lipids, or whether its T4 treatment, sufficient to normalize TSH, has a beneficial 
effect (Stockigt, 2002).   
A recent study made in 1534 Chinese subjects shows that patients with subclinical 
hypothyroidism (TSH > 4,8mIU/L) have higher serum triglyceride levels and lower serum 
HDL-C levels than euthyroid subjects (Lai et al., 2011). Similar results were found by Iqbal 
et al. (2006), after performing a follow-up study in subclinical hypothyroidism male 
patients. Subclinical hypothyroidism was also associated to a high serum total cholesterol, 
LDL-C and apo B levels in the female patients, and to significantly lower apo A-1 levels 
when males and females were analysed together. After an appropriate treatment with 
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2007). The altered serum concentrations of non-HDL-C in hypothyroidism may be related to 
the disturbed metabolism of LDL, remnant lipoprotein, and Apo B (Ito et al., 2007).  
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a continuous graded increase in serum cholesterol over a range of serum TSH values from 
<0.3 to >60mU/l, there is no consensus whether mild thyroid failure has an adverse effect 
on plasma lipids, or whether its T4 treatment, sufficient to normalize TSH, has a beneficial 
effect (Stockigt, 2002).   
A recent study made in 1534 Chinese subjects shows that patients with subclinical 
hypothyroidism (TSH > 4,8mIU/L) have higher serum triglyceride levels and lower serum 
HDL-C levels than euthyroid subjects (Lai et al., 2011). Similar results were found by Iqbal 
et al. (2006), after performing a follow-up study in subclinical hypothyroidism male 
patients. Subclinical hypothyroidism was also associated to a high serum total cholesterol, 
LDL-C and apo B levels in the female patients, and to significantly lower apo A-1 levels 
when males and females were analysed together. After an appropriate treatment with 
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thyroxine, patients showed a significant reduction in the serum total cholesterol, LDL-C and 
apo B levels (Iqbal et al., 2006). 
On the other hand, from a study of patients with Hashimoto thyroiditis it has been shown 
that subjects with subclinical hypothyroidism have significantly higher LDL-C and LDL-C 
to HDL-C ratio compared with euthyroid subjects. After treatment with small doses of levo-
thyroxine there was a significant decrease of total cholesterol, non-HDL-C, LDL-C, and 
LDL-C to HDL-C values (Iqbal et al., 2006). Recent evidence also shows that T4 replacement 
therapy may improve lipid profile in the cases of subclinical hypothyroidism with 
Hashimoto thyroiditis. A marked total cholesterol reduction was inversely correlated with 
an increase in free T4 levels, but not correlated with changes in TSH levels (Tagami et al., 
2010). However, properly controlled prospective studies with a larger sample size are 
neccesary to demonstrate whether replacement therapy alters several cardiovascular 
markers in patients with subclinical hypothyroidism and Hashimoto thyroiditis. 
Ito et al. (2007) found that patients with subclinical hypothyroidism had serum 
concentrations of total cholesterol, non-HDL-C, remnant-like particle cholesterol, and apo 
B significantly decreased, without significant changes in the serum concentrations of  
LDL-C, HDL-C, triglycerides, apolipoprotein A-I, and Lp(a) after levo-thyroxine 
replacement. They also did not find changes in the serum levels of triglycerides, HDL-C, 
apo A-1, and Lp(a). On the other hand, in a randomized, double-blind, crossover study, it 
found that after levo-thyroxine therapy (100 µg/day), patients with subclinical 
hypothyroidism showed a decrease in total cholesterol, LDL-C, HDL-C, apo B, apo A-1, 
and apo B to apo A-1 ratio, but only total cholesterol and LDL-C decrease were 
significantly reduced (5,5% and 7,3% reduction  respectively). The total cholesterol 
reduction was inversely correlated with an increase in free T4 levels, but was not 
correlated with changes in TSH levels. This would indicate that a significant increase in 
free T4, although within the normal reference range, may be a better marker for risk 
factors for cardiovascular disease in monitoring response to treatment in subclinical 
hypothyroidism than TSH level alone (Razvi et al., 2007). This last result contradicts what 
was observed by Asvold et al. (2007), who found that there is a linear increase in total 
cholesterol, LDL-C and triglyceride, and a linear decrease in HDL-C levels with increasing 
TSH, but this correlation was obtained with TSH values within the normal range. In 
opposition, a population-based study of 1350 participants did not show changes in mean 
levels of total cholesterol, triglycerides and LDL-C in both female and male subjects with 
subclinical hypothyroidism and euthyroid. Women with subclinical hypothyroidism had 
significantly lower HDL-C than those who were euthyroid. The differences remained 
significant after adjustment for age, sex, and body mass index. The HDL-C was not 
different between patients with subclinical hypothyroidism and euthyroid men. However, 
in this study it was also observed that the mean TSH levels were higher in subjects with 
dyslipidemia, indicating a relationship between TSH-total cholesterol, and TSH-LDL-C 
levels mainly in overweight women (Lu et al., 2011).  
On the other hand, in a study conducted in patients with subclinical hypothyroidism, with 
normocholesterolemie and normotriglyceridemie, a decreased triglycerides and 
phospholipids transference to HDL, which was corrected with appropriate levo-thyroxine 
therapy, were observed. These results, evaluated using an artificial triglyceride-rich 
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emulsion labeled with radioactive triglycerides, also showed abnormalities in plasma lipid 
metabolism, even when these are not detected in routine laboratory tests, in patients with 
subclinical hypothyroidims (Sigal et al., 2011). Moreover, contradictory results may be due 
to patient diversity. Mild thyroid failure may be present in two types of patients: patients 
with untreated mild thyroid failure and patients with a history of overt hypothyroidism, 
whose T4 dose are not sufficient to normalize the serum TSH level. It has been observed that 
the change in serum total cholesterol concentration, after an appropriate T4 treatment, is 
much higher in the second group of patients (Danese et al., 2000). On the other hand, the 
TSH influence on lipids is different in the overweight and normal weight populations, as 
well as in men and women. The combination of serum TSH, sex, and body mass index has 
important effects on serum lipid parameters (Lu et al., 2011). 
Hormone thyroid influences on atherogenic serum lipoproteins are attractive metabolic 
actions that could hypothetically be exploited to treat obesity (Danese et al., 2000) and 
dyslipidemia (Aronne & Thornton-Jones, 2007). However, using supraphysiological doses of 
the endogenous thyroid hormones, T4 and T3, for these purposes is predictably associated 
with risk of thyrotoxic adverse effects in other organ systems, particularly the heart (Morkin 
et al., 2004) and skeleton (Biondi & Cooper, 2008). A large number of hormone thyroid 
analogs have been synthesized and tested in experimental animal models for their lipid-
lowering activity (Johansson et al., 2005). In all case of thyromimetics therapy use, potential 
side-effects occur in a dose-dependent fashion; therefore dosing regimens in humans will 
need to be tightly controlled (Tancevski et al., 2009). Further prospective studies should be 
carried out to stablish that patients with subclinical hypothyroidism should receive levo-
thyroxine replacement. 
3. Hypothyroidism and erythrocytes  
There are many results indicating that thyroid hormones stimulate erythropoiesis, and also 
increase erythrocyte 2, 3-diphosphoglycerate concentrations, which serve to enhance the 
delivery of oxygen to tissues and affect steady-state levels of circulating erythropoietin, 
playing a major role in abrupt adjustments of erythropoietin production. Thus, 
hypothyroidism has been generally associated with anemia (Fein & Rivlin, 1975; Antonijević 
et al., 1999; Shevtsova et al., 1994). The anemia- hypothyroidism relation has even been 
observed in infants with congenital hypothyroidism, in who anemia has been found to be 
depended on the degree of neonatal hypothyroidism (Franzese et al., 1996). This anemia 
may be normocytic, hypochromic-microcytic, or macrocytic, although normocytic and 
macrocytic anaemia are the most frequent (Fein & Rivlin, 1975; Omar et al., 2010). 
Macrocytosis (found in up to 55% of patients) and normocytic anemia may result from the 
insufficiency of the thyroid hormones themselves without nutritive deficit (Antonijević et 
al., 1999).  
A case report of haemolytic anemia induced by hypothyroidism has been described in the 
literature (Nomura et al., 1991). An increased osmotic fragility is generally associated with 
haemolytic anemia (Schröter & Eber, 1989). In erythrocytes from streptozocin diabetic rats, 
an increase in red cell volume and osmotic fragility was accompanied by a defect in the 
ouabain-sensitive Na+ K+-ATPase (Kowluru et al., 1989). In hyperthyroidism it has been 
found that there are alterations in the number and the activity of Na+ K+-ATPase pump in 
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thyroxine, patients showed a significant reduction in the serum total cholesterol, LDL-C and 
apo B levels (Iqbal et al., 2006). 
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Hashimoto thyroiditis. A marked total cholesterol reduction was inversely correlated with 
an increase in free T4 levels, but not correlated with changes in TSH levels (Tagami et al., 
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neccesary to demonstrate whether replacement therapy alters several cardiovascular 
markers in patients with subclinical hypothyroidism and Hashimoto thyroiditis. 
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B significantly decreased, without significant changes in the serum concentrations of  
LDL-C, HDL-C, triglycerides, apolipoprotein A-I, and Lp(a) after levo-thyroxine 
replacement. They also did not find changes in the serum levels of triglycerides, HDL-C, 
apo A-1, and Lp(a). On the other hand, in a randomized, double-blind, crossover study, it 
found that after levo-thyroxine therapy (100 µg/day), patients with subclinical 
hypothyroidism showed a decrease in total cholesterol, LDL-C, HDL-C, apo B, apo A-1, 
and apo B to apo A-1 ratio, but only total cholesterol and LDL-C decrease were 
significantly reduced (5,5% and 7,3% reduction  respectively). The total cholesterol 
reduction was inversely correlated with an increase in free T4 levels, but was not 
correlated with changes in TSH levels. This would indicate that a significant increase in 
free T4, although within the normal reference range, may be a better marker for risk 
factors for cardiovascular disease in monitoring response to treatment in subclinical 
hypothyroidism than TSH level alone (Razvi et al., 2007). This last result contradicts what 
was observed by Asvold et al. (2007), who found that there is a linear increase in total 
cholesterol, LDL-C and triglyceride, and a linear decrease in HDL-C levels with increasing 
TSH, but this correlation was obtained with TSH values within the normal range. In 
opposition, a population-based study of 1350 participants did not show changes in mean 
levels of total cholesterol, triglycerides and LDL-C in both female and male subjects with 
subclinical hypothyroidism and euthyroid. Women with subclinical hypothyroidism had 
significantly lower HDL-C than those who were euthyroid. The differences remained 
significant after adjustment for age, sex, and body mass index. The HDL-C was not 
different between patients with subclinical hypothyroidism and euthyroid men. However, 
in this study it was also observed that the mean TSH levels were higher in subjects with 
dyslipidemia, indicating a relationship between TSH-total cholesterol, and TSH-LDL-C 
levels mainly in overweight women (Lu et al., 2011).  
On the other hand, in a study conducted in patients with subclinical hypothyroidism, with 
normocholesterolemie and normotriglyceridemie, a decreased triglycerides and 
phospholipids transference to HDL, which was corrected with appropriate levo-thyroxine 
therapy, were observed. These results, evaluated using an artificial triglyceride-rich 
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emulsion labeled with radioactive triglycerides, also showed abnormalities in plasma lipid 
metabolism, even when these are not detected in routine laboratory tests, in patients with 
subclinical hypothyroidims (Sigal et al., 2011). Moreover, contradictory results may be due 
to patient diversity. Mild thyroid failure may be present in two types of patients: patients 
with untreated mild thyroid failure and patients with a history of overt hypothyroidism, 
whose T4 dose are not sufficient to normalize the serum TSH level. It has been observed that 
the change in serum total cholesterol concentration, after an appropriate T4 treatment, is 
much higher in the second group of patients (Danese et al., 2000). On the other hand, the 
TSH influence on lipids is different in the overweight and normal weight populations, as 
well as in men and women. The combination of serum TSH, sex, and body mass index has 
important effects on serum lipid parameters (Lu et al., 2011). 
Hormone thyroid influences on atherogenic serum lipoproteins are attractive metabolic 
actions that could hypothetically be exploited to treat obesity (Danese et al., 2000) and 
dyslipidemia (Aronne & Thornton-Jones, 2007). However, using supraphysiological doses of 
the endogenous thyroid hormones, T4 and T3, for these purposes is predictably associated 
with risk of thyrotoxic adverse effects in other organ systems, particularly the heart (Morkin 
et al., 2004) and skeleton (Biondi & Cooper, 2008). A large number of hormone thyroid 
analogs have been synthesized and tested in experimental animal models for their lipid-
lowering activity (Johansson et al., 2005). In all case of thyromimetics therapy use, potential 
side-effects occur in a dose-dependent fashion; therefore dosing regimens in humans will 
need to be tightly controlled (Tancevski et al., 2009). Further prospective studies should be 
carried out to stablish that patients with subclinical hypothyroidism should receive levo-
thyroxine replacement. 
3. Hypothyroidism and erythrocytes  
There are many results indicating that thyroid hormones stimulate erythropoiesis, and also 
increase erythrocyte 2, 3-diphosphoglycerate concentrations, which serve to enhance the 
delivery of oxygen to tissues and affect steady-state levels of circulating erythropoietin, 
playing a major role in abrupt adjustments of erythropoietin production. Thus, 
hypothyroidism has been generally associated with anemia (Fein & Rivlin, 1975; Antonijević 
et al., 1999; Shevtsova et al., 1994). The anemia- hypothyroidism relation has even been 
observed in infants with congenital hypothyroidism, in who anemia has been found to be 
depended on the degree of neonatal hypothyroidism (Franzese et al., 1996). This anemia 
may be normocytic, hypochromic-microcytic, or macrocytic, although normocytic and 
macrocytic anaemia are the most frequent (Fein & Rivlin, 1975; Omar et al., 2010). 
Macrocytosis (found in up to 55% of patients) and normocytic anemia may result from the 
insufficiency of the thyroid hormones themselves without nutritive deficit (Antonijević et 
al., 1999).  
A case report of haemolytic anemia induced by hypothyroidism has been described in the 
literature (Nomura et al., 1991). An increased osmotic fragility is generally associated with 
haemolytic anemia (Schröter & Eber, 1989). In erythrocytes from streptozocin diabetic rats, 
an increase in red cell volume and osmotic fragility was accompanied by a defect in the 
ouabain-sensitive Na+ K+-ATPase (Kowluru et al., 1989). In hyperthyroidism it has been 
found that there are alterations in the number and the activity of Na+ K+-ATPase pump in 
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circulating erythrocytes (Gasawara & Ishikawa, 1993). Also, under this condition, an 
alteration in osmotic fragility has been observed (Asl et al., 2009). In erythrocytes of 
hypothyroid rats, it was observed that there is an increase in osmotic fragility, demonstrated 
by a right shift of hemolysis curve (Dariyerli et al., 2004). However, in hypothyroid subjects 
these alterations have not been found (Asl et al., 2009).  
On the other hand, hypothyroidism causes alterations in the lipid composition of red blood 
cells (Ishii & Nakao, 1968). In hypothyroid rats a 22% cholesterol and 30% phospholipid 
level reduction has been found, without change in fatty acid composition, in erythrocyte 
membranes. The simultaneous decrease in cholesterol and phospholipid levels did not alter 
the cholesterol/phospholipid molar ratio, thus avoiding the erythrocyte membrane 
abnormal function (Ruggiero et al., 1987). In a study realized in 38 patients with 
hypothyroidism, it was found that the level of arachidonate in erythrocyte membrane was 
significantly decreased both before the treatment and within the course of replacing 
hormonal therapy. The content of omega-3 fatty acids decreased in the course of 
conventional therapy (Serebriakova et al., 2008). Erythrocytes lipid changes are also found in 
patients with haemolytic anemia and hypothyroidism. In the red cell membrane, 
phosphatidylcholine and free cholesterol were increased, and the free cholesterol to 
phospholipid ratio was elevated. After levo-thyroxine therapy, the derangement of lipid 
levels was normalized with improvement of the hemolytic anemia (Nomura et al., 1991). In 
a hypothyroid patients group who were athyreotic as a consequence of ablation treatment 
for well-differentiated thyroid cancer, it was observed that the relative amounts of 18:2 
omega 6 rose and those of 20:3 omega 6 fell, while the levels of all monounsaturated fatty 
acids increased in erythrocytes. The nature of these alterations suggests a disturbance in the 
delta-6 desaturase activity. The cholesterol/phospholipids ratio, polyunsaturated fatty acids 
content, increased intracellular Ca++, protein phosphorylation, membrane protein cross-
linking and membrane lipid peroxidation, among other factors, may alter the red blood cell 
membrane deformability (Pescarmona et al., 1983). However, in an experimental model of 
hypothyroidism induced in rats by methimazole addition (75 mg/100 g) to the fodder, there 
was no change in the erythrocyte rigidity index between control and experimental groups 
(Toplan et al., 2005). 
Alteration in oxidative status has been observed in thyroid pathologies. Moderate 
hypothyroid state induced in female rabbits resulted in a significant decrease in the serum 
concentration of the lipid peroxidation end-product malondialdehyde. The erythrocytes of 
hypothyroid animals exhibited higher resistance to oxidative stress and lesser oxidative 
lipids damage characterized by measurement of compounds reacting with thiobarbituric 
acid (Brzezińska-Slebodzińska, 2003; Kowalczyk et al., 2001). Hypothyroidism induced by 
lithium-treatment, provoked a significant decrease in the glutathione content without 
change in superoxide dismutase activities, in red blood cells. This imbalance might render 
the erythrocytes vulnerability to oxidative stress and ultimately haemolysis (Engin et al., 
2005). Alterations in the activities of catalase and glucose-6-phosphate dehydrogenase 
activities have been found in erythrocytes of hypothyroid patients (Sal'nikova et al., 1983; 
Hübner et al., 1979).   
Acanthocytes are erythrocytes with several (usually 3 to 7) irregularly spaced blunted 
projections from the margin of the cells. These cells have increased cholesterol but normal 
content of phospholipids. Acanthocytes are the principal morphological abnormality in 
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abetalipoproteinemia and in the "spur cell anemia" associated with severe alcoholic liver 
disease (Horton et al., 1976; Lynch, 1990). Acanthocytosis findings in cytologic blood smear 
suggest hypothyroidism in about 90% of cases. Other diseases related to acanthocytes are 
very rare, hence hypothyroidism must be excluded in all cases where acanthocytes are 
observed on the blood film (Antonijević et al., 1999; Betticher & Pugin, 1991).  There appears 
to be no correlation between any of the clinical features of the hypothyroid state and the 
shape red cell change but patients lacking the misshapen red cells may have a less severe 
disturbance of serum lipids. The abnormal red cells slowly disappear by treating the 
hypothyroidism (Wardrop & Hutchison, 1970). 
4. Hypotyroidism and liver lipids 
4.1 Cholesterol 
Cholesterol is an essential constituent of most biological membranes and is also a precursor 
of bile acids, steroid hormones, and certain vitamins. Animals rely on two mechanisms to 
maintain a pool of cholesterol sufficient to meet these requirements; de novo cholesterol 
synthesis from acetyl coenzyme A and absorption of cholesterol from dietary sources 
(Angelin, 1995). The liver is central in cholesterol metabolism, balancing hepatic cholesterol 
synthesis and hepatic uptake of plasma lipoproteins from the circulation against the 
excretion of hepatic cholesterol and bile acids in the bile. Thyroid hormone is an important 
regulator of cholesterol metabolism. T3 can influence the metabolism of cholesterol at 
several critical steps in the liver: 1- the low-density lipoprotein  receptor (LDL-R), which 
mediates cholesterol uptake from the circulation, 2,3-hydroxy-3-methylglutaryl coenzyme A 
reductase, controlling cholesterol biosynthesis, and 3-cholesterol 7α-hydroxylase (CYP7A1), 
the rate-limiting enzyme in the synthesis of bile acids where cholesterol is used as substrate 
(Gullberg, 2002). To monitor the level of membrane sterols, cells employ two sterol-sensing 
domain (SSD)-containing proteins, sterol regulatory element-binding protein (SREBP), 
cleavage-activating protein (SCAP) and 2-3-hydroxy-3-methylglutaryl coenzyme A 
reductase that are localized within the endoplasmic reticulum. Under low sterol conditions, 
SCAP binds to SREBPs to escort them from the endoplasmic reticulum to the Golgi 
apparatus where they are processed into functional transcription factors that activate the 
expression of genes involved in the synthesis of cholesterol. When sterols accumulate, the 2-
3-hydroxy-3-methylglutaryl coenzyme A reductase is rapidly degraded, resulting in the 
termination of sterol synthesis (Eberlé, 2004; Dong & Tang, 2010). 
It is known that TRβ is a major mediator of T3 effects on serum cholesterol and that it is 
involved in the transcriptional regulation of the CYP7A1 gene. The dependence on TRβ for 
T3 regulation of serum cholesterol levels was supported by the fact that TRβ-selective 
agonist GC-1 was is as efficient as T3 in decreasing serum cholesterol in hypothyroid mice 
(Trost, 2000). The molecular mechanisms controlling CYP7A1 regulation by bile acids and 
cholesterol metabolites have been widely studied. Liver X receptor-β (LXRβ) and farnesoid 
X receptor are two ligand dependent transcription factors that are receptors for derivatives 
of cholesterol and bile acids in the control of CYP7A1 expression (Henkel, 2011). LXRβ, an 
oxysterol binding transcription factor, directly activates CYP7A1 transcription in response to 
challenge with dietary cholesterol to mice; thus LXRβ -/- mice fed cholesterol-rich diets fail 
to induce enzyme activity and therefore accumulate toxic levels of cholesterol in the liver 
(Alberti, 2001). In addition to T3, it has been recognized that growth hormone is required for 
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circulating erythrocytes (Gasawara & Ishikawa, 1993). Also, under this condition, an 
alteration in osmotic fragility has been observed (Asl et al., 2009). In erythrocytes of 
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these alterations have not been found (Asl et al., 2009).  
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cells (Ishii & Nakao, 1968). In hypothyroid rats a 22% cholesterol and 30% phospholipid 
level reduction has been found, without change in fatty acid composition, in erythrocyte 
membranes. The simultaneous decrease in cholesterol and phospholipid levels did not alter 
the cholesterol/phospholipid molar ratio, thus avoiding the erythrocyte membrane 
abnormal function (Ruggiero et al., 1987). In a study realized in 38 patients with 
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significantly decreased both before the treatment and within the course of replacing 
hormonal therapy. The content of omega-3 fatty acids decreased in the course of 
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phosphatidylcholine and free cholesterol were increased, and the free cholesterol to 
phospholipid ratio was elevated. After levo-thyroxine therapy, the derangement of lipid 
levels was normalized with improvement of the hemolytic anemia (Nomura et al., 1991). In 
a hypothyroid patients group who were athyreotic as a consequence of ablation treatment 
for well-differentiated thyroid cancer, it was observed that the relative amounts of 18:2 
omega 6 rose and those of 20:3 omega 6 fell, while the levels of all monounsaturated fatty 
acids increased in erythrocytes. The nature of these alterations suggests a disturbance in the 
delta-6 desaturase activity. The cholesterol/phospholipids ratio, polyunsaturated fatty acids 
content, increased intracellular Ca++, protein phosphorylation, membrane protein cross-
linking and membrane lipid peroxidation, among other factors, may alter the red blood cell 
membrane deformability (Pescarmona et al., 1983). However, in an experimental model of 
hypothyroidism induced in rats by methimazole addition (75 mg/100 g) to the fodder, there 
was no change in the erythrocyte rigidity index between control and experimental groups 
(Toplan et al., 2005). 
Alteration in oxidative status has been observed in thyroid pathologies. Moderate 
hypothyroid state induced in female rabbits resulted in a significant decrease in the serum 
concentration of the lipid peroxidation end-product malondialdehyde. The erythrocytes of 
hypothyroid animals exhibited higher resistance to oxidative stress and lesser oxidative 
lipids damage characterized by measurement of compounds reacting with thiobarbituric 
acid (Brzezińska-Slebodzińska, 2003; Kowalczyk et al., 2001). Hypothyroidism induced by 
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abetalipoproteinemia and in the "spur cell anemia" associated with severe alcoholic liver 
disease (Horton et al., 1976; Lynch, 1990). Acanthocytosis findings in cytologic blood smear 
suggest hypothyroidism in about 90% of cases. Other diseases related to acanthocytes are 
very rare, hence hypothyroidism must be excluded in all cases where acanthocytes are 
observed on the blood film (Antonijević et al., 1999; Betticher & Pugin, 1991).  There appears 
to be no correlation between any of the clinical features of the hypothyroid state and the 
shape red cell change but patients lacking the misshapen red cells may have a less severe 
disturbance of serum lipids. The abnormal red cells slowly disappear by treating the 
hypothyroidism (Wardrop & Hutchison, 1970). 
4. Hypotyroidism and liver lipids 
4.1 Cholesterol 
Cholesterol is an essential constituent of most biological membranes and is also a precursor 
of bile acids, steroid hormones, and certain vitamins. Animals rely on two mechanisms to 
maintain a pool of cholesterol sufficient to meet these requirements; de novo cholesterol 
synthesis from acetyl coenzyme A and absorption of cholesterol from dietary sources 
(Angelin, 1995). The liver is central in cholesterol metabolism, balancing hepatic cholesterol 
synthesis and hepatic uptake of plasma lipoproteins from the circulation against the 
excretion of hepatic cholesterol and bile acids in the bile. Thyroid hormone is an important 
regulator of cholesterol metabolism. T3 can influence the metabolism of cholesterol at 
several critical steps in the liver: 1- the low-density lipoprotein  receptor (LDL-R), which 
mediates cholesterol uptake from the circulation, 2,3-hydroxy-3-methylglutaryl coenzyme A 
reductase, controlling cholesterol biosynthesis, and 3-cholesterol 7α-hydroxylase (CYP7A1), 
the rate-limiting enzyme in the synthesis of bile acids where cholesterol is used as substrate 
(Gullberg, 2002). To monitor the level of membrane sterols, cells employ two sterol-sensing 
domain (SSD)-containing proteins, sterol regulatory element-binding protein (SREBP), 
cleavage-activating protein (SCAP) and 2-3-hydroxy-3-methylglutaryl coenzyme A 
reductase that are localized within the endoplasmic reticulum. Under low sterol conditions, 
SCAP binds to SREBPs to escort them from the endoplasmic reticulum to the Golgi 
apparatus where they are processed into functional transcription factors that activate the 
expression of genes involved in the synthesis of cholesterol. When sterols accumulate, the 2-
3-hydroxy-3-methylglutaryl coenzyme A reductase is rapidly degraded, resulting in the 
termination of sterol synthesis (Eberlé, 2004; Dong & Tang, 2010). 
It is known that TRβ is a major mediator of T3 effects on serum cholesterol and that it is 
involved in the transcriptional regulation of the CYP7A1 gene. The dependence on TRβ for 
T3 regulation of serum cholesterol levels was supported by the fact that TRβ-selective 
agonist GC-1 was is as efficient as T3 in decreasing serum cholesterol in hypothyroid mice 
(Trost, 2000). The molecular mechanisms controlling CYP7A1 regulation by bile acids and 
cholesterol metabolites have been widely studied. Liver X receptor-β (LXRβ) and farnesoid 
X receptor are two ligand dependent transcription factors that are receptors for derivatives 
of cholesterol and bile acids in the control of CYP7A1 expression (Henkel, 2011). LXRβ, an 
oxysterol binding transcription factor, directly activates CYP7A1 transcription in response to 
challenge with dietary cholesterol to mice; thus LXRβ -/- mice fed cholesterol-rich diets fail 
to induce enzyme activity and therefore accumulate toxic levels of cholesterol in the liver 
(Alberti, 2001). In addition to T3, it has been recognized that growth hormone is required for 
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normal CYP7A1 regulation in rats and mice. Experiments showed that in the absence of TRs 
(TRβ1-/- mice), neither cholesterol nor T3 stimulated CYP7A1 expression and activity. 
CYP7A1 mRNA expression and enzymatic activity remained on a high level in these mice 
regardless of the T3 status and irrespective of whether cholesterol was added to the diet or 
not. The blunted CYP7A1 stimulation in response to T3 confirms the importance of TRβ 
(Pramfalk et al., 2011). The absence of up-regulation in response to dietary cholesterol was at 
first unexpected, but is likely due to the critical dependence of normal CYP7A1 regulation 
on  growth hormone  and to the fact that TRβ1-/- mice have severely reduced growth 
hormone levels. TRβ also appears to be of major importance for the regulation of 2,3-
hydroxy-3-methylglutaryl coenzyme A reductase transcription by T3 (Gullberg, 2000). 
Reduced binding activity of hepatic LDL receptors is generally considered as a major 
mechanism of hyperlipidemia in hypothyroidism. There were clearly effects of T3 on LDL 
receptor mRNA, but they could not be distinctly ascribed to TRα1 or TRβ. Although T3 
rapidly regulates the transcription of the LDL receptor gene no specific TRE (thyroid 
response element) has so far been described in the LDL receptor gene promoter. The 
suppression of CYP7A activity would lead to down-regulation of LDL receptor mRNA, 
however, it cannot be concluded that T3 directly regulates the LDL receptor transcription 
(Lopez et al., 2007). 
4.2 LXR transcription factor  
The liver X receptors, LXRα (NR1H3) and LXRβ (NR1H2), are ligand-activated transcription 
factors that belong to the nuclear hormone receptor superfamily. LXRs play a critical role in 
cholesterol homeostasis, bile acid metabolism and carbohydrate metabolism. The oral 
administration of LXR agonists to mice results in elevated hepatic fatty acid synthesis and 
steatosis and increased secretion of triglyceride-rich very low density lipoprotein resulting 
in hypertriglyceridemia. This increased hepatic lipogenesis has been largely attributed to the 
LXR-dependent upregulation of sterol regulatory element-binding protein 1c (SREBP-1c) 
expression. However, it has been reported that treating Srebp-1c null mice with the synthetic 
LXR agonist T0901317 still results in enhanced expression of many lipogenic genes, 
suggesting additional mechanisms by which LXR can enhance hepatic lipogenesis (Cha & 
Repa, 2007; Talukdar & Hillgartner, 2006). 
LXR exists in two isoforms, LXRα and -β (also referred to as Nr1h3 and Nr1h2, respectively. 
LXRα is highly expressed in the liver, and expressed at lower levels in the adrenal glands, 
intestine, adipose tissue, macrophages, lung, and kidney, whereas LXRβ is ubiquitously 
expressed. The LXRs form heterodimers with the retinoid X receptor (RXR). The RXR/LXR 
heterodimers bind to LXR responsive elements (LXREs) consisting of direct repeats (DRs) of 
the core sequence AGGTCA separated by four nucleotides (DR-4). Although, the LXRs and 
TRs belong to two distinct receptor subgroups with respect to ligand-binding affinity, the 
two receptor systems show similarity with respect to molecular mechanisms, target genes, 
and physiological roles. Both TR and LXRs form heterodimers with RXR, and bind to DR-4 
with identical geometry and polarity. Recently it has been shown that TRβ and LXRα 
interact on the mouse CYP7A1 gene promoter, suggesting the possibility of cross talk 
between the two receptors at the transcription level in the liver. There are structural 
similarity between LXRs and TRs. The mouse LXRα mRNA expression is positively 
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regulated by TR at the transcriptional level, and a cross-talk pathway between LXRα and 
TRβ exists in the autoregulation of the LXRα gene.  The human LXRα mRNA expression 
and promoter activity are also positively regulated by thyroid hormone.A cross talk 
between TRβ and LXRα could be a therapeutic target against dyslipidemia and 
atherosclerosis (Hashimoto et al., 2007). LXRα plays a pivotal role in hepatic cholesterol 
metabolism, whereas LXRβ has not a comparable role. LXRα is inducible by thyroid 
hormone, whereas LXRβ is not. 
There are several possible models for explaining the molecular mechanism behind the 
dependence or independence on TRβ for T3 regulation of target genes. One possibility is 
that the promoter context determines the TR isoform that regulates expression of the target 
gene. This implies that TRα1 and TRβ bind certain T3 response elements with different 
affinities. TRα1 and TRβ, respectively, govern which TR regulates a target gene in a specific 
cell; this assumes that the spatial expression patterns are distinct for different TRs in the 
liver. This would be analogous to the metabolic zonation in the liver where different 
metabolic processes are spatially separated along the porto-central axis of the liver units .In 
fact, several of the aforementioned genes are known to be zonally expressed in the liver. The 
CYP7A gene is expressed in a narrow zone around the central vein. It has been reported that 
TRβ is expressed preferentially around the central vein in the rat (Zandieh-Doulabi et al., 
2004). This has supported the idea that hepatic target gene specificity by TRs may be 
preferentially governed by distinct zonal expression of TRs and their respective target 
genes, and less by promoter selection (Gullberg et al., 2000). 
4.3 Sterol regulatory element-binding proteins 
Sterol regulatory element-binding proteins (SREBPs) are transcription factors that belong to 
the basic helix-loop-helix leucine zipper family. The mammalian genome encodes three 
SREBP isoforms, designated SREBP-1a, SREBP-1c, and SREBP-2. SREBP-2 is encoded by a 
gene on human chromosome 22q13. Both SREBP-1a and -1c are derived from a single gene 
on human chromosome 17p11.2 through the use of alternative transcription starts sites that 
produce alternate forms of exon 1, designated 1a and 1c (Tarling et al., 2004). SREBP-1a is a 
potent activator of all SREBP-responsive genes, including those that mediate the synthesis of 
cholesterol, fatty acids, and triglycerides. High-level transcriptional activation is dependent 
on exon 1a, which encodes a longer acidic transactivation segment than does the first exon 
of SREBP-1c. SREBP-1c preferentially enhances the transcription of genes required for fatty 
acid synthesis but not cholesterol synthesis. LXRs bind to an LXR-binding site in the SREBP-
1c promoter and activate SREBP-1c transcription in the presence of LXR agonists such as 
oxysterol (Quack et al., 2002).  
There is evidence that T3 represses mouse SREBP-1c expression at the transcriptional level. 
The mouse SREBP-1c promoter is negatively regulated by thyroid hormone in the Hepa1–6 
cells. DNA binding of TR (RXR-TR heterodimer) is required for negative regulation of the 
mouse SREBP-1c gene promoter. In addition, SREBP-1c mRNA levels were increased in the 
hypothyroid status by about 1.5-fold compared with the control, and thyrotoxic treatment 
reduced the mRNA levels by about 50% compared with the control level. Thus mouse 
SREBP-1c gene expression in the liver is negatively regulated by thyroid hormone 
(Berkenstam et al., 2004). 
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4.4 Lipid β-oxidation in TRβPV/PV mice  
The PV mutation has been identified in a patient with resistance to thyroid hormone. PV 
exhibits potent dominant-negative activity. It is due to a C-insertion at codon 448 of the 
TRβ1 that leads to a mutant that has complete loss of T3 binding and transcription activity 
(Parrilla et al., 1991). To understand the role of TRs in lipid homeostasis in vivo, it has been 
adopted the loss-of-function approach by creating knock-in mutant mice with targeted 
mutation in the TRα gene (TRα1PV mouse) or TRβ gene (TRβPVmouse). 
The decreased β-oxidation could also contribute to lipid accumulation in the liver of wild-
type and TRβPV/PV mice. The β-oxidation activity in the primary hepatocytes of TRβPV/PV 
mice was found significantly lower (24-37%) than that of wild-type mice. Simultaneously 
it was observed that the expression of carnitine palmitoyl-transferase Iα (Cpt1a), a rate-
controlling enzyme regulating the import of fatty acids into mitochondria, was lower 
(37%) in the liver of TRβPV/PV mice than in wild-type mice and the expression of 
cytochrome P450 family 4 subfamily A polypeptide 10 (Cyp4a10) involved in microsomal 
ω-oxidation was significantly increased in TRβPV/PV mice, 40-fold higher than wild-type. 
These data suggest that the reduction of β-oxidation activity and the fatty liver phenotype 
is mainly mediated by the decreased expression of rate-determining step regulator, Cpt1a, 
in TRβPV/PV mice. Evidence indicates that the liver of the TRα1PV/+ mice, is smaller than 
the wild-type mice with paucity in hepatic fat accumulation. Further molecular analyses 
have indicated that the expression and activity of PPARγ are increased in the liver of 
TRβPV/PV mice, whereas the expression of PPAR is repressed in the liver of TRα1PV/+ mice 
(Araki et al., 2009). 
Differential regulation of lipogenic genes by apo-TRβ and apo-TRα1, in accord with the lipid 
phenotype, has also been observed in the liver of these two mutant mice.TRβ is known to be 
the major TR isoform in the liver, and many TR-mediated T3 effects are believed to act via 
TRβ in this target tissue. Therefore, it is reasonable to expect that the mutation of the TRβ 
isoform would lead to observable phenotypic abnormalities. However, it has been shown 
that mutation of TRα1, which is a less abundant TR isoform in the liver, led to the repression 
of PPARγ and manifestation of abnormality in lipid metabolism in TRα1PV/+ mice. The 
dominant-negative activity of TRβ is stronger in tissues where TRβ is the predominantly 
expressed isoform. Possibly, abnormal gene regulatory activity of the less abundantly 
expressed TRα1PV would be compensated by the predominantly expressed w-TRβ in the 
liver (Cheng, 2005). Thyroid hormone stimulates lipogenesis in the liver. Hepatic production 
of malonyl-CoA is the rate-limiting step in the synthesis of fatty acids and it is catalyzed by 
both acetyl-CoA carboxylase (ACC) 1 and 2. ACC1 is enriched in the liver and other 
lipogenic tissues and is regulated by TR, LXR and SREBP-1 at the transcriptional level 
through the ACC1 promoter II. SREBP-1 enhances ACC1 mRNA expression by forming a 
tetrameric complex with TR/RXR, which stabilizes SREBP-1 on its binding site. A PPARα 
agonist stimulates ACC1 gene expression by enhancing the expression of SREBP-1c 
processing enzymes, which increases nuclear SREBP-1c activity .LXR directly stimulates 
ACC1 gene expression (Grefhorst et al., 2005). In hypothyroidism all these processes are 
decreased. These findings indicate that apo-TRβ and apo-TRα1 have different effects on 
lipid metabolism and that both TR isoforms contribute to the pathogenesis of lipid 
metabolism changes in hypothyroidism.  
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4.5 Mitochondrial lipids 
The hepatic mitochondrial lipid composition is altered significantly in hypothyroid rats. The 
total cholesterol increases, the phospholipids decrease and the cholesterol/phospholipid 
molar ratio increases (around 40%). Among the phospholipids, cardiolipin shows the 
greatest alteration (30% decreases in the hypothyroid rats). The phosphatidylethanolamine/ 
phosphatidylcholine ratio also decreases. Alterations were also found in the pattern of fatty 
acids. These changes in lipid composition may be responsible, at least in part, for the 
depression of the phosphate carrier activity in the liver mitochondria from hypothyroid rats 
(Hoch et al., 1981). In addition, hypothyroidism and thyroxin substitution affect the n-3 fatty 
acid composition of rat liver mitochondria. The n-6 and n-3 polyunsaturated fatty acids are 
affected differently by the hypothyroid state. The levels of linoleic (18:2n-6), gamma-
linolenic (18:3n-6) and dihomo-gamma-linolenic acids (20:3n-6) have been found to be 
higher in hypothyroid rats than in controls, while the level of arachidonic acid (20:4n-6) was 
lower, which suggests an impairment of the elongase and desaturase activities. The n-3 
polyunsaturated fatty acids, eicosapentaenoic (20:5n-3) and docosapentaenoic (22:5n-3) 
acids, were higher in hypothyroid rats, whereas the linolenic acid (18:3n-3) content 
remained constant. The level of docosahexaenoic acid 22:6n-3 was dramatically decreased in 
hypothyroid rats, while the levels of C22 n-6 fatty acids were unchanged. The differences 
were probably due to the competition between n-3 and n-6 polyunsaturated fatty acids for 
desaturases, elongases and acyltransferases. When hypothyroid rats were treated with 
thyroxin, the changes induced by hypothyroidism in the proportions of n-6 fatty acids were 
rapidly reversed, while the changes in the n-3 fatty acids were only partially reversed. After 
21 days of thyroxin treatments, the 22:6n-3 content in liver mitochondria was only half as 
high in hypothyroid rats than in euthyroid rats. These results suggest that the conversion of 
18:2n-6 to 20:4n-6 is suppressed in the hypothyroid state which favors the transformation of 
18:3n-3 to 20:5n-3 (Raederstorff, 1991). The content of individual fatty acid component in 
mitochondria of livers from thyroidectomized and streptozotocin -induced diabetic rats has 
been measured to investigate how different hormones are interrelated to control the amount 
of a particular fatty acid in mitochondria. The results showed diabetes, in general, affected 
fatty acid contents more severely than hypothyroidism, regardless of the direction of the 
changes. Hypothyroidism and diabetes affected antagonistically the contents of C16 species 
and C18:1, which belong to a de novo synthesis (oleate series). However, the two 
pathological conditions affected synergistically those of higher unsaturated species, eg. 
C18:2, C20:3 and C20:4, which belong to a dietary-dependent synthesis (linoleate series). 
These findings strongly indicated that each desaturation site and elongation site is affected 
in a preferential order by either thyroid hormone or insulin, and that hypothyroidism and 
diabetes have their effects differently on the process of de novo synthesis and the pathways 
initiated from an essential fatty acid in mitochondria (Nishida et al., 1991). 
The phospholipid composition and the in vitro incorporation of radioactive cytidine 
diphosphate-choline into phosphatidylcholine were studied in mitochondria and 
microsomal fraction obtained from liver and brain of 20 day old hyperthyroid or 
hypothyroid rats. The chemical composition of the subcellular membranes isolated from 
brain differed markedly in both conditions. In hyperthyroidism the microsomal fraction was 
slightly affected while the mitochondria were also affected, but not as severely as in 
hypothyroidism, in which the microsomal fraction showed no alterations. The incorporation 
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of the radioactive precursor into brain mitochondria isolated from hyperthyroid rats was 
markedly decreased, while no changes were observed in microsomes. However, 
incorporation into brain microsomal fraction obtained from hypothyroid rats was increased, 
while no changes were observed in mitochondria. Similar results were obtained in the 
studies performed with liver subcellular membranes from hyperthyroid animals while no 
changes were found in those from hypothyroid rats. Thus, it seems possible that both 
experimental conditions affect in a different way the structure and function of brain 
mitochondria and microsomal fractions. These findings also give further support to authors’ 
hypothesis that mitochondria have a certain degree of autonomy for the synthesis of 
phosphatidylcholine (Faryna de Raveglia et al., 1982). 
5. Hypothyroidism and adipose tissue 
Recent evidence shows that during the adipogenesis of 3T3-L1 cells, TRα1 mRNA is 
constitutively expressed in preadipocytes. Its expression continues to increase during 
adipogenesis, concurrent with the appearance of lipid droplets. In contrast, very little, if any, 
TRβ1 mRNA is detectable in either preadipocytes or adipocytes. These findings suggest a 
critical role of TRα1 during adipogenesis of 3T3-L1 cells (Zhu et al., 2011). It is known that 
that thyroid hormone could also act via nongenomic action through a plasma membrane 
receptor. The plasma membrane receptor is located on integrin αvβ3 at the arginine-glycine-
aspartic acid (RGD) recognition site important to binding by the integrin of extracellular 
matrix proteins. Interestingly, snake venom-derived RGD-containing disintegrin was found 
to inhibit adipogenesis of primary cultured fibroblastic preadipocytes (Lin et al., 2005). 
These cell-based studies further expanded the complexity of understanding the regulation 
of adipogenesis by thyroid hormone.  
5.1 Peroxisome Proliferator-Activated Receptors (PPARs) 
Thyroid hormone receptors regulate adipogenesis via crosstalk signaling with PPARs. Both 
PPARs and TRs are ligand dependent transcription receptors of the subfamily 1 (NR1) in the 
nuclear receptor superfamily. The NR1 group also includes retinoic acid receptors (RARs), 
Rev-erb, RAR-related orphan receptors (RORs), LXRs, vitamin D3 receptors (VDRs), and the 
nuclear xenobiotic receptor (constitutive androstane receptor (CAR). PPARs and TRs share a 
conserved DNA-binding domain (DBD) and exert their activity partly by 
heterodimerization with a common partner, the RXR, to regulate the transcription of target 
genes (Liu & Brent, 2010; Hunter et al., 1996). 
TRs play important roles, as do PPARs, in lipid mobilization, lipid degradation, FA 
oxidation, and glucose metabolism. By direct or indirect effect, thyroid status influences the 
expression of a number of genes involved in lipid and glucose metabolism. For example, TR 
isoform-specific regulation of hepatic genes involved in lipogenesis and fatty acid-oxidation 
has been implicated by the cDNA array analysis of TRβ knockout mice treated with or 
without thyroid hormone (Flores-Morales et al., 2002). Among more than 200 hepatic genes 
responding to T3 treatment, ~60% of them are regulated by TRβ and the remaining 40% are 
regulated through TRα. PPARα is one of the T3-regulated genes (Flores-Morales et al., 2002). 
PPARs have been shown to affect the thyroid hormone functions in thermogenesis in vivo. 
Administration of the PPARγ agonist rosiglitazone to male rats shifts the energy usage to an 
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anabolic state and markedly reduces plasma thyroid hormones. Rosiglitazone also decreases 
mRNA levels of the TRα1and TRβ in brown adipose tissue, and the TRα1 and TRα2 in 
retroperitoneal white adipose tissue (WAT). These findings explain the functions of PPARγ 
in up-regulating thermogenesis-related genes in WAT and brown adipose tissue, while 
balancing the whole body thermogenesis by down-regulating the transcription activity of 
TRs in these processes (Festuccia et al., 2008). PPARδ exerts an inhibitory effect on T3-
induced transcription activation by TRβ on the TRE-CAT reporter gene even in the presence 
of overexpressed RXRα protein in cells. PPARδ could inhibit the transcriptional activity of 
TR action by competing for the heterodimerized partner RXR in the nucleus (Meier-Heusler 
et al., 1995). 
5.2 Leptin 
Leptin, a recently discovered protein produced in adipocytes, regulates body weight by 
suppressing food intake and/or increasing energy expenditure. Thyroid hormones, which 
increase the basal metabolic rate and thermogenesis, have been reported to be one of leptin's 
regulating factors because alternations in thyroid status might lead to compensatory 
changes in circulating leptin. Plasma leptin is significantly elevated in hypothyroid subjects, 
to levels similar to those seen in obese euthyroid subjects. Treatment of hypothyroidism 
results in a reduction in the raised plasma leptin levels. The data are consistent with the 
hypothesis that leptin and the pituitary-thyroid axis interact in the euthyroid state, and that 
hypothyroidism reversibly increases leptin concentrations. Thyroid status modifies leptin 
secretion independently of adiposity and noradrenaline. The data suggest leptin-thyroid 
interactions at hypothalamic and adipocyte level (Pinkney et al., 2000). 
Hypothyroidism is clearly related to body weight gain and greater adiposity, but the range 
of hormonal change in serum TSH concentration associated with weight gain remains a 
focus of debate.  It has been shown that in hypothyroidism: 1) glucose uptake in muscle and 
adipose tissue is resistant to insulin; 2) the suppression of lipolysis by insulin is not 
impaired; 3) plasma levels of triglycerides are elevated due to decreased clearance by the 
adipose tissue; 4) a major finding to explain most of the metabolic defects is the decrease in 
adipose tissue blood flow rates. These findings, taken together with published data on 
hyperthyroidism suggest that thyroid hormone excess and deprivation do not make a 
consistent story: in hypothyroidism the decrease of blood flow in adipose tissue and muscle 
may be considered as part of the pathogenetic mechanism of insulin resistance explaining 
most of the metabolic defects in these tissues; in contrast, in hyperthyroidism the increase of 
blood flow seems to correct the intrinsic metabolic defects in muscle and adipose tissue 
(Dimitriadis et al., 2006). Moreover, in hypothyroidism the targets of insulin action are not 
uniformly impaired: glucose uptake and proteolysis are resistant to insulin, but lipolysis is 
not; the latter may be necessary to relieve tissues from the burden of unsatured fatty acids 
surplus after meals. Low normal free T4 levels were significantly associated with increased 
insulin resistance. These findings are consistent with an increased cardiovascular risk in 
subjects with low normal thyroid function (Ross et al., 2007). In female patients with 
primary hypothyroidism, plasma levels of leptin were found to be increased (Hsieh et al., 
2002; Teixeira et al., 2009). Thyroid hormone plays a relevant role in regulating leptin 
metabolism independent of body mass index and body fat (Hsieh et al., 2002). These results 
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has been implicated by the cDNA array analysis of TRβ knockout mice treated with or 
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retroperitoneal white adipose tissue (WAT). These findings explain the functions of PPARγ 
in up-regulating thermogenesis-related genes in WAT and brown adipose tissue, while 
balancing the whole body thermogenesis by down-regulating the transcription activity of 
TRs in these processes (Festuccia et al., 2008). PPARδ exerts an inhibitory effect on T3-
induced transcription activation by TRβ on the TRE-CAT reporter gene even in the presence 
of overexpressed RXRα protein in cells. PPARδ could inhibit the transcriptional activity of 
TR action by competing for the heterodimerized partner RXR in the nucleus (Meier-Heusler 
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Leptin, a recently discovered protein produced in adipocytes, regulates body weight by 
suppressing food intake and/or increasing energy expenditure. Thyroid hormones, which 
increase the basal metabolic rate and thermogenesis, have been reported to be one of leptin's 
regulating factors because alternations in thyroid status might lead to compensatory 
changes in circulating leptin. Plasma leptin is significantly elevated in hypothyroid subjects, 
to levels similar to those seen in obese euthyroid subjects. Treatment of hypothyroidism 
results in a reduction in the raised plasma leptin levels. The data are consistent with the 
hypothesis that leptin and the pituitary-thyroid axis interact in the euthyroid state, and that 
hypothyroidism reversibly increases leptin concentrations. Thyroid status modifies leptin 
secretion independently of adiposity and noradrenaline. The data suggest leptin-thyroid 
interactions at hypothalamic and adipocyte level (Pinkney et al., 2000). 
Hypothyroidism is clearly related to body weight gain and greater adiposity, but the range 
of hormonal change in serum TSH concentration associated with weight gain remains a 
focus of debate.  It has been shown that in hypothyroidism: 1) glucose uptake in muscle and 
adipose tissue is resistant to insulin; 2) the suppression of lipolysis by insulin is not 
impaired; 3) plasma levels of triglycerides are elevated due to decreased clearance by the 
adipose tissue; 4) a major finding to explain most of the metabolic defects is the decrease in 
adipose tissue blood flow rates. These findings, taken together with published data on 
hyperthyroidism suggest that thyroid hormone excess and deprivation do not make a 
consistent story: in hypothyroidism the decrease of blood flow in adipose tissue and muscle 
may be considered as part of the pathogenetic mechanism of insulin resistance explaining 
most of the metabolic defects in these tissues; in contrast, in hyperthyroidism the increase of 
blood flow seems to correct the intrinsic metabolic defects in muscle and adipose tissue 
(Dimitriadis et al., 2006). Moreover, in hypothyroidism the targets of insulin action are not 
uniformly impaired: glucose uptake and proteolysis are resistant to insulin, but lipolysis is 
not; the latter may be necessary to relieve tissues from the burden of unsatured fatty acids 
surplus after meals. Low normal free T4 levels were significantly associated with increased 
insulin resistance. These findings are consistent with an increased cardiovascular risk in 
subjects with low normal thyroid function (Ross et al., 2007). In female patients with 
primary hypothyroidism, plasma levels of leptin were found to be increased (Hsieh et al., 
2002; Teixeira et al., 2009). Thyroid hormone plays a relevant role in regulating leptin 
metabolism independent of body mass index and body fat (Hsieh et al., 2002). These results 
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may explain, at least in part, low blood flow rates and insulin resistance in the forearm and 
adipose tissue in overt hipothyroidism. 
5.3 Lipoprotein lipase 
LPL is a central enzyme in lipid metabolism, and adipose LPL activity is increased in rats 
that are deficient in thyroid hormone. LPL is synthesized and secreted by adipocytes, and is 
important for the transfer of triacylglycerol fatty acids from the circulating blood into 
adipocytes. The cellular regulation of LPL is complex. Previous studies have described the 
effects of numerous hormones and physiologic conditions on the level of LPL catalytic 
activity, and more recent studies have identified a number of different mechanisms of LPL 
cellular regulation (Wang & Eckel, 2009). Among the hormonal regulators of LPL is thyroid 
hormone. Adipose tissue levels of LPL have consistently been increased in hypothyroid rats, 
although plasma triglycerides have been either decreased or unchanged during 
hypothyroidism. Triglyceride-derived fatty acid uptake was found to be increased in WAT 
in association with increased LPL activity but unaffected in oxidative tissues and decreased 
in liver (Klieverik et al., 2009).      
Studies by Saffari et al. (1992) have shown that WAT LPL is increased in hypothyroidism via 
a postranslational mechanism. This finding was amply confirmed by Klieverik et al. (2009) 
that in three WAT depots, fatty acid uptake from VLDL particles was increased in 
proportion to the LPL activity. The WAT fatty acid uptake in hypothyroidism is quite 
significant, amounting to approximately 3 nmol/mg tissue in 2 h, comparable to the 
combined (VLDL plus albumin) uptake by thyrotoxic muscle. The biological meaning of 
these observations is also intriguing. WAT only stores triglycerides so the fat is there to stay. 
Then, some questions have been raised ¿is the stimulation of lipoprotein lipase in WAT of 
hypothyroid animals a way to protect the liver from massive steatosis? Or do these depots 
contribute to the thermal insulation of these thermogenic deficient mice? After all, fat is an 
excellent thermal insulator. However, the hypothyroid rat does not obese, even after months 
of hypothyroidism. It is possible that as hypothyroidism extends, lipogenesis is 
progressively reduced and a new steady state with only moderate obesity is reached (Silva, 
2010). In adipose tissue, hypothyroidism results in a decreased responsiveness of lipolysis to 
catecholamines even though there is no change in beta adrenergic receptor levels. This 
impairment in lipolytic responsiveness is reflected in decreased cellular cAMP levels due to 
an increase in cAMP phosphodiesterase, which degrades cAMP. In addition, some studies 
have suggested some impairment in adenylate cyclase activity in hypothyroid adipose 
tissue. Thus, the decreased responsiveness of LPL to epinephrine in cells from hypothyroid 
rats is consistent with previous data on adipocyte lipolysis, and suggests that a second 
messenger common to both hormones, such as cAMP, is important for LPL translation 
(Carvalho et al., 1996; Germack et al., 2000). 
5.4 Adipose tissue of TR knockout mice  
Studies using TR subtype knockout mice have shown that TRα1 is essential for maintaining 
proper thermogenesis and that TRβ is important in regulating cholesterol metabolism. These 
findings suggest tissue-dependent T3-mediated TR isoform action in the maintenance of 
metabolic homeostasis. In hypothyroidism, however, TRs function as aporeceptors. Studies 
 
Hypothyroidism on Lipid Metabolism 
 
17 
of mice deficient in all TRs (TRα1−/− and TRβ−/− mice) have shown that they exhibit a milder 
overall phenotype than the debilitating symptoms of severe hypothyroidism, highlighting 
the important role of apo-TRs in the pathogenesis of hypothyroidism. Indeed, knock-in 
mutant mice harboring different mutations in the TRα gene exhibit abnormalities in lipid 
metabolism. The TRα1PV mouse that harbors a frameshift mutation in the C-terminal 16 
amino acids displays a lean phenotype, partly due to the reduction in white fat mass. The 
TRα1R384C knock-in mutant mouse also exhibits a lean phenotype with reduction in fat 
mass. The TRα1P398H knock-in mutant mouse, interestingly, has increased body fat 
accumulation and elevated serum levels of leptin, glucose, and insulin. These results 
indicate that apo-TRα1 severely perturbs lipid metabolism and energy balance but in a 
mutation-site-dependent manner (Liu et al., 2003). 
The creation of knock-in mutant mice with an identical mutation in the TRβ (TRβPV mouse) or 
TRα gene (TRα1PV mouse) at the same corresponding C terminus of receptors allowed to 
clarify whether apo-TRβ with the same mutation as the TRα1 mutant could lead to a similar or 
a distinct impairment in lipid metabolism. The TRβPV mouse faithfully reproduces human 
RTH with dysregulation of the pituitary-thyroid axis, whereas the TRα1PV mouse has normal 
thyroid-pituitary functions (Kaneshige et al., 2000). Although both the homozygous (TRβPV/PV) 
and heterozygous (TRβPV/+) mice are viable with no severe fertility defects, homozygous 
TRα1PV/PV mice die shortly after birth, and heterozygous TRα1PV/+ mice are dwarfs with 
reduced fertility (Kaneshige et al., 2001). Recently, it has been found that the reduction in the 
WAT contributes to the dwarfism of TRα1PV/+ mice and that apo-TRα1 (TRα1PV) acts to 
repress adipogenesis of WAT by inhibition of the expression and by repression of the 
transcriptional activity of PPARγ. It has been found that in contrast to TRα1PV/+ mice, no 
abnormality in the WAT of TRβPV mice was detected. The transcription activity of PPAR γ 
was repressed by TRα1PV. The dual repression effects of TRα1PV reduce the expression of 
several PPARγ downstream target genes involved in adipogenesis, resulting in reduced fat 
mass. In addition to these in vivo findings, it has been shown that the overexpression of 
TRα1PV blocked the T3-dependent adipogenesis of 3T3-L1 cells (Ying et al., 2007). 
Obesity and disorders of lipid metabolism are major health issues. The findings that the 
apo-TR isoforms act differentially in a target-tissue-dependent manner, could help direct the 
design and development of T3 analogs to treat these disorders. One could envision that if 
fatty liver were detected in patients with hypothyroidism, it would be more beneficial to 
treat them with a TRβ-specific analog such as GC-1 without a major undesirable effect in 
other organs such as the heart. As additional advances are made in better understanding the 
actions of TR isoforms in lipid metabolism, novel T3 analogs for improved treatment 
strategies would certainly be forthcoming. The finding that TRα1PV was more effective than 
TRβ1PV in blocking adipogenesis suggests that TRα1 could be considered as a potential 
therapeutic target for decreasing adipose tissue and reducing serum fatty acids. Moreover, 
3T3-L1 cells stably expressing TRα1PV or TRβ1PV could be used as model cell lines to 
further elucidate the role of T3 via TR in adipogenesis (Baxter & Webb, 2009).  
5.5 Fatty acid-beta oxidation 
The role of thyroid hormone in regulating lipolysis is also complex and controversial. It has 
been shown that in the fed state adipocytes from hypothyroid rats had markedly reduced 
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may explain, at least in part, low blood flow rates and insulin resistance in the forearm and 
adipose tissue in overt hipothyroidism. 
5.3 Lipoprotein lipase 
LPL is a central enzyme in lipid metabolism, and adipose LPL activity is increased in rats 
that are deficient in thyroid hormone. LPL is synthesized and secreted by adipocytes, and is 
important for the transfer of triacylglycerol fatty acids from the circulating blood into 
adipocytes. The cellular regulation of LPL is complex. Previous studies have described the 
effects of numerous hormones and physiologic conditions on the level of LPL catalytic 
activity, and more recent studies have identified a number of different mechanisms of LPL 
cellular regulation (Wang & Eckel, 2009). Among the hormonal regulators of LPL is thyroid 
hormone. Adipose tissue levels of LPL have consistently been increased in hypothyroid rats, 
although plasma triglycerides have been either decreased or unchanged during 
hypothyroidism. Triglyceride-derived fatty acid uptake was found to be increased in WAT 
in association with increased LPL activity but unaffected in oxidative tissues and decreased 
in liver (Klieverik et al., 2009).      
Studies by Saffari et al. (1992) have shown that WAT LPL is increased in hypothyroidism via 
a postranslational mechanism. This finding was amply confirmed by Klieverik et al. (2009) 
that in three WAT depots, fatty acid uptake from VLDL particles was increased in 
proportion to the LPL activity. The WAT fatty acid uptake in hypothyroidism is quite 
significant, amounting to approximately 3 nmol/mg tissue in 2 h, comparable to the 
combined (VLDL plus albumin) uptake by thyrotoxic muscle. The biological meaning of 
these observations is also intriguing. WAT only stores triglycerides so the fat is there to stay. 
Then, some questions have been raised ¿is the stimulation of lipoprotein lipase in WAT of 
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of mice deficient in all TRs (TRα1−/− and TRβ−/− mice) have shown that they exhibit a milder 
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mutant mice harboring different mutations in the TRα gene exhibit abnormalities in lipid 
metabolism. The TRα1PV mouse that harbors a frameshift mutation in the C-terminal 16 
amino acids displays a lean phenotype, partly due to the reduction in white fat mass. The 
TRα1R384C knock-in mutant mouse also exhibits a lean phenotype with reduction in fat 
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accumulation and elevated serum levels of leptin, glucose, and insulin. These results 
indicate that apo-TRα1 severely perturbs lipid metabolism and energy balance but in a 
mutation-site-dependent manner (Liu et al., 2003). 
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clarify whether apo-TRβ with the same mutation as the TRα1 mutant could lead to a similar or 
a distinct impairment in lipid metabolism. The TRβPV mouse faithfully reproduces human 
RTH with dysregulation of the pituitary-thyroid axis, whereas the TRα1PV mouse has normal 
thyroid-pituitary functions (Kaneshige et al., 2000). Although both the homozygous (TRβPV/PV) 
and heterozygous (TRβPV/+) mice are viable with no severe fertility defects, homozygous 
TRα1PV/PV mice die shortly after birth, and heterozygous TRα1PV/+ mice are dwarfs with 
reduced fertility (Kaneshige et al., 2001). Recently, it has been found that the reduction in the 
WAT contributes to the dwarfism of TRα1PV/+ mice and that apo-TRα1 (TRα1PV) acts to 
repress adipogenesis of WAT by inhibition of the expression and by repression of the 
transcriptional activity of PPARγ. It has been found that in contrast to TRα1PV/+ mice, no 
abnormality in the WAT of TRβPV mice was detected. The transcription activity of PPAR γ 
was repressed by TRα1PV. The dual repression effects of TRα1PV reduce the expression of 
several PPARγ downstream target genes involved in adipogenesis, resulting in reduced fat 
mass. In addition to these in vivo findings, it has been shown that the overexpression of 
TRα1PV blocked the T3-dependent adipogenesis of 3T3-L1 cells (Ying et al., 2007). 
Obesity and disorders of lipid metabolism are major health issues. The findings that the 
apo-TR isoforms act differentially in a target-tissue-dependent manner, could help direct the 
design and development of T3 analogs to treat these disorders. One could envision that if 
fatty liver were detected in patients with hypothyroidism, it would be more beneficial to 
treat them with a TRβ-specific analog such as GC-1 without a major undesirable effect in 
other organs such as the heart. As additional advances are made in better understanding the 
actions of TR isoforms in lipid metabolism, novel T3 analogs for improved treatment 
strategies would certainly be forthcoming. The finding that TRα1PV was more effective than 
TRβ1PV in blocking adipogenesis suggests that TRα1 could be considered as a potential 
therapeutic target for decreasing adipose tissue and reducing serum fatty acids. Moreover, 
3T3-L1 cells stably expressing TRα1PV or TRβ1PV could be used as model cell lines to 
further elucidate the role of T3 via TR in adipogenesis (Baxter & Webb, 2009).  
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The role of thyroid hormone in regulating lipolysis is also complex and controversial. It has 
been shown that in the fed state adipocytes from hypothyroid rats had markedly reduced 
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sensitivity to catecholamine-induced lipolysis, whereas there was no change in 
catecholamine-induced lipolysis in adipocytes from hyperthyroid rats (Ben Cheikh et al., 
1994). Thyroid hormones play a major role in regulating oxygen metabolism. Thyroid 
hormones increase both coupled and uncoupled respiration, and thyroid dysfunction 
impacts resting energy expenditure (REE). The underlying mechanisms are not clear, but 
uncoupling proteins (UCP) that produce heat instead of ATP may be involved. A positive 
correlation between thyroid hormones and UCP2 mRNA expression has been shown by 
Barbe et al. (2009). In addition, increased UCP2 mRNA expression has been demonstrated in 
fat biopsies from hyperthyroid patients (Hoffstedt et al., 2000). UCP2 levels in adipose tissue 
have been found to be significantly lower in patients in the hypothyroid state compared 
with the euthyroid state. The levels increased during treatment and became similar to those 
of healthy controls. The precise function of UCP2 in adipose tissue is not settled, but several 
theories exist. UCP2 may be involved in fatty acid metabolism, and UCP2 expression has 
been shown to be regulated by free fatty acids. UCP2 has also been suggested to be involved 
in the production of reactive oxygen species. Finally, UCP2 has been suggested to function 
as a genuine uncoupling protein, involved in lipid metabolism, since a positive association 
between basal free fatty acids and UCP2 expression has been demonstrated (Davis et al., 
2008). The gene expression of other mitochondrial proteins participating in lipid oxidation, 
namely ACC and carnitine palmitoiltransferase-1, has not shown any significant changes in 
patients before and after treatment nor in healthy controls (Gjedde et al., 2010). These 
findings support the notion of UCP2 as a specific target for T3- mediated gene regulation in 
human adipose tissue.  
6. Hypothyroidism and lipid during pregnancy and lactation 
Pregnancy is a state of significant dynamic changes in metabolism, with accumulation of 
lipids and nutrients during about the first half; whereas during late pregnancy and lactation, 
these accumulated reserves are used for fetal growth and subsequently for milk synthesis 
(Hapon et al., 2003). The regulation and coordination of lipid metabolism on pregnancy and 
lactation are very important because of the sudden and profound physiological changes 
occuring during these physiological states (Hapon et al., 2003, 2005). It is known that 
undiagnosed hypothyroidism during pregnancy will lead to irreparable central nervous 
system defects in the newborn because the development of the child in utero is critically 
affected by the mother’s thyroid status (Gartner, 2009). The prevalence of subclinical 
hypothyroidism in women of childbearing ages is 4-5% (Glinoer, 1997). Furthermore, at least 
in two population-based surveys carried out in areas with different iodine intake, suggest a 
2.5% overall prevalence of compensated or uncompensated hypothyroidism during 
pregnancy (Parrot et al., 1960), making it a significant risk for gestational outcome.  
6.1 Liver and mammary lipids in pregnancy 
During the last decade there has been an increasing appreciation for the incidence of thyroid 
dysfunction during pregnancy as well as the resultant adverse maternal and fetal effects 
(Okosieme & Lazarus, 2010; Lazarous, 2011). Pregnancy is accompanied by profound 
alterations in thyroidal economy, resulting from a complex combination of factors that are 
specific to the pregnant state: the rise in T4-binding globulin concentrations as a result 
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of estrogenic stimulation, the effects of chorionic gonadotropin on the maternal thyroid, 
alterations in the requirement for iodine, modifications in autoimmune regulation, and the 
role of the placenta in deiodination of iodothyronines (Glinoer, 1997, 2004). In rats, 
hypothyroidism has been associated with delayed paturition, subnormal number of fetuses, 
increased pup mortality, decreased pup growth, altered circulating hormones (Parrot et al., 
1960, Hapon et al., 2003) and also, altered functioning of the mammary gland during 
lactation (Hapon et al., 2003). A clinical state of hypothyroidism during late pregnancy may 
limit the capacity of the maternal organism to sustain itself and the fetus adequately and to 
prepare the mammary tissue for the subsequent lactation, thus compromising delivery and 
nutrition of the newborn (Hapon et al., 2003). A linear correlation between maternal and 
fetal plasma triglycerides has been described to have an important implication in newborn 
weight (Herrera, 2002). It contributes to provide circulating triglycerides in the form of 
lipoprotein to the mammary gland for milk lipid synthesis (Ramos & Herrera, 1996).  
Fatty acid synthesis is an important metabolic pathway that is controlled by nutrients and 
hormones. Thyroid hormones are involved in the regulation of hepatic lipogenesis by 
altering levels of fatty acid synthase and acetyl-CoA carboxylase mRNAs, and their 
activities (Radenne et al., 2008; Kim et al., 2005). It is known that pregnancy stimulates fatty 
acid synthase and glycerol-3-phosphate acyltransferase expressions in the rat liver, while a 
state of clinical hypothyroidism during pregnancy shows decreased hepatic triglyceride 
synthesis in terms of  14C[glucose]  incorporation and subsequently, decreases in 
triglycerides and enhanced cholesterol in the circulation (Bonet & Herrera, 1991; Lopez Luna 
& Morales, 1985). A decrease in the liver lipid synthesis has been also evidenced by the 
diminished incorporation of 3H[H2O] into triglycerides and by the expression and activity of 
fatty acid synthase and acetyl-CoA carboxylase in pregnant hypothyroid rats, which may be 
responsible for the decrease in circulating triglycerides (Hapon et al., 2005). Congenitally 
hypothyroid mice show alterations in apoB RNA editing that switch hepatic production 
from apoB-100 to apoB-48 isoform (Mukhopadhyay et al., 2003), and whose conformational 
competence directs the assembly of hepatic VLDL more effectively.  
The liver also plays a central role in the maintenance of whole body cholesterol homeostasis 
by integrating the regulation of a group of hepatic enzymes, receptors, and other proteins 
that are important for cholesterol, lipoprotein, and biliary metabolism (Smith et al., 1998). 
Changes in thyroid state indirectly modify the biosynthesis of cholesterol by 
its effects on metabolism and on the coefficient of intestinal absorption of cholesterol (Mathe 
& Chevallier, 1976). The mRNA levels of 3-hydroxy-3-methylglutaryl-coenzyme A 
reductase, which is the rate-limiting enzyme for de novo cholesterol biosynthesis, is 
increased in the liver during late gestation, but the change of 3-hydroxy-3-methylglutaryl-
coenzyme A reductase is not modified by hypothyroidism (Hapon et al., 2005). The mRNA 
levels of 7α-hydroxylase are not modified by pregnancy or by hypothyroidism. In addition, 
the LDL receptor mRNA, a factor involved in cholesterol uptake that is increased during 
late gestation, is decreased in the pregnant hypothyroid rats, contributing to the increased 
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sensitivity to catecholamine-induced lipolysis, whereas there was no change in 
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of estrogenic stimulation, the effects of chorionic gonadotropin on the maternal thyroid, 
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increased in the liver during late gestation, but the change of 3-hydroxy-3-methylglutaryl-
coenzyme A reductase is not modified by hypothyroidism (Hapon et al., 2005). The mRNA 
levels of 7α-hydroxylase are not modified by pregnancy or by hypothyroidism. In addition, 
the LDL receptor mRNA, a factor involved in cholesterol uptake that is increased during 
late gestation, is decreased in the pregnant hypothyroid rats, contributing to the increased 
circulating (LDL+VLDL)-C (Hapon et al., 2005). It is well known that hypothyroidism 
increases cholesterol through an enhancement of LDL. 
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acyl-CoA oxidase. Carnitine palmitoyltransferase 1α catalyzes the transport of long chain 
fatty acids from cytosol into mitochondria for β-oxidation and acyl-CoA oxidase catalyzes 
the first rate limiting reaction in peroxisome oxidation. Thyroid hormones modulate 
carnitine palmitoyltransferase 1α and acyl-CoA oxidase gene transcription (Liu & Brent, 
2010). It has been observed that hypothyroid rats on the 21th day of pregnancy decreased 
liver acyl-CoA oxidase mRNA levels but did not modify mitochondrial (carnitine 
palmitoyltransferase 1α) fatty acid β-oxidation. Because carnitine palmitoyltransferase 1 is 
regulated by the availability of malonyl-CoA, the diminished ACC activity may result in a 
decrease in malonyl CoA that may compensate for the effects of the hypothyroid state, 
resulting in no overall change in expression (Hapon et al., 2005). This is in accord with what 
is has was observed in vitro by Muller et al. (1981). 
Experimental evidence indicates that pregnancy does not alter mammary lipogenesis, but 
that PTU treatment has a negative effect in the pregnant mammary gland. Glycerol-3-
phosphate acyltransferase mRNA abundance, and that of LPL, is not modified by either 
gestation or PTU treatment (Hapon et al., 2005). Late pregnancy increases mammary acyl-
CoA oxidase mRNA levels, suggesting a stimulation of fatty acid oxidation, while 
hypothyroidism produces a diminution of acyl-CoA oxidase. In addition, it has been found 
in pregnant rats that hypothyroidism increases triglycerides and total lipid content and 
decreases phospholipids, without modifying cholesterol in mammary gland. These findings 
have been associated to a lower proportion of mammary lobuloalveolar epithelial tissue in 
the hypothyroid pregnant rats (Hapon et al., 2005). Those effects may be a consequence of 
the hypothyroid state per se and not direct consequences of the increase of circulating 
prolactin (Hapon et al., 2003), since in mammary tissue, the increased prolactin should have 
stimulated lipid synthesis. 
6.2 Lipids during lactation 
Lactation is characterized by low levels of plasma thyroid hormone, triglyceride and VLDL, 
and elevated levels of plasma cholesterol (Denis et al., 2003; Smith et al., 1998). Triglyceride-
rich particles are rapidly cleared from the circulation during the lactating phase, likely by 
conversion to IDL/LDL-size particles through the action of LPL in the mammary gland to 
supply lipids for milk production (Smith et al., 1998). Experiments in rats indicate that 
hypothyroidism in mothers produces a diminution in hepatic lipid synthesis due to a decrease 
in 3H[H2O]  incorporation to triglycerides, and a decrease of ACC expression and activity 
(Hapon et al., 2007). In addition, PTU-induced hypothyroid during lactation reduces 
mammary ACC activity (on days 15 and 20 of lactation) and ACC and LPL mRNA on day 20. 
It is well known that ACC and milk synthesis are induced during lactogenesis (Martyn & 
Falconer, 1983). These findings suggest less secretion of triglycerides-rich particles into 
circulation during mid to late lactation, compromising the fulfillment of lactational triglyceride 
requirements (Hapon et al., 2007). Also, a drastic diminution in milk quality has been found in 
PTU-induced hypothyroid during lactation. A decrease in triglycerides in mid and late 
lactation along with a decrease of milk lactose on mid lactation, may contribute significantly to 
the severe growth deficit previously observed in the litters born from hypothyroid mothers 
(Hapon et al., 2003).  Thyroid hormones also modulate the expression of various mammary 
proteins involved in cellular proliferation (de Launoit & Kiss, 1989; González-Sancho et al., 
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1999). Administration of a moderate oral dose of T3 to lactating rats and mice dams induces a 
higher growth rate in the pups; this positive effect seems to be mainly due to augmented 
secretion of milk that, in addition, contains an elevated proportion of triglycerides (Quevedo-
Corona et al., 2000; Capuco et al., 1999). The impaired growth of the litters of hypothyroid 
mothers can be largely attributed to the low milk quality along with the impaired milk 
ejection. In accordance with a reduced capacity to eject milk, the PTU-treated mothers show 
significantly lower circulating oxytocin concentrations after suckling compared with control 
mothers (Hapon et al., 2003). Because mammary gland physiology is similar across species, 
biological concepts developed for lactating rat model may be instructive for human lactation 
(Hapon et al., 2007).  It can be concluded that a state of clinical or subclinical hypothyroidism 
may well be aggravated by the pregnant state, and that the adequate function of the mammary 
glands may be compromised. In particular, the availability of triglycerides to the fetus and to 
the mammary gland that is preparing for lactation is affected (Hapon et al., 2003). This, along 
with the decrease in the proportion of epithelial mammary tissue and in lipid synthesis, at the 
time when the initiation of milk synthesis is about to proceed, may contribute to the future 
lactation deficit of hypothyroid mothers.  
7. Conclusion  
The experimental and epidemiological evidences presented in this review indicate that 
hypothyroidism severely disturbs the lipid homeostasis in liver and adipose tissue 
contributing to the alteration of circulating lipids. Lipid metabolism of liver and mammary 
gland are also markedly altered during pregnancy and lactation by hypothyroidism. 
Therefore monitoring thyroid status and adjusting the T4 dose during pregnancy is very 
important due to changes in T4 metabolism throughout pregnancy. Thus both maternal and 
neonatal alterations can easily be prevented. Further understanding of the molecular 
mechanisms behind the dependence or independence on thyroid receptors for T3 regulation 
of target genes involved in the lipid homeostasis will entail therapeutic potentials not only 
for the prevention and treatment of thyroid disorders but also for prevalent diseases in the 
world, such as obesity and cardiovascular disease. 
8. References 
Abbas, J.M.; Chakraborty, J.; Akanji, A.O. & Dói, S.A. (2008). Hypothyroidism results in 
small dense LDL independent of IRS traits and hypertriglyceridemia. Endocrine 
Journal, Vol.55, No.2, (May, 2008), pp. 381–389, ISSN: 0918-8959 
Angelin, B. (1995). Studies on the regulation of hepatic cholesterol metabolism in humans. 
The European Journal of Clinical Investigation, Vol .25, No.4, (April, 1995), pp. 215-224, 
ISSN: 0014-2972 
Antonijević, N.; Nesović, M.; Trbojević, B. & Milosević, R. (1999). Anemia in 
hypothyroidism. Medicinski Pregled, Vol.52, No.3-5, (March-May, 1999), pp. 136-140, 
ISSN: 0025-8105  
Alberti, S.;  Schuster, G.; Parini, P.; Feltkamp, D.; Diczfalusy, U.; Rudling, M.; Angelin, B.; 
Björkhem , I.; Pettersson, S. & Gustafsson, J.A. (2001). Hepatic cholesterol 
metabolism and resistance to dietary cholesterol in LXRbeta-deficient mice. The 
 
Hypothyroidism – Influences and Treatments 
 
20
acyl-CoA oxidase. Carnitine palmitoyltransferase 1α catalyzes the transport of long chain 
fatty acids from cytosol into mitochondria for β-oxidation and acyl-CoA oxidase catalyzes 
the first rate limiting reaction in peroxisome oxidation. Thyroid hormones modulate 
carnitine palmitoyltransferase 1α and acyl-CoA oxidase gene transcription (Liu & Brent, 
2010). It has been observed that hypothyroid rats on the 21th day of pregnancy decreased 
liver acyl-CoA oxidase mRNA levels but did not modify mitochondrial (carnitine 
palmitoyltransferase 1α) fatty acid β-oxidation. Because carnitine palmitoyltransferase 1 is 
regulated by the availability of malonyl-CoA, the diminished ACC activity may result in a 
decrease in malonyl CoA that may compensate for the effects of the hypothyroid state, 
resulting in no overall change in expression (Hapon et al., 2005). This is in accord with what 
is has was observed in vitro by Muller et al. (1981). 
Experimental evidence indicates that pregnancy does not alter mammary lipogenesis, but 
that PTU treatment has a negative effect in the pregnant mammary gland. Glycerol-3-
phosphate acyltransferase mRNA abundance, and that of LPL, is not modified by either 
gestation or PTU treatment (Hapon et al., 2005). Late pregnancy increases mammary acyl-
CoA oxidase mRNA levels, suggesting a stimulation of fatty acid oxidation, while 
hypothyroidism produces a diminution of acyl-CoA oxidase. In addition, it has been found 
in pregnant rats that hypothyroidism increases triglycerides and total lipid content and 
decreases phospholipids, without modifying cholesterol in mammary gland. These findings 
have been associated to a lower proportion of mammary lobuloalveolar epithelial tissue in 
the hypothyroid pregnant rats (Hapon et al., 2005). Those effects may be a consequence of 
the hypothyroid state per se and not direct consequences of the increase of circulating 
prolactin (Hapon et al., 2003), since in mammary tissue, the increased prolactin should have 
stimulated lipid synthesis. 
6.2 Lipids during lactation 
Lactation is characterized by low levels of plasma thyroid hormone, triglyceride and VLDL, 
and elevated levels of plasma cholesterol (Denis et al., 2003; Smith et al., 1998). Triglyceride-
rich particles are rapidly cleared from the circulation during the lactating phase, likely by 
conversion to IDL/LDL-size particles through the action of LPL in the mammary gland to 
supply lipids for milk production (Smith et al., 1998). Experiments in rats indicate that 
hypothyroidism in mothers produces a diminution in hepatic lipid synthesis due to a decrease 
in 3H[H2O]  incorporation to triglycerides, and a decrease of ACC expression and activity 
(Hapon et al., 2007). In addition, PTU-induced hypothyroid during lactation reduces 
mammary ACC activity (on days 15 and 20 of lactation) and ACC and LPL mRNA on day 20. 
It is well known that ACC and milk synthesis are induced during lactogenesis (Martyn & 
Falconer, 1983). These findings suggest less secretion of triglycerides-rich particles into 
circulation during mid to late lactation, compromising the fulfillment of lactational triglyceride 
requirements (Hapon et al., 2007). Also, a drastic diminution in milk quality has been found in 
PTU-induced hypothyroid during lactation. A decrease in triglycerides in mid and late 
lactation along with a decrease of milk lactose on mid lactation, may contribute significantly to 
the severe growth deficit previously observed in the litters born from hypothyroid mothers 
(Hapon et al., 2003).  Thyroid hormones also modulate the expression of various mammary 
proteins involved in cellular proliferation (de Launoit & Kiss, 1989; González-Sancho et al., 
 
Hypothyroidism on Lipid Metabolism 
 
21 
1999). Administration of a moderate oral dose of T3 to lactating rats and mice dams induces a 
higher growth rate in the pups; this positive effect seems to be mainly due to augmented 
secretion of milk that, in addition, contains an elevated proportion of triglycerides (Quevedo-
Corona et al., 2000; Capuco et al., 1999). The impaired growth of the litters of hypothyroid 
mothers can be largely attributed to the low milk quality along with the impaired milk 
ejection. In accordance with a reduced capacity to eject milk, the PTU-treated mothers show 
significantly lower circulating oxytocin concentrations after suckling compared with control 
mothers (Hapon et al., 2003). Because mammary gland physiology is similar across species, 
biological concepts developed for lactating rat model may be instructive for human lactation 
(Hapon et al., 2007).  It can be concluded that a state of clinical or subclinical hypothyroidism 
may well be aggravated by the pregnant state, and that the adequate function of the mammary 
glands may be compromised. In particular, the availability of triglycerides to the fetus and to 
the mammary gland that is preparing for lactation is affected (Hapon et al., 2003). This, along 
with the decrease in the proportion of epithelial mammary tissue and in lipid synthesis, at the 
time when the initiation of milk synthesis is about to proceed, may contribute to the future 
lactation deficit of hypothyroid mothers.  
7. Conclusion  
The experimental and epidemiological evidences presented in this review indicate that 
hypothyroidism severely disturbs the lipid homeostasis in liver and adipose tissue 
contributing to the alteration of circulating lipids. Lipid metabolism of liver and mammary 
gland are also markedly altered during pregnancy and lactation by hypothyroidism. 
Therefore monitoring thyroid status and adjusting the T4 dose during pregnancy is very 
important due to changes in T4 metabolism throughout pregnancy. Thus both maternal and 
neonatal alterations can easily be prevented. Further understanding of the molecular 
mechanisms behind the dependence or independence on thyroid receptors for T3 regulation 
of target genes involved in the lipid homeostasis will entail therapeutic potentials not only 
for the prevention and treatment of thyroid disorders but also for prevalent diseases in the 
world, such as obesity and cardiovascular disease. 
8. References 
Abbas, J.M.; Chakraborty, J.; Akanji, A.O. & Dói, S.A. (2008). Hypothyroidism results in 
small dense LDL independent of IRS traits and hypertriglyceridemia. Endocrine 
Journal, Vol.55, No.2, (May, 2008), pp. 381–389, ISSN: 0918-8959 
Angelin, B. (1995). Studies on the regulation of hepatic cholesterol metabolism in humans. 
The European Journal of Clinical Investigation, Vol .25, No.4, (April, 1995), pp. 215-224, 
ISSN: 0014-2972 
Antonijević, N.; Nesović, M.; Trbojević, B. & Milosević, R. (1999). Anemia in 
hypothyroidism. Medicinski Pregled, Vol.52, No.3-5, (March-May, 1999), pp. 136-140, 
ISSN: 0025-8105  
Alberti, S.;  Schuster, G.; Parini, P.; Feltkamp, D.; Diczfalusy, U.; Rudling, M.; Angelin, B.; 
Björkhem , I.; Pettersson, S. & Gustafsson, J.A. (2001). Hepatic cholesterol 
metabolism and resistance to dietary cholesterol in LXRbeta-deficient mice. The 
 
Hypothyroidism – Influences and Treatments 
 
22
Journal of Clinical Investigation, Vol.107, No.5, (March, 2001), pp. 565-573, ISSN: 
0021-9738 
Araki, O.; Ying, H.; Zhu, X.G.; Willingham, M.C. & Cheng ,S.Y. (2009). Distinct 
dysregulation of lipid metabolism by unliganded thyroid hormone receptor 
isoforms. Molecular Endocrinology, Vol.23, No.3, (March, 2009), pp. 308-315, ISSN: 
0888-8809  
Aronne, L.J. & Thornton-Jones, Z.D. (2007). New targets for obesity pharmacotherapy. 
Clinical Pharmacology Therapy, Vol.81, No.5, (May, 2007), pp. 748-752, ISSN: 0009-
9236 
Asl, S.Z.; Brojeni, N.K.; Ghasemi, A.; Faraji, F.; Hedayati, M. & Azizi, F. (2009). Alterations in 
osmotic fragility of the red blood cells in hypo- and hyperthyroid patients. Journal 
Endocrinology Investigation, Vol.32, No.1, (January, 2009), pp. 28-32, ISSN: 0391-4097 
Asvold, B.; Vatten, L.J.; Nilsen, T.I. & Bjoro, T. (2007). The association between TSH within 
the reference range and serum lipid concentrations in a population-based study. 
The HUNT Study. The European Journal of Endocrinology, Vol.156, No.2, (February, 
2007), pp. 181-186, ISSN: 0804-4643 
Axelband, F.; Dias, J.; Ferrão, F.M. & Einicker-Lamas, M. (2011). Nongenomic signaling 
pathways triggered by thyroid hormones and their metabolite 3-iodothyronamine 
on the cardiovascular system. Journal of  Cellular Physiology, Vol. 226, No.1, 
(January, 2011), pp. 21-28, ISSN: 0021-9541 
Barbe, P.; Larrouy D.; Boulanger, C.; Chevillotte, E.; Viguerie, N.; Thalamas, C.; Trastoy, 
M.O.; Roques, M.; Vidal, H. & Lnagin, D. (2001). Triiodothyronine- mediated up-
regulation of UCP2 and UCP3 mRNA expression in human skeletal muscle without 
coordinated induction of mitochondrial respiratory chain genes. FASEB Journal, 
Vol.15, No.1, (January 2001), pp. 13-15, ISSN: 0892-6638 
Baxter, J.D. & Webb, P. (2009). Thyroid hormone mimetics: potential applications in 
atherosclerosis, obesity and type 2 diabetes. Nature Reviews Drug Discovy, Vol.8, 
No.4, (April, 2009), pp. 308-320, ISSN: 1474-1776 
Ben Cheikh, R.; Chomard, P.; Dumas, P. & Autissier, N. (1994). Influence of prolonged 
fasting on thyroid hormone modulation of lipolysis in isolated epididymal 
adipocytes of Wistar rats. European Journal Endocrinoly, Vol.131, No.5, (Nov, 1994), 
pp. 516-521, ISSN: 0804-4643 
Benseñor, I.M.; Goulart, A.C.; Lotufo, P.A.; Menezes, P.R. & Scazufca, M. (2011). Prevalence 
of thyroid disorders among older people: results from the São Paulo Ageing & 
Health Study. Cad Saude Publica, Vol.27, No.1, (January, 2011), pp. 155-161, ISSN: 
0102-311X 
Berkenstam, A.; Farnegardh, M. & Gustafsson, J.A. (2004). Convergence of lipid homeostasis 
through liver X and thyroid hormone receptors. Mechanism Aging Development, 
Vol.125, No.10-11, (October-November, 2004), pp. 707-717, ISSN: 0047-6374 
Betticher, D.C. & Pugin, P. (1991). Hypothyroidism and acanthocytes: diagnostic 
significance of blood smear. Schweiz Medical Wochenschr, Vol.121, No.31-32, 
(August, 1991), pp. 1127-1132, ISSN:  0036-7672 
Biondi, B. & Cooper, D.S. (2008). The clinical significance of subclinical thyroid dysfunction. 
Endocronology Reviews, Vol.29, No.1, (February, 2008), pp. 76-131, ISSN: 0163-769X 
 
Hypothyroidism on Lipid Metabolism 
 
23 
Brzezińska-Slebodzińska, E. (2003). Influence of hypothyroidism on lipid peroxidation, 
erythrocyte resistance and antioxidant plasma properties in rabbits. Acta Veterinary 
Hungaric, Vol.51, No.3, (July, 2003), pp. 343-351, ISSN: 0236-6290 
Bonet, B. & Herrera, E. (1991). Maternal hypothyroidism during the first half of gestation 
compromises normal catabolic adaptations of late gestation in the rat. 
Endocrinology, Vol.129, No.1, (July, 1991), pp. 210-216, ISSN: 0013-7227 
Canaris, G.J.; Manowitz, N.R.; Maayor, G. & Riggway, C. (2000). The Colorado thyroid 
disease prevalence study. Archives of Internal Medicine, Vol.160, No.4,  (February, 
2000), pp. 526-534, ISSN: 0003-9926 
Capuco, A.V.; Kahl, S.; Jack, L.J.; Bishop, J.O. & Wallace, H. (1999). Prolactin and growth 
hormone stimulation of lactation in mice requires thyroid hormones. Proceedings of 
the Society for Experimental Biology and Meodicine, Vol.221, No.4, (September, 1999), 
pp. 345-351, ISSN: 0037-9737 
Carvalho, S.D.; Bianco, A.C. &  Silva, J.E. (1996). Effects of hypothyroidism on brown 
adipose tissue adenylyl cyclase activity. Endocrinology, Vol.137, No.12, (December, 
1996), pp. 5519-5529, ISSN: 0013-7227 
Castieiras Lacambra, M.J.; Fuentes Arderiu, X. & Queraltó Compañó, J.M. Bioquímica 
Clínica y patología molecular Volumen 2, Ed Reverte, España. ISBN: 8429118551 
Cha, J.Y; Repa, J.J. (2007). The liver X receptor (LXR) and hepatic lipogenesis. The 
carbohydrate-response element-binding protein is a target gene of LXR. Journal 
Biologycal Chemistry, Vol. 282, No.1, (January,  2007), pp. 743-751, ISSN: 1067-8816 
Cheng, S.Y. (2005).Thyroid hormone receptor mutations and disease: beyond thyroid 
hormone resistance. Trends Endocrinology Metabolism, Vol.16, No 4, (May-June, 
2005), pp. 176-182, ISSN: 1043-2760 
Cheng, S.Y.; Leonard, J.L. & Davis, P.J. (2010). Molecular aspects of thyroid hormone 
actions. Endocrine Reviews, Vol.31, No.2, (April, 2010), pp. 139-170, ISSN: 0163-769X 
Danese, M.D.; Ladenson, P.W.; Meinert, C.L. & Powe, N.R. (2000). Effect of Thyroxine 
Therapy on Serum Lipoproteins in Patients with Mild Thyroid Failure: A 
Quantitative Review of the Literature. Jounal of Clinical Endocrinoly Metabolism, 
Vol.85, No.9, (September, 2000), pp. 2993-3001 ISNN: 0021-972X 
Dariyerli, N.; Toplan, S.; Akyolcu, M.C.; Hatemi, H. & Yigit, G. (2004). Erythrocyte osmotic 
fragility and oxidative stress in experimental hypothyroidism. Endocrine, Vol.25, 
No.1, (October, 2004), pp. 1-5 ISSN: 1355-008X 
Davis, L.M.; Rho, J.M. & Sullivan, P.G. (2008). UCP-mediated free fatty acid uncoupling of 
isolated cortical mitochondria from fasted animals: correlations to dietary 
modulations. Epilepsia, Vol.1, No.8, (November, 2008), pp. 117-119, ISSN: 0013-9580 
de Launoit, Y. & Kiss, R. (1989). Influence of L-thyroxine, L-triiodothyronine, thyroid 
stimulating hormone, or estradiol on the cell kinetics of cultured mammary cancer 
cells. In Vitro Cell Developmental Biology, Vol.25, No.7, (July, 1989), pp. 585-591, 
ISSN: 0883-8364 
Denis, R.G.; Williams, G. & Vernon, R.G. (2003). Regulation of serum leptin and its role in 
the hyperphagia of lactation in the rat. Journal of Endocrinology, Vol.176, No.2, 
(February, 2003), pp. 193–203, ISSN: 0022-0795 
 
Hypothyroidism – Influences and Treatments 
 
22
Journal of Clinical Investigation, Vol.107, No.5, (March, 2001), pp. 565-573, ISSN: 
0021-9738 
Araki, O.; Ying, H.; Zhu, X.G.; Willingham, M.C. & Cheng ,S.Y. (2009). Distinct 
dysregulation of lipid metabolism by unliganded thyroid hormone receptor 
isoforms. Molecular Endocrinology, Vol.23, No.3, (March, 2009), pp. 308-315, ISSN: 
0888-8809  
Aronne, L.J. & Thornton-Jones, Z.D. (2007). New targets for obesity pharmacotherapy. 
Clinical Pharmacology Therapy, Vol.81, No.5, (May, 2007), pp. 748-752, ISSN: 0009-
9236 
Asl, S.Z.; Brojeni, N.K.; Ghasemi, A.; Faraji, F.; Hedayati, M. & Azizi, F. (2009). Alterations in 
osmotic fragility of the red blood cells in hypo- and hyperthyroid patients. Journal 
Endocrinology Investigation, Vol.32, No.1, (January, 2009), pp. 28-32, ISSN: 0391-4097 
Asvold, B.; Vatten, L.J.; Nilsen, T.I. & Bjoro, T. (2007). The association between TSH within 
the reference range and serum lipid concentrations in a population-based study. 
The HUNT Study. The European Journal of Endocrinology, Vol.156, No.2, (February, 
2007), pp. 181-186, ISSN: 0804-4643 
Axelband, F.; Dias, J.; Ferrão, F.M. & Einicker-Lamas, M. (2011). Nongenomic signaling 
pathways triggered by thyroid hormones and their metabolite 3-iodothyronamine 
on the cardiovascular system. Journal of  Cellular Physiology, Vol. 226, No.1, 
(January, 2011), pp. 21-28, ISSN: 0021-9541 
Barbe, P.; Larrouy D.; Boulanger, C.; Chevillotte, E.; Viguerie, N.; Thalamas, C.; Trastoy, 
M.O.; Roques, M.; Vidal, H. & Lnagin, D. (2001). Triiodothyronine- mediated up-
regulation of UCP2 and UCP3 mRNA expression in human skeletal muscle without 
coordinated induction of mitochondrial respiratory chain genes. FASEB Journal, 
Vol.15, No.1, (January 2001), pp. 13-15, ISSN: 0892-6638 
Baxter, J.D. & Webb, P. (2009). Thyroid hormone mimetics: potential applications in 
atherosclerosis, obesity and type 2 diabetes. Nature Reviews Drug Discovy, Vol.8, 
No.4, (April, 2009), pp. 308-320, ISSN: 1474-1776 
Ben Cheikh, R.; Chomard, P.; Dumas, P. & Autissier, N. (1994). Influence of prolonged 
fasting on thyroid hormone modulation of lipolysis in isolated epididymal 
adipocytes of Wistar rats. European Journal Endocrinoly, Vol.131, No.5, (Nov, 1994), 
pp. 516-521, ISSN: 0804-4643 
Benseñor, I.M.; Goulart, A.C.; Lotufo, P.A.; Menezes, P.R. & Scazufca, M. (2011). Prevalence 
of thyroid disorders among older people: results from the São Paulo Ageing & 
Health Study. Cad Saude Publica, Vol.27, No.1, (January, 2011), pp. 155-161, ISSN: 
0102-311X 
Berkenstam, A.; Farnegardh, M. & Gustafsson, J.A. (2004). Convergence of lipid homeostasis 
through liver X and thyroid hormone receptors. Mechanism Aging Development, 
Vol.125, No.10-11, (October-November, 2004), pp. 707-717, ISSN: 0047-6374 
Betticher, D.C. & Pugin, P. (1991). Hypothyroidism and acanthocytes: diagnostic 
significance of blood smear. Schweiz Medical Wochenschr, Vol.121, No.31-32, 
(August, 1991), pp. 1127-1132, ISSN:  0036-7672 
Biondi, B. & Cooper, D.S. (2008). The clinical significance of subclinical thyroid dysfunction. 
Endocronology Reviews, Vol.29, No.1, (February, 2008), pp. 76-131, ISSN: 0163-769X 
 
Hypothyroidism on Lipid Metabolism 
 
23 
Brzezińska-Slebodzińska, E. (2003). Influence of hypothyroidism on lipid peroxidation, 
erythrocyte resistance and antioxidant plasma properties in rabbits. Acta Veterinary 
Hungaric, Vol.51, No.3, (July, 2003), pp. 343-351, ISSN: 0236-6290 
Bonet, B. & Herrera, E. (1991). Maternal hypothyroidism during the first half of gestation 
compromises normal catabolic adaptations of late gestation in the rat. 
Endocrinology, Vol.129, No.1, (July, 1991), pp. 210-216, ISSN: 0013-7227 
Canaris, G.J.; Manowitz, N.R.; Maayor, G. & Riggway, C. (2000). The Colorado thyroid 
disease prevalence study. Archives of Internal Medicine, Vol.160, No.4,  (February, 
2000), pp. 526-534, ISSN: 0003-9926 
Capuco, A.V.; Kahl, S.; Jack, L.J.; Bishop, J.O. & Wallace, H. (1999). Prolactin and growth 
hormone stimulation of lactation in mice requires thyroid hormones. Proceedings of 
the Society for Experimental Biology and Meodicine, Vol.221, No.4, (September, 1999), 
pp. 345-351, ISSN: 0037-9737 
Carvalho, S.D.; Bianco, A.C. &  Silva, J.E. (1996). Effects of hypothyroidism on brown 
adipose tissue adenylyl cyclase activity. Endocrinology, Vol.137, No.12, (December, 
1996), pp. 5519-5529, ISSN: 0013-7227 
Castieiras Lacambra, M.J.; Fuentes Arderiu, X. & Queraltó Compañó, J.M. Bioquímica 
Clínica y patología molecular Volumen 2, Ed Reverte, España. ISBN: 8429118551 
Cha, J.Y; Repa, J.J. (2007). The liver X receptor (LXR) and hepatic lipogenesis. The 
carbohydrate-response element-binding protein is a target gene of LXR. Journal 
Biologycal Chemistry, Vol. 282, No.1, (January,  2007), pp. 743-751, ISSN: 1067-8816 
Cheng, S.Y. (2005).Thyroid hormone receptor mutations and disease: beyond thyroid 
hormone resistance. Trends Endocrinology Metabolism, Vol.16, No 4, (May-June, 
2005), pp. 176-182, ISSN: 1043-2760 
Cheng, S.Y.; Leonard, J.L. & Davis, P.J. (2010). Molecular aspects of thyroid hormone 
actions. Endocrine Reviews, Vol.31, No.2, (April, 2010), pp. 139-170, ISSN: 0163-769X 
Danese, M.D.; Ladenson, P.W.; Meinert, C.L. & Powe, N.R. (2000). Effect of Thyroxine 
Therapy on Serum Lipoproteins in Patients with Mild Thyroid Failure: A 
Quantitative Review of the Literature. Jounal of Clinical Endocrinoly Metabolism, 
Vol.85, No.9, (September, 2000), pp. 2993-3001 ISNN: 0021-972X 
Dariyerli, N.; Toplan, S.; Akyolcu, M.C.; Hatemi, H. & Yigit, G. (2004). Erythrocyte osmotic 
fragility and oxidative stress in experimental hypothyroidism. Endocrine, Vol.25, 
No.1, (October, 2004), pp. 1-5 ISSN: 1355-008X 
Davis, L.M.; Rho, J.M. & Sullivan, P.G. (2008). UCP-mediated free fatty acid uncoupling of 
isolated cortical mitochondria from fasted animals: correlations to dietary 
modulations. Epilepsia, Vol.1, No.8, (November, 2008), pp. 117-119, ISSN: 0013-9580 
de Launoit, Y. & Kiss, R. (1989). Influence of L-thyroxine, L-triiodothyronine, thyroid 
stimulating hormone, or estradiol on the cell kinetics of cultured mammary cancer 
cells. In Vitro Cell Developmental Biology, Vol.25, No.7, (July, 1989), pp. 585-591, 
ISSN: 0883-8364 
Denis, R.G.; Williams, G. & Vernon, R.G. (2003). Regulation of serum leptin and its role in 
the hyperphagia of lactation in the rat. Journal of Endocrinology, Vol.176, No.2, 
(February, 2003), pp. 193–203, ISSN: 0022-0795 
 
Hypothyroidism – Influences and Treatments 
 
24
Dimitriadis, G.; Mitrou, P.; Lambadiari, V.; Boutati, E.; Maratou, E.; Koukkou, E.; Tzanela, 
M.; Thalassinos, N. & Raptis, S.A. 2006. Glucose and lipid fluxes in the adipose 
tissue after meal ingestion in hyperthyroidism. The Journal of Clinical Endocrinology 
and Metabolism, Vol. 91, No.12, (December, 2006), pp. 1112–1118, ISSN: 0021-972X   
Dimitriadis, G.; Mitrou, P.; Lambadiari, V.; Boutati, E.; Maratou, E.; Koukkou, E.; Tzanela, 
M.; Thalassinos, N. & Raptis, S.A. 2006. Insulin action in adipose tissue and muscle 
in hypothyroidism.  The Journal of Clinical Endocrinology and Metabolism, Vol. 91, 
No.12, (December, 2006), pp. 4930-4937, ISSN: 0021-972X   
Dong, X.Y. & Tang, S.Q. (2010). Insulin-induced gene: a new regulator in lipid 
metabolism.Peptides  Vol.31, No.11, (November, 2004), pp. 2145-50, ISSN: 0196-9781 
Dullaart, R.P.; Hoogenberg, K.; Groener, J.E.; Dikkeschei, L.D.; Erkelens, D.W. & Doorenbos, 
H. (1990). The activity of cholesteryl ester transfer protein is decreased in 
hypothyroidism: a possible contribution to alterations in high-density lipoproteins. 
European Journal Clinical Investigation, Vol.20, No.6 (December, 1990), pp. 581-587, 
ISSN: 0014-2972 
Eberlé, D.; Hegarty, B.; Bossard, P.; Ferré, P. & Foufelle, F. (2004). SREBP   transcription 
factors: master regulators of lipid homeostasis. Biochimie. Vol.86, No 11, 
(November, 2004), pp. 839-48.ISSN: 0300-9084 
Engin, A.; Altan, N. & Isik, E. (2005). Erythrocyte glutathione levels in lithium-induced 
hypothyroidism. Drugs in R& D, Vol.6, No.1, (2005), pp. 35-40. ISSN: 1174-5886 
Erqou, S.; Kaptoge, S.; Perry, P.L.; Di Angelantonio, E.; Thompson, A.; White I.R., Marcovina 
S.M., Collins R., Thompson S.G. & Danesh J. (2009). Lipoprotein(a) concentration 
and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA, 
Vol.302, No.4, (July, 2009), pp. 412-423, ISSN: 0098-7484 
Evered, D. & Hall, R. (1972). Hypothyroidism. British Medical J, Vol.1, (Jan 1972), pp. 290-293. 
ISSN:  0007-1447. 
Faryna de Raveglia, I.A.; Pasquini, J.M. & Soto, E.F. (1982). Effect of thyroid dysfunction 
upon phospholipid composition and CDP-choline incorporation in mitochondria 
and microsomal fraction isolated from liver and brain of suckling rats. 
Neurochemical Research, Vol.7, No.1, (January, 1982), pp. 37-47, ISSN: 0364-3190 
Fein, H.G. & Rivlin, R.S. (1975). Anemia in thyroid diseases. The Medical Clinics of North 
American, Vol.59, No.5, (September, 1975), pp. 1133-1145, ISSN: 0025-7125 
Festuccia, W.T.; Oztezcan, S.; Laplante, M.; Berthiaume, M.; Michel, C.; Dohgu, S.; Denis, 
R.G.; Brito, M.N.; Brito, N.A.; Miller, D.S.; Banks, W.A.; Bartness, T.J.; Richard, D.& 
Deshaies, Y. (2008). Peroxisome proliferator-activated receptor-gamma-mediated 
positive energy balance in the rat is associated with reduced sympathetic drive to 
adipose tissues and thyroid status. Endocrinology, Vol.149, No.5, (May, 2008), pp. 
2121-2130, ISSN: 0013-7227 
Flores-Morales, A.; Gullberg, H.; Fernandez, L.; Ståhlberg N.; Lee, N.H.; Vennström, B. & 
Norstedt G. (2002). Patterns of liver gene expression governed by TRbeta. Molecular 
endocrinology, Vol.16, No.6, (June, 2002), pp. 1257-1268, ISSN: 0888-8809 
Fowler, P.B. (1973). Treatment of hypothyroidism. British Medical Journal, Vol.3, (August, 
1973), pp. 352-353, ISSN: 0007-1447 
 
Hypothyroidism on Lipid Metabolism 
 
25 
Franzese, A.; Salerno, M.; Argenziano, A.; Buongiovanni, C.; Limauro, R. & Tenore, A. 
(1996). Anemia in infants with congenital hypothyroidism diagnosed by neonatal 
screening. Journal of Endocrinoly Investigation, Vol.19, No.9, (October, 1996), pp. 613-
619.  ISSN: 0391-4097 
Gärtner, R. (2009). Thyroid diseases in pregnancy. Current Opinion in Obstetric Gynecology, 
Vol.21, No.6, (December, 2009), pp. 501-507, ISSN: 1040-872X 
Gasawara, H. & Ishikawa, M. (1993). Evaluation of Peripheral Metabolic Status by 
Determination of Na-K ATPase Pump Activity in Circulating Erythrocytes in 
Patients with Thyroid Diseases and Nonthyroidal Illnesses. Endocrine Journal, 
Vol.40, No.1, (February 1993), pp. 27-33, ISSN: 0918-8959 
Germack, R.; Starzec, A. & Perret, G.Y. (2000). Regulation of β1- and β3-adrenergic agonist-
stimulated lipolytic response in hyperthyroid and hypothyroid rat white 
adipocytes. British Journal of Pharmacology, Vol.129, No.3, (January, 2009), pp. 448-
456, ISSN: 1476-5381 
Gjedde, S.; Gormsen, L.C.; Riis, A.L.; Jørgensen, J.O.; Rungby, J.; Møller, N.; Weeke, J. & 
Pedersen, S.B. (2010). Reduced expression of uncoupling protein 2 in adipose tissue 
in patients with hypothyroidism. Clinical Endocrinology of Metabolism, Vol.95, No.7, 
(July, 2010), pp. 3537-3541, ISSN: 0021-972X 
Glinoer, D. (1997). The Regulation of thyroid function in pregnancy:pathways of endocrine 
adaptation from physiologyto pathology. Endocrine Reviews, Vol.18, No.3, (June, 
1997), pp. 404-433, ISSN: 0163-769X 
Glinoer, D. (2004). The regulation of thyroid function during normal pregnancy: importance 
of the iodine nutrition status. Best Practice & Research Clinical Endocrinology & 
Metabolism, Vol.18, No.2, (June, 2004), pp. 133-152, ISSN: 1521-690X 
Grefhorst, A.; van Dijk, T.H.; Hammer, A.; van der Sluijs, F.H.; Havinga, R.; Havekes, 
L.M.; Romijn, J.A.; Groot, P.H.; Reijngoud, D.J. &  Kuipers, F. (2005). Differential 
effects of pharmacological liver X receptor activation on hepatic and peripheral 
insulin sensitivity in lean and ob/ob mice. American Journal of Physiology, 
Endocrinology and Metabolism, Vol.298, No.5, (November, 2005), pp. 829-838, ISSN: 
0193-1849 
González-Sancho, J.M.; Alvarez-Dolado, M.; Caelles, C. & Muñoz, A. (1999). Inhibition of 
tenascin-C expression in mammary epithelial cells by thyroid hormone. Molecular 
Carcinogenesis, Vol.24, No.2, (February, 1999), pp.99-107, ISSN: 0899-1987 
Gullberg, H.; Rudling ,M.; Forrest ,D.; Angelin ,B.; Vennström B.( 2000).  Thyroid hormone 
receptor beta-deficient mice show complete loss of the normal cholesterol 7alpha-
hydroxylase (CYP7A) response to thyroid hormone but display enhanced 
resistance to dietary cholesterol. Molecular Endocrinology, Vol.14, No.11, (November, 
2000), pp. 1739-49, ISSN: 0888-8809 
Gullberg, H.; Rudling, M.; Saltó, C.; Forrest, D.; Angelin, B. & Vennström, B. (2002). 
Requirement for thyroid hormone receptor beta in T3 regulation of cholesterol 
metabolism in mice. Molecular Endocrinology, Vol.16, No.8, (August, 2002), pp. 1767-
1777, ISSN: 0888-8809 
 
Hypothyroidism – Influences and Treatments 
 
24
Dimitriadis, G.; Mitrou, P.; Lambadiari, V.; Boutati, E.; Maratou, E.; Koukkou, E.; Tzanela, 
M.; Thalassinos, N. & Raptis, S.A. 2006. Glucose and lipid fluxes in the adipose 
tissue after meal ingestion in hyperthyroidism. The Journal of Clinical Endocrinology 
and Metabolism, Vol. 91, No.12, (December, 2006), pp. 1112–1118, ISSN: 0021-972X   
Dimitriadis, G.; Mitrou, P.; Lambadiari, V.; Boutati, E.; Maratou, E.; Koukkou, E.; Tzanela, 
M.; Thalassinos, N. & Raptis, S.A. 2006. Insulin action in adipose tissue and muscle 
in hypothyroidism.  The Journal of Clinical Endocrinology and Metabolism, Vol. 91, 
No.12, (December, 2006), pp. 4930-4937, ISSN: 0021-972X   
Dong, X.Y. & Tang, S.Q. (2010). Insulin-induced gene: a new regulator in lipid 
metabolism.Peptides  Vol.31, No.11, (November, 2004), pp. 2145-50, ISSN: 0196-9781 
Dullaart, R.P.; Hoogenberg, K.; Groener, J.E.; Dikkeschei, L.D.; Erkelens, D.W. & Doorenbos, 
H. (1990). The activity of cholesteryl ester transfer protein is decreased in 
hypothyroidism: a possible contribution to alterations in high-density lipoproteins. 
European Journal Clinical Investigation, Vol.20, No.6 (December, 1990), pp. 581-587, 
ISSN: 0014-2972 
Eberlé, D.; Hegarty, B.; Bossard, P.; Ferré, P. & Foufelle, F. (2004). SREBP   transcription 
factors: master regulators of lipid homeostasis. Biochimie. Vol.86, No 11, 
(November, 2004), pp. 839-48.ISSN: 0300-9084 
Engin, A.; Altan, N. & Isik, E. (2005). Erythrocyte glutathione levels in lithium-induced 
hypothyroidism. Drugs in R& D, Vol.6, No.1, (2005), pp. 35-40. ISSN: 1174-5886 
Erqou, S.; Kaptoge, S.; Perry, P.L.; Di Angelantonio, E.; Thompson, A.; White I.R., Marcovina 
S.M., Collins R., Thompson S.G. & Danesh J. (2009). Lipoprotein(a) concentration 
and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA, 
Vol.302, No.4, (July, 2009), pp. 412-423, ISSN: 0098-7484 
Evered, D. & Hall, R. (1972). Hypothyroidism. British Medical J, Vol.1, (Jan 1972), pp. 290-293. 
ISSN:  0007-1447. 
Faryna de Raveglia, I.A.; Pasquini, J.M. & Soto, E.F. (1982). Effect of thyroid dysfunction 
upon phospholipid composition and CDP-choline incorporation in mitochondria 
and microsomal fraction isolated from liver and brain of suckling rats. 
Neurochemical Research, Vol.7, No.1, (January, 1982), pp. 37-47, ISSN: 0364-3190 
Fein, H.G. & Rivlin, R.S. (1975). Anemia in thyroid diseases. The Medical Clinics of North 
American, Vol.59, No.5, (September, 1975), pp. 1133-1145, ISSN: 0025-7125 
Festuccia, W.T.; Oztezcan, S.; Laplante, M.; Berthiaume, M.; Michel, C.; Dohgu, S.; Denis, 
R.G.; Brito, M.N.; Brito, N.A.; Miller, D.S.; Banks, W.A.; Bartness, T.J.; Richard, D.& 
Deshaies, Y. (2008). Peroxisome proliferator-activated receptor-gamma-mediated 
positive energy balance in the rat is associated with reduced sympathetic drive to 
adipose tissues and thyroid status. Endocrinology, Vol.149, No.5, (May, 2008), pp. 
2121-2130, ISSN: 0013-7227 
Flores-Morales, A.; Gullberg, H.; Fernandez, L.; Ståhlberg N.; Lee, N.H.; Vennström, B. & 
Norstedt G. (2002). Patterns of liver gene expression governed by TRbeta. Molecular 
endocrinology, Vol.16, No.6, (June, 2002), pp. 1257-1268, ISSN: 0888-8809 
Fowler, P.B. (1973). Treatment of hypothyroidism. British Medical Journal, Vol.3, (August, 
1973), pp. 352-353, ISSN: 0007-1447 
 
Hypothyroidism on Lipid Metabolism 
 
25 
Franzese, A.; Salerno, M.; Argenziano, A.; Buongiovanni, C.; Limauro, R. & Tenore, A. 
(1996). Anemia in infants with congenital hypothyroidism diagnosed by neonatal 
screening. Journal of Endocrinoly Investigation, Vol.19, No.9, (October, 1996), pp. 613-
619.  ISSN: 0391-4097 
Gärtner, R. (2009). Thyroid diseases in pregnancy. Current Opinion in Obstetric Gynecology, 
Vol.21, No.6, (December, 2009), pp. 501-507, ISSN: 1040-872X 
Gasawara, H. & Ishikawa, M. (1993). Evaluation of Peripheral Metabolic Status by 
Determination of Na-K ATPase Pump Activity in Circulating Erythrocytes in 
Patients with Thyroid Diseases and Nonthyroidal Illnesses. Endocrine Journal, 
Vol.40, No.1, (February 1993), pp. 27-33, ISSN: 0918-8959 
Germack, R.; Starzec, A. & Perret, G.Y. (2000). Regulation of β1- and β3-adrenergic agonist-
stimulated lipolytic response in hyperthyroid and hypothyroid rat white 
adipocytes. British Journal of Pharmacology, Vol.129, No.3, (January, 2009), pp. 448-
456, ISSN: 1476-5381 
Gjedde, S.; Gormsen, L.C.; Riis, A.L.; Jørgensen, J.O.; Rungby, J.; Møller, N.; Weeke, J. & 
Pedersen, S.B. (2010). Reduced expression of uncoupling protein 2 in adipose tissue 
in patients with hypothyroidism. Clinical Endocrinology of Metabolism, Vol.95, No.7, 
(July, 2010), pp. 3537-3541, ISSN: 0021-972X 
Glinoer, D. (1997). The Regulation of thyroid function in pregnancy:pathways of endocrine 
adaptation from physiologyto pathology. Endocrine Reviews, Vol.18, No.3, (June, 
1997), pp. 404-433, ISSN: 0163-769X 
Glinoer, D. (2004). The regulation of thyroid function during normal pregnancy: importance 
of the iodine nutrition status. Best Practice & Research Clinical Endocrinology & 
Metabolism, Vol.18, No.2, (June, 2004), pp. 133-152, ISSN: 1521-690X 
Grefhorst, A.; van Dijk, T.H.; Hammer, A.; van der Sluijs, F.H.; Havinga, R.; Havekes, 
L.M.; Romijn, J.A.; Groot, P.H.; Reijngoud, D.J. &  Kuipers, F. (2005). Differential 
effects of pharmacological liver X receptor activation on hepatic and peripheral 
insulin sensitivity in lean and ob/ob mice. American Journal of Physiology, 
Endocrinology and Metabolism, Vol.298, No.5, (November, 2005), pp. 829-838, ISSN: 
0193-1849 
González-Sancho, J.M.; Alvarez-Dolado, M.; Caelles, C. & Muñoz, A. (1999). Inhibition of 
tenascin-C expression in mammary epithelial cells by thyroid hormone. Molecular 
Carcinogenesis, Vol.24, No.2, (February, 1999), pp.99-107, ISSN: 0899-1987 
Gullberg, H.; Rudling ,M.; Forrest ,D.; Angelin ,B.; Vennström B.( 2000).  Thyroid hormone 
receptor beta-deficient mice show complete loss of the normal cholesterol 7alpha-
hydroxylase (CYP7A) response to thyroid hormone but display enhanced 
resistance to dietary cholesterol. Molecular Endocrinology, Vol.14, No.11, (November, 
2000), pp. 1739-49, ISSN: 0888-8809 
Gullberg, H.; Rudling, M.; Saltó, C.; Forrest, D.; Angelin, B. & Vennström, B. (2002). 
Requirement for thyroid hormone receptor beta in T3 regulation of cholesterol 
metabolism in mice. Molecular Endocrinology, Vol.16, No.8, (August, 2002), pp. 1767-
1777, ISSN: 0888-8809 
 
Hypothyroidism – Influences and Treatments 
 
26
Hapon, M.B.; Simoncini, M.; Via, G. & Jahn, G.A. (2003). Effect of hypothyroidism on 
hormone profiles in virgin, pregnant and lactating rats, and on lactation. 
Reproduction, Vol.126, No.3, (September, 2003), pp. 371-382, ISSN: 1470-1626 
Hapon, M.B.; Varas, S.M.; Jahn, G.A. & Gimenez, M.S. (2005). Effects of hypothyroidism on 
mammary and liver lipid metabolism in virgin and late-pregnant rats. Journal of 
Lipid Research, Vol.46, No.6, (June, 2005), pp. 1320-1330, ISSN: 0022-2275 
Hapon, M.B.; Varas, S.M.; Gimenez, M.S. & Jahn, G.A. (2007). Reduction of mammary and 
liver lipogenesis and alteration of milk composition during lactation in rats by 
hypothyroidism. Thyroid, Vol.17, No.1, (January, 2007), pp. 11-18, ISSN: 1050-7256 
Hashimoto, K.; Matsumoto, S.; Yamada, M.; Satoh, T. & Mori, M. (2007). Liver X Receptor-β 
Gene Expression Is Positively Regulated by Thyroid Hormone. Endocrinology, 
Vol.148, No 10, (October, 2007) pp. 4667–4675, ISSN:0013-7227 
Helfand, M. (2004). Screening for subclinical thyroid dysfunction in nonpregnant adults: a 
summary of the evidence for the U.S. Preventive Services Task Force. Annals of 
International Medicine, Vol.140, No.2, (January, 2004), pp. 128-141, ISSN: 0003-4819 
Henkel, A.S.; Anderson, K.A.; Dewey, A.M.; Kavesh, M.H.& Green RM. (2011) 
 A chronic high-cholesterol diet paradoxically suppresses hepatic CYP7A1 
expression in FVB/NJ mice. Journal of Lipid Research, Vol.52, No.2 (February, 2011), 
pp. 289-298, ISSN: 0022-2275 
Herrera, E. (2002). Lipid metabolism in pregnancy and its consequences in the fetus and   
newborn. Endocrine, Vol.19, No.1, (October, 2002), pp. 43-55, ISSN: 1355-008X 
Hoch, F.L.; Subramanian, C.; Dhopeshwarkar, G.A. & Mead, J.F. (1981). Thyroid control 
over biomembranes: VI. Lipids in liver mitochondria and microsomes of 
hypothyroid rats. Lipids, Vol.16, No.5, (May, 1981), pp. 328-335, ISSN: 0024-4201 
Hoffstedt J., Folkesson R., Wahrenberg H., Wennlund A., van Harmelen V. & Arner P. 
(2000). A marked upregulation of uncoupling protein 2 gene expression in adipose 
tissue of hyperthyroid subjects. Hormone and Metabolic Research, Vol.32, No.11-12, 
(November-December 2000), pp. 475-479, ISSN: 0018-5043 
Horton, L.; Coburn, R.J.; England, J.M. & Himsworth, R.L. (1976). The haematology of 
hypothyroidism. The Quaterly Journal of Medicine, Vol.45, No.177, (January, 1976), 
pp. 101-123. ISSN: 1460-2725 
Hsieh, C.J.; Wang, P.W.; Wang, S.T.; Liu, R.T.; Tung, S.C.; Chien, W.Y.; Lu, Y.C.; Chen. J.F.;  
Chen, C.H. & Kuo, M.C.  (2002). Serum leptin concentrations of patients with 
sequential thyroid function changes. Clinical Endocrinology, Vol.57, No.1, (July, 
2002), pp. 29-34, ISSN: 0300-0664 
Hübner, G.; Meng, W.; Meisel, P.; Ventz, M.; Hampel, R. & Bleyer, H. (1979). Behavior of the 
erythrocyte glucose-6-phosphate dehydrogenase in patients with functional 
thyroid disorders and in hyperthyroxinemic rats. Zeitscrift Für die Gesamte Innere 
Medizin, Vol.34, No.14, (July, 1979), pp. 386-389, ISSN: 0044-2542 
Hunter, J.; Kassam, A.; Winrow, C.J.; Rachubinskib, R.A. & Capone, J.P.  (1996). Crosstalk 
between the thyroid hormone and peroxisome proliferator-activated receptors in 
regulating peroxisome proliferator-responsive genes. Molecular and Cellular 
Endocrinology, Vol.116, No.2, (February, 1996), pp. 213-221, ISSN: 0303-7207 
 
Hypothyroidism on Lipid Metabolism 
 
27 
Iqbal, A; Jorde, R. & Figenschau, Y. (2006). Serum lipid levels in relation to serum thyroid-
stimulating hormone and the effect of thyroxine treatment on serum lipid levels in 
subjects with subclinical hypothyroidism: the Tromsø Study. Journal of International 
Medicine, Vol.260, No.1, (July, 2006), pp. 53-61, ISSN: 0954-6820 
Ishi,i J. & Nakao, K. (1968). Analysis of the human erythrocyte lipid in various functional 
conditions of the thyroid. Tohoku Journal Experiment of Medicine, Vol. 94, No.2, 
(February, 1968), pp. 169-175, ISSN: 0040-8727 
Ito, M.; Arishima, T.; Kudo, T.; Nishihara, E.; Ohye, H.; Kubota, S.; Fukata, S. & Amino, N. 
(2007).  Effect of Levo-Thyroxine Replacement on Non-High-Density Lipoprotein 
Cholesterol in Hypothyroid Patients. The Journal of Clinical Endocrinology and 
Metabolism, Vol.92, No.2, (February, 2007), pp. 608-611, ISSN: 0021-972X 
Johansson, L.; Rudling, M.; Scanlan, T.S.; Lundåsen, T.; Webb, P.; Baxter, J.; Angelin, B. & 
Parini, P. (2005). Selective thyroid receptor modulation by GC-1 reduces serum 
lipids and stimulates steps of reverse cholesterol transport in euthyroid mice. 
Proceeding of the National Academy of Sciences, Vol.102, No.29 (July, 2005), pp. 10297-
10302, ISSN: 0027-8424 
Kaneshige, M.; Kaneshige, K.; Zhu, X.; Dace, A.; Garrett, L.; Carter, T.A.;  Kazlauskaite, 
R.; Pankratz, D.G.; Wynshaw-Boris, A.; Refetoff, S.; Weintraub, B.; Willingham, 
M.C.; Barlow, C. & Cheng, S. (2000). Mice with a targeted mutation in the thyroid 
hormone beta receptor gene exhibit impaired growth and resistance to thyroid 
hormone. Proceeding of the National Academia of Sciences, Vol.97, No.24, (November, 
2000), pp. 13209-13214, ISSN: 0087-8424 
Kaneshige, M.; Suzuki, H.; Kaneshige, K.; Cheng, J.; Wimbrow, H.; Barlow, C.; Willigham, 
M.C. & Chang, S. (2001). A targeted dominant negative mutation of the thyroid 
hormone alpha 1 receptor causes increased mortality, infertility, and dwarfism in 
mice. Proceeding of the National Academia of Sciences, Vol.98, No.26, (December, 2001), 
pp. 15095-15100, ISSN: 0087-8424 
Kim, Y.J.; Lee, M.S.; Lee, H.J.; Wu, Y.; Freake, H.C.; Chun, H.S. & Kim, Y. (2005). Hormones 
and nutrients regulate acetyl-CoA carboxylase promoter I in rat primary 
hepatocytes. Journal of Nutritional Science and Vitaminolog, Vol.51, No.2, (April, 
2005), pp. 124-128, ISSN: 0301-4800 
Klieveri, L.P.; Coomans, C.P.; Endert, E.; Sauerwein, H.P.; Havekes, L.M.; Voshol, P.J.; 
Rensen, P.C.; Romijn J.A.; Kalsbeek, A. & Fliers, E. (2009). Thyroid hormone effects 
on whole-body energy homeostasis and tissue-specific fatty acid uptake in vivo. 
Endocrinology, Vol.150, No.12, (December, 2009), pp. 5639-5648, ISSN: 0013-7227 
Kowalczyk, E.; Urbanowicz, J.; Kopff, M.; Ciećwierz, J. & Andryskowski, G. (2011). Elements 
of oxidation/reduction balance in experimental hypothyroidism. Endokrynol Poskal, 
Vol.62, No.3, (2011), pp. 220-223, ISSN: 0423-104X 
Kowluru, R.; Bitensky, M.W.; Kowluru, A.; Dembo, M.; Keaton, P.A. & Buican, T. (1989). 
Reversible sodium pump defect and swelling in the diabetic rat erythrocyte: effects 
on filterability and implications for microangiopathy. Proceeding of the National 
Academy of Sciences, Vol.86, No.9, (May, 1989), pp. 3327-3331, ISSN: 0027-8424 
Lai, Y.; Wang, J.; Jiang, F.; Wang, B.; Chen, Y.; Li, M.; Liu, H.; Li, C.; Xue, H.; Li, N.; Yu, J.; 
Shi, L.; Bai, X.; Hou, X.; Zhu, L.; Lu, L.; Wang, S.; Xing, Q.; Teng, X.; Teng, W & 
 
Hypothyroidism – Influences and Treatments 
 
26
Hapon, M.B.; Simoncini, M.; Via, G. & Jahn, G.A. (2003). Effect of hypothyroidism on 
hormone profiles in virgin, pregnant and lactating rats, and on lactation. 
Reproduction, Vol.126, No.3, (September, 2003), pp. 371-382, ISSN: 1470-1626 
Hapon, M.B.; Varas, S.M.; Jahn, G.A. & Gimenez, M.S. (2005). Effects of hypothyroidism on 
mammary and liver lipid metabolism in virgin and late-pregnant rats. Journal of 
Lipid Research, Vol.46, No.6, (June, 2005), pp. 1320-1330, ISSN: 0022-2275 
Hapon, M.B.; Varas, S.M.; Gimenez, M.S. & Jahn, G.A. (2007). Reduction of mammary and 
liver lipogenesis and alteration of milk composition during lactation in rats by 
hypothyroidism. Thyroid, Vol.17, No.1, (January, 2007), pp. 11-18, ISSN: 1050-7256 
Hashimoto, K.; Matsumoto, S.; Yamada, M.; Satoh, T. & Mori, M. (2007). Liver X Receptor-β 
Gene Expression Is Positively Regulated by Thyroid Hormone. Endocrinology, 
Vol.148, No 10, (October, 2007) pp. 4667–4675, ISSN:0013-7227 
Helfand, M. (2004). Screening for subclinical thyroid dysfunction in nonpregnant adults: a 
summary of the evidence for the U.S. Preventive Services Task Force. Annals of 
International Medicine, Vol.140, No.2, (January, 2004), pp. 128-141, ISSN: 0003-4819 
Henkel, A.S.; Anderson, K.A.; Dewey, A.M.; Kavesh, M.H.& Green RM. (2011) 
 A chronic high-cholesterol diet paradoxically suppresses hepatic CYP7A1 
expression in FVB/NJ mice. Journal of Lipid Research, Vol.52, No.2 (February, 2011), 
pp. 289-298, ISSN: 0022-2275 
Herrera, E. (2002). Lipid metabolism in pregnancy and its consequences in the fetus and   
newborn. Endocrine, Vol.19, No.1, (October, 2002), pp. 43-55, ISSN: 1355-008X 
Hoch, F.L.; Subramanian, C.; Dhopeshwarkar, G.A. & Mead, J.F. (1981). Thyroid control 
over biomembranes: VI. Lipids in liver mitochondria and microsomes of 
hypothyroid rats. Lipids, Vol.16, No.5, (May, 1981), pp. 328-335, ISSN: 0024-4201 
Hoffstedt J., Folkesson R., Wahrenberg H., Wennlund A., van Harmelen V. & Arner P. 
(2000). A marked upregulation of uncoupling protein 2 gene expression in adipose 
tissue of hyperthyroid subjects. Hormone and Metabolic Research, Vol.32, No.11-12, 
(November-December 2000), pp. 475-479, ISSN: 0018-5043 
Horton, L.; Coburn, R.J.; England, J.M. & Himsworth, R.L. (1976). The haematology of 
hypothyroidism. The Quaterly Journal of Medicine, Vol.45, No.177, (January, 1976), 
pp. 101-123. ISSN: 1460-2725 
Hsieh, C.J.; Wang, P.W.; Wang, S.T.; Liu, R.T.; Tung, S.C.; Chien, W.Y.; Lu, Y.C.; Chen. J.F.;  
Chen, C.H. & Kuo, M.C.  (2002). Serum leptin concentrations of patients with 
sequential thyroid function changes. Clinical Endocrinology, Vol.57, No.1, (July, 
2002), pp. 29-34, ISSN: 0300-0664 
Hübner, G.; Meng, W.; Meisel, P.; Ventz, M.; Hampel, R. & Bleyer, H. (1979). Behavior of the 
erythrocyte glucose-6-phosphate dehydrogenase in patients with functional 
thyroid disorders and in hyperthyroxinemic rats. Zeitscrift Für die Gesamte Innere 
Medizin, Vol.34, No.14, (July, 1979), pp. 386-389, ISSN: 0044-2542 
Hunter, J.; Kassam, A.; Winrow, C.J.; Rachubinskib, R.A. & Capone, J.P.  (1996). Crosstalk 
between the thyroid hormone and peroxisome proliferator-activated receptors in 
regulating peroxisome proliferator-responsive genes. Molecular and Cellular 
Endocrinology, Vol.116, No.2, (February, 1996), pp. 213-221, ISSN: 0303-7207 
 
Hypothyroidism on Lipid Metabolism 
 
27 
Iqbal, A; Jorde, R. & Figenschau, Y. (2006). Serum lipid levels in relation to serum thyroid-
stimulating hormone and the effect of thyroxine treatment on serum lipid levels in 
subjects with subclinical hypothyroidism: the Tromsø Study. Journal of International 
Medicine, Vol.260, No.1, (July, 2006), pp. 53-61, ISSN: 0954-6820 
Ishi,i J. & Nakao, K. (1968). Analysis of the human erythrocyte lipid in various functional 
conditions of the thyroid. Tohoku Journal Experiment of Medicine, Vol. 94, No.2, 
(February, 1968), pp. 169-175, ISSN: 0040-8727 
Ito, M.; Arishima, T.; Kudo, T.; Nishihara, E.; Ohye, H.; Kubota, S.; Fukata, S. & Amino, N. 
(2007).  Effect of Levo-Thyroxine Replacement on Non-High-Density Lipoprotein 
Cholesterol in Hypothyroid Patients. The Journal of Clinical Endocrinology and 
Metabolism, Vol.92, No.2, (February, 2007), pp. 608-611, ISSN: 0021-972X 
Johansson, L.; Rudling, M.; Scanlan, T.S.; Lundåsen, T.; Webb, P.; Baxter, J.; Angelin, B. & 
Parini, P. (2005). Selective thyroid receptor modulation by GC-1 reduces serum 
lipids and stimulates steps of reverse cholesterol transport in euthyroid mice. 
Proceeding of the National Academy of Sciences, Vol.102, No.29 (July, 2005), pp. 10297-
10302, ISSN: 0027-8424 
Kaneshige, M.; Kaneshige, K.; Zhu, X.; Dace, A.; Garrett, L.; Carter, T.A.;  Kazlauskaite, 
R.; Pankratz, D.G.; Wynshaw-Boris, A.; Refetoff, S.; Weintraub, B.; Willingham, 
M.C.; Barlow, C. & Cheng, S. (2000). Mice with a targeted mutation in the thyroid 
hormone beta receptor gene exhibit impaired growth and resistance to thyroid 
hormone. Proceeding of the National Academia of Sciences, Vol.97, No.24, (November, 
2000), pp. 13209-13214, ISSN: 0087-8424 
Kaneshige, M.; Suzuki, H.; Kaneshige, K.; Cheng, J.; Wimbrow, H.; Barlow, C.; Willigham, 
M.C. & Chang, S. (2001). A targeted dominant negative mutation of the thyroid 
hormone alpha 1 receptor causes increased mortality, infertility, and dwarfism in 
mice. Proceeding of the National Academia of Sciences, Vol.98, No.26, (December, 2001), 
pp. 15095-15100, ISSN: 0087-8424 
Kim, Y.J.; Lee, M.S.; Lee, H.J.; Wu, Y.; Freake, H.C.; Chun, H.S. & Kim, Y. (2005). Hormones 
and nutrients regulate acetyl-CoA carboxylase promoter I in rat primary 
hepatocytes. Journal of Nutritional Science and Vitaminolog, Vol.51, No.2, (April, 
2005), pp. 124-128, ISSN: 0301-4800 
Klieveri, L.P.; Coomans, C.P.; Endert, E.; Sauerwein, H.P.; Havekes, L.M.; Voshol, P.J.; 
Rensen, P.C.; Romijn J.A.; Kalsbeek, A. & Fliers, E. (2009). Thyroid hormone effects 
on whole-body energy homeostasis and tissue-specific fatty acid uptake in vivo. 
Endocrinology, Vol.150, No.12, (December, 2009), pp. 5639-5648, ISSN: 0013-7227 
Kowalczyk, E.; Urbanowicz, J.; Kopff, M.; Ciećwierz, J. & Andryskowski, G. (2011). Elements 
of oxidation/reduction balance in experimental hypothyroidism. Endokrynol Poskal, 
Vol.62, No.3, (2011), pp. 220-223, ISSN: 0423-104X 
Kowluru, R.; Bitensky, M.W.; Kowluru, A.; Dembo, M.; Keaton, P.A. & Buican, T. (1989). 
Reversible sodium pump defect and swelling in the diabetic rat erythrocyte: effects 
on filterability and implications for microangiopathy. Proceeding of the National 
Academy of Sciences, Vol.86, No.9, (May, 1989), pp. 3327-3331, ISSN: 0027-8424 
Lai, Y.; Wang, J.; Jiang, F.; Wang, B.; Chen, Y.; Li, M.; Liu, H.; Li, C.; Xue, H.; Li, N.; Yu, J.; 
Shi, L.; Bai, X.; Hou, X.; Zhu, L.; Lu, L.; Wang, S.; Xing, Q.; Teng, X.; Teng, W & 
 
Hypothyroidism – Influences and Treatments 
 
28
Shan, Z. (2011). The relationship between serum thyrotropin and components of 
metabolic syndrome. Endocrine Journal, Vol.58, No.1, (November, 2010), pp. 23-30, 
ISSN: 0918-8959 
Lazarus, J.H. (2011). Screening for Thyroid Dysfunction in Pregnancy: Is It Worthwhile? 
Journal of Thyroid Research, (Jun 2011), ID397012, ISSN: 2042-0072 
Lin, Y.T.; Tang, C.H.; Chuang, W.J.; Wang, S.M.; Huang, T.F.; Fu, W.M. (2005). Inhibition of 
adipogenesis by RGD-dependent disintegrin. Biochemical Pharmacology, Vol.70, 
No.10, (November, 2005), pp. 1469-1478, ISSN: 0006-2952 
Lithell, H.; Boberg, J.; Hellsing, K.; Ljunghall, S.; Lundqvist, G.; Vessby, B. & Wide, L. (1981). 
Serum lipoprotein and apolipoprotein concentrations and tissue lipoprotein-lipase 
activity in overt and subclinical hypothyroidism: the effect of substitution therapy. 
European Journal of Clinical Investigation, Vol.11, No.1, (February, 1981), pp. 3-10, 
ISSN: 0014-2972 
Liu, Y.Y.; Schultz, J.J. & Brent, GA. (2003). A thyroid hormone receptor alpha gene mutation 
(P398H) is associated with visceral adiposity and impaired catecholamine-
stimulated lipolysis in mice. Journal of Biological Chemistry, Vol.278, No.40, (October, 
2003), pp. 38913–38920, ISSN: 0021-9258 
Liu, Y.Y. & Brent, G.A. (2010). Thyroid hormone crosstalk with nuclear receptor 
signaling in metabolic regulation. Trends in Endocrinology and Metabolism, Vol.21, 
No.3, (March, 2010), pp. 166-173, ISSN: 1043-2760 
Lopez, D.; Abisambra Socarrás, J.F.; Bedi, M.; Ness, G.C. (2007).  Activation of the hepatic 
LDL receptor promoter by thyroid hormone. Biochimica Biophysica Acta, Vol.1771, 
No.9, (September, 2007), pp. 1216-1225, ISSN: 0006-3002 
López-Luna, P. & Morales, S. (1985). Effect of the hypothyroidism on the levels of different 
metabolites in pregnant rats. Revista Española de Fisiologia, Vol.41, No.3, (September, 
1985), pp. 311-316, ISSN: 0034-9402 
Lu, L.; Wang, B.; Shan, Z.; Jiang, F.; Teng, X.; Chen, Y.; Lai, Y.; Wang, J.; Xue, H.; Wang, S.; 
Li, C.; Liu, H.; Li, N.; Yu, J.; Shi, L.; Hou, X.; Xing, Q.; Bai, X. & Teng W. (2011).  The 
correlation between thyrotropin and dyslipidemia in a population-based study. 
Journal of Korean Medical Science, Vol.26, No.2, (February, 2011), pp. 243-249, ISSN: 
1011-8934 
Lynch, E.C. (1990). Chapter 155 Peripheral Blood Smear, In: Clinical Methods: The History, 
Physical, and Laboratory Examinations, Walker HK, Hall WD, Hurst JW, editors. 3rd 
edition, Butterworths, Boston. ISBN-10: 0-409-90077-X 
Martyn, P. & Falconer, I.R. (1985). The effect of progesterone on prolactin stimulation of 
fatty acid synthesis, glycerolipid synthesis and lipogenic enzyme activities in 
mammary glands of pseudopregnant rabbits, after explant culture or intraductal 
injection. The Biochemical Journal, Vol.231, No.2, (October, 1985), pp. 321-328, ISSN: 
0264-6021 
Mathe, D. & Chevallier, F. (1976). Effects of the thyroid state on cholesterol metabolism in 
the rat. Biochimica Biophysica Acta, Vol.441, No.1, (July, 1976), pp.155-164, ISSN: 
0006-3002 
Meier-Heusler S.C.; Zhu X.; Juge-Aubry, C.; Pernin, A.; Burger, A.G.; Cheng, S.Y. & Meier, 
C.A.. (1995). Modulation of thyroid hormone action by mutant thyroid hormone 
 
Hypothyroidism on Lipid Metabolism 
 
29 
receptors, c-erbA alpha 2 and peroxisome proliferator-activated receptor: evidence 
for different mechanisms of inhibition. Molecular and cellular endocrinology, Vol.107, 
No.1, (January, 1995), pp. 55-66, ISSN: 0303-7207 
Millán, J.; Pintó, X.; Muñoz, A.; Zúñiga, M.; Rubiés-Prat, J.; Pallardo, L.F.; Masana, L.; 
Mangas, A.; Hernández-Mijares, A., González-Santos, P.; Ascaso, J.F. & Pedro-
Botet, J. (2009). Lipoprotein ratios: Physiological significance and clinical usefulness 
in cardiovascular prevention. Vascular Health Risk Management, Vol.5, (September, 
2009), pp. 757-765, ISSN: 1176-6344 
Morkin, E., Ladenson, P.; Goldman, S. & Adamson, C. (2004). Thyroid hormone analogs for 
treatment of hypercholesterolemia and heart failure: past, present and future 
prospects. Journal of Molecular and Cellular Cardiology, Vol.37, No.6, (December, 
2004), pp. 1137-1146, ISSN: 0022-2828 
Mukhopadhyay, D.; Plateroti, M., Anant, S.; Nassir, F.; Samarut, J. & Davidson, N.O. 
(2003).Thyroid hormone regulates hepatic triglyceride mobilization and 
apolipoprotein B messenger ribonucleic Acid editing in a murine model of 
congenital hypothyroidism. Endocrinology, Vol.144, No.2, (febrero, 2003), pp. 711-
719, ISSN: 0013-7227 
Müller, M.J.; Köster, H. & Seitz, H.J. (1981). Effect of thyroid state on ketogenic capacity of 
the isolated perfused liver of starved rats. Biochimica Biophysica Acta, Vol.666, No.3, 
(December, 1981), pp. 475-481, ISSN: 0006-3002 
Nikkilä, E.A. & Kekki, M. (1972). Plasma Triglyceride Metabolism in Thyroid Disease. 
Journal of Clinical Investigation, Vol.51, No.8, (August, 1972), pp. 2103-2114, ISSN: 
0021-9738 
Nishida, M., Sasaki, T.; Terada, H. & Kawada, J. (1991). Synergistic and antagonistic effects 
on fatty acid composition in the liver mitochondria of rats by thyroidectomy and 
streptozotocin-administration. Research Communication in Chemical Pathology and 
Pharmacology, Vol.74, No.3, (December, 1991), pp. 317-326, ISSN: 0034-5164 
Nomura, S.; Eimoto, T.; Osawa, G.; Yawata, Y. & Horino, M. (1991). Case report: 
hypothyroidism as a possible cause of an acquired reversible hemolytic anemia. The 
American Journal of Medical Sciences, Vol.302, No.1, (July, 1991), pp. 23-27, ISSN: 
0002-9629  
Oetting, A. & Yen, P.M. (2007). New insights into thyroid hormone action. Best Practice & 
Research.  Clinical Endocrinology and Metabetabolism, Vol.21, No.2, (June, 2007), pp. 
193-208, ISSN: 1521-690X 
Okosieme, O.E. & Lazarus, J.H. (2010). Thyroid dysfunction in pregnancy: optimizing fetal 
and maternal outcomes. Expert Review of Endocrinology and Metabolism, Vol.5, No.4, 
(July, 2010), pp. 521–529, ISSN:  1744-6651 
Omar, S.; Hadj Taeib, S.; Kanoun, F.; Hammami, M.B.; Kamoun, S.; Ben Romdhane, N.; Feki, 
M.; Slimane, H. & Kaabachi N. (2010). Erythrocyte abnormalities in thyroid 
dysfunction. La Tunisie Médicale, Vol.88, No.11, (November, 2010), pp. 783-788, 
ISSN: 0041-4131 
Parrilla, R.J.; Mixson, A.J.;  McPherson, J.A.;  McClaskey, J.H. & Weintraub, B.D. (1991). 
Characterization of seven novel mutations of the c-erbA beta gene in unrelated 
kindreds with generalized thyroid hormone resistance. Evidence for two "hot spot" 
 
Hypothyroidism – Influences and Treatments 
 
28
Shan, Z. (2011). The relationship between serum thyrotropin and components of 
metabolic syndrome. Endocrine Journal, Vol.58, No.1, (November, 2010), pp. 23-30, 
ISSN: 0918-8959 
Lazarus, J.H. (2011). Screening for Thyroid Dysfunction in Pregnancy: Is It Worthwhile? 
Journal of Thyroid Research, (Jun 2011), ID397012, ISSN: 2042-0072 
Lin, Y.T.; Tang, C.H.; Chuang, W.J.; Wang, S.M.; Huang, T.F.; Fu, W.M. (2005). Inhibition of 
adipogenesis by RGD-dependent disintegrin. Biochemical Pharmacology, Vol.70, 
No.10, (November, 2005), pp. 1469-1478, ISSN: 0006-2952 
Lithell, H.; Boberg, J.; Hellsing, K.; Ljunghall, S.; Lundqvist, G.; Vessby, B. & Wide, L. (1981). 
Serum lipoprotein and apolipoprotein concentrations and tissue lipoprotein-lipase 
activity in overt and subclinical hypothyroidism: the effect of substitution therapy. 
European Journal of Clinical Investigation, Vol.11, No.1, (February, 1981), pp. 3-10, 
ISSN: 0014-2972 
Liu, Y.Y.; Schultz, J.J. & Brent, GA. (2003). A thyroid hormone receptor alpha gene mutation 
(P398H) is associated with visceral adiposity and impaired catecholamine-
stimulated lipolysis in mice. Journal of Biological Chemistry, Vol.278, No.40, (October, 
2003), pp. 38913–38920, ISSN: 0021-9258 
Liu, Y.Y. & Brent, G.A. (2010). Thyroid hormone crosstalk with nuclear receptor 
signaling in metabolic regulation. Trends in Endocrinology and Metabolism, Vol.21, 
No.3, (March, 2010), pp. 166-173, ISSN: 1043-2760 
Lopez, D.; Abisambra Socarrás, J.F.; Bedi, M.; Ness, G.C. (2007).  Activation of the hepatic 
LDL receptor promoter by thyroid hormone. Biochimica Biophysica Acta, Vol.1771, 
No.9, (September, 2007), pp. 1216-1225, ISSN: 0006-3002 
López-Luna, P. & Morales, S. (1985). Effect of the hypothyroidism on the levels of different 
metabolites in pregnant rats. Revista Española de Fisiologia, Vol.41, No.3, (September, 
1985), pp. 311-316, ISSN: 0034-9402 
Lu, L.; Wang, B.; Shan, Z.; Jiang, F.; Teng, X.; Chen, Y.; Lai, Y.; Wang, J.; Xue, H.; Wang, S.; 
Li, C.; Liu, H.; Li, N.; Yu, J.; Shi, L.; Hou, X.; Xing, Q.; Bai, X. & Teng W. (2011).  The 
correlation between thyrotropin and dyslipidemia in a population-based study. 
Journal of Korean Medical Science, Vol.26, No.2, (February, 2011), pp. 243-249, ISSN: 
1011-8934 
Lynch, E.C. (1990). Chapter 155 Peripheral Blood Smear, In: Clinical Methods: The History, 
Physical, and Laboratory Examinations, Walker HK, Hall WD, Hurst JW, editors. 3rd 
edition, Butterworths, Boston. ISBN-10: 0-409-90077-X 
Martyn, P. & Falconer, I.R. (1985). The effect of progesterone on prolactin stimulation of 
fatty acid synthesis, glycerolipid synthesis and lipogenic enzyme activities in 
mammary glands of pseudopregnant rabbits, after explant culture or intraductal 
injection. The Biochemical Journal, Vol.231, No.2, (October, 1985), pp. 321-328, ISSN: 
0264-6021 
Mathe, D. & Chevallier, F. (1976). Effects of the thyroid state on cholesterol metabolism in 
the rat. Biochimica Biophysica Acta, Vol.441, No.1, (July, 1976), pp.155-164, ISSN: 
0006-3002 
Meier-Heusler S.C.; Zhu X.; Juge-Aubry, C.; Pernin, A.; Burger, A.G.; Cheng, S.Y. & Meier, 
C.A.. (1995). Modulation of thyroid hormone action by mutant thyroid hormone 
 
Hypothyroidism on Lipid Metabolism 
 
29 
receptors, c-erbA alpha 2 and peroxisome proliferator-activated receptor: evidence 
for different mechanisms of inhibition. Molecular and cellular endocrinology, Vol.107, 
No.1, (January, 1995), pp. 55-66, ISSN: 0303-7207 
Millán, J.; Pintó, X.; Muñoz, A.; Zúñiga, M.; Rubiés-Prat, J.; Pallardo, L.F.; Masana, L.; 
Mangas, A.; Hernández-Mijares, A., González-Santos, P.; Ascaso, J.F. & Pedro-
Botet, J. (2009). Lipoprotein ratios: Physiological significance and clinical usefulness 
in cardiovascular prevention. Vascular Health Risk Management, Vol.5, (September, 
2009), pp. 757-765, ISSN: 1176-6344 
Morkin, E., Ladenson, P.; Goldman, S. & Adamson, C. (2004). Thyroid hormone analogs for 
treatment of hypercholesterolemia and heart failure: past, present and future 
prospects. Journal of Molecular and Cellular Cardiology, Vol.37, No.6, (December, 
2004), pp. 1137-1146, ISSN: 0022-2828 
Mukhopadhyay, D.; Plateroti, M., Anant, S.; Nassir, F.; Samarut, J. & Davidson, N.O. 
(2003).Thyroid hormone regulates hepatic triglyceride mobilization and 
apolipoprotein B messenger ribonucleic Acid editing in a murine model of 
congenital hypothyroidism. Endocrinology, Vol.144, No.2, (febrero, 2003), pp. 711-
719, ISSN: 0013-7227 
Müller, M.J.; Köster, H. & Seitz, H.J. (1981). Effect of thyroid state on ketogenic capacity of 
the isolated perfused liver of starved rats. Biochimica Biophysica Acta, Vol.666, No.3, 
(December, 1981), pp. 475-481, ISSN: 0006-3002 
Nikkilä, E.A. & Kekki, M. (1972). Plasma Triglyceride Metabolism in Thyroid Disease. 
Journal of Clinical Investigation, Vol.51, No.8, (August, 1972), pp. 2103-2114, ISSN: 
0021-9738 
Nishida, M., Sasaki, T.; Terada, H. & Kawada, J. (1991). Synergistic and antagonistic effects 
on fatty acid composition in the liver mitochondria of rats by thyroidectomy and 
streptozotocin-administration. Research Communication in Chemical Pathology and 
Pharmacology, Vol.74, No.3, (December, 1991), pp. 317-326, ISSN: 0034-5164 
Nomura, S.; Eimoto, T.; Osawa, G.; Yawata, Y. & Horino, M. (1991). Case report: 
hypothyroidism as a possible cause of an acquired reversible hemolytic anemia. The 
American Journal of Medical Sciences, Vol.302, No.1, (July, 1991), pp. 23-27, ISSN: 
0002-9629  
Oetting, A. & Yen, P.M. (2007). New insights into thyroid hormone action. Best Practice & 
Research.  Clinical Endocrinology and Metabetabolism, Vol.21, No.2, (June, 2007), pp. 
193-208, ISSN: 1521-690X 
Okosieme, O.E. & Lazarus, J.H. (2010). Thyroid dysfunction in pregnancy: optimizing fetal 
and maternal outcomes. Expert Review of Endocrinology and Metabolism, Vol.5, No.4, 
(July, 2010), pp. 521–529, ISSN:  1744-6651 
Omar, S.; Hadj Taeib, S.; Kanoun, F.; Hammami, M.B.; Kamoun, S.; Ben Romdhane, N.; Feki, 
M.; Slimane, H. & Kaabachi N. (2010). Erythrocyte abnormalities in thyroid 
dysfunction. La Tunisie Médicale, Vol.88, No.11, (November, 2010), pp. 783-788, 
ISSN: 0041-4131 
Parrilla, R.J.; Mixson, A.J.;  McPherson, J.A.;  McClaskey, J.H. & Weintraub, B.D. (1991). 
Characterization of seven novel mutations of the c-erbA beta gene in unrelated 
kindreds with generalized thyroid hormone resistance. Evidence for two "hot spot" 
 
Hypothyroidism – Influences and Treatments 
 
30
regions of the ligand binding domain. The Journal of Clinical Investigation, Vol.88, 
No.6, (December, 1991), pp. 2123-2130, ISSN: 0021-9738 
Parrot, M.W.; Johnston, M.E. & Durbin, P.W. (1960). The effects of thyroid and parathyroid 
deficiency on reproduction in the rat. Endocrinology, Vol.67 (October, 1960), pp. 467-
483, ISSN: 0013-7227 
Pearce, E.N.; Wilson, P.W.; Yang, Q.; Vasan, R.S. & Braverman, L.E. (2008). Thyroid function 
and lipid subparticle sizes in patients with short-term hypothyroidism and a 
population-based cohort. Journal of Clinical Endocrinology and Metabolism, Vol.93, 
No.3, (March, 2008), pp. 888-894, ISSN: 0021-972X 
Pekkanen, J.; Linn, S.; Heiss, G.; Suchindran, C.M.; Leon, A.; Rifkind, B.M. & Tyroler,  H.A. 
(1990). Ten-year mortality from cardiovascular disease in relation to cholesterol 
level among men with and without preexisting cardiovascular disease. The New 
England Journal of Medicine, Vol.322, No.24, (June, 1990), pp. 1700-1777, ISSN: 0028-
4793 
Pescarmona, G.P.; Ghigo, D. & Bosia, A. (1983). The molecular basis for increased rigidity of 
the erythrocyte membrane. La Ricerca in Clinical e in Laboratorio, Vol.13, No.3, (1983), 
pp. 141-147, ISSN: 0390-5748 
Pinkney, J.H.; Goodrick, S.J.; Katz, J.R.; Johnson, A.B.; Lightman, S.L.; Coppack, S.W.; 
Medbak, S. & Mohamed-Ali, V. (2000).Thyroid and sympathetic influences on 
plasma leptin in hypothyroidism and hyperthyroidism. International Journal of 
Obesity and Related Metabolic Disorders, Vol.24, No.2, (June, 2000), pp. 165-166, ISSN: 
0307-0565 
Pramfalk, C.; Pedrelli, M. & Parini P. (2011). Role of thyroid receptor β in lipid metabolism. 
Biochimistry Biophysical Acta, Vol.1812, No.8, (August, 2011), pp. 929-937, ISSN: 
0006-3002 
Prasad, R. & Kumar, V. (2005). Thyroid hormones increase Na+-Pi co-transport activity in 
intestinal brush border membrane: role of membrane lipid composition and 
fluidity. Molecular and Cellular Biochemistry, Vol. 278, No.1-2, (October, 2005), pp. 
195-202, ISSN: 0.800-8177 
Prast, J.M. (2009). Effect of treatment with levothyroxine in the lipid profile of the patients 
with subclinical hypothyroidism. Endocrinologia y Nutrición, Vol.56, No.1, (March, 
2009), pp. 13-17, ISSN: 1575-0922 
Quack, M.; Frank, C. & Carlberg, C. ( 2002). Differential nuclear receptor signaling from 
DR4-type response elements. Journal Cell Biochemistry, Vol.86, No.3, (July, 2002), pp. 
601-612, ISSN: 0739-2312 
Quevedo-Corona, L.; Franco-Colin, M.; Caudillo-Romero, M.; Pacheco-Rosado, J.; Zamudio-
Hernandez, S. & Racotta, R. (2000). 3,5,3'-Triiodothyronine administered to rat 
dams during lactation increases milk yield and triglyceride concentration and 
hastens pups growth. Life Sciences, Vol.66, No.21, (April, 2000), pp. 2013-2021, ISSN: 
0024-3205 
Raederstorff, D.; Meier, C.A.; Moser, U. & Walter, P. (1991). Hypothyroidism and thyroxin 
substitution affect the n-3 fatty acid composition of rat liver mitochondria. Lipids, 
Vol.26, No.10, (October, 1991), pp. 781-787, ISSN: 0024-4201 
 
Hypothyroidism on Lipid Metabolism 
 
31 
Radenne, A.; Akpa, M.; Martel, C.; Sawadogo, S.; Mauvoisin, D. & Mounier, C. (2008). 
Hepatic regulation of fatty acid synthase by insulin and T3: evidence for T3 
genomic and nongenomic actions. American Journal of Physiology, Endocrinology and 
Metabolism, Vol.295, No.4, (October, 2008), pp. 884-894, ISSN: 0193-1849 
Ramos, P. & Herrera, E. (1996). Comparative responsiveness to prolonged hyperinsulinemia 
between adipose-tissue and mammary gland lipoprotein lipase activities in 
pregnant rats. Early Pregnancy, Vol.2, No.1, (March, 1996), pp. 29-35, ISSN: 1354-
4195 
Razvi, S.; Ingoe, L.; Keeka, G.; Oates, C.; McMillan, C. & Weaver, J.U. (2007). The beneficial 
effect of L-thyroxine on cardiovascular risk factors, endothelial function, and 
quality of life in subclinical hypothyroidism: randomized, crossover trial. The 
Journal of Clinical Endocrinology and Metabolism, Vol.92, No.5, (May, 2007), pp. 1715-
1723, ISSN: 0021-972X 
Robertson, J.D. & Kirkpatrick, H.F. (1952). Changes in basal metabolism, serumprotein-
bound iodine, and cholesterol during treatment of hypothyroidism with oral 
thyroid and L-thyroxine sodium. British Medical Journal, Vol.1, No.4750, (March, 
1952), pp. 624-628, ISSN: 007-1474 
Roos, A.; Bakker, S.J.; Links, T.P.; Gans, R.O. & Wolffenbuttel, B.H. ( 2007). Thyroid function 
is associated with components of the metabolic syndrome in euthyroid subjects. 
Clinical Endocrinology Metabolis, Vol.92, No2, (February, 2007), pp. 491-496, ISSN: 
0021-972X 
Roscini, A.R.; Lupattelli, G.; Siepi, D.; Pagliaricci, S.; Pirro, M. & Mannarino, E. (1999). Low-
density lipoprotein size in primary hypothyroidism. Effects of hormone 
replacement therapy. Annals of Nutrition and  Metabolism, Vol.43, No.6, (September, 
1999), pp. 374-379, ISSN: 0250-6807 
Ruggiero, F.M.; Gnoni, G.V. & Quagliariello, E. (1987). Effect of hypothyroidism on the lipid 
composition of rat plasma and erythrocyte membranes. Lipids, Vol.22, No.3, 
(March, 1987), pp. 148-151, ISSN: 0024-4201 
Saffari, B.;Ong,J.M. & Kern, P.A.(1992). Regulation of adipose tissue lipoprotein lipase gene 
expression by thyroid hormone in rats. Journal Lipid Research, Vol.33, No.2, 
(February, 1992), pp. 241–249, ISSN: 0022-2275 
Sal'nikova, L.A.; Nikolaeva, L.V. & Lopatina, N.I. (1983). Methemoglobin and catalase 
activity in erythrocytes of children with hypothyroidism. Voprosy Meditsinkoï 
Khimii, Vol.29, No.2, (March-April, 1983), pp. 101-104, ISSN: 0042-8809 
Sawin, C.T.; Bigos, S.T.; Land, S. & Bacharach P. (1985). The aging thyroid. Relationship 
between elevated serum thyrotropin level and thyroid antibodies in elderly 
patients. The American Journal of Medicene, Vol.79, No.5, (November, 1985), pp. 591-
595, ISSN: 0002-9343 
Sawin, C.T.; Castelli,W.P.; Hershman, J.M.; McNamara, P. & Bacharach, P. (1985). The aging 
thyroid: thyroid deficiency in the Framingham study. Archives of Internal Medicine, 
Vol.145, No.8, (August, 1985), pp. 1386-1388, ISSN: 0003-9926 
Serebriakova, O.V.; Govorin, A.V.; Prosianik, V.I. & Baksheeva, E.V. (2008). Fatty acid 
composition of the blood serum and erythrocyte membrane lipids in patients with 
 
Hypothyroidism – Influences and Treatments 
 
30
regions of the ligand binding domain. The Journal of Clinical Investigation, Vol.88, 
No.6, (December, 1991), pp. 2123-2130, ISSN: 0021-9738 
Parrot, M.W.; Johnston, M.E. & Durbin, P.W. (1960). The effects of thyroid and parathyroid 
deficiency on reproduction in the rat. Endocrinology, Vol.67 (October, 1960), pp. 467-
483, ISSN: 0013-7227 
Pearce, E.N.; Wilson, P.W.; Yang, Q.; Vasan, R.S. & Braverman, L.E. (2008). Thyroid function 
and lipid subparticle sizes in patients with short-term hypothyroidism and a 
population-based cohort. Journal of Clinical Endocrinology and Metabolism, Vol.93, 
No.3, (March, 2008), pp. 888-894, ISSN: 0021-972X 
Pekkanen, J.; Linn, S.; Heiss, G.; Suchindran, C.M.; Leon, A.; Rifkind, B.M. & Tyroler,  H.A. 
(1990). Ten-year mortality from cardiovascular disease in relation to cholesterol 
level among men with and without preexisting cardiovascular disease. The New 
England Journal of Medicine, Vol.322, No.24, (June, 1990), pp. 1700-1777, ISSN: 0028-
4793 
Pescarmona, G.P.; Ghigo, D. & Bosia, A. (1983). The molecular basis for increased rigidity of 
the erythrocyte membrane. La Ricerca in Clinical e in Laboratorio, Vol.13, No.3, (1983), 
pp. 141-147, ISSN: 0390-5748 
Pinkney, J.H.; Goodrick, S.J.; Katz, J.R.; Johnson, A.B.; Lightman, S.L.; Coppack, S.W.; 
Medbak, S. & Mohamed-Ali, V. (2000).Thyroid and sympathetic influences on 
plasma leptin in hypothyroidism and hyperthyroidism. International Journal of 
Obesity and Related Metabolic Disorders, Vol.24, No.2, (June, 2000), pp. 165-166, ISSN: 
0307-0565 
Pramfalk, C.; Pedrelli, M. & Parini P. (2011). Role of thyroid receptor β in lipid metabolism. 
Biochimistry Biophysical Acta, Vol.1812, No.8, (August, 2011), pp. 929-937, ISSN: 
0006-3002 
Prasad, R. & Kumar, V. (2005). Thyroid hormones increase Na+-Pi co-transport activity in 
intestinal brush border membrane: role of membrane lipid composition and 
fluidity. Molecular and Cellular Biochemistry, Vol. 278, No.1-2, (October, 2005), pp. 
195-202, ISSN: 0.800-8177 
Prast, J.M. (2009). Effect of treatment with levothyroxine in the lipid profile of the patients 
with subclinical hypothyroidism. Endocrinologia y Nutrición, Vol.56, No.1, (March, 
2009), pp. 13-17, ISSN: 1575-0922 
Quack, M.; Frank, C. & Carlberg, C. ( 2002). Differential nuclear receptor signaling from 
DR4-type response elements. Journal Cell Biochemistry, Vol.86, No.3, (July, 2002), pp. 
601-612, ISSN: 0739-2312 
Quevedo-Corona, L.; Franco-Colin, M.; Caudillo-Romero, M.; Pacheco-Rosado, J.; Zamudio-
Hernandez, S. & Racotta, R. (2000). 3,5,3'-Triiodothyronine administered to rat 
dams during lactation increases milk yield and triglyceride concentration and 
hastens pups growth. Life Sciences, Vol.66, No.21, (April, 2000), pp. 2013-2021, ISSN: 
0024-3205 
Raederstorff, D.; Meier, C.A.; Moser, U. & Walter, P. (1991). Hypothyroidism and thyroxin 
substitution affect the n-3 fatty acid composition of rat liver mitochondria. Lipids, 
Vol.26, No.10, (October, 1991), pp. 781-787, ISSN: 0024-4201 
 
Hypothyroidism on Lipid Metabolism 
 
31 
Radenne, A.; Akpa, M.; Martel, C.; Sawadogo, S.; Mauvoisin, D. & Mounier, C. (2008). 
Hepatic regulation of fatty acid synthase by insulin and T3: evidence for T3 
genomic and nongenomic actions. American Journal of Physiology, Endocrinology and 
Metabolism, Vol.295, No.4, (October, 2008), pp. 884-894, ISSN: 0193-1849 
Ramos, P. & Herrera, E. (1996). Comparative responsiveness to prolonged hyperinsulinemia 
between adipose-tissue and mammary gland lipoprotein lipase activities in 
pregnant rats. Early Pregnancy, Vol.2, No.1, (March, 1996), pp. 29-35, ISSN: 1354-
4195 
Razvi, S.; Ingoe, L.; Keeka, G.; Oates, C.; McMillan, C. & Weaver, J.U. (2007). The beneficial 
effect of L-thyroxine on cardiovascular risk factors, endothelial function, and 
quality of life in subclinical hypothyroidism: randomized, crossover trial. The 
Journal of Clinical Endocrinology and Metabolism, Vol.92, No.5, (May, 2007), pp. 1715-
1723, ISSN: 0021-972X 
Robertson, J.D. & Kirkpatrick, H.F. (1952). Changes in basal metabolism, serumprotein-
bound iodine, and cholesterol during treatment of hypothyroidism with oral 
thyroid and L-thyroxine sodium. British Medical Journal, Vol.1, No.4750, (March, 
1952), pp. 624-628, ISSN: 007-1474 
Roos, A.; Bakker, S.J.; Links, T.P.; Gans, R.O. & Wolffenbuttel, B.H. ( 2007). Thyroid function 
is associated with components of the metabolic syndrome in euthyroid subjects. 
Clinical Endocrinology Metabolis, Vol.92, No2, (February, 2007), pp. 491-496, ISSN: 
0021-972X 
Roscini, A.R.; Lupattelli, G.; Siepi, D.; Pagliaricci, S.; Pirro, M. & Mannarino, E. (1999). Low-
density lipoprotein size in primary hypothyroidism. Effects of hormone 
replacement therapy. Annals of Nutrition and  Metabolism, Vol.43, No.6, (September, 
1999), pp. 374-379, ISSN: 0250-6807 
Ruggiero, F.M.; Gnoni, G.V. & Quagliariello, E. (1987). Effect of hypothyroidism on the lipid 
composition of rat plasma and erythrocyte membranes. Lipids, Vol.22, No.3, 
(March, 1987), pp. 148-151, ISSN: 0024-4201 
Saffari, B.;Ong,J.M. & Kern, P.A.(1992). Regulation of adipose tissue lipoprotein lipase gene 
expression by thyroid hormone in rats. Journal Lipid Research, Vol.33, No.2, 
(February, 1992), pp. 241–249, ISSN: 0022-2275 
Sal'nikova, L.A.; Nikolaeva, L.V. & Lopatina, N.I. (1983). Methemoglobin and catalase 
activity in erythrocytes of children with hypothyroidism. Voprosy Meditsinkoï 
Khimii, Vol.29, No.2, (March-April, 1983), pp. 101-104, ISSN: 0042-8809 
Sawin, C.T.; Bigos, S.T.; Land, S. & Bacharach P. (1985). The aging thyroid. Relationship 
between elevated serum thyrotropin level and thyroid antibodies in elderly 
patients. The American Journal of Medicene, Vol.79, No.5, (November, 1985), pp. 591-
595, ISSN: 0002-9343 
Sawin, C.T.; Castelli,W.P.; Hershman, J.M.; McNamara, P. & Bacharach, P. (1985). The aging 
thyroid: thyroid deficiency in the Framingham study. Archives of Internal Medicine, 
Vol.145, No.8, (August, 1985), pp. 1386-1388, ISSN: 0003-9926 
Serebriakova, O.V.; Govorin, A.V.; Prosianik, V.I. & Baksheeva, E.V. (2008). Fatty acid 
composition of the blood serum and erythrocyte membrane lipids in patients with 
 
Hypothyroidism – Influences and Treatments 
 
32
hypothyroidism and left ventricular diastolic dysfunction. Klinichescaia 
Meditsina,Vol.86, No.2, (2008), pp. 40-43,  ISSN: 0023-2149 
Schröter, W. & Eber, S.W. (1989). Molecular pathology of the erythrocyte membrane. 
Erythrocyte membrane defects as a cause of congenital hemolytic anemia. 
Monatsschr Kinderheilkd, Vol.137, No.7, (July, 1989), pp. 368-379, ISSN: 0026-9298 
Shevtsova, N.M.; Kozlov, I. & Novitskiĭ, V.V. (1994). Mechanism of hematopoietic disorders 
in primary experimental hypothyroidism. Patologichescaia Fiziologiia i  
Ekpserimental’naia Terapiia, Vol.1, (January-March, 1994), pp. 14-16, ISSN: 0031-2991 
Sigal, G.A.; Medeiros-Neto, G.; Vinagre, J.C.; Diament, J. &  Maranhão, R.C. (2011). Lipid 
metabolism in subclinical hypothyroidism: plasma kinetics of triglyceride-rich 
lipoproteins and lipid transfers to high-density lipoprotein before and after 
levothyroxine treatment. Thyroid, Vol.21, No.4, (April, 2011), pp. 347-353, 
ISSN:1050-7256 
Silva, J.E. (2010). Fat and energy economy in hypo- and hyperthyroidism are not the mirror 
image of one another. Endocrinology, Vol.151, No.1, (January, 2010), pp. 4-6, ISSN: 
0013-7227 
Smith, J.L.; Lear, S.R.; Forte, T.M.; Ko, W.; Massimi, M. & Erickson, S.K. (1998). Effect of 
 pregnancy and lactation on lipoprotein and cholesterol metabolism in the rat. 
Journal of Lipid Research, Vol.39, No.11, (November, 1998), pp. 2237-2249, ISSN: 
0022-2275 
Staels, B.; Van Tol, A.; Chan, L.; Will, H.; Verhoeven, G. & Auwerx, J. (1990). Alterations in 
thyroid status modulate apolipoprotein, hepatic triglyceride lipase, and low 
density lipoprotein receptor in rats. Endocrinology, Vol.127, No.3, (September, 1990), 
pp. 1144-1152, ISSN: 0013-7227 
Stockigt, J.R. (2002). Case finding and screening strategies for thyroid dysfunction. Clinica 
Chimica Acta, Vol.315, No. 1-2, (January, 2002), pp.111-124, ISSN: 0009-8981 
Tagami, T.; Tamanaha, T.; Shimazu, S.; Honda, K.; Nanba, K.; Nomura, H.; Yoriko, S.U.; 
Usui, T.; Shimatsu A. & Naruse, M. (2010). Lipid profiles in the untreated patients 
with Hashimoto thyroiditis and the effects of thyroxine treatment on subclinical 
hypothyroidism with Hashimoto thyroiditis. Endocrine Journal, Vol.57, No.3, 
(December,  2010), pp. 253-258, ISSN: 0918-8959 
Tancevski, I.; Eller, P. ; Patsch, J.R. & Ritsch, A. (2009). The resurgence of thyromimetics as 
lipid-modifying agents. Current Opinion in Investigational Drugs, Vol.10, No.9, 
(September, 2009), pp. 912-918, ISSN: 1472-4472 
Talukdar, S. & Hillgartner, F.B. (2006).The mechanism mediating the activation of acetyl-
coenzyme A carboxylase-alpha gene transcription by the liver X receptor agonist 
T0-901317. Journal Research, Vol.47, No.11, ( November, 2006), pp. 2451-2461, ISSN: 
0022-2275. 
Tarling, E.; Salter, A. & Bennett, A. (2004).Transcriptional regulation of human SREBP-1c 
(sterol-regulatory-element-binding protein-1c): a key regulator of lipogenesis. 
Biochemical Society Transaction, Vol.32, No.1, (February, 2004), pp. 107-109, ISSN: 
0300-5127 
Teixeira, P.F.; Cabral, M.D.; Silva, N.A.; Soares, D.V.; Braulio, V.B.; Couto, A.P.; Henriques, 
J.L.; Costa, A.J.; Buescu, A & Vaisman, M. (2009). Serum leptin in overt and 
 
Hypothyroidism on Lipid Metabolism 
 
33 
subclinical hypothyroidism: effect of levothyroxine treatment and relationship to 
menopausal status and body composition. Thyroid, Vol.19, No.5, (May, 2009), pp. 
443-50, ISSN: 1050-7256 
Trost, S.U.; Swanson, E.; Gloss, B.; Wang-Iverson, D.B.; Zhang, H.; Volodarsky, T.; Grover, 
G.J.; Baxter, J.D.; Chiellini, G.; Scanlan,T.S.; et al. (2000) .The thyroid hormone 
receptor-beta-selective agonist GC-1 differentially affects plasma lipids and cardiac 
activity. Endocrinology. Vol.141, No.9, (September, 2000), pp. 3057-3064, ISSN: 0013-
7227 
Toplan, S.; Dariyerli, N.; Ozdemir, S.; Akyolcu, M.C.; Hatemi, H. & Yigit, G. (2005). The 
effects of experimental hypothyroidism on hemorheology and plasma fibrinogen 
concentration. Endocrine, Vol.28, No.2, (November, 2005), pp. 153-156, ISSN: 1355-
008X 
Tulloch, B.R. (1974). Lipid Changes in Thyroid Disease: The Effect of Thyroxine and 
Analogues. Proceeding of the Royal Society of Medice, Vol.67, No.7, (July, 1974), pp. 
670-671, ISSN: 0035-9157 
Tzotzas, T.; Krassas, G.E.; Konstantinidis, T. & Bougoulia, M. (2000). Changes in 
lipoprotein(a) levels in overt and subclinical hypothyroidism before and during 
treatment. Thyroid, Vol.10, No.9, (September, 2000), pp. 803-808, ISSN: 1050-7256 
Valeix, P.; Dos Santos, C.; Castetbon, K.; Bertrais, S.; Cousty, C. & Hercberg, S. (2004). 
Thyroid hormone levels and thyroid dysfunction of French adults participating in 
the SU.VI.MAX study.Annales d´Endocrinologie, Vol.65, No.6, (December, 2004), pp. 
477-486, ISSN: 003-4266 
Vanderpump, M.P.; Tunbridge, W.M.; French, J.M. & et al. (1995). The incidence of 
thyroid disorders in the community: a twenty-year follow-up of the Whickham 
Survey.Clinical Endocrinology, Vol.43, No.1, (July, 1995), pp. 55-68, ISSN: 0300-
0664 
van Doormaal, J.J.; Muskiet, F.A.; Jansen, G.; Wolthers, B.G.; Sluiter, W.J. & Doorenbos, H. 
(1986). Increase of plasma and red cell cholesterol sulfate levels in induced 
hypothyroidism in man. Clinica Chimica Acta, Vol.155, No.3, (March, 1986), pp. 195-
200, ISSN: 0009-8981 
Wang, H. & Eckel, R.H. (2009).Lipoprotein lipase: from gene to obesity. American Journal 
Physiology Endocrinology Metabolism, Vol.297, No.2, (August, 2009), pp. 271-288, 
ISSN: 0193-1849  
Wardrop, C.A. & Hutchison, H.E. (1969). Red cell shape in hypothyroidism. Lancet, Vol.1, 
No.7608, (June, 1969), pp. 1243. ISSN: 0140-6736 
Woeber, K.A. (1997). Subclinical thyroid dysfunction. Archives of Internal Medicene, Vol.157, 
No.10, (May, 1997), pp. 1065-1068,  ISSN: 0003-9926 
Ying, H.; Araki, O.; Furuya, F.; Kato, Y. & Cheng, S.Y. (2007). Impaired adipogenesis caused 
by a mutated thyroid hormone alpha 1 receptor. Molecular and Cellular  Biology, 
Vol.27, No.6, (March, 2007), pp. 2359–2371, ISSN: 0270-7306 
Zandieh-Doulabi, B.; Platvoet-ter Schiphorst, M.; Kalsbeek, A.; Wiersinga, W.M. & Bakker, 
O. (2004). Hyper and hypothyroidism change the expression and diurnal variation 
of thyroid hormone receptor isoforms in rat liver without major changes in their 
 
Hypothyroidism – Influences and Treatments 
 
32
hypothyroidism and left ventricular diastolic dysfunction. Klinichescaia 
Meditsina,Vol.86, No.2, (2008), pp. 40-43,  ISSN: 0023-2149 
Schröter, W. & Eber, S.W. (1989). Molecular pathology of the erythrocyte membrane. 
Erythrocyte membrane defects as a cause of congenital hemolytic anemia. 
Monatsschr Kinderheilkd, Vol.137, No.7, (July, 1989), pp. 368-379, ISSN: 0026-9298 
Shevtsova, N.M.; Kozlov, I. & Novitskiĭ, V.V. (1994). Mechanism of hematopoietic disorders 
in primary experimental hypothyroidism. Patologichescaia Fiziologiia i  
Ekpserimental’naia Terapiia, Vol.1, (January-March, 1994), pp. 14-16, ISSN: 0031-2991 
Sigal, G.A.; Medeiros-Neto, G.; Vinagre, J.C.; Diament, J. &  Maranhão, R.C. (2011). Lipid 
metabolism in subclinical hypothyroidism: plasma kinetics of triglyceride-rich 
lipoproteins and lipid transfers to high-density lipoprotein before and after 
levothyroxine treatment. Thyroid, Vol.21, No.4, (April, 2011), pp. 347-353, 
ISSN:1050-7256 
Silva, J.E. (2010). Fat and energy economy in hypo- and hyperthyroidism are not the mirror 
image of one another. Endocrinology, Vol.151, No.1, (January, 2010), pp. 4-6, ISSN: 
0013-7227 
Smith, J.L.; Lear, S.R.; Forte, T.M.; Ko, W.; Massimi, M. & Erickson, S.K. (1998). Effect of 
 pregnancy and lactation on lipoprotein and cholesterol metabolism in the rat. 
Journal of Lipid Research, Vol.39, No.11, (November, 1998), pp. 2237-2249, ISSN: 
0022-2275 
Staels, B.; Van Tol, A.; Chan, L.; Will, H.; Verhoeven, G. & Auwerx, J. (1990). Alterations in 
thyroid status modulate apolipoprotein, hepatic triglyceride lipase, and low 
density lipoprotein receptor in rats. Endocrinology, Vol.127, No.3, (September, 1990), 
pp. 1144-1152, ISSN: 0013-7227 
Stockigt, J.R. (2002). Case finding and screening strategies for thyroid dysfunction. Clinica 
Chimica Acta, Vol.315, No. 1-2, (January, 2002), pp.111-124, ISSN: 0009-8981 
Tagami, T.; Tamanaha, T.; Shimazu, S.; Honda, K.; Nanba, K.; Nomura, H.; Yoriko, S.U.; 
Usui, T.; Shimatsu A. & Naruse, M. (2010). Lipid profiles in the untreated patients 
with Hashimoto thyroiditis and the effects of thyroxine treatment on subclinical 
hypothyroidism with Hashimoto thyroiditis. Endocrine Journal, Vol.57, No.3, 
(December,  2010), pp. 253-258, ISSN: 0918-8959 
Tancevski, I.; Eller, P. ; Patsch, J.R. & Ritsch, A. (2009). The resurgence of thyromimetics as 
lipid-modifying agents. Current Opinion in Investigational Drugs, Vol.10, No.9, 
(September, 2009), pp. 912-918, ISSN: 1472-4472 
Talukdar, S. & Hillgartner, F.B. (2006).The mechanism mediating the activation of acetyl-
coenzyme A carboxylase-alpha gene transcription by the liver X receptor agonist 
T0-901317. Journal Research, Vol.47, No.11, ( November, 2006), pp. 2451-2461, ISSN: 
0022-2275. 
Tarling, E.; Salter, A. & Bennett, A. (2004).Transcriptional regulation of human SREBP-1c 
(sterol-regulatory-element-binding protein-1c): a key regulator of lipogenesis. 
Biochemical Society Transaction, Vol.32, No.1, (February, 2004), pp. 107-109, ISSN: 
0300-5127 
Teixeira, P.F.; Cabral, M.D.; Silva, N.A.; Soares, D.V.; Braulio, V.B.; Couto, A.P.; Henriques, 
J.L.; Costa, A.J.; Buescu, A & Vaisman, M. (2009). Serum leptin in overt and 
 
Hypothyroidism on Lipid Metabolism 
 
33 
subclinical hypothyroidism: effect of levothyroxine treatment and relationship to 
menopausal status and body composition. Thyroid, Vol.19, No.5, (May, 2009), pp. 
443-50, ISSN: 1050-7256 
Trost, S.U.; Swanson, E.; Gloss, B.; Wang-Iverson, D.B.; Zhang, H.; Volodarsky, T.; Grover, 
G.J.; Baxter, J.D.; Chiellini, G.; Scanlan,T.S.; et al. (2000) .The thyroid hormone 
receptor-beta-selective agonist GC-1 differentially affects plasma lipids and cardiac 
activity. Endocrinology. Vol.141, No.9, (September, 2000), pp. 3057-3064, ISSN: 0013-
7227 
Toplan, S.; Dariyerli, N.; Ozdemir, S.; Akyolcu, M.C.; Hatemi, H. & Yigit, G. (2005). The 
effects of experimental hypothyroidism on hemorheology and plasma fibrinogen 
concentration. Endocrine, Vol.28, No.2, (November, 2005), pp. 153-156, ISSN: 1355-
008X 
Tulloch, B.R. (1974). Lipid Changes in Thyroid Disease: The Effect of Thyroxine and 
Analogues. Proceeding of the Royal Society of Medice, Vol.67, No.7, (July, 1974), pp. 
670-671, ISSN: 0035-9157 
Tzotzas, T.; Krassas, G.E.; Konstantinidis, T. & Bougoulia, M. (2000). Changes in 
lipoprotein(a) levels in overt and subclinical hypothyroidism before and during 
treatment. Thyroid, Vol.10, No.9, (September, 2000), pp. 803-808, ISSN: 1050-7256 
Valeix, P.; Dos Santos, C.; Castetbon, K.; Bertrais, S.; Cousty, C. & Hercberg, S. (2004). 
Thyroid hormone levels and thyroid dysfunction of French adults participating in 
the SU.VI.MAX study.Annales d´Endocrinologie, Vol.65, No.6, (December, 2004), pp. 
477-486, ISSN: 003-4266 
Vanderpump, M.P.; Tunbridge, W.M.; French, J.M. & et al. (1995). The incidence of 
thyroid disorders in the community: a twenty-year follow-up of the Whickham 
Survey.Clinical Endocrinology, Vol.43, No.1, (July, 1995), pp. 55-68, ISSN: 0300-
0664 
van Doormaal, J.J.; Muskiet, F.A.; Jansen, G.; Wolthers, B.G.; Sluiter, W.J. & Doorenbos, H. 
(1986). Increase of plasma and red cell cholesterol sulfate levels in induced 
hypothyroidism in man. Clinica Chimica Acta, Vol.155, No.3, (March, 1986), pp. 195-
200, ISSN: 0009-8981 
Wang, H. & Eckel, R.H. (2009).Lipoprotein lipase: from gene to obesity. American Journal 
Physiology Endocrinology Metabolism, Vol.297, No.2, (August, 2009), pp. 271-288, 
ISSN: 0193-1849  
Wardrop, C.A. & Hutchison, H.E. (1969). Red cell shape in hypothyroidism. Lancet, Vol.1, 
No.7608, (June, 1969), pp. 1243. ISSN: 0140-6736 
Woeber, K.A. (1997). Subclinical thyroid dysfunction. Archives of Internal Medicene, Vol.157, 
No.10, (May, 1997), pp. 1065-1068,  ISSN: 0003-9926 
Ying, H.; Araki, O.; Furuya, F.; Kato, Y. & Cheng, S.Y. (2007). Impaired adipogenesis caused 
by a mutated thyroid hormone alpha 1 receptor. Molecular and Cellular  Biology, 
Vol.27, No.6, (March, 2007), pp. 2359–2371, ISSN: 0270-7306 
Zandieh-Doulabi, B.; Platvoet-ter Schiphorst, M.; Kalsbeek, A.; Wiersinga, W.M. & Bakker, 
O. (2004). Hyper and hypothyroidism change the expression and diurnal variation 
of thyroid hormone receptor isoforms in rat liver without major changes in their 
 
Hypothyroidism – Influences and Treatments 
 
34
zonal distribution. Molecular Cellular Endocrinology, Vol.219, No.1-2, (April, 2004), 
pp. 69-75, ISSN:0300-8177. 
Zhu, X. & Cheng, S.Y. (2010). New insights into regulation of lipid metabolism by thyroid 
hormone. Current  Opinion in Endocrinology, Diabetes and Obesity, Vol.17, No.5, 
(October, 2010), pp. 408-413, ISSN: 1752-296X 
Zhu, X.G.; Kim, D.W.; Goodson, M.L.; Privalsky, M.L. & Cheng, S.Y. (2011). NCoR1 
regulates thyroid hormone receptor isoform-dependent adipogenesis. Journal of 
Molecular Endocrinology, Vol.46, No.3, (June, 2011), pp. 233-244, ISSN: 0952-5041 
2 
Hypothyroidism After Hemithyroidectomy: 
Incidence, Risk Factors, Natural  
History and Management 
Jandee Lee and Woong Youn Chung  
Department of Surgery,Yonsei Univeristy College of Medicine 
South Korea 
1. Introduction  
Thyroid lobectomy or hemithyroidectomy is considered an adequate treatment for several 
thyroid diseases such as large benign nodules, follicular neoplasm, and some suspected 
malignancies. Thyroid lobectomy theoretically preserves sufficient functioning native 
thyroid tissue for patients to keep euthyroid status postoperatively without the need for 
thyroid hormone replacement. Still, it is known that some patients who have undergone 
hemithyroidectomy will require thyroid hormone replacement because they have developed 
hypothyroidism, which is commonly diagnosed as a result of elevated levels of thyroid-
stimulating hormone (TSH). Currently, the incidence and risk of hypothyroidism in patients 
undergoing partial thyroidectomy remains unclear. Several studies about thyroid function 
after hemithyroidectomy for benign thyroid disease have been published. The reported 
incidence of hypothyroidism ranges from 5% to 49%, with most between 15-30%. The 
incidence rates vary widely depending on the follow-up period and on how 
hypothyroidism is defined by authors. These variations have led to our interest in defining 
uniform criteria for diagnosis and treatment of postoperative hypothyroidism, thereby 
identifying patients at the greatest risk of requiring long-term thyroid hormone 
replacement.  
Hypothyroidism after hemithyroidectomy remains an unpredictable complication. Several 
results have pointed to the degree of lymphocytic infiltration within the thyroid gland and 
the amount of thyroid remnant as possible predictors of hypothyroidism. Other reports 
about risk factors for hypothyroidism have indicated links to the preoperative TSH level, 
anti-TPO antibodies, multinodular goiter, and preoperative thyrotoxicosis. However, 
definite risk factors for development of hypothyroidism after hemithyroidectomy have yet 
to be completely characterized. 
Patients with symptomatic hypothyroidism such as weight gain, fatigue, generalized edema, 
muscle pain and lethargy warrant treatment, as do patients with mild disease and medical 
comorbidities. Of late, some authors have advocated thyroxine replacement for all patients 
undergoing hemithyroidectomy to prevent progression of multi-nodular changes in the 
contralateral lobe, but others have asserted that it should not be necessary to prescribe 
thyroxine replacement for all patients. Patients who develop chronic hypothyroidism after 
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hemithyroidectomy may require life-long thyroxine replacement, as well as routine laboratory 
tests. The side effects of long-term thyroid hormone replacement have included arrhythmias, 
osteopenia, changes of lipid metabolism, and mood changes. Early diagnosis of the subclinical 
state, followed by treatment of symptomatic hypothyroidism should be priorities.  
The risk of postoperative hypothyroidism after thyroid lobectomy is not negligible and 
should not be overlooked. Careful monitoring for patients who may develop 
hypothyroidism will improve patient care. At present, there is no universal algorithm for 
monitoring postoperative residual thyroid function in patients who have undergone 
hemithyroidectomy. In most patients, the follow-up is dependent on the discretion of the 
physician in charge based on clinical suspicion or the development of definite symptoms. 
From a practical viewpoint, only select patients at risk of developing hypothyroidism after 
partial thyroidectomy have been followed on a regular schedule.  
In this chapter, we evaluate the incidence, natural history, and risk factors for 
hypothyroidism in patients undergoing thyroid lobectomy, and we review postoperative 
thyroid hormone replacement. We also aim to clarify a uniform monitoring and follow-up 
protocol for patients after hemithyroidectomy.  
2. Hypothyroidism after hemithyroidectomy 
2.1 Definition of hypothyroidism 
Thyroid hormones are essential regulators of metabolism and transport, and thyroid 
hormone deficiencies of any cause result in hypothyroidism. Hypothyroidism may be 
primary, i.e., resulting from a defect in the thyroid gland itself, or secondary, i.e., resulting 
from a TSH deficiency related to pituitary or hypothalamic disease. Although there is no 
universally accepted definition of normal thyroid function, thyroid function assays have 
indicated that a TSH concentration of 4.5 uIU/L is the upper limit of normal (Surks et al., 
2004; Hollowell et al., 2002). 
Thyroid hormone deficiency affects nearly all organs and functions in the human body 
(Laurberg et al., 2005). The changes induced by hypothyroidism include the slowing and 
lowering of processes, which may mimic the alterations associated with aging. Symptoms 
and signs of hypothyroidism differ according to the severity and duration of the thyroid 
deficiency, the age of the patient, and the occurrence of other systemic diseases. Early 
symptoms of hypothyroidism are often nonspecific and insidious in onset and can include 
fatigue, lethargy, constipation, cold intolerance, muscle stiffness and cramping, carpal 
tunnel syndrome, decreased libido, depression, hair loss, menstrual irregularity, 
menorrhagia, and infertility. With little functional thyroid reserve, the severity of 
hypothyroidism can progress to a clinical picture of myxedema. At this stage, patients 
appear bored, depressed, and hypokinetic, with a hoarse voice, dull, expressionless faces, 
sparse hair, and a large tongue. The skin is cool to the touch, dry, and rough, with facial and 
periorbital puffiness and often generalized edema. Fluid may collect in various parts of the 
body, and pleural effusion, pericardial effusion, and ascites are common. On physical 
examination or chest X-ray, the cardiac silhouette may appear enlarged, due to chamber 
dilatation or pericardial effusion. Constipation is common, due to slowed gastrointestinal 
motility, and a dynamic ileus may cause megacolon or intestinal obstruction. A psychiatric 
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syndrome (“myxedema madness”) has been described, and neurologic findings include a 
delayed or hung-up relaxation phase of deep tendon reflexes, muscle weakness, and ataxia 
(Wartofsky et al., 2006).  
Hypothyroidism can be classified as subclinical or overt (clinical), with the latter defined as 
abnormal serum TSH and free T4 concentrations, or as the development of hypothyroidism 
symptoms. Subclinical hypothyroidism is a mild degree of biochemical abnormality, 
characterized by increased serum TSH and T4 estimates within the laboratory reference 
range (Wartofsky et al., 2006). Although the cause and clinical abnormalities observed in 
individuals with subclinical hypothyroidism do not differ from those with overt 
hypothyroidism, including high TSH and low T4 concentrations, the former is milder. Either 
form of hypothyroidism, however, is a potential consequence of hemithyroidectomy and 
has a substantial impact on postoperative patient outcomes and quality of life. 
Hypothyroidism occurring soon after thyroid surgery or radioiodine therapy may 
normalize spontaneously after some months. In these patients, partial substitution therapy 
or control for some months before therapy is appropriate. This chapter focuses only on overt 
or subclinical hypothyroidism following hemithyroidectomy. 
2.2 Incidence 
Hemithyroidectomy, defined as the complete removal of the unilateral lobe, isthmus and 
where present, the pyramidal lobe of the thyroid, is a relatively common procedure for a 
variety of thyroid pathologies. Hemithyroidectomy is commonly indicated for patients with 
large benign tumors causing compressive symptoms or cosmetic concerns, as well as for 
toxic nodules. It is also indicated for patients with follicular lesions classified as 
“indeterminate” thyroid nodules to exclude thyroid carcinoma, as long as these nodules do 
not show any clinical features of malignancy other than in fine needle aspiration cytology 
(FNAC) results. Thyroid lobectomy is performed in patients with indeterminate nodules 
because 20-30% of nodules harbor thyroid malignancy. Hemithyroidectomy and central 
compartment lymph node dissection (CCND) are also usually performed on patients in 
Korea and Japan with papillary thyroid microcarcinoma (PTMC) (Tomoda et al., 2011). The 
worldwide incidence of PTMC has increased significantly, probably due to more frequent 
use of thyroid ultrasonography (US) as an essential part of initial health examinations. 
Although total thyroidectomy is the most common standard operation for thyroid cancers, 
hemithyroidectomy rather than total thyroidectomy may be preferred for low risk patients 
with PTMC to eliminate the risks of permanent hypocalcemia and bilateral recurrent and 
superior laryngeal nerve palsy associated with total thyroidectomy. In addition, 
hemithyroidectomy theoretically leaves sufficient functioning native thyroid tissue for the 
patient to remain euthyroid without the need for thyroid hormone replacement.  
Several studies have evaluated thyroid function after hemithyroidectomy for benign thyroid 
disease. The reported incidence of hypothyroidism after hemithyroidectomy has been found 
to vary from 5.0% to 49%, with most studies reporting a range of 15-30% (Wormald et al., 
2008; Chu et al., 2011; Su et al, 2009; Spanheimer et al, 2011). This disparity in results is 
partially due to differences in their definition of hypothyroidism and to differences in length 
of follow-up. Hypothyroidism, both clinical and subclinical, is a potential consequence of 
hemithyroidectomy and has been associated with a number of adverse clinical outcomes. 
However, hypothyroidism after hemithyroidectomy is an under-reported or under-
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recognized complication, with patients most often monitored only for a short time 














(overt or subclinical) (%) 
McHenry, et al. 
(2000) 71 




Total: 25/71 (35%) 
(Overt: 9/71 (12.7%) 
Subclinical: 16/71 (22.5%)) 
Miller, et al. 
(2006) 90 





Total: 24/90 (27%) 
 
Seiberling, et al. 
(2007) 58 
At least 6 weeks 
after surgery 
Serum 
TSH>4.0μIU/ml Total: 14/58 (24.1%) 
Koh, et al. 
(2008) 136 




Total: 58/136 (42.6%) 
(Overt: 11/136 (8.1%) 
Subclinical: 47/136 
(34.6%)) 
Wormald, et al. 
(2008) 82 




Total: 15/82 (18.3%) 
Overt: 5/82 (6.1%) 
Subclinical: 10/82(12.2%) 
Moon, et al. 
(2008) 101 
2 months, and 
every 2-3 months 
(more than 1 year) 
after surgery 
Serum 
TSH>4.7μIU/L Total: 37/101 (36.6%) 
De Carlucci Jr,  
et al. 
(2008) 
168 4 to 8 weeks after surgery 
Serum 
TSH>5.5mU/L Total: 61/186 (32.8%) 
Su, et al. 
(2009) 294 
At least 3 months 
after surgery 
Serum 
TSH>4.0mIU/L Total: 32/294 (10.9%) 
Stoll, et al. 
(2009) 547 
6 to 8 weeks after 
surgery 
Serum 




71 6 weeks after surgery 
Serum 
TSH>4.20μIU/mL Total: 24/71 (33.8%) 
Tomoda, et al. 
(2011) 233 
At least 4-6 weeks, 
and 3 months after 
surgery 
Serum 
TSH>5.0mIU/l Total: 57/233 (24.4%) 
Johner, et al. 
(2011) 117 
6 weeks(or 3 
months), 6 months 







Chu, et al. 
(2011) 263 
2 weeks, 3 months, 
6 months, and 
yearly after surgery 
Serum 
TSH>5.5mIU/L Total: 38/263 (14.4%) 
Table 1. Incidence of posthemithyroidectomy hypothyroidism 
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Recently, however, Johner et al (2011) reported that the overall incidence of early 
postoperative hypothyroidism was 21.6%, with the incidence of permanent hypothyroidism 
only 7.8%. In addition to showing that the incidence of hypothyroidism following 
hemithyroidectomy is low, this study showed that a significant proportion of individuals 
who become biochemically hypothyroid (asymptomatic) demonstrate only a transient 
elevation in their TSH levels. The low incidence of sustained hypothyroidism supports the 
adoption of a watch-and-wait approach in patients with biochemical hypothyroidism after 
hemithyroidectomy. Previously, it was common practice to prescribe suppressive doses of 
thyroxine after hemithyroidectomy, but it is now thought that  the remaining thyroid lobe 
may compensate. Since the pituitary-thyroid axis must adapt after hemithyroidectomy, 
serial TSH measurements after surgery will identify only those individuals who remain 
biochemically hypothyroid or become symptomatic and therefore require treatment with 
thyroid hormone. This will spare a significant number of patients the need for, and potential 
risks of, long-term thyroid hormone replacement therapy.  
2.3 Natural history 
TSH is important for pathologic thyroid growth, and elevated serum TSH may contribute to 
the development of recurrent nodular or diffuse thyroid enlargement. The efficacy of 
administering TSH-suppressive doses of thyroxine to prevent thyroid nodule recurrence 
after surgery has not been determined. Most studies that reported a beneficial effect of 
suppressive therapy in reducing recurrent nodular thyroid disease after thyroidectomy have 
been from areas of iodine deficiency, whereas most studies that found no benefit of 
suppressive therapy have been from iodine-sufficient areas (McHenry & Slusarczyk, 2000).  
Hypothyroidism is now one of the most common morbidities observed after 
hemithyroidectomy. Most patients will continue to have normal thyroid function after 
hemithyroidectomy, although some will have mildly elevated TSH during the perioperative 
period that may normalize without pharmacologic intervention due to compensation by the 
remaining thyroid lobe. This may be characterized by both an increase in serum TSH 
concentration and an augmented release of TSH in response to TRH signaling (Lombardi et 
al, 1983) (Campion et al., 1995), adaptive mechanisms that may persist for 12-18 months 
after surgery. Animal experiments have shown that serum TSH concentration declines 
initially, subsequently returning to normal with compensatory hypertrophy of the 
remaining thyroid lobe followed by a significant elevation in serum TSH for as long as 5 
months after surgery (Clark et al., 1976). Compensatory hypertrophy of the remaining 
thyroid lobe has been observed histologically following hemithyroidectomy (Marine et al., 
1926).  
Some patients with symptomatic hypothyroidism require treatment, as do patients with 
mild hypothyroidism and medical comorbidities. The physiological and clinical signs of 
hypothyroidism are generally completely reversed by appropriate thyroid hormone 
replacement treatment. Some physicians therefore advocate thyroxine replacement to 
prevent progression of multinodular changes in the contralateral lobe, whereas others 
prescribe thyroxine replacement for all patients after hemithyroidectomy. The possibility of 
compensatory hypertrophy of the residual lobe should be balanced by the need for close 
follow-up of patients with borderline thyroid reserves, and the potential for deterioration at 
times of physiological stress and progression of underlying thyroiditis. Routine thyroxine 
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recognized complication, with patients most often monitored only for a short time 
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(Overt: 9/71 (12.7%) 
Subclinical: 16/71 (22.5%)) 
Miller, et al. 
(2006) 90 





Total: 24/90 (27%) 
 
Seiberling, et al. 
(2007) 58 
At least 6 weeks 
after surgery 
Serum 
TSH>4.0μIU/ml Total: 14/58 (24.1%) 
Koh, et al. 
(2008) 136 




Total: 58/136 (42.6%) 
(Overt: 11/136 (8.1%) 
Subclinical: 47/136 
(34.6%)) 
Wormald, et al. 
(2008) 82 




Total: 15/82 (18.3%) 
Overt: 5/82 (6.1%) 
Subclinical: 10/82(12.2%) 
Moon, et al. 
(2008) 101 
2 months, and 
every 2-3 months 
(more than 1 year) 
after surgery 
Serum 
TSH>4.7μIU/L Total: 37/101 (36.6%) 
De Carlucci Jr,  
et al. 
(2008) 
168 4 to 8 weeks after surgery 
Serum 
TSH>5.5mU/L Total: 61/186 (32.8%) 
Su, et al. 
(2009) 294 
At least 3 months 
after surgery 
Serum 
TSH>4.0mIU/L Total: 32/294 (10.9%) 
Stoll, et al. 
(2009) 547 
6 to 8 weeks after 
surgery 
Serum 




71 6 weeks after surgery 
Serum 
TSH>4.20μIU/mL Total: 24/71 (33.8%) 
Tomoda, et al. 
(2011) 233 
At least 4-6 weeks, 
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TSH>5.0mIU/l Total: 57/233 (24.4%) 
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(2011) 117 
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6 months, and 
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TSH>5.5mIU/L Total: 38/263 (14.4%) 
Table 1. Incidence of posthemithyroidectomy hypothyroidism 
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Recently, however, Johner et al (2011) reported that the overall incidence of early 
postoperative hypothyroidism was 21.6%, with the incidence of permanent hypothyroidism 
only 7.8%. In addition to showing that the incidence of hypothyroidism following 
hemithyroidectomy is low, this study showed that a significant proportion of individuals 
who become biochemically hypothyroid (asymptomatic) demonstrate only a transient 
elevation in their TSH levels. The low incidence of sustained hypothyroidism supports the 
adoption of a watch-and-wait approach in patients with biochemical hypothyroidism after 
hemithyroidectomy. Previously, it was common practice to prescribe suppressive doses of 
thyroxine after hemithyroidectomy, but it is now thought that  the remaining thyroid lobe 
may compensate. Since the pituitary-thyroid axis must adapt after hemithyroidectomy, 
serial TSH measurements after surgery will identify only those individuals who remain 
biochemically hypothyroid or become symptomatic and therefore require treatment with 
thyroid hormone. This will spare a significant number of patients the need for, and potential 
risks of, long-term thyroid hormone replacement therapy.  
2.3 Natural history 
TSH is important for pathologic thyroid growth, and elevated serum TSH may contribute to 
the development of recurrent nodular or diffuse thyroid enlargement. The efficacy of 
administering TSH-suppressive doses of thyroxine to prevent thyroid nodule recurrence 
after surgery has not been determined. Most studies that reported a beneficial effect of 
suppressive therapy in reducing recurrent nodular thyroid disease after thyroidectomy have 
been from areas of iodine deficiency, whereas most studies that found no benefit of 
suppressive therapy have been from iodine-sufficient areas (McHenry & Slusarczyk, 2000).  
Hypothyroidism is now one of the most common morbidities observed after 
hemithyroidectomy. Most patients will continue to have normal thyroid function after 
hemithyroidectomy, although some will have mildly elevated TSH during the perioperative 
period that may normalize without pharmacologic intervention due to compensation by the 
remaining thyroid lobe. This may be characterized by both an increase in serum TSH 
concentration and an augmented release of TSH in response to TRH signaling (Lombardi et 
al, 1983) (Campion et al., 1995), adaptive mechanisms that may persist for 12-18 months 
after surgery. Animal experiments have shown that serum TSH concentration declines 
initially, subsequently returning to normal with compensatory hypertrophy of the 
remaining thyroid lobe followed by a significant elevation in serum TSH for as long as 5 
months after surgery (Clark et al., 1976). Compensatory hypertrophy of the remaining 
thyroid lobe has been observed histologically following hemithyroidectomy (Marine et al., 
1926).  
Some patients with symptomatic hypothyroidism require treatment, as do patients with 
mild hypothyroidism and medical comorbidities. The physiological and clinical signs of 
hypothyroidism are generally completely reversed by appropriate thyroid hormone 
replacement treatment. Some physicians therefore advocate thyroxine replacement to 
prevent progression of multinodular changes in the contralateral lobe, whereas others 
prescribe thyroxine replacement for all patients after hemithyroidectomy. The possibility of 
compensatory hypertrophy of the residual lobe should be balanced by the need for close 
follow-up of patients with borderline thyroid reserves, and the potential for deterioration at 
times of physiological stress and progression of underlying thyroiditis. Routine thyroxine 
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replacement may be recommended, rather than close follow-up monitoring, for some post-
hemithyroidectomy patients with risk factors, such as elevated thyroid antibody 
concentrations or histologic evidence of autoimmune thyroiditis (Su et al., 2009). In contrast, 
other researchers have reported that elevated serum TSH concentration alone may not 
justify the initiation of thyroid hormone replacement, since nearly 70% of individuals who 
developed biochemical (asymptomatic) hypothyroidism during the early postoperative 
period after hemithyroidectomy recovered normal thyroid function without pharmacologic 
intervention (Johner et al., 2011). Therefore, determination of the true indication is important 
prior to initiating thyroid hormone replacement therapy. 
A small number of patients who develop hypothyroidism after thyroid lobectomy require 
life-long thyroid hormone replacement, as well as routine laboratory examinations and 
medical adjustments. Furthermore, chronic thyroxine therapy may be associated with 
adverse effects, including arrhythmias (atrial fibrillation) or loss of calcium from the bones 
resulting in osteopenia or osteoporosis. High serum cholesterol concentrations may result in 
cardiac sclerosis with all its complications, suggesting that hormone replacement therapy be 
delayed. Thus, an increased ability to recognize which patients are most at risk for 
developing hypothyroidism will improve patient care. Although closer monitoring or earlier 
initiation of thyroid hormone replacement therapy may be advisable for these high-risk 
patients, no specific TSH concentration alone is indicative of increased risk of permanent or 
overt hypothyroidism, suggesting that transient biochemical hypothyroidism be closely 
monitored rather than routinely treated. Accurate detection and diagnosis of sustained 
hypothyroidism after thyroid surgery is also important to avoid its associated morbidity 
and mortality (Johner et al., 2011). 
2.4 Risk factors 
Among the factors found to predict hypothyroidism after hemithyroidectomy are patient 
age, sex, preoperative TSH concentration, the presence of anti-thyroid antibodies, 
autoimmune thyroiditis in the excised lobe, and volume of remnant thyroid bed. Although 
these factors are also important in determining treatment plans for patients with thyroid 
disease, the correlation between risk factors and onset of hypothyroidism remains unclear. 









(Postoperative hypothyroidism vs. Euthyroid state) 
McHenry, et al. 
(2000) 35% 
Higher preoperative serum TSH level (μIU/L) 
(1.94±1.00 vs. 1.10±0.74) 
Miller, et al. 
(2006) 27% 
Hashimoto’s thyroiditis, 
multinodular goiter, higher preoperative serum 
TSH level (mIU/L) 
(3.15±1.14 vs. 1.95±0.92) 
Seiberling, et al. 
(2007) 24.1% 
Higher preoperative serum TSH level (μIU/ml) 
(2.39 vs. 1.07), chronic inflammation (lymphocytic 
thyroiditis or Hashimoto’s thyroiditis) 
(50.0% vs. 6.8%)
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(Postoperative hypothyroidism vs. Euthyroid state) 
Koh, et al. 
(2008) 42.6% 
Higher preoperative serum TSH level (μU/ml) 
(2.15±1.30 vs. 1.29±0.9), 
preoperative microsomal Ab, thyroglobulin Ab, 
higher grade of lymphocytic infiltration of resected 
thyroid gland 
Wormald, et al. 
(2008) 18.3% 
Higher preoperative serum TSH level (μIU/L) 
(>1.6 vs. <1.6), 
higher grade of lymphocytic infiltration of resected 
thyroid gland 
Moon, et al. 
(2008) 36.6% 
Higher preoperative serum TSH level (μIU/L) 
(2.46±1.16 vs. 1.22±0.89), 
BSA-adjusted remnant thyroid volume 
(2.73±1.34 vs. 3.48±1.50) 




Higher preoperative serum TSH level (mU/L) 
(2.1 vs. 1.2), 
smaller remnant thyroid volume (mL) 
(3.9 vs. 6.0), 
right vs. left lobectomy, 
higher thyroperoxidase antibody serum levels 
Su, et al. 
(2009) 10.9% 
High-normal preoperaitve serum TSH level; TSH 
2.5-4.0mIU/L (%) 
(18.8 vs. 3.8), 
thyroiditis in histology (%) 
(46.8 vs. 11.8), 
elevated thyroid antibodies levels (%) 
(47.8 vs. 11.5) 
Stoll, et al. 
(2009) 14.3% 
Higher preoperative serum TSH level (μIU/mL) 
(2.12 vs. 1.35), 
lower mean free T4 (ng/dL) 
(1.03 vs. 1.34), 
Hashimoto’s thyroiditis 
Spanheimer, et al. 
(2011) 33.8% Thyroiditis on surgical pathology 
Tomoda, et al. 
(2011) 24.4% 
Higher preoperative serum TSH level (mIU/l) 
(2.73±1.36 vs. 1.24±0.82), 
older age (years) 
(56.2±13 vs. 48.97±15) 
Johner, et al. 
(2011) 21.6% 
Higher preoperative serum TSH level, 
high degree of lymphocytic infiltraiton, 
high degree of germinal center formation 
Chu, et al. 
(2011) 14.4% 
Older age, higher preoperative serum TSH level, 
longer follow-up period, more frequent thyroiditis 
on histology, lighter resected tissue weight, 
positive antimicrosomal antibodies. 
* By multivariate analysis, only resected tissue 
weight, and concomitant thyroiditis on histology 
turned out to be independent predicting factors. 
Table 2. Risk factors for predicting posthemithyroidectomy hypothyroidism 
 
Hypothyroidism – Influences and Treatments 
 
40
replacement may be recommended, rather than close follow-up monitoring, for some post-
hemithyroidectomy patients with risk factors, such as elevated thyroid antibody 
concentrations or histologic evidence of autoimmune thyroiditis (Su et al., 2009). In contrast, 
other researchers have reported that elevated serum TSH concentration alone may not 
justify the initiation of thyroid hormone replacement, since nearly 70% of individuals who 
developed biochemical (asymptomatic) hypothyroidism during the early postoperative 
period after hemithyroidectomy recovered normal thyroid function without pharmacologic 
intervention (Johner et al., 2011). Therefore, determination of the true indication is important 
prior to initiating thyroid hormone replacement therapy. 
A small number of patients who develop hypothyroidism after thyroid lobectomy require 
life-long thyroid hormone replacement, as well as routine laboratory examinations and 
medical adjustments. Furthermore, chronic thyroxine therapy may be associated with 
adverse effects, including arrhythmias (atrial fibrillation) or loss of calcium from the bones 
resulting in osteopenia or osteoporosis. High serum cholesterol concentrations may result in 
cardiac sclerosis with all its complications, suggesting that hormone replacement therapy be 
delayed. Thus, an increased ability to recognize which patients are most at risk for 
developing hypothyroidism will improve patient care. Although closer monitoring or earlier 
initiation of thyroid hormone replacement therapy may be advisable for these high-risk 
patients, no specific TSH concentration alone is indicative of increased risk of permanent or 
overt hypothyroidism, suggesting that transient biochemical hypothyroidism be closely 
monitored rather than routinely treated. Accurate detection and diagnosis of sustained 
hypothyroidism after thyroid surgery is also important to avoid its associated morbidity 
and mortality (Johner et al., 2011). 
2.4 Risk factors 
Among the factors found to predict hypothyroidism after hemithyroidectomy are patient 
age, sex, preoperative TSH concentration, the presence of anti-thyroid antibodies, 
autoimmune thyroiditis in the excised lobe, and volume of remnant thyroid bed. Although 
these factors are also important in determining treatment plans for patients with thyroid 
disease, the correlation between risk factors and onset of hypothyroidism remains unclear. 
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(2007) 24.1% 
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(2.39 vs. 1.07), chronic inflammation (lymphocytic 
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(50.0% vs. 6.8%)
Hypothyroidism After Hemithyroidectomy:  









(Postoperative hypothyroidism vs. Euthyroid state) 
Koh, et al. 
(2008) 42.6% 
Higher preoperative serum TSH level (μU/ml) 
(2.15±1.30 vs. 1.29±0.9), 
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(2.12 vs. 1.35), 
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(1.03 vs. 1.34), 
Hashimoto’s thyroiditis 
Spanheimer, et al. 
(2011) 33.8% Thyroiditis on surgical pathology 
Tomoda, et al. 
(2011) 24.4% 
Higher preoperative serum TSH level (mIU/l) 
(2.73±1.36 vs. 1.24±0.82), 
older age (years) 
(56.2±13 vs. 48.97±15) 
Johner, et al. 
(2011) 21.6% 
Higher preoperative serum TSH level, 
high degree of lymphocytic infiltraiton, 
high degree of germinal center formation 
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(2011) 14.4% 
Older age, higher preoperative serum TSH level, 
longer follow-up period, more frequent thyroiditis 
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* By multivariate analysis, only resected tissue 
weight, and concomitant thyroiditis on histology 
turned out to be independent predicting factors. 
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Some known risk factors can be determined only after surgery, such as lymphocytic 
infiltration, associated thyroiditis, and the weight of the resected gland, whereas others, such 
as preoperative TSH concentration, age, and presence of thyroid autoantibody, are known 
preoperatively. In addition, the remnant thyroid volume may be easily measured from 
preoperative US. Because most patients scheduled for hemithyroidectomy due to thyroid 
nodules are evaluated by thyroid US, the remnant thyroid volume could be easily determined, 
allowing the surgeon to decide whether to perform a diagnostic hemithyroidectomy.  
2.4.1 Elevated preoperative TSH concentration 
Preoperative TSH concentration is significantly associated with postoperative 
hypothyroidism. In addition, studies using a TSH cutoff value, such as >1.6 or >2.0 uIU/mL, 
have found that patients with elevated TSH are 7-10 times more likely to develop 
hypothyroidism after surgery. Thus, “normally elevated” preoperative TSH >1.5 uIU/mL, 
especially when combined with lower preoperative T4 concentrations or specific antibodies, 
may indicate a potentially increased risk of hypothyroidism after hemithyroidectomy, 
allowing appropriate preoperative counseling of patients (Table 2). 
2.4.2 Degree of chronic inflammation and autoimmune disease 
2.4.2.1 Hashimoto’s thyroiditis and presence of autoantibodies 
Thyroiditis is also associated with postoperative hypothyroidism. Hashimoto’s thyroiditis is 
an inflammatory disease that is the most common cause of hypothyroidism. Moreover, 
Hashimoto’s thyroiditis has been found to significantly increase the need for thyroid hormone 
supplementation following hemithyroidectomy. Patients diagnosed with Hashimoto’s 
thyroiditis were found to be almost four times more likely to develop hypothyroidism after 
hemithyroidectomy (Stoll et al., 2009). Hashimoto’s thyroiditis is also characterized by intense 
lymphocytic infiltration of the thyroid and the presence of thyroid autoantibodies. Moreover, 
several types of autoimmune thyroiditis are closely associated with circulating thyroid 
autoantibodies such as microsomal Ab and thyroglobulin Ab (Seiberling et al, 2007). The 
presence of thyroid autoantibodies was found to strongly correlate with post-
hemithyroidectomy hypothyroidism. Similar relationships have been observed among 
Hashimoto’s thyroiditis, autoimmune thyroiditis, the degree of lymphocytic infiltration, the 
presence of chronic inflammation, or detectable thyroid autoantibodies and the occurrence of 
hypothyroidism after hemithyroidectomy. The association among Hashimoto’s thyroiditis, a 
“normal elevated” TSH concentration, a low free T4 concentration, and thyroid autoantibodies 
is likely due to the underlying pathologic disease process. In addition, preoperatively 
measured thyroid autoantibodies may predict postoperative hypothyroidism. 
2.4.2.2 Degree of lymphocytic infiltration  
Lymphocytic infiltrate into the thyroid gland has been found to decrease thyroid function, 
and a semiquantitative analysis of this infiltrate usually reflects the risk of hypothyroidism. 
The degree of lymphocytic infiltration, graded on a scale of 0-IV, into the resected thyroid 
lobe may aid in predicting the development of hypothyroidism in post-hemithyroidectomy 
patients (Koh et al, 2008). An extensive review of histopathologic data, which assessed 
whether the degree of lymphocytic infiltration and germinal center formation within the 
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thyroid lobe could accurately predict the development of postoperative hypothyroidism, 
found that when inflammation was graded based on the extent of lymphocytic infiltration 
(graded 0-3) and the frequency of germinal centers was qualitatively assessed as a histologic 
measure of immunologic activation (graded 0-3), most patients with lymphocytic infiltration 
or germinal center formation in the resected thyroid lobe are at increased risk for post-
hemithyroidectomy hypothyroidism (Johner et al, 2011). Other studies have assessed the 
relationship between postoperative pathologic findings and risk of developing 
hypothyroidism, but, since these findings were detected after surgery, they could not be 
used to determine the need for postoperative thyroidectomy.  
Taken together, these findings indicate that Hashimoto’s thyroiditis and other risk factors, 
such as lymphocytic infiltration and the presence of autoantibodies, significantly increase 
the risks for developing postoperative hypothyroidism after thyroid lobectomy. 
Preoperative evaluation is therefore important in counseling patients about a possible future 
need for thyroid hormone replacement therapy.   
2.4.3 Amount of remnant thyroid gland 
One of the major risk factors for hypothyroidism after hemithyroidectomy is the amount of 
remnant thyroid gland. Small remnant thyroid volume has been recognized as a risk factor 
for hypothyroidism (De Carlucci Jr et al., 2008). Remnant thyroid volumes can be measured 
on preoperative US images and can be calculated using the equation (Miccoli et al., 2006):  
Volume = length X width X depth X π/6.  
Patients who developed post-hemithyroidectomy hypothyroidism were found to have a 
significant smaller body surface area (BSA)-adjusted remnant thyroid volume than patients 
who remained euthyroid (Moon et al, 2008). Another predictive factor may be BSA-adjusted 
remnant thyroid volume, determined by calculating remnant thyroid volume/BSA ratio. 
BSA can be calculated using the Mosteller formula:  
BSA= √(height X weight/3600). 
2.4.4 Risk scoring systems 
Risk-scoring systems that can predict hypothyroidism after hemithyroidectomy are 
summarized in Table 3. 
Having a valid model predictive of postoperative hypothyroidism is also useful when 
making follow-up plans for patients undergoing hemithyroidectomy. Most surgeons 
recommend regular postoperative visits to the clinic, although some counsel their patients to 
visit only when surgery-related symptoms develop.  
A unique risk-scoring system that can predict hypothyroidism after hemithyroidectomy was 
recently described (Tomoda et al, 2011). In this system, risk scores are calculated as the sum 
of a patient’s age and preoperative TSH concentration. The rates of hypothyroidism in 
patients with risk scores of 0, 1, 2, and 3 were found to be 3%, 20%, 39%, and 70%, 
respectively, suggesting that the potential risk of postoperative hypothyroidism should be 
discussed with patients before surgery based on this scoring system.  
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Some known risk factors can be determined only after surgery, such as lymphocytic 
infiltration, associated thyroiditis, and the weight of the resected gland, whereas others, such 
as preoperative TSH concentration, age, and presence of thyroid autoantibody, are known 
preoperatively. In addition, the remnant thyroid volume may be easily measured from 
preoperative US. Because most patients scheduled for hemithyroidectomy due to thyroid 
nodules are evaluated by thyroid US, the remnant thyroid volume could be easily determined, 
allowing the surgeon to decide whether to perform a diagnostic hemithyroidectomy.  
2.4.1 Elevated preoperative TSH concentration 
Preoperative TSH concentration is significantly associated with postoperative 
hypothyroidism. In addition, studies using a TSH cutoff value, such as >1.6 or >2.0 uIU/mL, 
have found that patients with elevated TSH are 7-10 times more likely to develop 
hypothyroidism after surgery. Thus, “normally elevated” preoperative TSH >1.5 uIU/mL, 
especially when combined with lower preoperative T4 concentrations or specific antibodies, 
may indicate a potentially increased risk of hypothyroidism after hemithyroidectomy, 
allowing appropriate preoperative counseling of patients (Table 2). 
2.4.2 Degree of chronic inflammation and autoimmune disease 
2.4.2.1 Hashimoto’s thyroiditis and presence of autoantibodies 
Thyroiditis is also associated with postoperative hypothyroidism. Hashimoto’s thyroiditis is 
an inflammatory disease that is the most common cause of hypothyroidism. Moreover, 
Hashimoto’s thyroiditis has been found to significantly increase the need for thyroid hormone 
supplementation following hemithyroidectomy. Patients diagnosed with Hashimoto’s 
thyroiditis were found to be almost four times more likely to develop hypothyroidism after 
hemithyroidectomy (Stoll et al., 2009). Hashimoto’s thyroiditis is also characterized by intense 
lymphocytic infiltration of the thyroid and the presence of thyroid autoantibodies. Moreover, 
several types of autoimmune thyroiditis are closely associated with circulating thyroid 
autoantibodies such as microsomal Ab and thyroglobulin Ab (Seiberling et al, 2007). The 
presence of thyroid autoantibodies was found to strongly correlate with post-
hemithyroidectomy hypothyroidism. Similar relationships have been observed among 
Hashimoto’s thyroiditis, autoimmune thyroiditis, the degree of lymphocytic infiltration, the 
presence of chronic inflammation, or detectable thyroid autoantibodies and the occurrence of 
hypothyroidism after hemithyroidectomy. The association among Hashimoto’s thyroiditis, a 
“normal elevated” TSH concentration, a low free T4 concentration, and thyroid autoantibodies 
is likely due to the underlying pathologic disease process. In addition, preoperatively 
measured thyroid autoantibodies may predict postoperative hypothyroidism. 
2.4.2.2 Degree of lymphocytic infiltration  
Lymphocytic infiltrate into the thyroid gland has been found to decrease thyroid function, 
and a semiquantitative analysis of this infiltrate usually reflects the risk of hypothyroidism. 
The degree of lymphocytic infiltration, graded on a scale of 0-IV, into the resected thyroid 
lobe may aid in predicting the development of hypothyroidism in post-hemithyroidectomy 
patients (Koh et al, 2008). An extensive review of histopathologic data, which assessed 
whether the degree of lymphocytic infiltration and germinal center formation within the 
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thyroid lobe could accurately predict the development of postoperative hypothyroidism, 
found that when inflammation was graded based on the extent of lymphocytic infiltration 
(graded 0-3) and the frequency of germinal centers was qualitatively assessed as a histologic 
measure of immunologic activation (graded 0-3), most patients with lymphocytic infiltration 
or germinal center formation in the resected thyroid lobe are at increased risk for post-
hemithyroidectomy hypothyroidism (Johner et al, 2011). Other studies have assessed the 
relationship between postoperative pathologic findings and risk of developing 
hypothyroidism, but, since these findings were detected after surgery, they could not be 
used to determine the need for postoperative thyroidectomy.  
Taken together, these findings indicate that Hashimoto’s thyroiditis and other risk factors, 
such as lymphocytic infiltration and the presence of autoantibodies, significantly increase 
the risks for developing postoperative hypothyroidism after thyroid lobectomy. 
Preoperative evaluation is therefore important in counseling patients about a possible future 
need for thyroid hormone replacement therapy.   
2.4.3 Amount of remnant thyroid gland 
One of the major risk factors for hypothyroidism after hemithyroidectomy is the amount of 
remnant thyroid gland. Small remnant thyroid volume has been recognized as a risk factor 
for hypothyroidism (De Carlucci Jr et al., 2008). Remnant thyroid volumes can be measured 
on preoperative US images and can be calculated using the equation (Miccoli et al., 2006):  
Volume = length X width X depth X π/6.  
Patients who developed post-hemithyroidectomy hypothyroidism were found to have a 
significant smaller body surface area (BSA)-adjusted remnant thyroid volume than patients 
who remained euthyroid (Moon et al, 2008). Another predictive factor may be BSA-adjusted 
remnant thyroid volume, determined by calculating remnant thyroid volume/BSA ratio. 
BSA can be calculated using the Mosteller formula:  
BSA= √(height X weight/3600). 
2.4.4 Risk scoring systems 
Risk-scoring systems that can predict hypothyroidism after hemithyroidectomy are 
summarized in Table 3. 
Having a valid model predictive of postoperative hypothyroidism is also useful when 
making follow-up plans for patients undergoing hemithyroidectomy. Most surgeons 
recommend regular postoperative visits to the clinic, although some counsel their patients to 
visit only when surgery-related symptoms develop.  
A unique risk-scoring system that can predict hypothyroidism after hemithyroidectomy was 
recently described (Tomoda et al, 2011). In this system, risk scores are calculated as the sum 
of a patient’s age and preoperative TSH concentration. The rates of hypothyroidism in 
patients with risk scores of 0, 1, 2, and 3 were found to be 3%, 20%, 39%, and 70%, 
respectively, suggesting that the potential risk of postoperative hypothyroidism should be 
discussed with patients before surgery based on this scoring system.  
 






of patients Risk scoring system 
Moon, et al. 
(2008) 101 
Risk scoring system using two independent risk 
predictors (TSH level and BSA-adjusted remnant 
thyroid volume) was created based on the results of 
logistic regression analyses. 
The incidences of hypothyroidism were 5.3%, 12.1%, 
51.7%, and 85.0% according to the risk scores of 0,1,2, 
and 3, respectively. 
Stoll, et al. 
(2009) 547 
When stratified into 3 groups based on their 
preoperative TSH measurement (≤1.5, 1.51-2.5, and 
≥2.51μIU/mL), the rate of hypothyroidism increased 
significantly at each level (13.5%, 20.5%, and 41. 3%, 
respectively) 
Tomoda, et al. 
(2011) 233 
A risk-scoring system was calculated by summing the 
score of risk factors such as preoperative TSH level (<1, 
1-2.49, and ≥2.5μIU/ml) and patient’s age (<55, and 
≥55 year). The incidences of hypothyroidism were 3, 
20, 39, and 70% according to the risk scores of 0, 1, 2 
and 3, respectively. 
Johner, et al. 
(2011) 117 
Assessment of the histologic scoring criteria for thyroid 
lymphocytic infiltration (score 0-3), and germinal 
centers (score 0-3) as well as classification of TSH levels 
(<5.5, 5.5-6.9, 7-14.9, and≥15μIU/L) can predict 
potential risks associated with long –term thyroid 
hormone replacement therapy. 
Table 3. Risk scoring system in posthemithyroidectomy hypothyroidism 
An alternative risk-scoring system using two factors, TSH concentration and remnant 
thyroid volume, was based on the results of logistic regression analyses (Moon et al, 2008). 
This score system was developed using independently predictive factors, with the highest 
score of each variable determined by its β regression coefficient. Logistic regression 
analysis was used to derive an equation that calculates the probability (P) of developing 
hypothyroidism after hemithyroidectomy:   
P = 1/ (1 + e- (-1.325+1.191*preoperative TSH-0.435*remnant thyroid volume). 
The incidences of hypothyroidism in patients with risk scores of 0, 1, 2, and 3 were found to 
be 5.3%, 12.1%, 51.7%, and 85.0%, respectively, with the model having an overall accuracy in 
predicting post-hemithyroidectomy hypothyroidism of about 77. 2%.  
In summary, elevated preoperative TSH concentration, Hashimoto’s thyroiditis, small 
remnant thyroid volume, and/or advanced age are associated with increased risk of 
developing hypothyroidism and a greater likelihood of requiring thyroid hormone 
supplementation after hemithyroidectomy. Patient counseling on the need for hormone 
replacement should therefore be based on these factors.  
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2.5 Postoperative thyroid hormone replacement after hemithyroidectomy 
Hypothyroidism is an underappreciated sequel of hemithyroidectomy. It is most often 
mild and subclinical, requiring low doses of thyroid hormone to normalize serum TSH 
concentrations. Hypothyroidism has been reported in up to one third of euthyroid 
patients who undergo hemithyroidectomy. Formerly, it was common practice to routinely 
start patients with nodular thyroid disease on “prophylactic” TSH-suppressive doses of 
thyroid hormone (L-thyroxine) following hemithyroidectomy to prevent recurrence 
(Gharib & Mazzaferri, 1998), based on the hypothesis that suppression of the 
hypothalamic-pituitary axis would reduce the risk of abnormalities developing in the 
contralateral thyroid remnant. Thus, routine administration of L-thyroxine to 
hemithyroidectomy patients could be expected to decrease the incidence of 
hypothyroidism. More recently, however, L-thyroxine (TSH-suppression therapy) has not 
been not routinely prescribed for all patients after hemithyroidectomy, largely due to its 
questionable efficacy in thyroid suppression and prevention of the development of 
nodules in the remaining contralateral thyroid lobe. In addition, thyroxine administration 
may cause subclinical hyperthyroidism, which has been associated with possible side 
effects including decreased bone mineral density, particularly in postmenopausal women, 
a three-fold increase in the incidence of atrial fibrillation, and aggravation of ischemic 
heart disease (Mchenry & Slusarczyk, 2000). Therefore, early detection of postoperative 
hypothyroidism and treatment with L-thyroxine may inhibit the development of overt 
hypothyroidism and its potential complications. Although administration of thyroid 
hormone to suppress serum TSH levels in euthyroid patients may not be of value, 
treatment of patients with elevated TSH is important for relieving the symptoms of 
hypothyroidism and may be important in reducing recurrent thyroid disease. 
Administration of thyroxine after hemithyroidectomy may also require long-term 
monitoring of thyroid function and it has not been determined how long these patients 
should continue on thyroxine. These problems encouraged us to investigate the frequency 
of hypothyroidism following hemithyroidectomy, as well as its potential risk factors and 
management.  
The unfavorable side effects of TSH-suppressive doses of thyroid hormone are known, 
whereas replacement doses of thyroxine have not been associated with the adverse sequelae 
observed with TSH-suppressive doses of thyroxine. Patients with postoperatively elevated 
TSH concentrations may represent a subgroup at high risk for the development of recurrent 
nodular or diffuse thyroid enlargement. Normalization of serum TSH concentrations may 
help minimize the potential negative effects of elevated serum TSH concentrations without 
subjecting patients to the adverse sequelae associated with TSH-suppressive doses of L-
thyroxine. Therefore, the selective use of L-thyroxine therapy for patients with elevated TSH 
after hemithyroidectomy may help prevent recurrent nodular or diffuse thyroid 
enlargement without the unnecessary administration of L-thyroxine to patients with a 
normal serum TSH level and exposing them to its harmful effects (McHenry and Slusarczyk, 
2000).  
In summary, hypothyroidism after hemithyroidectomy is usually mild and asymptomatic, 
and can be treated with lower than normal replacement doses of L-thyroxine to maintain 
serum TSH concentrations within their normal range.  
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This score system was developed using independently predictive factors, with the highest 
score of each variable determined by its β regression coefficient. Logistic regression 
analysis was used to derive an equation that calculates the probability (P) of developing 
hypothyroidism after hemithyroidectomy:   
P = 1/ (1 + e- (-1.325+1.191*preoperative TSH-0.435*remnant thyroid volume). 
The incidences of hypothyroidism in patients with risk scores of 0, 1, 2, and 3 were found to 
be 5.3%, 12.1%, 51.7%, and 85.0%, respectively, with the model having an overall accuracy in 
predicting post-hemithyroidectomy hypothyroidism of about 77. 2%.  
In summary, elevated preoperative TSH concentration, Hashimoto’s thyroiditis, small 
remnant thyroid volume, and/or advanced age are associated with increased risk of 
developing hypothyroidism and a greater likelihood of requiring thyroid hormone 
supplementation after hemithyroidectomy. Patient counseling on the need for hormone 
replacement should therefore be based on these factors.  
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hemithyroidectomy patients could be expected to decrease the incidence of 
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questionable efficacy in thyroid suppression and prevention of the development of 
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a three-fold increase in the incidence of atrial fibrillation, and aggravation of ischemic 
heart disease (Mchenry & Slusarczyk, 2000). Therefore, early detection of postoperative 
hypothyroidism and treatment with L-thyroxine may inhibit the development of overt 
hypothyroidism and its potential complications. Although administration of thyroid 
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help minimize the potential negative effects of elevated serum TSH concentrations without 
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after hemithyroidectomy may help prevent recurrent nodular or diffuse thyroid 
enlargement without the unnecessary administration of L-thyroxine to patients with a 
normal serum TSH level and exposing them to its harmful effects (McHenry and Slusarczyk, 
2000).  
In summary, hypothyroidism after hemithyroidectomy is usually mild and asymptomatic, 
and can be treated with lower than normal replacement doses of L-thyroxine to maintain 
serum TSH concentrations within their normal range.  
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2.6 Post-hemithyroidectomy follow-up guidelines 
Theoretically, a single thyroid lobe should possess enough functioning thyrocytes for a 
patient to remain euthyroid. In fact, many surgeons and patients choose hemithyroidectomy 
owing to the belief that postoperative thyroid hormone therapy will not be required. 
However, patients with risk factors for hypothyroidism, such as severe preoperative 
thyroiditis, may not have sufficient thyroid tissue remaining after thyroid lobectomy. Thus, 
all patients who undergo hemithyroidectomy should be counseled regarding the potential 
need for lifelong thyroid hormone therapy.  
There is no widely accepted guideline or algorithm for the monitoring of thyroid function 
after hemithyroidectomy, leaving hypothyroidism as the most common resulting 
complication. Follow-up guidelines vary widely and generally consist of a single 
postoperative measurement of TSH. Some patients may not be examined at all until the 
development of overt hypothyroidism. If thyroid dysfunction is detected, the decision to 
start thyroid hormone replacement therapy is usually based on the preference of the treating 
physician, patient symptoms, and the degree and duration of TSH elevation, rather than on 
evidence obtained from clinical trials. Therefore, it is important to identify those patients 
who are at risk of developing hypothyroidism soon after surgery so that they can be more 
attentively monitored using thyroid function tests. Additionally, it would be of benefit to 
identify risk factors predictive of the development of early hypothyroidism.  
One of the difficulties in monitoring thyroid function other than thyroid hormone 
concentrations after hemithyroidectomy is that many symptoms of subclinical 
hypothyroidism are nonspecific. Although most physicians recommend regular 
postoperative visits, some recommend visits only when patients develop surgery-related 
symptoms. Although routine and continuous long-term monitoring of thyroid hormone 
concentrations after hemithyroidectomy is a possible solution, it is often ineffective and not 
cost effective due to unnecessary hospital visits. In contrast, unrecognized hypothyroidism 
after hemithyroidectomy may have an unfavorable effect on a patient’s general health. This 
may inevitably result in overt hypothyroidism in some patients, increasing the risks of 
developing cardiovascular and/or neuropsychiatric diseases. To overcome this dilemma, 
preoperative risk factors for hypothyroidism after hemithyroidectomy have been 
formulated to identify high-risk patients. Table 4 summarizes several follow-up protocols 
followed after hemithyroidectomy.  
In most patients, hypothyroidism after hemithyroidectomy manifests as an increased serum 
TSH concentration within 3-12 months after surgery. Moreover, hypothyroidism in most of 
these patients is rarely severe or progressive. Therefore, patients who are postoperatively 
euthyroid rarely go on to develop hypothyroidism, making yearly evaluations by measuring 
serum TSH concentrations sufficient. Thus, most thyroid function should be monitored once 
yearly for life (McHenry & Sulsarczyk, 2000; Miller et al., 2006). 
The pituitary-thyroid axis undergoes adaptation following partial thyroidectomy, with most 
patients showing an increase in serum TSH at 1 month (Tomoda et al, 2011). Since most 
patients who will develop subclinical hypothyroidism will not do so within the first 3 
months after surgery, it may be advisable to measure TSH concentration 4 weeks and 3 
months after surgery. At 3 months, patients with subclinical hypothyroidism (>10 uIU/ml) 
may be prescribed L-thyroxine. TSH concentrations should again be measured at 6 and 12 
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(year) Recommended follow-up protocol 
McHenry, et al. 
(2000) 
All symptomatic patients should be treated with L-T4 replacement. 
If it is elected not to treat asymptomatic patients, they should have a 
baseline serum fT4 and total T3 level measured and a yearly 
evaluation including measurement of serum fT4, T3, TSH levels to 
assess for progression to overt hypothyroidism. 
Miller, et al. 
(2006) 
Recommendation is to obtain a postoperative TSH measurement 8 to 
12 weeks after surgery, followed by the measurement of TSH levels 
at 6 months and 12 months after surgery. 
If the TSH level is normal at 12 months, biannual to annual 
determination of TSH levels was encouraged unless symptoms of 
hypothyroidism manifest. 
Koh, et al. 
(2008) 
If preoperative risk factors (presence of microsomal Ab and 
thyroglobulin Ab, or higher degree of lymphocytic infiltration of 
resected thyroid gland) were present, these patients were to be 
follow up at least for 12 months with explanation of possibility of 
developing postsurgical hypothyroidism. 
Wormald, et al. 
(2008) 
Patients with risk factors (raised TSH level or lymphocytic 
infiltration) should undergo thyroid function tests at 3,6,12 months 
and annually thereafter postoperatively. In all other patients, testing 
of thyroid function once at 1-year is sufficient. 
Moon, et al. 
(2008) 
Frequent follow-up and thyroid function monitoring can be tailored 
to high-risk patients if a valid prediction model can be established in 
prospective studies. 
Su, et al. 
(2009) 
TSH monitoring at 6 months, 12 months, and then yearly for 2 years 
was recommended for asymptomatic patients. High-risk patients 
should have serial TSH for the first year, then yearly thereafter. 
Tomoda, et al. 
(2011) 
Postoperative TSH level should be checked 4 weeks after surgery 
and again 3 months. At 3 months after operation, the decision 
regarding prescription of levothyroxine to patients with subclinical 
hypothyroidism (more than 10μIU/ml). After 3 months after 
operation, the measurement of TSH levels was recommended at 6 
and 12 months after surgery. If the TSH level is normal at 12 months, 
biannual to annual determination of TSH levels could be checked 
unless symptoms of hypothyroidism manifest. 
Johner, et al. 
(2011) 
To obtain a postoperative TSH measurement for all patients at 6 
weeks after surgery, followed by the measurement of TSH levels at 6 
and 12 months after surgery was advised. TSH level at 3 months was 
no longer recommended because most patients displayed marked 
increase in their TSH level immediately after surgery, that 
subsequently normalized over time. 
Table 4. Recommendation protocol for follow-up after hemithyroidectomy 
Another follow-up protocol recommends that all symptomatic or asymptomatic patients 
with hypothyroidism be treated with L-thyroxine (McHenry & Slusarczyk, 2000). If 
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Theoretically, a single thyroid lobe should possess enough functioning thyrocytes for a 
patient to remain euthyroid. In fact, many surgeons and patients choose hemithyroidectomy 
owing to the belief that postoperative thyroid hormone therapy will not be required. 
However, patients with risk factors for hypothyroidism, such as severe preoperative 
thyroiditis, may not have sufficient thyroid tissue remaining after thyroid lobectomy. Thus, 
all patients who undergo hemithyroidectomy should be counseled regarding the potential 
need for lifelong thyroid hormone therapy.  
There is no widely accepted guideline or algorithm for the monitoring of thyroid function 
after hemithyroidectomy, leaving hypothyroidism as the most common resulting 
complication. Follow-up guidelines vary widely and generally consist of a single 
postoperative measurement of TSH. Some patients may not be examined at all until the 
development of overt hypothyroidism. If thyroid dysfunction is detected, the decision to 
start thyroid hormone replacement therapy is usually based on the preference of the treating 
physician, patient symptoms, and the degree and duration of TSH elevation, rather than on 
evidence obtained from clinical trials. Therefore, it is important to identify those patients 
who are at risk of developing hypothyroidism soon after surgery so that they can be more 
attentively monitored using thyroid function tests. Additionally, it would be of benefit to 
identify risk factors predictive of the development of early hypothyroidism.  
One of the difficulties in monitoring thyroid function other than thyroid hormone 
concentrations after hemithyroidectomy is that many symptoms of subclinical 
hypothyroidism are nonspecific. Although most physicians recommend regular 
postoperative visits, some recommend visits only when patients develop surgery-related 
symptoms. Although routine and continuous long-term monitoring of thyroid hormone 
concentrations after hemithyroidectomy is a possible solution, it is often ineffective and not 
cost effective due to unnecessary hospital visits. In contrast, unrecognized hypothyroidism 
after hemithyroidectomy may have an unfavorable effect on a patient’s general health. This 
may inevitably result in overt hypothyroidism in some patients, increasing the risks of 
developing cardiovascular and/or neuropsychiatric diseases. To overcome this dilemma, 
preoperative risk factors for hypothyroidism after hemithyroidectomy have been 
formulated to identify high-risk patients. Table 4 summarizes several follow-up protocols 
followed after hemithyroidectomy.  
In most patients, hypothyroidism after hemithyroidectomy manifests as an increased serum 
TSH concentration within 3-12 months after surgery. Moreover, hypothyroidism in most of 
these patients is rarely severe or progressive. Therefore, patients who are postoperatively 
euthyroid rarely go on to develop hypothyroidism, making yearly evaluations by measuring 
serum TSH concentrations sufficient. Thus, most thyroid function should be monitored once 
yearly for life (McHenry & Sulsarczyk, 2000; Miller et al., 2006). 
The pituitary-thyroid axis undergoes adaptation following partial thyroidectomy, with most 
patients showing an increase in serum TSH at 1 month (Tomoda et al, 2011). Since most 
patients who will develop subclinical hypothyroidism will not do so within the first 3 
months after surgery, it may be advisable to measure TSH concentration 4 weeks and 3 
months after surgery. At 3 months, patients with subclinical hypothyroidism (>10 uIU/ml) 
may be prescribed L-thyroxine. TSH concentrations should again be measured at 6 and 12 
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All symptomatic patients should be treated with L-T4 replacement. 
If it is elected not to treat asymptomatic patients, they should have a 
baseline serum fT4 and total T3 level measured and a yearly 
evaluation including measurement of serum fT4, T3, TSH levels to 
assess for progression to overt hypothyroidism. 
Miller, et al. 
(2006) 
Recommendation is to obtain a postoperative TSH measurement 8 to 
12 weeks after surgery, followed by the measurement of TSH levels 
at 6 months and 12 months after surgery. 
If the TSH level is normal at 12 months, biannual to annual 
determination of TSH levels was encouraged unless symptoms of 
hypothyroidism manifest. 
Koh, et al. 
(2008) 
If preoperative risk factors (presence of microsomal Ab and 
thyroglobulin Ab, or higher degree of lymphocytic infiltration of 
resected thyroid gland) were present, these patients were to be 
follow up at least for 12 months with explanation of possibility of 
developing postsurgical hypothyroidism. 
Wormald, et al. 
(2008) 
Patients with risk factors (raised TSH level or lymphocytic 
infiltration) should undergo thyroid function tests at 3,6,12 months 
and annually thereafter postoperatively. In all other patients, testing 
of thyroid function once at 1-year is sufficient. 
Moon, et al. 
(2008) 
Frequent follow-up and thyroid function monitoring can be tailored 
to high-risk patients if a valid prediction model can be established in 
prospective studies. 
Su, et al. 
(2009) 
TSH monitoring at 6 months, 12 months, and then yearly for 2 years 
was recommended for asymptomatic patients. High-risk patients 
should have serial TSH for the first year, then yearly thereafter. 
Tomoda, et al. 
(2011) 
Postoperative TSH level should be checked 4 weeks after surgery 
and again 3 months. At 3 months after operation, the decision 
regarding prescription of levothyroxine to patients with subclinical 
hypothyroidism (more than 10μIU/ml). After 3 months after 
operation, the measurement of TSH levels was recommended at 6 
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Johner, et al. 
(2011) 
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no longer recommended because most patients displayed marked 
increase in their TSH level immediately after surgery, that 
subsequently normalized over time. 
Table 4. Recommendation protocol for follow-up after hemithyroidectomy 
Another follow-up protocol recommends that all symptomatic or asymptomatic patients 
with hypothyroidism be treated with L-thyroxine (McHenry & Slusarczyk, 2000). If 
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treatment of asymptomatic patients is not preferred, serum free T4 and total 
triiodothyronine (T3) concentrations should be measured at baseline, followed by yearly 
evaluations including measurements of serum free T4, T3, and TSH to assess the 
progression to overt hypothyroidism.  
Another recommendation is to measure TSH 8 to 12 weeks after surgery, as well as at 6 and 
12 months. If TSH concentration is normal at 12 months, it should be measured every 6 to 12 
months thereafter, unless patients develop symptoms of hypothyroidism (Miller et al., 
2006).  
A recent modification of an earlier algorithm (Johner et al, 2011) recommended that TSH be 
measured 6 and 12 months after hemithyroidectomy, indicating that the measurement of 
TSH at 3 months was no longer required because most study participants displayed marked 
increases in serum TSH concentration immediately after surgery, which subsequently 
normalized over time. This new algorithm recommended that serum TSH be measured 
biannually in asymptomatic patients with mild biochemical hypothyroidism (TSH 5.6-6.9 
uIU/L). This follow-up schedule allows for the timely detection of biochemical 
hypothyroidism and appropriate surveillance for individuals managed conservatively, with 
an expectation of eventual return to normal thyroid function.  
Although it has been suggested that all hemithyroidectomy patients be monitored for as 
long as possible, it may be more practical to use a selective monitoring strategy in which 
monitoring is dependent on the presence of risk factors.  
3. Conclusion 
The incidence of hypothyroidism after hemithyroidectomy is not negligible and should not 
be overlooked. Approximately 15-30% of patients who undergo hemithyroidectomy may 
have this complication, and some may need thyroid hormone replacement therapy. Risk 
factors such as elevated preoperative TSH levels, elevated concentrations of thyroid 
autoimmune antibodies, degree of thyroiditis, age, and residual thyroid volume are 
associated with an increased risk of hypothyroidism after hemithyroidectomy. Patients at 
increased risk for postoperative hypothyroidism should be made aware of their risk factors 
and undergo more intensive follow-up. 
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treatment of asymptomatic patients is not preferred, serum free T4 and total 
triiodothyronine (T3) concentrations should be measured at baseline, followed by yearly 
evaluations including measurements of serum free T4, T3, and TSH to assess the 
progression to overt hypothyroidism.  
Another recommendation is to measure TSH 8 to 12 weeks after surgery, as well as at 6 and 
12 months. If TSH concentration is normal at 12 months, it should be measured every 6 to 12 
months thereafter, unless patients develop symptoms of hypothyroidism (Miller et al., 
2006).  
A recent modification of an earlier algorithm (Johner et al, 2011) recommended that TSH be 
measured 6 and 12 months after hemithyroidectomy, indicating that the measurement of 
TSH at 3 months was no longer required because most study participants displayed marked 
increases in serum TSH concentration immediately after surgery, which subsequently 
normalized over time. This new algorithm recommended that serum TSH be measured 
biannually in asymptomatic patients with mild biochemical hypothyroidism (TSH 5.6-6.9 
uIU/L). This follow-up schedule allows for the timely detection of biochemical 
hypothyroidism and appropriate surveillance for individuals managed conservatively, with 
an expectation of eventual return to normal thyroid function.  
Although it has been suggested that all hemithyroidectomy patients be monitored for as 
long as possible, it may be more practical to use a selective monitoring strategy in which 
monitoring is dependent on the presence of risk factors.  
3. Conclusion 
The incidence of hypothyroidism after hemithyroidectomy is not negligible and should not 
be overlooked. Approximately 15-30% of patients who undergo hemithyroidectomy may 
have this complication, and some may need thyroid hormone replacement therapy. Risk 
factors such as elevated preoperative TSH levels, elevated concentrations of thyroid 
autoimmune antibodies, degree of thyroiditis, age, and residual thyroid volume are 
associated with an increased risk of hypothyroidism after hemithyroidectomy. Patients at 
increased risk for postoperative hypothyroidism should be made aware of their risk factors 
and undergo more intensive follow-up. 
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1. Introduction 
Hypothyroidism is relatively a common disease worldwide. Overall prevalence in adults in 
the United States is 4.6%. (Golden et al., 2009) It can present as mild/subclinical form or overt 
hypothyroidism with a prevalence of 4.3% and 0.3% of adult populations, respectively. 
(Golden et al., 2009) Thyroid hormone deficiency has been linked to increased risk of 
cardiovascular morbidities and mortalities. (McQuade et al., 2011, Resta et al., 2004) 
Respiratory system like other body systems and organs is affected by hypothyroidism. The 
spectrum of diseases involvement can range from mild dyspnea to more severe and life-
threatening respiratory failure. Several pathophysiological mechanisms are responsible for the 
compromise in the respiratory system including reduction in central respiratory drive, 
respiratory muscle weakness and sleep-related breathing disorders (SBD). (Duranti et al., 1993, 
Saaresranta and Polo, 2002, Curnock et al., 1999) Hypothyroidism is characterized by 
mucopolysaccharides accumulation in the dermis, hypopharynx, tongue and other tissues. 
(Skatrud et al., 1981, Orr et al., 1981)  In its most severe form (myxedema), patients typically 
present with hypothermia, hypercapnia, hypotension and bradycardia. Both hypothyroidism 
and obstructive sleep apnea (OSA) share  common signs and symptoms. Increased fatigue and 
sleepiness, decreased cognitive function, decreased libido, obesity and depressed mood are 
common findings in both disorders. (Grunstein et al., 1993, Misiolek M and 2007, Chan et al., 
2010) Periorbital edema and pedal edema are other common findings in patients with either 
disorder. Nevertheless, snoring which is a hallmark of OSA is also reported in hypothyroid 
cases. (Misiolek M and 2007, Georgalas, 2011) The overlap between the two disorders may 
create a problem for the treating physician in differentiating both disorders and may result in a 
misdiagnosis or under-recognition of one of the disorders. Therefore, it is essential to consider 
both diseases in high risk patients and initiate the proper therapeutic plan accordingly. This 
chapter discusses how hypothyroidism interferes with respiratory physiology and then 
discusses the relationship between hypothyroidism and sleep disordered breathing. 
2. Obstructive Sleep Apnea (OSA)  
OSA is a disease characterized by repeated partial (hypopnea) or complete (apnea) collapse 
of the upper airway while asleep accompanied by surges in the sympathetic activity, cortical 
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arousals and episodes of hypoxia. (Chan et al., 2010) Patients usually present with 
complaints of excessive daytime sleepiness, un-refreshing sleep, fatigue or insomnia.  
Patients might have nocturnal awakenings with breathe holding, gasping, or choking. (Park 
et al., 2011, Madani and Madani, 2009) Very frequently, the bed partner report breathing 
interruptions, loud snoring or both during patient’s sleep. The main risk factors for OSA are 
obesity, older age, family history, increasing neck circumference and male gender. 
(BaHammam et al., 2008, Tsara et al., 2010) Menopause is the main risk factor for women 
even after adjustment for age and body mass index (BMI). (Ancoli-Israel et al., 1989, Block et 
al., 1980) Other predisposing factors include craniofacial features, maxillomandibular 
malformation or adenotonsillar enlargements. (Johns et al., 1998, Moser and Rajagopal, 1987, 
Orr and Martin, 1981) The prevalence of OSA syndrome (AHI> 5/hour and excessive 
daytime sleepiness) is estimated to be 2% to 4% of adults. (Young et al., 2002, Punjabi, 2008) 
Epidemiologic data suggest that roughly 1 of every 5 adults has at least mild OSA and 1 of 
every 15 adults has at least moderate OSA. (Young et al., 2002) The National Sleep 
Foundation survey found that 26% of the population has a high probability of OSA. 
(Hiestand et al., 2006) It is always essential to identify and treat persons with OSA because 
of its strong association with several medical conditions, occupational and social 
consequences. Untreated OSA can result in increased risk of cardiovascular morbidities such 
as myocardial infarction, congestive heart failure, stroke, refractory hypertension, and 
cardiac arrhythmia. (Guilleminault et al., 1983, Logan and Bradley, 2010, Somers et al., 2008, 
Ehrmann et al., 2011) Furthermore, cognitive dysfunction, depression, impaired glucose 
tolerance, occupational and increased motor vehicle accidents are the other consequences. 
(Sateia, 2003, Kaplan, 1992, Horne and Reyner, 1999, Radun and Summala, 2004) Treatment 
with continuous positive airway pressure (CPAP) can help in restoring the airway and 
reversing the majority of the associated morbidities. (Jean-Louis et al., 2010, Ferini-Strambi 
et al., 2003)   
3. Hypothyroidism and the respiratory system 
Respiratory system components (respiratory center, upper airway and lower respiratory 
system) can be affected by deficiencies in body hormones as well as excess hormonal 
secretion. (Saaresranta and Polo, 2002, Saaresranta and Polo, 2003, Behan et al., 2003, 
Takasaki and Hayashi, 1985) Thyroid hormone is one of the major body hormones. Its 
deficiency has been associated with multiple cardiovascular complications, respiratory 
failure and coma. (McQuade et al., 2011, Takamura et al., 2010, Behnia et al., 2000, Hall and 
Scanlon, 1979) The involvement of the respiratory system has resulted in a spectrum of 
clinical disorders including SBD, pulmonary hypertension, hypoventilation and severe 
respiratory failure. The following section explains the mechanisms through which 
hypothyroidism affect the respiratory system. 
Ventilatory drive 
Hypothyroidism is associated with diminished ventilatory drive for both hypoxia and 
hypercapnia. In animal models of induced hypothyroidism, a decrease in peripheral 
chemoreceptor response to hypoxia and hypercapnia has been observed. (Simsek et al., 
2004) In humans, approximately, one third of the hypothyroid patients have a blunted 
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ventilatory response to hypoxia/hypercapnia. (Zwillich et al., 1975, Duranti et al., 1993, 
Massumi RA, 1964) Predictors of blunted ventilatory response in hypothyroidism have 
been identified as female gender and very high levels of thyrotropin (>90 mIU/l). 
(Ladenson et al., 1988)  It is the severe form of hypothyroidism that is associated with 
diminished ventilatory control. Cases of myxedema and severe hypothyroidism (thyroid 
ablation) were found to have a diminished hypoxic ventilatory drive that was reversible 
with hormonal replacement therapy. (Zwillich et al., 1975) However, diminished 
hypercapnic ventilator drive was only seen in myxedema cases and was not responsive to 
hormonal therapy. (Zwillich et al., 1975) In a case report of a patient with 
hypothyroidism, central sleep apnea with blunted ventilatory response to hypoxia but 
normal hypercapnic ventilatory response, treatment with thyroxine therapy have resolved 
the central apneas and restored the hypoxic drive. The normal hypercapnic ventilatory 
drive has doubled with thyroxine therapy. (Millman et al., 1983) Hypoxic ventilatory 
drive has a rapid response to thyroxine replacement than hypercapnic ventilator drive. It 
might be that the central chemoreceptors require longer duration of therapy or they 
sustain a long-term impairment. The use of intravenous thyroxine therapy was shown to 
improve both hypoxic and hypercapnic ventilatory drive within one week of therapy. 
(Duranti et al., 1993) Severe degrees of alveolar hypoventilation and coma have also been 
reported in cases of severe hypothyroidism (myxedema). (Behnia et al., 2000, Orr et al., 
1981, Wall, 2000, Jordan, 1995)  
Hypothyroidism is reported in 3% of difficult to wean mechanically ventilated patients. 
(Datta and Scalise, 2004) Despite this low rate, it is a potentially treatable cause and 
should be considered when evaluating patients who fail to wean. Successful weaning 
from ventilator following correction of hypothyroidism has been reported. (Pandya et al., 
1989) Difficulty in weaning can be multifactorial in hypothyroid patients due to the 
multiple effects exerted by the hormone deficiency on different levels of the respiratory 
system.  
Upper respiratory tract 
- Mechanical Obstruction: Enlargement of the thyroid gland (goiter) in the presence of 
hypothyroidism or euthyroid state can create a mass effect on the upper 
airway,(Deegan PC, 1997, De Felice et al., 2006, Eloy et al., 2007) particularly when 
resuming the supine position. Such mechanical obstruction becomes prominent and can 
be associated with severe apneas. (Teramoto et al., 1995) Progressive enlargement of the 
thyroid goiter can further lead to stridor and an emergency intervention might be 
required in such severe cases. (Deegan PC, 1997) Reports have showed improvement of 
OSA with thyroidectomy. (Agrama, 2011) 
- Soft Tissue Infiltration: As a part of the generalized skin and soft tissue infiltration in 
hypothyroidism, the upper airway and particularly the pharynx gets narrowed. In 
hypothyroidism, mucopolysaccharides and proteins infiltrate the skin causing skin 
thickening, infiltrate the tongue causing enlargement and infiltrate the neck soft tissue 
resulting in variable degrees of upper airway obstruction. (Devdhar et al., 2007, Batniji 
RK, 2006 , Watson and Pearce, 1949) Hypothyroidism also alters the  myosin heavy 
chain profile specifically in the main dilator muscle the genioglossus muscle, which 
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results in compromising the muscle function. (Petrof et al., 1992) Despite these changes 
in upper airway structure and function, hypothyroidism per se is not an independent 
risk factor for OSA if other known risk factors as male gender and obesity are not 
present. (Pelttari et al., 1994)  Upper airway obstruction in hypothyroid patients might 
not be very evident initially. During stressful situations, occult hypothyroidism can 
result in devastating outcomes such as in post-extubation upper airway obstruction 
following emergency intubation or post-operatively. Cases of severe emergency 
obstruction in undiagnosed hypothyroidism have been reported. (Sherry and 
Hutchinson, 1984, Stahl N, 1988)  
Lower respiratory tract 
As with upper respiratory tract, the different structures of the lower respiratory tract can be 
affected to a variable degree with alterations in thyroid hormone levels.  
- Airways: Very few studies have investigated airway diseases in hypothyroidism. In 
one study, patients with treated hypothyroidism were found to have more symptoms 
of breathlessness and wheeze. (Birring et al., 2003) And when evaluated by 
Methacholine challenge test, patients with treated hypothyroidism had more airways 
hyperreactivity than normal healthy individuals. Induced sputum showed higher 
levels of inflammatory cells, absolute neutrophil count, absolute lymphocyte count 
and increased levels of sputum interleukin-8 suggesting increased airway 
inflammation compared to control. (Birring et al., 2005) 
- The lung parenchyma: The interstitium can also be affected in hypothyroidism; two 
cases of lung fibrosis have been reported in patients with severe hypothyroidism. 
Initiating therapy for hypothyroidism was associated with significant clinical and 
radiological improvement in lung fibrosis. (George et al., 2009)  
- Respiratory Muscles: Both inspiratory and expiratory respiratory muscles are 
weakened in hypothyroidism in a direct linear relationship to the thyroid hormone 
level and it is reversible with thyroxine therapy. (Siafakas et al., 1992) Furthermore, 
thyroid deficient muscles have impaired free fatty acid utilization, which enhances their 
glycogen consumption, thereby reducing skeletal muscle endurance. (Baldwin et al., 
1980) One of the major inspiratory muscles that are involved in hypothyroidism is the 
diaphragm. Diaphragm weakness can be very severe and associated with 
hypoventilation. (Martinez et al., 1989, Laroche et al., 1988)  
- Pulmonary Vasculature: Both hyper/hypothyroidism has been associated with 
pulmonary arterial hypertension (PAH). (Li et al., 2007, Arroliga et al., 2000) A 
prevalence of 22-24% of hypothyroidism is reported in patients with PAH. (Curnock et 
al., 1999, Silva et al., 2009) It is thought that hypoxia/hypercapnia in hypothyroid 
patients is responsible for causing and worsening PAH. It is also known that both 
disorders are associated with autoimmune diseases, which raises the possibility of an 
immune pathyphysiological mechanism. (Badesch et al., 1993, Chu et al., 2002)   
4. Prevalence studies of hypothyroidism in OSA 
The first case reporting an apneic episode in a patient with myxedema was published in 
1964. (Massumi RA, 1964) Following that, studies have investigated further the prevalence 
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of OSA in hypothyroidism population and vice versa (Table 1).  Overall, the prevalence of 
clinical hypothyroidism in patients diagnosed with OSA or referred to sleep centers with 
a clinical suspicion of OSA is not higher than the prevalence in the general population. 
The prevalence in patients evaluated by polysomnography for OSA is 0.7-3.4%, 
depending on the upper limit set for normal TSH, gender and age distribution of the 
studied samples. (Lin CC, 1992, Meslier et al., 1992, Winkelman JW, 1996, Kapur VK and 
BM, 1998, Winkelman et al., 1996)  Kapur et al, reported a prevalence of 1.4% of 
subclinical hypothyroidism in OSA patients and this association was greater in females 
and those less than 50 years of age. (Kapur VK and BM, 1998) In a group of Taiwanese 
patients with OSA, a prevalence of 3.1% was reported despite using higher TSH level (>25 
mIU/l) to define hypothyroidism. (Lin et al., 1992) The prevalence is also not significantly 
different in patients highly suspected to have OSA (1.5%) than those already diagnosed to 
have OSA by overnight sleep study (2.4%). (Skjodt et al., 1999) This is similar to 
Winkelman and co-workers who reported a prevalence of 1.6% in patients suspected to 
have OSA and 2.9% in those confirmed to have OSA. (Winkelman et al., 1996)  Other 
studies have reported a much higher prevalence. In a study of 78 overweight and obese 
adult patients referred to a sleep clinic, a prevalence rate of 11.5% was reported. (Resta O, 
2004) The studied population was characterized by higher BMI, older age and more 
females. All these three variables are known risk factors for hypothyroidism, which might 
have resulted in a higher rate. (Sawin CT, 1979, Bilous and Tunbridge, 1988, Fox et al., 
2008) Females with OSA have been reported to have higher rates of undiagnosed and 
diagnosed hypothyroidism. (Winkelman et al., 1996, Alotair and Bahammam, 2008) In 
clinical practice, these variables are important to consider when assessing the risk of 
hypothyroidism in patients with suspected or diagnosed OSA. Female gender, increased 
BMI and older age are also well established risk factors for hypothyroidism. (Sawin CT, 
1979) This might explain the higher prevalence of hypothyroidism reported in some studies. 
(Resta O, 2004) Nevertheless, increased age and BMI are the main risk factors for OSA. 
(Punjabi, 2008, Hiestand et al., 2006) Thus, the co-existence of both diseases is expected 
and a high index of suspension is required in high risk patients. 
Some of the previous studies defined hypothyroidism as the presence of a high serum 
thyroid-stimulating hormone (TSH) level without commenting on thyroxine hormone level. 
This means that some of the patients thought to have hypothyroidism may actually have 
had subclinical hypothyroidism, which carries different therapeutic and prognostic 
implications (Miller and Husain, 2003, Winkelman et al., 1996, Pham and Shaughnessy, 
2008).  In a recent study, Bahammam et al. reported the prevalence of newly diagnosed 
clinical hypothyroidism as 0.4%, and the prevalence of newly diagnosed subclinical 
hypothyroidism as 11.1%. (Bahammam et al., 2011) In the non-OSA patients, the prevalence 
of newly diagnosed clinical hypothyroidism was reported as 1.4%, and the prevalence of 
newly diagnosed subclinical hypothyroidism as 4%. (Bahammam et al., 2011)  The authors 
concluded that the prevalence of newly diagnosed clinical hypothyroidism was low; 
however, subclinical hypothyroidism was common among patients with OSA. In lieu of the 
uncertainty of the benefit achieved by treating subclinical hypothyroidism, the authors 
recommended not to perform routine thyroid function testing for OSA patients. 
(Bahammam et al., 2011) 
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results in compromising the muscle function. (Petrof et al., 1992) Despite these changes 
in upper airway structure and function, hypothyroidism per se is not an independent 
risk factor for OSA if other known risk factors as male gender and obesity are not 
present. (Pelttari et al., 1994)  Upper airway obstruction in hypothyroid patients might 
not be very evident initially. During stressful situations, occult hypothyroidism can 
result in devastating outcomes such as in post-extubation upper airway obstruction 
following emergency intubation or post-operatively. Cases of severe emergency 
obstruction in undiagnosed hypothyroidism have been reported. (Sherry and 
Hutchinson, 1984, Stahl N, 1988)  
Lower respiratory tract 
As with upper respiratory tract, the different structures of the lower respiratory tract can be 
affected to a variable degree with alterations in thyroid hormone levels.  
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one study, patients with treated hypothyroidism were found to have more symptoms 
of breathlessness and wheeze. (Birring et al., 2003) And when evaluated by 
Methacholine challenge test, patients with treated hypothyroidism had more airways 
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and increased levels of sputum interleukin-8 suggesting increased airway 
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- The lung parenchyma: The interstitium can also be affected in hypothyroidism; two 
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hypoventilation. (Martinez et al., 1989, Laroche et al., 1988)  
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pulmonary arterial hypertension (PAH). (Li et al., 2007, Arroliga et al., 2000) A 
prevalence of 22-24% of hypothyroidism is reported in patients with PAH. (Curnock et 
al., 1999, Silva et al., 2009) It is thought that hypoxia/hypercapnia in hypothyroid 
patients is responsible for causing and worsening PAH. It is also known that both 
disorders are associated with autoimmune diseases, which raises the possibility of an 
immune pathyphysiological mechanism. (Badesch et al., 1993, Chu et al., 2002)   
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1964. (Massumi RA, 1964) Following that, studies have investigated further the prevalence 
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of OSA in hypothyroidism population and vice versa (Table 1).  Overall, the prevalence of 
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5. Prevalence studies of OSA in hypothyroidism 
Limited data are available about the prevalence of OSA in hypothyroid patients (Table 2). 
The incidence is estimated to range from 25-82%. Most of the obtained data are from case 
reports and case series and their findings are variable. In a study of 50 patients with primary 
hypothyroidism, 30% where found to have OSA (AHI ≥5/hour). (Jha et al., 2006) These 
patients had overt severe hypothyroidism as manifested by TSH levels and symptoms. For 
milder cases and subclinical cases, the prevalence might be less. The variability in the results 
is influenced by the characteristics of the studied group. Predominance of male gender can 
result in a higher prevalence of OSA as it is one of the main risk factors for OSA. In smaller 
studies, a higher prevalence has been reported. (Rajagopal et al., 1984)    
 
 No. of 
Patients 
OSA Citeria No. of OSA (%) Patients Characteristics 
Jha A, et al (Jha 




Mild OSA 8, 
Moderate 1, 
Severe 6 
Females 58%, Mean 
Age 34±11 years, 
Overweight 36%, 
Obese 16% 
Rajagopal et al 
(Rajagopal et 
al., 1984) 
11 -- 9 (82%) 
Mean AHI 
(71.8/hour) 
6 patients obese  
(AHI 99/hour) 
3 non-obese (AHI 
16.3/hour) 





5 (33%) 11 Females, Mean Age 
50.3 (30-70) years, Mean 
BMI 29.2 (21.3-
41)kg/m2 





3 mild OSA, 2 
severe OSA 
4 Females, Mean Age 
49.4±7.3 years, IBW 
134.6±23.2% 
Hira et al (Hira 
HS, 1999) 
20  9 (45%) ----- 





4 (40%) ---- 
RDI: Respiratory Disturbance Index, IBW: Ideal Body Weight 
Table 2. Prevalence Studies of OSA in Hypothyroidism 
6. The clinical effects of treating hypothyroidism in OSA patients 
Theoretically, replacing thyroid hormone should reverse most if not all the complications 
associated with the state of deficiency. However, in real clinical practice, this is not 
absolutely correct. Changes such as respiratory muscle weakness can be reversible with 
thyroxine therapy. Difficult weaning in hypothyroid patients can be facilitated with 
thyroxine therapy too and mechanical obstruction due to thyroid goiter can be reverted with 
thyroidectomy. However, OSA response to thyroxine therapy is variable. In a case series of 
10 hypothyroid patients with OSA, treatment with thyroxine was associated with nocturnal 
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angina and arrhythmia in two patients. Initiation of CPAP therapy prevented angina and 
arrhythmia. Eight of these patients were followed after achieving euthyroid state and six of 
them had persistent sleep apnea requiring CPAP therapy. (Grunstein and Sullivan, 1988) 
Thereby, treatment of hypothyroidism in the presence of OSA can be potentially hazardous 
and lead to cardiovascular complications even with small doses of thyroxine as thyroxine 
therapy may increase metabolic rate in the presence of significant hypoxia. Combination 
therapy (CPAP + Thyroxine) can be helpful in such situation. In another series of nine 
hypothyroid patients with OSA (AHI range 17-176/hour), thyroxine therapy improved 
outcome. Six of them were obese and had the higher range of AHI and showed significant 
improvement in AHI after 3-12 months of thyroxine therapy despite no improvement in 
weight. (Rajagopal et al., 1984) Another series of 5 patients with OSA who received 
thyroxine therapy showed significant reduction in AHI after 4 months of therapy; however, 
snoring persisted and required longer duration of therapy to improve. (Lin et al., 1992) 
Snoring refers to upper airway resistance and the longer duration required to improve it is 
basically related to the duration needed to resolve or improve upper airway changes 
induced by hypothyroidism. In a larger group of patients, Resta and co-workers divided 
patients into 3 groups: group A: 63 patients with normal thyroid function, group B: 30 
patients affected with subclinical hypothyroidism and treated with levothyroxine for at least 
2 years and group C: 15 patients with TSH >4mIU/l and not treated with levothyroxine. 
(Resta et al., 2005) The prevalence and severity of OSA did not differ between the three 
groups and levothyroxine therapy did not influence OSA outcome in patients with 
subclinical hypothyroidism. It was also noticed that levothyroxine therapy in patients with 
subclinical hypothyroidism and OSA was associated with less daytime sleepiness as 
measured by the Epworth sleepiness scale when compared to the untreated group. (Resta et 
al., 2005) Untreated subclinical hypothyroidism by itself is a known cause of excessive 
daytime sleepiness measured both subjectively and objectively, which improved with 
thyroxine therapy. (Shinno et al., 2009) On the other hand, the outcome of treating primary 
hypothyroidism with levothyroxine in patients with OSA has resulted in a significant 
improvement in AHI within 7-11 months of therapy. This improvement was accompanied 
by significant reduction in BMI, skinfold thickness, pedal edema and other biochemical 
markers. (Jha et al., 2006) However, in the same study, two patients have lost follow-up and 
both failed to show any improvement in OSA following levothyroxine therapy. One is 
thought to be due to his overweight that did not reduce with therapy. (Jha et al., 2006) 
Failure to improve OSA by achieving euthyroid state suggests that hypothyroidism is not 
the only factor and other factors play a role in causing OSA.  It is also thought that thyroid 
hormone deficiency results in long term changes in the upper airway and thus improvement 
in OSA lags behind achieving the euthyroid state. (Grunstein et al., 1993) Furthermore, it is 
the treatment of the severe forms of hypothyroidism (myxedema) that improves the 
concomitant OSA. (Orr et al., 1981) Based on the available evidence, thyroxine cannot be 
considered as the only therapeutic option for OSA in patients with hypothyroidism 
especially in elderlies and those with cardiovascular diseases. (Veasey et al., 2006) The 
degree of hypoxia accompanying apneas may worsen with initiation of thyroxine therapy. 
In the hypothyroid state and as a result of the low metabolic rate, oxygen consumption by 
several body organs is less than usual, which can help to maintain a reasonable oxygen level 
compared to the duration and severity of apneas. With the increment in basal metabolic rate 
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seen with the commencement of thyroxine therapy, oxygen consumption is increased by 
body organs and short-duration apneas/hypopneas can result in dramatic oxygen 
desaturation. Therefore, CPAP therapy should not be delayed for months awaiting the 
results of thyroxine use. The lack of response to thyroxine suggests that either there is no 
casual association between hypothyroidism and OSA or those alterations in breathing 
mechanics and upper airways require longer duration of therapy to reverse them and that 
longer duration of follow up might show a beneficial effect of thyroxine therapy. 
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Other Outcomes 
Jha A, et al 
(Jha et al., 
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12 9 months Significant 
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et al., 1984) 
9 3-12 months AHI decreased 71.8 ± 
18.0  to 12.7 ± 6.1 
No change in BMI 
Misiolek et al 
(Misiolek M 
and 2007) 
5 5-6 months RDI persisted in two 
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showed insignificant 
reduction in RDI 
BMI and loud 
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1999) 
9 3 months 6 complete recovery, 
partial recovery in two 
and no recovery in one 
 
Table 3. Summary of outcome studies of thyroxine therapy in OSA patients 
7. Evaluating thyroid function in OSA patients 
It is important when ordering a laboratory investigation for any disease to consider the 
prevalence of the problem, the associated complications, cost-effectiveness and the 
effectiveness of treating the disease. Blood tests TSH, thyroxine (T4) are not clinically 
indicated in patients with OSA. Hypothyroidism can be associated with severe cases of 
OSA +/- hypoventilation but it is not an independent risk factor. Nocturnal upper airway 
obstruction has been evaluated in both hypothyroid and euthyroid subjects. The incidence 
of upper airway obstruction is higher in hypothyroid 7.7% compared to euthyroid 1.5% 
but after controlling for weight, age and gender, hypothyroidism does not significantly 
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7. Evaluating thyroid function in OSA patients 
It is important when ordering a laboratory investigation for any disease to consider the 
prevalence of the problem, the associated complications, cost-effectiveness and the 
effectiveness of treating the disease. Blood tests TSH, thyroxine (T4) are not clinically 
indicated in patients with OSA. Hypothyroidism can be associated with severe cases of 
OSA +/- hypoventilation but it is not an independent risk factor. Nocturnal upper airway 
obstruction has been evaluated in both hypothyroid and euthyroid subjects. The incidence 
of upper airway obstruction is higher in hypothyroid 7.7% compared to euthyroid 1.5% 
but after controlling for weight, age and gender, hypothyroidism does not significantly 
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predict upper airway obstruction. (Pelttari et al., 1994) Thus, upper airway obstruction is 
related to obesity and male gender and not to hypothyroidism per se. The prevalence of 
clinical hypothyroidism, as mentioned above, is not higher than the general population. 
Furthermore, there is no strong evidence to support the resolution of OSA with thyroxine 
therapy. However, thyroxine therapy should be initiated in hypothyroid patients to 
manage the other co-morbidities associated with hypothyroidism but not as a medical 
therapy for OSA. Thyroxine therapy can not abandon the need for CPAP therapy and 
should not delay its initiation. The recommended practice is to be selective when ordering 
TSH/T4 test to high risk population (females, morbidly obese and older age), persistent 
symptoms of fatigue and sleepiness despite proper CPAP therapy and in those with 
secondary causes for hypothyroidism (thyroid ablation, thyroidectomy, panpituitarism).  
8. Conclusion 
For OSA patients, the prevalence of clinical hypothyroidism is not higher than the general 
population. It is essential to consider the risk factors for hypothyroidism when evaluating 
patients for sleep apnea as well as considering OSA risk factors when evaluating 
hypothyroid cases. Routine blood testing for TSH and T4 should be saved for OSA patients 
with severe obesity, persistent sleepiness despite adequate CPAP therapy and with overt 
hypothyroid symptoms and signs. For hypothyroid patients with symptoms suggestive of 
OSA, a diagnostic sleep study is warranted and CPAP therapy should be commenced prior 
to thyroxine therapy especially in the elderly and patients with cardiovascular diseases. Re-
evaluating OSA patients after achieving euthyroid state can be done, especially if 
accompanied by weight reduction. Some of OSA cases might resolve but the majority seems 
to persist. Long-term studies might be able to explore better the impact of thyroxine therapy 
and help in understanding time-course of the problem. 
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predict upper airway obstruction. (Pelttari et al., 1994) Thus, upper airway obstruction is 
related to obesity and male gender and not to hypothyroidism per se. The prevalence of 
clinical hypothyroidism, as mentioned above, is not higher than the general population. 
Furthermore, there is no strong evidence to support the resolution of OSA with thyroxine 
therapy. However, thyroxine therapy should be initiated in hypothyroid patients to 
manage the other co-morbidities associated with hypothyroidism but not as a medical 
therapy for OSA. Thyroxine therapy can not abandon the need for CPAP therapy and 
should not delay its initiation. The recommended practice is to be selective when ordering 
TSH/T4 test to high risk population (females, morbidly obese and older age), persistent 
symptoms of fatigue and sleepiness despite proper CPAP therapy and in those with 
secondary causes for hypothyroidism (thyroid ablation, thyroidectomy, panpituitarism).  
8. Conclusion 
For OSA patients, the prevalence of clinical hypothyroidism is not higher than the general 
population. It is essential to consider the risk factors for hypothyroidism when evaluating 
patients for sleep apnea as well as considering OSA risk factors when evaluating 
hypothyroid cases. Routine blood testing for TSH and T4 should be saved for OSA patients 
with severe obesity, persistent sleepiness despite adequate CPAP therapy and with overt 
hypothyroid symptoms and signs. For hypothyroid patients with symptoms suggestive of 
OSA, a diagnostic sleep study is warranted and CPAP therapy should be commenced prior 
to thyroxine therapy especially in the elderly and patients with cardiovascular diseases. Re-
evaluating OSA patients after achieving euthyroid state can be done, especially if 
accompanied by weight reduction. Some of OSA cases might resolve but the majority seems 
to persist. Long-term studies might be able to explore better the impact of thyroxine therapy 
and help in understanding time-course of the problem. 
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1. Introduction  
The hypothalamic-pituitary thyroid (HPT) axis plays a critical role in mediating changes in 
metabolism and thermogenesis. Its regulation is mainly determined by thyrotropin-
releasing hormone (TRH), which is a tripeptide (pGlu-His-ProNH2) synthesized in the 
paraventricular nucleus (PVN) of the hypothalamus. TRH-containing-neurons of medial 
and periventricular parvocellular compartments of the PVN are essential for HPT axis 
regulation since they are the only ones with hypophysiotrophic properties (Lechan & 
Fekete, 2006). Axon terminals of TRHergic neurons are highly dense in the median 
eminence (ME), in close apposition to capillaries of the hypophysial-portal system (Toni & 
Lechan, 1993), where TRH is released and able to stimulate the synthesis and release of 
thyrotropin (TSH) and prolactin from anterior pituitary (Bowers et al., 1968; Harris et al., 
1978). TSH then stimulates thyroxine (T4) and triiodothyronine (T3) synthesis in the thyroid 
gland as well as their release into the peripheral circulation. Under normal conditions only a 
small fraction of T3 is generated by the thyroid gland, the remainder of T3, which is available 
for binding sites in the plasma and body cells, is produced by monodeiodination of T4 
(Danforth, 1983). This action is catalyzed by both type 1 (D1) or type 2 (D2) iodothyronine 
deiodinases, the first is abundant in liver, kidney and pituitary (Araujo et al., 2008) whereas 
the latter is mainly present in brown adipose tissue (BAT), pituitary and Central Nervous 
System (CNS) (Diano et al., 1998). The enzyme activity of the liver and kidney is responsive 
to the nutritional status of an organism and is found to be more active during states of 
accelerated glucose metabolism (Danforth, 1983).  
Thyroid hormones (TH) are highly active in the metabolism and necessary for most bodily 
functions such as growth, development and maintenance of homeostasis; they are able to 
increase metabolic rate by accelerating fuel oxidation in nearly all tissues: TH activate 
lipolysis, glucose metabolism and protein synthesis (Yen, 2001).  
Hypothalamic TRH expression in the PVN and TSH release from the anterior pituitary are 
inhibited by T3, performing a negative feedback loop that regulates HPT axis function 
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System (CNS) (Diano et al., 1998). The enzyme activity of the liver and kidney is responsive 
to the nutritional status of an organism and is found to be more active during states of 
accelerated glucose metabolism (Danforth, 1983).  
Thyroid hormones (TH) are highly active in the metabolism and necessary for most bodily 
functions such as growth, development and maintenance of homeostasis; they are able to 
increase metabolic rate by accelerating fuel oxidation in nearly all tissues: TH activate 
lipolysis, glucose metabolism and protein synthesis (Yen, 2001).  
Hypothalamic TRH expression in the PVN and TSH release from the anterior pituitary are 
inhibited by T3, performing a negative feedback loop that regulates HPT axis function 
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(Ching & Utiger, 1983; Lechan & Hollenberg, 2003; Reichlin et al., 1978). TRH synthesis is 
negatively controlled by T3 that acts through its binding to thyroid hormone receptor (TR); 
TRs are derived from two genes (TRα and TRβ) encoding different T3-binding TR active 
isoforms (Yen, 2001).  TRs are DNA binding transcription factors able to recognize specific 
DNA sequences in the promoter regions of T3 target genes; in fact, T3 regulates DNA-
dependent RNA polymerase enzyme activity increasing or decreasing content of several 
mRNAs. Pro-TRH gene promoter contains a consensus region for the thyroid-hormone 
response element (TRE) (Segerson et al., 1987). Hyperthyroidism facilitates that TR sites are 
occupied by its ligand, which in turn are translocated to the nucleus and by binding to the 
TRE region in the DNA, inhibit TRH transcription. In contrast, when a decreased T3 tissue 
concentration is present, un-liganded TR is bound to a co-activator protein, increasing pro-
TRH transcription (Lechan & Kakucska, 1992; Perello et al., 2006).  
Besides its regulation at the transcription level, THs are also involved in the processing of 
the large inactive precursor (pre-pro-TRH): once proTRH is transported from the 
endoplasmic reticulum (ER) to the trans-Golgi network (TGN), a proteolytic processing 
occurs. Those processes are conducted by two prohormone convertases (PCs), PC1/3 and 
PC2, which cleave proTRH at basic residues flanking TRH sequence (Nillni et al., 1995, 1996; 
Schaner et al., 1997). PCs activity may also be regulated by TH (Espinosa et al., 2007; Perello 
et al., 2006). During hypothyroidism, end products of proTRH processing increase (Perello 
et al., 2006), while a decreased post-translational processing of proTRH is observed in T4 
treatment-induced hyperthyroidism (Segerson et al., 1987) rendering an accumulation of 
TRH unprocessed intermediate forms combined with a down-regulation of PCs (Perello et 
al., 2006). Several studies suggest that thyroid hormones negatively regulate the PC 
expression through the binding of its receptors to a consensus region localized in PC genes 
promoters (Li et al., 1999, 2000; Shen et al., 2005). Therefore, HPT axis regulation by thyroid 
status in the PVN may lead to an altered hormonal biosynthesis.  
Besides TH control of proTRH transcription, corticosterone is also able to regulate it. Rat 
TRH gene promoter also contains a consensus region for glucocorticoids; it is a composite 
GRE element (cGRE) that is located at -218, -197 bp. It has been studied the effect of 
corticosterone or the synthetic corticosteroid dexamethasone under different conditions: it is 
observed in vivo that adrenalectomized animals present an increased TRH expression in the 
PVN, while administering rats with glucocorticoids on their drinking water, it is induced a 
decrease in peptide mRNA levels. Moreover, hypothalamic primary cultured cells added 
with dexamethasone present a reduced TRH synthesis. Furthermore, although nuclear 
extracts of hypothalamic cells incubated with 8Br-cAMP, present an increased transcription 
rate of TRH, the combined effect of glucocorticoids and cAMP pathway activators, is unable 
to elevate peptide synthesis (Diaz-Gallardo et al., 2010).  
Degradation of the released peptide is achieved by the pyroglutamyl peptidase II (PPII, EC 
3.4.19.6). It is a highly specific membrane-bound metallopeptidase that exclusively 
hydrolyzes the pyroglutamyl-histidyl peptide bond of TRH (Charli et al., 1998) in the 
extracellular space. PPII is widely distributed in the CNS and in some peripheral tissues 
(Heuer et al., 2000; Vargas et al., 1987). Its soluble form is named thyroliberinase present in 
serum, which is thought to be synthesized in the liver and derived from the same gene than 
PPII.  
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Anterior pituitary PPII enzyme is regulated by different factors and hormones: low serum 
TH levels decrease its activity and mRNA content, while hyperthyroidism increases both, 
suggesting that PPII regulation participates in the negative feedback of the TH that controls 
the HPT axis function (Bauer, 1988; Ponce et al., 1988; Schomburg & Bauer, 1995). Estrogens 
in contrast, affect PPII activity negatively, which may allow TRH to increase the duration of 
its effect in the anterior pituitary (Bauer, 1988). On the other hand, the addition of TRH to 
pituitary cultured cells induces a down-regulation of both PPII mRNA levels and activity 
(Vargas et al., 1994, 1998); furthermore, incubation with activators of cAMP pathway may 
mimic TRH effect on PPII (Vargas et al., 1998).  
Body weight changes in obesity, fasting or food restriction are associated to alterations in 
circulating TH content. In vivo studies have shown that inhibition of pituitary PPII, increases 
the duration of TRH-induced release of TSH (Scalabrino et al., 2007), thus it is likely that 
PPII regulation might contribute to the reestablishment of the HPT axis homeostasis. The 
activity in serum of the soluble enzyme thyroliberinase, is known to be modified by body 
weight changes in obese humans independently of their thyroid hormone levels  (Friedman 
et al., 1995). Thus, all those data support that TRH degradation plays a regulating role in the 
HPT axis function. 
2. Adaptive hypothyroidism  
Adaptive function of HPT axis allows animals to respond to changes in energy demands 
during growth, gestation, lactation or sickness periods. Nutrient availability that is modified 
with seasons or changing weather, triggers adaptive changes in the HPT function leading 
organisms to enlarge fat and glycogen deposits or to slow its degradation, depending on 
energy needs.   
Main function of the thyroid gland is to maintain the basal metabolic rate in all cells. 
Thyroid hormone levels are challenged during the transition from fed to a starvation state; 
during starvation a reduced metabolic rate helps to preserve energy stores. This response is 
considered as the major evolutionary mechanism designed to ensure survival when food is 
scarce, although nowadays it may represent a risk to become obese during times of great 
food availability (Levin, 2006; Ogden et al., 2007a, 2007b).  
During food restriction and starvation the feedback mechanism exerted by TH on 
hypothalamus and pituitary, is altered. Low body weight accompanied by decreased leptin 
serum levels induce a decrease in TH serum concentration (Ahima et al., 1996). In spite of 
the induced hypothyroidism, food deprivation for 3 days reduces the hypothalamic proTRH 
mRNA content, the amount of proTRH-derived peptides in the PVN, TRH release into 
hypophysial portal blood (Rondeel et al., 1992), pituitary levels of TSHβ mRNA and TSH 
plasma levels; it also induces a marked increase in plasma corticosterone content (van 
Haasteren et al., 1995). Re-feeding of starved male rats normalizes T4 serum levels within 3 
days, while T3 and TSH content increases above the values observed before starvation. 
Both male and female rats respond to a 4 day food deprivation with a body weight loss 
however, females have a better adaptation to energy deficit than males: they present 
decreased T4 and T3 levels together with reduced TSH serum levels after starvation (Rondeel 
et al., 1992), also their basal hypothalamic TRH release is lower than in males (Rondeel et al., 
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et al., 2006), while a decreased post-translational processing of proTRH is observed in T4 
treatment-induced hyperthyroidism (Segerson et al., 1987) rendering an accumulation of 
TRH unprocessed intermediate forms combined with a down-regulation of PCs (Perello et 
al., 2006). Several studies suggest that thyroid hormones negatively regulate the PC 
expression through the binding of its receptors to a consensus region localized in PC genes 
promoters (Li et al., 1999, 2000; Shen et al., 2005). Therefore, HPT axis regulation by thyroid 
status in the PVN may lead to an altered hormonal biosynthesis.  
Besides TH control of proTRH transcription, corticosterone is also able to regulate it. Rat 
TRH gene promoter also contains a consensus region for glucocorticoids; it is a composite 
GRE element (cGRE) that is located at -218, -197 bp. It has been studied the effect of 
corticosterone or the synthetic corticosteroid dexamethasone under different conditions: it is 
observed in vivo that adrenalectomized animals present an increased TRH expression in the 
PVN, while administering rats with glucocorticoids on their drinking water, it is induced a 
decrease in peptide mRNA levels. Moreover, hypothalamic primary cultured cells added 
with dexamethasone present a reduced TRH synthesis. Furthermore, although nuclear 
extracts of hypothalamic cells incubated with 8Br-cAMP, present an increased transcription 
rate of TRH, the combined effect of glucocorticoids and cAMP pathway activators, is unable 
to elevate peptide synthesis (Diaz-Gallardo et al., 2010).  
Degradation of the released peptide is achieved by the pyroglutamyl peptidase II (PPII, EC 
3.4.19.6). It is a highly specific membrane-bound metallopeptidase that exclusively 
hydrolyzes the pyroglutamyl-histidyl peptide bond of TRH (Charli et al., 1998) in the 
extracellular space. PPII is widely distributed in the CNS and in some peripheral tissues 
(Heuer et al., 2000; Vargas et al., 1987). Its soluble form is named thyroliberinase present in 
serum, which is thought to be synthesized in the liver and derived from the same gene than 
PPII.  
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Anterior pituitary PPII enzyme is regulated by different factors and hormones: low serum 
TH levels decrease its activity and mRNA content, while hyperthyroidism increases both, 
suggesting that PPII regulation participates in the negative feedback of the TH that controls 
the HPT axis function (Bauer, 1988; Ponce et al., 1988; Schomburg & Bauer, 1995). Estrogens 
in contrast, affect PPII activity negatively, which may allow TRH to increase the duration of 
its effect in the anterior pituitary (Bauer, 1988). On the other hand, the addition of TRH to 
pituitary cultured cells induces a down-regulation of both PPII mRNA levels and activity 
(Vargas et al., 1994, 1998); furthermore, incubation with activators of cAMP pathway may 
mimic TRH effect on PPII (Vargas et al., 1998).  
Body weight changes in obesity, fasting or food restriction are associated to alterations in 
circulating TH content. In vivo studies have shown that inhibition of pituitary PPII, increases 
the duration of TRH-induced release of TSH (Scalabrino et al., 2007), thus it is likely that 
PPII regulation might contribute to the reestablishment of the HPT axis homeostasis. The 
activity in serum of the soluble enzyme thyroliberinase, is known to be modified by body 
weight changes in obese humans independently of their thyroid hormone levels  (Friedman 
et al., 1995). Thus, all those data support that TRH degradation plays a regulating role in the 
HPT axis function. 
2. Adaptive hypothyroidism  
Adaptive function of HPT axis allows animals to respond to changes in energy demands 
during growth, gestation, lactation or sickness periods. Nutrient availability that is modified 
with seasons or changing weather, triggers adaptive changes in the HPT function leading 
organisms to enlarge fat and glycogen deposits or to slow its degradation, depending on 
energy needs.   
Main function of the thyroid gland is to maintain the basal metabolic rate in all cells. 
Thyroid hormone levels are challenged during the transition from fed to a starvation state; 
during starvation a reduced metabolic rate helps to preserve energy stores. This response is 
considered as the major evolutionary mechanism designed to ensure survival when food is 
scarce, although nowadays it may represent a risk to become obese during times of great 
food availability (Levin, 2006; Ogden et al., 2007a, 2007b).  
During food restriction and starvation the feedback mechanism exerted by TH on 
hypothalamus and pituitary, is altered. Low body weight accompanied by decreased leptin 
serum levels induce a decrease in TH serum concentration (Ahima et al., 1996). In spite of 
the induced hypothyroidism, food deprivation for 3 days reduces the hypothalamic proTRH 
mRNA content, the amount of proTRH-derived peptides in the PVN, TRH release into 
hypophysial portal blood (Rondeel et al., 1992), pituitary levels of TSHβ mRNA and TSH 
plasma levels; it also induces a marked increase in plasma corticosterone content (van 
Haasteren et al., 1995). Re-feeding of starved male rats normalizes T4 serum levels within 3 
days, while T3 and TSH content increases above the values observed before starvation. 
Both male and female rats respond to a 4 day food deprivation with a body weight loss 
however, females have a better adaptation to energy deficit than males: they present 
decreased T4 and T3 levels together with reduced TSH serum levels after starvation (Rondeel 
et al., 1992), also their basal hypothalamic TRH release is lower than in males (Rondeel et al., 
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1992). HPT axis adaptation depends on the age of animals: fasted weaning rats do not 
decelerate the HPT axis function; in spite of its 30% loss of weight compared to non fasted 
animals, TRH release remains active, TSH serum levels do not decay and PPII enzymatic 
activity is reduced, presumably allowing the peptide to exert its effects on the pituitary for a 
longer time (de Gortari et al., 2000). In contrast, adult animals after 72 h of fasting show a 
decreased TRH content in the ME, reduced TSH serum levels and no change in PPII activity 
(de Gortari et al., 2000). The fact that TSH does not change or is reduced when T3 and T4 
serum levels are low is probably due to a decreased expression of the thyroid receptors in 
thyrotrophes induced by starvation (Bavli, 1980; St Germain & Galton, 1985; van Doom et 
al., 1984). A more recent explanation involves a central deregulation of deiodinases activities 
causing the fasting-associated changes in thyroid function.  
Food deprivation is a stressful situation that enhances adrenal release of corticosteroids 
(Garcia-Belenguer et al., 1993; Mitev et al., 1993; Woodward et al., 1991). Starvation-induced 
corticosterone secretion reduces TRH and TSH-β synthesis and release; dexamethasone 
treatment also reduces the hypothalamic TRH secretion into hypophysial portal blood (van 
Haasteren et al., 1995). Thus, corticosterone is a factor that may be participating in the HPT 
adaptive changes to nutrient deficit. 
2.1 Underlying factors of negative energy balance-associated hypothyroidism 
Some factors have been studied as contributors to decreased synthesis of TRH in the PVN 
during fasting or food restriction, such as the activity of deiodinases. Type 2 deiodinase (D2) 
enzyme activity and its mRNA content in the tanycytes of the medial basal hypothalamus, 
increases with fasting (Lechan & Fekete, 2005); D2 converts T4 to T3 and therefore is 
responsible for the maintenance of the medial basal hypothalamic (MBH) local T3 
concentration (Diano et al., 1998), thus the inhibition of TRH expression observed in the 
medial PVN of starved rats may be a consequence of a higher production of local T3 
(Coppola et al., 2005). 
Besides corticosterone and deiodinase activity, leptin peripheral administration can prevent 
the fall of TH in starved rodents, and the reduced expression of proTRH in the PVN after 
fasting (Ahima et al., 1996; Legradi et al., 1997). In other words, fasting-induced decrease of 
serum leptin content is able to reduce proTRH expression in the PVN, also to facilitate the 
high secretion of corticosterone that contributes to elevate D2 activity (Coppola et al., 2005) 
around the third ventricle. Thus, starvation and food restriction create a state of tertiary 
hypothyroidism and of reduced metabolic rate in the whole body that might serve as an 
important energy-conserving mechanism until re-feeding occurs.  
Leptin is not only modified in situations of negative energy balance; patients with primary 
hypothyroidism due to autoimmune thyroid disease, present an increase in body weight, 
decreased appetite and low leptin serum levels, so it is suggested that changes in leptin 
levels do not explain the alterations in appetite usually found in these patients; but as 
mentioned, lower leptin serum levels could contribute to the decrease in energy expenditure 
in hypothyroidism (Valcavi et al., 1997). 
At the central level, the hypothalamus is the primary component in the nervous system that 
interprets adiposity or nutrient related inputs; it finally directs hormonal and behavioral 
responses to regulate energy intake. Neurons in the hypothalamic arcuate nucleus (ARC) 
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receive circulating adiposity levels and relay their responses to second-order neurons in the 
PVN and lateral hypothalamus to mediate effects on food intake and energy homeostasis; 
TRHergic neurons are among those second-order neurons stimulated by the melanocortin 
system (Nillni, 2010). 
Hypophysiotrophic TRH neurons receive inputs from other regions of the brain as well as 
from the circulation. The most important afferent connections to PVN TRHergic cells 
include catecholamine neurons from the brainstem (Sawchenko & Swanson, 1982) and from 
the ARC, a nucleus with a prominent role in energy homeostasis.  
Two are the main populations of neurons arising from ARC that send their axons to PVN 
TRHergic cells: those co-expressing neuropeptide Y and agouti-related protein (NPY/AgRP) 
(Broberger et al., 1998) and those co-expressing cocaine and amphetamine regulated 
transcript and α-melanocyte stimulating hormone (CART/α-MSH) (Vrang et al., 1999). Both 
NPY and AgRP stimulate food intake, whereas CART/ α-MSH reduce it. Hypothalamic T3 
production, catalyzed by D2, triggers the synthesis of mitochondrial uncoupling protein 2, 
which is critical for the activation of NPY/AgRP neurons during fasting (Coppola et al., 
2007). NPY and AgRP inhibit TRH gene expression on hypophysiotrophic TRH neurons 
(Fekete et al., 2001, 2002), in contrast, CART/α-MSH stimulate TRH gene expression in the 
PVN, and this effect is enhanced by leptin (Fekete et al., 2000a, 2000b); both neuronal 
populations of ARC express leptin receptors and are inversely regulated by circulating 
leptin concentrations (Ahima et al., 2000). 
Neuropeptides derived from the ARC play a significant role in the response of thyroid 
axis to both starvation and illness. Physiologically, the interaction of the ARC inputs on 
hypophysiotropic TRH neurons may be the primary mechanism for the development of 
central hypothyroidism associated with fasting, initiated by leptin (Ahima et al., 1996; 
Lechan & Fekete, 2004; Legradi et al., 1997). Serum leptin concentrations drop 
dramatically during fasting, and leptin replacement partly prevents starvation-induced 
decrease in serum T4 levels and increases serum corticosterone in mice (Ahima et al., 
1996). In general, leptin has a central physiologic role in providing information about 
energy stores and energy balance to brain centers that regulate appetite, energy 
expenditure and neuroendocrine functions (Campfield et al., 1995; Pelleymounter et al., 
1995).The fall in circulating levels of leptin is sensed by the hypothalamus, which triggers 
increased appetite, decreased energy expenditure and a changed neuroendocrine function 
in a direction that favors survival.  
Although the hypothalamic effects of leptin are mediated via the melanocortin system, 
which plays a role in feeding behavior, evidence exists about a direct role of leptin on PVN 
TRHergic cells (Harris et al., 2001; Nillni et al., 2000); nevertheless, ARC-derived 
neuropeptides still play the most significant role in the regulation of proTRH neurons, via 
synaptic input from leptin-responsive POMC and NPY/AgRP neurons located in the ARC 
(Fekete et al., 2000; Legradi & Lechan, 1998; Schwartz et al., 1996).   
As a consequence of negative energy balance, the normal feedback mechanism for the 
regulation of hypophysiotrophic TRH neurons is overridden and a state of central 
hypothyroidism is induced, commonly referred to as “nonthyroidal illness” or the “sick 
euthyroid syndrome” (Wiersinga & Boelen, 1996). 
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1992). HPT axis adaptation depends on the age of animals: fasted weaning rats do not 
decelerate the HPT axis function; in spite of its 30% loss of weight compared to non fasted 
animals, TRH release remains active, TSH serum levels do not decay and PPII enzymatic 
activity is reduced, presumably allowing the peptide to exert its effects on the pituitary for a 
longer time (de Gortari et al., 2000). In contrast, adult animals after 72 h of fasting show a 
decreased TRH content in the ME, reduced TSH serum levels and no change in PPII activity 
(de Gortari et al., 2000). The fact that TSH does not change or is reduced when T3 and T4 
serum levels are low is probably due to a decreased expression of the thyroid receptors in 
thyrotrophes induced by starvation (Bavli, 1980; St Germain & Galton, 1985; van Doom et 
al., 1984). A more recent explanation involves a central deregulation of deiodinases activities 
causing the fasting-associated changes in thyroid function.  
Food deprivation is a stressful situation that enhances adrenal release of corticosteroids 
(Garcia-Belenguer et al., 1993; Mitev et al., 1993; Woodward et al., 1991). Starvation-induced 
corticosterone secretion reduces TRH and TSH-β synthesis and release; dexamethasone 
treatment also reduces the hypothalamic TRH secretion into hypophysial portal blood (van 
Haasteren et al., 1995). Thus, corticosterone is a factor that may be participating in the HPT 
adaptive changes to nutrient deficit. 
2.1 Underlying factors of negative energy balance-associated hypothyroidism 
Some factors have been studied as contributors to decreased synthesis of TRH in the PVN 
during fasting or food restriction, such as the activity of deiodinases. Type 2 deiodinase (D2) 
enzyme activity and its mRNA content in the tanycytes of the medial basal hypothalamus, 
increases with fasting (Lechan & Fekete, 2005); D2 converts T4 to T3 and therefore is 
responsible for the maintenance of the medial basal hypothalamic (MBH) local T3 
concentration (Diano et al., 1998), thus the inhibition of TRH expression observed in the 
medial PVN of starved rats may be a consequence of a higher production of local T3 
(Coppola et al., 2005). 
Besides corticosterone and deiodinase activity, leptin peripheral administration can prevent 
the fall of TH in starved rodents, and the reduced expression of proTRH in the PVN after 
fasting (Ahima et al., 1996; Legradi et al., 1997). In other words, fasting-induced decrease of 
serum leptin content is able to reduce proTRH expression in the PVN, also to facilitate the 
high secretion of corticosterone that contributes to elevate D2 activity (Coppola et al., 2005) 
around the third ventricle. Thus, starvation and food restriction create a state of tertiary 
hypothyroidism and of reduced metabolic rate in the whole body that might serve as an 
important energy-conserving mechanism until re-feeding occurs.  
Leptin is not only modified in situations of negative energy balance; patients with primary 
hypothyroidism due to autoimmune thyroid disease, present an increase in body weight, 
decreased appetite and low leptin serum levels, so it is suggested that changes in leptin 
levels do not explain the alterations in appetite usually found in these patients; but as 
mentioned, lower leptin serum levels could contribute to the decrease in energy expenditure 
in hypothyroidism (Valcavi et al., 1997). 
At the central level, the hypothalamus is the primary component in the nervous system that 
interprets adiposity or nutrient related inputs; it finally directs hormonal and behavioral 
responses to regulate energy intake. Neurons in the hypothalamic arcuate nucleus (ARC) 
Differential Adaptations of the  
Hypothalamus-Pituitary-Thyroid Axis Between Food Restriction and Anorexia 71 
receive circulating adiposity levels and relay their responses to second-order neurons in the 
PVN and lateral hypothalamus to mediate effects on food intake and energy homeostasis; 
TRHergic neurons are among those second-order neurons stimulated by the melanocortin 
system (Nillni, 2010). 
Hypophysiotrophic TRH neurons receive inputs from other regions of the brain as well as 
from the circulation. The most important afferent connections to PVN TRHergic cells 
include catecholamine neurons from the brainstem (Sawchenko & Swanson, 1982) and from 
the ARC, a nucleus with a prominent role in energy homeostasis.  
Two are the main populations of neurons arising from ARC that send their axons to PVN 
TRHergic cells: those co-expressing neuropeptide Y and agouti-related protein (NPY/AgRP) 
(Broberger et al., 1998) and those co-expressing cocaine and amphetamine regulated 
transcript and α-melanocyte stimulating hormone (CART/α-MSH) (Vrang et al., 1999). Both 
NPY and AgRP stimulate food intake, whereas CART/ α-MSH reduce it. Hypothalamic T3 
production, catalyzed by D2, triggers the synthesis of mitochondrial uncoupling protein 2, 
which is critical for the activation of NPY/AgRP neurons during fasting (Coppola et al., 
2007). NPY and AgRP inhibit TRH gene expression on hypophysiotrophic TRH neurons 
(Fekete et al., 2001, 2002), in contrast, CART/α-MSH stimulate TRH gene expression in the 
PVN, and this effect is enhanced by leptin (Fekete et al., 2000a, 2000b); both neuronal 
populations of ARC express leptin receptors and are inversely regulated by circulating 
leptin concentrations (Ahima et al., 2000). 
Neuropeptides derived from the ARC play a significant role in the response of thyroid 
axis to both starvation and illness. Physiologically, the interaction of the ARC inputs on 
hypophysiotropic TRH neurons may be the primary mechanism for the development of 
central hypothyroidism associated with fasting, initiated by leptin (Ahima et al., 1996; 
Lechan & Fekete, 2004; Legradi et al., 1997). Serum leptin concentrations drop 
dramatically during fasting, and leptin replacement partly prevents starvation-induced 
decrease in serum T4 levels and increases serum corticosterone in mice (Ahima et al., 
1996). In general, leptin has a central physiologic role in providing information about 
energy stores and energy balance to brain centers that regulate appetite, energy 
expenditure and neuroendocrine functions (Campfield et al., 1995; Pelleymounter et al., 
1995).The fall in circulating levels of leptin is sensed by the hypothalamus, which triggers 
increased appetite, decreased energy expenditure and a changed neuroendocrine function 
in a direction that favors survival.  
Although the hypothalamic effects of leptin are mediated via the melanocortin system, 
which plays a role in feeding behavior, evidence exists about a direct role of leptin on PVN 
TRHergic cells (Harris et al., 2001; Nillni et al., 2000); nevertheless, ARC-derived 
neuropeptides still play the most significant role in the regulation of proTRH neurons, via 
synaptic input from leptin-responsive POMC and NPY/AgRP neurons located in the ARC 
(Fekete et al., 2000; Legradi & Lechan, 1998; Schwartz et al., 1996).   
As a consequence of negative energy balance, the normal feedback mechanism for the 
regulation of hypophysiotrophic TRH neurons is overridden and a state of central 
hypothyroidism is induced, commonly referred to as “nonthyroidal illness” or the “sick 
euthyroid syndrome” (Wiersinga & Boelen, 1996). 
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2.2 Non-thyroidal illness syndrome 
Alterations in neuroendocrine axis develop secondary to illness. An activation of the 
hypothalamic-pituitary-adrenal (HPA) axis is well documented (Vermes & Beishuizen, 
2001). Although acute or chronic sickness can cause alterations on TSH and/or T4 
concentrations in plasma (Fliers et al., 2001), low circulating T3 levels are the most common 
consequence of HPT axis adaptations. The main accepted term to make reference to these 
changes on HPT axis is the non-thyroidal illness syndrome (NTIS) (Warner & Beckett, 2010), 
given that not primary alterations in the thyroid gland are involved and that patients are 
considered clinically euthyroid. Probably this reduction on HPT axis function is a beneficial 
adaptive response in order to reduce energy expenditure in a sick organism. 
There are many factors involved in the hormonal changes that result in the NTIS; these 
include modifications to the hypothalamic-pituitary axis, altered binding of thyroid 
hormone to circulating binding proteins, a modified entry of thyroid hormones into tissues, 
changes in thyroid hormone metabolism or alterations that are due to a modified expression 
of deiodinase enzymes (Warner & Beckett, 2010).  
It seems that the low TSH levels associated with critical illness (or failure of TSH to increase 
in the presence of low T3 and T4) arise from a central hypothyroidism caused by alterations 
in the set point of the HPT axis regulation. This idea is supported by the fact that the 
administration of TRH to patients with prolonged critical illness at least partially restores 
serum T3, TSH and T4 content (Van den Berghe et al., 1998, 1999). The underlying 
mechanisms for the decreased TRH in hypothalamic neurons in patients who died with 
serum biochemistry of the NTIS may include the secretion of pro-inflammatory cytokines 
(Fliers et al., 1997); a different cause may be the chronic low food intake. 
As mentioned previously, activation and inactivation of TH are carried out by a group of 
three iodotiroinine deiodinases. Changes on peripheral deiodinase enzymes’ activity during 
illness are known to be an effect rather than the cause of alterations on circulating T3 and T4 
in the NTIS (Debaveye et al., 2008; O'Mara et al., 1993). The rapid fall in T3 seen in acute 
illness is more likely due to either impaired thyroidal production of T3 (induced by a central 
hypothyroidism) and/or the result of the acute phase response leading to a decrease in 
serum thyroid hormone-binding protein (Warner & Beckett, 2010).  
Administration of bacterial lipopolysaccharide (LPS) is a manner to study acute infection 
and immune activation. It has been shown that after 12 h of LPS administration, type 2 
deiodinase mRNA synthesis increases in tanycytes lining the third ventricle. The ensuing 
local thyrotoxicosis may suppress the HPT axis by local feedback inhibition of 
hypophysiotrophic TRH synthesis and contribute to the mechanism of central 
hypothyroidism associated to infection (Fekete et al., 2004), which as previously mentioned, 
is probably an homeostatic response to preserve energy deposits during illness (De Groot, 
1999). Contrary to the mechanism of central hypothyroidism associated to fasting (Legradi 
et al., 1997; Rondeel et al., 1992; van Haasteren et al., 1995), infection increases the gene 
expression of pro-opiomelanocortin (POMC) (the precursor molecule of α-MSH) and CART 
in the ARC, it does not increase NPY expression (Sergeyev et al., 2001) and elevates 
circulating levels of leptin (Grunfeld et al., 1996). These changes should elevate TRH 
expression; nevertheless during infection, stimulation of D2 synthesis by the increased LPS-
induced pro-inflammatory cytokines concentration, is a more powerful stimulus that 
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maintains low PVN TRH expression (Fekete et al., 2004). As happens during starvation, the 
increase in hypothalamic T3 content may suppress the synthesis of TRH in 
hypophysiotrophic neurons either by local feedback inhibition through the release of T3 
from tanycytes’ apical processes into the cerebrospinal fluid (CSF), or by its uptake from 
hypophysiotrophic TRH axonal processes in the median eminence and by its retrograde 
transport to the hypothalamic PVN. T3 may also be released into the portal capillary system 
for conveyance to the anterior pituitary and exerts a direct effect on the thyrotrophes of the 
anterior pituitary where, it inhibits TSH secretion (Lechan & Fekete, 2005). 
3. Dehydration-induced anorexia  
There is a balance between food intake and energy utilization: an increased feeding behavior 
in animals compensates high energy waste. However, this equilibrium may be altered by 
different psychological and physiological stimuli that may induce the display of an aberrant 
behavior such as anorexia. Anorexia is defined as a loss of appetite despite of a low body 
weight and of an energy deficit. It may result during illness, after stress exposure, or as a 
response to homeostatic challenges such as cellular dehydration (Siegfried et al., 2003). In 
contrast to food restricted or dieting individuals, anorexic patients present normal or 
subnormal serum levels of T4 and TSH (Stoving et al., 2001); also, a blunted TSH release 
form the pituitary after TRH administration (Tamai et al., 1986). Alterations of the HPT axis 
in anorexia nervosa have most likely a central origin, due to the reduced hypothalamic TRH 
secretion, and resemble those of the NTIS. 
Besides its hypophysiotrophic role, TRH is implicated with neuromodulating effects in the 
CNS. As an icv injection of TRH in different animal species, reduces their food and liquid 
intake (Choi et al., 2002; Karydis & Tolis, 1998; Vijayan & McCann, 1977; Vogel et al., 1979), 
it has been proposed as an anorexigenic factor, which has been tested in ad libitum feeding 
animals, in those subjected to stress-induced eating models, and also in fasted and hungry 
animals during the re-feeding period (Horita, 1998; Morley & Levine, 1980; Steward et al., 
2003; Suzuki et al., 1982; Vijayan & McCann, 1977). As mentioned, PVN TRHergic neurons 
express receptors for different feeding-regulating peptides synthesized in the ARC, such as 
NPY, AgRP, CART and α-MSH; also for leptin (Ob-Rb) which suggests that the hormone 
has an indirect effect on TRH expression by acting on feeding-related synthesizing neurons 
of the ARC, but also has a direct action on PVN TRHergic cells (Wittmann et al., 2009). As 
TRHergic neurons of the anterior part of the PVN are known to have projections to the ARC, 
to dorsomedial and to ventromedial hypothalamic nuclei, it is likely that besides its role in 
energy homeostasis, motivational aspects related to food intake might also be under TRH 
control.  
To investigate TRH participation in feeding motivation we have used the dehydration-
induced anorexia (DIA) model. Male and female adult animals subjected to this paradigm 
ingest a hyperosmolar solution of NaCl (2.5%) during 7 days, which reduces its food intake 
and body weight since day 1.  Analysis of the expression of feeding-regulating peptides in 
the ARC of males after 5 days has shown a decreased synthesis of POMC and increased 
NPY mRNA levels (Watts et al., 1999), which have anorexigenic and orexigenic effects, 
respectively. All those changes are signals that should be increasing appetite and food 
ingestion in animals, however feeding is suppressed in dehydrated rats, which suggests that 
inhibitory control networks, other than those of the ARC, are activated (Watts, 2001, 2007). 
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consequence of HPT axis adaptations. The main accepted term to make reference to these 
changes on HPT axis is the non-thyroidal illness syndrome (NTIS) (Warner & Beckett, 2010), 
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changes in thyroid hormone metabolism or alterations that are due to a modified expression 
of deiodinase enzymes (Warner & Beckett, 2010).  
It seems that the low TSH levels associated with critical illness (or failure of TSH to increase 
in the presence of low T3 and T4) arise from a central hypothyroidism caused by alterations 
in the set point of the HPT axis regulation. This idea is supported by the fact that the 
administration of TRH to patients with prolonged critical illness at least partially restores 
serum T3, TSH and T4 content (Van den Berghe et al., 1998, 1999). The underlying 
mechanisms for the decreased TRH in hypothalamic neurons in patients who died with 
serum biochemistry of the NTIS may include the secretion of pro-inflammatory cytokines 
(Fliers et al., 1997); a different cause may be the chronic low food intake. 
As mentioned previously, activation and inactivation of TH are carried out by a group of 
three iodotiroinine deiodinases. Changes on peripheral deiodinase enzymes’ activity during 
illness are known to be an effect rather than the cause of alterations on circulating T3 and T4 
in the NTIS (Debaveye et al., 2008; O'Mara et al., 1993). The rapid fall in T3 seen in acute 
illness is more likely due to either impaired thyroidal production of T3 (induced by a central 
hypothyroidism) and/or the result of the acute phase response leading to a decrease in 
serum thyroid hormone-binding protein (Warner & Beckett, 2010).  
Administration of bacterial lipopolysaccharide (LPS) is a manner to study acute infection 
and immune activation. It has been shown that after 12 h of LPS administration, type 2 
deiodinase mRNA synthesis increases in tanycytes lining the third ventricle. The ensuing 
local thyrotoxicosis may suppress the HPT axis by local feedback inhibition of 
hypophysiotrophic TRH synthesis and contribute to the mechanism of central 
hypothyroidism associated to infection (Fekete et al., 2004), which as previously mentioned, 
is probably an homeostatic response to preserve energy deposits during illness (De Groot, 
1999). Contrary to the mechanism of central hypothyroidism associated to fasting (Legradi 
et al., 1997; Rondeel et al., 1992; van Haasteren et al., 1995), infection increases the gene 
expression of pro-opiomelanocortin (POMC) (the precursor molecule of α-MSH) and CART 
in the ARC, it does not increase NPY expression (Sergeyev et al., 2001) and elevates 
circulating levels of leptin (Grunfeld et al., 1996). These changes should elevate TRH 
expression; nevertheless during infection, stimulation of D2 synthesis by the increased LPS-
induced pro-inflammatory cytokines concentration, is a more powerful stimulus that 
Differential Adaptations of the  
Hypothalamus-Pituitary-Thyroid Axis Between Food Restriction and Anorexia 73 
maintains low PVN TRH expression (Fekete et al., 2004). As happens during starvation, the 
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hypophysiotrophic neurons either by local feedback inhibition through the release of T3 
from tanycytes’ apical processes into the cerebrospinal fluid (CSF), or by its uptake from 
hypophysiotrophic TRH axonal processes in the median eminence and by its retrograde 
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for conveyance to the anterior pituitary and exerts a direct effect on the thyrotrophes of the 
anterior pituitary where, it inhibits TSH secretion (Lechan & Fekete, 2005). 
3. Dehydration-induced anorexia  
There is a balance between food intake and energy utilization: an increased feeding behavior 
in animals compensates high energy waste. However, this equilibrium may be altered by 
different psychological and physiological stimuli that may induce the display of an aberrant 
behavior such as anorexia. Anorexia is defined as a loss of appetite despite of a low body 
weight and of an energy deficit. It may result during illness, after stress exposure, or as a 
response to homeostatic challenges such as cellular dehydration (Siegfried et al., 2003). In 
contrast to food restricted or dieting individuals, anorexic patients present normal or 
subnormal serum levels of T4 and TSH (Stoving et al., 2001); also, a blunted TSH release 
form the pituitary after TRH administration (Tamai et al., 1986). Alterations of the HPT axis 
in anorexia nervosa have most likely a central origin, due to the reduced hypothalamic TRH 
secretion, and resemble those of the NTIS. 
Besides its hypophysiotrophic role, TRH is implicated with neuromodulating effects in the 
CNS. As an icv injection of TRH in different animal species, reduces their food and liquid 
intake (Choi et al., 2002; Karydis & Tolis, 1998; Vijayan & McCann, 1977; Vogel et al., 1979), 
it has been proposed as an anorexigenic factor, which has been tested in ad libitum feeding 
animals, in those subjected to stress-induced eating models, and also in fasted and hungry 
animals during the re-feeding period (Horita, 1998; Morley & Levine, 1980; Steward et al., 
2003; Suzuki et al., 1982; Vijayan & McCann, 1977). As mentioned, PVN TRHergic neurons 
express receptors for different feeding-regulating peptides synthesized in the ARC, such as 
NPY, AgRP, CART and α-MSH; also for leptin (Ob-Rb) which suggests that the hormone 
has an indirect effect on TRH expression by acting on feeding-related synthesizing neurons 
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The involvement of some hypothalamic peptides in feeding motivation may be identified 
using this paradigm, since changes in their synthesis due to dehydration in DIA animals are 
compared to those of a forced food-restricted group (pair-fed, FFR) that eat the exact 
amount of food ingested by DIA  
Studies from other laboratories and ours have shown that when sacrificed either after 5 or 7 
days (Jaimes-Hoy et al., 2008; Watts et al., 1999), both experimental animals from DIA and FFR 
groups present reduced leptin serum levels and high corticosterone concentrations (Table 1). 
Thus, both groups have a negative energy balance that only in FFR animals, activates feeding.  
 
 TSH T3 T4 Leptin Corticosterone Prolactin 
Control 100 ± 13 100 ± 4 100 ± 2.5 100 ± 8 100 ± 7 100 ± 9 
DIA 151 ± 21*+ 64 ± 3* 99 ± 16 37 ± 5* 218 ± 17* 101 ± 9+ 
FFR 73 ± 12* 74 ± 9* 75 ± 9 33 ± 4* 263 ± 23* 20 ± 4* 
Table 1. Serum hormones content in female rats after 7 days of dehydration or food 
restriction. Values are expressed as the mean ± SEM in percentage of difference vs C= 100%, 
n= 8 animals/group). Control values of TSH: 2.1 ± 0.22 ng/ml; T3: 74 ± 2.7 ng/dl; T4: 1.58 ± 
0.09 µg/dl; leptin: 425 ± 33 pg/ml; corticosterone: 151 ± 15 ng/ml; prolactin: 0.97 ± 0.09 
ng/ml) *p<0.05 vs C, +p<0.05 vs FFR. Modified from Jaimes-Hoy et al., 2008. 
In order to identify changes in HPT axis function during those metabolic alterations, and 
with the notion that an icv injection of TRH has an anorectic role, female and male Wistar 
rats have been subjected to DIA paradigm for 7 days; their body weight and food intake is 
registered daily and is compared to that of FFR animals and to those of a control (C) group 
that is offered food ad libitum and tap water along the experiment. When compared food 
ingestion of animals from the same group by gender, results show that males eat more than 
females: dehydration induces a drastic decrease in food intake of males during the first four 
days, and a steady intake thereafter (Table 2); in contrast, females continuously decrease 
their food consumption up to day 6. DIA group of males have a dramatic weight loss since 
the first day, achieving a reduction of 32% of body weight by the 7th day when compared to 
controls (C=100%, FFR =73%, DIA = 68%). Females do not have such a drastic decrease, by 
the end of the experiment they lose 25% of controls’ weight (C=100%, FFR =82.4%, DIA = 
75%). Despite FFR group is pair-fed to dehydrated animals their body weight loss is less 
pronounced than in DIA rats (Figure 1).  
 
 Day  0 1 2 3 4 5 6 7 
Females 
Control 100 ± 1 100 ± 3 100 ± 7 100 ± 6 100 ± 5 100± 11 100± 10 100 ± 4 
DIA 100 ± 1 48 ± 3** 25 ± 5** 15 ± 4** 12 ± 3** 6 ± 2** 3 ± 2** 5 ± 3** 
Males 
Control 100 ± 1 100 ± 6 100 ± 8 100 ± 5 100 ± 5 100± 10 100± 10 100 ± 7 
DIA 100 ± 1 55 ± 2* 22 ± 2* 12 ± 2* 11 ± 3* 9 ± 3** 9.4 ± 4** 10 ± 4* 
Table 2. Food intake of female and male adult rats subjected to dehydration-induced 
anorexia model during 7 days. Values are expressed as the mean ± SEM as percentage of 
controls (C=100%) (n= 6 animals/group). *p<0.001, **p<0.0001 vs. control values. 
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Fig. 1. Body weight of female and male adult rats subjected to dehydration-induced 
anorexia model or to forced-food restriction during 7 days.  Controls: C, dehydrated-
induced anorexic: DIA, forced-food restricted animals FFR. Values are expressed as the 
mean ± SEM in grams (n= 6/group). Modified from de Gortari et al., 2009. ***p<0.001, 
****p<0.0001 vs. control group; +p<0.05, ++p<0.01 vs FFR. 
We have also analyzed weight changes in white and brown adipose tissue of females 
affected by dehydration or food restriction, but there is no change. Thus, dehydration seems 
to contribute to the greater body weight loss of DIA animals. Different analysis of muscle 
hormonal content, such as T3 local levels produced by deiodinases activity, would be 
necessary to identify a specific high catabolic rate of dehydrated animals in that tissue.  
Measuring the content of TRH (by radioimmunoassay) in the ME of dehydrated and FFR 
animals, it is observed that DIA group of both sexes has reduced peptide content.  Analysis 
of some other parameters of the HPT axis function, such as TSH, T4 and T3 serum levels 
have been described; also, TRH mRNA levels in the PVN and expression of TRH-R1 and of 
PPII in the anterior pituitary. As TSH levels increase after 7 days of dehydration, and TRH 
content in the ME is low (and is high in FFR), we have inferred an active peptide release 
from the hypothalamus in dehydrated animals that maintains elevated TSH serum content 
(Table 1). Knowing that at least in cultured cells, TRH addition down-regulates synthesis of 
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its receptor (Yang & Tashjian, Jr., 1993), the reduced expression of anterior pituitary TRH-R1 
of male and female DIA animals (Table 3) have supported that TRH is being released only 
after dehydration.  
 
 PVN pro-TRH mRNA ME TRH content Pituitary TRH-R1 mRNA 
Control 100 ± 4.8 100 ± 11 100 ± 16 
DIA 130 ± 9*+ 76 ± 4*+ 77 ± 10*+ 
FFR 62 ± 5* 148 ± 10* 138 ± 22* 
Table 3. PVN proTRH expression, peptide content in the ME, and TRH-R1 mRNA levels in 
the pituitary of female rats exposed to dehydration for 7 days. Expression changes are 
measured by RT-PCR. Values are expressed as the mean ± SEM as percentage of controls 
(C=100%) (n= 6 animals/group). *p<0.05 vs. control; +p<0.05 vs. FFR. (Jaimes-Hoy et al., 
2008) 
The low expression of TRH-R1 in the pituitary of anorexic animals resembles the delayed 
response of TSH to a TRH injection in anorexic patients (Tamai et al., 1986). The down-
regulation of TRH-R1 receptors is most likely a result of the high release of TRH from the 
ME of DIA animals that in a long term may alter the function of the pituitary. 
In spite of the high TSH serum levels observed in DIA, a low T3 serum content is present 
when compared to C and FFR groups. It is possible that in the thyroid gland of dehydrated 
animals, the TSH receptor is internalized as is observed in hypothyroid conditions using 
both in vivo and in vitro studies (Baratti-Elbaz et al., 1999; Denereaz & Lemarchand-Beraud, 
1995) when TSH content is elevated; results suggest a low binding of TSH to its receptor that 
is observed (up to 70%) in the hypothyroid condition when compared to euthyroid subjects 
but only when T3 levels decrease (Denereaz & Lemarchand-Beraud, 1995). 
An elevation of pro-TRH expression, analyzed by RT-PCR is observed in both males and in 
female dehydrated animals when compared to C and to FFR (Table 3). As expected, FFR of 
both gender present reduced TRH mRNA levels in the PVN (Table 3). Among the factors 
that are known to affect PVN TRH expression, we can mention the decreased leptin and 
increased corticosterone serum levels. However, since the concentration of those hormones 
is similarly changed in both experimental animals, the differential mRNA levels of TRH 
between DIA and FFR cannot be attributed to their hypothalamic effects. It would be 
possible, that D2 activity in the medial basal hypothalamus is decreased in DIA animals. As 
previously stated, D2 converts T4 in the active hormone T3 controlling its hypothalamic 
levels that may differ from those in the peripheral content. If dehydration causes a decrease 
on D2 activity, this would lead to a low T3 local content that may stimulate TRH synthesis. 
The opposite has been shown in fasted animals: an increased D2 expression and activity 
seems responsible for the low TRH mRNA levels in the PVN during a negative energy 
balance.  
All changes in the HPT axis of DIA group are representative of a primary hypothyroidism 
that is paradoxical since animals are under a negative energy balance and is contrasting to 
the tertiary hypothyroidism developed in fasting or food restriction.  
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However, it is still un-known which TRHergic neurons of the PVN are activated during 
dehydration.  
TRHergic cells of the anterior part of the PVN (aPVN) do not project to the median 
eminence (Ishikawa et al., 1988; Kawano et al., 1991; Merchenthaler & Liposits, 1994) thus, 
they are neither hypophysiotropic nor under negative feedback by TH (Nishiyama et al., 
1985; Segerson et al., 1987). Two of the major projection fields of aPVN TRH neurons are the 
ARC and the dorsomedial hypothalamus (DMH) (Morton et al., 2006; Wittmann et al., 2009) 
thus, it is possible that the observed anorectic effect of the icv administered TRH is mediated 
by neurons of that subdivision (Wittmann et al., 2009), but it awaits to be elucidated. 
Feeding-regulating role of TRH from the anterior part of the PVN TRH is also supported by 
studies showing an unaltered expression of the peptide in suckling rats (Sanchez et al., 2001) 
that are known to develop hyperphagia during lactation periods (Xu et al., 2009). It is likely 
that the lack of increase in TRH synthesis only in the aPVN of suckling rats would allow 
them to increase their food intake. Moreover, NPY from DMH is responsible for the 
hyperphagic drive during lactation, a major projection field of TRHergic neurons from the 
aPVN (Wittmann et al., 2009). 
TRH from the aPVN may also have different roles to those related to food intake. Through 
its connections with the preoptic area, TRH from that subdivision of the PVN may regulate 
thermogenesis by activating the sympathetic nervous system (Morrison et al., 2008). This 
idea is supported by the fact that DIA female animals exposed to cold do not have a further 
increase on TRH expression than those maintained at room temperature (Jaimes-Hoy et al., 
2008).  
Activation of TRHergic neurons of the aPVN during dehydration, would be explaining the 
lack of decrease prolactin serum levels present in female rats subjected to DIA (Jaimes-Hoy 
et al., 2008) when compared to FFR rats (Table 1); besides its direct effect on prolactin 
secretion from pituitary lactotrophs (Grosvenor & Mena, 1980), TRH from the aPVN is able 
to inhibit the tuberoinfundibular dopaminergic system (Goldstein et al., 2007) increasing 
hormone release from the anterior pituitary to the blood. The main projection of aPVN TRH 
neurons is the dorsomedial part of the ARC (Wittmann et al., 2009), a region involved in the 
regulation of prolactin secretion (Freeman et al., 2000), suggests that aPVN subdivision may 
be involved in changes induced by dehydration, however, speculations may be confirmed 
by in situ hybridization analysis that would allow the identification of PVN TRHergic 
neurons activated in DIA.  
Different signals that regulate food intake may be responsible for the paradoxical HPT 
function and the increased TRH mRNA levels of the PVN in dehydrated rats. One of them is 
the orexinergic system. During fasting, pre-pro-orexin-synthesizing cells in the lateral 
hypothalamic area (LHA) are activated; its derived peptides, orexin A and B, are factors that 
stimulate feeding (Sakurai et al., 1998). Orexins-containing neurons from LHA project to the 
PVN (Peyron et al., 1998) where its receptors have been identified (Backberg et al., 2002). 
Those are findings that support orexins participation in energy homeostasis (Yamamoto et 
al., 1999) and thermoregulation (Jaszberenyi et al., 2002). Orexin A is the peptide involved in 
activation of food intake, its injection increases feeding and decreases body temperature 
(Jaszberenyi et al., 2002). Those effects of orexin A are mediated through its interaction with 
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the NPY system (Muroya et al., 2004). In contrast, orexin B is implicated in arousal and with 
wakefulness effects (Lin et al., 1999; Siegel, 1999). 
Besides information arriving from LHA orexinergic neurons, PVN also receives connections 
from the ARC including NPY-synthesizing neurons. In the PVN, some of the target cells of 
NPY are those that synthesize TRH that contain NPY-Y1 receptors (Broberger et al., 1999); 
NPY-Y1 receptors are activated during fasting or food restriction by the increased release of 
NPY, which in turn inhibits TRH synthesis (Fekete et al., 2001, 2002).  
Thus, changes in the LHA pre-pro-orexin (Ox) mRNA levels and PVN orexin (Ox-1R) and 
NPY (Y1, Y5) receptors of male rats subjected to DIA paradigm for seven days, have been 
analyzed and compared to those of animals that are food-restricted. As PVN receives direct 
information from circulating leptin levels concerning size and volume of adiposities and 
TRHergic neurons of that hypothalamic region contain Ob-Rb receptors, thus studies have 
been made to analyze alterations in the expression of PVN leptin receptor that would 
account for the differential expression of TRH between DIA and FFR male animals.  
LHA of dehydrated animals, present unchanged expression of the pre-pro-orexin mRNA 
content, in contrast to that of FFR rats that have increased synthesis of the orexigenic 
peptide (Figure 2), supporting that this area is responsive to the negative energy balance. It 
has been previously described that c-fos expression is not activated in LHA orexinergic cells 
in DIA paradigm (Watts et al., 2007). Furthermore, non-responding orexinergic neurons 
have been observed in animals where an anorexic behavior is induced by a LPS injection 
(Becskei et al., 2008). Results support that the anorexic behavior presented by DIA animals 
may be due to an inactivation of the orexinergic system in the LHA that should be 
stimulating energy intake through its connections to the PVN (Peyron et al., 1998). It is 
known that orexins act directly on NPYergic projections coming from the ARC and afferent 
to the PVN through its orexin receptors expressed in NPY-synthesizing neurons. Thus, it 
would be possible that TRH expression in the PVN is increased in DIA animals by the 
impaired inhibiting effect of the orexinergic system during dehydration. 
In the PVN of FFR animals, the expression of the orexin-receptor is lower than in DIA and C 
groups; this may be due to the inferred increased orexins release in the PVN that as for other 
receptors induces a desensitization mechanism that leads to a protein down-regulation. DIA 
animals present a higher synthesis of Ox-R1 than that of FFR, which may be interpreted as a 
compensatory increase due to poor peptide release in those animals, and also as an impaired 
receptor signaling; it has been observed in other models of anorexia (Ballinger et al., 2001).  
It is likely that orexins released in the PVN or food-restricted rats inhibit TRH release, and in 
consequence, TSH serum levels also are low, as has been observed by an icv injection of 
orexins (Mitsuma et al., 1999). Using the DIA paradigm it is evident that anorexic animals 
do not have that pathway activated thus, the differential change in Ox-R1 mRNA levels 
between FFR and DIA groups could be an additional responsible factor for the enhanced 
expression of proTRH in the PVN of dehydrated rats. Since LHA orexin-containing neurons 
send projections to magnocellular and also to parvocellular neurons of the PVN (Backberg et 
al., 2002), it is possible that orexins may be affecting energy homeostasis, but also that they 
may be participating in regulation of water balance or blood pressure, processes in which 
TRH has also been implicated.  
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similar values to the control group. This suggests that NPY in FFR is able to activate Y1 and 
to favor food-seeking behavior; the unchanged synthesis in anorexic animals may be related 
to a failed inhibition of their PVN TRH synthesis. A similar NPY release than a control 
group and a differential expression of NPY-Y1 occurs in another model of anorexia 
(Ballinger et al., 2001); furthermore, an Y1 agonist injection facilitates a positive energy 
balance. Thus, an impaired function of the Y1 receptor in the PVN may also be participating 
in the anorexic behavior of dehydrated animals.  
3.1 CRH actions on the regulation of HPT axis in anorexic animals 
CRH and its receptors regulate in concert, the autonomic, behavioral, immunologic and 
endocrine responses of the organism allowing it to face a changing environment. Starvation, 
body weight loss and negative energy balance are some of the stressful conditions that 
induce differential changes in the hypothalamus-pituitary adrenal axis (HPA) axis, as well 
as in central CRH metabolism, enabling the organism to adapt to situations of nutrient 
deficit. CRH also participates in the regulation of energy intake and utilization through its 
actions on the sympathetic nervous system, activating thermogenesis in the BAT (Arase et 
al., 1988; LeFeuvre et al., 1987).  
In DIA paradigm (Jaimes-Hoy et al., 2008; Watts et al., 1999), CRH expression in the PVN 
decreases in a greater extent than in food restricted rats (Brady et al., 1990; Isse et al., 1999) 
after 7 days. Although expression of CRH-R1 receptor in the PVN is up-regulated in several 
stressful conditions supposedly by CRH release into the PVN which in turn, up-regulates 
CRH expression (Imaki et al., 1996; Mansi et al., 1996; Turnbull & Rivier, 1997), CRH-R1 
mRNA levels are unchanged in DIA animals. In contrast, the expression of CRH-R2 
decreases only in the PVN of DIA group. The lack of response of FFR animals is coincident 
with that reported after starvation (Makino et al., 1998). CRH-R2 is the receptor involved in 
the anorexigenic effects of administered CRH (Arase et al., 1988; Krahn et al., 1990; Morley 
& Levine, 1982) since, the knockdown of CRH-R2, but not of CRH-R1, attenuates CRH-
induced appetite and food intake reduction (Smagin et al., 1998).  
CRH synthesis in the LHA of DIA animals is increased when compared to those of food-
restricted and control groups (Watts et al., 1999). LHA CRHergic neurons have projections 
directly to the PVN, and are proposed as important targets for osmosensitive afferents from 
the forebrain, the middle preoptic nucleus and subfornical organ and from the fusiform 
nucleus of the bed nucleus of the stria terminallis, which are projections that mediate part of 
the response of peptidergic mRNAs in the LHA during dehydration (Kelly & Watts, 1996). It 
is possible that an increased release of CRH from the LHA impinges on CRH-R2 receptors of 
the PVN, causing a receptor down-regulation, as shown in the pituitary for CRH-R1 
(Rabadan-Diehl et al., 1996).  
Using in vitro studies with cultured hypothalamic cells, it is observed that the addition of 
CRH (10 nM) increases TRH mRNA levels after 1 h, analyzed by RT-PCR (de Gortari et al., 
2009). Thus, it has been performed an injection in the PVN of a specific antagonist of CRH-
R2 receptors to dehydration-subjected animals. Three different doses of antisauvagine-30 
(ASG-30) have been administered since the first day of DIA paradigm. Anorexic animals 
injected with the middle dose (30 nM= MD) increase their food intake on day 4 to 288 ± 25% 
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compared to the control group (saline injected and also subjected to DIA, 100 ± 26%). 
Weight loss of those animals does not change in saline-injected DIA animals (S-DIA), in 
contrast, changes of the HPT axis induced by dehydration are antagonized by the intra-PVN 
injections of ASG-30: pro-TRH mRNA levels decrease when compared to saline-injected 
DIA group (Figure 3); TRH-R1 expression in anterior pituitary increases and serum levels of 
TSH and T4 decrease with the administration of the medial and high doses of the CRH-R2 
antagonist. Antagonizing CRH-R2 in the PVN of animals subjected to DIA paradigm, the 
anorexigenic effects of dehydration are attenuated and the ability of the HPT axis to adjust 
to the negative energy balance condition is restored. These results together with the in vitro 
stimulation of CRH on pro-TRH expression of hypothalamic cultured cells, suggest that the 
DIA-induced activation of HPT axis is affected at the PVN level by CRH through CRH-R2 
activation. It however remains to be shown that the DIA-activated CRHergic neurons of the 
lateral hypothalamus, which project to the PVN, target TRH synthesizing cells and that 
those cells express CRH-R2. The negative correlation found between PVN-pro-TRH mRNA 
levels and food intake gives further support for TRH anorectic effects (Choi et al., 2002; 
Schuhler et al., 2007). 
The failure of HPT adaptation during anorexia becomes deleterious to the subject as greater 
body weight loss is observed; it is possible that the use of CRH-R2 antagonists in anorexic 





Fig. 3. Expression changes of pro-TRH mRNA levels in the PVN of dehydrated male 
animals injected with a specific antagonist of CRH-R2 (antisauvagina-30, ASG-30) directly in 
the PVN during seven days. S-DIA: saline injected dehydrated animals; LD, low-dose group 
of dehydrated animals and injected with 15 nM of ASG-30; MD, medium-dose group of 
dehydrated animals injected with 30 nM of ASG-30; HD, high dose group of dehydrated 
animals injected with 60 nM of ASG-30. Values are the means ± SEM of the ratio of proTRH 
cDNA/cyclophilin signal cDNA (arbitrary units); data is expressed as % of S-DIA values, 
considered as 100% (n=3 for LD, HD, n=6 for S-DIA and MD). +p<0.05 vs. MD group, 
*p<0.05 vs. S-DIA. Modified from de Gortari et al., 2009. 
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4. Developed hypothyroidism during zinc deficiency 
Zinc is a mineral with a relevant role in growing, cell differentiation and regulation of 
metabolism. It participates in different biological functions such as DNA synthesis and genes 
expression (Vallee, 1977). It is also crucial to several enzymatic processes (Vallee & Falchuk, 
1993), that in turn influence hormonal and neural transmissions (Xie & Smart, 1991). 
There are both saturated a non-saturated mechanisms of Zn absorption (Seal & Mathers, 
1989; Tacnet et al., 1990). Two main protein families are in charge of Zn transport: 1) at least 
15 members of the ZIP (i.e., Zn-regulated metal transporter, Iron-regulated metal 
transporter-like protein) family (Eide, 2004) and 2) ten members of the ZnT (Zn Transporter) 
family (Liuzzi & Cousins, 2004). Absorption rate is able to adjust to Zn availability, i.e., there 
is an increase on the maximum Zn absorption rate in rat enterocytes cell cultures, following 
a reduction on dietary Zn (Hoadley et al., 1987), just as there is an increase on trans-
epithelial Zn flux on CACO-2 cells after treatment with 5 μM when compared to one of 25 
μM Zn (Reeves et al., 2001).  
Zinc widespread functions impinge on several aspects of organism physiology, best 
demonstrated by the variety of symptoms associated with zinc-deficiency (Prasad, 1984). 
Clinic manifestations comprehend anorexia, growth retardation, dermatitis, diarrhea, 
weight loss and impaired immune responses. Among mineral deficiency causes we can 
mention malnutrition, alcoholism, absorption alterations, chronic renal insufficiency, etc. 
In most studies, Zn deficiency results in an overall 40% to 50% decrease in food intake 
(Gaetke et al., 2002; Rains et al., 1998). However, in severe Zn deficiency, food intake can be 
reduced by as much as 70% (Essatara et al., 1984; Kasarskis et al., 1996). Although severe Zn 
deficiency is considered to be rare, mild or moderate deficiency is believed to be widespread 
throughout the world (Caulfield et al., 1998). In rodents, the most striking feature of 
experimental Zn deficiency is the cyclic feeding behavior that develops during Zn 
deprivation. Early studies report that this behavior is characterized by both a reduction of 
mean food intake, and periodic cyclic changes in daily food intake that disappear as soon as 
Zn is reintroduced in the diet (Chesters & Quarterman, 1970; Williams & Mills, 1970); an 
underlying alteration in hypothalamic galanin and NPY gene expression may be responsible 
for the altered feeding patterns in Zn deficient rats (Selvais et al., 1997). 
Zinc deficient rats weight less than rats that consume the same amount of Zn-adequate food 
(Gaetke et al., 2002). This observation suggests that Zn deficiency has an impact on 
metabolic rate that is independent on food intake; however, it seems that the most profound 
effect of Zn status on metabolic rate and substrate utilization is the result of Zn deficiency-
induced anorexia (Evans et al., 2004). 
Both caloric restriction and Zn deficiency are known to reduce T3 serum levels when 
compared to ad libitum fed animals, in addition, T3 concentration is lower in Zn deficient vs. 
caloric restricted rats. In adult Zn deficient rats, a reduced hypothalamic TRH content and 
inhibited release from ME are observed, also T4 and TSH levels are diminished. Because Zn 
deficiency causes a major decrease in serum free (fT3) and fT4 levels than caloric restriction, 
it seems that lack of Zn impairs the extra-thyroidal T3 synthesis (Morley et al., 1980).  In fact, 
there is a decrease in D1 liver activity secondary to Zn deficiency. Also Pekary et al., (Pekary 
et al., 1991) have shown that processing of the pro-TRH is altered, since the convertases are 
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Zn-dependent enzymes, moreover, T3 receptors, in common with other members of the 
nuclear receptor family, are thought to be included among the nuclear zinc-binding 
proteins. They all contain nine invariant cysteine residues in the DNA-binding region 
(Evans, 1988). If Zn is removed through chelating processes, T3 receptors produced from a 
bacterial expression system lose their ability to bind to DNA (Miyamoto et al., 1991), thus it 
is clear that Zn deficiency affects TH metabolism (Kralik et al., 1996).  
Since during gestation and lactation periods metal demand increases, Zn requirements are 
also greater. In fact, it is recognized that around 80% of pregnant women world-wide are 
likely to have inadequate zinc intakes (Shah & Sachdev, 2001). The increased requirements 
need to be fulfilled by an enhanced ingestion or by adjusting metal homeostasis. One of 
these adjustments involves an increase on intestinal Zn absorption during both pregnancy 
and lactation (Davies & Williams, 1977; Moser-Veillon, 1995). Moreover, during lactation in 
humans and rodents, milk Zn concentration is maintained over a wide range of dietary Zn 
intake, and decreases only after plasma Zn concentration is reduced (Krebs, 1998; Moore et 
al., 1984). Zn transporters in the rat mammary gland respond to marginal Zn intake during 
lactation, when there is a reduced Zn-T1  protein level, thus allowing the mammary gland to 
reduce serosal Zn export through this ubiquitous transporter during Zn deficiency, also a 
higher ZnT-4 mRNA expression and protein levels is observed in order to maintain milk Zn 
concentration (Kelleher & Lonnerdal, 2002); this is due to the fact that vesicular ZnT-4 
participates in the import of Zn into endocytotic or secretory vesicles, which ultimately 
releases Zn into milk (Murgia et al., 1999). Gestational Zn deficiency affects different 
processes where TRH has an active role: thyroid axis function, energetic homeostasis, body 
weight regulation, stress responses and growth. Offspring may present increases in T4 
content in the umbilical cord, decreased T3 concentration, impaired TR function and a 
reduced body weight (Mahajan et al., 2005) as a result of intrauterine under nutrition. As 
pituitary PPII is a metalloenzyme and its activity depends on Zn, it might be affected during 
intrauterine Zn deficiency, leading to HPT alterations, although this remains to be studied.  
It is possible that HPT axis adapts during Zn deficiency differently than in response to fast 
and malnutrition. This would be important, since animals with a Zn deficient diet have a 
reduction in the amount of food intake, thus it would be possible that some changes in the 
HPT axis function are due to an associated malnutrition however, there might be alterations 
that are only due to Zn deficiency. 
5. Conclusions 
Trying to identify if the degradation of TRH in the portal blood by the ectoenzyme 
pyroglutamyl aminopeptidase II (PPII) is an event involved in the adaptive regulation of the 
HPT axis during fasting, we evaluated PPII activity changes in the anterior pituitary of 
adults and young fasted animals and found a differential enzyme regulation that depends 
on the age of animals. While adults show the expected deceleration of the HPT axis function, 
the reduced TRH release and TSH serum content, weaning rats have a decreased PPII 
activity that may facilitate TRH effects on the thyrotrophes, which maintain elevated their 
TSH blood concentration, impairing adaptation of young animals to the negative energy 
balance. It supports that PPII-induced TRH degradation in the anterior pituitary may be a 
regulatory site of the HPT axis function that depends on the age of animals and on the 
etiology of hypothyroidism.  
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demonstrated by the variety of symptoms associated with zinc-deficiency (Prasad, 1984). 
Clinic manifestations comprehend anorexia, growth retardation, dermatitis, diarrhea, 
weight loss and impaired immune responses. Among mineral deficiency causes we can 
mention malnutrition, alcoholism, absorption alterations, chronic renal insufficiency, etc. 
In most studies, Zn deficiency results in an overall 40% to 50% decrease in food intake 
(Gaetke et al., 2002; Rains et al., 1998). However, in severe Zn deficiency, food intake can be 
reduced by as much as 70% (Essatara et al., 1984; Kasarskis et al., 1996). Although severe Zn 
deficiency is considered to be rare, mild or moderate deficiency is believed to be widespread 
throughout the world (Caulfield et al., 1998). In rodents, the most striking feature of 
experimental Zn deficiency is the cyclic feeding behavior that develops during Zn 
deprivation. Early studies report that this behavior is characterized by both a reduction of 
mean food intake, and periodic cyclic changes in daily food intake that disappear as soon as 
Zn is reintroduced in the diet (Chesters & Quarterman, 1970; Williams & Mills, 1970); an 
underlying alteration in hypothalamic galanin and NPY gene expression may be responsible 
for the altered feeding patterns in Zn deficient rats (Selvais et al., 1997). 
Zinc deficient rats weight less than rats that consume the same amount of Zn-adequate food 
(Gaetke et al., 2002). This observation suggests that Zn deficiency has an impact on 
metabolic rate that is independent on food intake; however, it seems that the most profound 
effect of Zn status on metabolic rate and substrate utilization is the result of Zn deficiency-
induced anorexia (Evans et al., 2004). 
Both caloric restriction and Zn deficiency are known to reduce T3 serum levels when 
compared to ad libitum fed animals, in addition, T3 concentration is lower in Zn deficient vs. 
caloric restricted rats. In adult Zn deficient rats, a reduced hypothalamic TRH content and 
inhibited release from ME are observed, also T4 and TSH levels are diminished. Because Zn 
deficiency causes a major decrease in serum free (fT3) and fT4 levels than caloric restriction, 
it seems that lack of Zn impairs the extra-thyroidal T3 synthesis (Morley et al., 1980).  In fact, 
there is a decrease in D1 liver activity secondary to Zn deficiency. Also Pekary et al., (Pekary 
et al., 1991) have shown that processing of the pro-TRH is altered, since the convertases are 
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Zn-dependent enzymes, moreover, T3 receptors, in common with other members of the 
nuclear receptor family, are thought to be included among the nuclear zinc-binding 
proteins. They all contain nine invariant cysteine residues in the DNA-binding region 
(Evans, 1988). If Zn is removed through chelating processes, T3 receptors produced from a 
bacterial expression system lose their ability to bind to DNA (Miyamoto et al., 1991), thus it 
is clear that Zn deficiency affects TH metabolism (Kralik et al., 1996).  
Since during gestation and lactation periods metal demand increases, Zn requirements are 
also greater. In fact, it is recognized that around 80% of pregnant women world-wide are 
likely to have inadequate zinc intakes (Shah & Sachdev, 2001). The increased requirements 
need to be fulfilled by an enhanced ingestion or by adjusting metal homeostasis. One of 
these adjustments involves an increase on intestinal Zn absorption during both pregnancy 
and lactation (Davies & Williams, 1977; Moser-Veillon, 1995). Moreover, during lactation in 
humans and rodents, milk Zn concentration is maintained over a wide range of dietary Zn 
intake, and decreases only after plasma Zn concentration is reduced (Krebs, 1998; Moore et 
al., 1984). Zn transporters in the rat mammary gland respond to marginal Zn intake during 
lactation, when there is a reduced Zn-T1  protein level, thus allowing the mammary gland to 
reduce serosal Zn export through this ubiquitous transporter during Zn deficiency, also a 
higher ZnT-4 mRNA expression and protein levels is observed in order to maintain milk Zn 
concentration (Kelleher & Lonnerdal, 2002); this is due to the fact that vesicular ZnT-4 
participates in the import of Zn into endocytotic or secretory vesicles, which ultimately 
releases Zn into milk (Murgia et al., 1999). Gestational Zn deficiency affects different 
processes where TRH has an active role: thyroid axis function, energetic homeostasis, body 
weight regulation, stress responses and growth. Offspring may present increases in T4 
content in the umbilical cord, decreased T3 concentration, impaired TR function and a 
reduced body weight (Mahajan et al., 2005) as a result of intrauterine under nutrition. As 
pituitary PPII is a metalloenzyme and its activity depends on Zn, it might be affected during 
intrauterine Zn deficiency, leading to HPT alterations, although this remains to be studied.  
It is possible that HPT axis adapts during Zn deficiency differently than in response to fast 
and malnutrition. This would be important, since animals with a Zn deficient diet have a 
reduction in the amount of food intake, thus it would be possible that some changes in the 
HPT axis function are due to an associated malnutrition however, there might be alterations 
that are only due to Zn deficiency. 
5. Conclusions 
Trying to identify if the degradation of TRH in the portal blood by the ectoenzyme 
pyroglutamyl aminopeptidase II (PPII) is an event involved in the adaptive regulation of the 
HPT axis during fasting, we evaluated PPII activity changes in the anterior pituitary of 
adults and young fasted animals and found a differential enzyme regulation that depends 
on the age of animals. While adults show the expected deceleration of the HPT axis function, 
the reduced TRH release and TSH serum content, weaning rats have a decreased PPII 
activity that may facilitate TRH effects on the thyrotrophes, which maintain elevated their 
TSH blood concentration, impairing adaptation of young animals to the negative energy 
balance. It supports that PPII-induced TRH degradation in the anterior pituitary may be a 
regulatory site of the HPT axis function that depends on the age of animals and on the 
etiology of hypothyroidism.  
 
Hypothyroidism – Influences and Treatments 84
Using the model of DIA, we have been able to analyze the expression changes of peptides 
involved in feeding motivation, and to discriminate from those that decelerate energy 
utilization. DIA animals lose weight since day one of dehydration and develop an anorexic 
behavior. 
We have found that a primary hypothyroidism is induced in anorexic rats, in contrast to the 
tertiary hypothyroidism of the pair-fed animals, despite of the negative energy balance 
developed in both groups. Dehydration impairs the adaptation of the HPT axis to the 
nutrient deficit: TRH expression is increased in the PVN, its release from the median 
eminence is active and TSH serum content is higher than in pair-fed and control animals. 
We also have found a reduced expression of the TRH receptors in the pituitary of anorexic 
animals that may be the result of the increased release of the peptide, as a desensitization 
mechanism. This resembles the blocked response of the pituitary to TRH administration in 
anorexic patients. Thus, we have been able to induce with this paradigm, changes of the 
HPT axis similar to those that are developed in anorexia nervosa. 
The increased mRNA levels of TRH found in the PVN of anorexic animals and not in the 
pair-fed group support that the peptide of that hypothalamic region participates not only in 
energy homeostasis but in feeding motivation and anorexic behavior.  
Given that TRHergic PVN neurons receive orexinergic input from LHA and NPYergic 
afferents from ARC, we analyzed changes in the LHA pre-pro-orexin (Ox) mRNA levels and 
PVN orexin (Ox-1R) and NPY (Y1, Y5) receptors of male rats. LHA prepro-orexinergic cells 
are activated in forced food restricted animals; Ox1-R and Y1 expression is reduced in food 
restricted vs. controls and anorexic group. Thus, compensatory changes in PVN receptor 
expression of some feeding-related peptides in anorexic rats may alter TRHergic neural 
response to energy demands. 
CRH is another likely responsible factor for the increased TRH mRNA levels of the PVN of 
anorexic animals. Injection of a specific CRH-R2 antagonist in the PVN of dehydrated 
animals reduces TRH expression, the TSH blood concentration, and is able to attenuate 
anorexic behavior of DIA animals. Thus, specific antagonists of the CRHergic pathway may 
be potential therapeutic agents for anorexic patients.  
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Hypothyroidism may create major cardiovascular changes, such as a decrease in cardiac 
output because of decrease in oxygen and substrate utilization, a decrease in cardiac 
contractility, a reduction in heart rate and an increase in peripheral vascular resistance 
(Klein & Danzi, 2007). Thyroid hormones may also play a critical role in brain development 
in infants and in modulating brain metabolic activity in adults as shown by structural 
changes related to myelin, studied by brain imaging techniques (Bernal, 2002). Recent 
research aims to combine modern brain imaging techniques with years of experience in 
neuropsychological and clinical evaluations of thyroid dysfunctions. It is now clear that 
without optimal thyroid function, mood disturbance, cognitive impairment and other 
psychiatric symptoms can emerge. 
As the symptoms of hypothyroidism are non-specific, but the consequences affect virtually 
every organ system, an early systematic laboratory evaluation and control of thyroid 
function is recommended in all TMp annually. Iron overload induced hypothyroidism may 
respond to adequate chelation therapy promoting prevention or/and reversal of the disease 
and other associated comorbidities. In one case of hereditary hemochromatosis, reversal of 
hypothyroidism was reported after iron depletion (Hudec et al, 2008). Also, a long-term 
follow-up study of Italian TMp demonstrated that regular iron chelation may prevent 
thyroid dysfunction and the development of clinically significant myocardial dysfunction. 
In addition, therapy with L-thyroxin should be considered in hypothyroidic, moderately 
and severely iron overloaded TMp (De Sanctis et al, 2008a). 
The newer challenges of chelation therapy include the prevention and reversal of iron 
related morbidities by reducing and maintaining iron and free iron to very low levels 
(Kolnagou et al, 2009). With adequate chelation therapy, endocrinopaties may be stable or 
reversible in thalassemia major patients (TMp). (Gamberini et al, 2008). Each chelator has 
different properties influencing the clinical management of iron overload (Kalinowski et al, 
2005). Additionally, each patient has a different safety and efficacy profile with regards to 
their response to chelation therapy. Iron excretion is dose dependent with wide subject-to-
subject variability. A negative iron balance, which ensures prevention or/and reversal of 
iron overload complications, is difficult to achieve with monotherapy. Combined chelation 
treatment may be a better approach. It results in increased iron excretion compared to 
monotherapy alone, probably acting by a shuttle or/and additive effect and it was proved to 
increase overall survival (Telfer,2009) and achieve treatment goals with manageable adverse 
reactions (Kontoghiorghes et al, 2010). Also with combined chelation, compliance to the 
daily lifelong commitment was improved as short-term results were readily evident to TMp 
themselves. 
Our group has had significant experience with the use of combined chelation regimen in 
TMp regarding the reversal of endocrine complications (Farmaki, 2008; 2010a; 2010b; 2011). 
Our results on hypothyroidism will be highlighted throughout this chapter. Controversies 
about exploration of thyroid function and regular follow up in TMp, adequate chelation and 
arguments for and against T4 treatment will be discussed.  
2. Patients and methods 
This was an open label, observational, single centre study conducted in the Thalassemia 
Unit, of the General Hospital of Corinth, Greece, for a period of seven years. The study was 
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approved by the hospital ethical committee and written informed consent was obtained 
from all patients.  
2.1 All participants were transfusion-dependent thalassemia major patients (TMp), who 
presented with more than one iron-overload complication as defined by clinical and 
laboratory criteria.  
2.2  Prior to initiation of this study, all patients received chelation monotherapy with DFO, 
40 mg/kg; 8–12 h, subcutaneously, 3–5 days/week. 
2.3 All participants were switched to an intensive combination scheme with DFO and 
Deferiprone (DFP) consisting of both daily oral administration of DFP 75–100 mg/kg/d 
in three divided doses and subcutaneous DFO (20–40 mg/kg; 8–12 h, 2–6 d/week. 
Individual dosing and frequency of DFO infusions were determined by patients’ 
clinical and laboratory assessments, such as iron overload indices and comorbidities. 
2.4 Although serum ferritin is not an accurate index, we estimated the trends of monthly 
serial measures of serum ferritin by Chemiluminescent Microparticle Immunoassay 
(CMIA) by Architect Abbott Diagnostics.  
2.5 Quantification of heart and liver iron load was determined annually by Signa-MRI 1.5 
Tesla, multi-echo T2* and liver iron concentration (LIC) in mg/gr dry weight (g dw) 
derived from the T2*L value by Ferriscan (St Pierre et al 2005, Wood et al, 2005). 
2.6 A systematic control of thyroid function was performed annually by thyroid-stimulating 
hormone (TSH), free triiodothyronine (FT3) and free thyroxine (FT4) screening. At 
baseline and after 5-7 years a thyroid releasing hormone TRH stimulation test was 
conducted. Following intravenous infusion of 200 mcg TRH, blood samples were taken at 
0, 30, 60, 90 and 120 min for TSH measurements. The area under the curve (AUC) was 
also calculated for estimating integrated response during the test. All patients on hormone 
replacement therapy discontinued thyroxin at least 30 days before the test.  
2.7 Cardiac function was assessed annually, with tissue 1Echo-Doppler TD (Philips ie33 
system). Patients were classified according to the New York Heart Association (NYHA) 
criteria. 
2.8 Gonadal function was assessed by peripheral hormone levels: testosterone and free 
testosterone or oestradiol and progesterone. In addition, serum basal levels of follicle-
stimulating hormone (FSH) and luteinizing hormone (LH) were assayed. 
Gonadotrophin response was also assayed after intravenous infusion of 200 lg 
gonadotrophin-releasing hormone (GnRH). Samples were taken at 0, 30, 60, 90 and 120 
for the measurement of FSH and LH. All analyses were performed by CMIA technology 
using the automatic immuno-analyzer ARCITECT, i2000SR, 
2.9 Safety was evaluated by close clinical and laboratory monitoring of adverse reactions, 
according to each drug SPC. A full check up of each patient was implemented at 
baseline before protocol initiation and patients’ records were thoroughly reviewed 
systematically in order to determine any changes. 
2.10 All statistical analyses were carried out using the statistical package for the social 
sciences software (SPSS release 13.0, Chicago, IL, USA). All p values were two sided; 
the level of significance was < 0.05. 
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Fifty-two patients, 25 males and 27 females, aged 10–49 years at baseline, were followed 
over a period of 5–7 years. The mean age at baseline was 25.2 ± 8.9 years compared to 32.9 ± 
9.8 at the end of the study. Two patients discontinued the study after experiencing repeated 
episodes of neutropenia and withdrew their consent.  
3.1  After combined chelation (DFO & DFP) there was a statistically significant reduction of 
the total body iron load, as indicated by mean ferritin levels, MRI liver and heart iron 
quantification (T2*L & T2*H) and LIC calculated by Ferriscan, shown in table 1. 
 
Parameter Baseline  studies End of study p-value 
Ferritin (μg/L) 3421.6 ± 882.0 87 ± 25 <.001 
MRI T2*H (ms) 13.8 ± 9.8 35.5 ± 8.1 <.001 
MRI T2*L (ms) 1.5 ± 8.2 34.4 ± 5.4 <.001 
LIC (mg/g dwt) 15.7 ± 11.1 0.9 ± 0.2 <.001 
Table 1. Results (mean ± SD) of iron load assessments in Thalassemia patients  
3.2 Euthyroid patients 32/50 demonstrated a significant increase in the mean FT4 (0.80±0.09 
vs. 1.10±0.09 ng/ml p<0.001) and FT3 levels (1.6±0.2 vs. 2.9±0.5 pg/ml, p<0.001). No 
new cases of hypothyroidism were observed after combined chelation. 
 
Fig. 1. FT4 levels at baseline (DFO monotherapy) and after combined chelation in euthyroid 
Thalassemia patients 
3.3 At baseline, while on DFO monotherapy 18/50 patients were hypothyroid. After 
combined chelation 14/18 who had subclinical or compensated hypothyroidism 
presented a significant increase in mean FT4 (0.70±0.06 vs. 1.07±0.12 ng/ml, p<0.001) 
and mean FT3 (1.30±0.3 vs. 2.50±0.6 pg/ml, p<0.001). In addition, a significant decrease 
in the mean TSH (4.12±0.63 vs. 6.27±1.08μIU/ml p<0.001) and TSH quantitative 
secretion, calculated as the area under the curve (AUC=2231±241 vs. 1332±131 p<0.001) 
in response to the TRH stimulation test were observed.  
 




Fig. 2. TRH test at baseline (gray line) and during the reassessment (black line) after 
combined chelation in TMp with hypothyroidism. Basal TSH: 4.12 ± 0.63 vs. 6.27 ± 1.08, 
p=0.01. At 30’ mins TSH: 22.13 ± 2.18 vs. 34.06 ± 4.75, p=0.005. At 60’ mins TSH: 15.89 ± 1.13 
vs. 25.69 ± 3.72, p=0.002.  At 90’ mins TSH: 11.83±1.26 vs. 19.44±3.27, p=0.001.  
3.4 Regarding safety, apart from the 2 patients who withdrew from the study, combined 
chelation was otherwise well tolerated. Adverse events like joint symptoms (5%), 
gastrointestinal upset (8%) were managed with symptomatic treatment and an increase 
in liver enzymes (11%) with a temporarily dose reduction of DFP. One case of tinnitus 
and one with ocular problems required a transient interruption of DFO for 1-2 months 
after which were reversed, in both cases.  
4. Discussion 
4.1 An early systematic laboratory evaluation and control of thyroid function is 
recommended in all TMp annually because thyroid hormones may affect the function of 
virtually every organ system.  
4.1.1 Hypothyroidism symptoms are not typical (fatigue, cold intolerance, weight gain). 
Criteria for the diagnosis of subclinical hypothyroidism (SH) was an elevated basal TSH 
concentration (>5 TSH μIU/ml) or an increase of the TSH levels during the test more than 
20 μIU/ml from the basal value or additional low levels of FT4 and FT3 respectively. 
4.1.2 In case of borderline TSH and FT4 levels a TRH stimulation test has to be performed. 
An exaggerated TSH response (> or = 21 microIU/Ml) to TRH may occur in 20%-33% of 
thalassemia patients with normal FT4 levels (Zervas et al, 2002; De Sanctis et al, 2008c). 
Also, a 15-year longitudinal study has demonstrated that more than 30% of TMp had an 
abnormal response to TRH test and that 14% change from normal to uncompensated 
hypothyroidism (Landau et al, 1993). Moreover, TRH stimulation test can also 
differentiate primary from central hypothyroidism.  
4.1.3 In our study, while on DFO monotherapy 18/50 (36%) patients presented with 
laboratory findings of hypothyroidism. Classification of hypothyroidism in TMp 
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20 μIU/ml from the basal value or additional low levels of FT4 and FT3 respectively. 
4.1.2 In case of borderline TSH and FT4 levels a TRH stimulation test has to be performed. 
An exaggerated TSH response (> or = 21 microIU/Ml) to TRH may occur in 20%-33% of 
thalassemia patients with normal FT4 levels (Zervas et al, 2002; De Sanctis et al, 2008c). 
Also, a 15-year longitudinal study has demonstrated that more than 30% of TMp had an 
abnormal response to TRH test and that 14% change from normal to uncompensated 
hypothyroidism (Landau et al, 1993). Moreover, TRH stimulation test can also 
differentiate primary from central hypothyroidism.  
4.1.3 In our study, while on DFO monotherapy 18/50 (36%) patients presented with 
laboratory findings of hypothyroidism. Classification of hypothyroidism in TMp 
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according to laboratory tests is shown in table 2. Among them 14/18 (78%) had 
subclinical or compensated hypothyroidism and 4/18 (22%), mostly older patients, had 
overt hypothyroidism.  
 
  FT4 T3 TSH TSH response to TRH Test 
Subclinical 
Hypothyroidism normal normal 













Hypothyroidism  decreased 
normal or 
decreased Increased >10 mU/L 
 
exaggerated 
Table 2. Classification of hypothyroidism in TMp according to laboratory tests  
4.1.4 Although ultrasonography is one of the techniques most frequently used to evaluate 
the volume and structure of thyroid gland, it is not ubiquitous in TMp as autoimmune 
thyroiditis is absent (Mariotti et al, 2011) and most echogenicity patterns are not 
specific. However, Pitrolo et al, 2004 reported a reduced echogenicity in 47% of TMp 
and a diffuse spotty echogenicity in 33% of them, indicative of thyroid dysfunction. 
Also, Filosa et al, 2006 reported features of dyshomogeneity of the parenchyma with 
different degrees of severity in TMp, which were in accordance with the criteria of 
Sostre and Reyes and also a slow worsening of thyroid function in 25% of TMp during a 
12 year-period of follow up.  
4.1.5 Magnetic resonance imaging (MRI) plays an adjunctive role in the further investigation 
of primary hypothyroidism or/and central hypothyroidism with pituitary dysfunction. 
Hekmatnia et al, 2010 demonstrated that signal reduction may precede pituitary 
volume loss and could be expected first on MRI especially in hypogonadic thalassemia 
patients. Additionally the use of pituitary R2, have allowed to define age-specific norms 
for pituitary volume allowing earlier recognition of relevant iron deposition and 
damage and prevention of pan-hypopituitarism (Wood et al, 2010). 
4.2 Hypothyroidism & total body iron overload 
4.2.1 Serum ferritin levels of approximately 3,000 ng/ml in TMp were found to correlate 
with hypothyroidism according to Gamberini et al, 2008. De Sanctis et al, 2008c, 
reported that TSH peak values correlated directly with ferritin levels, ALT, and the 
compliance index to chelation therapy. In our study, the intensification of chelation 
with combined therapy and the achievement of normal serum ferritin levels, led to an 
amelioration of thyroid function with significant increase in the secretion of FT4 and FT3 
levels both in euthyroid as well as in hypothyroid TMp. While on DFO monotherapy, 
there were safety concerns with low ferritin levels ( Piga et al, 1988), with combined 
chelation, no significant adverse effects associated with lowering patients’ body iron 
load to normal levels were observed. In some TMp, thyroid impairment was transient, 
and their secretory capacity improved. In the elderly TMp, with a late onset of chelation 
therapy, the detrimental effect of iron accumulation led to a permanent impairment of 
thyroid function suggesting that iron-induced toxicity is mainly time dependent.  
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4.2.2 Liver iron concentration (LIC) has been regarded as the reference standard for 
estimating body iron loading and has been shown to accurately predict total body iron 
stores (Angelucci et al, 2000). R2 and R2* magnetic resonance imaging (MRI) relaxation 
time techniques allow for non-invasive estimation of LIC in patients with 
hemoglobinopathies. The LIC cut-off points of 7 and 15 mg Fe/g dw have been used to 
categorize iron overload status, predict morbidity and mortality, and tailor iron 
chelation therapy in TMp for the past two decades. However, LIC ≥6 mg Fe/g dw was 
found to be the best threshold for discriminating the presence and absence of 
endocrine/bone morbidity (hypothyroidism, osteoporosis, or hypogonadism). 
According to Musallam et al, 2011, Thalassemia patients with a LIC ≥6 mg Fe/g dw 
were 4.05 times more likely to have endocrine morbidity compared with patients with a 
LIC <6 mg Fe/g dw. Liver iron overload also seems to influence hormonal peripheral 
metabolism (Maggiolini et al, 1995). In our study at baseline, 98% of patients had 
hepatic iron overload (LIC ≥ 1.5 mg/g dw), and among them 64% had severe iron 
overload (LIC>12 mg/g dw). After 5 to 7 years of intensive combined chelation, TMp 
had a normal mean LIC: 0.9±0.2 vs. 15.7±11,1 mg/g dw and this was correlated r= -
0.679 p<0.03 with a significant increase of FT4 levels in all TMp. This provides clear 
evidence that iron-induced tissue damage is reversible, suggesting that such reductions 
may prevent or reverse thyroid dysfunction. 
4.2.3 Extrahepatic tissues have different kinetics of iron uptake and clearance than the liver, 
because they selectively, or almost selectively, load circulating non-transferrin bound 
iron (NTBI) (Glickstein et al, 2005). Long periods of unprotected exposure to NTBI 
could predispose to increased iron uptake in endocrine glands. The cellular labile iron 
(LIP) expansion in iron overload conditions poses a threat to cell integrity. Iron-
mediated oxidative stress triggers apoptosis, volume loss, and fatty replacement in the 
organs leading to their dysfunction over time. 
4.3 Hypothyroidism and iron chelators 
4.3.1 With DFO monotherapy the incidence of primary hypothyroidism in TMp was 
approximately 30%. In some retrospective studies this incidence was shown to decrease 
over time according to compliance, but in most cases there was a progression from 
subclinical to overt hypothyroidism (De Sanctis, 2008c). In our study, at baseline while on 
DFO monotherapy, 18/50 TMp (36%), were treated with thyroxin replacement therapy. 
Among them 14/18 (78%) had subclinical or compensated hypothyroidism and 4/18 
(22%), mostly older patients had overt hypothyroidism. The incidence was high possibly 
because of inadequate dosing, poor compliance, or relative poor thyroid protection from 
DFO-specific properties. Monotherapy usually maintains iron balance but does not 
decrease iron that has accumulated over an extensive period. As TMp require transfusions 
indefinitely, a negative iron balance is difficult to achieve. Besides, chelator efficacy 
depend on their availability in plasma or interstitial fluids and their membrane-crossing 
ability in accessing and neutralizing intracellular LIP which pose a threat to cell integrity. 
DFO contrary to oral chelators, is a large positively charged, lipophobic molecule with 
low membrane permeation abilities and thereby low cell iron extraction capacity.  
4.3.2 Combined chelation with DFO and DFP because of an additive or synergistic effect on 
iron excretion, seems to be the treatment of choice in achieving a negative iron balance, 
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according to laboratory tests is shown in table 2. Among them 14/18 (78%) had 
subclinical or compensated hypothyroidism and 4/18 (22%), mostly older patients, had 
overt hypothyroidism.  
 
  FT4 T3 TSH TSH response to TRH Test 
Subclinical 
Hypothyroidism normal normal 













Hypothyroidism  decreased 
normal or 
decreased Increased >10 mU/L 
 
exaggerated 
Table 2. Classification of hypothyroidism in TMp according to laboratory tests  
4.1.4 Although ultrasonography is one of the techniques most frequently used to evaluate 
the volume and structure of thyroid gland, it is not ubiquitous in TMp as autoimmune 
thyroiditis is absent (Mariotti et al, 2011) and most echogenicity patterns are not 
specific. However, Pitrolo et al, 2004 reported a reduced echogenicity in 47% of TMp 
and a diffuse spotty echogenicity in 33% of them, indicative of thyroid dysfunction. 
Also, Filosa et al, 2006 reported features of dyshomogeneity of the parenchyma with 
different degrees of severity in TMp, which were in accordance with the criteria of 
Sostre and Reyes and also a slow worsening of thyroid function in 25% of TMp during a 
12 year-period of follow up.  
4.1.5 Magnetic resonance imaging (MRI) plays an adjunctive role in the further investigation 
of primary hypothyroidism or/and central hypothyroidism with pituitary dysfunction. 
Hekmatnia et al, 2010 demonstrated that signal reduction may precede pituitary 
volume loss and could be expected first on MRI especially in hypogonadic thalassemia 
patients. Additionally the use of pituitary R2, have allowed to define age-specific norms 
for pituitary volume allowing earlier recognition of relevant iron deposition and 
damage and prevention of pan-hypopituitarism (Wood et al, 2010). 
4.2 Hypothyroidism & total body iron overload 
4.2.1 Serum ferritin levels of approximately 3,000 ng/ml in TMp were found to correlate 
with hypothyroidism according to Gamberini et al, 2008. De Sanctis et al, 2008c, 
reported that TSH peak values correlated directly with ferritin levels, ALT, and the 
compliance index to chelation therapy. In our study, the intensification of chelation 
with combined therapy and the achievement of normal serum ferritin levels, led to an 
amelioration of thyroid function with significant increase in the secretion of FT4 and FT3 
levels both in euthyroid as well as in hypothyroid TMp. While on DFO monotherapy, 
there were safety concerns with low ferritin levels ( Piga et al, 1988), with combined 
chelation, no significant adverse effects associated with lowering patients’ body iron 
load to normal levels were observed. In some TMp, thyroid impairment was transient, 
and their secretory capacity improved. In the elderly TMp, with a late onset of chelation 
therapy, the detrimental effect of iron accumulation led to a permanent impairment of 
thyroid function suggesting that iron-induced toxicity is mainly time dependent.  
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4.2.2 Liver iron concentration (LIC) has been regarded as the reference standard for 
estimating body iron loading and has been shown to accurately predict total body iron 
stores (Angelucci et al, 2000). R2 and R2* magnetic resonance imaging (MRI) relaxation 
time techniques allow for non-invasive estimation of LIC in patients with 
hemoglobinopathies. The LIC cut-off points of 7 and 15 mg Fe/g dw have been used to 
categorize iron overload status, predict morbidity and mortality, and tailor iron 
chelation therapy in TMp for the past two decades. However, LIC ≥6 mg Fe/g dw was 
found to be the best threshold for discriminating the presence and absence of 
endocrine/bone morbidity (hypothyroidism, osteoporosis, or hypogonadism). 
According to Musallam et al, 2011, Thalassemia patients with a LIC ≥6 mg Fe/g dw 
were 4.05 times more likely to have endocrine morbidity compared with patients with a 
LIC <6 mg Fe/g dw. Liver iron overload also seems to influence hormonal peripheral 
metabolism (Maggiolini et al, 1995). In our study at baseline, 98% of patients had 
hepatic iron overload (LIC ≥ 1.5 mg/g dw), and among them 64% had severe iron 
overload (LIC>12 mg/g dw). After 5 to 7 years of intensive combined chelation, TMp 
had a normal mean LIC: 0.9±0.2 vs. 15.7±11,1 mg/g dw and this was correlated r= -
0.679 p<0.03 with a significant increase of FT4 levels in all TMp. This provides clear 
evidence that iron-induced tissue damage is reversible, suggesting that such reductions 
may prevent or reverse thyroid dysfunction. 
4.2.3 Extrahepatic tissues have different kinetics of iron uptake and clearance than the liver, 
because they selectively, or almost selectively, load circulating non-transferrin bound 
iron (NTBI) (Glickstein et al, 2005). Long periods of unprotected exposure to NTBI 
could predispose to increased iron uptake in endocrine glands. The cellular labile iron 
(LIP) expansion in iron overload conditions poses a threat to cell integrity. Iron-
mediated oxidative stress triggers apoptosis, volume loss, and fatty replacement in the 
organs leading to their dysfunction over time. 
4.3 Hypothyroidism and iron chelators 
4.3.1 With DFO monotherapy the incidence of primary hypothyroidism in TMp was 
approximately 30%. In some retrospective studies this incidence was shown to decrease 
over time according to compliance, but in most cases there was a progression from 
subclinical to overt hypothyroidism (De Sanctis, 2008c). In our study, at baseline while on 
DFO monotherapy, 18/50 TMp (36%), were treated with thyroxin replacement therapy. 
Among them 14/18 (78%) had subclinical or compensated hypothyroidism and 4/18 
(22%), mostly older patients had overt hypothyroidism. The incidence was high possibly 
because of inadequate dosing, poor compliance, or relative poor thyroid protection from 
DFO-specific properties. Monotherapy usually maintains iron balance but does not 
decrease iron that has accumulated over an extensive period. As TMp require transfusions 
indefinitely, a negative iron balance is difficult to achieve. Besides, chelator efficacy 
depend on their availability in plasma or interstitial fluids and their membrane-crossing 
ability in accessing and neutralizing intracellular LIP which pose a threat to cell integrity. 
DFO contrary to oral chelators, is a large positively charged, lipophobic molecule with 
low membrane permeation abilities and thereby low cell iron extraction capacity.  
4.3.2 Combined chelation with DFO and DFP because of an additive or synergistic effect on 
iron excretion, seems to be the treatment of choice in achieving a negative iron balance, 
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normalizing body iron load and reversing clinical and subclinical iron overload 
complications. Of the 50 patients completing the study, 18 (36%) were treated with 
thyroxin replacement therapy at baseline while on DFO monotherapy. After combined 
chelation and an important decrease in total body iron overload 14/18 who had 
subclinical or compensated hypothyroidism presented a significant increase in mean 
FT4, FT3 (p<0.001)and an decrease in TSH (reflected by the AUC calculation). Among 
them, 10/18 (56%) discontinued thyroxin therapy (Fisher’s exact test p<0.001) and 4/18 
(22%) reduced their thyroxin dose. The remaining 4 (8% of the total study group) who 
had biochemical overt hypothyroidism, while they all improved their TRH stimulation 
test, only 2 converted to compensated hypothyroidism with TSH levels 5-10mIU/ml 
and normal FT4 & FT3 levels. The time needed to reverse hypothyroidism with 
combined chelation varies according to the patient age and iron load status. Besides 
combined chelation may prevent hypothyroidism as no new-onset nor worsening of 
thyroid dysfunction was observed during the study period. Whether the overall 
improvement in thyroid function that was achieved in our patients can be solely 
attributed to the intensification of chelation therapy and better compliance or if there is 
a tissue-specific effectiveness of DFP in iron removal from thyroid gland is debatable. 
4.3.3 To our knowledge, this is the first report that documents, the beneficial effect of long-
term combined therapy in normalizing total body iron load and reversing most of the 
cases of subclinical and compensate hypothyroidism in TMp. 
4.4 Hypothyroidism & cardiac dysfunction  
4.4.1 Thyroid hormones control several enzymes involved in regulating calcium fluxes in the 
heart including the calcium-dependent adenosine triphosphatase and phospholamban. In 
case of hypothyroidism, the decreases in the expression and activity of these enzymes 
could potentially impair systolic performance and diastolic relaxation of the ventricles, 
leading to a reduction in cardiac output (Klein & Danzi, 2007). Additionally thyroid 
hormones play a role in reducing peripheral vascular resistance by relaxing vascular 
smooth muscle cells. Thus, in case of hypothyroidism there is an increase in peripheral 
vascular resistance and a reduction in tissue perfusion and oxygen utilization. Symptoms 
of cardiovascular dysfunction are not common or prominent but may include dyspnea, 
exercise intolerance, and edema. Findings on physical examination may include 
bradycardia, hypertension, nonpitting edema, and pleural or pericardial effusion. 
Laboratory indices like dyslipidemia with high serum total and low-density-lipoprotein 
(LDL) cholesterol concentrations are common in hypothyroidism.  
4.4.2 In a recent long-term follow-up study (De Sanctis, 2008a), was mentioned that cardiac 
involvement may be present in 50% of hypothyroid TMp with moderate or severe iron 
overload. Among them, 16,6% died during the follow-up from heart failure and 
arrhythmia, in a 4-year interval. The changes in cardiovascular function in 
hypothyroidism respond to replacement therapy with L-thyroxine and an adequate 
chelation regimen (De Sanctis, 2008b).  
4.4.3 In our study, all hypothyroid TMp were presented at baseline with moderate to severe 
cardiac iron overload (mean MRI T2*Η: 13.8 ± 9.8 msec) and 16/18 (88,8%) with a cardiac 
dysfunction (mean LVEF of 54 ± 1.5%) and classified according to their symptoms 4/16 
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(25%) NYHA Class I, 7/16 (44%) Class II, 3/16 (19%) Class III and 2/16 (12%) Class IV. 
Twelve of them were on cardiac medications (angiotensin-converting enzyme [ACE] 
inhibitors, anti-arrhythmics, digoxin or diuretics). After combined chelation therapy, the 
overall change from cardiac iron loaded to non-iron loaded was significant (Fisher’s exact 
test p< 0.001) with mean MRI T2*Η increased to normal levels 35.5 ± 8.1ms and mean 
LVEF: 65 ± 2.8%, respectively. Only in 2/16 less compliant TMp, although ameliorated 
cardiac dysfunction (one of Class IV and one of Class III improved to Class II) kept on 
cardiac medication. None of our TMp died during the follow-up interval, from heart 
failure or arrhythmia. No new cases of cardiac dysfunction were observed suggesting that 
combined chelation may prevent or reverse cardiac complications. A considerable body of 
data now exists confirming that DFP is superior to DFO in reducing iron in the heart 
(Pennell et al, 2006) and reversing cardiac complications and that combined chelation 
(DFP–DFO) can have a more marked effect in purging cardiac iron (Anderson et al, 2002; 
Tanner et al, 2007, 2008), as it was observed in this study. Maggio et al, 2009 speculated 
that DFP had a protective effect on the heart even before cardiac iron declined 
significantly, most likely because of the clearance of cellular toxic labile iron. In any case, 
reversal of cardiac complications and discontinuation of cardiac medication, as 
documented here, is a significant achievement. Reversal of hypothyroidism, in the same 
TMp, possibly sustained cardiac amelioration. 
4.5 Hypothyroidism & hypogonadism 
4.5.1 Subclinical hypothyroidism may be associated with male and female gonad 
dysfunction and interferes with their reproductive ability (Trokoudes et al 2006). The 
awareness of the thyroid status in any infertile couple is crucial, because of its 
significant, frequent and often reversible or preventable effect on infertility.  
4.5.2 Indeed, among our hypothyroid TMp one female with secondary amenorrhea, after 5 
years of combined chelation, the normalization of her total body iron load and the 
improvement of her overall hormonal profile, gave birth to 2 healthy children after 
normal conception.  
4.6 The decision to treat TMp with L-thyroxin 
4.6.1 Although the course of thyroid disease in TMp is a slow process and it might take 
years to progress from normal to uncompensated hypothyroidism, the decision to treat 
with L-thyroxin is crucial. In the normal population, experts recommend treatment with 
thyroid hormone if TSH levels >10 mU/l. In thalassaemic patients more criteria are 
taken into consideration (Gharib et al, 2005; De Sanctis et al, 2008b). It is particularly 
recommended in TMp with cardiac dysfunction because of the potential for reducing 
the risk of cardiac problems (Biondi & Cooper, 2008). The therapeutic use of thyroid 
hormones in the clinical treatment of mood disorders or memory impairment is taking 
on a new dimension even in patients with euthyroid hormonal state (Bauer et al, 2008). 
Additionally, thyroxine treatment in subclinical hypothyroidism may restore ovulatory 
dysfunction and adverse pregnancy outcome. Trokoudes et al, 2006 underlined that 
awareness of the thyroid status in the infertile couple is crucial, because of its 
significant, frequent and often reversible or preventable effect on infertility. 
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normalizing body iron load and reversing clinical and subclinical iron overload 
complications. Of the 50 patients completing the study, 18 (36%) were treated with 
thyroxin replacement therapy at baseline while on DFO monotherapy. After combined 
chelation and an important decrease in total body iron overload 14/18 who had 
subclinical or compensated hypothyroidism presented a significant increase in mean 
FT4, FT3 (p<0.001)and an decrease in TSH (reflected by the AUC calculation). Among 
them, 10/18 (56%) discontinued thyroxin therapy (Fisher’s exact test p<0.001) and 4/18 
(22%) reduced their thyroxin dose. The remaining 4 (8% of the total study group) who 
had biochemical overt hypothyroidism, while they all improved their TRH stimulation 
test, only 2 converted to compensated hypothyroidism with TSH levels 5-10mIU/ml 
and normal FT4 & FT3 levels. The time needed to reverse hypothyroidism with 
combined chelation varies according to the patient age and iron load status. Besides 
combined chelation may prevent hypothyroidism as no new-onset nor worsening of 
thyroid dysfunction was observed during the study period. Whether the overall 
improvement in thyroid function that was achieved in our patients can be solely 
attributed to the intensification of chelation therapy and better compliance or if there is 
a tissue-specific effectiveness of DFP in iron removal from thyroid gland is debatable. 
4.3.3 To our knowledge, this is the first report that documents, the beneficial effect of long-
term combined therapy in normalizing total body iron load and reversing most of the 
cases of subclinical and compensate hypothyroidism in TMp. 
4.4 Hypothyroidism & cardiac dysfunction  
4.4.1 Thyroid hormones control several enzymes involved in regulating calcium fluxes in the 
heart including the calcium-dependent adenosine triphosphatase and phospholamban. In 
case of hypothyroidism, the decreases in the expression and activity of these enzymes 
could potentially impair systolic performance and diastolic relaxation of the ventricles, 
leading to a reduction in cardiac output (Klein & Danzi, 2007). Additionally thyroid 
hormones play a role in reducing peripheral vascular resistance by relaxing vascular 
smooth muscle cells. Thus, in case of hypothyroidism there is an increase in peripheral 
vascular resistance and a reduction in tissue perfusion and oxygen utilization. Symptoms 
of cardiovascular dysfunction are not common or prominent but may include dyspnea, 
exercise intolerance, and edema. Findings on physical examination may include 
bradycardia, hypertension, nonpitting edema, and pleural or pericardial effusion. 
Laboratory indices like dyslipidemia with high serum total and low-density-lipoprotein 
(LDL) cholesterol concentrations are common in hypothyroidism.  
4.4.2 In a recent long-term follow-up study (De Sanctis, 2008a), was mentioned that cardiac 
involvement may be present in 50% of hypothyroid TMp with moderate or severe iron 
overload. Among them, 16,6% died during the follow-up from heart failure and 
arrhythmia, in a 4-year interval. The changes in cardiovascular function in 
hypothyroidism respond to replacement therapy with L-thyroxine and an adequate 
chelation regimen (De Sanctis, 2008b).  
4.4.3 In our study, all hypothyroid TMp were presented at baseline with moderate to severe 
cardiac iron overload (mean MRI T2*Η: 13.8 ± 9.8 msec) and 16/18 (88,8%) with a cardiac 
dysfunction (mean LVEF of 54 ± 1.5%) and classified according to their symptoms 4/16 
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(25%) NYHA Class I, 7/16 (44%) Class II, 3/16 (19%) Class III and 2/16 (12%) Class IV. 
Twelve of them were on cardiac medications (angiotensin-converting enzyme [ACE] 
inhibitors, anti-arrhythmics, digoxin or diuretics). After combined chelation therapy, the 
overall change from cardiac iron loaded to non-iron loaded was significant (Fisher’s exact 
test p< 0.001) with mean MRI T2*Η increased to normal levels 35.5 ± 8.1ms and mean 
LVEF: 65 ± 2.8%, respectively. Only in 2/16 less compliant TMp, although ameliorated 
cardiac dysfunction (one of Class IV and one of Class III improved to Class II) kept on 
cardiac medication. None of our TMp died during the follow-up interval, from heart 
failure or arrhythmia. No new cases of cardiac dysfunction were observed suggesting that 
combined chelation may prevent or reverse cardiac complications. A considerable body of 
data now exists confirming that DFP is superior to DFO in reducing iron in the heart 
(Pennell et al, 2006) and reversing cardiac complications and that combined chelation 
(DFP–DFO) can have a more marked effect in purging cardiac iron (Anderson et al, 2002; 
Tanner et al, 2007, 2008), as it was observed in this study. Maggio et al, 2009 speculated 
that DFP had a protective effect on the heart even before cardiac iron declined 
significantly, most likely because of the clearance of cellular toxic labile iron. In any case, 
reversal of cardiac complications and discontinuation of cardiac medication, as 
documented here, is a significant achievement. Reversal of hypothyroidism, in the same 
TMp, possibly sustained cardiac amelioration. 
4.5 Hypothyroidism & hypogonadism 
4.5.1 Subclinical hypothyroidism may be associated with male and female gonad 
dysfunction and interferes with their reproductive ability (Trokoudes et al 2006). The 
awareness of the thyroid status in any infertile couple is crucial, because of its 
significant, frequent and often reversible or preventable effect on infertility.  
4.5.2 Indeed, among our hypothyroid TMp one female with secondary amenorrhea, after 5 
years of combined chelation, the normalization of her total body iron load and the 
improvement of her overall hormonal profile, gave birth to 2 healthy children after 
normal conception.  
4.6 The decision to treat TMp with L-thyroxin 
4.6.1 Although the course of thyroid disease in TMp is a slow process and it might take 
years to progress from normal to uncompensated hypothyroidism, the decision to treat 
with L-thyroxin is crucial. In the normal population, experts recommend treatment with 
thyroid hormone if TSH levels >10 mU/l. In thalassaemic patients more criteria are 
taken into consideration (Gharib et al, 2005; De Sanctis et al, 2008b). It is particularly 
recommended in TMp with cardiac dysfunction because of the potential for reducing 
the risk of cardiac problems (Biondi & Cooper, 2008). The therapeutic use of thyroid 
hormones in the clinical treatment of mood disorders or memory impairment is taking 
on a new dimension even in patients with euthyroid hormonal state (Bauer et al, 2008). 
Additionally, thyroxine treatment in subclinical hypothyroidism may restore ovulatory 
dysfunction and adverse pregnancy outcome. Trokoudes et al, 2006 underlined that 
awareness of the thyroid status in the infertile couple is crucial, because of its 
significant, frequent and often reversible or preventable effect on infertility. 
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4.6.2 Therefore in our group of TMp the decision to treat was individualized and based on 
patients’ clinical history and aggravating factors (hyperlipidaemia, cardiac dysfunction, 
diabetes, pregnancy, depression). For this reason, the overall prevalence in our group 
(18/50 36%) was higher than that reported by others (Cunningham et al, 2004; Borgna-
Pignatti et al, 2005). After the use of combined chelation and the reversal of cardiac, 
glucose metabolism abnormalities and hypogonadism and other aggravating factors, 
thyroxine treatment was reconsidered according to thyroid investigation of each 
individual patient. Thereby 56% of TMp with subclinical or compensated 
hypothyroidism discontinued thyroxin therapy and 22% reduced their thyroxin dose. 
4.6.3 Special attention has to be paid in hypothyroid children and adolescents presenting 
clinical features that include declining growth velocity, short stature and pubertal delay. 
Replacement therapy with T4 should be installed in order to restore normal growth and 
development. Once growth and pubertal development are complete, thyroid hormone 
treatment can be discontinued and thyroid function re-evaluated. Patients and families 
should be aware that treatment may sometimes cause temporary behavior symptoms, 
poorer school achievement, and may not restore full growth potential. 
4.6.4 After initiation of T4 therapy, the patient should be reevaluated and serum TSH should 
be measured in six weeks, and the dose adjusted accordingly. A systematic follow-up 
biochemical monitoring (TSH) should be performed every six months to determine if re-
titration of the dose is necessary. For patients whose serum TSH is confirmed to be at the 
upper limits or above the normal reference range, is recommended to increase the dose of 
T4 with the aim of lowering the serum TSH value into the lower half of the normal range. 
4.6.5 As T4 should be taken once per day, on an empty stomach (one hour before eating or 
two hours after), sometimes compliance is difficult to achieve, considering that TMp 
take many medications. Also some of them may interfere with T4 absorption and 
should be taken several hours after the T4 dose. Additionally a high-fiber diet or coffee 
uptake can interfere with the absorption of T4.  
4.6.6 A close monitoring of TSH is recommended in hypothyroid TMp with cardiac 
dysfunction and osteoporosis, as over-replacement with T4 may cause atrial fibrillation 
and accelerated bone loss with risk of fractures.  
5. Conclusion 
This study demonstrated that hypothyroidism in Thalassemia, is a frequent iron overload 
complication. In most TMp there are no obvious clinical signs of hypothyroidism, so a 
regular follow-up for early detection and a timely replacement treatment should be 
implemented especially in children and adolescents with growth failure and pubertal 
delay. The use of intensive combined chelation and the reduction of total body iron load 
to normal levels may play a leading role in the prevention or/and reversal of 
hypothyroidism in Thalassemia. As shown in our study there was a reversal of most cases 
of subclinical and compensated hypothyroidism. Additionally this treatment regimen 
may prevent the progression from subclinical to overt hypothyroidism or may improve 
some cases of overt hypothyroidism, suggesting that even iron-induced damage of the 
thyroid pituitary axis might be reversed. Combined chelation was well tolerated and had 
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a positive impact on patient quality of life. It remains to be established, possibly through 
clinical trials in the future, whether other chelation regimens, will offer comparable 
benefits. 
6. References 
Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ, (2002) Comparison of 
effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron 
concentrations and ventricular function in beta-thalassaemia. Lancet, Vol. 360, pp. 
516-520. 
Angelucci E, Brittenham GM, McLaren CE, Ripalti M, Baronciani D, Giardini C, Galimberti 
M, Polchi P, Lucarelli G, (2000), Hepatic iron concentration and total body iron 
stores in thalassemia major. N Engl J Med. Vol. 343(5), pp. 327-31. 
Bauer M, Goetz T, Glenn T, Whybrow PC, Gjessing R, (2008) The thyroid-brain interaction 
in thyroid disorders and mood disorders. Journal of Neuroendocrinology, Vol. 20, 
pp. 1101–1114.  
Bernal J. (2002) Action of thyroid hormone in brain, Journal of Endocrinological 
Investigation, Vol. 25, pp. 268–288. 
Biondi B, Cooper DS, (2008) The clinical significance of subclinical thyroid dysfunction, 
Endocr Rev, Vol. 29(1), pp. 76-131.  
Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC. 
(2004) Survival and complications in patients with thalassemia major treated with 
transfusion and deferoxamine, Haematologica, Vol. 89(10), pp. 1187-93. 
Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, 
Ghilardi R, Piga A, Romeo MA, Zhao H, Cnaan A, (2006) Cardiac morbidity and 
mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. 
Blood, Vol. 107, pp. 3733-3737. 
Cavallo L, Licci D, Acquafredda A, Marranzini M, Beccasio R, Scardino ML, Altomare M, 
Mastro F, Sisto L, Schettini F, (1984) Endocrine involvement in children with beta-
thalassaemia major. Transverse and longitudinal studies. I. Pituitary-thyroidal axis 
function and its correlation with serum ferritin levels, Acta Endocrinol (Copenh). 
Vol. 107(1), pp. 49-53. 
Delvecchio, M.; Cavallo, L. (2010). Growth and endocrine function in thalassemia major in 
childhood and adolescence. J. Endocrinol. Invest, Vol.33, pp. 61-68. 
De Sanctis V, Eleftheriou A, Malaventura C. (2004) Prevalence of endocrine complications 
and short stature in patients with thalassaemia major: a multicenter study by the 
Thalassaemia International Federation (TIF). Pediatr Endocrinol Rev, Suppl 2, pp. 
249-55. 
De Sanctis V, Roos M, Gasser T, Fortini M, Raiola G, Galati MC; Italian Working Group on 
Endocrine Complications in Non-Endocrine Diseases. (2006). Impact of long-term 
iron chelation therapy on growth and endocrine functions in thalassaemia. J Pediatr 
Endocrinol Metab, Vol.19, pp. 471-80. 
De Sanctis V, De Sanctis E, Ricchieri P, Gubellini E, Gilli G, Gamberini MR. (2008a). Mild 
subclinical hypothyroidism in thalassaemia major: prevalence, multigated 
radionuclide test, clinical and laboratory long-term follow-up study, Pediatr 
Endocrinol Rev, Vol.6, Suppl 1, pp. 174-80. 
 
Hypothyroidism – Influences and Treatments 
 
106 
4.6.2 Therefore in our group of TMp the decision to treat was individualized and based on 
patients’ clinical history and aggravating factors (hyperlipidaemia, cardiac dysfunction, 
diabetes, pregnancy, depression). For this reason, the overall prevalence in our group 
(18/50 36%) was higher than that reported by others (Cunningham et al, 2004; Borgna-
Pignatti et al, 2005). After the use of combined chelation and the reversal of cardiac, 
glucose metabolism abnormalities and hypogonadism and other aggravating factors, 
thyroxine treatment was reconsidered according to thyroid investigation of each 
individual patient. Thereby 56% of TMp with subclinical or compensated 
hypothyroidism discontinued thyroxin therapy and 22% reduced their thyroxin dose. 
4.6.3 Special attention has to be paid in hypothyroid children and adolescents presenting 
clinical features that include declining growth velocity, short stature and pubertal delay. 
Replacement therapy with T4 should be installed in order to restore normal growth and 
development. Once growth and pubertal development are complete, thyroid hormone 
treatment can be discontinued and thyroid function re-evaluated. Patients and families 
should be aware that treatment may sometimes cause temporary behavior symptoms, 
poorer school achievement, and may not restore full growth potential. 
4.6.4 After initiation of T4 therapy, the patient should be reevaluated and serum TSH should 
be measured in six weeks, and the dose adjusted accordingly. A systematic follow-up 
biochemical monitoring (TSH) should be performed every six months to determine if re-
titration of the dose is necessary. For patients whose serum TSH is confirmed to be at the 
upper limits or above the normal reference range, is recommended to increase the dose of 
T4 with the aim of lowering the serum TSH value into the lower half of the normal range. 
4.6.5 As T4 should be taken once per day, on an empty stomach (one hour before eating or 
two hours after), sometimes compliance is difficult to achieve, considering that TMp 
take many medications. Also some of them may interfere with T4 absorption and 
should be taken several hours after the T4 dose. Additionally a high-fiber diet or coffee 
uptake can interfere with the absorption of T4.  
4.6.6 A close monitoring of TSH is recommended in hypothyroid TMp with cardiac 
dysfunction and osteoporosis, as over-replacement with T4 may cause atrial fibrillation 
and accelerated bone loss with risk of fractures.  
5. Conclusion 
This study demonstrated that hypothyroidism in Thalassemia, is a frequent iron overload 
complication. In most TMp there are no obvious clinical signs of hypothyroidism, so a 
regular follow-up for early detection and a timely replacement treatment should be 
implemented especially in children and adolescents with growth failure and pubertal 
delay. The use of intensive combined chelation and the reduction of total body iron load 
to normal levels may play a leading role in the prevention or/and reversal of 
hypothyroidism in Thalassemia. As shown in our study there was a reversal of most cases 
of subclinical and compensated hypothyroidism. Additionally this treatment regimen 
may prevent the progression from subclinical to overt hypothyroidism or may improve 
some cases of overt hypothyroidism, suggesting that even iron-induced damage of the 
thyroid pituitary axis might be reversed. Combined chelation was well tolerated and had 
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a positive impact on patient quality of life. It remains to be established, possibly through 
clinical trials in the future, whether other chelation regimens, will offer comparable 
benefits. 
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BNP is synthesized both in an inactive N-terminal fragment with 76 amino acids (NTpro-
BNP) and an active hormone with 32 amino acids (BNP). ANP and related precursor 
peptides comprise 98% of all natriuretic peptides in healthy subjects (9). 
Like ANP, BNP is induced by pathophysiological conditions of the heart, including 
hypertrophy, myocardial infarction, and heart failure. BNP levels have been shown to be a 
good predictor of left ventricular dysfunction and decompensated heart failure, and recently 
BNP infusion has been approved as an effective treatment for acute heart failure (10,11). 
Distinct physiological roles of BNP have been elucidated by generation of knockout (KO) 
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functions more as a traditional circulating hormone with pronounced diuretic, natriuretic, 
and anti-hypertensive effects. (3) 
In addition to ventricular myocardium, extracardiac sources of BNP have been detected in 
tissues at autopsy, including the lungs, kidneys, and adrenal glands, although at much 
lower levels than ventricular BNP (13). BNP is produced , to a small degree, by the renal 
glomerular epithelial and mesangial cells (14,15) is a counter-regulatory hormone that 
physiologically opposes and suppresses the renin-angiotensin aldosterone system (RAAS), 
endothelin-1 and the sympathetic nervous system (SNS). Endogenous BNP and ANP 
production maintain renal function and sodium balance when cardiac function acutely 
deteriorates (16).  
Routine BNP testing has recently been introduced as a noninvasive, low-risk test that 
measures circulating levels of BNP, which are elevated in individuals with both 
symptomatic and asymptomatic heart failure. The BNP test is used to detect preclinical 
heart disease or to confirm the cardiac etiology in symptomatic patients. It not only enables 
the early identification of patients with incipient heart failure but also provides prognostic 
information based on the magnitude of the increase. Also administration of exogenous 
intravenous (IV) BNP shown to rapidly improve hemodynamic, volume, neurohormonal, 
and symptomatic abnormalities in patients with acute decompensated heart failure and to 
decrease rates of rehospitalization (17,18). Nesiritide IV (human recombinant BNP) is 
approved for the treatment of acute decompensated CHF. The physiologic effects of 
nesiritide include veno- and arterial dilatation (without reflex tachycardia), diuresis, and 
natriuresis (without reduction in renal perfusion or function). Thus, nesiritide increases 
cardiac index and reduces pulmonary capillary wedge pressure (PCWP) (18). In addition, 
nesiritide is lusitropic, anti-fibrotic, and inhibits RAAS; thus, nesiritide should stabilize renal 
function acutely and chronically while improving cardiac function and hemodynamics in 
CHF patients. 
The cardiovascular system is very sensitive to thyroid hormones. Hyperthyroidism and 
hypothyroidism induce significant changes in cardiac functions. The effects of 
hyperthyroidism on the heart include hemodynamic changes such as decreased systemic 
vascular resistance as well as increased cardiac output, heart rate, blood volume, blood 
pressure and impaired cardiac contractility. It may also lead to atrial arrhythmias (19). These 
changes result in ventricular stretch and pressure overload, which might cause concomitant 
rise in BNP concentrations (20). Recent attention has been drawn to the relation of BNP and 
hyperthyroidism. Studies suggest that plasma BNP and NT-pro-BNP concentrations are 
frequently increased in hyperthyroidism. This increase is partly due to hyperthyroidism-
induced left ventricular dysfunction. Also in vitro animal studies have suggested that T4 
and T3 stimulate BNP release from both cultured atrial and ventricular myocytes (21). 
There are only a limited number of studies with contradictory results investigating the effect 
of thyroid function abnormalities on the measurement of BNP. Wei et al. have measured the 
BNP levels and left ventricular functions of 67 hyperthyroid patients and 32 healthy 
subjects. The average BNP level was found to be higher in the patients especially the ones 
with left ventricular dysfunction than the healthy individuals. Nonsignificant correlations 
between thyroid hormones and BNP levels were identified (19). Biondi et al. demonstrated 
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an increase of left ventricular mass more specifically, an increase of septal and posterior wall 
thickness, enhanced resting systolic function and significantly impaired Doppler parameters 
of diastolic function (22). Smit et al. demonstrated that diastolic dysfunction was impaired in 
exogenous subclinical hyperthyroidism induced by levothyroxine treatment in 25 
differentiated thyroid carcinoma patients (23). Two small studies suggest a beneficial effect 
of treatment of subclinical hyperthyroidism on cardiac function (24,25). Schultz et al. studied 
NT-pro-BNP levels in different thyroid function states and found that serum levels of NT-
pro-BNP were strongly affected by thyroid function; the higher the thyroid function, the 
higher the serum levels of NT-pro-BNP. Likewise the treatment of the dysthyroid state 
resulted in a significant increase in NT-pro-BNP in both overt and subclinical hypothyroid 
patients and a decrease in both overt and subclinical hyperthyroid patients. In order to 
evaluate whether those findings were the direct effect of thyroid hormones or were the 
results of changes in heart function and structure, they compared NT-pro-BNP, thyroid 
function and cardiac output (CO) or resting pulse rate in a subgroup of patients under 
study. CO or resting pulse rate did not have any independent effect on NT-pro-BNP levels, 
whereas , thyroid function had a significant effect on NT-pro-BNP levels (26). Ertugrul et al 
evaluated the serum BNP levels in 18 overt and 47 subclinical hyperthyroid patients 
together with 39 subclinical and 13 overt hypothyroid patients. BNP levels were more than 
five times higher in hyperthyroid than euthyroid control subjects. BNP levels were also 
higher in subclinical hyperthyroidism than euthyroid control subjects. Free T4 and free T3 
concentrations were found to be associated with high serum BNP levels. The BNP level in 
patients with subclinical or overt hypothyroidism was similar to that of the controls (27). On 
the other hand, Christ-Crain et al. found that there was no significant difference in NT-
proBNP levels of euthyroid and overt hypothyroid, subclinical hypothyroid and subclinical 
hyperthyroid subjects, and NT-pro-BNP levels were higher in overt hyperthyroidism 
compared to other groups (9). Kohno et al. have found higher BNP levels in untreated 
hyperthyroid patients and rats with hyperthyroidism induced by thyroxine than their 
normal counterparts. Hypothyroid rats had lower plasma BNP concentration than the 
euthyroid ones. In-vitro effects of T3 and T4 on the release of BNP were investigated in 
newborn rat atrial and ventricular myocytes in primary culture. T3 and T4 stimulated 
release of BNP from both cultured atrial and ventricular myocytes in a dose-dependent 
manner (21). Triiodothyronine also increases BNP gene transcription and amplifies 
endothelin-dependent BNP gene transcription in rat ventricular myocytes (28). The effect of 
hyperthyroidism and subclinical hyperthyroidism on the heart may also cause an increase in 
BNP. At the moment, we do not know which one of these mechanisms is actually 
responsible for alterations in BNP levels in thyroid dysfunction. There is little known about 
the effects of endogenous subclinical hyperthyroidism on the heart. Faber et al. 
demonstrated an increase in cardiac output and a reduction in total peripheral resistance 
when treating subclinical hypothyroid subjects with L-T4, whereas the opposite is seen on 
treating subclinical hyperthyroidism with radioiodine (24).  
Ertugrul et al studied BNP levels in patients with hyperthyroidism before specific 
treatment for hyperthyroidism and after euthyroidism was achieved. This study showed 
that BNP levels were significantly higher in hyperthyroid than euthyroid status of the 
same patients. It was found that the decrease in BNP levels was positively correlated with 
the decrease in fT3 and fT4 (29). Kato et al measured serum ANP and BNP levels in 130 
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patients with thyrotoxicosis and correlated them with serum thyroid hormone levels and 
with the degree of severity of the heart failure. They reported a significant elevation of 
BNP and atrial natriuretic peptide levels which returned to normal values after 
euthyroididsm was established in patients with thyrotoxicosis. It was concluded that both 
serum thyroid hormones and cardiovascular dysfunction contribute to the increase of 
serum BNP levels and atrial fibrillation is an independent contributing factor for the 
increase of BNP (30).  
In conclusion, natriuretic peptide levels are altered in different thyroid states with a more 
pronounced effect in hyperthyroidism compared to hypothyroidism. This seems to reflect 
distinct atrial and ventricular cardiac dysfunction in thyroid hormone excess or, 
alternatively, mirrors a direct effect of thyroid hormones on gene expression of natriuretic 
peptides. As hyperthyroidism results in increased serum levels of pro-ANP, NT-proBNP 
and BNP levels as typically seen in mild heart failure, hyperthyroidism should be 
considered in patients presenting with unclear symptoms and mildly elevated natriuretic 
peptide levels (9). Since the treatment of hyperthyroidism is quite different than the 
treatment of heart failure, thyroid hormones should be checked in patients with high levels 
of BNP. Mild elevations in NT-pro-BNP levels should therefore always be accompanied by a 
thyroid function screening test (26,29).  
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1. Introduction 
It is well known that in both sexes thyroid hormones influence sexual development and 
reproductive function; clinical and experimental evidences suggest that the hypothalamic-
pituitary-thyroid axis and the hypothalamic-pituitary-ovary axis are physiologically related 
and act together as unified system in a number of pathological conditions (Doufas & 
Mastorakos, 2000).  
In women, both hyper- and hypo-thyroidism may result in menstrual disturbances. In 
hyperthyroidism the most common manifestations are simple oligomenorrhea and 
anovulatory cycles. Hypothyroidism results in changes in cycle length, amount of bleeding, 
and usually is associated with abnormal menstrual cycles characterized mainly by 
polymenorrhea and anovulatory cycles (Krassas et al., 1999). Also subclinical 
hypothyroxinemia can be associated with short luteal phase and insufficient progesterone 
secretion (Bohnet et al., 1981); similar pictures are present in a variety of situations 
characterized by low T3 levels (malnutrition, chronic illness, exercise), known as “non-
thyroidal illness” (De Groot, 2006). 
Interference between thyroid gland function and the ovary are described in three main 
areas: the secretion of GnRH, the peripheral metabolism of steroids and prolactin secretion. 
Previous studies demonstrated a direct ovarian effect: TSH possesses a luteotropic activity 
(Wurfel, 1992) and the expression of thyroid hormone receptors has been documented in all 
ovarian cell types: surface epithelial cells, oocytes, granulosa and theca cells, stromal cells 
(Dittrich et al., 2011). Many studies were also performed in males, both in animals and 
humans and extensively reviewed (Krassas et al., 2010). 
Despite the clinical relevance of the association between thyroid and reproductive health, its 
physiopathological mechanisms are still poorly understood and no definitive trials on 
thyroid hormone replacement allow unequivocal conclusions. Among the new mechanisms 
proposed, a link could be related to oxidative stress (OS). 
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Oxidative stress is defined as the unbalancing between production of free radicals, 
molecules characterized by high reactivity due to one or more unpaired electrons in the 
external orbital, and antioxidant defenses in the biological systems. Nowadays, it is 
considered an important pathogenetic mechanism in different diseases (Halliwell & 
Gutteridge, 1979). Among free radicals the most important and studied are reactive oxygen 
species (ROS), of which most in vivo production occurs mainly during oxidative processes of 
energetic substrates in the mitochondrial respiratory chain (Littarru, 1994; Kang & 
Hamasaki, 2003). However, other important kinds of free radicals exist, besides ROS, among 
which nitrogen reactive species are the most studied (Lancaster, 1992). 
An augmented ROS production can be the consequence of an augmented electronic flow in 
the respiratory chain, when it is activated by an increased energetic demand or contribution 
of substrates (Turrens & Boveris, 1980), as occurs in obesity. An uncontrolled production of 
free radicals is linked to many pathological events, such as rheumatoid arthritis and 
myocardial infarction (Littarru, 1994), and in general ROS damage occurs in inflamed 
tissues, characterized by cellular lysis and intracellular content release. Moreover in diabetes 
mellitus, oxidation accompanies glycation in vivo, while antioxidant capacity is decreased, 
finally resulting in an increased susceptibility to oxidative stress (Wolff et al., 1991). 
It is possible to characterize different cellular defensive mechanisms against the free radical 
damage (Littarru, 1994). The first mechanism is the prevention of production or the rapid 
inactivation of free radicals, thanks to the action of enzymes, like catalase, peroxidase 
glutathion complex and superoxydedismutase (SOD), or of transition-metal binding 
proteins, like transferrin, ferritin and ceruloplasmin. The second mechanism interrupts 
propagation of the lipid peroxidation chain by a reaction with the intermediate radicals and 
the consequent neutralization. This mechanism is acted by molecules called "scavengers", 
which can be water-soluble, such as albumin, bilirubin, ascorbic acid, urates and thiols, or 
liposoluble, such as vitamin E and coenzyme Q10, the only liposoluble antioxidant 
synthesized in living organisms. The mobility of scavengers, particularly the liposoluble 
ones and above all at membrane level, allows to intercept radicals and transform them into 
more stable molecules and therefore to stop radical chain. The third defensive mechanism 
uses processes which remove molecules damaged by oxidative attack, allowing the 
reconstitution of normal structures (e.g. specific phospholypases remove the peroxidized 
fatty acids, making possible the re-acylation of damaged molecule by an acyl-CoA and the 
respective enzyme) (Littarru, 1994). Different studies suggest that OS can be present in 
hypothyroidism and could be a factor involved in infertility associated to thyroid 
insufficiency. 
2. Thyroid hormones and oxidative stress 
Previous studies have shown that both hyperthyroidism and hypothyroidism are associated 
with enhanced oxidative stress involving enzymatic and non-enzymatic antioxidants (Resch 
et al., 2002). Besides, some complications of hyperthyroidism are due just to the oxidative 
stress in target tissues (Asayama & Kato, 1990). Thyroid hormones per se can act as oxidants 
and produce DNA-damage (contrasted by catalase), probably through the phenolic group, 
similar to that of steroidal estrogens (Dobrzynska et al., 2004). Many other mechanisms, 
reviewed by Venditti & Di Meo (2006), can be involved: enhanced NOS gene expression 
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with NO overproduction; activation of hepatic nuclear factor-kB and following increase of 
cytokines stimulating ROS generation; uncoupling mechanisms involving UCP-2 and UCP-
3, regulated by thyroid hormones; increased turnover of mitochondrial proteins; mitoptosis, 
regulated by peroxisome proliferator-activated receptor gamma coactivator-1, which is 
upregulated by T3 administration. Thyroid hormones influence lipid composition of rat 
tissues (Hoch, 1988) and therefore the susceptibility to oxidative stress.  
However, there is a specificity in tissue response, and discrepant effects of T3 and T4 are 
possible. In rat liver, T3-induced hyperthyroidism was found to be associated with altered 
lipid-peroxidation indices, including elevated levels of TBARS and hydroperoxydes 
(Fernandez et al., 1985; Venditti et al., 1997; Huth et al., 1998; Venditti et al., 1999). On the 
contrary, no change in TBARS was found in homogenized livers from rats made 
hyperthyroid by administration of T4 over a 4-week period (Asayama et al., 1987). As 
regards testis, no significant change (TBARS or hydroperoxydes) was observed in lipid 
peroxidation of hyperthyroid adult rats, but hyperthyroidism promoted protein oxidation 
rate as indicated by an enhanced content of protein-bound carbonyls (Choudhury et al., 
2003). In conclusion, we should emphasize the fact of a tissue-linked variability in the effects 
of hyperthyroidism on the activity of antioxidant enzymes (Mn-SOD or Cu,Zn-SOD, 
catalase, glutathion-peroxidase) with differential effects of the two thyroid hormones 
(Venditti & Di Meo, 2006).  
At a systemic level, also in humans, hyperthyroidism has been associated with reduced 
circulating levels of alpha-tocopherol (Ademoglu et al., 1998; Bianchi et al., 1990) and 
Coenzyme Q10 (Bianchi et al., 1990; Mancini et al., 1991). Coenzyme Q10 showed a trend to 
increase in hypothyroidism (Mancini et al., 1991); it appeared to be a sensitive index of 
tissue effect of thyroid hormones, in situations in which drug interference, such as 
amiodarone (Mancini et al., 1989) or systemic illness inducing a low-T3 conditions (Mancini 
et al., 2005) complicate the interpretation of thyroid hormone levels. 
However, data on hypothyroidism in humans are conflicting. Baskol et al showed in a 
group of 33 patients with primary hypothyroidism elevated malondialdehyde (MDA) and 
nitric oxide (NO) levels and low paraoxonase (PON1) activity, while superoxide dismutase 
(SOD) was not different from controls. Interestingly, thyroid treatment decreased MDA and 
increased PON1, without reaching levels observed in controls (Baskol et al., 2007). They 
concluded that a prooxidant environment in hypothyroidism could play a role in the 
pathogenesis of atherosclerosis in such patients. Elevated MDA levels were also shown in 
subclinical hypothyroidism (Torun et al., 2009); the increased in OS was attributed to lack of 
antioxidants but also to altered lipid metabolism, since MDA showed a correlation with 
LDL-cholesterol, total cholesterol and triglycerides.  Total antioxidant status (TAS) was 
similar in overt hypothyroidism, subclinical hypothyroidism and controls. 
Different studies confirmed the NO elevation (Coria et al., 2009; Erdamar et al., 2008).  Data 
on other parameters are more conflicting. As PON-1 is concerned, a decreased activity was 
observed both in hypo- and hyperthyroidism (Azizi et al., 2003), while not significant 
differences with controls were shown in other studies (Coria et al., 2009). 
Another study (Santi et al., 2010) showed increased levels of thiobarbituric acid reactive 
substances (TBARS), but also of antioxidants, such as SOD, catalase (CAT) and Vitamin E. 
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All these parameters correlated with T3; moreover the correlation between T3 and CAT 
remained significant also when corrected with total cholesterol. While TBARS elevation was 
also shown also in some studies (Nanda et al., 2007; Erdamar et al., 2008), other studies did 
not confirm the datum in overt hypothyroidism (Coria et al., 2009) and in subclinical 
hypothyroidism (Kebapcilar et al., 2007).  
We showed low Total Antioxidant Capacity (TAC) levels in hypothyroid patients (Mancini 
et al., 2010a) and increased CoQ10 levels also in secondary hypothyroidism (mainly due to 
its metabolic role in mitochondrial respiratory chain and therefore underutilized in 
hypothyroid tissue). In the last case, hypothyroidism has a predominant effect on other 
conditions influencing CoQ10 in opposite direction, such as acromegaly and hypoadrenalism 
(Mancini et al., 2010a; Mancini et al., 2010b). 
Finally, new perspectives concern DUOX (Dual OXidase) genes expression, which is crucial 
for H2O2 generation essential for thyroid peroxidase (TPO)-catalyzed thyroid hormone 
synthesis (Ohye & Sugawara, 2010). Two oxidases of such family are present in thyroid 
(DUOX1 and DUOX2) and work together maturation factors (DUOXA1 and DUOXA2), 
which allow DUOX proteins to translocate to the follicular cell membrane and exert their 
enzymatic activity (OHYE). Cases of hypothyroidism due to mutation of DUOX or DUOXA 
genes have been presented in literature (Varela et al., 2006; Ohye et al., 2008). While defects 
of this system interfere with thyroid hormone synthesis, another new intracellular ROS 
generating system has been demonstrated in the human thyroid gland: NADPH oxidase 4 
(NOX4) (Weyemi et al., 2010); defects in such a system could be associated with thyroid 
cancer (via activation by H-Ras oncongene) and Hashimoto’s thyroiditis (in such a situation 
increased extracellular production cause an increased ICAM-1 expression and cytokine 
release) (Sharma et al., 2008). 
3. Hypothyroidism and male infertility 
Hypothyroidism can cause interference with male fertility, both via endocrine mechanisms 
and direct effect on spermatogenesis, as recently reviewed (Krassas et al., 2010). The best 
definite alteration is the decrease in SHBG and total testosterone (T) concentrations, while 
free T are reduced in approximately 60% of hypothyroid male; thyroxine therapy induces an 
increase in free T (Donnelly & White, 2000). While in females PRL elevation in 
hypothyroidism is a crucial phenomenon inducing hypogonadism, in males PRL levels are 
not frequently augmented. Similarly, gonadotropin levels are often in the normal range, but 
a blunted gonadotropin (Gn) response to GnRH  support the hypothesis of a reduced 
pituitary responsiveness to hypothalamic stimulation (Velazquez & Bellabarba Arata, 1997). 
The exaggerated T response to hCG also underlines the role of hypothalamic-pituitary unit 
rather than a primary testicular effect. A decrease has also been shown in DHEA, DHEAS, 
andostendiol and pregnenolone sulfate (Tagawa et al., 2001). The endocrine dysfunction 
partially explain the sexual symptoms complained in such patients, such as decreased libido 
or erectile dysfunction (Carani et al., 2005; Krassas et al., 2008). 
The studies on hypothyroidism and spermatogenesis are not conclusive, since reports 
concerning small groups of patients are reported in literature (Krassas et al., 2010); the 
hypothesis that severe and prolonged thyroid deficiency occurring early in life can result in 
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abnormal testicular biopsies is based on histological and endocrine evaluation of 6 adult 
hypothyroid men (De la Balze et al., 1962). Similarly, in a group of 8 hypothyroid males, 
various degrees of testicular atrophy were shown (Wortsman et al., 1987). Another group of 
10 hypothyroid patients treated with T4 (with a discontinuation or decrease of therapy for at 
least a spermatogenetic cycle) presented a decrease in semen volume, progressive forward 
motility and cumulative percentage of mobile spermatozoa forms, but without significant 
changes in these parameters during the phase of reinduced hypothyroidism; it was 
concluded therefore that short-term postpubertal hypothyroidism does not cause severe 
seminal alterations (Corrales Hernàndez et al., 1990). 
Another prospective, controlled study evaluated semen analysis, biochemical parameters 
(fructose and acid phosphatase), teratozoospermia index and acridine orange test, in 25 
hypothyroid men, before and after 6-9 months T4 treatment (Krassas et al., 2008) in 
comparison with 15 normal fertile men. The authors concluded that hypothyroidism had an 
adverse effect on spermatogenesis, with sperm morphology as the only parameter that was 
significantly affected. These data, therefore, need to be reevaluated, considering the 
variations in parameters of fertile men which have been introduced by the new version of 
the WHO manual for semen analysis (WHO, 2010) which are remarkably different from 
those previously adopted as normal range (WHO, 1999). 
Finally, even if the topic of autoimmune thyroid disease (AITD) is extensively studied in 
females (see the following paragraph), some data in males are reported. The prevalence of 
thyroid antibody positivity in a population of infertile men was found to be 7.5%; there was 
no difference in prevalence of abnormal thyroid function tests in normozoospermic vs 
pathozoospermic patients (11.1 vs 11.8%), but when correlating thyroid autoimmunity with 
semen parameters, the authors found a significantly higher presence of TPO-Abs in 
pathozoospermic and asthenozoospermic vs normozoospermic infertile men (6.7% and 7.2% 
respectively vs 1.6%) (Trummer et al., 2001). This datum was not confirmed in other studies 
(Krassas et al., 2010). The causal effect of thyroid autoimmunity is far to be understood; only 
one study showed the presence of TPO-Abs in men with serum sperm autoantibodies 
(Paschke et al., 1994). 
The hypothesis that OS, which is well known to interfere with male fertility (Iwasaki & 
Gagnon, 1992; Aitken & Krausz, 2001; Agarwal & Saleh, 2002), can be related to thyroid 
disfunction induced us to perform a case-control study, evaluating TAC and seminal 
parameters in an unselected group of infertile man and controls (Mancini et al., 2009) and 
correlating these values with systemic hormones. TAC was measured using the system 
H2O2-metmyoglobin as source of radicals. They interact with the chromogenous 
compound 2,2I,-azinobis (3-ethylbenzothiazoline-6-sulphonate) (ABTS) generating its 
radical cationic form (ABTS•+) which can be spectroscopically and kinetically detected 
(Rice-Evans & Miller, 1994;  Meucci et al., 2003). This colorimetric assay was compared 
with the enhanced chemiluminescence one, which is the most commonly used method for 
measuring TAC in seminal plasma (Said et al., 2003). The colorimetric assay was found to 
be a reliable and accurate method, simpler and cheaper than the chemiluminescence one. 
Antioxidants induce a “lag time” in accumulation and appearance of ABTS•+ which is 
proportional to the antioxidant concentration itself, so that TAC can be expressed as Lag 
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All these parameters correlated with T3; moreover the correlation between T3 and CAT 
remained significant also when corrected with total cholesterol. While TBARS elevation was 
also shown also in some studies (Nanda et al., 2007; Erdamar et al., 2008), other studies did 
not confirm the datum in overt hypothyroidism (Coria et al., 2009) and in subclinical 
hypothyroidism (Kebapcilar et al., 2007).  
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hypothyroid tissue). In the last case, hypothyroidism has a predominant effect on other 
conditions influencing CoQ10 in opposite direction, such as acromegaly and hypoadrenalism 
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for H2O2 generation essential for thyroid peroxidase (TPO)-catalyzed thyroid hormone 
synthesis (Ohye & Sugawara, 2010). Two oxidases of such family are present in thyroid 
(DUOX1 and DUOX2) and work together maturation factors (DUOXA1 and DUOXA2), 
which allow DUOX proteins to translocate to the follicular cell membrane and exert their 
enzymatic activity (OHYE). Cases of hypothyroidism due to mutation of DUOX or DUOXA 
genes have been presented in literature (Varela et al., 2006; Ohye et al., 2008). While defects 
of this system interfere with thyroid hormone synthesis, another new intracellular ROS 
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increased extracellular production cause an increased ICAM-1 expression and cytokine 
release) (Sharma et al., 2008). 
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hypothyroidism is a crucial phenomenon inducing hypogonadism, in males PRL levels are 
not frequently augmented. Similarly, gonadotropin levels are often in the normal range, but 
a blunted gonadotropin (Gn) response to GnRH  support the hypothesis of a reduced 
pituitary responsiveness to hypothalamic stimulation (Velazquez & Bellabarba Arata, 1997). 
The exaggerated T response to hCG also underlines the role of hypothalamic-pituitary unit 
rather than a primary testicular effect. A decrease has also been shown in DHEA, DHEAS, 
andostendiol and pregnenolone sulfate (Tagawa et al., 2001). The endocrine dysfunction 
partially explain the sexual symptoms complained in such patients, such as decreased libido 
or erectile dysfunction (Carani et al., 2005; Krassas et al., 2008). 
The studies on hypothyroidism and spermatogenesis are not conclusive, since reports 
concerning small groups of patients are reported in literature (Krassas et al., 2010); the 
hypothesis that severe and prolonged thyroid deficiency occurring early in life can result in 
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abnormal testicular biopsies is based on histological and endocrine evaluation of 6 adult 
hypothyroid men (De la Balze et al., 1962). Similarly, in a group of 8 hypothyroid males, 
various degrees of testicular atrophy were shown (Wortsman et al., 1987). Another group of 
10 hypothyroid patients treated with T4 (with a discontinuation or decrease of therapy for at 
least a spermatogenetic cycle) presented a decrease in semen volume, progressive forward 
motility and cumulative percentage of mobile spermatozoa forms, but without significant 
changes in these parameters during the phase of reinduced hypothyroidism; it was 
concluded therefore that short-term postpubertal hypothyroidism does not cause severe 
seminal alterations (Corrales Hernàndez et al., 1990). 
Another prospective, controlled study evaluated semen analysis, biochemical parameters 
(fructose and acid phosphatase), teratozoospermia index and acridine orange test, in 25 
hypothyroid men, before and after 6-9 months T4 treatment (Krassas et al., 2008) in 
comparison with 15 normal fertile men. The authors concluded that hypothyroidism had an 
adverse effect on spermatogenesis, with sperm morphology as the only parameter that was 
significantly affected. These data, therefore, need to be reevaluated, considering the 
variations in parameters of fertile men which have been introduced by the new version of 
the WHO manual for semen analysis (WHO, 2010) which are remarkably different from 
those previously adopted as normal range (WHO, 1999). 
Finally, even if the topic of autoimmune thyroid disease (AITD) is extensively studied in 
females (see the following paragraph), some data in males are reported. The prevalence of 
thyroid antibody positivity in a population of infertile men was found to be 7.5%; there was 
no difference in prevalence of abnormal thyroid function tests in normozoospermic vs 
pathozoospermic patients (11.1 vs 11.8%), but when correlating thyroid autoimmunity with 
semen parameters, the authors found a significantly higher presence of TPO-Abs in 
pathozoospermic and asthenozoospermic vs normozoospermic infertile men (6.7% and 7.2% 
respectively vs 1.6%) (Trummer et al., 2001). This datum was not confirmed in other studies 
(Krassas et al., 2010). The causal effect of thyroid autoimmunity is far to be understood; only 
one study showed the presence of TPO-Abs in men with serum sperm autoantibodies 
(Paschke et al., 1994). 
The hypothesis that OS, which is well known to interfere with male fertility (Iwasaki & 
Gagnon, 1992; Aitken & Krausz, 2001; Agarwal & Saleh, 2002), can be related to thyroid 
disfunction induced us to perform a case-control study, evaluating TAC and seminal 
parameters in an unselected group of infertile man and controls (Mancini et al., 2009) and 
correlating these values with systemic hormones. TAC was measured using the system 
H2O2-metmyoglobin as source of radicals. They interact with the chromogenous 
compound 2,2I,-azinobis (3-ethylbenzothiazoline-6-sulphonate) (ABTS) generating its 
radical cationic form (ABTS•+) which can be spectroscopically and kinetically detected 
(Rice-Evans & Miller, 1994;  Meucci et al., 2003). This colorimetric assay was compared 
with the enhanced chemiluminescence one, which is the most commonly used method for 
measuring TAC in seminal plasma (Said et al., 2003). The colorimetric assay was found to 
be a reliable and accurate method, simpler and cheaper than the chemiluminescence one. 
Antioxidants induce a “lag time” in accumulation and appearance of ABTS•+ which is 
proportional to the antioxidant concentration itself, so that TAC can be expressed as Lag 
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phase. The possible release of intracellular antioxidants from broken cells was 
preliminarily excluded by measuring the enzyme LDH in seminal plasma specimens 
(Mancini et al., 1994). 
The correlation analysis between hormones and seminal parameters showed an inverse 
correlation between PRL and sperm motility, and a direct correlation of TAC with PRL and 
FT4, but not with gonadotropins or gonadal steroids. Our data suggest that systemic 
hormones may play a role in regulating seminal antioxidant capacity. This is interesting also 
because some hormones, such as thyroid and pituitary ones, are not usually tested in the 
first level evaluation of male patients with fertility problems. 
4. Hypothyroidism and female infertility 
Hypothyroidism is frequently associated with infertility, due to different reasons: altered 
peripheral estrogen metabolism, alterations in GnRH secretion causing abnormal pulsatile 
LH release, hyperprolactinemia and defects in hemostasis (Krassas, 2000).  
Similarly to what observed in males, plasma SHBG is decreased, with lowering of total T 
and estradiol, but their ubound fractions are increased. The metabolism is profoundly 
affected, with decrease of metabolic clearance rate of androstendione and estrone and 
increase in peripheral aromatization (Redmond, 2004; Longcope et al., 1990). The 5α/β ratio 
of androgen metabolism is decreased and there is an augmented excretion of 2-oxygenated 
estrogens (Gallagher, 1966).  The alterations in steroid metabolism are corrected by 
replacement therapy (Gordon & Southren, 1977). As in male, gonadotropin levels are 
usually normal (Larsen, 1998), but with blunted or delayed response to GnRH (Marino et al., 
2006; Valenti et al., 1984). Hyperprolactinemia can be induced by augmented TRH secretion, 
also causing galactorrhea in some patients, reversible with thyroid therapy  (Honbo et al., 
1978). Finally, decreased levels of clotting factors VII, VIII, IX and XI have been shown and 
can contribute to polymenorrhea and menorrhagia (Ansell, 1996).  
Many studies have been performed also in subclinical hypothyroidism (SCH); the 
prevalence of SCH in infertile women was 11% in one study (Bohnet et al., 1981), but not  
considered as an infertility factors by others (Bals-Pratsch et al., 1997). A positive correlation 
was found in early follicular phase between basal TSH, LH and T; moreover women with 
elevated TSH response to TRH had lower pregnancy rate than women with normal TSH 
response (Gerhard et al., 1991). In a controlled prospective study of 438 women with 
infertility of various origin, the median TSH levels were significantly higher than controls 
(Poppe et al., 2002). Moreover more frequent miscarriages were observed in women with 
higher basal TSH levels, irrespective of the presence of AITD (Raber et al., 2003). 
We want to focuse our attention on luteal deficiency, on one side, and AITD, the most 
prevalent associated etiology in patients of reproductive age, on the other one.   
Progesterone secreted by the corpus luteum plays an important role in the maintenance of 
early pregnancy. Immediately after implantation, under the influence of human chorionic 
gonadotropin (hCG) secreted by the trophoblast, the corpus luteum receives a signal to 
continue to producing 17-α-progesterone along with estradiol, estrone, and relaxin 
(Szlachter et al., 1980; Bigazzi et al., 1981). The corpus luteum maintains its capacity to 
synthesize progesterone almost throughout the pregnancy, but at approximately 7 weeks 
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gestation, its functional ability decreases markedly at the start of the luteoplacental 
transition. The removal of the corpus luteum before the eighth week of gestation results in 
abortion, whereas after the ninth week it does not (Csapo et al., 1973). Abnormalities of the 
luteal phase have been reported to occur in up to 35% of women with recurrent pregnancy 
losses (Insler, 1992). There are several causes for luteal phase deficiency, including stress, 
exercise, weight loss, hyperprolactinemia, and menstrual cycles at the onset of puberty or 
perimenopause. 
Luteal phase deficiency (LPD) presents without any significant change in menstrual cycle 
lenght, despite prolonged follicular phases and shortened progesterone-deficient luteal 
phases (De Souza et al., 1998). Clinically, LPD is associated with abnormal corpus luteal 
function, which includes the mentionated short luteal phases and inadequate progesterone 
production, and also inappropriate endometrial stimulation and maturation (Ginsburg, 
1992). These luteal phase alterations cause asynchronous follicular growth, compromised 
oocyte maturation, and differentiated (out of phase) function of the endometrium, which is 
associated with low rates of cycle fecundity and high rates of embryonic loss, i.e. infertility 
and spontaneous abortion (Ginsburg, 1992). 
As above stated, hypoactive thyroid hormone is associated with infertility, even if severe 
forms of hypothyroidism rarely complicate pregnancy because they are associated with 
anovulation. However, in mild hypothyroidism, pregnancies can occur and are associated 
with higher rates of pregnancy loss and maternal complications (Davis et al., 1988; Stray-
Pedersen & Stray-Pedersen, 1984). Even if an association exists between low thyroid 
function and pregnancy loss, a direct evidence for a causal role is missing  (Clifford et al., 
1994). One hypothesis for this correlation is that luteal phase defect has been linked to 
thyroid hypofunction. In consideration that production of progesterone is a pivotal element 
of a successful pregnancy, it is possible that pregnancy loss could be related to a deficient 
corpus luteum action ( Daya et al., 1988). 
An important study was published by Negro et al (2006) showing, in a large cohort of 
women, that patients with positive thyroid autoantibodies (TPO-ab), even if euthyroid at the 
early stages of pregnancy, would benefit from L-thyroxine administration to improve 
outcome of pregnancy, and namely the rate of spontaneous miscarriage and premature 
delivery. Ab-positive women  were significantly older than control population (suggesting 
that AITD could delay conception due to its relation with infertility) but exhibit a mean 
serum TSH, although normal, significantly higher than controls; women were randomly 
assigned to two groups, one without treatment, and the other with L-thyroxine treatment. In 
group without therapy, serum TSH progressively increased during gestation, in the 
meantime serum free T4 (FT4) decreased by 30%, suggesting reduced functional thyroid 
reserve due to AITD. On the contrary, in treated group, the miscarriage rate was reduced by 
75% and frequency of premature delivery by 69%.   Similar results were reported by other 
authors showing that age, TPO positivity and high TSH levels were independently 
associated with the risk of miscarriage in multivariate analysis (Sieiro Netto et al., 2004). An 
association between miscarriage and AITD had been previously described (Stagnaro-Green 
et al., 1990; Glinoer et al., 1991) and support in other population studies, confirming this 
association also in the case of apparent normal thyroid function (Poppe & Glinoer, 2003). A 
recent review separately considered association of AITD and miscarriage, AITD and 
recurrent miscarriage and finally AITD and early pregnancy loss after in vitro fertilization 
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phase. The possible release of intracellular antioxidants from broken cells was 
preliminarily excluded by measuring the enzyme LDH in seminal plasma specimens 
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The correlation analysis between hormones and seminal parameters showed an inverse 
correlation between PRL and sperm motility, and a direct correlation of TAC with PRL and 
FT4, but not with gonadotropins or gonadal steroids. Our data suggest that systemic 
hormones may play a role in regulating seminal antioxidant capacity. This is interesting also 
because some hormones, such as thyroid and pituitary ones, are not usually tested in the 
first level evaluation of male patients with fertility problems. 
4. Hypothyroidism and female infertility 
Hypothyroidism is frequently associated with infertility, due to different reasons: altered 
peripheral estrogen metabolism, alterations in GnRH secretion causing abnormal pulsatile 
LH release, hyperprolactinemia and defects in hemostasis (Krassas, 2000).  
Similarly to what observed in males, plasma SHBG is decreased, with lowering of total T 
and estradiol, but their ubound fractions are increased. The metabolism is profoundly 
affected, with decrease of metabolic clearance rate of androstendione and estrone and 
increase in peripheral aromatization (Redmond, 2004; Longcope et al., 1990). The 5α/β ratio 
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considered as an infertility factors by others (Bals-Pratsch et al., 1997). A positive correlation 
was found in early follicular phase between basal TSH, LH and T; moreover women with 
elevated TSH response to TRH had lower pregnancy rate than women with normal TSH 
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gestation, its functional ability decreases markedly at the start of the luteoplacental 
transition. The removal of the corpus luteum before the eighth week of gestation results in 
abortion, whereas after the ninth week it does not (Csapo et al., 1973). Abnormalities of the 
luteal phase have been reported to occur in up to 35% of women with recurrent pregnancy 
losses (Insler, 1992). There are several causes for luteal phase deficiency, including stress, 
exercise, weight loss, hyperprolactinemia, and menstrual cycles at the onset of puberty or 
perimenopause. 
Luteal phase deficiency (LPD) presents without any significant change in menstrual cycle 
lenght, despite prolonged follicular phases and shortened progesterone-deficient luteal 
phases (De Souza et al., 1998). Clinically, LPD is associated with abnormal corpus luteal 
function, which includes the mentionated short luteal phases and inadequate progesterone 
production, and also inappropriate endometrial stimulation and maturation (Ginsburg, 
1992). These luteal phase alterations cause asynchronous follicular growth, compromised 
oocyte maturation, and differentiated (out of phase) function of the endometrium, which is 
associated with low rates of cycle fecundity and high rates of embryonic loss, i.e. infertility 
and spontaneous abortion (Ginsburg, 1992). 
As above stated, hypoactive thyroid hormone is associated with infertility, even if severe 
forms of hypothyroidism rarely complicate pregnancy because they are associated with 
anovulation. However, in mild hypothyroidism, pregnancies can occur and are associated 
with higher rates of pregnancy loss and maternal complications (Davis et al., 1988; Stray-
Pedersen & Stray-Pedersen, 1984). Even if an association exists between low thyroid 
function and pregnancy loss, a direct evidence for a causal role is missing  (Clifford et al., 
1994). One hypothesis for this correlation is that luteal phase defect has been linked to 
thyroid hypofunction. In consideration that production of progesterone is a pivotal element 
of a successful pregnancy, it is possible that pregnancy loss could be related to a deficient 
corpus luteum action ( Daya et al., 1988). 
An important study was published by Negro et al (2006) showing, in a large cohort of 
women, that patients with positive thyroid autoantibodies (TPO-ab), even if euthyroid at the 
early stages of pregnancy, would benefit from L-thyroxine administration to improve 
outcome of pregnancy, and namely the rate of spontaneous miscarriage and premature 
delivery. Ab-positive women  were significantly older than control population (suggesting 
that AITD could delay conception due to its relation with infertility) but exhibit a mean 
serum TSH, although normal, significantly higher than controls; women were randomly 
assigned to two groups, one without treatment, and the other with L-thyroxine treatment. In 
group without therapy, serum TSH progressively increased during gestation, in the 
meantime serum free T4 (FT4) decreased by 30%, suggesting reduced functional thyroid 
reserve due to AITD. On the contrary, in treated group, the miscarriage rate was reduced by 
75% and frequency of premature delivery by 69%.   Similar results were reported by other 
authors showing that age, TPO positivity and high TSH levels were independently 
associated with the risk of miscarriage in multivariate analysis (Sieiro Netto et al., 2004). An 
association between miscarriage and AITD had been previously described (Stagnaro-Green 
et al., 1990; Glinoer et al., 1991) and support in other population studies, confirming this 
association also in the case of apparent normal thyroid function (Poppe & Glinoer, 2003). A 
recent review separately considered association of AITD and miscarriage, AITD and 
recurrent miscarriage and finally AITD and early pregnancy loss after in vitro fertilization 
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(Stagnaro-Green & Glinoer, 2004). Finally another confirmation came from a meta-analysis 
of all case-controlled and longitudinal studies, with an increased risk by 3-fold. Poppe et al. 
performed a prospective cohort study in women undergoing the first Assisted Reproduction 
Technology (ART) cycle, excluding over thyroid dysfunction. The prevalence of antiTPO 
was 14%, without differences in TSH,  FT4 and age; in this positive group, pregnancy rate 
was 53% vs 43%, with an odds ratio of 0.67, but in pregnant  group the miscarriage rate was 
53% and 23% respectively, with and odds ratio of 3.77 (Poppe et al., 2003). Autoimmune 
thyroiditis are clearly associated with clinically relevant events occurring before, during and 
after pregnancy (Muller & Berghout, 2003). The hypothesis to explain this strong association 
were, of course, based on the concept of a generalized autoimmune disorders or a subtle 
thyroid hormone deficiency. 
In this sense, a light is brought by studies performed with the administration of L-thyroxine. 
Vaquero et al (2000)  included patients with Ab positivity and two previous first-trimester 
miscarriage, achieving a greater pregnancy outcome than untreated patients (81% vs 55%). 
Negro reported a reduction of miscarriage rate after L-thyroxine treatment in Ab positive 
infertile women who underwent in vitro fertilization (Negro et al., 2006). Finally, Abalovich 
et al. (2002) underlined the importance of adequate hormone treatment, comparing patients 
with hypothyroidism already known before pregnancy (adequate treatment) and patients 
with uncompletely adjusted replacement therapy: the pregnancy ended with abortion  in 
60% and 71% of cases, respectively.     
In conclusion we believe it is prudent to screen for thyroid disease and normalize thyroid 
functions, when these are found abnormal, prior to conception or to return to a “normal” 
menstrual cycle, moreover Ab+ women should be carefully evaluated before pregnancy for 
sublinical hypothyroidism.  
We report here some personal data on subclinical hypothyroidism, in couples users of  
Billings Ovulation Method (BOM); it is based on vulvar observation of the “Mucus 
Symptom”, whose pattern is an accurate and precise marker of the ovarian function (Bllings, 
1972), validated by laboratory research and field trials (Billings, 1991; Brown et al., 1987).  
BOM can be useful in studying subtle abnormalities in thyroid-gonadotropin interaction; the 
simple identification of the mucus peak and the evaluation of luteal phase length allow to 
detect a precise timing to perform hormonal assays. Therefore, we used BOM to evaluated 
the prevalence of subclinical hypothyroidism in women, users of the method for achieving 
or spacing pregnancy, and whose cycle abnormalities were not referred to cervical 
pathology. Preliminary data, still unpublished, but presented at the World Congress on 
Fertility & Sterility (Giacchi et al., 2007) were collected in 42 couples consulting our Center: 
22 exhibited an history of infertility (1-4 ys), with a range age of women: 26-42 ys.  Criteria 
of exclusion were male infertility and cervical pathology. Evaluation of progesterone levels 
was performed on the 6th-7th day after the “peak of mucus symptom”, or on the 6th-7th day 
before the expected menses, when no peak occurred. We evaluated basal plasma levels of 
FT3, FT4, TSH, PRL and performed a TRH test (200 ug iv, with TSH evaluation at 0, 30, 60 
min) when TSH was normal or high normal. The presence of anti-TPO and anti-
thyroglobulin autoantibodies was also evaluated. Progesterone (P), FT3 and FT4 were 
assayed by RIA; TSH was assayed by IRMA method. Coefficients of variation: intra-assay 
CV 2.6% for P, 3.8% for FT3, 4.1% for FT4, 4.5% for TSH; inter-assay CV 3.9% for P, 3.9% for 
FT3, 4.9% for FT4, 3.4% for TSH.  Normal ranges: Progesterone: 7-30 ng/ml; FT3: 2.3-4.2 
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pg/ml; FT4 8.5-15.5 pg/ml; TSH 0.35-2.80 µUI/ml. TRH (Relefact 200 µg) was fournished by 
Hoechst, Italy. Subclinical hypothyroidism was defined as TSH peak response > 15 µg/ml, 
according to previous studies and comparison with age-matched controls (Giacchi et al., 
2001). Women were classified in three groups according to the BOM mucus symptom 
different patterns: Anovulatory pattern of the mucus symptom (n=2),  post-peak phases 
shortened and/or affected by spotting (n=22), normal lenght of luteal phase, but P in the 
lower  range of postovulatory values (n=18); among these  two presented hypermenorrhea. 
Mean ± levels of the studied hormones are reported in table 1. Normal PRL levels were 
present in this group of patients. The prevalence of subclinical hypothyroidism, as above 
defined, in this group was 80%; prevalence of thyroid autoantibodies: 10%. After L-thyroxine 
treatment, we observed a clear and significant increase in progesterone levels (evaluated 6-7 
day after the “peak” of the “mucus symptom”) and the resumption of ovulation in the two 
women with anovulatory cycles (Fig. 1), strongly supporting a pathogenetic role of 
hypothyroidism in anovulation or luteal failure. 
women 




TSH peak  
μU/ml PRL (ng/ml)
2 0,3 + 0,2 3,6  + 1,5 9,0 + 0,5 3,4 + 0,8 24,5 + 1,5 19,5 + 1,0
< 11 g 22 10,7 + 1,1 4,0 + 1,0 10,1 + 0,8 2,7 + 0,2 21,2 + 1,5 16,1  + 1,6









Table 1. Mean ± SEM hormone levels in patients consulting our Center for infertility and 
monitored by Billings’ Ovulation Method. 
An hypothesis linking thyroid dysfunction and luteal deficiency is that concerning OS. 
Oxidative stress is associated with decreased female fertility in animals and in vitro models, 
but some observations in humans also reinforces this concept. Exposures associated with OS 
(extremes of body weight, alcohol, tobacco and caffeine intake) may induce pregnancy 
complications (e.g. preeclampsia) ; while intake of antioxidants nutrients, included use of 
multivitamins, have a beneficial role in female fertility (Ruder et al., 2009). More recently, it 
has been hypothesized that the exposure to environmental pollutants in fetal life may alter 
DNA methylation, causing altered gene expression in adult life (Li et al., 1997; Anway et al., 
2005); therefore this widespread condition should be added to the factors favouring OS.  A 
role of reduced antioxidant defence has also been hyothesized in polycystic ovary, 
unexplained infertility and outcome of in vitro fertilization (Ruder et al., 2008). 
When specifically considering luteal function, it has been shown than the corpus luteum has 
a high concentrations of antioxidants, especially β-carotene, to which is related the bright 
yellow color (Rodgers et al., 1995); other carotenoids and vitamins C and E are also present 
and may contribute to ROS scavenging (Aten et al., 1992;  Matzuk et al., 1998; Behrman et 
al., 2001. Moreover ROS are produced during luteal regression (Behrman et al., 2001), in part 
through cytochrome P450 enzymes involved in the first step of steroidogenesis (Rodgers et 
al., 1995).  
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(Stagnaro-Green & Glinoer, 2004). Finally another confirmation came from a meta-analysis 
of all case-controlled and longitudinal studies, with an increased risk by 3-fold. Poppe et al. 
performed a prospective cohort study in women undergoing the first Assisted Reproduction 
Technology (ART) cycle, excluding over thyroid dysfunction. The prevalence of antiTPO 
was 14%, without differences in TSH,  FT4 and age; in this positive group, pregnancy rate 
was 53% vs 43%, with an odds ratio of 0.67, but in pregnant  group the miscarriage rate was 
53% and 23% respectively, with and odds ratio of 3.77 (Poppe et al., 2003). Autoimmune 
thyroiditis are clearly associated with clinically relevant events occurring before, during and 
after pregnancy (Muller & Berghout, 2003). The hypothesis to explain this strong association 
were, of course, based on the concept of a generalized autoimmune disorders or a subtle 
thyroid hormone deficiency. 
In this sense, a light is brought by studies performed with the administration of L-thyroxine. 
Vaquero et al (2000)  included patients with Ab positivity and two previous first-trimester 
miscarriage, achieving a greater pregnancy outcome than untreated patients (81% vs 55%). 
Negro reported a reduction of miscarriage rate after L-thyroxine treatment in Ab positive 
infertile women who underwent in vitro fertilization (Negro et al., 2006). Finally, Abalovich 
et al. (2002) underlined the importance of adequate hormone treatment, comparing patients 
with hypothyroidism already known before pregnancy (adequate treatment) and patients 
with uncompletely adjusted replacement therapy: the pregnancy ended with abortion  in 
60% and 71% of cases, respectively.     
In conclusion we believe it is prudent to screen for thyroid disease and normalize thyroid 
functions, when these are found abnormal, prior to conception or to return to a “normal” 
menstrual cycle, moreover Ab+ women should be carefully evaluated before pregnancy for 
sublinical hypothyroidism.  
We report here some personal data on subclinical hypothyroidism, in couples users of  
Billings Ovulation Method (BOM); it is based on vulvar observation of the “Mucus 
Symptom”, whose pattern is an accurate and precise marker of the ovarian function (Bllings, 
1972), validated by laboratory research and field trials (Billings, 1991; Brown et al., 1987).  
BOM can be useful in studying subtle abnormalities in thyroid-gonadotropin interaction; the 
simple identification of the mucus peak and the evaluation of luteal phase length allow to 
detect a precise timing to perform hormonal assays. Therefore, we used BOM to evaluated 
the prevalence of subclinical hypothyroidism in women, users of the method for achieving 
or spacing pregnancy, and whose cycle abnormalities were not referred to cervical 
pathology. Preliminary data, still unpublished, but presented at the World Congress on 
Fertility & Sterility (Giacchi et al., 2007) were collected in 42 couples consulting our Center: 
22 exhibited an history of infertility (1-4 ys), with a range age of women: 26-42 ys.  Criteria 
of exclusion were male infertility and cervical pathology. Evaluation of progesterone levels 
was performed on the 6th-7th day after the “peak of mucus symptom”, or on the 6th-7th day 
before the expected menses, when no peak occurred. We evaluated basal plasma levels of 
FT3, FT4, TSH, PRL and performed a TRH test (200 ug iv, with TSH evaluation at 0, 30, 60 
min) when TSH was normal or high normal. The presence of anti-TPO and anti-
thyroglobulin autoantibodies was also evaluated. Progesterone (P), FT3 and FT4 were 
assayed by RIA; TSH was assayed by IRMA method. Coefficients of variation: intra-assay 
CV 2.6% for P, 3.8% for FT3, 4.1% for FT4, 4.5% for TSH; inter-assay CV 3.9% for P, 3.9% for 
FT3, 4.9% for FT4, 3.4% for TSH.  Normal ranges: Progesterone: 7-30 ng/ml; FT3: 2.3-4.2 
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pg/ml; FT4 8.5-15.5 pg/ml; TSH 0.35-2.80 µUI/ml. TRH (Relefact 200 µg) was fournished by 
Hoechst, Italy. Subclinical hypothyroidism was defined as TSH peak response > 15 µg/ml, 
according to previous studies and comparison with age-matched controls (Giacchi et al., 
2001). Women were classified in three groups according to the BOM mucus symptom 
different patterns: Anovulatory pattern of the mucus symptom (n=2),  post-peak phases 
shortened and/or affected by spotting (n=22), normal lenght of luteal phase, but P in the 
lower  range of postovulatory values (n=18); among these  two presented hypermenorrhea. 
Mean ± levels of the studied hormones are reported in table 1. Normal PRL levels were 
present in this group of patients. The prevalence of subclinical hypothyroidism, as above 
defined, in this group was 80%; prevalence of thyroid autoantibodies: 10%. After L-thyroxine 
treatment, we observed a clear and significant increase in progesterone levels (evaluated 6-7 
day after the “peak” of the “mucus symptom”) and the resumption of ovulation in the two 
women with anovulatory cycles (Fig. 1), strongly supporting a pathogenetic role of 
hypothyroidism in anovulation or luteal failure. 
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Table 1. Mean ± SEM hormone levels in patients consulting our Center for infertility and 
monitored by Billings’ Ovulation Method. 
An hypothesis linking thyroid dysfunction and luteal deficiency is that concerning OS. 
Oxidative stress is associated with decreased female fertility in animals and in vitro models, 
but some observations in humans also reinforces this concept. Exposures associated with OS 
(extremes of body weight, alcohol, tobacco and caffeine intake) may induce pregnancy 
complications (e.g. preeclampsia) ; while intake of antioxidants nutrients, included use of 
multivitamins, have a beneficial role in female fertility (Ruder et al., 2009). More recently, it 
has been hypothesized that the exposure to environmental pollutants in fetal life may alter 
DNA methylation, causing altered gene expression in adult life (Li et al., 1997; Anway et al., 
2005); therefore this widespread condition should be added to the factors favouring OS.  A 
role of reduced antioxidant defence has also been hyothesized in polycystic ovary, 
unexplained infertility and outcome of in vitro fertilization (Ruder et al., 2008). 
When specifically considering luteal function, it has been shown than the corpus luteum has 
a high concentrations of antioxidants, especially β-carotene, to which is related the bright 
yellow color (Rodgers et al., 1995); other carotenoids and vitamins C and E are also present 
and may contribute to ROS scavenging (Aten et al., 1992;  Matzuk et al., 1998; Behrman et 
al., 2001. Moreover ROS are produced during luteal regression (Behrman et al., 2001), in part 
through cytochrome P450 enzymes involved in the first step of steroidogenesis (Rodgers et 
al., 1995).  
 




Fig. 1. Post-peak (according to BOM) Progesterone  levels (ng/ml) before and after 
replacement l-T4 treatment . 
However, the role of ROS in ovary is particularly complex.  On one side, they play a 
physiological role: regulated ROS generation by the pre-ovulatory follicle is an important 
promoter of ovulatory sequence; in particular, the resumption of meiosis I (MI) induced by 
hormonal factor after puberty, is induced by ROS and inhibited by antioxidants (Takami et 
al., 1999; Kodman & Behrman, 2001). Another beneficial effects could be related to a ROS 
involvement in intracellular signalling between hypoxia and angiogenig response (Basini et 
al.,2004). Surprisingly, antioxidants are, on the contrary, beneficial for MII, which arises in 
response to periovulatory LH peak (Behrman et al., 2001). Follicular ROS initiate apoptosis 
whereas follicular glutathione (GSH), in addition to FSH, protect against apoptosis in 
cultured preovulatory rat follicles (Tsai-Turton & Luderer, 2006). Moreover,  cyclical ROS 
production may contribute to oophoritis associated with autoimmune premature ovarian 
failure (Behrman et al., 2001).  It has been suggested that ROS under moderate 
concentrations play a role in signal transduction processes involved in growth and 
protection from apoptosis (Basini  et al., 2004). In rat thecal-intestitial cells, which regulate 
steroidogesis and follicle growth in secondary follicle, ROS induced a biphasic effect on 
proliferation (positive at lower and negative at higher concentrations). Therefore controlled 
ROS levels may be needed to maintain DNA synthesis, cell proliferation and growth of 
ovarian mesenchyme in such animal model (Duleba et al., 2004). Finally, epidemiologic data 
suggest a positive role of dietary antioxidants (Ruder et al., 2008): preconceptional 
multivitamin supplementation may enhance fertility, perhaps increasing menstrual cycle 
regularity (Czeizel et al., 1994;  Dudas et al., 1995) or via prevention of ovulatory disorders 
(Chavarro et al., 2007). Despite all these evidences, it must be reminded the difference by in 
vitro models and in vivo conditions and the need of more data of antioxidants levels in 
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Taken together, all the reported data confirm the role of thyroid hormones in human 
fertility; also subclinical hypothyroidism should be considered in the evaluation of an 
infertile couple, even if it is not routinely evaluated in the first level approach to this 
problem. Oxidative stress could be a phenomenon  liking hypothyroidism, also in 
subclinical form, with altered sperm motility, in males, and luteal phase deficiency in 
females, even if more experimental data are needed to give statistical evidence to this 
fascinating hypothesis. 
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1. Introduction 
Hypothyroidism is the most common pathological hormone deficiency (Roberts et al, 2004). 
The variety of end-organ effects and wide range of disease severity—from entirely 
asymptomatic individuals to patients in coma with multisystem failure—can make 
hypothyroidism an elusive clinical entity (Roberts et al, 2004). Hypothyroidism was first 
described in the 19 th century. 
Impaired memory, slowed mental processing, depression, nerve entrapment syndromes, 
ataxia, muscle weakness and muscle cramps are the most common neurological symptoms 
which may be caused by hypothyroidism (Roberts et al, 2004). Disorders of the thyroid 
gland are among the most common endocrine maladies. Hypothyroidism is the most 
prevalent form of thyroid disease and symptoms may include memory and learning 
impairment, depression, psychotic behaviour, retarded locomotor ability, somnolence, 
progressive intellectual deterioration and, in extreme cases, coma (Anderson, 2001; Smith et 
al., 2002). Since the thyroid hormones dramatically affect the maturation of specific neuronal 
populations, the absence of these hormones during the period of active neurogenesis leads 
to irreversible mental retardation and is accompanied by multiple morphological alterations 
in the brain (Smith et al., 2002). 
2. Central nervous system nvolvement due to hypothyrodsm 
Disruption of thyroid hormone production during fetal and early neonatal development 
leads to a suite of permanent deficits in intelligence and sensorimotor function in humans 
(Dong et al, 2005). 
Clinical hypothyroidism indicates a pervasive deficit in thyroid hormone actions, including 
modulation of calorigenesis and oxygen consumption in most tissues and additional organ-
specific effects (Roberts et al, Lancet). 
Brain-derived neurotrophic factor (BDNF) is a neurotrophin critical for many 
developmental and physiological aspects of CNS function. Severe hypothyroidism in the 
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early neonatal period results in developmental and cognitive impairments and reductions in mRNA 
and protein expression of BDNF in a number of brain regions (Lasley et al., 2011).  
The action of thyroid hormones (THs) in the brain is strictly regulated, since these hormones 
play a crucial role in the development and physiological functioning of the central nervous 
system (CNS) (Ahmed et al., 2008). 
Transient reductions in thyroid hormone during critical periods of brain development can 
have devastating and irreversible effects on neurological function (Gilbert et al, 2004). The 
hippocampus is a brain region sensitive to thyroid hormones and is a necessary substrate for 
some forms of learning and memory. Subregions within the hippocampus display distinct 
ontogenetic profiles and have shown differential vulnerability to some indices of thyrotoxic 
insult. Synaptic function can be readily assessed in the hippocampus, yet little information 
exists on the consequences of early thyroid hormone insufficiency on the neurophysiological 
integrity of this structure (Gilbert et al, 2004). 
Thyroid hormone deficiency during the critical period of neural differentiation produces 
permanent and severe alterations in the morphology and function of the nervous system 
leading to cretinism. Perinatal hypothyroidism results in permanent alterations of 
hippocampal synaptic functions in adult rats consequently causing learning and memory 
impairment (Calloni et al., 2005). 
It has been established that both L-thyroxine (T4) and L-3,5,39-triiodothyronine (T3) are 
present in the adult brain. Moreover, the enzyme deiodinase type II, which is mainly 
responsible for converting inactive T4 to active form T3, is also present in glial and neural 
cells (Calza et al., 1997). 
Finally, receptors for thyroid hormone T3 are localized in nuclei of glial cells and neurons in 
different brain areas (Calza et al., 1997). 
Thyroid hormone is essential for proper development of the mammalian CNS. Previous 
studies have documented a decrease in the ability of neonatal hypothyroid animals to learn 
and to habituate to maze tests and an increase in spontaneous activity (Darbra et al, 2003). 
On the other hand some observers stated that children with hypothyroidism had no 
apparent specific impediments to learning unrelated to intelligence (England Congenital 
Hypothyroidism Collaborative New, 1990). 
Cognitive neurological symptoms are common in myxoedema, in particular a general 
slowing of cognitive functions with memory impairment and apathy. This may progress 
insidiously to a global cognitive impairment of dementia. Appropriate treatment with 
replacement therapy will sometimes improve mental changes,though they are frequently 
only partially reversible (Osterweil et al., 1992). The longer the condition remains 
undiagnosed, the worse the outcome (Dennis et al., 2005). 
The in vitro studies demonstrate that adult hippocampal progenitors exhibit enhanced 
proliferation, survival and glial differentiation in response to thyroid hormone. These 
results support a role for thyroid hormone in the regulation of adult hippocampal 
neurogenesis and raise the possibility that altered neurogenesis may contribute to the 
cognitive and behavioral deficits associated with adult-onset hypothyroidism (Desouzo et 
al., 2005). 
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According to a study by Bhanja et al., the results suggest that the antioxidant defence system 
of the developing cerebellum is sensitive to thyroid hormone deficiency and consequent 
alterations in oxidative stress status may play a role in regulation of cell proliferation of the 
cerebellum during neonatal brain development (Bhanja et al.,2010). 
In vitro, THs (thyroid hormones) have been reported to modulate astrocyte morphology, 
differentiation, and proliferation and to regulate extracellular matrix (ECM) organization 
and synthesis (Dezonne et al, 2009). In vivo, THs regulate radial gliaastrocyte transition and 
the vimentin-GFAP (glial fibrillary acidic protein) switch, a hallmark of astrocyte 
differentiation, in the basal forebrain and hippocampus (Dezonne et al., 2009). 
Prompt treatment of maternal hypothyroidism, identified by increased TSH, is being 
advocated to mitigate a negative effect on the woman and her child. However, even a 
moderate transient period of maternal hypothyroxinemia at the beginning of rat 
neurogenesis disrupts neuronal migration into cortical layers. These findings reinforce the 
epidemiological evidence that early maternal hypothyroxinemia—when neuronal migratory 
waves are starting—is potentially damaging for the child. Detection of an inappropiate first 
trimester FT4 surge that may not result in increased TSH, may be crucial for the prevention 
of learning disabilities in a significant number of unborn children (Escobar et al., 2004) 
The positive effects of thyroid hormones on cognition has led to some new therapeutic 
approaches regarding the usage of these hormones in dementia therapy. The results of a 
study by Fu et al, indicate that the use of TH has some therapeutic potential in AD (Fu et 
al.,2009).  
The congenital absence of thyroid hormone alters neuronal firing behavior during early 
stages of the development in rat. These changes in neuronal discharge are related to their 
spike ADP, which is clearly involved in the burst-firing behavior in developing CA1 
pyramidal neurons (Sanchez Alonso et al., 2010; Chen et al., 2005). 
The relationship between the thyroid axis and psychiatric symptoms and disease is well 
established. In particular, clinical hypothyroidism leads to depressive symptoms which 
resolve with replacement therapy. The relationship between alterations of thyroid function 
and primary major depression is more complex. While various abnormalities of the thyroid 
axis have been identified, none is specific for depression and there is no clear evidence that 
thyroid hypofunction is a significant etiological factor in major depression. The literature on 
thyroid hormone treatment of depression, particularly treatment-resistant major depression, 
is highly promising and warrants further investigation. Greater understanding about 
thyroid–brain relationships may yield important information about the etiology of major 
mood disorders (Joffe et al., 2009). 
It is already known that hypothyroidism may alter the evoked potentials. Since 1990s some 
studies were performed to show this. 
In order to detect the dysfunction of central and peripheral nervous systems among rats 
with varied duration of hypothyroidism and to elucidate the pattern of recovery after 
thyroxine replacement, a series of BAEP (Brainstem auditory evoked potentials) and PNCS 
(Peripheral Nerve Conduction Study) were conducted and compared with age-matched 
controls. BAEP and PNCS were performed in three groups of hypothyroid animals 1, 3 and 
5 months after thyroidectomy, respectively. Following initial electrophysiological 
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assessment, thyroxine replacement was administered to each group of hypothyroid rats, and 
BAEP and PNCS were performed at two month intervals, up to two successive normal 
studies, or six months after the initiation of therapy, whichever came first. For BAEP, 
prolonged I–V interpeak latency was the most consistent abnormal finding in all groups of 
hypothyroid rats, and longer hypothyroid states correlated well with more severe central 
conduction disorder (Lai et al., 1997). 
Nevertheless, these abnormalities usually returned to normal after thyroxine replacement if 
the duration of hypothyroidism was less than 5 months. Regarding PNCS, all groups of 
thyroidectomized rats showed normal conduction before and after thyroxine therapy. This 
study indicated that, in rats: (1) the peripheral nervous system seemed to be more resistant 
to hypothyroidism than the central nervous system, or (2) the pathogenesis of central and 
peripheral nerve dysfunction in hypothyroid rats might occur through different 
mechanisms (Lai et al., 1997). 
After thyroxine replacement, the central conduction dysfunction usually returned to normal 
if the hypothyroid state was not more than 5 months in duration. However, when 
hypothyroid state persisted over 7 months or more, there would be an incomplete recovery 
for central conduction disorder. This study brought out the concept of ‘therapeutic window’ 
in reversing the central nervous dysfunction caused by hypothyroidism in adult rats (Lai et 
al, 2000). 
According to a study by MacNabb et al., the results suggested that congenital 
hypothyroidism impaired learning when a discrimination between correct and incorrect 
operations is made available (Mac Nabb et al., 1999). 
Hypothyroidism was also linked to some degenerative diseases of the brain. According to a 
study performed by Munhoz et al., thyroid function should be assessed in parkinson 
patients showing worsening of symptoms that cannot be explained by disease progression 
or resistance to therapy adjustment (Munhoz et al., 2004). 
Hypothyroidism during Iodine-therapy is associated with clinically relevant cognitive 
dysfunctions, especially with effortful attention demanding tasks (Munte et al.,2004). 
Processes under the control of TH (thyroid hormones) range from learning and anxiety-like 
behaviour to sensory function. At the cellular level,TH controls events as diverse as axonal 
outgrowth, hippocampal synaptic activity and the patterning of opsin photopigments 
necessary for colour vision. Overall, TH coordinates this variety of events in both central 
and sensory systems to promote the function of the nervous system as a complete entity 
(Nunez et al., 2008). 
Age at onset of hypothyroidism is suggested to be an important factor for the memory 
impairment induced by hypothyroidism. In a study performed by Tong et al.,the 2-month-
old hypothyroid mice had significantly impaired abilities in both the olfactory 
discrimination and the spatial cognitive tasks relative to the 2-month-old controls. The 8-
month-old hypothyroid mice had only impaired ability in the spatial cognitive task relative 
to the same age controls. The 15-month-old hypothyroid mice retained these cognitive 
abilities relative to the same age controls. These results suggested that adult-onset 
hypothyroidism could induce an age- and task-dependent impairment of memory in female 
KM mice (Tong et al.,2007). 
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Thyroid hormone deficiency has profound effects on the brain during development and less 
marked effects on the adult brain. These effects are considered to be the result of the direct 
regulation of specific target genes by thyroid hormone. Previous studies have shown that 
the expression of the neuronal gene RC3, encoding a 78-amino-acid calmodulin-binding 
protein kinase C substrate, is under the influence of thyroid hormone in vivo (Piosik et al, 
1997). In their study Piosik et al., investigated the role of thyroid hormone in RC3 mRNA 
expression at earlier stages of fetal development and in mature goats using in situ 
hybridization. Their data indicated that in both fetal and adult goats thyroid hormone, at 
least partly, affected the expression of RC3 mRNA in the striatum and not the cerebral 
cortex (Piosik et al, 1997). 
It was shown that in the rat cerebellar cortex, the expression of mabN210-immunoreactivity in 
basket cell axons was severely suppressed in hypothyroidism while neurofilament antigen 
expression in other cerebellar axons seemed not to require thyroid hormones (Plioplys et al., 
1986). In hypothyroid rats there is a marked supression of mabN210-immunoreactivity in the 
cerebral cortex and corpus callosum and, to a lesser extent, there is a reduction in staining in 
the internal capsule. By contrast, hypothyroidism did not reduce mabN210-immunoreactivity 
in the lateral olfactory tract or the stria medullaris. In rats, serum thyroid hormone starts to rise 
to adult levels on postnatal day 4. It appears that axons that have attained their mature 
distribution prior to the onset of thyroid hormone expression are not affected by 
hypothyroidism whereas mabN210-immunoreactivity is suppressed in those axonal tracts that 
reach a mature distribution after P4(Plioplys et al., 1986).  
Cerebellar development on the postnatal period is mainly characterized by cellular 
proliferation in the external granular layer (EGL) followed by migration of granular cells in 
the molecular layer through the Bergmann glia (BG) fibers in order to form the granular 
layer in the adult. All these events are drastically affected by thyroid hormones (TH), actions 
of which are mainly mediated by alpha (TRα) and beta (TRβ) nuclear receptor isoforms 
(Portello et al., 2010).  
Portello et al., analyzed the effects of a natural human mutation (337T) in the TRβ locus, 
which impaired T3 binding to its receptor, on the mouse cerebellum ontogenesis. They 
reported that target inactivation of TRβ-TH binding led to a smaller cerebellum area 
characterized by impaired lamination and foliation. Further, TRβ mutant mice presented 
severe deficits in proliferation of granular precursors, arborization of Purkinje cells and 
organization of BG fibers. They reported that their data suggested that the action of TH via 
TRβ regulated important events of cerebellar ontogenesis contributing to a better 
understanding of some neuroendocrine disorders. Further, their data correlated TRβ with 
cerebellar foliation, and provided, for the first time, evidence of a receptor-mediated 
mechanism underlying TH actions on this event (Portello et al., 2010). 
Hypothyroidism has numerous effects on brain. It produces a hypometabolic state. 
Hypometabolic state following hypothermia is known to protect tissues from ischemic 
injury. A study by Rastogi et al., provided evidence that hypothyroidism made neuronal 
tissue less vulnerable to severe ischemic insult (Rastogi et al., 2006).  
In a study by Rovet et al.,sixty-nine children with congenital hypothyroidism detected 
through thyroid screening were compared with 39 unaffected siblings for cognitive and 
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assessment, thyroxine replacement was administered to each group of hypothyroid rats, and 
BAEP and PNCS were performed at two month intervals, up to two successive normal 
studies, or six months after the initiation of therapy, whichever came first. For BAEP, 
prolonged I–V interpeak latency was the most consistent abnormal finding in all groups of 
hypothyroid rats, and longer hypothyroid states correlated well with more severe central 
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After thyroxine replacement, the central conduction dysfunction usually returned to normal 
if the hypothyroid state was not more than 5 months in duration. However, when 
hypothyroid state persisted over 7 months or more, there would be an incomplete recovery 
for central conduction disorder. This study brought out the concept of ‘therapeutic window’ 
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study performed by Munhoz et al., thyroid function should be assessed in parkinson 
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to the same age controls. The 15-month-old hypothyroid mice retained these cognitive 
abilities relative to the same age controls. These results suggested that adult-onset 
hypothyroidism could induce an age- and task-dependent impairment of memory in female 
KM mice (Tong et al.,2007). 
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temperamental characteristics. Intelligence test results revealed: (1) IQs of hypothyroid 
children were normal but lower than siblings; (2) hypothyroid children were lower than 
siblings in gross motor and perceptual performance abilities; (3) athyrotic children had 
lower IQs than those with ectopic thyroids, goiter, or hypoplastic disease; (4) athyrotic, 
hypoplastic, and ectopic thyroid children had lower performance than verbal IQs, but there 
was no scale difference for those with goiter; (5) deficits differed according to test age; and 
(6) age of onset of treatment was not related to IQ or pattern of deficit. Temperament test 
findings revealed: (1) no increase in difficult or slow-to-warm-up children, (2) lower ratings 
were found for hypothyroid children than siblings on approach/withdrawal and 
persistence scales, and (3) higher rating was given for athyrotic children than those with 
goiter (Rovet et al, 1984). 
In a study performed by the same authors, hearing loss and its functional consequences 
were evaluated retrospectively in children with congenital hypothyroidism. Hearing 
impaired children differed from children with normal hearing in age of treatment onset (22 
vs 14 days) but not disease severity or duration. A comparison of language and auditory 
processing skills at ages 3, 5, and 7 years revealed that early speech was delayed in hearing 
impaired children, whereas deficits persisted in later receptive language and auditory 
discrimination skills. Comparing hearing impaired children and children with normal 
hearing with matched control subjects at grade 3 showed that hearing impaired children 
were poorer readers because of less adequate phonologic processing skills (Rovet et al, 
1996). 
In another study that evaluated the influence of thyroid function on the activity and 
exploratory behaviour of rats, chronic hyperthyroidism produced a significant increase in 
activity, but did not affect exploration. On the other hand, hypothyroidism did not affect 
activity, but did increase exploration. This increase in exploration was observed in activity 
independent behavioural parameters, such as head dipping and glancing (Sala-Roca et al., 
2002). 
In a study by Sawin et al., the effects of hypothyroidism on development of cholinergic 
system in brain regions (prefrontal cortex and hippocampus) were evaluated by measuring 
choline acetyltransferase (ChAT) activity and hemicholinium-3 binding to the high-affinity 
choline transporter (Sawin et al., 1998). The results suggested that alterations of cholinergic 
system caused by perinatal hypothyroidism were associated with neurobehavioral deficits 
at weaning, and these developmental deviations might cause permanent impairment of 
cognitive function despite recovery from the hormonal imbalance at adult ages (Sawin et al., 
1998). 
The association of ocular abnormalities with thyroid disorders is well-known, wherein 
iodine plays an important role. Iodine deficiency and excess can both lead to abnormalities 
of thyroid function. 
Neuromuscular ocular dysfunction in hypothyroidism includes ptosis, ophthalmoplegia, 
myokymia, cranial nerve dysfunction and cosmetic changes (Seah et al., 2009). 
In addition to their role in cellular metabolic activity, thyroid hormones also regulate neural 
development. Central nervous system is dependent on thyroid hormones for normal 
maturation and function. Specifically there appears to be extensive inter-reliance between 
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thyroid hormones and acetylcholine, nerve growth factor and hippocampal function (Smith 
JW et al, 2002).  
Thyroid abnormalities have been associated with attention deficit/hyperactivity disorder 
(ADHD) and with other childhood psychiatric disorders. In a study designed to determine 
the relationships between thyroid hormone concentrations, neurocognitive functioning, and 
psychiatric diagnosis in children; thyroxine concentrations were associated with mood 
symptoms and unusual behaviors, and were less strongly related to attentional functioning. 
Thyroxine concentrations were not related to hyperactivity (Stein MA et al., 2002). 
Insufficiency of thyroid hormones in the adulthood causes a wide range of cognitive 
dysfunctions, including deficits in learning and memory. In a study that investigated 
whether adult-onset hypothyroidism would alter synaptic functions in the dorsal 
hippocampo-medial prefrontal cortex (mPFC) pathway, a neural pathway important for 
learning and memory, the results suggested that alterations in synaptic plasticity of the 
dorsal hippocampo-mPFC pathway might contribute to understanding basic mechanisms 
underlying learning and memory deficits associated with adult-onset hypothyroidism (Sui 
et al., 2006). 
Adult-onset hypothyroidism is associated with neurological changes such as cognitive 
dysfunction and impaired learning, which may be related to alterations of synaptic 
plasticity. In a study designed to investigate the consequence of adult-onset hypothyroidism 
on thyroid-mediated transcription events in striatal synaptic plasticity, and the effect of 
triiodothyronine (T3) replacement; the authors suggested that thyroid hormone modulation 
had a major impact on striatal synaptic plasticity of adult mice which produced in turn 
motor behavior modifications (Vallortigara et al.,2007). 
Thyroid hormone action on brain development is essentially exerted through regulation of 
the expression rate of a number of genes some of which have been identified in the past 10 
years (Vargiu et al., 2001). 
Attention-deficit hyperactivity disorder (ADHD) is thought to have a biologic basis, but the 
precise cause is unknown. It is one of the neurodevelopmental abnormalities frequently 
observed in children with generalized resistance to thyroid hormone (GRTH), suggesting 
that thyroid abnormalities may be related to ADHD. According to a study by Weiss et al., 
the prevalence of thyroid abnormalities is higher (5.4%) in children with ADHD than in the 
normal population (<1%) (Weiss et al., 1993). 
According to a study to assess the impact on neonatal neurobehavioral development of 
methimazole (MMI)-induced in-utero hypothyroxinemia and of correction by maternal-fetal 
thyroxine (T4) transfer in the rat by Weller et al., prenatal T4 treatment resulted in correction 
of MMI-induced delayed appearance of three different reflexes. Body-weight gain of treated 
pups was similar to that of controls and more rapid than development of rats treated with 
MMI-alone. T4 treatment did not prevent, however, MMI-induced delay in maturation of 
physiological landmarks (e.g. ear opening). The authors suggested that at least a portion of 
the developmental delay resulting from prenatal (maternal) MMI administration might be 
reversed by maternal-fetal transfer of T4 administered to the gravid dam (Weller et al, 1996).  
Thyroid hormone insufficiency leads to impaired neurogenesis, behavioral alterations and 
cognitive deficits. Thyroid hormone receptors, expressed in brain regions involved in these 
 
Hypothyroidism – Influences and Treatments 
 
140 
temperamental characteristics. Intelligence test results revealed: (1) IQs of hypothyroid 
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thyroid hormones and acetylcholine, nerve growth factor and hippocampal function (Smith 
JW et al, 2002).  
Thyroid abnormalities have been associated with attention deficit/hyperactivity disorder 
(ADHD) and with other childhood psychiatric disorders. In a study designed to determine 
the relationships between thyroid hormone concentrations, neurocognitive functioning, and 
psychiatric diagnosis in children; thyroxine concentrations were associated with mood 
symptoms and unusual behaviors, and were less strongly related to attentional functioning. 
Thyroxine concentrations were not related to hyperactivity (Stein MA et al., 2002). 
Insufficiency of thyroid hormones in the adulthood causes a wide range of cognitive 
dysfunctions, including deficits in learning and memory. In a study that investigated 
whether adult-onset hypothyroidism would alter synaptic functions in the dorsal 
hippocampo-medial prefrontal cortex (mPFC) pathway, a neural pathway important for 
learning and memory, the results suggested that alterations in synaptic plasticity of the 
dorsal hippocampo-mPFC pathway might contribute to understanding basic mechanisms 
underlying learning and memory deficits associated with adult-onset hypothyroidism (Sui 
et al., 2006). 
Adult-onset hypothyroidism is associated with neurological changes such as cognitive 
dysfunction and impaired learning, which may be related to alterations of synaptic 
plasticity. In a study designed to investigate the consequence of adult-onset hypothyroidism 
on thyroid-mediated transcription events in striatal synaptic plasticity, and the effect of 
triiodothyronine (T3) replacement; the authors suggested that thyroid hormone modulation 
had a major impact on striatal synaptic plasticity of adult mice which produced in turn 
motor behavior modifications (Vallortigara et al.,2007). 
Thyroid hormone action on brain development is essentially exerted through regulation of 
the expression rate of a number of genes some of which have been identified in the past 10 
years (Vargiu et al., 2001). 
Attention-deficit hyperactivity disorder (ADHD) is thought to have a biologic basis, but the 
precise cause is unknown. It is one of the neurodevelopmental abnormalities frequently 
observed in children with generalized resistance to thyroid hormone (GRTH), suggesting 
that thyroid abnormalities may be related to ADHD. According to a study by Weiss et al., 
the prevalence of thyroid abnormalities is higher (5.4%) in children with ADHD than in the 
normal population (<1%) (Weiss et al., 1993). 
According to a study to assess the impact on neonatal neurobehavioral development of 
methimazole (MMI)-induced in-utero hypothyroxinemia and of correction by maternal-fetal 
thyroxine (T4) transfer in the rat by Weller et al., prenatal T4 treatment resulted in correction 
of MMI-induced delayed appearance of three different reflexes. Body-weight gain of treated 
pups was similar to that of controls and more rapid than development of rats treated with 
MMI-alone. T4 treatment did not prevent, however, MMI-induced delay in maturation of 
physiological landmarks (e.g. ear opening). The authors suggested that at least a portion of 
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reversed by maternal-fetal transfer of T4 administered to the gravid dam (Weller et al, 1996).  
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behaviors, mediate the effects of thyroid hormone deficiency or excess. Thyroid hormone-
regulated genes potentially responsible for the learning deficit found in TR_o/o mice 
include GR, RC3 and GAP-43 (Wilcoxon et al., 2007). 
Developmental thyroid hormone (TH) deficiency leads to mental retardation and 
neurological deficits in humans. According to a study by Zamoner et al., the thyroid status 
could modulate the integrity of neuronal cytoskeleton acting on the endogenous NF-
associated phosphorylating system and that such effect could be related to glutamate-
induced excitotoxicity (Zamoner et al., 2008). 
Myxoedema coma is a complication of long-standing untreated hypothyroidism. The term is 
largely a misnomer since most patients are not comatose. This condition is characterised by 
marked impairment of the central nervous system and of cardiovascular function (Jansen et 
al.,2006). 
Hashimoto encephalopathy, also known as steroid-responsive encephalopathy associated 
with autoimmune thyroiditis, is a potentially fatal condition associated with a presentation 
of myoclonus, altered conscious state, strokelike episodes, rapid cognitive decline, and 
neuropsychiatric symptoms, including psychosis, hallucinations, and abulia.It is an 
important differential diagnosis of rapidly progressive dementia. It is also an important 
cause of potentially reversible dementia because with prompt and appropriate treatment its 
symptoms can be completely reversed. Controversially, Hashimoto encephalopathy can 
present in the absence of associated thyroid function abnormalities, even though it is 
associated with high titers of antithyroid peroxidase and antithyroglobulin antibodies. 
(Brodtmann et al.,, 2009) 
3. Effects of hypothyroidism on the peripheral nervous system 
The connection between hypothyroidism and polyneuropathy was known thouroughly 
even in the 70s. In a case study by Shirabe et al., it was suggested that myxoedematous 
polyneuropathy might be intrinsic neuropathy due to metabolic disorder of Schwann cells 
related to hypothyroidism, resulting in segmental demyelination, not merely compressive 
neuropathy due to mucinous deposits in the peripheral nerves (Shirabe et al.,1975). More 
case studies followed in 80s also (Martin et al., 1983). 
Muscle involvement in a variety of forms is a common complication of adult-onset 
hypothyroidism. Hypothyroid myopathy spans a clinical spectrum that includes a number 
of different manifestations. The reported prevalence of hypothyroid myopathy symptoms 
and signs is variable. In a prospective cohort study, 79% of adult patients with 
hypothyroidism had muscle complaints (myalgias, cramps or weakness) . Asymptomatic 
CK elevation has been reported to occur in 37% to 60% of hypothyroid patients . Other 
significant manifestations associated with hypothyroidism include: myalgias, severe muscle 
weakness, polymyositis-like syndrome, rhabdomyolysis, and acute compartment syndrome 
(ACS). Rhabdomyolysis after withdrawal of thyroid hormone in a patient with papillary 
thyroid cancer has been described previously (Ramadhan et al., 2009). 
The frequency of myopathy in hypothyroidism ranges from 30 to 80%. The major symptoms 
related are weakness, muscular cramps and myalgia. The pseudohyperthrophic form is 
called Hoffman's syndrome. The electrophysiological study reveals myopathy, neuropathy 
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or mixed pattern. Laboratorial investigation generally shows increased levels of muscle 
enzymes and low serum thyroid hormones, with thyrotrophic-stimulating hormone (TSH) 
elevated. The treatment consists in hormone replacement and the prognosis is good in most 
of the cases (Vasconcellos LFR et al.,2003). 
In a study performed by Magri et al., intraepidermal nerve fiber density reduction was 
evaluated as a marker of preclinical asymptomatic small-fiber sensory neuropathy in 
hypothyroid patients. Their findings suggested that a considerable number of untreated 
hypothyroid patients may have preclinical asymptomatic small-fiber sensory neuropathy 
(Magri et al., 2010). 
According to a study by Salvi et al., visual evoked potentials in patients with thyroid-
associated ophthalmopathy (TAO) identify asymptomatic optic nerve involvement. The 
authors observed a prolongation of the latency of the evoked cortical response in patients 
with TAO without subjective visual complaints and without optic nerve compression. They 
reported that the study of visual evoked potentials in TAO is complementary to the study of 
the visual field in identifying early optic nerve dysfunction in the absence of decreased 
visual acuity (Salvi et al, 1997). 
4. Hypothyroidism and muscle disease 
The relationship between hypothyroidism and muscle disease is known since 19 th century 
but it is precisely documented ever since 60s (Wilson et al., 1959; Fessel et al, 1968; Golding 
et al.,1970). In 70s hypothyroid-rheumatic diseases were also described which were defined 
having symptoms as muscle pain. Muscle pain and stiffness, arthralgia, synovial thickening 
with effusion, osteolytic lesions, hypothyroid myopathy, acroparaesthesiae, pain, cramps, 
and stiffness of muscles are common symptoms in hypothyroidism, and mild proximal 
muscle weakness occurs in over a third of patients (Golding et al., 1971). Pseudomyotonia 
with delayed relaxation of muscle may occur and a prolonged tendon reflex relaxation time 
is typical. Myoedema, the "mounding phenomenon," may be elicited in some hypothyroid 
patients on direct percussion of the muscle. A rare association is Hoffman's syndrome, 
which is characterised by muscle hypertrophy, weakness, and slowness of movement. The 
differential diagnosis is from other causes of painful, stiff muscles such as polymyalgia 
rheumatica and polymyositis. The reflex relaxation time is a useful diagnostic test, and the 
serum thyroid stimulating hormone concentration should be measured when the doctor is 
in any doubt. Increased serum activities of enzymes of muscle origin, particularly the 
creatine kinase isoenzyme, are found in hypothyroidism whether or not muscle symptoms 
are present. Serum myoglobin concentrations are also raised. Electromyographic studies 
show a reduction in the mean action potential duration and an increase in the number of 
polyphasic units in over a third of hypothyroid patients with either normal or 
hypertrophied muscles. Routine histopathological studies show non-specific findings, but 
histochemical studies have shown atrophy and reduced frequency of type 2 fibres (Taylor et 
al., 1983).  
Muscle fibre type changes in hypothyroid myopathy were studied by serial percutaneous 
needle biopsy of vastus lateralis before and during treatment with L-thyroxine by Mc Karen 
et al. A type II fibre atrophy and loss was found, which correlated with the clinical and 
biochemical evidence of a myopathy. The type II fibre atrophy was corrected by L-thyroxine 
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and signs is variable. In a prospective cohort study, 79% of adult patients with 
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CK elevation has been reported to occur in 37% to 60% of hypothyroid patients . Other 
significant manifestations associated with hypothyroidism include: myalgias, severe muscle 
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called Hoffman's syndrome. The electrophysiological study reveals myopathy, neuropathy 
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or mixed pattern. Laboratorial investigation generally shows increased levels of muscle 
enzymes and low serum thyroid hormones, with thyrotrophic-stimulating hormone (TSH) 
elevated. The treatment consists in hormone replacement and the prognosis is good in most 
of the cases (Vasconcellos LFR et al.,2003). 
In a study performed by Magri et al., intraepidermal nerve fiber density reduction was 
evaluated as a marker of preclinical asymptomatic small-fiber sensory neuropathy in 
hypothyroid patients. Their findings suggested that a considerable number of untreated 
hypothyroid patients may have preclinical asymptomatic small-fiber sensory neuropathy 
(Magri et al., 2010). 
According to a study by Salvi et al., visual evoked potentials in patients with thyroid-
associated ophthalmopathy (TAO) identify asymptomatic optic nerve involvement. The 
authors observed a prolongation of the latency of the evoked cortical response in patients 
with TAO without subjective visual complaints and without optic nerve compression. They 
reported that the study of visual evoked potentials in TAO is complementary to the study of 
the visual field in identifying early optic nerve dysfunction in the absence of decreased 
visual acuity (Salvi et al, 1997). 
4. Hypothyroidism and muscle disease 
The relationship between hypothyroidism and muscle disease is known since 19 th century 
but it is precisely documented ever since 60s (Wilson et al., 1959; Fessel et al, 1968; Golding 
et al.,1970). In 70s hypothyroid-rheumatic diseases were also described which were defined 
having symptoms as muscle pain. Muscle pain and stiffness, arthralgia, synovial thickening 
with effusion, osteolytic lesions, hypothyroid myopathy, acroparaesthesiae, pain, cramps, 
and stiffness of muscles are common symptoms in hypothyroidism, and mild proximal 
muscle weakness occurs in over a third of patients (Golding et al., 1971). Pseudomyotonia 
with delayed relaxation of muscle may occur and a prolonged tendon reflex relaxation time 
is typical. Myoedema, the "mounding phenomenon," may be elicited in some hypothyroid 
patients on direct percussion of the muscle. A rare association is Hoffman's syndrome, 
which is characterised by muscle hypertrophy, weakness, and slowness of movement. The 
differential diagnosis is from other causes of painful, stiff muscles such as polymyalgia 
rheumatica and polymyositis. The reflex relaxation time is a useful diagnostic test, and the 
serum thyroid stimulating hormone concentration should be measured when the doctor is 
in any doubt. Increased serum activities of enzymes of muscle origin, particularly the 
creatine kinase isoenzyme, are found in hypothyroidism whether or not muscle symptoms 
are present. Serum myoglobin concentrations are also raised. Electromyographic studies 
show a reduction in the mean action potential duration and an increase in the number of 
polyphasic units in over a third of hypothyroid patients with either normal or 
hypertrophied muscles. Routine histopathological studies show non-specific findings, but 
histochemical studies have shown atrophy and reduced frequency of type 2 fibres (Taylor et 
al., 1983).  
Muscle fibre type changes in hypothyroid myopathy were studied by serial percutaneous 
needle biopsy of vastus lateralis before and during treatment with L-thyroxine by Mc Karen 
et al. A type II fibre atrophy and loss was found, which correlated with the clinical and 
biochemical evidence of a myopathy. The type II fibre atrophy was corrected by L-thyroxine 
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but type II fibre loss was still apparent in severely myopathic patients up to two years after 
starting treatment (Mc Karen et al.,1975). Hypothyroid myopathy has not only been 
reported in long standing cases of hypothyroidism. 
Adult patients with myopathy associated with acute transient hypothyroidism were also 
described. Patients presented with severe muscle aches and cramps, stiffness and spasms. 
Muscle enzymes were markedly elevated and electromyography in one patient showed 
myopathic features. Histological changes were absent in muscle biopsy, probably because of 
the short duration of metabolic disturbance. The myopathy subsided promptly when the 
hypothyroid state was reversed (Kung et al, 1987). 
Muscle weakness, aches and cramps, stiffness and delayed tendon jerk relaxation are usual 
features of hypothyroid myopathy (30–80%), while muscle hypertrophy, myoedema and 
wasting are occasionally seen. They evolve gradually over a long period of time (Bhansali et 
al.,1999). Hypothyroidism should be differentiated from polymyositis (Mace et al., 1980, 
Cabili et al.,1982). 
Hypothyroidism is also a risk factor for statin-induced myopathy (SIM) and even 
spontaneous myopathy. Muscle aches, cramps, and weakness are the typical clinical 
features, irrespective of the precipitant (Bar et al., 2007). 
Rhabdomyolysis, the most feared and potentially fatal complication of SIM, is also rarely 
caused by isolated hypothyroidism. When this is seen, it is usually characterized by a 
moderate rise in creatine phosphokinase (Khaleli et al., 1983). Data from clinical trials show 
the rate of SIM in the general population to be 0.1% to 0.2%; the rate of hypothyroid-induced 
myopathy is unknown. Because of these associations, patients’ thyroid status should always 
be considered before initiating lipid-lowering medications and, for patients receiving statin 
therapy, thyroid function should be assessed whenever myopathic symptoms or resistance 
to therapy is noted (Bar et al., 2007). 
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but type II fibre loss was still apparent in severely myopathic patients up to two years after 
starting treatment (Mc Karen et al.,1975). Hypothyroid myopathy has not only been 
reported in long standing cases of hypothyroidism. 
Adult patients with myopathy associated with acute transient hypothyroidism were also 
described. Patients presented with severe muscle aches and cramps, stiffness and spasms. 
Muscle enzymes were markedly elevated and electromyography in one patient showed 
myopathic features. Histological changes were absent in muscle biopsy, probably because of 
the short duration of metabolic disturbance. The myopathy subsided promptly when the 
hypothyroid state was reversed (Kung et al, 1987). 
Muscle weakness, aches and cramps, stiffness and delayed tendon jerk relaxation are usual 
features of hypothyroid myopathy (30–80%), while muscle hypertrophy, myoedema and 
wasting are occasionally seen. They evolve gradually over a long period of time (Bhansali et 
al.,1999). Hypothyroidism should be differentiated from polymyositis (Mace et al., 1980, 
Cabili et al.,1982). 
Hypothyroidism is also a risk factor for statin-induced myopathy (SIM) and even 
spontaneous myopathy. Muscle aches, cramps, and weakness are the typical clinical 
features, irrespective of the precipitant (Bar et al., 2007). 
Rhabdomyolysis, the most feared and potentially fatal complication of SIM, is also rarely 
caused by isolated hypothyroidism. When this is seen, it is usually characterized by a 
moderate rise in creatine phosphokinase (Khaleli et al., 1983). Data from clinical trials show 
the rate of SIM in the general population to be 0.1% to 0.2%; the rate of hypothyroid-induced 
myopathy is unknown. Because of these associations, patients’ thyroid status should always 
be considered before initiating lipid-lowering medications and, for patients receiving statin 
therapy, thyroid function should be assessed whenever myopathic symptoms or resistance 
to therapy is noted (Bar et al., 2007). 
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Hypothyroidism is a common endocrine disorder resulting from deficiency of thyroid 
hormone or its effects on peripheral tissues. It usually is caused by an insufficient 
production of thyroid hormone by thyroid gland (primary hypothyroidism), but it could be 
also caused by  inadequate secretion of either thyrotropin (ie. thyroid-stimulating hormone- 
TSH) from the pituitary gland (secondary hypothyroidism) or thyrotropin-releasing 
hormone (TRH) from the hypothalamus (tertiary hypothyroidism) (Bharaktiya, 2011). 
Mixedema (previously a sinonim for hypothyroidism) is reffered to a skin and subcutaneous 
tissue changes in severe hypothyroid patients.   
Hypothyroidism is a very common condition. It is estimated that about 2% of adult women 
and about 0,1-0,2% of men have clinical hypothyroidism, while the prevalence of subclinical 
disease is more frequent, up to 9% of adult population (Canaris et al., 2000; Danese et al., 
1996 ; Vanderpump et al., 1995). The incidence however increases with age (Bharaktiya, 
20111). The prevalence of hypothyroidism in newborns (congenital hypothyroidism) is 
about 1:3500 (LaFranchi, 1999).   
2. Causes of hypothyroidism 
The most common cause of hypothyroidism in adults may be summarised as follows 
(McPhee & Bauer, 1997): 
1. Congenital: 
a. aplasia, hypoplasia, thyroid ectopy  
b. defect of hormones’ synthesis and effects 
2. Acquired: 
a. autoimmune thyroiditis  
b. iodide deficient diet  
c. thyroid ablation (as a consequence of radiation, surgical interventions etc) 
3. Pharmacological: iodide, propylthiouracil, methimazole, lithium, thiocyanate etc 
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The most common cause of hypothyroidism in adults is autoimmune thyroid disease 
(AITD) where autoimmune thyroiditis (AT) is one of the entities. AT can begin suddenly or 
it can develop slowly over the years. The most frequent forms are Hashimoto’s thyroiditis 
and atrophic thyroiditis (American Thyroid Association, 2008). 
The second frequent cause is a thyroid ablation as a consequence of surgical removal of part 
or all of the gland in case of thyroid nodules, thyroid cancer, or Graves’ disease. If part of 
the gland is left, it may be able to make enough thyroid hormone to keep blood levels 
normal. It is necessary that at least 90% of the gland be destroyed in order to develop 
hypothyroidism (American Thyroid Association, 2008). 
Another cause of thyroid ablation is the radiation treatment during radiotherapy of neck for 
patients with Hodgkin’s lymphoma, or cancers of the head or neck, or the use of radioactive 
iodine (I-131) in some patients with Graves’ disease, nodular goiter, or thyroid cancer 
(American Thyroid Association, 2008). 
Third most common are all causes of congenital hypothyroidism (in newborns), where one 
could find newborns without a thyroid (aplasia) or with only a partly formed one 
(hypoplasia). There are also babies with partial or all thyroid tissue in the wrong place 
(ectopic thyroid) or in some cases the thyroid is in place, but biosynthetic enzymes are 
defective (American Thyroid Association, 2008). 
Although autoimmune thyroiditis is the most frequent cause of hypothyroidism, there are 
also a few forms of infective processes in thyroid. According to the duration, infective 
thyroiditis could be acute (generally caused by bacteria) or subacute (generally caused by 
viral agents). During the course of infective thyroiditis there could be a transient episode of 
thyroid hormones liberation in circulation from destroyed or damaged thyroid cells, called 
thyrotoxicosis. Subsequently if more than 90% of thyroid tissue is destroyed, 
hypothyroidism develops (McPhee & Bauer, 2007). 
In some cases, medicines could be the cause of hypothyroidism, usually by interfering with 
normal thyroid hormone synthesis. Very often it is found in patients taking  amiodarone, 
lithium, interferon alpha, and interleukin-2. These drugs are most likely to trigger 
hypothyroidism in patients who have a genetic tendency to develop AITD (American 
Thyroid Association, 2008). Potassium perchlorate could be used to treat thyrotoxicosis and 
hypothyroidism induced by amiodarone (Wolff, 1998). Perchlorate is a competitive inhibitor 
of the sodium-iodide symporter (NIS) that can suppress T3 and T4 production. Also, the 
drugs used for the hyperthyroidism treatment such as methimazole and propylthiouracil, 
could cause hypothyroidism.  
In 1998 it is estimated that about one third of world’s population lived in iodine-deficient 
areas, primarily in Africa, Southeast and Central Asia, but also in some European countries 
(like Germany, Belgium, France and Italy) (Dunn, 1996). Since iodine is the essential factor 
for thyroid hormone synthesis and it is concentrated in thyroid, any disequilibrium (too 
much or too little) in circulating iodine levels could cause or worsen hypothyroidism. Since 
more than 90% of dietary iodine is excreted in the urine, the World Health Organization 
(WHO) has determined 100mcg/L of urinary iodine as cut-off level for iodine deficiency 
(WHO, UNICEF & ICCID, 2001). In areas of the world with very low iodine intake in the 
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diet (like India, Chile, Ecuador, Himalayas), severe hypothyroidism can be seen in 5% to 
15% of the population (Mathur, 2011).  
If the pituitary or hypothalamus are damaged by a tumor, radiation, or surgery, 
hypothyroidism could be developed (secondary or tertiary hypothyroidism, respectively), 
characterized by diminished both, TSH and thyroid hormone levels. 
Finally, in some cases the deposit of abnormal substances in the thyroid, could be the cause 
of hypothyroidism. For example, in the course of amyloidosis there can be deposit of 
amyloid protein, in the course of sarcoidosis there can form granulomas, and in the course 
of hemochromatosis there can be deposit iron (American Thyroid Association, 2008) 
3. Pathogenesis of autoimmune thyroid disease (AITD) 
3.1 The role of genetic factors in the development of AITD 
It is generally believed that AITD is a complex of several entities that could overlap: 
Hashimoto’s thyroiditis (HT), Graves’ disease (GD) and orbitopathy. The majority of 
autoimmune endocrinopathies are inherited as complex genetic traits, with multiple genetic 
and environmental factors interactions which confer susceptibility to such disorders. The 
genetic factors remain largely unknown, with the exception of the human leukocyte antigen 
(HLA). It is known that AITD are more frequent in families with HLA DR3 and DR5 HLA 
alleles. Predominantly involved are women. Indeed, HT is 5 to 10 times more common in 
women than in men. Since the basis for autoimmune diseases may have a common origin, it 
is possible that patients with HT or their first degree relatives, have one or more other 
autoimmune diseases such as type 1 diabetes mellitus or pernicious anemia (with antibodies 
against gastric parietal cells or B12) (Mathur, 2011).  
In recent years however, considerable efforts have been made to discover other genetic 
factors responsible for autoimmune endocrinopathies (Vaidya & Pearce, 2004). There are 
several studies confirming that genetic polymorphism of the cytotoxic T lymphocyte antigen 
(CTLA)-4 alleles on 2q33 chromosome have been associated with HT (Awata et al., 1998; 
Donner et al., 1997; Nithiyananthan et al., 2002; Tomoyose et al., 2002). CTLA-4 is a co-
stimulatory molecule expressed on the surface of activated T cells (Brunet et al., 1987). 
CTLA-4 (49) A/G allele was significantly more frequent in the group of HT patients 
compared to the healthy controls. Additionally, linkage and association of CTLA-4 with the 
presence of thyroid antibodies have also been reported (Tomer et al., 2001; Zaletel et al., 
2002).  
3.2 Autoimmune mechanisms 
The thyroid is a major target for autoimmune disease, as exemplified by autoimmune 
thyroiditis (which include HT type 1 and 2, and atrophic thyroiditis), and GD with opposite 
clinical outcomes. Both diseases, but particularly HT, are characterized by lymphocytic 
infiltration of the gland which can result in tissue destruction, fibrosis and hypothyroidism. 
The follicular spaces shrink and colloid is absent or sparse. Fibrosis may be completely 
absent or present in degrees ranging from slight to moderate. Heuer and coll. (Bernet et al., 
1996; Heuer et al., 1996) found increased expression of IFN-gamma, IL-2 and CD25 positive 
T cells in the thyroid specimens of patients with HT.  
 
Hypothyroidism – Influences and Treatments 
 
152 
The most common cause of hypothyroidism in adults is autoimmune thyroid disease 
(AITD) where autoimmune thyroiditis (AT) is one of the entities. AT can begin suddenly or 
it can develop slowly over the years. The most frequent forms are Hashimoto’s thyroiditis 
and atrophic thyroiditis (American Thyroid Association, 2008). 
The second frequent cause is a thyroid ablation as a consequence of surgical removal of part 
or all of the gland in case of thyroid nodules, thyroid cancer, or Graves’ disease. If part of 
the gland is left, it may be able to make enough thyroid hormone to keep blood levels 
normal. It is necessary that at least 90% of the gland be destroyed in order to develop 
hypothyroidism (American Thyroid Association, 2008). 
Another cause of thyroid ablation is the radiation treatment during radiotherapy of neck for 
patients with Hodgkin’s lymphoma, or cancers of the head or neck, or the use of radioactive 
iodine (I-131) in some patients with Graves’ disease, nodular goiter, or thyroid cancer 
(American Thyroid Association, 2008). 
Third most common are all causes of congenital hypothyroidism (in newborns), where one 
could find newborns without a thyroid (aplasia) or with only a partly formed one 
(hypoplasia). There are also babies with partial or all thyroid tissue in the wrong place 
(ectopic thyroid) or in some cases the thyroid is in place, but biosynthetic enzymes are 
defective (American Thyroid Association, 2008). 
Although autoimmune thyroiditis is the most frequent cause of hypothyroidism, there are 
also a few forms of infective processes in thyroid. According to the duration, infective 
thyroiditis could be acute (generally caused by bacteria) or subacute (generally caused by 
viral agents). During the course of infective thyroiditis there could be a transient episode of 
thyroid hormones liberation in circulation from destroyed or damaged thyroid cells, called 
thyrotoxicosis. Subsequently if more than 90% of thyroid tissue is destroyed, 
hypothyroidism develops (McPhee & Bauer, 2007). 
In some cases, medicines could be the cause of hypothyroidism, usually by interfering with 
normal thyroid hormone synthesis. Very often it is found in patients taking  amiodarone, 
lithium, interferon alpha, and interleukin-2. These drugs are most likely to trigger 
hypothyroidism in patients who have a genetic tendency to develop AITD (American 
Thyroid Association, 2008). Potassium perchlorate could be used to treat thyrotoxicosis and 
hypothyroidism induced by amiodarone (Wolff, 1998). Perchlorate is a competitive inhibitor 
of the sodium-iodide symporter (NIS) that can suppress T3 and T4 production. Also, the 
drugs used for the hyperthyroidism treatment such as methimazole and propylthiouracil, 
could cause hypothyroidism.  
In 1998 it is estimated that about one third of world’s population lived in iodine-deficient 
areas, primarily in Africa, Southeast and Central Asia, but also in some European countries 
(like Germany, Belgium, France and Italy) (Dunn, 1996). Since iodine is the essential factor 
for thyroid hormone synthesis and it is concentrated in thyroid, any disequilibrium (too 
much or too little) in circulating iodine levels could cause or worsen hypothyroidism. Since 
more than 90% of dietary iodine is excreted in the urine, the World Health Organization 
(WHO) has determined 100mcg/L of urinary iodine as cut-off level for iodine deficiency 
(WHO, UNICEF & ICCID, 2001). In areas of the world with very low iodine intake in the 
 
Causes of Hypothyroidism 
 
153 
diet (like India, Chile, Ecuador, Himalayas), severe hypothyroidism can be seen in 5% to 
15% of the population (Mathur, 2011).  
If the pituitary or hypothalamus are damaged by a tumor, radiation, or surgery, 
hypothyroidism could be developed (secondary or tertiary hypothyroidism, respectively), 
characterized by diminished both, TSH and thyroid hormone levels. 
Finally, in some cases the deposit of abnormal substances in the thyroid, could be the cause 
of hypothyroidism. For example, in the course of amyloidosis there can be deposit of 
amyloid protein, in the course of sarcoidosis there can form granulomas, and in the course 
of hemochromatosis there can be deposit iron (American Thyroid Association, 2008) 
3. Pathogenesis of autoimmune thyroid disease (AITD) 
3.1 The role of genetic factors in the development of AITD 
It is generally believed that AITD is a complex of several entities that could overlap: 
Hashimoto’s thyroiditis (HT), Graves’ disease (GD) and orbitopathy. The majority of 
autoimmune endocrinopathies are inherited as complex genetic traits, with multiple genetic 
and environmental factors interactions which confer susceptibility to such disorders. The 
genetic factors remain largely unknown, with the exception of the human leukocyte antigen 
(HLA). It is known that AITD are more frequent in families with HLA DR3 and DR5 HLA 
alleles. Predominantly involved are women. Indeed, HT is 5 to 10 times more common in 
women than in men. Since the basis for autoimmune diseases may have a common origin, it 
is possible that patients with HT or their first degree relatives, have one or more other 
autoimmune diseases such as type 1 diabetes mellitus or pernicious anemia (with antibodies 
against gastric parietal cells or B12) (Mathur, 2011).  
In recent years however, considerable efforts have been made to discover other genetic 
factors responsible for autoimmune endocrinopathies (Vaidya & Pearce, 2004). There are 
several studies confirming that genetic polymorphism of the cytotoxic T lymphocyte antigen 
(CTLA)-4 alleles on 2q33 chromosome have been associated with HT (Awata et al., 1998; 
Donner et al., 1997; Nithiyananthan et al., 2002; Tomoyose et al., 2002). CTLA-4 is a co-
stimulatory molecule expressed on the surface of activated T cells (Brunet et al., 1987). 
CTLA-4 (49) A/G allele was significantly more frequent in the group of HT patients 
compared to the healthy controls. Additionally, linkage and association of CTLA-4 with the 
presence of thyroid antibodies have also been reported (Tomer et al., 2001; Zaletel et al., 
2002).  
3.2 Autoimmune mechanisms 
The thyroid is a major target for autoimmune disease, as exemplified by autoimmune 
thyroiditis (which include HT type 1 and 2, and atrophic thyroiditis), and GD with opposite 
clinical outcomes. Both diseases, but particularly HT, are characterized by lymphocytic 
infiltration of the gland which can result in tissue destruction, fibrosis and hypothyroidism. 
The follicular spaces shrink and colloid is absent or sparse. Fibrosis may be completely 
absent or present in degrees ranging from slight to moderate. Heuer and coll. (Bernet et al., 
1996; Heuer et al., 1996) found increased expression of IFN-gamma, IL-2 and CD25 positive 
T cells in the thyroid specimens of patients with HT.  
 
Hypothyroidism – Influences and Treatments 
 
154 
Although the two disorders, HT and GD, have striking differences in clinical symptoms, 
they share the same histopathological features: lymphocytic infiltration and aberrant 
expression of HLA class II molecules on thyrocytes (Bernet et al., 1996). It is possible that HT 
and GD are caused by a similar immunologic dysfunction because similar autoantibodies 
(Abs) have been found in these patients.  
The cause of the autoimmune process is probably a combination of an inherited tendency 
and an as yet unknown trigger (American Thyroid Association, 2008). Previous studies have 
shown that HLA class II–expressing thyrocytes could stimulate the proliferation of 
autologous T cells grown from thyroid glands during autoimmune diseases (Dayan et al., 
1991; Londei et al., 1984; Weetman et al., 1986). Local up-regulation of the antigen-
presenting function on thyrocytes may be an early event in the development of AITD 
(Dayan et al., 1991). Autoantigen presentation by thyrocytes is more efficient than by 
professional antigen-presenting cells (APC), because the thyroid autoantigens thyroid 
peroxidase and thyrotropin (TSH) receptor are membrane proteins. These proteins can be 
recycled and presented by class II molecules, and the effective concentration of these 
antigens on thyroid epithelial cells may be higher than when picked up by other antigen-
presenting cells (Feldmann et al., 1992). However, lack of expression of costimulators such 
as B7.1 (CD80) or B7.2 (CD86) by thyrocytes undermines their ability to present antigens. 
Instead, class II–expressing thyrocytes may induce tolerance in autoreactive CD4+T cells 
(Matsuoka et al., 1996). 
On the other hand,  increased  expression  of  intercellular  adhesion molecule-1 (ICAM-1)  
has  been  shown  present  in  specimens  from patients  with  HT,  while  expression  was 
less  or  absent  in  GD  (Bagnasco  et  al.,  1991;  Ciampolillo  et  al.,  1993;  Pesce  et  al.,  
2002; Weetman  et  al.,  1990).  ICAM-1 is a member of the Ig gene superfamily and present 
on the surface of various cell types, serves as a ligand for lymphocyte function associated 
antigen-1 (LFA-1), and can be induced by various stimuli, such as cytokines (IL-1, tumor 
necrosis factor [TNF]-alpha, interferon [IFN]-gamma), hormones, cellular stresses (H2O2), 
and other environmental factors (Roebuck & Finnegan, 1999). Upon up-regulation it 
promotes cell–cell interactions, providing intense signals to the immune system that cause 
the T cells to home in on the inflamed site (Bonita et al., 2002). 
An  earlier  investigation  had  found  that  elevated  (rather  than  reduced) plasma  levels  of  
soluble  CTLA-4  (sCTLA-4)  protein  were  more frequent  in  patients with AITD than in  
healthy  controls  (Oaks  &  Hallett, 2000). CTLA-4 molecule,  together with CD28  co-
stimulatory molecule (both expressed on the  T cell  surface), plays  a critical role  in the  T cell 
response to antigen  presentation. For T cell activation  two signals  are needed: TCR engages 
antigen (the first signal), which is bound to a HLA class II molecule on the surface of an APC, 
and a co-stimulatory signal, that could be stimulatory or inhibitory.  This stimulatory second 
signal is provided mainly  by the  interaction of  CD28  with  its ligands, B7.1 (CD80) and B7.2 
(CD86)  on APC.  CTLA-4 also binds to the same B7 ligands (CD80 and CD86) but it delivers 
inhibitory signals to T-cell activation  (Walunas et al., 1994). In the absence of  a stimulatory 
second signal,  the antigen–TCR engagement is ineffective, and causes functional  inactivation 
of the T cell (anergy) or induces apoptosis of the cell  (Alegre et al., 2001).  
Soluble  CTLA4  molecules  (sCTLA4),  more  frequently  found  in  AITD patients,  could  
compete  with  membrane-bound  CTLA-4  for  CD80 / CD86-binding  sites  and  cause  a  
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reduction  of  inhibitory  signaling (Vaida  &  Pearce,  2004).  Thus,  autoreactive  T   cells  
will  become activated  leading  to  autoimmune  process.  The  altered  levels  of  sCTLA-4  
could  lead to either  blockade of  available  B7  ligands,  leading to  a  decreased  
stimulatory  signal (if  sCTLA-4  is  increased),  or  to  an inability  of  membranous  CTLA-4  
to  bind  the  B7 ligand,  leading  to subsequently  less  inhibitory  signal  (if  sCTLA-4  is  
decreased). 
3.3 The possible role of iodide excess on thyroid mild inflammation and the 
development of hypothyroidism  
Many epidemiological studies have demonstrated the toxic effects of iodide excess on 
thyroid function. In one study, about 10% of European  patients receiving 0.5 mg of iodide 
per day  for 6 months developed  lymphocytic infiltration of the thyroid gland, accompanied  
by  hypothyroidism  or  less often hyperthyroidism. Both the infiltration and the 
hypofunction were reversible upon discontinuation of iodide (Kahaly et al., 1998). The 
thyroid response to excess iodide is known as thyroid autoregulation. Most commonly, 
studies that examined the effects of toxic doses of iodide were usually performed in Fisher’s 
rat thyroid low-serum-5 (FRTL-5) cells, which can synthesize and secrete thyroglobulin (Tg), 
absorb and transport iodide, and produce thyroid peroxidase (Ambesi-Impiombato et al., 
1980). Although iodide doses over 10 mM caused toxic effects on the thyroid gland in vivo 
(Li & Boyages, 1994), higher concentrations of iodide were needed in order to influence cell 
proliferation (Becks et al., 1987; Eng et al., 2001; Smerdely et al., 1993) or even to induce 
apoptosis (Smerdely et al., 1993; Vitale et al., 2000) in cell culture.  
Possible sources of excess iodide for humans are: amiodarone, povidone-iodine, iodinated 
radiographic contrast media, Lugol’s 5% solution (used as 0,1-0,3ml for the treatment of 
simple goiter, equivalent of 12,5-37,5 mg of iodine) (Gennaro, 1995), dry or powdered algae 
(in many vitamin-mineral supplements and preparations for weight-loosing programs and 
herbal products).  
The U.S.  recommended  daily  intake  (RDI)  for  dietary  iodine  is  150 mcg for adults,  220 
mcg for pregnant women, and 270 mcg during lactation (Surks et al., 2004).  The safe upper  
limit  has  been  set  at  1,000 mcg (1 mg)  as  a result of studies assessing TSH levels with 
supplementation.  Iodine intake over 1 mg daily could potentially contribute to an 
underlying thyroid pathology-AITD, or even could exacerbate nodularities in euthyroid 
individuals in those taking over 20 mg of iodide (Burgi et al., 2001; Dunn et al., 1998; 
Robison et al., 1998). Population studies have shown that an excess of  iodine  intake  may  
increase  the  prevalence  of  autoimmune thyroiditis  (HT and atrophic thyroiditis)  in  
animals  and  humans, increasing  the  risk  of  clinically evident hypothyroidism (Teng et 
al., 2006).  
Iodide excess could influence thyroid cell growth and immunological profile. It is known that 
Lugol’s solution given a couple of days before surgery in GD patients reduced HLA class I and 
II mRNA expression in thyroid cells in vivo and in vitro (Schuppert et al., 1996). It has also 
been reported that ICAM-1 mRNA was doubled in suspensions of isolated human thyroid 
follicles incubated with 10 mM sodium iodide (NaI) (Yamazaki et al., 2003). Furthermore, 
iodide excess did not change Tg level in FRTL-5 cells (Pregliasco et al., 1996), but it inhibited 
iodine organification  (Davies et al., 1989), thyroid hormone secretion (Sato et al., 1990), and 
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cAMP production and secretion  (Miyazaki et al., 1999) in isolated human thyroid follicles. 
Recently, it was reported (Kostic et al., 2009) that iodide excess inhibited human primary 
thyroid cell proliferation and gradually increased ICAM-1 on cell surface. In the presence of 
low-dose IFN-gamma, KI additionally augmented ICAM-1 expression, and such effect could 
induce lymphocytic infiltration in the thyroid gland and secretion of proinflammatory 
cytokines. Decreased Tg production in the presence of KI excess and IFN-gamma could 
explain the development of hypothyroidism after iodide dietary addition in patients that 
already have lymphocytic infiltration and/or mild inflammation in the thyroid gland. 
Among the subjects exposed to iodine supplementation for the prevention of iodine 
deficiency or fed diet with high iodine intake, besides a few cases of focal and reversible 
lymphocyte infiltration of the thyroid, severe cases of hypothyroidism, not reversed by the 
suspension of iodine administration, with severe lymphocyte infiltration and parenchymal 
destruction have been described. 
Various animal strains genetically susceptible to autoimmune thyroiditis have been 
described, such as Cornell and obese strain (OS) chickens, BB/Worcester and Buffalo rats, 
and diabetic non-obese mice NOD.H-2h4. 
NOD mice expressing the H-2Jg7 allele of MHC class II, are genetically predisposed to 
develop type I diabetes and other autoimmune diseases, such as spontaneous autoimmune 
thyroiditis, which appears with low incidence. On the contrary, transgenic mice NOD.H-
2h4, expressing the H-2Ak allele on the NOD background, do not develop diabetes but 
develop, with higher frequency, a spontaneous autoimmune thyroiditis (SAT). Moreover, as 
in BB/Worcester rats, SAT is increased by the addition of iodide in the drinking water. In 
these animals, deletion of IFN-gamma is associated with a strong reduction of anti-TG 
antibodies and of thyroid infiltration with B, T and plasma cells. 
High iodide doses transiently inhibit Tg iodination by thyroperoxidase (TPO) (Wolff-
Chaikoff effect). This is because, at high iodide to Tg ratios (mM to microM), iodide 
peroxidation to molecular iodine (I2) by TPO prevails over iodination of tyrosyl residues of 
Tg (Km 6 x 10-3M and 8 x 10-5, respectively). The iodination of tyrosyl residues leads to the 
production of one mole of OH- ions per mole of tyrosyl residue formed, whereas the 
peroxidation of iodide to I2 leads to the formation of two moles of OH- ions per mole of I2 
produced. Hydrogen peroxide (H2O2), produced by the NADPH-oxidase of the apical 
membrane of thyroid epithelial cells (TECs), is the limiting electron acceptor in the TPO-
catalized reactions. Its production leads to the production of superoxide anion (O2-) as an 
intermediate. Excess I- ions inhibit both the enzymatic degradation of H2O2 by TPO and 
non enzymatic oxidation of H2O2 by I2.  
However, in dog thyroid slices, iodide excess seems to inhibit H2O2 generation, through the 
formation of oxidized iodine compounds. Thus, excess iodide inhibits thyroid functions by 
multiple mechanisms, which include, besides true anion effects, the oxidative modification 
and/or iodination of important enzymes, the inhibitory effect of the products of the 
iodination or peroxidation of polyunsaturated fatty acid, which, in turn, can act as free 
radicals. An imbalanced production of free radicals and/or dysfunctions of enzymes 
involved in their detoxication, such as glutathione peroxidase, catalase and superoxide 
dismutase, have been associated with aging, neurodegenerative diseases, cancer and 
autoimmune diseases. 
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At persistingly high doses, iodide can determine thyroid involution. Preliminary studies 
showed the accumulation of lipid peroxidation products, with necrosis and inflammation of 
murine and human thyroid exposed to toxic iodide doses (23, 24). More recently, it has been 
demonstrated that thyroid cell apoptosis is the prevalent cause of TEC death in thyroid 
iodide-dependent involution in goitrogen-treated rats. However, TEC necrosis induced by 
iodide excess has been indicated as a preliminary step in a model of the development of 
autoimmune thyroiditis.  
Iodide excess induces apoptosis in thyroid cultured cells, through a p53-independent 
oxidative mechanism. Diminished levels of bcl-2 gene expression and increased levels of bax 
gene expression have been found in the brain and the thyroid of guinea-pigs exposed to 
excess iodide. In OS chickens, the TEC damage, preceding the development of autoimmune 
thyroiditis, is mediated by the production of ROS. H2O2 induces apoptosis in cultured pig 
thyroid cells. 
Cellular products of thyroid iodinated lipids include arachidonic acid derivatives, such as 6-
iodo-5-hydroxy-8,11,14-eicosatrienoic acid and 14-iodo-15-hydroxy-5,8,11 eicosatrienoic acid 
(I-OH-A), and their respective delta and omega iodolactones (IL-d and IL-ω). IL-ω inhibits 
iodide organification in dog thyroid slices, by inhibiting H2O2 production (31). IL-ω and IL-
d inhibit the proliferation of rat FRTL-5 cultured thyroid cells and cause the involution of 
thyroid in goitrogen-treated rats. IL-d inhibits inositol-3-phosphate production and EGF and 
beta FGF signal transduction in human and pig thyroid cells. 2-iodoesadecanal (2-IHDA), 
produced from the rat thyroid exposed to iodide, inhibits adenylate cyclase activity and 
cAMP-stimulated activities of NADPH oxidase and TPO. The non-iodinated products 
derived from arachidonic acid oxidation induce apoptosis in smooth muscle vessel cells. 4-
Hydroxynonenal, the most important product of arachidonic acid oxidation, induces 
apoptosis in a number of cell types, including endotelial cells. As with iodide in the thyroid, 
it can do so through a p53-idependent mechanism 
The current vision of the pathogenesis of autoimmunity favors the triggering role of the 
exposure of cryptic self epitopes. It has been demonstrated that a hormonogenic carboxy-
terminal fragment of Tg , beginning at residue 2384, was released during enzymatic 
iodination or metal-catalyzed oxidation of Tg in vitro, as well as during oxidative stress in 
vivo. Because it was recognized by autoantibodies of patients affected with autoimmune 
thyroid disease (AITD), it was suggested that oxidative proteolysis can expose 
immunopathogenetic cryptic epitopes. 
In vitro iodination of murine Tg , used to immunize susceptible rats, determined the 
transformation of a T-cell epitope (residues 2495-2511) from cryptic to immunodominant in 
vivo. It is well known that the iodination of Tg with TPO in vitro is accompanied by the 
formation of proteolytic peptides, whose amount is related to their iodine and hormone 
content. 
Thyroid autoantigens could be also transferred to thyroidal dendritic cells (DC) and cross-
presented to T lymphocytes. Apoptosis of TECs, induced by iodide excess, could play a 
pivotal role in this process. Apoptotic cells are a preferred source of antigens for cross-
presentation, being captured by DCs via alpha(v)-beta5 or alpha(v)-beta 5 integrins and 
CD36. Although DC can cross-present both apoptotic and necrotic cells, MHC class II-
restricted presentation can occur with both of them, while MHC class I-restricted 
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presentation can only occur with apoptotic cells. Moreover, even if immature DCs 
phagocytose efficiently both apoptotic and necrotic cells, the exposition to the latter is 
necessary in order to induce their maturation to APC, with optimal abilities of antigen 
processing and presentation and elevate levels of CD38, DC-LAMP, and CD40 and CD86 co-
stimulatory molecules. Moreover, DC can cross-activate CTL by the internalization of heat 
shock proteins gp96 and Hsp70 loaded with antigenic peptides. Finally, the processing and 
the class II-restricted presentation are increased by receptor-mediated internalization of 
mannosylated antigens, such as Tg. 
3.4 Other cell stressors that could induce hypothyroidism 
It has  been  shown  that  human  primary  thyroid  cells  increase  HLA-DR surface  
expression  in  response  to  a variety of   cell stressors,  such  as  IFN-gamma  (Montani et 
al.,  1998;  Otten et al.,  1998;  Wu et al.,  1999)  and ionizing radiations (Czirjak et al., 1990) or 
transiently modify  HLA-DR expression in vitro in the presence of iodide excess (Kostic et 
al.,  2009). Recently,  Kostic et al. (Kostic et al.,  2010)  showed  that  HLA-DR expression was 
also transiently increased  24 hours after  UVC  treatment of human primary thyroid cells in 
vitro, and subsequently returned to normal level 48 h after irradiation. This local up-
regulation of antigen presenting function on thyrocytes in vivo could be sustained by a local 
inflammatory network (formed by cytokines and other cells of the immune system) and it 
may be an early event in the development of AITD  (Botazzo et al., 1983; Liu et al., 2008).  
Another consequence of UVC as physical mutagen is a cell cycle arrest or apoptosis 
induction in human primary thyroid cells. As already mentioned, the local up-regulation of 
HLA-DR by thyrocytes together with the expression of proteins from apoptotic cells may 
represent an early event in the development of AITD (Botazzo et al., 1983).  
The model for the cellular response of human thyroid cells after UVC irradiation (Kostic et 
al., 2010) suggested that UV induced dimers lead to activation of p53 that is in turn able to 
induce G0 / G1 cell cycle arrest in order to repair DNA damage. Cells that are able to repair 
damaged DNA or that do not have a large DNA damage enter S phase of the cell cycle, but 
secondary lesions generated during replication, induce apoptosis. The cells that are severely 
damaged after UVC irradiation, diminish Bcl-2 expression in the mitochondria and start 
apoptosis. 
It has also been shown that in microgravity conditions the thyroid cells FRTL5 in culture do 
not respond to TSH treatment and present an irregular shape with condensed chromatin, a 
modification of the cell membrane with shedding of the TSH-receptor in the culture 
medium, and an increase of sphingomyelin-synthase and bax proteins. It is possible that 
microgravity induces a rearrangement of specific sections of the cell membrane, which act as 
platforms for molecular receptors, thus influencing thyroid cell function in astronauts 
during space missions. 
It has been recently reported that FTRL-5 cells cultured in the presence or absence of TSH in 
the International Space Mission during the Eneide and Experia missions presented a similar 
cell growth pattern, which indicates an absence of response to TSH in space (Albi et al., 
2010). It is difficult to establish whether this modification that occurs in space is due to 
cosmic radiation or microgravity. 
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It was previously reported that simulated weightlessness changed the cytoskeleton of 
normal thyroid cells (Infanger et al., 2004), increased the extracellular matrix proteins 
(Infanger et al., 2006), reduced thyroglobulin, FT3 and FT4 secretion, (Grimm et al., 2002), 
and induced apoptosis (Kossmehl et al., 2002, Grimm et al., 2002) of thyroid carcinoma cells. 
These data were supported by exposing mitochondria-rich thyroid carcinoma cells and 
normal thyroid cells to simulated microgravity conditions and obtaining apoptotic cells 
(Kossmehl et al., 2003). We reported for the first time the modifications of thyroid cells 
under real microgravity conditions. 
We have shown that, in microgravity, the FRTL5 cells appeared aggregated and presented 
chromatin condensation, the TSH-induced cAMP production was significantly attenuated, 
and the TSHR was increased about 4.4 fold in the culture medium. At Earth's gravity, the 
TSHR was unaltered, and the cells responded to TSH treatment with normally high levels of 
cAMP production (Albi et al., 2011). 
It is possible that the loss of TSHR from the cells in microgravity was due to the 
disorganization of microdomains within the cell membrane, depending on Sphingomyelin 
and Cholesterol incorporation from the culture medium that yielded a more rigid 
membrane structure. These data were consistent with the observation that a medium 
lacking TSH caused cessation of FRTL-5 cell proliferation due to the decrease in membrane 
lipid fluidity, which in turn was caused by an absolute increase of membrane cholesterol. 
It has been shown that microgravity induced the FRTL5 cells treated with TSH to release 
Cholesterol and Sphingomyelin to the culture medium probably by modifying the 
microdomain structure (Albi et al., 2011). The lower amount of TSHR in the culture medium 
after TSH stimulation with respect to the TSH- samples may have been due to the fact that 
raft-TSHR complexes are regulated by TSH, which stimulates the formation of monomers 
and allows their rapid exit from the rafts (Latif et al., 2003). Therefore, the modification of 
lipid rafts consequent to the removal of Cholesterol and Sphingomyelin may have been 
preceded by a transfer of the receptor, which would explain the reduction but not the 
absence of the cAMP response. The disorganization of microdomains in microgravity was 
confirmed by the presence of caveolin 1 in the pellet obtained after fixation, which was 
absent in the samples maintained in Earth's gravity. 
4. Types of AITD 
The types of AITD may be summarised as follows: 
 Type 1 (Thyroiditis chronica Hashimoto type 1): 
 euthyroidism with anti-TPO Abs and 
 1A: with goiter; 
 1B: without goiter 
 Type 2 (Thyroiditis chronica Hashimoto type 2): 
 hypothyroidism with anti-TPO Abs and 
 2A with goiter; 2B without goiter; 
 2C transitory forms (postpartal hypothyroidism, Hashitoxicosis) 
 Type 3 (Morbus Graves): 
 3A hyperthyroidism with 
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 stimulating anti-TSH R Abs;  
 anti-TPO Abs and anti-Tg Abs +/- 
 3B Euthyroidism with supressed TSH and anti-TSH R Abs 
 3C Hypothyroidism. Orbitopathy and anti-TPO Abs +/– 
The Abs present in the sera of patients with AITD are only the witnesses of autoimmune 
destruction or activation of thyroid gland.  
The most frequent in HT are Abs against thyroperoxidase (anti-TPO), Abs associated with 
euthyroidism (HT type 1) or hypothyroidism (HT type 2) and accompanied or not by goiter. 
On the other hand, in GD (AITD type 3) Abs against Tg (anti-Tg Abs) in AITD type 3A, and 
stimulating or inhibiting Abs against TSH receptor (anti-TSHR Abs) may also be found.  
According to the prevalence of stimulating or blocking anti-TSHR Abs, GD patients could 
develop hyperthyroidism (stimulating anti-TSHR Abs), hypothyroidism (inhibiting anti-
TSHR Abs) or be euthyroid (GD type 3B). 
Of great interest is the relationship between Interferon and Autoimmune Thyroid Disease. 
Three different types of thyroid dysfunction associated with IFN treatment have been 
reported: (1) autoimmune (often subclinical) hypothyroidism; (2) destructive thyroiditis; 
and (3) Graves' hyperthyroidism. 
These abnormalities can occur at any time during IFN therapy, from as early as 4 weeks 
until as late as 23 months after initiation, and there is no clear difference between the three 
types, with a median date of onset of 17 weeks after start of IFN treatment. Pooling of 
several studies shows that hypothyroidism seems to be more frequent than thyrotoxicosis. 
The majority of patients with hypothyroidism also have TPO antibodies (87%), indicating 
the autoimmune nature of this event. According to most studies hypothyroidism can be 
transient, subsiding after discontinuation of IFN. In a large Italian survey, hypothyroidism 
was, however, permanent in 59% of the patients. A similar result was found in the review of 
the literature (Koh et al.), which showed that 56% of the patients had permanent 
hypothyroidism. In a recent long-term follow-up study, it was found (Carella et al.) that 10 
of 36 (28%) TPO antibody-positive patients lost their antibodies at 6 years after 
discontinuation. On the other hand, 26 patients remained antibody-positive at that time, and 
subclinical hypothyroidism was detected in seven of them 
5. Conclusion 
Hypothyroidism is a common endocrine disorder resulting from deficiency of thyroid 
hormone. It usually is a primary process in which the thyroid gland produces insufficient 
amounts of thyroid hormone. It can also be secondary—that is, lack of thyroid hormone 
secretion due to inadequate secretion of either thyrotropin (ie, thyroid-stimulating hormone 
[TSH]) from the pituitary gland or thyrotropin-releasing hormone (TRH) from the 
hypothalamus (secondary or tertiary hypothyroidism). The patient's presentation may vary 
from asymptomatic to, rarely, coma with multisystem organ failure (myxedema coma). 
Localized disease of the thyroid gland that results in decreased thyroid hormone production 
is the most common cause of hypothyroidism. 
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The most common cause of hypothyroidism in adults is autoimmune thyroid disease (AITD. 
The second frequent cause is a thyroid ablation as a consequence of surgical removal of part 
or all of the gland. Third most common are all causes of congenital hypothyroidism (in 
newborns). There are also a few forms of infective processes in thyroid. 
In some cases, medicines could be the cause of hypothyroidism, usually by interfering with 
normal thyroid hormone synthesis. 
Because all metabolically active cells require thyroid hormone, deficiency of the hormone 
has a wide range of effects. Systemic effects are due to either derangements in metabolic 
processes or direct effects by myxedematous infiltration (ie, accumulation of 
glucosaminoglycans in the tissues). 
The myxedematous changes in the heart result in decreased contractility, cardiac 
enlargement, pericardial effusion, decreased pulse, and decreased cardiac output. In the GI 
tract, achlorhydria and decreased intestinal transit with gastric stasis can occur. Delayed 
puberty, anovulation, menstrual irregularities, and infertility are common. Decreased 
thyroid hormone effect can cause increased levels of total cholesterol and low-density 
lipoprotein (LDL) cholesterol and a possible change in high-density lipoprotein (HDL) 
cholesterol due to a change in metabolic clearance. In addition, hypothyroidism may result 
in an increase in insulin resistance.  
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1. Introduction 
The most common cause of hypothyroidism is the autoimmune disorder Hashimoto’s 
thyroiditis, the stages of which can be accurately and objectively assessed by serial, real-
time thyroid ultrasonography. Early stages of chronic thyroiditis include; increased 
vascularity and a patchy heterogeneous texture reflecting the inflammatory infiltrations, 
enlargement of the thyroid gland and sometimes associated lymphadenopathy. As the 
autoimmune destruction of the thyroid gland continues the normal thyroid texture 
progressively changes until the tissue is replaced by empty spaces, so called end-stage. 
We can follow the course of the thyroiditis, which typically proceeds over several years, 
correlating with clinical features, thyroid [thyroid peroxidase (TPO), thyroglobulin (Tg)] 
antibody titres and serum levels of thyroid stimulating hormone (TSH) and free thyroxin 
(T4). We can confirm change in thyroid status from Hashimoto's thyroiditis to Graves’ 
disease when TSH-receptor antibodies are additionally produced, document remission in 
young patients with Hashimoto's thyroiditis and we can obtain diagnostic information in 
patients with the rare but serious Riedel's thyroiditis. In the hands of an experienced 
operator real-time thyroid ultrasonography can provide information about the underlying 
autoimmune process. For example, ultrasound abnormalities can be correlated with; the 
eye changes that are found in about 25% of patients (1), serum levels of calsequestrin and 
collagen XIII antibodies (2-5), serum levels of thyroid antibodies and other parameters of 
the autoimmune process including phenotypes and numbers of infiltrating T lymphocytes 
in the thyroid.  
In this chapter, we will highlight the use of real-time ultrasound in the assessment of 
patients with Hashimoto’s thyroiditis, not only for clinical purposes but also to provide 
information about the pathogenesis of Hashimoto’s thyroiditis and its variants such as silent 
and post partum thyroiditis and Riedel’s thyroiditis.  
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2. Serial studies in Hashimoto’s thyroiditis 
In the hands of a single operator using standard criteria for assessing the ultrasound 
changes of Hashimoto’s thyroiditis, real-time thyroid ultrasonography is a valuable new 
tool for diagnostic and management purposes. Images can be stored and changes compared 
serially in individual patients and correlated with immune parameters in cohorts of patients 
in research studies. Fine needle aspiration (FNA) biopsy can characterise any nodules and 
features of the Hashimoto’s thyroiditis process itself, such as numbers of lymphocytes and 
other mononuclear cells and overall architectural changes. Typically, the most classical 
appearance in early thyroiditis is the formation of small cystic areas throughout the gland 
which reflect the lymphoid infiltrations (fig 1) which progresses to a stage of multi-cystic 
disease (fig. 2). Later, there is increased destruction of the thyroid follicles, scarring and 
pseudo nodule formation (fig. 3) and the gland becomes shrunken and avascular (fig 4). 
Finally, in long standing cases, there may be tissue calcification (fig. 4). The full process 
takes from many months to 2-3 yr although this needs to be shown in a long term 
prospective study of patients who were diagnosed early, i.e. with no symptoms, normal 
TSH and positive serum thyroid antibodies, correlating ultrasound changes with parameters 
of thyroid function and the autoimmune reactions. We have followed a few such patients 
 
Fig. 1. Thyroid ultrasound changes in a 23 yr old female with early Hashimoto’s thyroiditis 
and subclinical hypothyroidism (normal fT4, TSH 4.5) showing minimal cystic changes and 
a patchy texture, reflecting the autoimmune reactions. 
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with Hashimoto’s thyroiditis over a course of the natural history of the disease before and 
after treatment with thyroxin, observing that the correlation between findings on real time 
ultrasound, thyroid function and thyroid antibody levels are indeed close (Wall, Champion 
et al unpublished observations). Moreover, ultrasonographic changes correlate closely with 
serum TSH and T4 values and clinical features of both the thyroiditis (tender painful gland, 
goitre) and hypothyroidism and can indicate accurately the stage of the disease and whether 












Fig. 2. Ultrasound changes in a 30 yr old male with more severe Hashimoto’s thyroiditis and 
overt hypothyroidism showing extensive cystic changes throughout the lobe, especially in 
the upper parts, scarring and pseudo nodule formation. 
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Fig. 3. Typical ultrasound changes in a 50 yr old female with long standing hypothyroidism 
due to Hashimoto’s thyroiditis. The thyroid tissue has been destroyed and replaced by 
empty spaces (seen as black areas) and linear scarring, giving the appearance of pseudo 
nodules. This can be called “end stage” disease. In this patient, the gland is slightly enlarged 
although with time it becomes shrunken and small.  
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Fig. 4. Late stage Hashimoto’s thyroiditis in a 45 yr old female showing chronic, egg shell, 
calcification seen as a 1 cm calcified ball with shadowing (due to inability of the ultrasound 
waves to penetrate the calcified material). 
3. Thyroid nodules in Hashimoto’s thyroiditis 
There is an increased prevalence of thyroid cancer in patients with Hashimoto’s thyroiditis 
(6) so any nodules (fig. 5) should be carefully documented, assessed for signs of malignancy 
and ultrasound-guided fine needle aspiration biopsy (FNA) performed where appropriate. 
The possibility that the number and/or size of any nodules might reflect the severity and 
extent of the autoimmune process or represent a surrogate for the development of 
ophthalmopathy, could be studied.  
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Fig. 5. A suspicious hypo echoic nodule in the thyroid of a 35 yr old female patient with 
early Hashimoto’s thyroiditis. Apart from a few small cystic areas around the nodule and 
mild patchiness throughout, the texture of the gland itself is relatively normal 
4. Conversion of Hashimoto’s thyroiditis to Graves’ hyperthyroidism 
Changes in the status of the autoimmune reactions of Hashimoto’s thyroiditis can be 
quantified by measurement of serial TPO, Tg and TSH-receptor antibodies and some 
patients show dramatic changes from one disorder to the other, particularly development of 
Graves’ disease even after the apparent destruction of the thyroid gland by the Hashimoto’s 
thyroiditis process. We have studied a 14 yr old female patient who presented with 
profound hypothyroidism due to Hashimoto’s thyroiditis with high levels of TSH and 
unmeasurable T4 and ultrasound appearances typical of end stage Hashimoto’s thyroiditis 
who later converted to Graves’ hyperthyroidism with the development of TSH-r antibodies 
(7). We were able to show by serial real time thyroid US, destruction of the thyroid gland 
initially then re filling with newly formed follicular cells through the action of the TSH 
receptor antibodies, followed by overall thyroid enlargement and finally, the typical 
heterogeneous appearance of Graves’ hyperthyroidism that reflect the lymphoid infiltration, 
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including increased vascularity (fig. 6a, 6b). This is the first documented observation of 
change from hypothyroidism to hyperthyroidism recorded by real time thyroid 














Fig. 6a. Ultrasound appearance of the thyroid gland in a 14 year old female patient 10 
months after presenting with Hashimoto’s thyroiditis and profound hypothyroidism and 9 
months after biochemical and clinical conversion to Graves’ hyperthyroidism. The typical 
appearances of Hashimoto’s thyroiditis namely, a small, shrunken lobe and isthmus and 
generalized hypo echoicity due to inflammation of the thyroid tissue, are still present. 
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Fig. 6b. Thyroid ultrasonography 16 months later (30 months after biochemical and clinical 
conversion from Hashimoto’s hypothyroidism to Graves’ hyperthyroidism). The thyroid is 
larger, particularly the isthmus, more hyper echoic throughout and typical of fully 
established Graves’ hyperthyroidism 
5. Remission in young patients with Hashimoto’s thyroiditis 
We have studied a 12 yr old girl with Hashimoto's thyroiditis was initially euthyroid and 
later treated with 50 µg l-thyroxin (L-T4) when her fT4 had declined from 17 to 7 pmol/L 
(normal range, 8-22 pmol/L). At this time her TSH was 4.1 mIU/L (normal range, 0.30-4.0 
mIU/L) and thyroid ultrasonography demonstrated features of early inflammation. Two 
years later, while on the same dose of T4, ultrasound examination revealed severe end-stage 
Hashimoto's thyroiditis (fig 7a) and thyroid function tests showed a T4 of 14.0 pmol/L and 
TSH of 0.81 mIU/L. Twelve months later, however, the thyroid ultrasound had returned to 
almost normal with only minimal features of inflammation (fig 7b). Thyroid function tests 
showed an fT4 of 12.8 pmol/L and TSH of 0.75 mIU/L. Her T4 treatment was then stopped. 
Eight, 17, and 30 weeks after this, her fT4 levels were 16.8, 9.7, and 13.9 pmol/L, 
respectively. Twelve months later her goitre suddenly enlarged and became tender; 
ultrasound revealed that she now had features of end stage disease with a huge empty 
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thyroid gland (fig 7c) and fT4 level was low (8 pmol/L) and TSH elevated (11 mU/L) and 
she was again treated with thyroxin, this time permanently. This is the first recording of 
serial thyroid ultrasound changes in a patient with Hashimoto's thyroiditis that paralleled 
changes in thyroid function. This case (8) indicates that thyroiditis can have a fluctuating 
course, including go into remission in some children. Thyroid ultrasound may be useful to 
make presumptive therapeutic decisions in children and adolescents with Hashimoto's 
thyroiditis whose dose of thyroid hormone seems to be less than is full replacement. 
Thyroid function tests, however, should ultimately guide T4 dosage. It is well recognised 
that Hashimoto’s thyroiditis can be transient in about a third of young patients whereas it is 
presumed that in adults in all cases it is progressive into end stage destruction and 
hypothyroidism which is permanent. Use of real time thyroid ultrasonography provides an 
additional aid to studies of cohorts of children and teenagers to objectively characterise the 





Fig. 7a. Thyroid ultrasonography in a 12-year-old girl with Hashimoto's thyroiditis who was 
initially euthyroid and later treated with 50 µg l-thyroxin (L-T4) when her fT4 had declined 
from 17 to 7 pmol/L (normal range, 8-22 pmol/L). At this time her TSH was 4.1 mIU/L 
(normal range, 0.30-4.0 mIU/L) and thyroid ultrasonography demonstrated features of 
severe thyroiditis similar to those seen in fig. 3. 
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Fig. 7b. Eighteen months later, the thyroid ultrasound in this patient has returned to almost 
normal with only minimal features of inflammation. Thyroid function tests showed an fT4 
of 12.8 pmol/L and TSH of 0.75 mIU/L and she was clinically euthyroid and well. 
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Fig. 7c. Twelve months later this patient’s goitre suddenly enlarged greatly and was tender; 
ultrasound revealed that she now had features of end stage disease with a huge empty 
thyroid gland and fT4 level was low (8 pmol/L) and TSH elevated (11 mU/L) and she was 
again treated with thyroxin, this time permanently. 
6. Riedel’s thyroiditis  
A female aged 25 with a very large, firm goitre, strongly positive thyroid antibodies and 
marked and resistant hypothyroidism was studied by ultrasound. Her gland was non-
tender, stony hard to palpation, diffusely enlarged with no associated adenopathy. (fig. 8). 
On ultrasound (fig. 8), the texture was quite different to that found in classical Hashimoto’s 
thyroiditis (see above) and consistent with massive fibrosis. Indeed, this patient also had 
evidence for generalised fibrotic process with radiologically and biopsy proven 
retroperitoneal fibrosis causing bilateral ureteric obstruction. She was treated with thyroxin 
as well as glucocorticoids and azathiaprine to control her systemic fibrotic process. 
Tamoxifen, with anti-transforming growth factor (TGF) beta properties, is also another 
potential therapeutic strategy. 
Riedel thyroiditis, or Riedel's thyroiditis, is a rare, chronic inflammatory disease of the 
thyroid gland characterized by a dense fibrosis that replaces normal thyroid parenchyma 
(9). At the Mayo clinic, 37 cases were diagnosed in a series of 57,000 thyroidectomies that 
were performed between 1920 and 1984. The operative incidence was 0.06% and the overall 
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incidence in outpatients was 1.06 per 100,000 (10). The fibrotic process invades adjacent 
structures of the neck and extends beyond the thyroid capsule. This feature differentiates 
Riedel's thyroiditis from other inflammatory or fibrotic disorders of the thyroid. Because of 
the encroachment beyond the thyroid capsule, other problems can be associated with 
Riedel's thyroiditis, including hypoparathyroidism, hoarseness (due to recurrent laryngeal 
involvement), and stridor (due to tracheal compression). Approximately one third of 
Riedel's thyroiditis cases are associated with clinical findings of multifocal fibrosclerosis at 
the time of diagnosis. Riedel's thyroiditis is also associated with other fibrous inflammatory 
processes, including retroperitoneal fibrosis, orbital pseudotumor, mediastinal fibrosis, 
sclerosing cholangitis and fibrosis in other organ systems. 
 
Fig. 8. Thyroid ultrasound in a 32 yr old woman with Riedel’s thyroiditis, a very large goiter, a 
systemic fibrotic reaction, strongly positive thyroid antibodies and marked and resistant 
hypothyroidism. The isthmus is 2.20 cm thick, approximately 3 times normal, and the texture 
of the thyroid contents is quite different from that found in classical end-stage Hashimoto’s 
thyroiditis (see above), with large oblong hypo echoic spaces scattered among more iso echoic 
areas, consistent with a combination of thyroiditis and diffues fibrosis, respectively. 
7. Eye changes in patients with Hashimoto’s thyroiditis 
Mild eye signs (ophthalmopathy) are common in patients with Hashimoto’s thyroiditis (1) if 
looked for (since the main and sometimes only sign is upper eyelid lag) and correlate fairly 
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closely with a variety of eye muscle antibodies which are probably secondary to the putative 
inflammation of the levator palpebrae superioris muscle. We have studied patients with 
Graves’ hyperthyroidism, addressing whether the thyroid size – as a surrogate for the 
severity of the “thyroiditis” - is a marker for associated ophthalmopathy (Oliffe, Wall 
submitted). While we did not demonstrate a significant correlation between bigger thyroid 
size and ophthalmopathy we have not yet studied patients with Hashimoto’s thyroiditis in 
whom goitre size varies a lot and could – in the early stages before destruction – provide a 
better marker for subsequent eye signs. Ultrasound changes can also be correlated with 
serum titres of calsequestrin and collagen XIII antibodies and eye signs in patients with 
Hashimoto’s thyroiditis.  
8. Relationship between thyroid and orbital immune reactions in pregnant 
patients with Hashimoto’s thyroiditis 
Changes in the thyroid and orbital inflammatory processes may run in parallel or diverge in 
pregnancy and real-time ultrasound has been used to study patients with Graves’ disease and 
Hashimoto’s thyroiditis from pre-pregnancy through pregnancy and in the post-partum 
period. Changes in the status of Hashimoto’s thyroiditis is common during pregnancy and 
afterwards. We are studying whether these abnormalities are reflected in ultrasound changes, 
goitre size and thyroid antibody titres and whether they run parallel to changes in eye signs 
and serum titres of calsequestrin and collagen XIII antibodies or run divergent courses. 
Preliminary results suggest that thyroid and eye muscle antibody levels fall in parallel during 
pregnancy and rebound together in the post partum period and correlate with changes in eye 
signs in patients with Graves’ disease and Hashimoto’s thyroiditis (Wall, Champion et al., 
unpublished observations). This suggests that the ophthalmopathy of both Graves’ disease 
and Hashimoto’s thyroiditis is closely linked with the thyroid autoimmune process in both 
disorders, although this study is ongoing. In Hashimoto's thyroiditis the eye changes are 
usually mild and confined to the upper eyelids with mild proptosis, but the underlying 
process seems to be the same. While most workers (11-13) believe that the reason for the 
association is due to cross reactive antibodies targeting the TSHr in the thyroid follicular cell 
and orbital fibroblast and pre adipocyte TSHr antibodies are not always detected in patients 
with eye signs (1). For this reason we propose that there may be a primary eye muscle reaction 
against calsequestrin. and possibly collagen XIII (2-5, 14). 
9. Conclusions 
Real-time thyroid ultrasonography is an under utilised tool for the assessment of 
Hashimoto’s thyroiditis and hypothyroidism in individual patients and in research studies. 
Use of real-time thyroid ultrasonography gives us a unique opportunity to directly observe 
the consequences of the thyroid autoimmune process in the thyroid gland. We have shown 
how the ultrasonographic changes closely reflect the nature of the immune reactions, their 
effects on thyroid follicles and tissue architecture in general and on the ability of the thyroid 
gland to produce thyroid hormones.  
There are limitations to ultrasonography, in particular that we have not proven that the 
observed visual changes can be directly extrapolated to the immune reactions in the thyroid. 
However, as technology improves, for example when we can characterise and quantify the 
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lymphoid patches, we can expect to be able to better correlate what is seen on ultrasound 
with the underlying autoimmune reactions.  
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1. Introduction 
1.1 History of replacement therapy of hypothyroidism 
Before the middle of XX century treatment of hypothyroidism implied prescription to the 
patients animals’ thyroid extracts, containing both, thyroxine and triiodothyronine 
[Oppenheimer JH, 1995]. Those drugs, in which it was almost impossible to measure the dose 
of thyroid hormones precisely, could not adequately provide euthyroidism. Moreover, it 
was rather difficult to prescribe proper doses. Furthermore there weren’t any objective 
control parameter for dose adjustment like modern TSH-assays. Synthetic preparations of 
levothyroxine (L-T4) have been used since about 1958, and levotriiodothyronine (L-T3) - 
since 1956 (figure 1). 
 
Fig. 1. Production of thyroid hormones 
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1. Introduction 
1.1 History of replacement therapy of hypothyroidism 
Before the middle of XX century treatment of hypothyroidism implied prescription to the 
patients animals’ thyroid extracts, containing both, thyroxine and triiodothyronine 
[Oppenheimer JH, 1995]. Those drugs, in which it was almost impossible to measure the dose 
of thyroid hormones precisely, could not adequately provide euthyroidism. Moreover, it 
was rather difficult to prescribe proper doses. Furthermore there weren’t any objective 
control parameter for dose adjustment like modern TSH-assays. Synthetic preparations of 
levothyroxine (L-T4) have been used since about 1958, and levotriiodothyronine (L-T3) - 
since 1956 (figure 1). 
 
Fig. 1. Production of thyroid hormones 
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Based on the concept that the thyroid gland produces two hormones - thyroxine (T4) and 
triiodothyronine (T3), there was a long-term understanding that in the treatment of 
hypothyroidism it is preferable to use a combination of L-T3 and L-T4, rather than 
monotherapy with one of those drugs [Oppenheimer JH, 1995]. In the 70s, it was shown that 
the majority of circulating in blood T3 (80%) is produced not by the thyroid gland, but is 
formed by deiodination of T4 in peripheral tissues [Braverman LE, 1970; Surks MI, 1973]. 
These data allowed to consider T4 as prohormone to T3, which shows a stronger affinity to 
the receptors of thyroid hormones than T4. In addition, it was demonstrated, that L-T3 has 
unfavorable pharmacokinetics: it is rapidly and almost completely gets absorbed, the serum 
level of T3 reaches a peak after 2 - 4 hours, but after 6 - 8 hours it considerably declines. 
Thus, after taking the L-T3, the serum level of T3 reaches a non-physiological level for a 
short time and then rapidly gets metabolized [Toft, 1994]. These data led to the concept of 
the predominant use of replacement monotherapy with L-T4 (figure 2). 
 
Year Event 
1891 Treatment with animals’ thyroid extracts 
1926 Description of the structure and synthesis of Т4  
1952 Description of the structure and synthesis of T3 
1956  Start of treatment with synthetic L-Т3  
1958 Start of treatment with synthetic L-T4  (200-400 µg daily)  
1973-74 
Recommended dose of L-T4 100-150 μg daily  
The widespread use of combination with L-Т4 + Т3  
1980-85 
Appearance of highly sensitive methods for determination of TSH 
Concept of preferable use of replacement monotherapy with L-T4 
Fig. 2. History of replacement therapy of hypothyroidism 
Together with fundamental studies, which investigated the thyroid hormones metabolism 
intensive development of laboratory diagnostics led to the development of modern concepts 
of replacement therapy with thyroid hormones. Thus, while determining the TSH level with 
methods of poor sensitivity in the lower range of values (unable to distinguish the 
suppressed level of TSH from the low-normal value) in the 1960s a replacement dose of L-T4 
was recommended, ranged between 200 and 400 micrograms daily, which was accompanied 
by a significant increase in T4 level in serum [Toft, 1999]. 
The situation changed in the 1980s with appearance of highly sensitive methods for the 
determination of TSH levels. It became obvious that the doses of L-T4, leading to 
suppression of TSH, even in normal levels of T4 and T3 in blood, were accompanied by 
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similar, but less evident changes in the liver, heart, kidneys and bones, like in thyrotoxicosis 
[Gow,1987]. Thus, by the early 1980s the concept of preferable use of replacement 
monotherapy with L-T4 was formulated. TSH level, determined by methods of high 
sensitivity, has become the main indicator for assessment the adequacy of hypothyroidism 
replacement therapy. 
1.2 The principles of generally recommended replacement therapy 
Overt hypothyroidism is an absolute indication for replacement therapy with thyroid 
hormones. According to current recommendations, monotherapy with L-T4 is the "gold 
standard" of replacement therapy, because a single daily dose of the drug can maintain 
euthyroid state. 
To date, L-T4 is the most commonly prescribed hormonal drug. The replacement dose of L-T4 
is initially calculated as 1.6 µg per kilogram of body mass. In most cases, full replacement dose 
for women is about 100-150 µg of L-T4 daily and about 125-200 µg for men. How long it takes 
to reach full replacement doses of thyroid hormones, depends on several factors, first of all on 
the patient's age, history and severity of hypothyroidism, and presence of comorbidity and 
above all, cardiac diseases. In most cases, a full replacement dose of L-T4 can be prescribed to 
young patients immediately. Herewith, to date there is insufficient number of studies that 
could investigate the advantages and disadvantages of immediate prescribing of the full 
replacement dose of L-T4 as compared with slow titration. The results of recently published 
prospective randomized double-blind study compared the safety of the prescribing 
immediately the full replacement dose of L-T4 (1.6 µg per kg body mass) vs. the beginning 
with low-dose (25 µg daily) and gradual increase every four weeks in patients with newly 
diagnosed overt hypothyroidism without cardiac disease history [Roos A, 2005]. Safety was 
assessed by frequency of cardiac symptoms or acute cardiovascular events, and effectiveness – 
by the levels of TSH, freeT4, symptoms of hypothyroidism dynamics and quality of life. Fifty 
patients were randomized into two groups; the groups were comparable in terms of baseline 
TSH levels (61 vs. 48 mU/l), fT4 (7.2 vs. 8.2 pmol/l) and age (47 vs. 47 years). During the study 
at baseline and after 12 and 24 weeks, there were no cardiac symptoms or acute cardiovascular 
events. Hypothyroidism compensation was achieved more quickly in the group of treatment 
with full replacement dose initition, as compared with initial low-dose treatment: in 13 and 1 
patients compensation was achieved after 4 weeks, in 19 and 3 patients after 8 weeks, in 19 and 
9 patients after 12 weeks, in 20 and 14 patients over 16 weeks, in 20 and 18 patients after 20 
weeks and in 21 and 20 patients in 24 weeks respectively (p = 0.005). Nevertheless, the 
dynamics of hypothyroidism symptoms and quality of life parameters in both groups were 
rather similar. Based on these results, the authors concluded that the prescribing of a full 
replacement dose of L-T4 immediately in patients with overt hypothyroidism without cardiac 
disease anamnesis is safe and may be more convenient and cost-effective as compared with the 
beginning with low doses of L-T4. However, in clinical practice traditionally the most widely 
used is the beginning of replacement therapy with relatively low doses of L-T4, with a 
subsequent increase to a full replacement (“start slow and go low”). Exceptions are only 
pregnant women with hypothyroidism. 
As a rule, L-T4 preparations are recommended to take in the morning upon starving, 30-40 
minutes before breakfast and taking other drugs. When taken per os, about 70-80% of the 
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As a rule, L-T4 preparations are recommended to take in the morning upon starving, 30-40 
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dose gets absorbed: 20% of the drug is absorbed in the duodenum and 40% - in the upper 
part of the ileum, the remaining 40% - in the lower ileum. The peak absorption of the drug is 
reached between 30 and 60 minutes after the administration, the drug is absorbed 
completely in 90 minutes [Centanni M., 2006]. 
The adequacy of replacement therapy of hypothyroidism is estimated over 6-8 weeks after 
the beginning of a full replacement dose of L-T4 or dose adjustment. The normal TSH level 
is the main criterion of hypothyroidism compensation. If necessary to adjust (decrease or 
increase) the dose, the “step” of L-T4 is 12.5-25 µg. After reaching euthyroidism, it is 
necessary to monitor the adequacy of therapy annually. In some cases, adjustment of the 
dose may be required and, therefore, further assessment of the therapy adequacy. Thus, the 
necessity to increase doses of L-T4 may occur in the following situations: use of the drugs 
that increase L-T4 clearance (phenobarbital, carbamazepine, rifampicin, phenytoin, 
sertraline, chloroquine); use of the drugs that hinder the absorption of L-T4 in the gut 
(calcium carbonat, cholestyramine, sucralfate, aluminum hydroxide, sulphate of iron, fiber 
supplements); in conditions of increased concentrations of thyroxine-binding globulin due 
to pregnancy or estrogen administration; in malabsorption or celiac disease [Arafah B., 2000; 
Havrankova J., 1992; Singh N., 2000]. Besides, thyroxine dose adjustment may be required in 
such diseases as lactose deficiency, hypoacidic gastritis, atrophic gastritis, chronic gastritis, 
associated with Helicobacter pylori, intestinal parasitic diseases [Centanni M., 2006]. 
1.3 Factors, that influence on the quality of compensation of replacement therapy  
In general, replacement therapy with thyroid hormones is rather simple, but despite this 
fact, according to different authors, the part of patients receiving L-T4 replacement therapy 
and remains in decompensation varies from 32.5 to 62% [Diez J.J., 2002; Canaris G.J., 2000; 
Parle J., 1991]. 
Thus, in the study by Diez J.J., patients over 55 years with hypothyroidism, receiving 
replacement therapy with L-T4 were screened for TSH level. Among 385 patients, 
hypothyroidism was compensated only in 67.5%, and decompensated in 32.5%. The degree 
of compensation depended on the hypothyroidism duration, but was independent on age, 
sex, history and severity of hypothyroidism [Diez, 2002]. 
In a large-population Colorado study, which included 25 862 people, it was shown that 
among 1525 patients treated with L-T4, only 916 patients (60.1%) were compensated. 
Among 609 patients with decompensated hypothyroidism overt hypothyroidism was 
detected in 11 patients (0.7%) and subclinical hypothyroidism in 269 patients (17.6%) , in 13 
(0.9%) – overt hyperthyroidism, and in 316 patients (20.7%) subclinical hyperthyroidism 
were found [Canaris GJ, 2000]. It is remarkable, that 92% of patients visited a physician less 
than one year prior to enrollment in the study. 
In a small study, performed by Parle J. et al., among 97 patients with primary 
hypothyroidism, who received monotherapy with L-T4, 46.8% of patients were 
decompensated, of whom 26.8% (26 patients) had elevated TSH (and in 13 (50 %) - above 10 
mU/l), while in 21% (20 patients) the TSH was decreased [J. Parle, 1991]. 
So, what are the reasons for decompensation in so many patients with hypothyroidism? It is 
well known, that control of any chronic disease, including hypothyroidism, is at least partly 
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dependents on patient compliance. Compliance is a patient's adherence to the 
recommended course of treatment. According to a number of studies the main reason for 
decompensation of hypothroidism is poor compliance of patients [Hueston W., 2001; Hanna 
F., 1999]. 
The study conducted by Leese G.P. et al. has shown that among 1180 patients, receiving 
replacement therapy with L-T4, 58.5% had a decreased level of TSH, 3.5% - increased TSH, 
and only in 38% of patients the TSH level was within the normal range. In patients with 
suppressed TSH recommended dose of L-T4 was usually higher than in the group with 
normal TSH (114.2 ± 56.9 μg as compared with 100.4 ± 45.9 μg, p < 0.01). In the group with 
elevated TSH, the situation was different: in patients treated with lower doses of L-T4 the 
reason for decompensation was insufficient dose of the drug, while in patients receiving 
high dose of L-T4 (137.1 ± 58.8 µg) the decompensation was due to poor compliance [Leese 
G., 1993]. 
In clinical practice, there are some methods to improve the quality of compensation: 
patient’s education, using of registers (patients with compensated hypothyroidism are 
included in the database, and their status is evaluated annually). However, the registers’ 
formation, despite their potential economic benefits, remains difficult to be updated [Hanna 
F., 1999]. 
In the study by Cuthbertson D.J. et al. authors evaluated the compensation of 
hypothyroidism in 6205 patients, entered in the electronic register. The following 
parameters were entered into the database: etiology of hypothyroidism, levels of TSH and 
free T4 at baseline, type of the replacement therapy. The levels of TSH for patients entered in 
the register were measured every 18 months. In step of the of L-T4 dose adjustment, the 
patients were invited for a follow-up visit every 6 months. The L-T4 dose adjustment was 
made in accordance with the level of TSH: if TSH was above 4 mU/l, the daily dose was 
increased by 25 µg; if the TSH level was normal or reduced (in the range 0.03 - 0.4 mU/l), 
the dose remained unchanged, but if the TSH level was below 0.03 mU/l, the dose was 
reduced by 50 µg (with the dose of L-T4 within 225-300 µg), or 25 µg (with the dose of L-T4 
175 - 200 µg). With the dose less than 150 µg a reduction was recommended only in case of 
increased level of free T4 above 24 pmol/l. The study demonstrated, that there were 58.5% 
of patients with suppressed TSH (<0.03 mU/l) before 1991. Later the rate of patient with 
decompensation of hypothyroidism decreased markedly to 15,7 ± 3,6% in the period from 
1993 to 2001 [Cuthbertson DJ, 2006]. 
One of the reasons for decompensation of hypothyroidism could be the changing of L-T4 
preparation even in the same dose. To date, several L-T4 preparations produced by 
different manufacturers are available in the pharmaceutical market. Preparations of L-T4 
produced by different companies may be insufficiently bioequivalent. In addition, even 
drugs produced by one company but with different technologies may be not bioequivalent. 
That is why the problem of bioequivalence and interchangeability of L-T4 is recently under 
discussion.  
In addition to the above-mentioned reasons, it has been suggested, that the psychological 
state of patients can affect the quality of compensation. In particular, patients with 
depression rarely take medicines regularly and correctly [Sevinc A., 2004]. It is well known, 
that depression is diagnosed more frequently in patients with hypothyroidism than in 
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general population; herewith, it is irrespective of the quality of the disease compensation. 
Sometimes hypothyroidism can be manifested with the symptoms of depression [Lindsay 
RS, 1997, Weetman AP, 1997, Demet, 2003; Joffe RT, 1992; Rack SK, 2000]. For the first time the 
relationship between hypothyroidism and depression was mentioned more than 100 years 
ago, in 1888 [Oppenheimer J.H., 1995]. According to some studies, the prevalence of 
depression in patients with hypothyroidism may be as high as 40% [Haggerty JJ, 1995], 
which is often accompanied by psychomotor retardation and a moderate decrease in 
cognitive function [Pies RW, 1997]. Thus, Munoz-Cruzado Poce et al. while examining 108 
patients with depression, has found previously undiagnosed thyroid abnormalities in 24.1% 
of them, hypothyroidism was diagnosed in 7.4% of cases [Munoz-Crusado Poce, 2000]. In a 
similar study made by Gold MS et al., hypothyroidism was diagnosed in 20 out of 250 
patients with depression [Gold MS, 1981]. In addition, depression may often be the first sign 
of subclinical hypothyroidism. 
We have organized a study with the aim of investigating medical and social factors, 
affecting the quality of compensation in hypothyroid patients on L-T4 replacement therapy 
[Fadeyev, 2006]. The study included 200 patients with overt hypothyroidism taking L-T4 for 
a year or more. Patients were examined at the baseline and after 6 months. The symptoms of 
hypothyroidism, thyroid hormone levels and lipid profiles were analyzed. In case of 
decompensation, we were trying to clarify the main reasons thereof: accuracy and regularity 
of taking the medication and its dose; and in case of incorrect admission or taking 
inadequate doses of L-T4 we identified the main reasons for that (the doctor did not explain, 
the patient supposed the regular use of medication as unnecessary, the patient noted 
subjective changes in well-being, while taking the full replacement dose of L-T4). As a result 
only 58% (84/200) of patients were euthyroid in the beginning of the study while 26% of 
them had increased TSH level and 16% had low TSH.  
In nearly in one third of patients (24/84; 28.6%) the main reason of decompensation was 
medication incompliance (the drug was taken after a meal or less than 30 minutes before 
breakfast; dividing the dose - one part before breakfast, another one before dinner; taking L-
T4 together with calcium or iron supplements). Six months later, after the education, the 
hypothyroidism was decompensated only in 8 patients from this group (8/19, 42.1%). The 
reason for decompensation in the other 11 patients was also the incompliance in taking of 
medication or self-changing (increase or decrease) of the L-T4 dose. Only in 13 of 84 patients 
with decompensated hypothyroidism the main reason for that was the inadequate 
recommendations of a doctor. In this group, in 6 months after the dose adjustment, out of 9 
re-examined patients the hypothyroidism was compensated in 8 cases (88.9%). 
2. Сhallenges of the replacement therapy  
2.1 Dissatisfaction with monotherapy of hypothyroidism  
It is well known that in clinical practice there is a significant number of patients, who still 
complains about unspecific symptoms similar to hypothyroid despite the compensation of 
hypothyroidism and normal TSH level. The most common of them are: fatigue, muscle pain, 
impaired mood and poor memory [Wekking E., 2005]. The presence of these complaints 
affects the overall well-being and quality of life. The most interesting are results of the study 
performed in the UK by Saravanan P. et al. [Saravanan P., 2002]. The study included 961 
 
Options of Replacement Therapy in Hypothyroidism 
 
187 
patients with hypothyroidism at the age of 18 - 75 years, taking L-T4 for at least four 
months. The control group included healthy people of the same age. Patients completed two 
questionnaires: General Health Questionnaire - GHQ-12 and Thyroid symptom 
questionnaire - TSQ. All the participants were divided into three groups: general group of 
patients (n = 597), a subgroup of patients with normal TSH (n = 397) and control group (n = 
551). The study showed that the mean score under 36-point GHQ scale in patients receiving 
L-T4 was 12.1, in patients with compensated hypothyroidism - also 12.1, whereas in control 
group it was 11.4 ( p = 0,03 and 0.01 as compared to control, respectively), indicating greater 
dissatisfaction with their well-being in patients receiving L-T4. Similarly, according to the 
TSQ, in patients receiving L-T4 results were even worse than in other patients (12.6, 12.8 and 
11.5 points respectively; p <0.001). These differences remained after the assessment with 
regard to other chronic illnesses, including depression. The authors concluded that patients, 
receiving replacement therapy with L-T4, even normal TSH have lower indicators of overall 
health than in the people without hypothyroidism. 
It is still not quite clear, whether the results of these studies are specific to hypothyroidism, 
or they reflect the reducing of the overall well-being in patients with any chronic disease, 
sometimes regardless of its compensation, often from a patient's awareness of their illness 
[Ladenson P., 2002]. 
2.2 Quality of life and cognitive functioning in patients with compensated 
hypothyroidism  
The assessment of quality of life associated with health, allows us to study the effect of the 
disease and its treatment on the indictors of the patient’s quality of life. A questionnaire is 
the standard research tool in the quality of life assessment. 
In general, according to various authors, the development of hypothyroidism leads to a 
decline of the patients’ quality of life. In most cases, achieving the compensation of disease 
is accompanied by improvement of well-being of patients and, consequently, improves the 
quality of life. However, according to some authors, despite the adequate replacement 
therapy and stable achieving of normal TSH level, the number of parameters of quality of 
life of those patients (in general groupe) remains decreased compared with healhy control 
[Wekking E.M., 2005; Bianchi P., 2004]. 
This can be confirmed by the results of the study carried out by Wekking EM et al. [Wekking 
EM, 2005], where the authors assessed the neurocognitive function and quality of life in the 
patients with hypothyroidism. The study included 141 patients with compensated 
hypothyroidism aged from 18 to 70 years. The quality of life was assessed by the 
questionnaire RAND-36 (Dutch version of the questionnaire MOS SF-36). The results of the 
quality of life assessment were compared with the quality of life of a representative sample 
of the population of Denmark (n = 1063). It was shown that the levels of vitality and mental 
health by questionnaire RAND-36 were significantly lower in patients receiving L-T4, as 
compared with those in representative sample. 
We also assessed the quality of life of patients with hypothyroidism and compared it with 
the quality of life of patients with nodular euthyroid goiter and people without thyroid 
disease. Thirty patients with compensated primary hypothyroidism (aged from 25 to 55 
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years), 28 patients with nodular (multinodular) euthyroid goiter of the same age not 
receiving L-T4, and 30 healthy people were assessed (figure 3, 4). The scores for the Short-
Form 36 (SF-36) and Beck Depression Inventory Scale were analyzed. Almost all scales of 
the questionnaire SF-36 (except for general health and role emotional functioning) in 
patients with compensated hypothyroidism were significantly lower (p 0.05), than in 
healthy people. While comparing quality of life in patients with hypothyroidism with 
quality of life in patients with nodular goiter the rates of role physical functioning (p = 
0.042), vitality (p = 0.015), social functioning (p = 0.0) and psychological health (p = 0.021) of 
patients with hypothyroidism were significantly lower compared with patients with 
euthyroid goiter. In assessing the severity of depression we have shown that the value on a 
scale of depression in patients with compensated hypothyroidism was significantly higher 
compared with the results of patients with nodular goiter and healthy individuals (p = 
0.014). So, in patients with compensated hypothyroidism in almost all parameters the 
quality of life is worse than in people without thyroid disease, and on many scales (role 
physical functioning, vitality, social functioning and psychological health) is worse than in 
patients with euthyroid goiter. Severity of depression in patients with compensated 
hypothyroidism is higher compared to patients with nodular goiter and healthy people, 
which may be one of the reasons for the decrease of quality of life of these patients 





Fig. 3. Quality of life for patients with compensated hypothyroidism and with nodular goiter 
 




Fig. 4. Quality of life for patients with compensated hypothyroidism and healthy people 
2.3 Modification of L-T4 intake (evening vs. morning) 
General recommendation that L-T4 should be taken upon starving, 30-40 minutes before 
breakfast can lead to the poor compliance of the patients. On the other hand, failure to 
comply with this recommendation could result in significant worsening of the L-T4 
absorption. However, as an alternative, patients can take drugs L-T4 in the evening or at 
night, finding the optimal time for an intake. Currently, in literature there is a discussion on 
a possibility of clinically significant change in TSH levels when changing the time of taking 
of L-T4. However, to date there are insufficient data on the feasibility and effectiveness of 
changing the time of taking the L-T4 drugs. 
Elliott D.P. et al. have shown that the TSH level did not significantly change when shifting 
the time of L-T4 intake from morning (1-2 hours before breakfast) to evening hours 
(midnight) [Elliott DP., 2001]. 
2.4 Circadian rhythms of TSH and thyroid hormones  
One of the factors which should be considered while adjusting the replacement dose of 
thyroid hormones is the physiological fluctuation of TSH and thyroid hormones, which is 
based on circadian rhythm secretion thereof. Normally, the TSH secretion occurs in a 
pulsating mode, whereas frequency and amplitude of pulsation increases at night, resulting 
in the circadian changes in TSH levels. TSH level is rising after midday, reaching a 
maximum of 2 - 4 hours in the morning, followed by a "plateau" for several hours and then 
decreasing to minimum values at midday [Darzy KH, 2005, Persani L, 1995]. Thus, 
fluctuations in TSH during the day can range from 1 to 3 mU/l. Thyroid hormone levels 
during the day also varies, but far less than the TSH. Thus, the study of Lucke C. et al. has 
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shown that the level of T4 reached a maximum from 8 to 12 a.m., and reached the minimum 
values from 11 p.m. to 3 a.m. T3 level was highest from 7 a.m. to 1 p.m. and the lowest - 
from 11 p.m. to 3 a.m. Herewith, those changes in hormone levels were insignificant and did 
not exceed the normal indicators [Lucke C., 1977]. 
The clinical significance of TSH circadian variability is defined, first of all, by the diagnostics 
of thyroid dysfunction. If in a number of patients, whose level of TSH is identified in the 
early morning hours, allows to diagnose subclinical hypothyroidism, but when the test is 
made later, the TSH level in some patients falls within the reference range. Thus, in a 
prospective study, performed by Scobbo R.R. et al., in 97 out of 100 of outpatients, the level 
of TSH, identified early in the morning was approximately by 26.4% higher as compared 
with the repeated tests made later in the afternoon. Based on the second (later) TSH tests, in 
6% of patients the diagnosis of subclinical hypothyroidism was renounced [Darzy KH, 2005]. 
Similar results were obtained by in our study of 27 healthy persons at the age of 18–60 years. 
Measurements of serum TSH, fT4, fT3 were performed at 8.00–9.00 and 14.00–16.00 during 
the day and at 8.00–9.00 in 4–6 weeks. The median of TSH concentrations in the morning 
was 2.28 mU/l, at the daytime – 1.6 mU/l (р 0.05). The amplitude of TSH circadian 
variability reached 58% (Me = 21.45%). According to the current TSH reference ranges (0.4–
4.0 mU/l) all participants had an euthyroidism in the morning and at the daytime (figure 5). 
According to the proposed TSH reference ranges (0.4–2.5 mU/l) 12 participants (44.4%) in 
the morning and 4 participants (14.8%) at the daytime have been classified as having a 
hypothyroidism. TSH levels in 4–6 weeks differed from initial on 42.8–7.71% [Sviridonova 
M., 2010]. 
 
Fig. 5. Circadian variability of TSH in subjects with euthyroidism 
In addition, of course, the data on circadian rhythms of TSH secretion plays an important 
role in assessing the adequacy of replacement therapy with thyroid hormones. Herewith, if 
the patients with overt hypothyroidism lose typical to healthy people increase in amplitude 
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and frequency of TSH secretion during the night [Adriaanse R, 1992], the prescribing of 
adequate replacement therapy with thyroid hormones leads to restore of circadian rhythm 
of TSH secretion [Persani L, 1995].  
2.5 Combined therapy with T3 and T4  
2.5.1 Controlled trials comparing L-T4 and L-T4 + L-T3 
In the last decade the problem of combined therapy with L-T4+LT3 was in the centre of 
attention for many publications and some controlled randomized studies were performed. 
There are some publications where the authors, referring to their own clinical experience in 
treating of patients with hypothyroidism, are in favor of combined therapy of L-T3 + L-T4. 
For example, according to Mazzaferri E.L., some patients taking the preparations of thyroid 
gland extracts of animals (containing T3 and T4) over decades, noted the deterioration of 
well-being during switching to monotherapy with L-T4 [Mazzaferri EL, 1999]. 
First studies about comparison of two types of treatments, mono- and combined therapy 
with thyroid hormones were made in the 1970s. Thus, in 1970, Smith R.N. et al. published 
results of a double-blind crossover study. The study included 99 patients with primary 
hypothyroidism (postsurgical or after treatment with radioactive iodine), previously treated 
with L-T4 in the doses of 200-300 µg/day. All patients were randomized into 2 groups and 
within 2 months received L-T4 (200 or 300 µg) or L-T3 + L-T4 (2 or 3 tablets, respectively, 20 
µg of L-T3 and 80 µg of L-T4 in each tablet). After 2 months, the treatment mode has been 
changed: patients from group 1 received L-T3 + L-T4, and those from group 2 received L-T4. 
Among 87 patients who completed the study, 42 patients (48%) did not prefer any type of 
therapy, 29 (33%) preferred monotherapy with L-T4 and 16 (18%) - a combination of L-
T3+L-T4. During the study, a higher frequency of side effects was observed (palpitations, 
nervousness, feeling short of breath, etc.) on the combination of L-T3 + L-T4, as compared to 
monotherapy with L-T4. Authors concluded that tolerability of monotherapy with L-T4 is 
better as compared with the combination of L-T3 + L-T4, as well as the fact that L-T4 is 
effective as monotherapy and is preferable because of a longer half-life [Smith RN, 1970]. 
However, it should be noted that in this study rather large doses of thyroid hormones were 
prescribed, especially L-T3 (40-60 µg/day), which could lead to a high frequency of side 
effects. 
In a relatively small study by Bunevičius R. et al., which however, attracted a high interest, 
the authors also compared the efficacy of monotherapy and combination therapy with L-T4 
and L-T3 in patients with primary hypothyroidism. The study involved 33 patients with 
primary hypothyroidism, developed as a result of chronic autoimmune thyroiditis (16 
patients) or after thyroidectomy due to a cancer (17 patients). All the patients at the moment 
of enrollment received a replacement or suppressive therapy with L-T4. Patients were 
randomized into 2 groups: patients from group 1 received L-T4 for 5 weeks, and then a 
combination of L-T4 + L-T3 for 5 weeks (when changing the type of therapy, the L-T4 dose 
was reduced by 50 µg and supplemented with 12,5 µg of L-T3); in group 2 patients initially 
received L-T3 + L-T4, followed by L-T4. The results showed that the levels of cholesterol and 
triglycerides in both groups were similar, whereas the level of SHBG (sex hormone-binding 
globulin) was significantly higher on combined therapy. The authors noted that on the 
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combined therapy, the pulse rate at rest was slightly higher, but blood pressure and results 
of neurophysiologic tests were similar on both regimens of treatment. To assess cognitive 
function and mood 17 tests were performed. Among 17 tests the results in 16 patients of 
both groups were normal. However, in six of 16 tests they were better or patients reported a 
better mood on the combined therapy with L-T4 and L-T3, rather than with L-T4 
monotherapy. These results were confirmed by visual analogue scales. None of the 
performed tests demonstrated better results with L-T4 monotherapy versus combination 
therapy with L-T4 and L-T3. According to the results of the study, the authors concluded 
that: in patients with hypothyroidism, the use of combined therapy L-T3 and L-T4 leads to 
improved psychological and neurophysiological parameters, and the prescription of a 
combined therapy of L-T3 and L-T4 leads to a better quality of life than monotherapy with 
L-T4 [Bunevičius R., 1999]. Among disadvantages of this study that coud be mentioned, 
firstly - short treatment period (5 weeks), which is sufficient only for reaching the stable 
thyroid status after changing of the therapy [Walsh JP, 2001], but insufficient for assessment 
of the dynamics of the lipids, and secondly, the lack of adequate assessment of the 
cardiovascular system, which could help to identify possible changes in heart rate. Finally 
small number of patients was included in the study [Walsh JP, 2001]. 
Later, the results of some other similar studies were published. It should be noted, that these 
studies differed in the number of patients, monitoring duration and the ratio of L-T4 to L-T3 
in the combined regimens. The majority of studies found no benefits of combined therapy L-
T4 + L-T3, as compared with monotherapy L-T4 [Levitt A., 2002; Sawka AM, 2003; Clyde PW, 
2003; Siegmund, 2004; Rodriquez, 2005]. 
One of the most interesting studies, comparing mono- and combination therapy of 
hypothyroidism was conducted by Walsh JP et al. [Walsh J.P., 2003]. The double-blind 
controlled study with crossover design included 110 patients with compensated 
hypothyroidism receiving L-T4. The patients enrolled in the study were satisfied or 
dissatisfied with their well-being on the replacement therapy. Patients were randomized 
into 2 groups: one group continued to receive monotherapy with L-T4, and the patients of 
the second group were switched to a combined therapy with L-T4 + L-T3, while the dose of 
L-T4 was reduced by 50 µg and L-T3 dose of 10 µg was added. After 10 weeks of therapy 
and a follow-up washout period (4 weeks of monotherapy with L-T4) replacement therapy 
was adjusted: the patients from group 1 were switched to a combination of L-T4 + L-T3, 
while the patients from the second group - to L-T4 monotherapy. All patients at each stage 
of treatment have undergone psychological tests (General Health Questionnaire 28 - GHQ-
28, a visual analog scale), quality of life assessment (Short Form 36 - SF-36) and tests for 
hypothyroidism symptoms (Zulewski et al. scale, Thyroid Symptom Questionnaire - TSQ), 
which determined the level of TSH, freeT4, freeT3, SHBG, deoxypyridinoline, osteocalcin, 
alkaline phosphatase and cholesterol. The study included only women, whose average age 
was 47.7 ± 11.7 years. According to the results, during the combined therapy with L-T4 + L-
T3, the TSH level was significantly higher than that demonstrated on monotherapy with L-
T4. Increased TSH was due to inadequate replacement of L-T4 50 µg by L-T3 10 μg, and 
there was no L-T4 dose adjustment during the study. Thus, according to the authors, the 
tentative positive changes in the transition to a combination of L-T4 + L-T3 were balanced 
by high TSH [Walsh J.P., 2003]. No dynamics in the body mass and blood pressure was 
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noted during the study. It was shown that on the combined therapy L-T4 + L-T3, the score 
as per Zulewski scale and total cholesterol were significantly higher than on the L-T4 
monotherapy. However, given the significant increase in TSH during the combination 
therapy, the authors also identified a group of patients, whose TSH levels did not change. 
The analysis in this subgroup showed that on the L-T4 + L-T3 combined therapy, the level of 
freeT4 was lower than on the L-T4 monotherapy, while the total cholesterol, the sum of 
Zulewski scale scores and pulse rate were the same. Quality of life and psychological state 
of patients did not differ on those types of therapy. At the same time, indictors of anxiety 
were significantly higher in the combination therapy. 
We also conducted a study to compare two types of replacement therapy in 
hypothyroidism. We conducted a randomized controlled trial with a crossover design in 36 
premenopausal women with hypothyroidism. All patients were divided into two groups: 
Group A (n=20) was randomized to L-T4; Group B received the combined therapy first, 
followed by the monotherapy. The treatment periods lasted for 6 months. No significant 
difference between monotherapy and combined therapy was demonstrated on TSH level, 
ECG monitoring, densitometry, thyroid symptoms score. The lipid profiles were better 
during combined treatment than L-T4 alone. In the Group B during combined treatment the 
levels of cholesterol and LDL decreased, in the Group A during treatment with L-T4 alone 
the levels of cholesterol and LDL were unchanged. The levels of osteocalcin were 
unchanged, but the level of deoxypyridinoline decreased during combined treatment. 
According to other authors, there were no significant differences in total cholesterol and 
lipoproteins during monotherapy with L-T4 and the combination of L-Т4+L-Т3 [Clyde P.W., 
2003, Bunevicius R., 1999, Saravanan P., 2005]. Apparently, the registered changes in 
lipoprotein profiles can be explained by the homogeneity of the groups, i.e., in this study 36 
premenopausal women without any concomitant diseases were enrolled. Other studies, on 
the contrary, were conducted on both men and women, and the women group consisted 
both from women of reproductive age and women in peri- and postmenopause. According 
to our results, compared with L-T4 alone, replacement treatment with combination of L-
T4+L-T3 shows beneficial changes in serum lipids, but higher activation of bone resorbtion 
[Fadeyev, 2010].  
However, despite the lack of obvious advantages in influencing the psycho-emotional 
status, patients often prefer the combination compared with monotherapy L-T4 [Saravanan 
P., 2005, Escobar-Morreale H.F., 2005, Appelhof B., 2005]. According to Escobar-Morreale H.F. et 
al, of the 26 patients, 18 preferred the combination of L-T4+L-T3 [Escobar-Morreale H.F., 
2005]. A similar result was confirmed in a large study, conducted by Appelhof B. et al 
[Appelhof B., 2005]. In this study 141 patients were randomized to receive monotherapy with 
L-T4, the combination of L-T4+L-T3, ratio 10:1 and L-T4+L-T3, ratio 5:1. Studied therapy 
was preferred to usual treatment by 29,2%, 41,3% and 52,2% in the L-T4, 10:1 ratio and 5:1 
ratio groups respectively. Although patients preferred combined L-T4+L-T3 therapy to 
usual L-T4 therapy, but changes in mood, fatigue, well-being and neurocognitive functions 
could not satisfactorily explain why the primary outcome (i.e. preference of the treatment) 
was in favor of L-T4+L-T3 combination therapy. According to our results from 36 patients 
completing the study 10 preferred L-T4+L-T3 treatment (27,8 %) and 8 preferred L-T4 
treatment (22,2%). It is an interesting that 50% of the patients (18 from 36) had no preference. 
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Among the reasons why the patients chose monotherapy with L-Т4 the main ones were the 
following: absence of anxiety and irritability, quiet sleep. Besides, a strong reason for the 
patients taking 100 μg of L-Т4 (i.e. 1 pill of «L-thyroxin-100») was convenient 
administration. Patients who preferred combination of L-Т4+L-Т3 noticed, improvement of 
mood, higher working capacity, body weight reduction (in those patients who were initially 
overweight; but this difference was not significant) [Fadeyev, 2010]. 
2.5.2 Levels of thyroid hormones on the replacement monotherapy with L-T4 and 
combination of LT4+L-T3  
Several studies have shown that in patients on replacement monotherapy with L-T4 with 
normal serum levels of TSH and T3, an increased level of T4 is observed [Fish LH, 1987, 
Ross DS, 2001, Salmon D., 1982]. On the contrary the normal serum levels of T4 and TSH 
are often accompanied by lower values of T3 than in healthy people [Woeber KA, 2002]. 
Thus, the ratio of T4 to T3 is significantly higher in patients with hypothyroidism on the 
replacement monotherapy with L-T4 than in healthy controls. According to Woeber K.A., 
a higher ratio of T4 to T3 is due to the suppression of the residual T3 secretion by the 
thyroid gland and low conversion of T4 to T3 in the peripheral tissues on the exogenous 
L-T4 therapy. It has been demonstrated in earlier studies, that replacement therapy of 
hypothyroidism with L-T4 is accompanied by increased ratio of T4 to T3 in the blood 
[Pearce CJ, 1984, Rendell M., 1985, Stock JM, 1974], and this ratio grows up with increasing 
doses of L-T4. 
According to Woeber K.A., higher level of T4 and lower level of T3 during the replacement 
therapy with L-T4, as compared with healthy people is because TSH secretion is regulated 
mainly by T4. Therefore, the normal level of TSH on the monotherapy with L-T4 may be 
accompanied by the decreased level of T3. According to Woeber K.A., among 35 patients 
treated with L-T4, four patients had a reduced T3 level, and three of them had it in the lower 
limit of normal range [Woeber KA, 2002]. In addition, according to Bunevicius R. et al., in 
patients who received monotherapy with L-T4, total serum T3 was close to the lower limit of 
normal range [Bunevičius R., 1999]. Similar results were obtained by Alevizaki M. et al. in a 
large group of patients (114 healthy people and 130 patients with hypothyroidism on L-T4 
monotherapy) the serum level of T3 and T3/T4 ratio in patients on the L-T4 therapy were 
significantly lower than in the healthy group [Alevizaki M., 2002]. 
A number of studies have shown that switching of patients with hypothyroidism from L-T4 
to the combination of L-T4+L-T3 results in a reduction of FT4 levels [Bunevičius R.,1999, 
Clyde P.W., 2003], while FT3 levels increase [Clyde P.W., 2003, Levitt A., 2002] or remain 
unchanged [Bunevičius R.,1999, Walsh J.P., 2003]. This is most likely caused by the use of 
different L-T4 and L-T3 doses since there are no comprehensive recommendations for L-T4 
and L-T3 dose calculation for combined therapy. Moreover, it is not clear how the L-T4 dose 
should be reduced after the addition of L-T3. According to available publications, the 
additional prescription of 10 µg [Walsh J.P., 2003] or 12.5 µg [Bunevičius R.,1999] L-T3 is 
associated with a reduction of L-T4 by 50 µg. However, in the study of Walsh et al, it was 
reported that after replacement of 50 µg of L-T4 with 10 µg of L-T3, TSH concentrations 
increased considerably [Walsh J.P., 2003]. According to Walsh et al, the increase of TSH level 
may be caused either by a decrease of T4 level in serum, which is considered to play the 
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main role in the regulation of TSH production, or by the incorrect concept about the 
required T3:T4-ratio, which is in fact about 4:1 or even 3:1, but not 5:1 [Walsh J.P., 2003]. 
We also conducted a study to assess the level of thyroid hormones in patients with 
hypothyroidism receiving L-T4 monotherapy or combination therapy with L-T4 + L-
T3.Fifty-eight women with primary hypothyroidism receiving L-T4 were enrolled in the 
study. The patients were randomised into two groups: Group 1 (n=42) patients continued 
monotherapy with L-T4, and Group 2 (n=16) patients were switched to combined therapy 
with L-T4+L-T3 (25 µg L-T4 was replaced with 12.5 µg L-T3). The final examination was 
carried out 6 months thereafter. There was also a third group of 20 healthy women (control 
group). Under monotherapy with L-T4, serum FT4 levels were higher (p <0.05) and FT3 
lower (p<0.05) than in the control group. 
Serum FT4 under combined therapy was significantly lower than in both control and 
monotherapy groups. FT3 levels did not differ between the two groups of combined and 
monotherapy subjects; the highest FT3 levels were in the control group (figure 6). So, 
monotherapy with L-T4 in hypothyroidism is associated with non-physiologically high FT4 
and low FT3 levels; but therapy with L-T3 once a day does not simulate the normal 
production of T3 by the thyroid [Fadeyev V., 2005]. 
 
Fig. 6. Free T3 levels in patients with hypothyroidism on different replacement regimens 
and in controls (Me [25; 75]) 
2.6 Peripheral markers of thyroid hormones effects on tissues  
The level of TSH is the main indicator which helps to assess the adequacy of replacement 
therapy of hypothyroidism. However, it reflects thyroid hormones action only on 
hypothalamic-pituitary axis.  
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Herewith, the issue of peripheral markers of replacement therapy adequacy in 
hypothyroidism is discussed in literature. At the same time, in clinical practice the 
identification of essential markers of the thyroid hormones peripheral action is difficult. In 
general, according to various authors, the markers of peripheral thyroid hormone effects 
may include: the level of total cholesterol, sex hormone-binding protein (SHBG), 
angiotensin-converting enzyme and markers of bone metabolism (bone formation and bone 
resorption) [Ferretti E., 1999; Meier C., 2003]. The soluble receptors of interleukin-2 may serve 
as a marker of the action of thyroid hormones on the lymphocytes [Toft A.D., 2003].  
3. Target TSH level in L-T4 replacement therapy  
The adequacy of the replacement therapy of hypothyroidism is estimated by the TSH level. 
To date, the reference range for TSH is generally accepted as 0.4 - 4.0 mU/l. However, in 
general population in 97% of people the TSH level is less than 5 mU/l, and upon exclusion 
from the sample persons with anti-thyroid-antibodies and those with goiter or close 
relatives with thyroid pathology, only in 8% of people the TSH level is higher than 2.5-3 
mU/l [Hollowell J., 2002]. In 2003, the U.S. National Academy of Clinical Biochemistry has 
published the data that the TSH level more than 2.5 mU/l can be a predictor of 
hypothyroidism in the future. In addition, recommendations were given on a closer 
monitoring of persons with "high-normal" TSH level [Baloch Z, 2003]. 
However, to date there is insufficient evident data about advantages and disadvantages of 
maintaining “low-” or “high-normal” TSH levels on L-T4 replacement therapy. In 2006 were 
published results of a double-blind study examining the psycho-emotional state, cognitive 
function and some biochemical parameters in patients with hypothyroidism taking different 
doses of L-T4 [Walsh J.P., 2006]. The study included 56 women with hypothyroidism taking 
L-T4 and having normal TSH level at the time of enrollment. Patients took L-T4 in small, 
medium and high doses (dose was changed to 25 µg) for 8 weeks at each stage. According to 
the results, statistically significant changes were observed in the level of biochemical 
markers of thyroid hormones effects: the level of sex hormone binding globulin (SHBG), 
total cholesterol, alkaline phosphatase and deoxypyridinoline. The levels of SHBG, alkaline 
phosphatase and deoxypyridinoline with high L-T4 dose were significantly higher, and total 
cholesterol level was lower than the parameters with low-dose of L-T4. However, there was 
no statistically significant dynamics in quality of life parameters, symptoms of 
hypothyroidism and cognitive function when the dose of L-T4 was changed. The authors 
concluded that there are no clear advantages to maintain “low-normal” TSH levels in 
patients receiving L-T4 in terms of impact on psycho-emotional status and quality of life 
[Walsh J.P., 2006]. 
Thus, by now according to clinical studies there is not enough evidance to recommend 
maintenance of TSH levels in the lower range of normal values for patients with 
hypothyroidism on L-T4 replacement therapy.  
Interesting results were obtained in the study of McDermott M.T. et al. According to a 
survey conducted among members of the American Thyroid Association (ATA) and general 
practitioners, it was found that more than 40% of the ATA-members considered the target 
TSH levels on L-T4 replacement therapy should be within the range of 0.5-2.0 mU/l and for 
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elderly patients - 1.0-4.0 mU/l. GPs more often designated the target TSH levels within 0.5 - 
5.0 mU/l [McDermott M.T., 2001]. 
4. Replacement therapy of hypothyroidism in specific conditions  
4.1 Elderly patients with concomitant disorders  
The question of the beginning of replacement therapy in elderly patients especially in the 
presence of concomitant cardiac pathology should be discussed separately. It is generally 
recommended and agreed to start replacement therapy in these situations with small doses 
of L-T4 (12.5 - 25 µg) with a gradual increase to full replacement during 4 – 6 months or 
sometimes even longer. Although treatment of hypothyroidism with L-T4 could improve 
myocardial function and reduce peripheral vascular resistance, it could increase the need for 
oxygen in the myocardium. In patients with an already compromised myocardial blood 
supply due to coronary atherosclerosis, L-T4 treatment may provoke anginal symptoms. 
Patients with preexisting angina should be evaluated for obstructive coronary lesions before 
the beginning of L-T4 therapy.  
4.2 Secondary hypothyroidism  
Replacement therapy with thyroid hormones in the secondary hypothyroidism (SH) has some 
special features. First of all, as secondary hypothyroidism in adults is often associated with 
deficit of other pituitary hormones, the symptoms of thyroid hormone deficiency are 
“disguised” by deficiency of other hormones. In addition the level of TSH in SH is often 
normal at the time of diagnosis [Ferretti E.,1999, Alexopoulou, 2004], and decreases after the 
beginning of replacement therapy (in 2/3 of patients) [Carrozza V, 1999]. Corticosteroids taking 
for secondary hypocorticism also lead to reducing the TSH level. Thus, the TSH level cannot 
be a criterion for the compensation of SH. That is why generally recommended marker for its 
compensation is free T4 level which suggested to be in the upper third of the reference range 
in combination with normal level of free T3. Although the T3 level in spite of L-T4 substitution 
is often reduced. Thus, according to Alexopoulou et al, the level of free T3 is reduced in more 
than half of patients, despite normal levels of freeT4 [Alexopoulou, 2004]. 
Monotherapy with L-T4 is a preferred method of treatment in secondary hypothyroidism. 
Estimated dose, as in the situation with primary hypothyroidism, is about 1.6 µg per 
kilogram of body weight on average. However, the dose of L-T4 may differ significantly 
between patients often due to the effect of some medications. Most frequently, the L-T4 dose 
adjustment is required when patients are taking injections of growth hormone leading to 
increase of T4 to T3 deiodination in peripheral tissues finally leading to increase of L-T4 
dose. The same situation could be due to estrogens replacement therapy in women. The 
adequacy of replacement therapy with L-T4 should be assessed in 4 - 6 weeks after the 
appointment of full replacement dose. After the adjustment of adequate L-T4 dose, the level 
of thyroid hormones is also advisable to control at least once per year.  
4.3 Pregnancy 
The recommended treatment of hypothyroidism during pregnancy is with oral L-T4. 
According to Guidelines of the American thyroid association the goal of L-T4 treatment is to 
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normalize maternal serum TSH values within the trimester-specific pregnancy reference 
range (first trimester, 0,1-2,5 mIU/L; second trimester, 0,2-3,0 mIU/L; third trimester, 0,3-3,0 
mIU/L).  
Clinical studies have confirmed that the increased requirement for L-T4 occurs beginning 
from 4-6 weeks of gestation. About 50-85% of women with compensated hypothyroidism 
(receiving L-T4) need to increase the dose of L-T4 during pregnancy [Abalovich M., 2002, 
Mandel S.J., 1990, Alexander E.K., 2004]. The greater dose increase will required to the 
patients with hypothyroidism after radioablation, surgery in comparison with women with 
autoimmune thyroiditis [Kaplan M.M., 1996, Loh J.A., 2009].  
4.4 Subclinical hypothyroidism 
Whether or not subclinical hypothyroidism in adults should be treated was and still is hotly 
debated; there are strong defenders as well as strong opponents to levothyroxine treatment. 
Pregnancy or the desire to become pregnant in case of infertility are the indications for 
replacement therapy.  
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1. Introduction 
Thyroid diseases are the most common endocrinopathies. In the Czech Republic they make 
up 80 to 90% workload of the endocrine centers. Thyroid diseases requiring treatment or at 
least follow up affect at least 5% of our population, for women middle-aged and older 10 to 
15%. 
In some thyroid diseases radioiodine 131I has been used for treatment.  
Hypothyroidism arises most often in the Czech Republic on the basis of chronic 
autoimmune thyroiditis, hypothyroidism is relatively common as artificial - after surgical or 
radioiodine therapy (RAIT) of various diseases of the thyroid gland. 
2. Hyperthyroidism 
In hyperthyroidism three major treatment modalities are currently available: antithyroid 
drugs, radioiodine and surgery, each of  which presents advantages and restrictions (Surk et 
al.,1990). RAIT is considered as the most comfortable and economical approach of 
hyperthyroidism treatment caused by Graves´ disease or toxic nodular goiter. Such 
treatment is indicated in patients with/or without functional autonomy to normalize 
thyroid function, and to reduce thyroid volume (Meier et al., 2002). 
The therapeutic use of radioiodine to treat hyperthyroidism from Grave's disease was first 
reported by Saul Hertz in 1941. Hertz administered produced a I-130 - I-131 mixture as a 
therapeutic dose to the first human patient with Graves’  disease at Massachusetts General 
Hospital. This was the first successful treatment of humans with an artificially produced 
radioactive material. Gradually a series of 29 patients were treated and documented 
(http://en.wikipedia.org/wiki/Saul_Hertz#cite_note-10). The Journal of the American 
Medical Association published in May 1946 the  paper with results of  a five year follow up 
study of the 29 patients and documented the successful treatment and safety of radioactive 
iodine for the treatment of hyperthyroidism. The follow-up study firmly launched the use of 
RAIT as a standard treatment for Graves´ disease (Hertz & Roberts, 1946). 
RAIT is applied mostly in hyperthyroid adults. However, it has recently gained appreciation 
also in children (Brown, 2009). In children radioiodine treatment should be considered in 
recurrent toxic goiter and in cases of ineffective thyrostatic drugs (Cooper, 2003). RAIT of 
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Graves’ disease was introduced 70 years ago, and it is estimated that more than one million 
individuals have been treated with 131I for hyperthyroidism (Chapman, 1983). The use of 
radioactive iodine has been detailed for more than 1200 children (Rivkees et al., 1998). 
Patients as young as 1 yr of age have been treated with 131I with excellent outcomes (Rivkees 
et al.1998). Some studies have reported remission rates that exceed 95%, with very rare 
complications (Levy et al., 1988, Read et al., 2004, Rivkees et al.1998). Properly administered 
radioactive iodine remains an ideal form of treatment for Graves’ disease in the pediatric 
population and it is an effective cure for Graves’ disease which is associated with few acute 
side effects (Rivkees & Dinauer 2007). When radioiodine is used at appropriate doses, there 
is a very high cure rate without increased risks of thyroid cancer or genetic damage 
(Rivkees, 2001). Also data of Moll & Patel (Moll & Patel, 1997) from nearly 8 years 
experience with 131I therapy support consideration of RAIT  within 3 to 6 months of 
diagnosis of pediatric Graves´ disease as an effective, efficient, and probably safe alternative 
approach to the traditional antithyroid therapy of Graves´ disease in children. 
For 70 years  radioidine has been used to treat most cases of Graves´ disease and thyroid 
autonomies. The thyroid gland utilizes iodine for the synthesis of thyroid hormones. The 
cells do not differentiate between stable and radioactive iodine. If radioactive iodine is 
administered, it is trapped and then organified by thyroid follicular cells like nonradioactive 
iodine. The therapeutic effects of  131I sodium iodide are due to the emission of ionizing 
radiation from the decaying radionuclide. The therapy is based on short-range beta 
radiation from radioactive 131I. The beta particles, due to their high mean energy (190 keV, 
with typical beta-decay spectra present) have a tissue penetration of 0.6 to 2 mm (Skugor, 
2006). Radioiodine administration should be preceded by pharmacological normalization of 
fT4 and fT3 levels, beacause post-radiation thyrocyte destruction and thyroid hormone 
release can lead to hyperthyroidism exacerbation (Gurgul & Sowinski, 2011). In some cases 
it is possible to withdraw antithyroid drugs 10-14 days before radioiodine administration to 
restore appropiate iodine uptake. It is known that one of the cause of reduced 131I uptake 
and shortened effective half life is pre-treatment with antithyroid drugs (ATD), which may 
have an additional radio-protective effect. It can influence the outcome of 131I therapy (Sabri 
et al., 2001, Walter et al., 2002) with possibility a risk of treatment failure for lower delivered 
radioiodine doses to the target tissue (Dunkelmann et al., 2005). Tuttle et al. describe that 
antithyroid drug therapy has been associated with relative radioresistance and with a 
decrease in radioiodine therapy effectiveness (Tuttle et al., 1995).   A similar effect as longer 
discontinuation of ATD (10-14 days) can be obtained when ATD is discontinued 24 hours 
before 131I administration („bounce effect“) (Gurgul & Sowinski, 2011). But in severe 
hyperthyreoidism it is not possible to withdraw ATD for a long time, that is why 
discontinuation of ATD starting two or three days before 131I is now widely accepted 
(Walter et al., 2002). 2-day ATD withdrawal prior to radioiodine administration sufficiently 
increases the radioiodine uptake and does not exacerbate hyperthyroidism compared to 7-
day withdrawal in Graves´ disease patients. There is not significant diference in RAIT 
outcomes between 2-day and 7-day groups. In order to prevent serum thyroid hormone 
increase after ATD withdrawal and RAIT, a 2-day ATD withdrawal period before RAIT may 
be useful for high-risk patients such as the elderly and patients with cardiac complications 
(Kubota et al., 2006). Pretreatment with propylthiouracil but not methimazole, discontinued 
even 15 days before radioiodine administration, reduces the rate of success of 131I therapy. 
Propylthiouracil pretreatment and large goiters are related to failure of radioiodine therapy. 
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Propylthiouracil should be avoided if radioiodine is considered in the management of 
hyperthyroid patients with Graves´ disease (Santos et al., 2004). Bonnema et al. (Bonnema et 
al., 2004) have shown, in a randomized set-up, that propylthiouracil treatment before 131I 
therapy for hyperthyroid diseases approximately halves the cure rate at 1 year and that after 
classification the outcome into two categories, cured (euthyroidism or hypothyroidism) or 
not cured (recurrence), the treatment failure rate in patients with toxic nodular goiter was 
approximately 4 times as high in the propylthiouracil pretreatment group as in the group 
without propylthiouracil pretreatment, whereas the diference among patients with Graves’ 
disease was less obvious. Andrade et al. have demonstrated  that thyroid hormone levels 
stabilize or decrease after RAIT in patients with Graves’ hyperthyroidism who are not 
pretreated with ATD (Andrade et al., 1999). Andrade et al. proved that short term increase 
in thyroid hormone levels in patients with Graves’ hyperthyroidism  receiving RAIT occurs 
mainly as a result of discontinuing antithyroid drug therapy. Among patients who received 
RAIT without pretreatment, serum thyroid hormone levels did not change or decreased in 
the 30-day interval after radioiodine administration. They postulated that RAIT without 
pretreatment with ATD can be safely prescribed (Andrade et al., 1999). Burch et al. (Burch et 
al., 2001) concluded that pretreatment with ATD does not protect against worsening 
thyrotoxicosis after radioiodine, but this pretreatment provides a measure of protection by 
establishing lower baseline values should an exacerbation of thyrotoxicosis occur. The 
findings support the recommendation that most patients with Graves’ disease do not 
require antithyroid drug pretreatment before receiving radioiodine. 
In benign conditions such as Graves´ disease, division of some metabolically active cells is 
prevented by the effect of the ionizing radiation of radioiodine. Cell death is another 
mechanism activated when the cells are exposed to high levels of radiation, for example in 
autonomous adenoma, where the suppressed normal thyroid tissue is essentially spared 
with delivery of a very high concentration to the cells of the autonomous adenoma (toxic 
nodule). Cell death is followed by replacement with connective tissue, which may lead to 
hypothyroidism, depending on the number of cells destroyed and replaced by fibrous 
nonfunctioning tissue. Since 90% of the radiation effects of 131I are due to beta radiation, 
which has a short range in tissue, the extrathyroid radiation, and consequently the side 
effects, are minimal. 
The potential risk after radioiodine therapy of hyperthyroidism that is most extensively 
discussed in the literature is cancer induction  (Lacko et al., 2001, Reiners, 1997, Vlček & 
Neumann, 2002). Since the 1980s, large-scale, long-term (15–17 years) follow-up studies of 
cancer risk in patients treated with radioiodine for hyperthyroidism have been reported 
(Franklyn et al., 1999, Goldman et al., 1988, Hoffman et al., 1982, Holm et al., 1991) with 
conflicting results. The first 2 longterm studies were continuations of the Cooperative 
Thyrotoxicosis Therapy Follow-up Study (Hoffman et al., 1982, Goldman et al., 1988). 
Hoffman et al. (Hoffman et al., 1982) reported no difference between 1005 women treated 
with radioactive iodine and 2141 women treated with surgery for hyperthyroidism in 
total cancer incidence, breast cancer, or leukemia. Although based on a small number of 
cases, an elevated risk of cancer was observed in the thyroid gland and other organs that 
concentrate radioiodine (salivary glands, digestive tract, kidney, and bladder) (Hoffman 
et al., 1982). In a study of Goldman et al. (Goldman et al., 1988) the cancer incidence of 
1762 hyperthyroid women (80% treated with radioactive iodine) did not differ from that 
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of US white women. In a large population-based study of 10552 Swedish patients who 
received RAIT for hyperthyroidism, significantly elevated overall cancer incidence was 
observed compared with the Swedish population (Holm et al., 1991). Among 10-year 
survivors, significantly elevated risks were seen for cancers of the stomach, brain, and 
kidney ( Holm et al., 1991). In a population-based study of 7417 patients treated with 
radioiodine for hyperthyroidism in Birmingham (UK), the overall cancer incidence and 
mortality decreased, but the incidence and mortality of cancers of the small bowel and the 
thyroid gland were increased compared with expected rates (Franklyn et al., 1999). 
According to the American Cooperative Thyrotoxicosis Therapy Follow-up Study (Ron et 
al., 1998) RAIT of hyperthyroidism was linked to a slightly increased risk for thyroid 
cancer. Metso proved that cancer incidence, especially cancer of the stomach, kidney, and 
breast, was higher in patients treated with radioiodine for hyperthyroidism (Metso et al., 
2007).  On the other hand, a Swedish follow-up study did not reveal any increased risk of 
thyroid cancer (Holm et al., 1991). Although radioactive iodine is being used in 
progressively younger ages, it is not known if there is an age below which high-dose 131I 
therapy should be avoided. Risks of thyroid cancer after external irradiation are highest in 
children younger than 5 yr of age and progressively decline with advancing age (Boice, 
1998, 2006, Dolphin, 1968, Read et al., 2004). If there is residual thyroid tissue in young 
children after RAIT, there is a theoretical risk of thyroid cancer. It may therefore be 
prudent to avoid RAIT  in children younger than 5 years (Rivkees & Dinauer, 2007). In 
addition to thyroid cancer, potential influences of 131I therapy on other cancers need to be 
considered. Follow-up from the large cohort of the Cooperative Thyrotoxicosis Therapy 
Follow-Up Study did not find increased risks of leukemia in the 131I -treated group, as 
compared with the drug- and surgery-treated groups (Saenger et al., 1968). No increase in 
overall cancer mortality was seen in the 131I-treated patients either (Ron et al., 1998). In 
one other study, excess thyroid cancer mortality after 131I therapy for Graves’ disease was 
observed during early, but not late, follow-up (Hall et al., 1992a). Yet this was related to 
increased cancer surveillance and detection, not 131I effects (Hall et al., 1992a). Edmonds 
and Smith (Edmonds & Smith, 1986) reported a small but significant excess of incidence 
and mortality of leukemia in 258 patients treated with high-activity radioiodine for 
thyroid cancer (2960 MBq to 5550 MBq). However, no increased risk for malignancies of 
the hematopoietic system was found in the study of Metso et al. (Metso et al., 2007), which 
is in the agreement with earlier studies on patients treated with radioactive iodine (370 
MBq to 555 MBq) for hyperthyroidism (Franklyn et al., 1999, Hall et al., 1992b, Hoffman et 
al., 1982, Holm et al., 1991). No increase in the risk of thyroid malignancies has been 
observed in patients treated with radioiodine for hyperthyroidism in most of the 
published long-term follow-up studies (Augusti et al., 2000, Goldman et al., 1988, Holm et 
al., 1991). 
Several factors affect the therapeutic activity  to be administered to patients suffering from 
hyperthyroidism including factors related to gland itself, particularly its size, the level of 
radioiodine uptake, the rate of iodine turnover in the gland (measured by the effective half-
life), scintigraphic findings of uniform or nonuniform uptake, and whether nodules are 
present. The dose (in Gray) is dependent on how the nuclear medicine physician defines the 
goals of therapy. If the control of hyperthyroidism is the most important consideration, the 
total activity (in megabecquerels - MBq) or the dose per gram of estimated thyroid tissue 
 
Hypothyroidism and Radioiodine Therapy 
 
207 
weight will be higher than when the physician is trying to avoid or delay hypothyroidism. 
In our department we use individually calculated therapeutic radioiodine activity (in MBq) 
using Marinelli´s formula (Marinelli et al., 1948): 
Absorbed Dose * VolumeActivity = K *
Max. Uptake (%) * eff. Half - life
 
K = 24,94; absorbed dose in Gray-Gy; volume of target thyroid tissue in ml or weight in g;  
effective half time in days 
We calculate it from a formula referring to thyroid volume, radioiodine uptake and its half-
life time. But it is difficult to determine the radioiodine sensitivity of thyroid tissue which 
depends on the structure of normal sized thyroid or goiter and is individually variable. This 
parameter cannot be estimated and that is why it is difficult to predict the effectiveness of 
RAIT. While waiting for the effects of the RAIT, thyroid function should be controlled 
regularly. If hyperthyreoidism is still present 4-6 months after 131I administration, the 
therapy can be repeated. However, in some patients the therapeutic effects can be observed 
up to 12 months later (Cooper, 2003, Gurgul & Sowinski, 2011, Nygaard et al., 1999b). In our 
opinion calculated radioiodine activity is advantageous and we prefer it in RAIT, but some 
authors prefer fixed activities (Leslie et al., 2003). 
2.1 Graves´ disease 
Thyroid scintigraphy shows uniform uptake throughout thyroid gland (Fig. 1) or varying 
degrees of nonuniform uptake. 
This nonuniformity is related predominantly to different stages of involution of the disease 
with variable amounts of fibrosis based on the duration of the disease.  Infiltration of 
extraocular muscles by an inflammatory reaction consisting predominantly of lymphocytes 
is the main pathological feature of ophtalmopathy. These lymphocytes are sensitized to 
antigens common to the orbital muscles and thyroid gland. 
Indications for RAIT include recurrent hyperthyroidism after thyrostatic treatment or 
thyroidectomy. It is also recommended in patients with concomitant severe diseases 
(Gurgul & Sowinski, 2011). The first activity of 131I is sufficient in 70% of patients with 
Graves´ disease (Cooper, 2003). The rest requires repeated RAIT.  
Absolute contraindications to 131I therapy is pregnancy and breastfeeding (Sisson et al., 
2011). 
Although there is general consensus that radioiodine is a safe and effective treatment for 
Graves’ hyperthyroidism, debate remains in terms of the optimal method for calculating the 
activity (in MBq) and even what the criteria should be for defining optimal. Sustained 
euthyroidism would clearly be the most desirable outcome, but this appears to be a futile 
objective, because high rates of cumulative hypothyroidism are reported in most series. 
Findings of Leslie et al. (Leslie et al., 2003) confirm this result, with the vast majority 
developing permanent hypothyroidism and very few with euthyroidism. Therefore, the 
objective of eradicating hyperthyroidism at the lowest effective radioiodine dose may well 
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be the preferred strategy. This has led some groups to suggest a larger initial radioiodine 
dose (in Gy) and activity (in MBq) to minimize the need for retreatment and the morbidity 
and medical costs associated with ineffective primary treatment. Alternatively, others favor 
a low activity approach (185 MBq), at least for those with mild disease and without 
complications (Nordyke & Gilbert, 1991). Allahabadia et al. (Allahabadia et al., 2001), who 
use fixed therapetic activity reported these results: patients given a single activity of 370 
MBq had a higher cure rate than those given 185 MBq, but an increase in hypothyroidism 
incidence at 1 year. There was no difference in cure rate between the groups with Graves’ 
disease and those with toxic nodular goiter, but Graves’ patients had a higher incidence of 
hypothyroidism. Males had a lower cure rate than females, whereas younger patients (<40 
years) had a lower cure rate than patients over 40 years old (Allahabadia et al., 2001). 
 
Fig. 1. Thyroid scintigraphy – diffuse goiter in Graves´ disease 
2.2 Toxic nodular goiter (Plummer´s disease) 
It means hyperthyroidism in glands with both single and multiple toxic nodules. The toxic 
nodular goiter contains nodules that are not hyperactive. 
Therapy of Graves´ disease and toxic nodular goiter can be conservative with drugs, 
surgical and by radioiodine. Surgery is connected with higher risk, RAIT is indicated most 
often. RAIT in the world today is the most common and the least expensive therapy. It is 
indicated mainly for failure of conservative treatment, also in the organ complications, 
especially circulation (atrial fibrillation, circulatory failure), or where the operation is 
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contraindicated for other reasons. In toxic nodular goiter radioiodine is used mostly in 
recurrent goiter. This therapy reduces thyroid volume by approximately 40%. The efficiency 
of RAIT is estimated at 70% (Nygaard et al., 1999b). 
Late complication after radioiodine therapy is the development of transient or permanent 
hypothyroidism. The early transient hypothyroidism is that which arose within six months 
of treatment with radioiodine. It is a block of hormonogenesis after radioiodine. It is caused 
by an immunological mechanism. 
As the early permanent hypothyroidism we consider a steady increase of TSH levels within 
1 year after therapeutic application of radioiodine. In the permanent hypothyroidism the 
failure of hormonogenesis is involved in addition to immunological processes, damage of 
the follicular cell nuclei, which leads to accelerated aging and cell death. Hypothyroidism 
develops after radioiodine therapy like postoperatively in patients with hyperthyroidism. 
Hypothyroidism after RAIT gradually increases with time, several years after this therapy. It 
is detected at several tens of percent of such treated patients. Hypothyroidism develops in 
10-30% of patients treated with radioiodine, especially due to Graves´ disease (Cooper, 
2003). However, it cannot be considered as a side-effect of such therapy. Hypothyroidism 
ocurrence is estimated at 1-2% per year (Cooper, 2003). Despite the numerous attempts to 
design dosage schedules aiming at euthyroidism, hypothyroidism occurs in the majority of 
patients throughout life (Pauwels et al., 2000). 
Hypothyroidism occurs at a linear rate on a permanent basis (Staffurth, 1987, Taylor et al., 
1984). Besides permanent hypothyroidism, transient hypothyroidism may be seen in 
patients 2-5 months (or in the first year) after RAIT with spontaneous recovery in the 
following months (Connell et al., 1983,  Dorfman et al., 1977). 
 131I activities are typically calculated to deliver the desired amount of radiation based on 
gland size and radioactive iodine uptake (Quimby et al., 1970). Some centers administer to 
all patients the same fixed activity of 131I with excellent outcome (Nebesio et al., 2002). When 
children are treated with the dose more than 200–250 Gy/g, hypothyroidism is achieved in 
nearly 95% of patients (Rivkees & Cornelius, 2003). But in our opinion these doses per gram 
are too high. Gland size also influences treatment outcome, as higher doses of 131I are 
needed to induce hypothyroidism when large glands are present (up to 60 g) (Rivkees & 
Cornelius, 2003). When thyroid size exceeds 80 g, remission rates after 131I therapy are poor 
(Peters et al., 1996). Thus, surgery is preferred when thyroid gland size is large (>60–80 g). 
Hamburger reported the largest series of pediatric patients with Graves´ disease in which 
131I therapy resulted in relatively uncomplicated clinical courses, except for hypothyroidism 
requiring lifelong thyroid hormone replacement in 89% (Hamburger, 1985). 
Several studies have attempted to determine the optimal activity of radioiodine for curing 
hyperthyroidism, while avoiding the development of permanent hypothyroidism.  
Regimens used have included low activity 80 MBq (Franklyn et al., 1991, Lowdell et al., 
1985, Nordyke & Gilbert 1991), various fixed activity (185, 370, and 555 MBq) (Franklyn et 
al., 1991, Jarlov et al., 1995, Nordyke & Gilbert, 1991, Watson et al., 1988), and activities 
calculated on the basis of thyroid size, the uptake of radioiodine, or the turnover of 
radioiodine (Franklyn et al., 1991,  Jarlov et al., 1995, Sridama et al., 1984). Most dosimetric 
methods have the benefit of including a measure of thyroid size in their formulas, thereby 
administering a dose of radioiodine proportional to size of the gland and theoretically 
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be the preferred strategy. This has led some groups to suggest a larger initial radioiodine 
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Fig. 1. Thyroid scintigraphy – diffuse goiter in Graves´ disease 
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increasing the probability of cure, because this has been considered to be an important 
prognostic factor for success after RAIT. In addition, the use of isotope uptake 
measurements, as part of the activity calculation protocol, can confirm the absence of 
thyroiditis and identify patients with values at the extreme ends of the reference range of 
isotope uptake or turnover, which may predict failure of RAIT (Kaplan et al., 1998). Despite 
these potential benefits of calculated acitivities, several studies have failed to demonstrate 
improvements in cure rate over fixed activities (Catargi et al., 1999, Jarlov et al., 1995, Peters 
et al., 1995). Furthermore, there is little evidence that using a calculated activity has any 
advantage over a fixed-activity regimen, in terms of preventing hypothyroidism (Turner et 
al., 1985, Sridama et al., 1984), so many centers and clinicians prefer the use of a fixed-
activity regimen (Hedley et al., 1992, Franklyn, 1994). 
Although low fixed activities (185 MBq) are associated with a reduced early incidence of 
hypothyroidism, they often result in unacceptably low cure rates. Moreover, the 
development of long-term hypothyroidism seems to be inevitable, irrespective of the 
amount of radioiodine administered, with an annual incidence of 2–3% many years after 
therapy (Franklyn et al., 1991, Hennemann et al., 1986). Some clinicians now prefer to give a 
large ablative activity (555 MBq and upwards), which results in early hypothyroidism, so 
that the need for long-term follow-up of thyroid function in euthyroid patients is obviated. 
2.3 Endocrine orbitopathy 
Very advanced endocrine orbitopathy has a significant symptomatology. Therapy of 
endocrine orbitopathy complicated thyreotoxicosis is done with the cooperation with 
ocularist. RAIT may increase the inflammatory process and exacerbate the ophtalmological 
symptoms. This is due to radiation thyroiditis, which releases thyroid antigens and 
stimulates antithyroid antibody production. Therefore, in these patients, high doses of 131I 
are recommended to assure complete thyroid tissue destruction, especially when high 
thyroid stimulating hormone receptor antibody (TRAb) levels are observed. The elimination 
of thyroid antigens and lymphocytes infiltration may reduce the autoimmunological process 
that is responsible for hyperthyroidism and endocrine orbitopathy (Gurgul & Sowinski, 
2011). After calming of thyrotoxicosis we must think of definitive therapy - thyroidectomy 
followed by ablative radioiodine therapy. Of course then the patient is without the thyroid 
gland, with rapid development of hypothyroidism. The hormonal replacement therapy is 
necessary. 
2.4 Thyroid autonomies 
Autonomously functioning thyroid tissue is characterized by the ability to function without 
TSH. Neither the antibodies nor TSH is involved. The group of follicular cells just continues 
autonomously to produce excess amount of thyroid hormones. For clinical diagnosis, 
radioiodine or 99mTc-pertechnetate imaging of the thyroid gland is performed. Normally the 
scan would show increased radionuclide uptake by the autonomous thyroid area (with or 
without nodule) compared with surrounding normal thyroid tissue. Histological 
examinations of tissue corresponding to scintigraphically autonomous areas show different 
architectural patterns and histological features of follicular cells compared with normal 
quiescent tissue (Kraft, 2006). 
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The main cause of functional autonomies of the thyroid is iodine deficiency. A higher 
prevalence of functional autonomies in thyroid tissue have been described in areas with an 
endemic iodine deficiency (Belfore et al., 1983, Guglmann et al., 1995), the prevalence in 
countries replete with iodine is below (Hamburger, 1980). 
The main pathologic attribute of thyroid functional autonomies is the loss of regulation in 
the axis of hypothalamus-hypophysis-thyroid. 
The histopathology of goiter varies with etiology and age of the goiter. Initially, uniform 
follicular epithelial hyperplasia (diffuse goiter) is present with an increase in thyroid mass. 
As the disorder persists, the thyroid architecture loses uniformity, with the development of 
areas of involution and fibrosis interspersed with areas of focal hyperplasia. This process 
results in multiple nodules. On scintigraphy, some nodules are “hot,” with a high 
radionuclide uptake (in the end autonomous), or “cold,” with a low radionuclide uptake, 
compared with the normal thyroid tissue. The development of nodules correlates with the 
progression of functional autonomy and a reduction in TSH levels. Clinically, the natural 
history of a nontoxic goiter is growth, nodule production, and functional autonomy, 
resulting in thyrotoxicosis in a minority of patients (Lee & Ananthakrishnan 
http://www.emedicine.com/med/TOPIC919). 
Functional autonomous tissue can present as an autonomous adenoma with nodule (Fig. 2),  
multifocal functional autonomy in multinodular goiter (MFA) (Fig. 3), or unifocal functional 
autonomy in thyroid glands without nodules (UFA) or diffuse functional autonomy (DFA). 
 
Fig. 2. Thyroid scintigraphy - autonomous adenoma before (on the left) and after (on the 
right) successful RAIT 
Thyroid adenomas (and most nodules in goiters), even if morphologically heterogenous, are 
true benign tumors (Studer & Derwahl, 1995). 
For the diagnostics of thyroid fuctional autonomy and the evaluation of the radioiodine 
therapeutic effect of functional autonomies, a thyroid scintigraphy is the basic and necessary 
procedure. Decisions concerning the definitive treatment of thyroid autonomy should take 
into account previous episodes of hyperthyroidism, objective parameters of risk 
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increasing the probability of cure, because this has been considered to be an important 
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symptoms. This is due to radiation thyroiditis, which releases thyroid antigens and 
stimulates antithyroid antibody production. Therefore, in these patients, high doses of 131I 
are recommended to assure complete thyroid tissue destruction, especially when high 
thyroid stimulating hormone receptor antibody (TRAb) levels are observed. The elimination 
of thyroid antigens and lymphocytes infiltration may reduce the autoimmunological process 
that is responsible for hyperthyroidism and endocrine orbitopathy (Gurgul & Sowinski, 
2011). After calming of thyrotoxicosis we must think of definitive therapy - thyroidectomy 
followed by ablative radioiodine therapy. Of course then the patient is without the thyroid 
gland, with rapid development of hypothyroidism. The hormonal replacement therapy is 
necessary. 
2.4 Thyroid autonomies 
Autonomously functioning thyroid tissue is characterized by the ability to function without 
TSH. Neither the antibodies nor TSH is involved. The group of follicular cells just continues 
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without nodule) compared with surrounding normal thyroid tissue. Histological 
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architectural patterns and histological features of follicular cells compared with normal 
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stratification in euthyroid patients, concomitant diseases, and the probability of future 
iodine exposure. 
 
Fig. 3. Thyroid scintigraphy - multifocal functional autonomy in multinodular goiter before 
(on the left) and after (on the right) successful RAIT 
Autonomous adenoma in single thyroid nodule or unifocal or multifocal thyroid 
autonomies can secrete sufficient thyroid hormones to cause hyperthyroidism.  In 
autonomous adenoma palpable nodule can suppress paranodular tissue (decompensated 
adenoma) with suppressed TSH with normal or higher fT3 and/or fT4 or the function of the 
surrounding tissue  is preserved (compensated adenoma). Initial thyreosuppressive 
conservative therapy cannot have  permanent effect and we cannot expect remission and it 
should be treated with radioiodine or operate. 
Patients with autonomy who develop hyperthyroidism spontaneously or after iodine excess 
carry a high risk of recurrence, ranging from 55% up to 81% (Voth et al., 1990). There is 
general agreement that if hyperthyroidism occurs or has occurred in autonomy, definitive 
treatment is indicated. RAIT is indicated in patients with functionally relevant autonomy to 
normalize thyroid function, to remove functional autonomy, and to reduce thyroid volume 
(Meier et al., 2002). 
Radioiodine treatment should be preferred over surgery in patients with smaller goiters 
(volume <100 ml), the absence of cold nodules or cysts, or the lack of suspicion for 
malignancy, as well as in those who have undergone previous surgery or would be at 
increased risk from a surgical intervention. On the other hand, surgery should be preferred 
in all patients who do not meet these criteria, as well as in the presence of compression 
symptoms and when there is a need for an immediate therapeutic effect. The risk of relapse 
on medical treatment with ATD alone is very high, exceeding 80% and long-term 
antithyroid treatment is not safe in elderly patients, mainly because of poor compliance or a 
dose reduction by inexperienced physicians. Ablative treatment should be preferred in 
patients with overt hyperthyroidism owing to functional autonomy. RAIT represents the 
most comfortable and economic approach (cost of radioiodine and short hospitalization is 
lower than surgery or long-term conservative therapy). The aim of RAIT in autonomy is the 
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destruction of autonomous tissue with restoration of euthyroidism. Some groups have 
successfully used standard activities without any activity calculation. We advocate 
individual pretherapeutic dosimetry to determine the activity necessary to achieve a 
targeted radiation dose in autonomously functioning tissue. If the elimination of 
hyperthyroidism in patients with autonomy is achieved, RAIT can be considered successful. 
The normalization of serum TSH has been proposed as a criterion in the evaluation of a 
post-therapeutic outcome. Serum TSH >0,5 mU/l excludes autonomous thyroid function 
with a probability of 88% in an iodine deficiency area (Becker et al., 1992). Therefore, the 
normalization of this parameter following radionuclide treatment usually indicates a 
favorable result. Long-term suppressed serum TSH after 131I, on the other hand, has a low 
predictive potential, as it is often decreased for a prolonged period, despite therapeutic 
success (Seeger et al., 1995). 
In our great group of 868 patients with unifocal and multifocal functional autonomy, and 
disseminated functional autonomy who received at least one treatment of radioiodine side-
effects were minimal. Postradiation hypothyroidism was diagnosed in 38 patients (4,4%). 
Such a low incidence of hypothyroidism can be influenced by these factors: 1. A very low 
number of patients had previous treatment with methimazole, which is associated with a 
faster progression toward hypothyroidism (Ceccarelli et al., 2005); 2. Before 131I therapy in 
patients with functional autonomy, the degree of nonautonomous thyroid tissue 
suppression was high, and this tissue was not influenced by radioiodine beta rays 
(radioiodine is absorbed only in autonomous nodule or tissue, therefore it destroys only this 
area and does not damage the remaining thyroid tissue); 3. follow-up of our patients was 2 
years long, and certainly later, the number of hypothyroid patients can (but maybe not) 
increase (Ceccarelli et al., 2005). In the literature, the incidence of hypothyrodism after RAIT  
for functional autonomy of the thyroid is described in 10%–20% cases (Reiners & Schneider, 
2002) and even in 60% (Ceccarelli et al., 2005). 4. pretherapeutic dosimetry with a treatment by 
means of individually calculated 131I  activity  (Kraft & Stepien, 2007). Generally, in thyroid 
autonomies, focused radioiodine absorption only or almost only in autonomous areas results 
in selective destruction of these areas. Low TSH levels decreases radioiodine uptake in 
surrounding tissue, which additionally protects healthy thyroidal tissue. Therefore, the 
effectiveness of RAIT in thyroid autonomies is very high and the risk of hypothyroidism is low 
(Gurgul & Sowinski, 2011). This is in contrast to the situation for example in RAIT of Graves´ 
disease and toxic nodular goiter. Non-suppressed serum TSH before 131I therapy has been 
mentioned as a risk factor for development of hypothyroidism (Farrari et al., 1996). Nygaard 
(Nygaard et al., 1999a) had a cure-rate of 75% within 3 months when treating autonomous 
solitary thyroid nodules with 131I  in 62 patients. The thyroid volume was reduced by 35% 
within 3 months and 45% after 2 years. Side effects  were few and consist of hypothyroidism in 
8% with a median follow-up of 5 years (Nygaard et al., 1999a). 
3. Euthyroid goiter 
Small eufunctional goiter usually does not carry any trouble. The growth of goiter gradually 
creates local problems and in advanced stages we can objectively find the compression of 
the trachea and esophagus, abnormal innervation of the larynx, possibly obturation of the 
upper aperture. On scintigraphy the diffuse goiter accumulates homogeneously, in nodular 
goiter some areas accumulate with reduced and often with increased activity (Fig.4). 
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stratification in euthyroid patients, concomitant diseases, and the probability of future 
iodine exposure. 
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Fig. 4. Thyroid scintigraphy – nodular goiter with normal function and mechanical 
syndrome 
Goiter with mechanical syndrome is a disease that has to be solved urgently and radically 
(Fig.5). In the first place surgery comes. If thyroidectomy is contraindicated, the use of RAIT 
is appropriate.  
 
Fig. 5. Thyroid scintigraphy – retrostrernal goiter after thyroidectomy with mechanical 
syndrome 
After this treatment, postradiation hypothyroidism is a common finding with need to use 
replacement therapy of thyroid hormones. 
4. Differentiated Thyroid Cancers (DTC) 
Radioiodine is the mainstay of therapy for residual, recurrent, and metastatic thyroid cancer 
that takes up iodine and cannot be resected. About 90% or more of thyroid carcinomas are 
well differentiated (papillary or follicular types), which take up iodine and accordingly can 
be successfully treated with 131I. The therapeutic effects on differentiated thyroid cancer is 
based on destruction of cells by high dose of administered radioiodine. RAIT is defined as 
the systemic administration of 131I - sodium or potassium iodide for selective irradiation of 
thyroid remnants, microscopic DTC or other nonresectable or incompletely resectable DTC, 
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or both purposes. Based on the primary goal of the RAIT, there are two main forms of the 
procedure (Luster et al., 2008). The first form, radioiodine ablation, is a post-surgical 
adjuvant modality. It seeks to eliminate thyroid remnants to increase the sensitivity and 
specificity of follow-up testing for DTC persistence or recurrence, namely, of assays of 
serum thyroglobulin (Tg) as a tumour marker and of diagnostic whole-body scintigraphy 
(dxWBS) (Fig. 6). Ablation also allows sensitive “post-therapy” whole-body scintigraphy 
(rxWBS) (Fig. 7) that may detect previously occult metastases (Dietlein et al., 2007) and 
serves to treat any microscopic tumour deposits. 
Ablation, therefore, may reduce long-term morbidity and possibly, mortality (Dietlein et al., 
2007, Sawka et al., 2004, Pacini et al., 2005). Ablation success is evaluated 6–12 months after 
the ablation procedure. The second form of RAIT, radioiodine treatment of nonresectable or 
incompletely resectable lesions, e.g. microscopic disease, macroscopic local tumour or 
lymph node or distant metastases, is performed as curative or paliative therapy either as a 
component of primary treatment of DTC or to address persistent or recurrent disease 
(Luster et al., 2008). Radioiodine ablation after total or near-total thyroidectomy is a 
standard procedure in patients with DTC. When radioiodine uptake is scintigraphically 
proven before or after RAIT, then RAIT of nonresectable or incompletely resectable tumour, 
e.g. local recurrences, lymph node metastases or disseminated iodineavid lung metastases 
or other distant lesions, has shown to be effective in eradicating disease, slowing disease 
progression or providing symptomatic relief (Durante et al., 2006). Decision on whether or 
not to give RAIT with the intention of cure or palliation should be individualised to the 
patient and should consider several factors, among others also the patient health status — 
inability to tolerate surgery or other potential therapeutic interventions, e.g. chemotherapy. 
  
Fig. 6. Diagnostic whole-body scintigraphy - normal finding  
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Fig. 5. Thyroid scintigraphy – retrostrernal goiter after thyroidectomy with mechanical 
syndrome 
After this treatment, postradiation hypothyroidism is a common finding with need to use 
replacement therapy of thyroid hormones. 
4. Differentiated Thyroid Cancers (DTC) 
Radioiodine is the mainstay of therapy for residual, recurrent, and metastatic thyroid cancer 
that takes up iodine and cannot be resected. About 90% or more of thyroid carcinomas are 
well differentiated (papillary or follicular types), which take up iodine and accordingly can 
be successfully treated with 131I. The therapeutic effects on differentiated thyroid cancer is 
based on destruction of cells by high dose of administered radioiodine. RAIT is defined as 
the systemic administration of 131I - sodium or potassium iodide for selective irradiation of 
thyroid remnants, microscopic DTC or other nonresectable or incompletely resectable DTC, 
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or both purposes. Based on the primary goal of the RAIT, there are two main forms of the 
procedure (Luster et al., 2008). The first form, radioiodine ablation, is a post-surgical 
adjuvant modality. It seeks to eliminate thyroid remnants to increase the sensitivity and 
specificity of follow-up testing for DTC persistence or recurrence, namely, of assays of 
serum thyroglobulin (Tg) as a tumour marker and of diagnostic whole-body scintigraphy 
(dxWBS) (Fig. 6). Ablation also allows sensitive “post-therapy” whole-body scintigraphy 
(rxWBS) (Fig. 7) that may detect previously occult metastases (Dietlein et al., 2007) and 
serves to treat any microscopic tumour deposits. 
Ablation, therefore, may reduce long-term morbidity and possibly, mortality (Dietlein et al., 
2007, Sawka et al., 2004, Pacini et al., 2005). Ablation success is evaluated 6–12 months after 
the ablation procedure. The second form of RAIT, radioiodine treatment of nonresectable or 
incompletely resectable lesions, e.g. microscopic disease, macroscopic local tumour or 
lymph node or distant metastases, is performed as curative or paliative therapy either as a 
component of primary treatment of DTC or to address persistent or recurrent disease 
(Luster et al., 2008). Radioiodine ablation after total or near-total thyroidectomy is a 
standard procedure in patients with DTC. When radioiodine uptake is scintigraphically 
proven before or after RAIT, then RAIT of nonresectable or incompletely resectable tumour, 
e.g. local recurrences, lymph node metastases or disseminated iodineavid lung metastases 
or other distant lesions, has shown to be effective in eradicating disease, slowing disease 
progression or providing symptomatic relief (Durante et al., 2006). Decision on whether or 
not to give RAIT with the intention of cure or palliation should be individualised to the 
patient and should consider several factors, among others also the patient health status — 
inability to tolerate surgery or other potential therapeutic interventions, e.g. chemotherapy. 
  
Fig. 6. Diagnostic whole-body scintigraphy - normal finding  
 




Fig. 7. Post-therapy whole-body scintigraphy. Multiple lung metastases which accumulate 
radioiodine  
It can make RAIT the preferred or the only therapeutic option; conversely, where use of 
recombinant human thyroid-stimulating hormone (rhTSH) is not economically feasible, 
inability to tolerate hypothyroidism could rule out RAIT. 
Absolute contraindications of RAIT is pregnancy and  breastfeeding (as in RAIT in 
hyperthyroidism). 
The effectiveness of RAIT depends on the patient’s serum TSH level being sufficiently 
elevated. A TSH level of ≥30 mU/l is believed to increase sodium iodine symporter (NIS) 
expression and thereby to optimise radioiodine uptake (Cooper et al., 2006). Such TSH 
elevation can be reached by waiting at least 3 weeks after thyroidectomy or 4–5 weeks after 
discontinuing treatment with levothyroxine (T4). Triiodothyronine (T3) may be substituted 
for T4 until 2 weeks before RAIT in an attempt to decrease the duration of hypothyroidism. 
When thyroid hormone is withheld, it should be initiated or resumed 2 days after 
radioiodine administration. Traditional thyroid hormone withdrawal  has the major 
drawback of causing weeks to months of hypothyroid symptoms in most patients (Duntas & 
Biondi, 2007, Luster et al., 2005, Dow et al., 1997, Schroeder et al., 2006). Such physical and 
psychological morbidity may include fatigue, depression, impaired ability to concentrate, 
sleep disturbance, weight gain, constipation, dry skin, hoarseness, puffy face or hands, 
cardiovascular abnormalities, impaired renal function and exacerbation of dyslipidemia 
(Billewicz et al., 1969, Botella-Carretero et al., 2003, 2004, 2005, 2006, Luster et al., 2005, 
Tagay et al., 2005). These manifestations in turn frequently significantly decrease patient 
quality of life, cause absenteeism from or impaired performance in work or study or lead to 
debilitating or even life-threatening worsening in psychological, cardiovascular, renal or 
other concomitant conditions (Borget et al., 2007, Dow et al., 1997, Duntas & Biondi, 2007, 
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Haugen et al., 1999, Ladenson et al., 1997,  Leclere et al., 2000, Luster et al., 2005, Nijhuis et 
al., 1999, Schroeder et al., 2006). 
An alternative to thyroid hormones withdrawal for attaining TSH elevation is rhTSH 
administration. In Europe and elsewhere, this drug has been approved for use in adults as 
preparation for serum Tg testing, dxWBS or both or for radioiodine ablation (Luster, 2006). 
Radiosensitivity of thyroid gland is relatively high. For destruction and ablation of normal 
thyroid gland is needed higher activity than for destruction of tumor tissue. 
 Because of the larger dose of radioiodine and the lower uptake by the tissue in thyroid 
cancer, more side effects can be seen, particularly transient sialoadenitis, than in the therapy 
of hyperthyroidism. The mortality of patients treated with less than total thyroidectomy and 
limited 131I treatment was found to be three to four times higher than that of patients treated 
with total thyroidectomy and RAIT to ablate known foci of radioiodine uptake. 
Thyroglobulin is the major tumour marker for thyroid cancer of the follicular epithelium. It 
is not only specific for tumour tissue but is also specific component of normal thyroid tissue. 
Since thyroglobulin is produced exclusively by thyroid tissue, only very small amounts can 
be found in the blood after thyroidectomy and ablative radioiodine therapy. Any post-
therapeutic elevation of its levels indicates either remnant of thyroid tissue, requiring 
further ablative therapy, or the presence of metastases or local recurrence. Following total or 
near-total thyroidectomy, TSH elevation reaches a maximum in 4-6 weeks. In the follow-up 
care, patients are maintained on suppressive doses of thyroid hormone. The goals of follow-
up after initial therapy are to maintain adequate levothyroxine (T4) therapy and to detect 
persistent or recurrent thyroid carcinoma. All patients with thyroid cancer must be treated 
with thyroid hormone after thyroidectomy for correction of surgically induced 
hypothyroidism and to suppress stimulated growth of persistent or recurrent thyroid cancer 
by reducing TSH levels. Thus thyroid hormone therapy ensures „replacement“ therapy, 
which corrects hypothyroidism, and „suppressive“ therapy, which inhibits TSH secretion. 
Thyroid cell proliferation and differentiation is mainly TSH dependent. Therefore TSH 
secretion must be inhibited by thyroid hormone therapy in all patients with differentiated 
thyroid cancers. Thyroid hormone is a basic principle that is included in the guidelines of 
thyroid cancer therapy. Before administration of radioiodine, thyroid homone therapy has 
to be interrupted for diagnosis or treatment. Radioiodine uptake, thyroglobulin synthesis 
and its secretion by thyroid cancer cells will be stimulated by increased TSH. Neoplastic as 
wel as normal thyroid cell differentiation depends on TSH. Accordingly, metastases take up 
radioiodine only if the patient is hypothyroid with high serum TSH levels, while no uptake 
is seen when the patient is on hormone suppressive therapy with low or undetectable serum 
TSH concentrations. Serum TSH level should be taken into account when interpreting the 
serum thyroglobulin value as the presence or absence neoplastic disease. In most patients 
with persistent or recurrent neoplastic disease, thyroglobulin concentration will increase 
dramatically during hypothyroidism following withdrawal of thyroid hormone treatment.  
If there is histologically confirmed thyroid cancer, then 6-8 weeks after thyroidectomy the 
patient is admitted for radioiodine thyroablation. The patient comes in a fully developed 
deep clinical hypothyroidism (TSH level usually above 100 mU/l). To achieve sufficient 
accumulation of radioiodine in the thyroid remnants it is needed to be TSH higher than 30 
mU/l. Then we perform ablation of thyroid remnant by radioiodine, which in addition to 
destruction of the remaining thyroid tissue removed also possible intrathyroidal metastases. 
 




Fig. 7. Post-therapy whole-body scintigraphy. Multiple lung metastases which accumulate 
radioiodine  
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recombinant human thyroid-stimulating hormone (rhTSH) is not economically feasible, 
inability to tolerate hypothyroidism could rule out RAIT. 
Absolute contraindications of RAIT is pregnancy and  breastfeeding (as in RAIT in 
hyperthyroidism). 
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limited 131I treatment was found to be three to four times higher than that of patients treated 
with total thyroidectomy and RAIT to ablate known foci of radioiodine uptake. 
Thyroglobulin is the major tumour marker for thyroid cancer of the follicular epithelium. It 
is not only specific for tumour tissue but is also specific component of normal thyroid tissue. 
Since thyroglobulin is produced exclusively by thyroid tissue, only very small amounts can 
be found in the blood after thyroidectomy and ablative radioiodine therapy. Any post-
therapeutic elevation of its levels indicates either remnant of thyroid tissue, requiring 
further ablative therapy, or the presence of metastases or local recurrence. Following total or 
near-total thyroidectomy, TSH elevation reaches a maximum in 4-6 weeks. In the follow-up 
care, patients are maintained on suppressive doses of thyroid hormone. The goals of follow-
up after initial therapy are to maintain adequate levothyroxine (T4) therapy and to detect 
persistent or recurrent thyroid carcinoma. All patients with thyroid cancer must be treated 
with thyroid hormone after thyroidectomy for correction of surgically induced 
hypothyroidism and to suppress stimulated growth of persistent or recurrent thyroid cancer 
by reducing TSH levels. Thus thyroid hormone therapy ensures „replacement“ therapy, 
which corrects hypothyroidism, and „suppressive“ therapy, which inhibits TSH secretion. 
Thyroid cell proliferation and differentiation is mainly TSH dependent. Therefore TSH 
secretion must be inhibited by thyroid hormone therapy in all patients with differentiated 
thyroid cancers. Thyroid hormone is a basic principle that is included in the guidelines of 
thyroid cancer therapy. Before administration of radioiodine, thyroid homone therapy has 
to be interrupted for diagnosis or treatment. Radioiodine uptake, thyroglobulin synthesis 
and its secretion by thyroid cancer cells will be stimulated by increased TSH. Neoplastic as 
wel as normal thyroid cell differentiation depends on TSH. Accordingly, metastases take up 
radioiodine only if the patient is hypothyroid with high serum TSH levels, while no uptake 
is seen when the patient is on hormone suppressive therapy with low or undetectable serum 
TSH concentrations. Serum TSH level should be taken into account when interpreting the 
serum thyroglobulin value as the presence or absence neoplastic disease. In most patients 
with persistent or recurrent neoplastic disease, thyroglobulin concentration will increase 
dramatically during hypothyroidism following withdrawal of thyroid hormone treatment.  
If there is histologically confirmed thyroid cancer, then 6-8 weeks after thyroidectomy the 
patient is admitted for radioiodine thyroablation. The patient comes in a fully developed 
deep clinical hypothyroidism (TSH level usually above 100 mU/l). To achieve sufficient 
accumulation of radioiodine in the thyroid remnants it is needed to be TSH higher than 30 
mU/l. Then we perform ablation of thyroid remnant by radioiodine, which in addition to 
destruction of the remaining thyroid tissue removed also possible intrathyroidal metastases. 
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After radioiodine therapy the suppressive therapy is started. 6 to 12 months after ablation 
the control whole-body scintigraphy is performed in hypothyroidism after 4 weeks 
withdrawal of thyroid hormones. 
In the postoperative monitoring of patients with differentiated thyroid cancer should be 
solved a serious problem that is disturbing the patient life. This is hypothyroidism, which is 
a prerequisite for the implementation of thyroablation, whole body radioiodine scintigraphy 
and any further RAIT. It must be deep enough, which can be in actively working patients 
after withdrawal of suppressive therapy considerable difficult. Fortunately the rapid tumor 
growth is rarely stimulated by a brief rise in TSH concentration. The usual scheme is to 
carry out the treatment or control of patients during hospitalization after discontinuation of 
levothyroxine replacement for approximately 4-5 weeks. This has lead to profound 
hypothyroidism. In a small number of patients on long-term suppressive therapy we have 
observed only a moderate response to TSH after withdrawal of T4. Another option is to 
combine T4 and triiodothyronine (T3). Short-term administration of T3 alleviates some of 
the symptoms of prolonged hypothyroidism and must be stopped 2 weeks before 
radioiodine administration. This procedure also achieves a corresponding increase in TSH 
levels and hypothyroid patients subjectively perceived better. The third option is 
administration of recombinant human thyrotropin (rhTSH - Thyrogen) which stimulates 
thyroid tissue without requiring the discontinuation of thyroid hormone therapy. rhTSH 
can be used for diagnostic purposes (determination of thyroglobulin, scintigraphy) and 
before RAIT. Thyrogen should be used in patients who are either unable to mount an 
adequate endogenous TSH response to thyroid hormone withdrawal or in whom 
withdrawal is medically contraindicated. The use of Thyrogen allows for radioiodine 
imaging while the patient are euthyroid on levothyroxine. The clearance of radioiodine is 
approximately 50% greater in euthyroid patients than in hypothyroid patients, who have 
decreased renal function. Thus, radioiodine retention is less in euthyroid patients at the time 
of imaging and this factor should be considered when selecting the activity of radioiodine 
for imaging. Thyrotropin also stimulates the production of thyroglobulin and increases the 
usefulness of this tumour marker in patients treated with thyroid hormone who have had 
thyroid tissue ablated. For its high price Thyrogen unfortunately cannot be used in all 
patients with thyroid cancer. 
Suppression of endogenous secretion of TSH should be always maintained in patients with 
differentiated thyroid cancer. In low risk patients considered as cured, the levothyroxine 
dose is modified to maintain a low but detectable serum TSH concentration (0,1 to 0,5 
mU/l). In high risk patients with persistent/recurrent disease and even those considered as 
cured, higher doses of levothyroxine are continued, with the objective of attaining a serum 
TSH level of 0,1 mU/l or less, the free triiodothyronine concentration should be maintained 
within the normal range to avoid any significant overdosage. Reduction of serum 
thyroglobulin concentration is achieved with doses of thyroid hormone that reduce serum 
TSH to very low levels. 
5. Conclusion 
This chapter describes treatment options for some kinds of benign thyroid disease and 
differentiated thyroid cancers with radioactive iodine and context of this therapy with the 
development of post-radiation  hypothyroidism. Moreover, deliberately induced 
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hypothyroidism by thyroablation and in the further course also by the withdrawal of 
substitution and suppressive thyroid hormone therapy is used in the diagnosis and 
treatment of differentiated thyroid carcinomas. 
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1. Introduction 
Hypothyroidism is the most common disorder of thyroid dysfunction. Sometimes, it can be 
caused by a variety of medical treatments that leads to a decrease in thyroidal production 
and secretion of thyroxine and triiodothyronine. Radiation treatment, either radioactive 
iodine treatment of hyperthyroidism or external radiation treatment for cancer therapy is a 
major cause of treatment related hypothyroidism. Others include various drugs associated 
with thyroid suppression, include lithium, iodine, iodine-containing drugs, radiographic 
contrast agents and cytotoxic chemotherapy. Thyroid dysfunction is one of the most 
common complications in endocrine system after hematological stem cell transplantation. 
This chapter will discuss certain type of primary hypothyroidism, including those 
encountered commonly in clinical practice, such as radioactive iodine therapy, tyrosine 
kinase inhibitor, hematological stem cell transplantation or other entities.  
2. Causes of treatment related hypothyroidism 
 
Thyroid ablation Surgery 
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Hematological stem cell transplantation Autologous stem cell transplantation 
 Allogeneic stem cell transplantation 
Fig. 1. Causes of treatment-related hypothyroidism 
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2.1 Hypothyroidism due to thyroid ablation 
Radioactive iodine therapy 
Thyroid ablation using radioactive iodine for thyroid cancer is one of the most common 
causes of nonspontaneous hypothyroidism since the treatment modality is an important 
step in adjuvant or palliative setting of thyroid cancer. Radioactive iodine is an effective 
agent for delivering high radiation doses to the thyroid tissue with low spillover to other 
portions of the body. The radiation dose to the thyroid tissue is related to the tissue 
concentration, the ratio between the total tissue uptake and the volume of functional tissue, 
and the effective half-life of radioactive iodine in the tissue. Radioactive iodine therapy 
generally results in hypothyroidism, necessitating levothyroxine treatment. In thyroid 
cancer, total ablation of thyroid function can be achieved after administration of either 
100 mCi or 30 mCi in more thane 80% of patients who had at least a near-total 
thyroidectomy. After less extensive surgery, ablation can be achieved in only two thirds of 
patients with 30 mCi. 
External radiotherapy 
Radiotherapy is a frequently applied treatment in patients with head and neck cancer, and 
sometimes in patients with inoperative thyroid cancer as well as lymphoma. Despite its 
beneficial effects on locoregional tumor control, radiation may also cause a variety of acute 
or late side effects, which may be progressive and hamper health-related quality of life 
(Langendijk et al. 2008). Hypothyroidism may develop within the first year after 
radiotherapy, especially in patients under 20 years of age. After external radiotherapy, 
hypothyroidism develops at a median interval of 1.4-1.8 (range 0.3-7.2) years, but may 
continue to develop many years following therapy (Mercado et al. 2001; Tell et al. 2004). 
Approximately 30% of patients with solid tumors of the head and neck cancer treated with 
external radiotherapy develop hypothyroidism (Tami et al. 1992). In stem cell 
transplantation, hypothyroidism occurs in approximately 9% to 16 % of adults who undergo 
total body irradiation (Al-Fiar et al. 1997). From a 30 years’ experience at the Fred 
Hutchinson Cancer Research Center in treating children with stem cell transplantation, 
hypothyroidism is the most common type of thyroid dysfunction as 30% developed 
hypothyroidism at various times after stem cell transplantation. The incidence of 
hypothyroidism increased with total body irradiation and the use of busulfan-based 
regimen (Sanders et al. 2009). 
2.2 Hypothyroidism due to therapeutic pharmacological agents 
Several drugs can cause hypothyroidism by interfering with thyroid hormone production or 
provoking thyroid autoimmunity. Pharmacological iodine, such as those to which patients 
treated with amiodarone or other iodine-containing compounds are exposed, can inhibit 
thyroid hormone production, especially when combined with underlying autoimmune 
thyroiditis, and cause hypothyroidism.  
Amiodarone 
Amiodarone is a commonly prescribed anti-arrhythmic drug because of its ability to treat 
various types of cardiac arrhythmia including ventricular arrhythmia, paroxysmal 
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supraventricular tachycardia, atrial fibrillation and flutter with minimal negative inotropic 
and proarrhythmic effects. It is benzofuran derivative containing 37.5% iodine by weight. 
Daily maintenance dosages of 100 to 600 mg result in a 35 to 140 fold excess in 
recommended daily iodine intake of 100 to 150 µg. Such a high iodine content and inherent 
effects of amiodarone and its active metabolite desethylamiodarone are postulated to result 
in thyroid dysfunction in 14 to 18 % subjects after 2 to 3 years of treatment (Martino et al. 
2001). Amiodarone induced hypothyroidism is due to the inhibition of iodine oxidation 
because of excess intrathyroidal iodine, which is known as the Wolff-Chaikoff effect (Eng et 
al. 1999). In addition to iodine related effects, amiodarone can alter the activity of deiodinase 
enzymes. The inhibition of iodothyronine deiodinase activity in peripheral tissues results in 
decreased triiodothyronine concentration, increased total thyrosine concentration and 
increased reverse triiodothyronine concentration in serum (Martino et al. 2001). Whether to 
discontinue amiodarone is still controversial. Withdrawal of the drug may precipitate 
dysrhythmia, especially as most other alternative anti-arrhythmics are seldom as effective. 
The treatment of choice for amiodarone induced hypothyroidism is levothyroxine. 
Amiodarone can be continued at discretion of the cardiologist, keeping in mind that 
spontaneous remission of hypothyroidism may occur. If amiodarone treatment is 
discontinued, the decision to initiate thyroid hormone replacement can be delayed (Cohen-
Lehman et al. 2010). 
Lithium  
One in 200 people receives lithium for treatment of bipolar disorder. Lithium has many 
actions on thyroid physiology. The most important clinical relevant action is the inhibition 
of thyroid hormone release. The effect of lithium on inhibition of cyclic AMP-mediated 
cellular events and its inhibitory effect on the phosphoinositol pathway help to explain the 
intracellular disturbances, but the full mechanism is still not clear. The immunological 
influence of lithium on thyroid antibody concentrations leads to a more rapid onset of 
thyroid autoimmunity characterized usually by goiter and hypothyroidism. The clinical side 
effects of the drug are goiter in up to 40% and hypothyroidism in about 20% (Lazarus 2009). 
Treatment of lithium-induced hypothyroidism with levothyroxine is no different from 
treatment of primary hypothyroidism. In these cases there is often a concern that even mild 
hypothyroidism may contribute to depressive symptoms and that increased thyroid 
stimulating hormone levels may favor further growth of goiter. The presence of thyroid 
abnormalities alone is almost never a reason for lithium discontinuation, as this medication 
is often crucial in maintaining these patients free of the most severe manifestations of their 
psychiatric illness (Barbesino 2010). 
Interferon alpha 
Interferon alpha is used for the treatment of hepatitis B and C, as well as various 
neoplasms, including malignant carcinoid, Kaposi’s sarcoma and hairy cell leukemia. 
Dose-limited side effects of interferon alpha are common, most frequently malaise, 
depression and hematological side effects. Thyroid dysfunction during interferon alpha is 
also quite common. Hypothyroidism was initially described as a side effect of interferon 
alpha therapy in patients receiving long-term interferon alpha treatment for breast cancer 
(Fentiman et al. 1985). Thyroid effects of interferon alpha have been classified as 
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2.1 Hypothyroidism due to thyroid ablation 
Radioactive iodine therapy 
Thyroid ablation using radioactive iodine for thyroid cancer is one of the most common 
causes of nonspontaneous hypothyroidism since the treatment modality is an important 
step in adjuvant or palliative setting of thyroid cancer. Radioactive iodine is an effective 
agent for delivering high radiation doses to the thyroid tissue with low spillover to other 
portions of the body. The radiation dose to the thyroid tissue is related to the tissue 
concentration, the ratio between the total tissue uptake and the volume of functional tissue, 
and the effective half-life of radioactive iodine in the tissue. Radioactive iodine therapy 
generally results in hypothyroidism, necessitating levothyroxine treatment. In thyroid 
cancer, total ablation of thyroid function can be achieved after administration of either 
100 mCi or 30 mCi in more thane 80% of patients who had at least a near-total 
thyroidectomy. After less extensive surgery, ablation can be achieved in only two thirds of 
patients with 30 mCi. 
External radiotherapy 
Radiotherapy is a frequently applied treatment in patients with head and neck cancer, and 
sometimes in patients with inoperative thyroid cancer as well as lymphoma. Despite its 
beneficial effects on locoregional tumor control, radiation may also cause a variety of acute 
or late side effects, which may be progressive and hamper health-related quality of life 
(Langendijk et al. 2008). Hypothyroidism may develop within the first year after 
radiotherapy, especially in patients under 20 years of age. After external radiotherapy, 
hypothyroidism develops at a median interval of 1.4-1.8 (range 0.3-7.2) years, but may 
continue to develop many years following therapy (Mercado et al. 2001; Tell et al. 2004). 
Approximately 30% of patients with solid tumors of the head and neck cancer treated with 
external radiotherapy develop hypothyroidism (Tami et al. 1992). In stem cell 
transplantation, hypothyroidism occurs in approximately 9% to 16 % of adults who undergo 
total body irradiation (Al-Fiar et al. 1997). From a 30 years’ experience at the Fred 
Hutchinson Cancer Research Center in treating children with stem cell transplantation, 
hypothyroidism is the most common type of thyroid dysfunction as 30% developed 
hypothyroidism at various times after stem cell transplantation. The incidence of 
hypothyroidism increased with total body irradiation and the use of busulfan-based 
regimen (Sanders et al. 2009). 
2.2 Hypothyroidism due to therapeutic pharmacological agents 
Several drugs can cause hypothyroidism by interfering with thyroid hormone production or 
provoking thyroid autoimmunity. Pharmacological iodine, such as those to which patients 
treated with amiodarone or other iodine-containing compounds are exposed, can inhibit 
thyroid hormone production, especially when combined with underlying autoimmune 
thyroiditis, and cause hypothyroidism.  
Amiodarone 
Amiodarone is a commonly prescribed anti-arrhythmic drug because of its ability to treat 
various types of cardiac arrhythmia including ventricular arrhythmia, paroxysmal 
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supraventricular tachycardia, atrial fibrillation and flutter with minimal negative inotropic 
and proarrhythmic effects. It is benzofuran derivative containing 37.5% iodine by weight. 
Daily maintenance dosages of 100 to 600 mg result in a 35 to 140 fold excess in 
recommended daily iodine intake of 100 to 150 µg. Such a high iodine content and inherent 
effects of amiodarone and its active metabolite desethylamiodarone are postulated to result 
in thyroid dysfunction in 14 to 18 % subjects after 2 to 3 years of treatment (Martino et al. 
2001). Amiodarone induced hypothyroidism is due to the inhibition of iodine oxidation 
because of excess intrathyroidal iodine, which is known as the Wolff-Chaikoff effect (Eng et 
al. 1999). In addition to iodine related effects, amiodarone can alter the activity of deiodinase 
enzymes. The inhibition of iodothyronine deiodinase activity in peripheral tissues results in 
decreased triiodothyronine concentration, increased total thyrosine concentration and 
increased reverse triiodothyronine concentration in serum (Martino et al. 2001). Whether to 
discontinue amiodarone is still controversial. Withdrawal of the drug may precipitate 
dysrhythmia, especially as most other alternative anti-arrhythmics are seldom as effective. 
The treatment of choice for amiodarone induced hypothyroidism is levothyroxine. 
Amiodarone can be continued at discretion of the cardiologist, keeping in mind that 
spontaneous remission of hypothyroidism may occur. If amiodarone treatment is 
discontinued, the decision to initiate thyroid hormone replacement can be delayed (Cohen-
Lehman et al. 2010). 
Lithium  
One in 200 people receives lithium for treatment of bipolar disorder. Lithium has many 
actions on thyroid physiology. The most important clinical relevant action is the inhibition 
of thyroid hormone release. The effect of lithium on inhibition of cyclic AMP-mediated 
cellular events and its inhibitory effect on the phosphoinositol pathway help to explain the 
intracellular disturbances, but the full mechanism is still not clear. The immunological 
influence of lithium on thyroid antibody concentrations leads to a more rapid onset of 
thyroid autoimmunity characterized usually by goiter and hypothyroidism. The clinical side 
effects of the drug are goiter in up to 40% and hypothyroidism in about 20% (Lazarus 2009). 
Treatment of lithium-induced hypothyroidism with levothyroxine is no different from 
treatment of primary hypothyroidism. In these cases there is often a concern that even mild 
hypothyroidism may contribute to depressive symptoms and that increased thyroid 
stimulating hormone levels may favor further growth of goiter. The presence of thyroid 
abnormalities alone is almost never a reason for lithium discontinuation, as this medication 
is often crucial in maintaining these patients free of the most severe manifestations of their 
psychiatric illness (Barbesino 2010). 
Interferon alpha 
Interferon alpha is used for the treatment of hepatitis B and C, as well as various 
neoplasms, including malignant carcinoid, Kaposi’s sarcoma and hairy cell leukemia. 
Dose-limited side effects of interferon alpha are common, most frequently malaise, 
depression and hematological side effects. Thyroid dysfunction during interferon alpha is 
also quite common. Hypothyroidism was initially described as a side effect of interferon 
alpha therapy in patients receiving long-term interferon alpha treatment for breast cancer 
(Fentiman et al. 1985). Thyroid effects of interferon alpha have been classified as 
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autoimmune and nonautoimmune, mostly based on the presence or absence of markers of 
thyroid autoimmunity such as serum thyroid peroxidase and / or thyroglobulin 
antibodies (Mandac et al. 2006). The observed incidence of interferon alpha associated 
hypothyroidism in patients with hepatitis C has been reported from approximately 6% to 
10% (Deutsch et al. 1997; Koh, Greenspan, and Yeo 1997). Transient hypothyroidism 
occurs more commonly with interferon alpha therapy than does persistent 
hypothyroidism, although pooled data from several series indicates that 30% to 44% of 
patients who develop hypothyroidism during interferon alpha treatment develop 
persistent thyroid failure (Preziati et al. 1995).  
Interleukin-2 
Interleukin-2 is used in the treatment of melanoma and renal cell carcinoma. In one series, 
32% of 111 patients with cancer developed hypothyroidism during interleukin-2 treatment, 
and 14% had hypothyroidism postimmunotherapy, persisting from 44 to greater than 149 
days (Schwartzentruber et al. 1991). Earlier studies showed a higher incidence of 
hypothyroidism up to 21% after treatment of interleukin-2 in combination with lymphokine-
activated killer cells (Atkins et al. 1988). Most patients who developed hypothyroidism had 
positive thyroglobulin or thyroid peroxidase antibodies, suggesting autoimmune 
thyroiditis. Similarly to interferon alpha-induced thyroid disorders, hypothyroid patients 
are easily treated with thyroid hormone, while destructive thyrotoxicosis only requires 
symptom control with beta-blockers. 
Tyrosine kinase inhibitors 
Tyrosine kinase inhibitors have recently emerged as promising chemotherapeutic agents in 
several types of malignant neoplasms, including thyroid cancer. Several tyrosine kinase 
inhibitors exert distinctive effects on thyroid function. Tyrosine kinase inhibitors affect 
thyroid function through two major mechanisms: by increasing thyroid hormone 
requirements in patients on thyroid hormone replacement and by causing primary 
hypothyroidism in patients with previously normal thyroid function. In a small clinical 
report, imatinib caused a fourfold increase in thyroid stimulating hormone level in all eight 
patients taking levothyroxine after total thyroidectomyt for medullary thyroid cancer. The 
effect was reversible after discontinuation of treatment and it could be corrected by a 
doubling in the daily levothyroxine dosage in some patients. There was no change in total 
thyroxine to suggest increased serum protein binding of thyroid hormone as a possible 
explanation. Hence, these effects of imatinib are most likely related to increase liver 
metabolism of thyroid hormone (Barbesino 2010; de Groot et al. 2005). Sunitinib is an oral, 
multitargeted tyrosine kinase inhibitor of vascular growth receptors, stem cell factor 
receptor and platelet-derived growth factor receptors. It has been approved for the 
treatment of gastrointestinal stromal tumor and metastatic renal cell carcinoma. 
Hypothyroidism has been observed as an adverse event and a clinically relevant toxicity of 
sunitinib. In one study, 36% of patients with gastrointestinal stromal tumor treated with 
sunitinib, developed primary hypothyroidism (Desai et al. 2006). Rini et al reported that 
hypothyroidism occurred in 56 (85%) of 66 patients with metastatic renal cell carcinoma 
(Rini et al. 2007). Although the mechanism behind this complication remains unclear, it is 
considered that treatment with levothyroxine can control subclinical and overt 
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hypothyroidism. There have been cases of thyroid atrophy following sunitinib treatment, 
suggesting a direct effect of sunitinib that leads to degeneration of thyroid follicular cells 
(Shinohara et al. 2011). 
Cytotoxic chemotherapy 
Cytotoxic chemotherapy can alter thyroid function in a small proportion of patients. An 
increased incidence of primary hypothyroidism has been documented in patients treated 
with multiple drug regimens (Yeung et al. 1998). There is some evidence that L-asparaginase 
can cause pituitary hypothyroidism, which is resulted from reducing the thyroid 
stimulating hormone response to thyroid releasing hormone (Heidemann, Stubbe, and Beck 
1981). In patients with testicular cancer who received combinations of cisplatin, bleomycin, 
vinblastine, etoposide, and dactinomycin, 4 of 27 individuals (15%) developed 
hypothyroidism. In particular, the cumulative doses of cisplatin and vincristine seem to 
exacerbate these symptoms (Stuart et al. 1990). Forty-four percent of patients who received 
six cycles of MOPP regimen (mechlorethamine, vinblastine, procarbazine, and 
prednisolone) for Hodgkin’s disease developed an elevated serum thyroid stimulating 
hormone concentration (Sutcliffe, Chapman, and Wrigley 1981).  
2.3 Hypothyroidism after hematopoietic stem cell transplantation 
Thyroid dysfunction is an important problem in patents receiving hematopoietic stem cell 
transplantation and several forms of thyroid disorders have been reported including 
hypothyroidism, euthyroid sick syndrome, transfer of autoimmune thyroiditis, graft-versus-
host disease, and secondary thyroid tumors (Kami et al. 2001). Hypothyroidism is one of the 
common forms of thyroid disorder after hematopoietic stem cell transplantation. Its 
frequency was found to be as high as 40% (Borgstrom, and Bolme 1994; Sklar, Kim, and 
Ramsay 1982) and it appeared to increase with the duration of post-transplant follow-up. In 
less common instance, patients appeared to have hyperthyroidism after stem cell 
transplantation, even six months later from clinical reports (Feng et al. 2008). Development 
of hypothyroidism has been attributed largely to exposure to radiation (Sanders 1990), but it 
also does occur after chemotherapy-based preparative regimens.  
Mechanism of thyroid dysfunction after hematopoietic stem cell transplantation 
Hematopoietic stem cell transplantation is a potentially curative procedure for a variety of 
malignant and non-malignant conditions. When developed initially, hematopoietic stem cell 
transplantation was considered an approach to rescue patients from toxic side effects of 
supralethal doses of radiation and chemotherapy used to treat various underlying diseases 
by transplanting hematopoietic stem cells, which had the ability to reconstitute 
hematopoiesis. In allogeneic hematopoietic stem cell transplantation, healthy hematopoietic 
stem cell s are harvested from a separate, related or unrelated, ideally human leukocyte 
antigen-matched donor, and used to replace the patient’s own abnormal hematopoietic stem 
cells. Conditioning regimen for allogeneic hematopoietic stem cell transplantation often 
combine total body irradiation and high-dose chemotherapy to eradicate the patient’s 
malignant cell population at the cost of partial or complete bone marrow ablation. 
Autologous hematopoietic stem cell transplantation requires the extraction of hematopoietic 
stem cells from the patient. The harvested hematopoietic stem cells return to the patient’s 
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autoimmune and nonautoimmune, mostly based on the presence or absence of markers of 
thyroid autoimmunity such as serum thyroid peroxidase and / or thyroglobulin 
antibodies (Mandac et al. 2006). The observed incidence of interferon alpha associated 
hypothyroidism in patients with hepatitis C has been reported from approximately 6% to 
10% (Deutsch et al. 1997; Koh, Greenspan, and Yeo 1997). Transient hypothyroidism 
occurs more commonly with interferon alpha therapy than does persistent 
hypothyroidism, although pooled data from several series indicates that 30% to 44% of 
patients who develop hypothyroidism during interferon alpha treatment develop 
persistent thyroid failure (Preziati et al. 1995).  
Interleukin-2 
Interleukin-2 is used in the treatment of melanoma and renal cell carcinoma. In one series, 
32% of 111 patients with cancer developed hypothyroidism during interleukin-2 treatment, 
and 14% had hypothyroidism postimmunotherapy, persisting from 44 to greater than 149 
days (Schwartzentruber et al. 1991). Earlier studies showed a higher incidence of 
hypothyroidism up to 21% after treatment of interleukin-2 in combination with lymphokine-
activated killer cells (Atkins et al. 1988). Most patients who developed hypothyroidism had 
positive thyroglobulin or thyroid peroxidase antibodies, suggesting autoimmune 
thyroiditis. Similarly to interferon alpha-induced thyroid disorders, hypothyroid patients 
are easily treated with thyroid hormone, while destructive thyrotoxicosis only requires 
symptom control with beta-blockers. 
Tyrosine kinase inhibitors 
Tyrosine kinase inhibitors have recently emerged as promising chemotherapeutic agents in 
several types of malignant neoplasms, including thyroid cancer. Several tyrosine kinase 
inhibitors exert distinctive effects on thyroid function. Tyrosine kinase inhibitors affect 
thyroid function through two major mechanisms: by increasing thyroid hormone 
requirements in patients on thyroid hormone replacement and by causing primary 
hypothyroidism in patients with previously normal thyroid function. In a small clinical 
report, imatinib caused a fourfold increase in thyroid stimulating hormone level in all eight 
patients taking levothyroxine after total thyroidectomyt for medullary thyroid cancer. The 
effect was reversible after discontinuation of treatment and it could be corrected by a 
doubling in the daily levothyroxine dosage in some patients. There was no change in total 
thyroxine to suggest increased serum protein binding of thyroid hormone as a possible 
explanation. Hence, these effects of imatinib are most likely related to increase liver 
metabolism of thyroid hormone (Barbesino 2010; de Groot et al. 2005). Sunitinib is an oral, 
multitargeted tyrosine kinase inhibitor of vascular growth receptors, stem cell factor 
receptor and platelet-derived growth factor receptors. It has been approved for the 
treatment of gastrointestinal stromal tumor and metastatic renal cell carcinoma. 
Hypothyroidism has been observed as an adverse event and a clinically relevant toxicity of 
sunitinib. In one study, 36% of patients with gastrointestinal stromal tumor treated with 
sunitinib, developed primary hypothyroidism (Desai et al. 2006). Rini et al reported that 
hypothyroidism occurred in 56 (85%) of 66 patients with metastatic renal cell carcinoma 
(Rini et al. 2007). Although the mechanism behind this complication remains unclear, it is 
considered that treatment with levothyroxine can control subclinical and overt 
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hypothyroidism. There have been cases of thyroid atrophy following sunitinib treatment, 
suggesting a direct effect of sunitinib that leads to degeneration of thyroid follicular cells 
(Shinohara et al. 2011). 
Cytotoxic chemotherapy 
Cytotoxic chemotherapy can alter thyroid function in a small proportion of patients. An 
increased incidence of primary hypothyroidism has been documented in patients treated 
with multiple drug regimens (Yeung et al. 1998). There is some evidence that L-asparaginase 
can cause pituitary hypothyroidism, which is resulted from reducing the thyroid 
stimulating hormone response to thyroid releasing hormone (Heidemann, Stubbe, and Beck 
1981). In patients with testicular cancer who received combinations of cisplatin, bleomycin, 
vinblastine, etoposide, and dactinomycin, 4 of 27 individuals (15%) developed 
hypothyroidism. In particular, the cumulative doses of cisplatin and vincristine seem to 
exacerbate these symptoms (Stuart et al. 1990). Forty-four percent of patients who received 
six cycles of MOPP regimen (mechlorethamine, vinblastine, procarbazine, and 
prednisolone) for Hodgkin’s disease developed an elevated serum thyroid stimulating 
hormone concentration (Sutcliffe, Chapman, and Wrigley 1981).  
2.3 Hypothyroidism after hematopoietic stem cell transplantation 
Thyroid dysfunction is an important problem in patents receiving hematopoietic stem cell 
transplantation and several forms of thyroid disorders have been reported including 
hypothyroidism, euthyroid sick syndrome, transfer of autoimmune thyroiditis, graft-versus-
host disease, and secondary thyroid tumors (Kami et al. 2001). Hypothyroidism is one of the 
common forms of thyroid disorder after hematopoietic stem cell transplantation. Its 
frequency was found to be as high as 40% (Borgstrom, and Bolme 1994; Sklar, Kim, and 
Ramsay 1982) and it appeared to increase with the duration of post-transplant follow-up. In 
less common instance, patients appeared to have hyperthyroidism after stem cell 
transplantation, even six months later from clinical reports (Feng et al. 2008). Development 
of hypothyroidism has been attributed largely to exposure to radiation (Sanders 1990), but it 
also does occur after chemotherapy-based preparative regimens.  
Mechanism of thyroid dysfunction after hematopoietic stem cell transplantation 
Hematopoietic stem cell transplantation is a potentially curative procedure for a variety of 
malignant and non-malignant conditions. When developed initially, hematopoietic stem cell 
transplantation was considered an approach to rescue patients from toxic side effects of 
supralethal doses of radiation and chemotherapy used to treat various underlying diseases 
by transplanting hematopoietic stem cells, which had the ability to reconstitute 
hematopoiesis. In allogeneic hematopoietic stem cell transplantation, healthy hematopoietic 
stem cell s are harvested from a separate, related or unrelated, ideally human leukocyte 
antigen-matched donor, and used to replace the patient’s own abnormal hematopoietic stem 
cells. Conditioning regimen for allogeneic hematopoietic stem cell transplantation often 
combine total body irradiation and high-dose chemotherapy to eradicate the patient’s 
malignant cell population at the cost of partial or complete bone marrow ablation. 
Autologous hematopoietic stem cell transplantation requires the extraction of hematopoietic 
stem cells from the patient. The harvested hematopoietic stem cells return to the patient’s 
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body to resume normal blood cell production after conditioning treatment. Individuals 
successfully treated with hematopoietic stem cell transplantation are at risk of developing 
post-transplant complications as a result of drug and radiation toxicity, as are those treated 
with allogeneic hematopoietic stem cell transplantation as a consequence of graft versus 
host disease. Endocrine complications are among the most prevalent late effects observed in 
hematopoietic stem cell transplantation recipients (Chemaitilly, and Sklar 2007; Hows et al. 
2006). Several thyroid abnormalities have been described following hematopoietic stem cell 
transplantation. These include therapy-induced primary hypothyroidism, autoimmune 
thyroid disease, and thyroid neoplasms. 
Autologous hematopoietic stem cell transplantation 
Autologous hematopoietic stem cell transplantation is performed more frequently than any 
allogeneic type of organ transplantation worldwide. The endocrine system is one of the 
most common targets of post-transplant complications. The relative risk of developing 
endocrine disorders was found to be related to underlying diseases, previous treatments, 
use of radiation therapies and type of irradiation schedule, post-transplant treatment and 
age (Brennan, and Shalet 2002; Shalet et al. 1995). Carlson et al. described hypothyroidism 
developed in 20 of 111 (18%) individuals after autologous stem cell transplantation and the 
incidence of hypothyroidism was more frequent in patients treated with total body 
irradiation (Carlson et al. 1992). There were some reports on development of 
hypothyroidism after non-total body irradiation preparative regimens (Michel et al. 1997; 
Toubert et al. 1997). Considering the wide differences in the total doses of radiation applied, 
during treatment of Hodgkin’s disease versus preparative conditioning for hematopoietic 
stem cell transplantation, the incidence of hypothyroidism after hematopoietic stem cell 
transplantation remains striking. These findings suggest that irradiation of the thyroid gland 
may not be the sole cause of hypothyroidism after hematopoietic stem cell transplantation. 
Early effect of thyroid dysfunction was reported by Tauchmanova in patients first year after 
autologous hematopoietic stem cell transplantation. Subclinical hypothyroidism was 
diagnosed in 10% of patients and worsened progressively in all but one patient 
(Tauchmanova et al. 2005).  
Allogeneic hematopoietic stem cell transplantation 
Hypothyroidism haven been reported to be as high as 52% of patients with allogeneic 
hematopoietic stem cell transplantation (Al-Hazzouri et al. 2009; Bailey et al. 2008; Berger et 
al. 2005; Sanders et al. 2009). The time course of developing hypothyroidism after 
hematopoietic stem cell transplantation varied based on the conditioning regimen. In one 
study, patients who received single fraction total body irradiation developed compensated 
hypothyroidism at a mean of 3.2 (range 1-8.2) years after hematopoietic stem cell 
transplantation and progressed to overt hypothyroidism about 1-2 years later (Thomas et al. 
1993). Hypothyroidis was recognized between 0.9 and 7.3 (median 4.1) years after 
hyperfractionated radiation and at a median of 4.2 years in patients conditioned with 
busulfan and cyclophosphamide (Boulad et al. 1995). In a 30 year-surveillance of post-
transplant, 30% of children developed hypothyroidism at various times after hematopoietic 
stem cell transplantation and among these 20% were treated with thyroid hormone. Thyroid 
dysfunction continues to occur as long as 28 years after hematopoietic stem cell 
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transplantation conditioning with total body irradiation and as long as 10 years after 
busulfan-cyclophosphamide preparative regimen (Sanders et al. 2009).  
The mechanism for hypothyroidism after transplant is unknown. Donor antibody transfers, 
immune-mediated injury, conditioning treatment effects, post-transplant medications and 
patient susceptibility may play a role in post-hematopoietic stem cell transplantation 
hypothyroidism. Case studies have shown that a donor with autoimmune thyroid disorder 
may transfer cell capable of injuring the recipient’s thyroid gland after hematopoietic stem cell 
transplantation (Lee et al. 2001; Marazuela, and Steegman 2000). Immune-mediated thyroid 
injury arising in the host has been suggested in other studies and may be a form of graft-
versus-host-disease (Kami et al. 2001; Katsanis et al. 1990; Somali et al. 2005). Patients receiving 
single-agent graft-versus-host-disease prophylaxis were found to have a 9.5 times greater risk 
of developing hypothyroidism than patients with multi-agent prophylaxis (Katsanis et al. 
1990). From an immunological standpoint, stem cells from matched sibling donors are though 
to be less immunologically reactive than those from unrelated donors. Patients who received 
stem cells from an unrelated donor had over an eightfold increased risk of hypothyroidism 
compared to those who received matched sibling stem cells (Bailey et al. 2008). Total body 
irradiation is a well established risk factor for hypothyroidism after hematopoietic stem cell 
transplantation and used of fractionated instead of single-dose total body irradiation decreases 
its risk (Boulad et al. 1995). Other risk factor for developing hypothyroidism after 
hematopoietic stem cell transplantation includes young age at transplantation and stem cell 
transplantation during second complete remission (Berger et al. 2005; Ishiguro et al. 2004). A 
study focused on reduced-intensity conditioning regimen in hematopoietic stem cell 
transplantation disclosed that the incidence of post-transplant hypothyroidism was similar in 
myeloablative or reduced-intensity conditioning regimen (Al-Hazzouri et al. 2009). 
3. Conclusions 
The endocrine system is one of the most common targets of post-treatment complications in 
cancer survivors. The relative risk of developing endocrine disorders was found to be 
related to underlying diseases, previous treatments, use of radiation therapies, and post-
transplant treatments. Thyroid dysfunction has been frequently reported after 
hematopoietic cell transplantation. Radiation has been considered the main cause for this 
and for thyroid malignancies, but in the context of hematopoietic cell transplantation, total 
body irradiation has been considered to be the major cause. The incidence of post-transplant 
thyroid disorder ranging from 0% to 57% was reported previously. Sick euthyroid 
syndrome was more frequently observed. Most patients developed a mild compensated 
primary hypothyroidism that may be transient and can be resolved spontaneously. 
Hypothyroidism can be an early complication but is usually considered as a late 
complication identified several years after hematopoietic cell transplantation. 
Approximately 15 % of patients develop overt primary hypothyroidism and 30% have 
compensated hypothyroidism. The incidence is lower in patients treated with autologous 
hematopoietic cell transplantation or conditioned with chemotherapy alone.  
With the cumulative experiences in hematopoietic cell transplantation and advances in 
supportive care, the number of long-term survivors has increased. Knowledge about 
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body to resume normal blood cell production after conditioning treatment. Individuals 
successfully treated with hematopoietic stem cell transplantation are at risk of developing 
post-transplant complications as a result of drug and radiation toxicity, as are those treated 
with allogeneic hematopoietic stem cell transplantation as a consequence of graft versus 
host disease. Endocrine complications are among the most prevalent late effects observed in 
hematopoietic stem cell transplantation recipients (Chemaitilly, and Sklar 2007; Hows et al. 
2006). Several thyroid abnormalities have been described following hematopoietic stem cell 
transplantation. These include therapy-induced primary hypothyroidism, autoimmune 
thyroid disease, and thyroid neoplasms. 
Autologous hematopoietic stem cell transplantation 
Autologous hematopoietic stem cell transplantation is performed more frequently than any 
allogeneic type of organ transplantation worldwide. The endocrine system is one of the 
most common targets of post-transplant complications. The relative risk of developing 
endocrine disorders was found to be related to underlying diseases, previous treatments, 
use of radiation therapies and type of irradiation schedule, post-transplant treatment and 
age (Brennan, and Shalet 2002; Shalet et al. 1995). Carlson et al. described hypothyroidism 
developed in 20 of 111 (18%) individuals after autologous stem cell transplantation and the 
incidence of hypothyroidism was more frequent in patients treated with total body 
irradiation (Carlson et al. 1992). There were some reports on development of 
hypothyroidism after non-total body irradiation preparative regimens (Michel et al. 1997; 
Toubert et al. 1997). Considering the wide differences in the total doses of radiation applied, 
during treatment of Hodgkin’s disease versus preparative conditioning for hematopoietic 
stem cell transplantation, the incidence of hypothyroidism after hematopoietic stem cell 
transplantation remains striking. These findings suggest that irradiation of the thyroid gland 
may not be the sole cause of hypothyroidism after hematopoietic stem cell transplantation. 
Early effect of thyroid dysfunction was reported by Tauchmanova in patients first year after 
autologous hematopoietic stem cell transplantation. Subclinical hypothyroidism was 
diagnosed in 10% of patients and worsened progressively in all but one patient 
(Tauchmanova et al. 2005).  
Allogeneic hematopoietic stem cell transplantation 
Hypothyroidism haven been reported to be as high as 52% of patients with allogeneic 
hematopoietic stem cell transplantation (Al-Hazzouri et al. 2009; Bailey et al. 2008; Berger et 
al. 2005; Sanders et al. 2009). The time course of developing hypothyroidism after 
hematopoietic stem cell transplantation varied based on the conditioning regimen. In one 
study, patients who received single fraction total body irradiation developed compensated 
hypothyroidism at a mean of 3.2 (range 1-8.2) years after hematopoietic stem cell 
transplantation and progressed to overt hypothyroidism about 1-2 years later (Thomas et al. 
1993). Hypothyroidis was recognized between 0.9 and 7.3 (median 4.1) years after 
hyperfractionated radiation and at a median of 4.2 years in patients conditioned with 
busulfan and cyclophosphamide (Boulad et al. 1995). In a 30 year-surveillance of post-
transplant, 30% of children developed hypothyroidism at various times after hematopoietic 
stem cell transplantation and among these 20% were treated with thyroid hormone. Thyroid 
dysfunction continues to occur as long as 28 years after hematopoietic stem cell 
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transplantation conditioning with total body irradiation and as long as 10 years after 
busulfan-cyclophosphamide preparative regimen (Sanders et al. 2009).  
The mechanism for hypothyroidism after transplant is unknown. Donor antibody transfers, 
immune-mediated injury, conditioning treatment effects, post-transplant medications and 
patient susceptibility may play a role in post-hematopoietic stem cell transplantation 
hypothyroidism. Case studies have shown that a donor with autoimmune thyroid disorder 
may transfer cell capable of injuring the recipient’s thyroid gland after hematopoietic stem cell 
transplantation (Lee et al. 2001; Marazuela, and Steegman 2000). Immune-mediated thyroid 
injury arising in the host has been suggested in other studies and may be a form of graft-
versus-host-disease (Kami et al. 2001; Katsanis et al. 1990; Somali et al. 2005). Patients receiving 
single-agent graft-versus-host-disease prophylaxis were found to have a 9.5 times greater risk 
of developing hypothyroidism than patients with multi-agent prophylaxis (Katsanis et al. 
1990). From an immunological standpoint, stem cells from matched sibling donors are though 
to be less immunologically reactive than those from unrelated donors. Patients who received 
stem cells from an unrelated donor had over an eightfold increased risk of hypothyroidism 
compared to those who received matched sibling stem cells (Bailey et al. 2008). Total body 
irradiation is a well established risk factor for hypothyroidism after hematopoietic stem cell 
transplantation and used of fractionated instead of single-dose total body irradiation decreases 
its risk (Boulad et al. 1995). Other risk factor for developing hypothyroidism after 
hematopoietic stem cell transplantation includes young age at transplantation and stem cell 
transplantation during second complete remission (Berger et al. 2005; Ishiguro et al. 2004). A 
study focused on reduced-intensity conditioning regimen in hematopoietic stem cell 
transplantation disclosed that the incidence of post-transplant hypothyroidism was similar in 
myeloablative or reduced-intensity conditioning regimen (Al-Hazzouri et al. 2009). 
3. Conclusions 
The endocrine system is one of the most common targets of post-treatment complications in 
cancer survivors. The relative risk of developing endocrine disorders was found to be 
related to underlying diseases, previous treatments, use of radiation therapies, and post-
transplant treatments. Thyroid dysfunction has been frequently reported after 
hematopoietic cell transplantation. Radiation has been considered the main cause for this 
and for thyroid malignancies, but in the context of hematopoietic cell transplantation, total 
body irradiation has been considered to be the major cause. The incidence of post-transplant 
thyroid disorder ranging from 0% to 57% was reported previously. Sick euthyroid 
syndrome was more frequently observed. Most patients developed a mild compensated 
primary hypothyroidism that may be transient and can be resolved spontaneously. 
Hypothyroidism can be an early complication but is usually considered as a late 
complication identified several years after hematopoietic cell transplantation. 
Approximately 15 % of patients develop overt primary hypothyroidism and 30% have 
compensated hypothyroidism. The incidence is lower in patients treated with autologous 
hematopoietic cell transplantation or conditioned with chemotherapy alone.  
With the cumulative experiences in hematopoietic cell transplantation and advances in 
supportive care, the number of long-term survivors has increased. Knowledge about 
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increased risk for long term complications due to cancer therapy and pre-hematopoietic cell 
transplantation preparative regimen should encourage each physician to improve their 
quality of care. 
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1. Introduction 
In developing mammals (including humans), a deficiency or excess of thyroid hormone 
(TH) in the developing brain during the fetal and neonatal periods can lead to 
morphological and functional abnormalities (Nunez et al., 1992; Pasquini & Adamo, 1994; 
Morreale de Escobar et al., 2004; Harakawa et al., 1989). The most severe form of 
hypothyroidism in human fetus and neonate is the syndrome of cretinism. Recent studies 
indicate that abnormalities in intelligence quotient (IQ) and other neuropsychological tests 
may be found in children of women with subclinical hypothyroidism during pregnancy 
(Haddow et al., 1999; Mitchell & Klein, 2004; Casey et al., 2005). Subtle health impairment 
and reduced socio-educational achievement are observed in young adults with congenital 
hypothyroidism identified by neonatal screening and subsequently treated (Leger et al., 
2011). This suggests the inadequacy in the current strategy with neonatal screening – it may 
already be too late to secure normal neurological development. Studies of populations 
indicate that congenital hypothyroidism affects 1 in 3,000 to 4,000 newborns; twice as many 
females as males. A recent report showed that the incidence in the United States increased 
from ~ 1:4100 in 1987 to ~ 1:2400 in 2002 (Rastogi & LaFranchi, 2010; Harris & Pass, 2007). 
The causes for this change are not entirely clear even though the screening strategy may 
have contributed to the increase (Rastogi & LaFranchi, 2010). 
2. Etiology of congenital hypothyroidism  
Most cases of congenital hypothyroidism are sporadic. But an estimated 15 to 20 percent of 
cases are inherited including mutations in the DUOX2, PAX8, SLC5A5(NIS), SLC26A4(PDS), 
TG, TPO, DEHAL1, TSHB, and TSHR genes (Table 1; Rastogi & LaFranchi, 2010; Grasberger 
& Refetoff, 2011). Many inherited cases are autosomal recessive but those with a mutation in 
the PAX8 gene or certain TSHR gene mutations have an autosomal dominant pattern of 
inheritance. Another possible cause of fetal hypothyroidism is anti-thyroid medication 
treatment for maternal hyperthyroidism during pregnancy (Rastogi & LaFranchi, 2010; 
Rovet et al., 1999; Mirabella et al., 2000; Vanmiddlesworth et al., 2011). In severe iodine-
deficient regions, the prevalence of cretinism can reach 10% of the local population; WHO 
 14 
A 3,3’-Diiodothyronine Sulfate  
Cross-Reactive Material (Compound W), 
a Potential Marker for Fetal Hypothyroidism 
Sing-Yung Wu and William L. Green 
University of California, Irvine, VA Medical Center, Long Beach, California, and 
University of Washington, Seattle, Washington 
USA 
1. Introduction 
In developing mammals (including humans), a deficiency or excess of thyroid hormone 
(TH) in the developing brain during the fetal and neonatal periods can lead to 
morphological and functional abnormalities (Nunez et al., 1992; Pasquini & Adamo, 1994; 
Morreale de Escobar et al., 2004; Harakawa et al., 1989). The most severe form of 
hypothyroidism in human fetus and neonate is the syndrome of cretinism. Recent studies 
indicate that abnormalities in intelligence quotient (IQ) and other neuropsychological tests 
may be found in children of women with subclinical hypothyroidism during pregnancy 
(Haddow et al., 1999; Mitchell & Klein, 2004; Casey et al., 2005). Subtle health impairment 
and reduced socio-educational achievement are observed in young adults with congenital 
hypothyroidism identified by neonatal screening and subsequently treated (Leger et al., 
2011). This suggests the inadequacy in the current strategy with neonatal screening – it may 
already be too late to secure normal neurological development. Studies of populations 
indicate that congenital hypothyroidism affects 1 in 3,000 to 4,000 newborns; twice as many 
females as males. A recent report showed that the incidence in the United States increased 
from ~ 1:4100 in 1987 to ~ 1:2400 in 2002 (Rastogi & LaFranchi, 2010; Harris & Pass, 2007). 
The causes for this change are not entirely clear even though the screening strategy may 
have contributed to the increase (Rastogi & LaFranchi, 2010). 
2. Etiology of congenital hypothyroidism  
Most cases of congenital hypothyroidism are sporadic. But an estimated 15 to 20 percent of 
cases are inherited including mutations in the DUOX2, PAX8, SLC5A5(NIS), SLC26A4(PDS), 
TG, TPO, DEHAL1, TSHB, and TSHR genes (Table 1; Rastogi & LaFranchi, 2010; Grasberger 
& Refetoff, 2011). Many inherited cases are autosomal recessive but those with a mutation in 
the PAX8 gene or certain TSHR gene mutations have an autosomal dominant pattern of 
inheritance. Another possible cause of fetal hypothyroidism is anti-thyroid medication 
treatment for maternal hyperthyroidism during pregnancy (Rastogi & LaFranchi, 2010; 
Rovet et al., 1999; Mirabella et al., 2000; Vanmiddlesworth et al., 2011). In severe iodine-
deficient regions, the prevalence of cretinism can reach 10% of the local population; WHO 
 
Hypothyroidism – Influences and Treatments 
 
242 
estimates indicate a prevalence in the millions worldwide (World Health Organization 
[WHO], 2004; WHO et al., 2007).  
 
Category Etiology Mechanism  Note 
Thyroid Failure Developmental 
Anomaly 
Dysgenesis 98% unknown; others 
associated genetic 
mutation: TTF, NKX2.1, 
NKX2.5, PAX-8 




Pendred syndrome, Tg,  
Iodotyrosine deiodinase 
(DEHAL1, SECISBP2) 
 TSH Binding Receptor defect  
 TSH Signaling G-protein   
Secondary 
Hypothyroidism 
TSH Recetor TSH β  
 TRH Synthetic defect PSIS**, Hypothalamic 
lesion 







HESX1, LHX3, LhX4, PIT1, 
PROP1 gene mutations 
Peripheral Tissue TH resistance TSH β  








 Antibodies Autoimmune TSHR blocking antibody 
 Iodine Excess or 
deficient 
Endemic goiter, a major 









Cleft palate  TTF-2 mutation 
 Respiratory distress, 
Benign Chorea  
Choreoathetosis NKX2.1/TTF-1 mutation 
** NIS: Sodium-iodide symporter; ** PSIS: pituitary stalk interruption syndrome 
Table 1. Causes of Congenital Hypothyroidism 
Concerns regarding fetal hypothyroidism and timely treatment warrant close monitoring of 
fetal thyroid status. One method, cordocentesis, is invasive and has a fetal loss rate of 0.5 to 
1% (Daffos, 1989). Recently, ultrasonography has been utilized to assess the fetal thyroid 
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gland (Harris & Pass, 2007; Polak & Van Vliet, 2010; Luton et al., 2005; Abuhamad et al., 
1995; Ribault et al., 2009). Cordocentesis and serial ultrasonographic measurements are 
either invasive or laborious. The development of a convenient non-invasive means to 
monitor fetal thyroid function is definitely needed.  
3. Alternate pathways of Iodothyronines 
The alternate pathways of thyroid hormone metabolism include conjugation (sulfation or 
sulfonation, and glucuronidation of the phenolic hydroxy group) and, to a lesser extent, 
oxidative deamination of the alanine side-chain leading to the formation of the 
corresponding iodothyroacetates and ether link cleavage (Fig. 1; Wu et al., 2005).  
 
Fig. 1. Alternate pathways of thyroid hormone metabolism. The alternate pathways of 
thyroid hormone metabolism include conjugation (sulfation or sulfonation, and 
glucuronidation) and oxidative deamination of the alanine side-chain leading to the 
formation of the corresponding iodothyroacetates and ether link cleavage. DIT: 
diiodotyrosine; tetrac: tetraiodothyroacetic acid; tetram: tetraiodothyronamine. 
Alternate pathways may serve as mechanisms for further regulation of the bioavailabilities 
of thyroid hormones in tissues, in addition to deiodination in various physiological and 
pathophysiological states. Sulfoconjugation of iodothyronines, for example, is an important 
pathway in developing mammals (Wu et al., 2005); and sulfated iodothyronines can also be 
deiodinated, even at a faster rate. Likewise, iodothyroacetates can be sulfated and further 
deiodinated. Iodothyronine glucuronides are rapidly excreted in the bile. Furthermore, 
sulfoconjugation and glucuronidation are not irreversible pathways for thyroid hormone 
metabolism. Glucuronides can be hydrolyzed in the intestine and reabsorbed, and 
sulfoconjugates can be desulfated in selective tissues, e.g. liver and brain, and become 
available to nuclear receptors, especially in fetuses where type I deiodinase (D1) activity is 
low. The in vivo occurrence of the decarboxylated metabolites of T4 and T3, 3,3’,5,5’-
 
Hypothyroidism – Influences and Treatments 
 
242 
estimates indicate a prevalence in the millions worldwide (World Health Organization 
[WHO], 2004; WHO et al., 2007).  
 
Category Etiology Mechanism  Note 
Thyroid Failure Developmental 
Anomaly 
Dysgenesis 98% unknown; others 
associated genetic 
mutation: TTF, NKX2.1, 
NKX2.5, PAX-8 




Pendred syndrome, Tg,  
Iodotyrosine deiodinase 
(DEHAL1, SECISBP2) 
 TSH Binding Receptor defect  
 TSH Signaling G-protein   
Secondary 
Hypothyroidism 
TSH Recetor TSH β  
 TRH Synthetic defect PSIS**, Hypothalamic 
lesion 







HESX1, LHX3, LhX4, PIT1, 
PROP1 gene mutations 
Peripheral Tissue TH resistance TSH β  








 Antibodies Autoimmune TSHR blocking antibody 
 Iodine Excess or 
deficient 
Endemic goiter, a major 









Cleft palate  TTF-2 mutation 
 Respiratory distress, 
Benign Chorea  
Choreoathetosis NKX2.1/TTF-1 mutation 
** NIS: Sodium-iodide symporter; ** PSIS: pituitary stalk interruption syndrome 
Table 1. Causes of Congenital Hypothyroidism 
Concerns regarding fetal hypothyroidism and timely treatment warrant close monitoring of 
fetal thyroid status. One method, cordocentesis, is invasive and has a fetal loss rate of 0.5 to 
1% (Daffos, 1989). Recently, ultrasonography has been utilized to assess the fetal thyroid 
A 3,3’-Diiodothyronine Sulfate Cross-Reactive Material  
(Compound W), a Potential Marker for Fetal Hypothyroidism 
 
243 
gland (Harris & Pass, 2007; Polak & Van Vliet, 2010; Luton et al., 2005; Abuhamad et al., 
1995; Ribault et al., 2009). Cordocentesis and serial ultrasonographic measurements are 
either invasive or laborious. The development of a convenient non-invasive means to 
monitor fetal thyroid function is definitely needed.  
3. Alternate pathways of Iodothyronines 
The alternate pathways of thyroid hormone metabolism include conjugation (sulfation or 
sulfonation, and glucuronidation of the phenolic hydroxy group) and, to a lesser extent, 
oxidative deamination of the alanine side-chain leading to the formation of the 
corresponding iodothyroacetates and ether link cleavage (Fig. 1; Wu et al., 2005).  
 
Fig. 1. Alternate pathways of thyroid hormone metabolism. The alternate pathways of 
thyroid hormone metabolism include conjugation (sulfation or sulfonation, and 
glucuronidation) and oxidative deamination of the alanine side-chain leading to the 
formation of the corresponding iodothyroacetates and ether link cleavage. DIT: 
diiodotyrosine; tetrac: tetraiodothyroacetic acid; tetram: tetraiodothyronamine. 
Alternate pathways may serve as mechanisms for further regulation of the bioavailabilities 
of thyroid hormones in tissues, in addition to deiodination in various physiological and 
pathophysiological states. Sulfoconjugation of iodothyronines, for example, is an important 
pathway in developing mammals (Wu et al., 2005); and sulfated iodothyronines can also be 
deiodinated, even at a faster rate. Likewise, iodothyroacetates can be sulfated and further 
deiodinated. Iodothyronine glucuronides are rapidly excreted in the bile. Furthermore, 
sulfoconjugation and glucuronidation are not irreversible pathways for thyroid hormone 
metabolism. Glucuronides can be hydrolyzed in the intestine and reabsorbed, and 
sulfoconjugates can be desulfated in selective tissues, e.g. liver and brain, and become 
available to nuclear receptors, especially in fetuses where type I deiodinase (D1) activity is 
low. The in vivo occurrence of the decarboxylated metabolites of T4 and T3, 3,3’,5,5’-
 
Hypothyroidism – Influences and Treatments 
 
244 
tetraiodothyronamine (T4AM), and 3,3’5-triiodothyronamine (T3AM) have not been 
demonstrated (Leonard & Kohrle, 2000). However, recently, 3-monoiodothyronamine (3-
monoam or 3-T1AM) and thyronamine (T0AM) have been identified in brain and other 
tissues in rodents (Scanlan et al., 2004); monoam was found to have rapid effect on reducing 
rectal temperature in mice and is a potent agonist of the G protein-coupled trace amine 
receptor TAR1 (Scanlan, 2009). A single dose of T1AM administered to rodents induces a 
hypometabolic state that in certain ways resembles hibernation. Monoam may be derived 
from low iodinated iodothyronines by aromatic amino acid decarboxylase (Fig. 1 & 2), 
however, its role in developing mammals is not known. 
 
Fig. 2. Postulated T1 AM (monoam) formation. T4AM is not a substrate for type I or II 
deiodinase (D1 or D2) and cannot be deiodinated to T3AM. However, T4AM is readily 
deiodinated to rT3AM by D3, and rT3AM can be further deiodinated to ultimately provide 
T1AM. This suggests a unique biosynthetic deiodination pathway for T1AM starting from 
the decarboxylation products of either T4 or rT3. 
4. Sulfoconjugation of Iodothyronines 
Sulfoconjuation has been found to be a major pathway for thyroid hormone metabolism in 
mammalian fetuses (Fig. 1; Burrow et al., 1994; Wu et al., 2005; Simpson et al., 2005). The 
sulfation of thyroxine (T4) and triiodothyronine (T3) and their metabolites [reverse T3 (rT3) 
and 3,3’- diiodothyronine (T2)] may accelerate their further degradation and excretion. The 
sulfation of T4 completely blocks the outer-ring deiodination to T3S. In addition, sulfated 
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iodothyronines may serve as a reservoir for biologically active hormones such as T3, which 
can be recovered from T3S by sulfatases in selective tissues (Wu et al., 2005).  
By far, T2 is the preferred substrate for various mammalian sulfotransferases (SULTs). The 
purpose of rapid sulfation of T2, as well as rT3 in some tissues studied, is unknown. It is 
interesting that T2 has been found to stimulate mitochondrial respiration in various rat 
tissues (Moreno et al., 1997) and rT3 may play a role in regulating actin polymerization in 
brain cells (Leonard & Farwell, 1997). Also, sulfated T2 is the preferred substrate for both 
human and rat arylsulfatase (ARS) in the microsomal fraction of liver and placenta (Wu et 
al., 2005). Thus, the possibility that these T4 metabolites may play a physiological role in 
developing animals cannot be excluded.  
5. Sulfoconjugation of Iodothyronines and their placental transfer in sheep 
Before the onset of active synthesis and release of TH, iodothyronines detected in the fetus 
clearly are maternal in origin. This period is approximately the first 17 gestational days (d) 
in rats, 50d in sheep (Fig. 3) and 90d in humans.  
 
Fig. 3. Postulated metabolic pathways for ovine fetal thyroid hormones. D1, D2, and D3: 
type I, type II, and type III iodothyronine deiodinases; ST: iodothyronine sulfotransferases 
(SULT). LAO/AT: L-amino acid oxidase/aminotransferase; DiacS: sulfated 3,3’-
diiodothyroacetic acid. Heavy solid lines indicate pathways that are more active in fetuses 
than in adults; thin solid lines, pathways that are less active in fetuses. The upper horizontal 
light dotted line depicts T4 of maternal origin moving to the fetal compartment in the first 
trimester, before the fetal thyroid begins functioning. Other broken lines represent 
unconfirmed pathways. Numbers in parentheses indicate published production rates 
(µg/kg/d). 
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Fig. 3. Postulated metabolic pathways for ovine fetal thyroid hormones. D1, D2, and D3: 
type I, type II, and type III iodothyronine deiodinases; ST: iodothyronine sulfotransferases 
(SULT). LAO/AT: L-amino acid oxidase/aminotransferase; DiacS: sulfated 3,3’-
diiodothyroacetic acid. Heavy solid lines indicate pathways that are more active in fetuses 
than in adults; thin solid lines, pathways that are less active in fetuses. The upper horizontal 
light dotted line depicts T4 of maternal origin moving to the fetal compartment in the first 
trimester, before the fetal thyroid begins functioning. Other broken lines represent 
unconfirmed pathways. Numbers in parentheses indicate published production rates 
(µg/kg/d). 
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The proposed scheme for ovine fetal iodothyronine metabolism in late gestation (near term) 
depicts the production rates for sulfoconjugated thyroid hormone analogs (shown as numbers 
in parentheses along the thick arrows in Fig. 3). The high production rate (ug/kg/d) of T4 
sulfate (T4S) reflects the activity of the sulfation pathway. The rT3S production rate likely 
represents both sulfation of rT3 and inner-ring deiodination of T4S. This scheme shown in Fig. 3 
also predicts 3,3’-T2S is a major thyroid hormone metabolite in the fetus.  
The transfer of TH and their metabolites may be a two-way street. We have shown high 
concentrations of sulfated iodothyronine analogs in human and ovine fetal serum. These 
include T4S, T3S, rT3S, and 3,3’-T2S (T2S) (Wu et al., 2005). The high gradient between fetal 
and maternal serum concentrations of iodothyronine sulfates raises the possibility that there 
may be significant fetal to maternal transfer of iodothyronine sulfoconjugates. When the 
ovine fetus was infused with pharmacological amounts (0.46 µmoles) of T3 or T3S, significant 
fetal to maternal transfer of T2S and T3S occurred (Wu et al., 1995; Wu et al., 1999; Wu et al., 
2006). It is noteworthy that significantly more T3S than T2S of fetal origin was recovered in 
maternal urine following the fetal infusion of either T3 or T3S.  
Furthermore, maternal T2S and T3S levels were significantly higher after fetal T3 than after 
T3S infusion despite the fact that the mean fetal serum concentration of T3S after fetal T3S 
infusion was 20 times higher than following T3 infusion (Wu et al., 1995). On the other hand, 
after fetal infusion of 125I-T3, without disturbing the fetal stable T3 pool, a mean of 19% of 
infused radioactive dose was recovered in maternal urine in 4 h. T2S, not T3S, was identified 
as the major radioactive iodothyronine in fetal to maternal transfer; only minimal amounts 
of T3S or T3, were found (Wu et al., 2006).  
We also assessed the contribution of fetal TH to the urinary T2S and T3S pool in ewes. Maternal 
urinary T2S excretion (pmol/g creatinine) is significantly reduced by fetal thyroidectomy (Tx) 
but not by maternal Tx (Wu et al., 2001). Maternal urinary T2S excretion correlated positively 
with fetal serum T4 concentrations but not with maternal serum T3 or T4 levels (Wu et al., 2001). 
In view of a possible functional role of T2 to stimulate mitochondrial respiration, the removal 
of T2 from fetal compartment may be necessary for normal maturation of mammalian fetuses 
(Wu et al., 2005). Furthermore, recent study showed that ARSC, the only sulfatase that 
hydrolyzes iodothyronine sulfates, has a substrate preference for T2 (Kester et al., 2002), which 
raises the possibility that T2S could be readily reversed back to its precursor, an active 
iodothyronine. This would suggest a need for the fetus to remove T2S from fetal compartment. 
Furthermore, in the sheep model, T2S of fetal origin contributes significantly to maternal 
urinary T2S excretion and may reflect fetal iodothyronine production. 
6. The Evaluation a T2S-crossreactive material (compound w) as a potential 
marker for fetal thyroid function 
In humans, we found high levels of radioimmunoassayable T2S in maternal serum (Wu et 
al., 1994) and urine (Wu et al., 1998). Levels increased with the progression of pregnancy 
and peaked before parturition. At delivery, a 20-fold increase in serum “T2S” was found 
compared to non-pregnant women and “T2S” levels returned to non-pregnant values in 7 to 
10 days (Fig. 4 & 5). On closer examination, the radioimmunoassayable “T2S” did not 
cochromatograph with synthetic T2S by HPLC (Wu et al., 1994). The authentic T2S was 
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hydrolyzed by hot-acid digestion (Wu et al., 1994). Using this procedure, the recovery of 
T2S-crossreactive material was near 82% in fetal and maternal serum (Fig. 6; Wu et al., 2007).  
 
Fig. 4. Change of serum concentrations of compound W in cord and maternal serum. 
Compound W, expressed as ng/dl of T2S, in newborns and maternal serum samples at the 
time of delivery (D). The connected lines represent serial measurements in the same patients (n 
= 18). T2S concentrations also were measured in 14 nonpregnant women (NP) for comparison. 
The decrease in serum compound W concentrations after parturition is depicted in the semilog 
plot in the inset. The closed circles and vertical bars represent the mean ± SEM and (n) 
represents the total number of samples studied at each time period in a total of 35 patients. 
 
Fig. 5. Changes of compound W at different gestation periods. Normal values of T2S-
crossreactive material (compound W) in serum from pregnant women, nonpregnant women 
(NP), and newborns. Vertical bars are mean ± 1 SD. * p < 0.05 cf. 3-7 weeks pregnancy. 
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Fig. 6. Recovery of T2S-crossreactive material following hot-acid treatment. Top: Percent of 
T2S-crossreactive fraction that is hot-acid stable in cord (n = 6) and maternal (n = 12) serum 
samples.  
The maternal and paired cord serum concentrations of T2S-reactive material presented were 
adjusted by this percentage to obtain the hot-acid-resistant T2S-equivalent activity, or the 
“corrected” value. Over 40 known synthetic thyroid hormone analogs were examined and 
none was found to be identical to the T2S-like material in pregnant women’s serum. Thus, 
the name Compound W was given. It is postulated that W is a side-chain modification of 
T2S, which cross-reacts with T2S antibody but is slightly more hydrophobic than T2S. A 
possible candidate is N, N-dimethylated T2S (Fig. 7; Wu et al., 2007).  
To explore the possible origin of compound W, the serum concentrations of sulfated 
iodothyronines from cord arterial and venous samples were compared. There were no 
significant differences between the mean T3S, T4S, or rT3S concentrations of arterial and 
venous serum samples. However, the venous T2S-equivalent concentration was higher than 
arterial in seven of the paired samples and lower in two. The mean “corrected” W 
concentration in paired arterial/venous cord serum was found to be significantly higher in 
venous samples than in arterial samples (Wu et al., 2007). In addition, the mean of the 
maternal serum concentrations of T2S-reactive material was significantly lower than that of 
the paired cord serum concentrations. The rapid disappearance of W from maternal serum 
immediately after delivery supports this hypothesis (Wu et al., 1994). A similar 
disappearance slope of serum W was also found in newborn infants (Chen et al., 2010). 
These findings support the postulation that W is produced in the placenta. 
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Fig. 7. Postulated pathway converting T2S to N, N-methyl- T2S. N, N-methyl- T2S has the 
same physico-chemical characteristics on HPLC and reaction to T2S-specific antibody.  
 
Fig. 8. Levels of T2S-crossreactive material in paired maternal and cord serum at term. The 
solid line is the trend-line from lineal regression analysis for the correlation 
(n = 436, R = 0.686).  
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Prior studies suggest strongly that compound W is a metabolite of fetal thyroid hormone 
capable of transplacental fetal to maternal transfer (Wu et al., 2005; Wu et al., 1994; 
Cortelazzi et al., 1999; Wu et al., 2007). Both maternal and fetal compound W levels increase 
progressively during gestation with significant direct correlation (in both mothers and 
fetuses). Additionally, in 436 paired cord and maternal sera obtained at delivery, a highly 
significant positive correlation was observed between fetal and maternal compound W (Fig. 
8). A significant positive correlation was also observed between serum levels of fetal 
compound W and fetal FT4 and between maternal and fetal compound W (Fig. 9; Cortelazzi 
  
Fig. 9. Compound W levels in fetal serum: correlation with serum fetal FT4 (n=29) and 
maternal compound W (n=42). [Cortelazzi et al., 1999, reproduced with permission from 
European J. Endocrinology] 
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et al., 1999) whereas no correlation was observed between maternal serum compound W 
and maternal serum FT4 in euthyroid or hyperthyroid women. Furthermore, maternal 
compound W levels seem to reflect the effects of drugs on fetal thyroid function (Cortelazzi 
et al., 1999). In women on propylthiouracil (PTU), maternal compound W levels were in the 
low normal range and did not show the usual increase with progression of gestation 
(Cortelazzi et al., 1999). The lack of progression in maternal compound W levels was 
confirmed in a recent study of 22 pregnant women treated with anti-thyroid medication 
(Fig. 10; Vanmiddlesworth et al., 2011). A significant increase in maternal compound W was 
observed when the PTU dose was decreased or discontinued.  
 
Fig. 10. Courses of compound W in serum of pregnant patients with hyperthyroidism 
receiving antithyroid therapy. Two or more points on dotted lines mark the course of 
compound W in each patient, and the thick continuous black line shows the marginal mean 
course. Thick gray lines represent the 10th (lower) and 90th (upper) percentiles. Square 
markers on solid lines indicate suppressed or nonprogressive serial measurements in 5 
patients; triangular markers on solid lines denote 2 patients who had transient progression 
and then reduction below the 10th percentile at term.  
Cortelazzi, et al. (Cortelazzi et al., 1999) suggest that abnormal thyroid function will be 
revealed by an absence of the normal rise of compound W during gestation. In 
comparison with relatively low incidence of congenital hypothyroidism in this population 
(Rastogi & LaFranchi, 2010; Harris & Pass, 2007), serial measurements of compound W in 
maternal serum can be considered a safe and practical test for the assessment of fetal 
thyroid function, particularly in hyperthyroid women treated with anti-thyroid drugs, 
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whose fetuses can become hypothyroid due to the transplacental passage of the drug (Fig. 
10; Vanmiddlesworth et al., 2011).  
Further study is needed to include compound W levels in a greater number of hyperthyroid 
pregnant women treated with anti-thyroid medication or pregnant women with evidence of 
autoimmune thyroid illnesses, followed by long-term follow-up of psychomotor 
development in these seemingly euthyroid babies. Suppressed W levels may help to define 
the sub-group of children exposed to PTU in utero or born to mothers with autoimmune 
disease who have been shown to have an adverse cognitive outcome (Grasberger & Refetoff, 
2011; Rovet et al., 1999; Mirabella et al., 2000; Mitchell & Klein, 2004; Casey et al., 2005). 
7. Conclusion 
Sulfoconjugation is a major metabolic pathway for thyroid hormone in developing 
mammals. The significant rise of sulfated iodothyronines in mammalian fetal compartments 
raises the possibility that significant fetal to maternal transfer of the conjugates may occur in 
late gestation as the fetal hypothalamic-pituitary-thyroid system becomes more mature. This 
transfer may be a novel mechanism to maintain low T3 states or regulate serum T2, a 
thermogenic hormone that is important for normal tissue maturity. The possibility that the 
transferred iodothyronine sulfate, especially T2S and its metabolite, may serve as a marker 
of fetal thyroid function needs to be further explored. 
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1.Introduction 
Thyroid hormones play essential roles in mammalian life, especially in neurodevelopment 
(Porterfield & Hendrich, 1993). This fact is clearly shown in patients with neurological 
deficits from endemic cretinism, who reside in iodine-deficient areas (DeLong et at., 1985). 
In addition to neurological impairments, thyroid dysfunctions, such as hyperthyroidism 
and hypothyroidism, lead to a wide variety of clinical manifestations. Hypothyroidism is 
defined as deficient thyroid hormone action. It is caused most often by decreased thyroid 
hormone production, although in rare cases it is caused by reduced tissue responsiveness 
to or consumptive degradation of the hormone (Huang et al., 2000; Refetoff, Weiss, & 
Usala, 1993). There are two types of deficient thyroid hormone production: primary 
(thyroidal) hypothyroidism and central hypothyroidism. The former is commonly caused 
by iodine deficiency (DeLong et al., 1985) or chronic autoimmune thyroiditis, known as 
Hashimoto’s thyroiditis (Dayan & Daniels, 1996). In iodine-sufficient areas, Hashimoto’s 
thyroiditis is a major cause of primary hypothyroidism. The loss of functional follicles 
caused by intrathyroidal lymphocytic infiltration is attributable to impaired thyroid 
hormone production. Central hypothyroidism is due to reduced thyroid stimulation by 
thyroid-stimulating hormone (TSH) resulting from pituitary disease (secondary 
hypothyroidism) or hypothalamic disease (tertiary hypothyroidism) (Lania et al., 2008). 
Pituitary macroadenomas or radiotherapy of brain tumours and pituitary adenomas are 
frequently associated with insufficient TSH production in adults (Rose, 2001). In some 
cases of central hypothyroidism, abnormally glycosylated TSH with a reduced bioactivity 
is secreted (Faglia et al., 1979; Taylor & Weintraub, 1989). Because thyroid hormones 
negatively regulate pituitary TSH synthesis, decreased serum thyroid hormone 
concentrations lead to the stimulation of TSH production. Therefore, in primary 
hypothyroidism, serum TSH levels are increased, even at the stage of subclinical 
hypothyroidism (Fatourechi, 2009). By contrast, an increase in serum TSH is generally not 
observed in central hypothyroidism because of the impaired hypothalamic-pituitary-
thyroid axis. Based on these observations, serum TSH serves as a useful indicator for the 
presence and the type of hypothyroidism. Therefore, measurements of TSH are quite 
useful in clinical practice (Ladenson et al., 2000).  
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2. Regulation of thyroid-stimulating hormone synthesis 
TSH is produced in pituitary thyrotrophs and activates thyroid follicular cells by binding to 
the TSH receptor (Magner, 1990). This hormone promotes thyroid cell proliferation and 
thyroid hormone synthesis by inducing expression of thyroglobulin, thyroid peroxidase, 
sodium iodide symporter and type I iodothyronine deiodinase (D1) (Tang et al., 1995). TSH 
consists of an α and a  subunit (Shupnik et al., 1989). The α subunit is common to both TSH 
and gonadotropins. The  subunit is a prerequisite for the bioactivity of TSH. Both subunits 
are glycosylated posttranslationally, which is controlled by the thyrotropin-releasing 
hormone (TRH) and is essential for exerting sufficient hormonal bioactivity (Menezes-
Ferreira et al., 1986; Taylor & Weintraub, 1989). In fact, abnormally glycosylated TSH with 
reduced bioactivity is found in some patients with central hypothyroidism (Faglia et al., 
1979; Petersen et al., 1978). 
TSH synthesis is largely dependent on serum thyroid hormone levels. Patients with primary 
hyperthyroidism or primary hypothyroidism consistently demonstrate suppressed or 
increased serum TSH levels, respectively (Ladenson et al., 2000). Clinically, serum TSH 
concentrations serve as a sensitive indicator of thyroid dysfunction since patients with 
abnormal thyroid function have altered serum TSH levels, even at a subclinical stage 
(Fatourechi, 2009). Thus, the measurement of serum TSH is routine for a thyroid evaluation 
in daily clinical practice. In addition to TSH production, the metabolic clearance rate of TSH 
is also influenced by serum thyroid hormone levels, i.e., increased in hyperthyroidism and 
decreased in hypothyroidism (Ridgway et al., 1974). 
In contrast to the negative regulation of TSH production by thyroid hormones, the 
production is positively regulated by TRH. Mice devoid of the TRH gene exhibit 
hypothyroidism accompanied by low circulating TSH levels and reduced numbers of TSH-
immunopositive cells in their pituitary glands (Yamada et al., 1997). In TRH and thyroid 
hormone receptor (TR) -subunit double knockout mice, basal serum TSH levels are low, 
and hypothyroidism fails to increase serum TSH concentrations (Nikrodhanond et al., 2006). 
These studies have demonstrated the pivotal role of TRH in the regulation of TSH 
production. 
Recent studies have demonstrated the presence of TSH receptors in the hypothalamus and 
pituitary folliculo-stellate cells (Crisanti et al., 2001; Prummel et al., 2000), suggesting short 
and ultra-short loop feedback regulation of TSH secretion (Prummel et al., 2004). However, 
their significance remains unknown. 
3. Thyrotropin-releasing hormone as a positive regulator of thyroid-
stimulating hormone production 
TRH is synthesised in neurons located in the parvocellular part of the hypothalamic 
paraventricular nucleus (PVN) (Fekete & Lechan, 2007). These neurons project their axons to 
the median eminence where TRH is released into the portal vein, and the hormone 
subsequently reaches the anterior pituitary. The binding of TRH to its receptor activates 
phospholipase C and is followed by calcium mobilisation and protein kinase C (PKC) 
activation (Carr et al., 1991). However, recent studies suggest that cyclic adenosine 
monophosphate (cAMP) response element binding protein (CREB) rather than the calcium 
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and PKC signalling pathways may play a central role in TRH-stimulated TSH synthesis 
(Hashimoto et al., 2000). In addition, the transcription factor Pit-1, which is pivotal in the 
differentiation of thyrotrophs, lactotrophs and somatotrophs (Andersen & Rosenfeld, 1994), 
induces a synergistic increase in TSH subunit gene transcription in the presence of CREB-
binding protein (Hashimoto et al., 2000). 
TRH synthesis is negatively regulated by thyroid hormones. In the brain, up to 80% of the 
triiodothyronine (T3) bound to nuclear TRs is locally generated through the conversion of 
thyroxine (T4) to T3 by the type 2 deiodinase (D2) (Crantz et al., 1982). Therefore, rather 
than T3, the amount of T4 in circulation is pivotal for the maintenance of adequate T3 
levels in the brain. However, D2 is expressed in the tanycytes lining the third ventricle 
and in astrocytes, but not in neurons (Guadano-Ferraz et al., 1997; Tu et al., 1997). The T3 
produced by tanycytes is the primary source of T3 in TRH neurons. In these neurons, the 
cellular uptake of T3 is mediated by monocarboxylate transporter 8 (MCT8) (Heuer & 
Visser, 2009). T3 binds to the TRs, of which there are three isoforms (TRα1, 1 and 2) in 
the brain (Cheng, 2005). Notably, TR2 is central in the suppression of TRH production 
since mice devoid of the TR2 gene exhibit increased TRH gene expression in the PVN 
(Abel et al., 2001). There are consensus sequences for thyroid hormone response element 
(TRE) half-sites (AGGTCA) in the TRH gene, which may be involved in the negative 
regulation of TRH gene expression by T3 (Wilber & Xu, 1998). The promotor region of the 
gene also contains a cAMP response element (CRE) that overlaps with a TRE (Wilber & 
Xu, 1998), which suggests that there is cross talk between the thyroid hormone and 
cAMP-dependent signalling pathways. 
4. Triiodothyronine is a negative regulator of thyroid-stimulating hormone 
production 
Transcription of the TSHα and  subunit genes is negatively regulated by T3 (Magner, 1990; 
Shupnik et al., 1989). Mice lacking the TR gene have been shown to exhibit inappropriate 
secretion of TSH (Abel et al., 1999; Weiss et al., 1997). By contrast, TSH subunit expression 
was not altered in mice devoid of the TRα gene (Wikstrom et al., 1998). Thus, a series of 
studies suggest a pivotal role for the TR isoforms, especially TR2, in T3-mediated TSH 
suppression. There is a TRE half-site-like sequence (GGGTCA) in the  subunit gene, and 
previous studies have suggested that it might act as a negative TRE in thyrotrophs (Carr et 
al., 1989). However, later studies demonstrated that this putative negative TRE was not 
required in TSH suppression (Matsushita et al., 2007). Instead, the transcription factor 
GATA2 interacts with Pit-1 and TR to play an essential role in both the T3-induced 
suppression and the TRH-induced potentiation of TSH expression (Matsushita et al., 2007; 
Nakano et al., 2004). 
Approximately 50 to 60 % of T3 bound to TRs is locally produced by D2-mediated T4 to T3 
conversion in the rat pituitary gland (Silva & Larsen, 1978). Human pituitary tissues also 
contain D2 (Itagaki et al., 1990). D2 inhibition by iopanoic acid results in an increase in rat 
serum TSH levels (Obregon et al., 1980), which indicates that D2-mediated T4 deiodination 
is the primary source of T3 in the pituitary. D2 activity is increased in hypothyroidism and 
is decreased in hyperthyroidism (Bianco et al., 2002). Thus, the intrapituitary T3 levels are 
carefully maintained by the fine-tuning of D2 activity. 
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5. Neuronal control of thyroid-stimulating hormone secretion (Fig. 1) 
TSH secretion is indirectly controlled by neuronal afferents innervating hypothalamic TRH 
neurons. Adrenergic input from the C1-3 brainstem stimulates TRH synthesis in response to 
cold exposure (Arancibia et al., 1996; Arancibia et al., 1989). Catecholamine binding to α1 
adrenergic receptors leads to CREB phosphorylation and subsequent activation of the TRH 
promoter (Thonberg et al., 2002). Adrenergic neurons that are in contact with the TRH 
neurons also contain cocaine- and amphetamine-regulated transcript (CART) and 
neuropeptide Y (NPY) (Wittmann et al., 2002, 2004). Previous studies have demonstrated 
that CART stimulates TRH synthesis, whereas NPY inhibits it (Fekete et al., 2000, 2001). 
 
III, the third ventricle; AGRP, agouti-related protein; ARC, hypothalamic arcuate nucleus; C1-3, C1-3 
adrenergic area of the brainstem; CART, cocaine- and amphetamine-regulated transcript; D2, type 2 
iodothyronine deiodinase; DMN, hypothalamic dorsomedial nucleus; α-MSH, α-melanocyte 
stimulating hormone; ME, median eminence; NPY; neuropeptide Y; PVN, hypothalamic 
paraventricular nucleus; TRH, thyrotropin-releasing hormone; TSH, thyroid stimulating hormone. 
Fig. 1. Regulatory mechanism of the hypothalamic-pituitary-thyroid axis.  
Peptidergic input from the arcuate nucleus may mediate a fasting-induced decrease in TRH 
production (Lechan & Fekete, 2006). Leptin administration during fasting prevents the 
inhibition of TRH synthesis, suggesting its involvement in this process (Legradi et al., 1997). 
The arcuate nucleus also sends axon terminals containing NPY and agouti-related protein 
(AGRP) or α-melanocyte stimulating hormone (α-MSH) and CART to the TRH neurons and 
thus negatively or positively regulates TRH gene expression (Elias et al., 1998; Hahn et al., 
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1998; Mizuno et al., 1998). Also, α-MSH-containing neurons innervate the hypothalamic 
dorsomedial nucleus (DMN), and the DMN subsequently projects to the TRH neurons in the 
PVN (Mihaly et al., 2001). Thus, there are two pathways to the TRH neurons: the direct 
arcuate-PVN and the indirect arcuate-DMN-PVN. 
6. Drugs affecting thyroid-stimulating hormone secretion 
Glucocorticoids can lower serum TSH concentrations through TRH suppression in the PVN 
(Alkemade et al., 2005; Wilber & Utiger, 1969). TRH neurons possess glucocorticoid 
receptors, and a response element to the hormone has been identified in the TRH gene 
(Cintra et al., 1990). 
Dopamine can reduce TSH production and secretion through its binding to dopamine D2 
receptors in the pituitary gland (Shupnik et al., 1986). Interestingly, it stimulates TRH 
secretion in the rat (Lewis et al., 1987), but this effect cannot override its inhibitory effect on 
the pituitary gland. 
Somatostatin suppresses TSH secretion from the pituitary gland (Lamberts et al., 1989), and 
its analogues are therefore used for the treatment of TSH-producing adenomas (Beck-Peccoz 
et al., 1989). 
In addition to drugs, several cytokines, such as interleukin-1 (IL-1), IL-6 and tumour 
necrosis factor-α (TNFα), have been shown to inhibit TSH secretion (Bartalena et al., 1994; 
Pang et al., 1989). These cytokines can stimulate the D2 activity in pituitary cells (Baur et al., 
2000), suggesting increased T4 to T3 conversion as one possible mechanism for the 
suppressed TSH production in cytokine-treated animals. 
7. Quantitative analysis of thyroid-stimulating hormone transcription in 
hypothyroidism (Sugimoto et al., 2007) 
TSH (thyrotropin) is the primary regulatory peptide for the synthesis and secretion of 
thyroid hormones, including T3 and T4. TRH secretion from the hypothalamus stimulates 
the release of TSH from the anterior lobe of the pituitary gland. TSH is then secreted into the 
blood to stimulate the release of T4, which is produced by the thyroid gland, and T3, which 
is produced by both the thyroid gland and by conversion of T4 in peripheral tissues. T3 has 
stronger biological effects than T4. This TRH–TSH–thyroid hormone (T3, T4) secretion 
relationship is called the hypothalamic–pituitary–thyroid axis (HPT axis), which operates on 
both short- and long-feedback mechanisms (O'Shea & Williams, 2002). The plasma levels of 
T3 and T4 are maintained by this mechanism. 
Thyroid hormones are essential for maintaining many physiological functions, including 
metabolism, growth, and development. In hypothyroidism, TSH and TRH levels are 
elevated, owing to the lack of a suppressive action of the T3. Hypothyroidism in rats, 
induced by propylthiouracil (PTU) administration, is associated with high TSH mRNA 
expression, which is measured semiquantitatively by northern blotting or in situ 
hybridisation; however, these results varied widely from 3 to 22 times the level seen in 
control rats (Carr & Chin, 1988; Franklyn et al., 1987; Samuels et al., 1989; Shupnik & 
Ridgway, 1987; Steel et al., 1990; Taylor et al., 1990). 
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The LightCycler® system (Roche Applied Science, Switzerland) was developed for the 
quantitative analysis of gene expression by real-time polymerase chain reaction (PCR). It 
combines a thermocycler and a microvolume fluorimeter (Lyon, 2001) with the fluorescence-
based assay requiring less manipulation than a basic PCR assay (Contini et al., 2005). 
Therefore, the LightCycler® is a highly sensitive quantitative method for the detection of 
RNA expression (Emrich et al., 2002; Schuster et al., 2004; Tan et al., 2004). 
Posttranscriptional control of mRNA steady-state levels can occur at many steps after the 
synthesis of the initial heterogeneous nuclear RNA (hnRNA) transcript. hnRNA is therefore 
the primary transcript produced by RNA polymerase, which includes both the exonic and 
the intronic regions of the DNA. Transcriptional control of the mRNA occurs at the levels of 
hnRNA stability, splicing, polyadenylation, capping, methylation, editing, the nuclear-
cytoplasmic transport of mature mRNA, and mRNA stability. Mature mRNA synthesised in 
the nucleus translocates into the cytoplasm, where it is stabilised, translated into protein, or 
degraded (Kren & Steer, 1996). The half-life of mRNA is comparatively longer than that of 
hnRNA, and changes in mRNA levels in the cell do not necessarily reflect the transcriptional 
level. It takes at least 0.5 h, and sometimes up to 2 h, for mRNA to accumulate to detectable 
levels after the start of transcription for most genes (Kren & Steer, 1996). A more reliable 
measure for evaluating the rate of transcription is hnRNA because of its short half-life of 15–
30 min (Darnell, 1983), which makes it a valuable quantitative indicator of transcriptional 
activation. 
In 2002, Johnson et al. (Johnson et al., 2002) reported a quantitative real-time reverse 
transcription (RT)-PCR analysis of prostaglandin endoperoxide H synthase hnRNA. Since 
then, several studies have successfully detected hnRNA expression using real-time PCR 
systems (Danzi et al., 2005; Ginsberg et al., 2006; Johnson et al., 2003; Kuroda et al., 2005; Li 
et al., 2005). However, only semiquantitative analyses of hnRNA have been reported for 
TSH gene transcription (Franklyn et al., 1987; Samuels et al., 1989; Shupnik & Ridgway, 
1987; Taylor et al., 1990). In this study, we performed a quantitative analysis of TSH gene 
expression by real-time RT-PCR using the LightCycler® system. We present here the first 
quantitative demonstration of increased mRNA and hnRNA expression of TSH under a 
chronic condition of hypothyroidism in rats. This method for the detection of quantitative 
hnRNA is illustrated in Fig. 2.  
7.1 Materials and methods 
7.1.1 Animals and the induction of hypothyroidism 
Adult male Wistar rats (Nippon Clea Inc., Shizuoka, Japan) weighing 280 g were allowed free 
access to food and water and were maintained on a 12 h light/12 h dark cycle (lights on 07:00–
19:00 h). The rats were divided into two groups of four animals each: a hypothyroidism group 
and a control group. The rats were allowed free access to either 0.05% methimazole (MMI) in 
water (hypothyroid group) or water alone (controls). Fourteen days later, all rats were 
decapitated between 08:00 and 10:00 h, and blood was collected from their trunks to avoid 
contamination with the pituitary portal blood, which contains high TSH levels. The sample 
was collected into a tube containing ice-cold ethylenediaminetetraacetic acid (EDTA) and 
centrifuged at 1008×g for 30 min. Serum T3 and T4 levels were measured to assess the degree 
of hypothyroidism induced by MMI administration. 
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All animal experiments were conducted in accordance with the international standards for 
animal welfare from the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals and the Animal Experiments Guidelines of the Institute for Animal 
Experimentation, Tohoku University Graduate School of Medicine. 
 
Real-time PCR was performed using the cDNA as a template, which was reverse transcribed from total 
RNA. The intron-specific primer pair was used to amplify hnRNA for primary transcript quantification. 
Figure modified from Strachan, T & Read, AP. (2004). DNA structure and gene expression, In: Human 
Molecular Genetics 3rd, pp15, Garland Science, ISBN 0-8153-4184-9, New York, USA.  
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7.1.2 Assay of serum T3 and T4 by EIA 
Serum samples taken from the trunk blood were analysed for T3 and T4 levels by an 
Enzyme Immunoassay (EIA) kit (IMX Dynapac, Abbott Japan, Tokyo, Japan). The 
sensitivities of the assay were <15 ng/dl for T3 and 1.0 ug/dl for T4.  
7.1.3 RNA isolation and reverse transcription for real-time PCR 
Following decapitation, the rat brains were removed within 1 min. The pituitaries were 
dissected out, snap frozen in liquid nitrogen, homogenised and treated with a combination 
of Trizol and chloroform (Invitrogen, San Diego, CA) to extract total RNA (Guevremont et 
al., 2006). The RNA from the rat pituitary was purified using DNase I to remove genomic 
DNA, and the RNA concentration was determined by absorbance readings at 260 nm on a 
UV spectrophotometre (Bio-Rad, Hercules, CA). A total of 2 µg of RNA was reverse 
transcribed using the Omniscript Reverse Transcription (RT) kit (Qiagen, Hilden, Germany) 
with random hexamer primers. Refined cDNA was synthesised in a total volume of 20 ul, 
treated with RNase H and stored at −20°C until use.  
The integrity of the RNA used for the cDNA preparations was tested by PCR 
amplification (using a thermal cycler) of the glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) housekeeping gene (primer sequences are listed in Table 1). After 
electrophoresis on 2% agarose gels, staining with ethidium bromide and visualisation by a 
UV light, the sizes of the PCR products were verified by comparing them against 
molecular weight markers. 
 
 Forward primer 5’ – 3’ Reverse primer 5’ – 3’ Product size 
TSHβ mRNA ggcaaactgtttcttcccaa gttggttttgacagcctcgt 210 bp 
TSHβ hnRNA gaccagtgatccagtcggtt cgggctgtagaaaccaggta 447 bp 
GAPDH mRNA tgaacgggaagctcactgg tccaccaccctgttgctgta 307 bp 
Primers were designed using the computer programme Primer 3 Software 
(http://frodo.wi.mit.edu/cgibin/primer3/primer3_www.cgi). 
All the produced sequences were checked for homology by the NCBI database BLASTn. 
Table 1. Primer sequences for quantitative real-time RT-PCR. 
7.1.4 Primer design and quantitative analysis by real-time PCR 
TSH primers were designed to amplify two specific regions in the TSH RNA. To amplify 
mRNA, the exon-specific primer pair, which was designed to target sequences from exon 3, 
was used (Table 1). The intron-specific primer pair, which was designed to target sequences 
found in intron 1, was used to amplify hnRNA (Table 1). The amplified mRNA and hnRNA 
products were 210 and 447 bp, respectively. All RT-PCR assays were normalised against rat 
GAPDH using commercial PCR primers (Nihon Gene Research Laboratories) that amplify a 
307 bp product (Table 1).  
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Quantification of the TSH mRNA and hnRNA was performed by real-time PCR using 
the LightCycler® system (Roche Diagnostics, Japan) with SYBR green detection of 
amplification products. PCR for all genes was performed in a final volume of 20 ul using 
the LC FastStart DNA Master SYBR Green I (Roche Molecular Biochemicals) with 2 ul of 
each primer at 0.5 M, 3 mM MgCl2 and 2 ul of extracted cDNA, but without dimethyl 
sulfoxide (DMSO). 
Table 2 shows the LightCycler® PCR amplification programmes. A single fluorescence 
reading for each sample was taken at the annealing step. Quantitative results were 
determined from the crossing point (CP), which marked the cycle when the fluorescence of a 
given sample significantly exceeded the baseline signal, and are expressed as a fractional 
cycle number. CP values plotted against known concentrations of TSH mRNA and hnRNA 
were used to obtain a standard curve. The TSH mRNA and hnRNA counts for 
 
Gene 
 Programme for Real-time LightCycler 
Melting curve 




(°C) 95 62 72 95 62 96 
Incubation time 









(°C) 95 62 72 95 62 96 
Incubation time 









(°C) 95 62 72 95 62 96 
Incubation time 




20 20 20 20 20 0.1 
Table 2. LightCycler PCR amplification conditions. 
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the LC FastStart DNA Master SYBR Green I (Roche Molecular Biochemicals) with 2 ul of 
each primer at 0.5 M, 3 mM MgCl2 and 2 ul of extracted cDNA, but without dimethyl 
sulfoxide (DMSO). 
Table 2 shows the LightCycler® PCR amplification programmes. A single fluorescence 
reading for each sample was taken at the annealing step. Quantitative results were 
determined from the crossing point (CP), which marked the cycle when the fluorescence of a 
given sample significantly exceeded the baseline signal, and are expressed as a fractional 
cycle number. CP values plotted against known concentrations of TSH mRNA and hnRNA 
were used to obtain a standard curve. The TSH mRNA and hnRNA counts for 
 
Gene 
 Programme for Real-time LightCycler 
Melting curve 




(°C) 95 62 72 95 62 96 
Incubation time 
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Incubation time 
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20 20 20 20 20 0.1 
Table 2. LightCycler PCR amplification conditions. 
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a given rat sample were calculated by interpolation from this standard curve (Software 
LightCycler® 3.5). The melting point of each amplified product was calculated to check the 
PCR specificity (Fukushima et al., 2003), and transcription of each cDNA was quantified 
(Fig. 3). 
 
The horizontal and vertical axes show the PCR cycle number and the degree of fluorescence, 
respectively. In the hypothyroid rat group, the PCR amplification lines curve upward at lower PCR 
cycle numbers than those of the control group, indicating that the initial hnRNA content was higher in 
the hypothyroid rat group than in the control group.  
Figure Inset: The unknown relative concentration of hnRNA can be calculated from the sample 
concentration (the horizontal axis; log X) and the cycle number (the vertical axis).  
Fig. 3. Original graph from the LightCycler® 3.5 system for the quantification of TSH 
hnRNA.  
7.1.5 Statistical analysis 
All data are expressed as means ± S.D. T3 and T4 measurements and real-time PCR data 
were analysed for statistical significance using an unpaired Student’s t-test. A p-value less 
than 0.01 was considered statistically significant difference. 
Control Hypothyroidism
 




7.2.1 Serum T3 and T4 levels 
The serum T3 and T4 levels for the hypothyroid rats and control rats are listed in Table 3. 
Oral administration of 0.05% MMI ad libitum was sufficient to induce hypothyroidism in 
rats. MMI administration resulted in a complete suppression of T3 levels.  
 
 T3 T4 
Hypothyroidism n.d.* 1610 ± 1100* 
Control 48.7 ± 2.1 6730 ± 210 
Values are means ± SD. *p < 0.01 compared with the control group. Not detected (n.d.). 
Table 3. Serum T3 and T4 levels (ng/dl).  
7.2.2 Quantitative analysis of TSHβ mRNA and hnRNA by real-time PCR 
TSH gene regulation at the transcriptional and posttranscriptional levels was evaluated by 
real-time RT-PCR to assess mRNA and hnRNA (mRNA precursor) expression. The total 
RNA extracts from pituitaries isolated from weight-matched rats were treated with DNase 
I to remove contaminating genomic DNA prior to RT-PCR. The TSH-specific primers 
were subsequently checked for their ability to amplify during PCR reactions in the 
thermal cycler using total RNA with or without DNase I treatment. Although a PCR 
product was created from the total RNA template in the absence of DNase I (Fig. 4), the 
presence of DNase I inhibited the reaction, and no product was produced (data not 
shown).  
The TSH mRNA and hnRNA levels measured from real-time RT-PCR analysis were 
estimated relative to the values of GAPDH (the internal standard) and expressed as 
percentages of the control (Fig. 5). The expression levels of both TSH mRNA and hnRNA 
in hypothyroidism were approximately fourfold higher than the respective levels in control 
rats. The difference in CP between TSH mRNA and hnRNA was approximately 3–5 (Fig. 
3), indicating that hnRNA expression was 8- to 32-fold lower than mRNA expression in 
chronically hypothyroid rats.  
7.3 Discussion  
The aim of this study was to detect hnRNA expression by quantitative real-time PCR 
analysis, and, in particular, the up-regulation of TSH gene transcription under the 
condition of hypothyroidism. Previous reports have shown a range of levels for the up-
regulation of TSH mRNA (Table 4). Although these results were obtained under different 
experimental conditions, such as the length of PTU administration and the method of 
mRNA detection, our results confirmed a significant increase in TSH mRNA expression in 
hypothyroid rats.  
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Both bands ofthe TSH mRNA and the hnRNA bands in the hypothyroid rats group looked were 
thicker than that those in the control group. The far left lanes show ladder is a DNA markerladder. 
After checking the size of the PCR ampliconslength by this ladder, we can forward proceed to the next 
step for a quantitative real-time PCR. Hypothyroid rats group: lanes 1-4. Control group: lanes 5-7.  
Fig. 4. Detection of the RT-PCR amplicons for TSH mRNA and hnRNA by thermal cycler 
 
TSH mRNA and hnRNA levels in hypothyroid rats were approximately fourfold higher than those of 
the control rats. Control values were normalised to 100%. Data are expressed as means ± S.D. *p < 0.01 
compared with the control group. 
Fig. 5. Quantitative analysis of TSH mRNA and hnRNA levels in control and hypothyroid 
rats using a LightCycler® PCR system.  
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Most previous reports have used PTU to induce hypothyroidism (Franklyn et al., 1987; 
Samuels et al., 1989; Shupnik & Ridgway, 1987; Taylor et al., 1990). However, there is 
ample evidence that MMI should be used first as an antithyroid drug for Graves’ disease 
(Ginsberg et al., 2006). In addition, some studies have shown that MMI is more effective 
than PTU at equivalent doses by reducing thyroid hormone levels more rapidly and 
achieving euthyroidism more quickly (Ginsberg et al., 2006). In this study, free access to a 
0.05% MMI solution in drinking water for 2 weeks induced hypothyroidism in rats (Table 
3). Because of its longer half-life, MMI can also be used as a single daily agent and is 
therefore more likely to be associated with patient compliance (Cooper, 1984, 1986). Most 
importantly, MMI may have a more favourable safety profile than PTU (Ginsberg et al., 
2006).  
 
Reference Duration of PTU administration TSH mRNA Method 
(Taylor et al., 1990) 
2 weeks 4-fold up-regulation in situ 
hybridisation 4 weeks 16-fold up-regulation 
(Steel et al., 1990)  22-fold up-regulation in situ hybridisation 
(Samuels et al., 
1989) 6 weeks 3-fold up-regulation 
Northern blot 
analysis 
(Carr & Chin, 1988)  6- to 8-fold up-regulation Northern blot analysis 
(Shupnik & 
Ridgway, 1987) 6 weeks 10-fold up-regulation 
Northern blot 
analysis 
(Franklyn et al., 
1987) 
3 weeks 10-fold up-regulation Northern blot 
analysis 10 weeks 20-fold up-regulation 
PTU administration; oral administration of 0.05% propylthiouracil in the drinking water  
Table 4. Previous reports of semi-quantitative analysis of TSHβ mRNA expression in rat 
hypothyroidism. 
In this study, we accurately measured the increased rate of TSH gene transcription in 
hypothyroid rats by detecting mRNA and hnRNA expression levels over time using the 
LightCycler® system. Our main recommendations for success with this system are as 
follows: (1) the extracted total RNA should be treated with DNase to ensure exclusion of 
genomic DNA and (2) degenerate oligonucleotide random primers should be used instead 
of the degenerate oligonucleotide dT primers that are more commonly used for mRNA 
detection.  
The poly-A tail of a mature mRNA is immediately appended by poly-A polymerase at the 
final step of RNA processing. Oligonucleotide dT primers attach to the poly-A tail of the 
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mRNA for cDNA synthesis until the RT reaction stops. Therefore, only the exonic regions of 
the DNA are reflected by RT-PCR when use of Oligonucleotide dT primers. However, in our 
experiments, we used a random hexamer primer, which attaches to DNA complementarily 
and randomly. When a hexamer primer attaches to any intronic region of the hnRNA, the 
RT reaction accurately makes cDNA, reflecting primary transcription. Using this cDNA 
containing intronic sequences as a template, we successfully amplified primary TSH 
transcripts with a TSH-specific intron primer.  
The only difficulty in our method was dissecting tissues of the same size and location 
from the animals. In this study, we easily removed pituitary glands of the same size 
because the pituitary gland differentiates from a dual embryonic origin, unlike other 
nearby tissues (Kelberman et al., 2009), which allows the pituitary gland to be easily 
separated. However, in the case of continuous tissues, such as the hypothalamus, it may 
be difficult to dissect an area from the same location within the brain. If the dissected area 
dose not contain the target neurons, the internal gene of the area should show a relative 
increase.  
The increased level of TSH mRNA was nearly equal to that of TSH hnRNA in 
hypothyroid rats. Since the transcriptional rate is often masked by the abundance of pre-
existing mature mRNA, quantitative detection of hnRNA is important for the precise 
examination of transcriptional changes during an acute response. Therefore, the use of a 
quantitative real-time PCR method is beneficial for the analysis of genes with low 
expression levels, such as those genes that are undetectable when using an in situ 
hybridisation method.  
In this report, we demonstrated for the first time that optimal conditions for real-time PCR 
enable the detection of TSH hnRNA expression levels in hypothyroid rats. In addition to its 
critical role in homeostasis, thyroid hormone can also regulate gene transcription in relation 
to various aspects of brain function (Refetoff et al., 1993), including synapse formation 
(Nicholson & Altman, 1972). Thus, our results are of particular importance for 
neuroendocrinological studies. 
Finally, we determined the exact ratio for the up-regulation of TSH mRNA and hnRNA 
levels in hypothyroid rats using quantitative real-time PCR. Using this method, we can 
perform similar investigations on the transcription rates of other genes. 
8. Conclusion 
We have summarised TSH regulation (e.g., TSH secretion and synthesis), the HPT axis as a 
positive/negative regulator of TSH, the neuronal control of TSH, and drugs affecting TSH in 
hypothyroidism. We also described a method for the quantitative analysis of TSH hnRNA 
and mRNA expression using real-time PCR in induced hypothyroidism. Both the TSH 
mRNA and hnRNA expression levels in hypothyroidism induced by methimazole 
administration were increased approximately fourfold over the respective levels in control 
rats. Further, the level of TSH hnRNA expression was 8- to 32-fold lower than that of TSH 
mRNA in chronically hypothyroid rats. Using this method, we can perform similar 
investigations of the transcription rates for other genes. 
 
Thyroid-Stimulating Hormone Regulation and Transcription in Hypothyroidism 
 
269 
9. Acknowledgement  
This work was supported by a Grant-in-Aid for Exploratory Research (#22659380) from the 
Japan Society for the Promotion of Science.  
10. References 
Abel, E. D., Ahima, R. S., Boers, M. E., Elmquist, J. K., & Wondisford, F. E. (2001). Critical 
role for thyroid hormone receptor beta2 in the regulation of paraventricular 
thyrotropin-releasing hormone neurons. The Journal of clinical investigation, Vol.107, 
No.8, pp. 1017-1023, ISSN 0021-9738 
Abel, E. D., Boers, M. E., Pazos-Moura, C., Moura, E., Kaulbach, H., Zakaria, M., Lowell, B., 
Radovick, S., Liberman, M. C., & Wondisford, F. (1999). Divergent roles for thyroid 
hormone receptor beta isoforms in the endocrine axis and auditory system. The 
Journal of clinical investigation, Vol.104, No.3, pp. 291-300, ISSN 0021-9738 
Alkemade, A., Unmehopa, U. A., Wiersinga, W. M., Swaab, D. F., & Fliers, E. (2005). 
Glucocorticoids decrease thyrotropin-releasing hormone messenger ribonucleic 
acid expression in the paraventricular nucleus of the human hypothalamus. The 
Journal of clinical endocrinology and metabolism, Vol.90, No.1, pp. 323-327, ISSN 0021-
972X 
Andersen, B., & Rosenfeld, M. G. (1994). Pit-1 determines cell types during development of 
the anterior pituitary gland. A model for transcriptional regulation of cell 
phenotypes in mammalian organogenesis. The Journal of biological chemistry, 
Vol.269, No.47, pp. 29335-29338, ISSN 0021-9258 
Arancibia, S., Rage, F., Astier, H., & Tapia-Arancibia, L. (1996). Neuroendocrine and 
autonomous mechanisms underlying thermoregulation in cold environment. 
Neuroendocrinology, Vol.64, No.4, pp. 257-267, ISSN 0028-3835 
Arancibia, S., Tapia-Arancibia, L., Astier, H., & Assenmacher, I. (1989). Physiological 
evidence for alpha 1-adrenergic facilitatory control of the cold-induced TRH release 
in the rat, obtained by push-pull cannulation of the median eminence. Neuroscience 
letters, Vol.100, No.1-3, pp. 169-174, ISSN 0304-3940 
Bartalena, L., Grasso, L., Brogioni, S., & Martino, E. (1994). Interleukin 6 effects on the 
pituitary-thyroid axis in the rat. European journal of endocrinology / European 
Federation of Endocrine Societies, Vol.131, No.3, pp. 302-306, ISSN 0804-4643 
Baur, A., Bauer, K., Jarry, H., & Kohrle, J. (2000). Effects of proinflammatory cytokines on 
anterior pituitary 5'-deiodinase type I and type II. The Journal of endocrinology, 
Vol.167, No.3, pp. 505-515, ISSN 0022-0795 
Beck-Peccoz, P., Mariotti, S., Guillausseau, P. J., Medri, G., Piscitelli, G., Bertoli, A., 
Barbarino, A., Rondena, M., Chanson, P., Pinchera, A., & et al. (1989). Treatment of 
hyperthyroidism due to inappropriate secretion of thyrotropin with the 
somatostatin analog SMS 201-995. The Journal of clinical endocrinology and metabolism, 
Vol.68, No.1, pp. 208-214, ISSN 0021-972X 
Bianco, A. C., Salvatore, D., Gereben, B., Berry, M. J., & Larsen, P. R. (2002). Biochemistry, 
cellular and molecular biology, and physiological roles of the iodothyronine 
selenodeiodinases. Endocrine reviews, Vol.23, No.1, pp. 38-89, ISSN 0163-769X 
 
Hypothyroidism – Influences and Treatments 
 
268 
mRNA for cDNA synthesis until the RT reaction stops. Therefore, only the exonic regions of 
the DNA are reflected by RT-PCR when use of Oligonucleotide dT primers. However, in our 
experiments, we used a random hexamer primer, which attaches to DNA complementarily 
and randomly. When a hexamer primer attaches to any intronic region of the hnRNA, the 
RT reaction accurately makes cDNA, reflecting primary transcription. Using this cDNA 
containing intronic sequences as a template, we successfully amplified primary TSH 
transcripts with a TSH-specific intron primer.  
The only difficulty in our method was dissecting tissues of the same size and location 
from the animals. In this study, we easily removed pituitary glands of the same size 
because the pituitary gland differentiates from a dual embryonic origin, unlike other 
nearby tissues (Kelberman et al., 2009), which allows the pituitary gland to be easily 
separated. However, in the case of continuous tissues, such as the hypothalamus, it may 
be difficult to dissect an area from the same location within the brain. If the dissected area 
dose not contain the target neurons, the internal gene of the area should show a relative 
increase.  
The increased level of TSH mRNA was nearly equal to that of TSH hnRNA in 
hypothyroid rats. Since the transcriptional rate is often masked by the abundance of pre-
existing mature mRNA, quantitative detection of hnRNA is important for the precise 
examination of transcriptional changes during an acute response. Therefore, the use of a 
quantitative real-time PCR method is beneficial for the analysis of genes with low 
expression levels, such as those genes that are undetectable when using an in situ 
hybridisation method.  
In this report, we demonstrated for the first time that optimal conditions for real-time PCR 
enable the detection of TSH hnRNA expression levels in hypothyroid rats. In addition to its 
critical role in homeostasis, thyroid hormone can also regulate gene transcription in relation 
to various aspects of brain function (Refetoff et al., 1993), including synapse formation 
(Nicholson & Altman, 1972). Thus, our results are of particular importance for 
neuroendocrinological studies. 
Finally, we determined the exact ratio for the up-regulation of TSH mRNA and hnRNA 
levels in hypothyroid rats using quantitative real-time PCR. Using this method, we can 
perform similar investigations on the transcription rates of other genes. 
8. Conclusion 
We have summarised TSH regulation (e.g., TSH secretion and synthesis), the HPT axis as a 
positive/negative regulator of TSH, the neuronal control of TSH, and drugs affecting TSH in 
hypothyroidism. We also described a method for the quantitative analysis of TSH hnRNA 
and mRNA expression using real-time PCR in induced hypothyroidism. Both the TSH 
mRNA and hnRNA expression levels in hypothyroidism induced by methimazole 
administration were increased approximately fourfold over the respective levels in control 
rats. Further, the level of TSH hnRNA expression was 8- to 32-fold lower than that of TSH 
mRNA in chronically hypothyroid rats. Using this method, we can perform similar 
investigations of the transcription rates for other genes. 
 
Thyroid-Stimulating Hormone Regulation and Transcription in Hypothyroidism 
 
269 
9. Acknowledgement  
This work was supported by a Grant-in-Aid for Exploratory Research (#22659380) from the 
Japan Society for the Promotion of Science.  
10. References 
Abel, E. D., Ahima, R. S., Boers, M. E., Elmquist, J. K., & Wondisford, F. E. (2001). Critical 
role for thyroid hormone receptor beta2 in the regulation of paraventricular 
thyrotropin-releasing hormone neurons. The Journal of clinical investigation, Vol.107, 
No.8, pp. 1017-1023, ISSN 0021-9738 
Abel, E. D., Boers, M. E., Pazos-Moura, C., Moura, E., Kaulbach, H., Zakaria, M., Lowell, B., 
Radovick, S., Liberman, M. C., & Wondisford, F. (1999). Divergent roles for thyroid 
hormone receptor beta isoforms in the endocrine axis and auditory system. The 
Journal of clinical investigation, Vol.104, No.3, pp. 291-300, ISSN 0021-9738 
Alkemade, A., Unmehopa, U. A., Wiersinga, W. M., Swaab, D. F., & Fliers, E. (2005). 
Glucocorticoids decrease thyrotropin-releasing hormone messenger ribonucleic 
acid expression in the paraventricular nucleus of the human hypothalamus. The 
Journal of clinical endocrinology and metabolism, Vol.90, No.1, pp. 323-327, ISSN 0021-
972X 
Andersen, B., & Rosenfeld, M. G. (1994). Pit-1 determines cell types during development of 
the anterior pituitary gland. A model for transcriptional regulation of cell 
phenotypes in mammalian organogenesis. The Journal of biological chemistry, 
Vol.269, No.47, pp. 29335-29338, ISSN 0021-9258 
Arancibia, S., Rage, F., Astier, H., & Tapia-Arancibia, L. (1996). Neuroendocrine and 
autonomous mechanisms underlying thermoregulation in cold environment. 
Neuroendocrinology, Vol.64, No.4, pp. 257-267, ISSN 0028-3835 
Arancibia, S., Tapia-Arancibia, L., Astier, H., & Assenmacher, I. (1989). Physiological 
evidence for alpha 1-adrenergic facilitatory control of the cold-induced TRH release 
in the rat, obtained by push-pull cannulation of the median eminence. Neuroscience 
letters, Vol.100, No.1-3, pp. 169-174, ISSN 0304-3940 
Bartalena, L., Grasso, L., Brogioni, S., & Martino, E. (1994). Interleukin 6 effects on the 
pituitary-thyroid axis in the rat. European journal of endocrinology / European 
Federation of Endocrine Societies, Vol.131, No.3, pp. 302-306, ISSN 0804-4643 
Baur, A., Bauer, K., Jarry, H., & Kohrle, J. (2000). Effects of proinflammatory cytokines on 
anterior pituitary 5'-deiodinase type I and type II. The Journal of endocrinology, 
Vol.167, No.3, pp. 505-515, ISSN 0022-0795 
Beck-Peccoz, P., Mariotti, S., Guillausseau, P. J., Medri, G., Piscitelli, G., Bertoli, A., 
Barbarino, A., Rondena, M., Chanson, P., Pinchera, A., & et al. (1989). Treatment of 
hyperthyroidism due to inappropriate secretion of thyrotropin with the 
somatostatin analog SMS 201-995. The Journal of clinical endocrinology and metabolism, 
Vol.68, No.1, pp. 208-214, ISSN 0021-972X 
Bianco, A. C., Salvatore, D., Gereben, B., Berry, M. J., & Larsen, P. R. (2002). Biochemistry, 
cellular and molecular biology, and physiological roles of the iodothyronine 
selenodeiodinases. Endocrine reviews, Vol.23, No.1, pp. 38-89, ISSN 0163-769X 
 
Hypothyroidism – Influences and Treatments 
 
270 
Carr, F. E., Burnside, J., & Chin, W. W. (1989). Thyroid hormones regulate rat thyrotropin 
beta gene promoter activity expressed in GH3 cells. Molecular endocrinology, Vol.3, 
No.4, pp. 709-716, ISSN 0888-8809 
Carr, F. E., & Chin, W. W. (1988). Differential thyroid hormone-regulated rat thyrotropin 
beta gene expression detected by blot hybridization. Mol Endocrinol, Vol.2, No.8, 
pp. 667-673, ISSN  
Carr, F. E., Galloway, R. J., Reid, A. H., Kaseem, L. L., Dhillon, G., Fein, H. G., & Smallridge, 
R. C. (1991). Thyrotropin-releasing hormone regulation of thyrotropin beta-subunit 
gene expression involves intracellular calcium and protein kinase C. Biochemistry, 
Vol.30, No.15, pp. 3721-3728, ISSN 0006-2960 
Cheng, S. Y. (2005). Thyroid hormone receptor mutations and disease: beyond thyroid 
hormone resistance. Trends in endocrinology and metabolism: TEM, Vol.16, No.4, 
pp. 176-182, ISSN 1043-2760 
Cintra, A., Fuxe, K., Wikstrom, A. C., Visser, T., & Gustafsson, J. A. (1990). Evidence for 
thyrotropin-releasing hormone and glucocorticoid receptor-immunoreactive 
neurons in various preoptic and hypothalamic nuclei of the male rat. Brain research, 
Vol.506, No.1, pp. 139-144, ISSN 0006-8993 
Contini, C., Seraceni, S., Cultrera, R., Incorvaia, C., Sebastiani, A., & Picot, S. (2005). 
Evaluation of a Real-time PCR-based assay using the lightcycler system for 
detection of Toxoplasma gondii bradyzoite genes in blood specimens from patients 
with toxoplasmic retinochoroiditis. Int J Parasitol, Vol.35, No.3, pp. 275-283, ISSN  
Cooper, D. S. (1984). Antithyroid drugs. N Engl J Med, Vol.311, No.21, pp. 1353-1362, ISSN  
Cooper, D. S. (1986). Which anti-thyroid drug? Am J Med, Vol.80, No.6, pp. 1165-1168, ISSN  
Crantz, F. R., Silva, J. E., & Larsen, P. R. (1982). An analysis of the sources and quantity of 
3,5,3'-triiodothyronine specifically bound to nuclear receptors in rat cerebral cortex 
and cerebellum. Endocrinology, Vol.110, No.2, pp. 367-375, ISSN 0013-7227 
Crisanti, P., Omri, B., Hughes, E., Meduri, G., Hery, C., Clauser, E., Jacquemin, C., & 
Saunier, B. (2001). The expression of thyrotropin receptor in the brain. 
Endocrinology, Vol.142, No.2, pp. 812-822, ISSN 0013-7227 
Danzi, S., Dubon, P., & Klein, I. (2005). Effect of serum triiodothyronine on regulation of 
cardiac gene expression: role of histone acetylation. Am J Physiol Heart Circ Physiol, 
Vol.289, No.4, pp. H1506-1511, ISSN  
Darnell, J. E., Jr. (1983). The processing of RNA. Sci Am, Vol.249, No.4, pp. 90-100, ISSN  
Dayan, C. M., & Daniels, G. H. (1996). Chronic autoimmune thyroiditis. The New England 
journal of medicine, Vol.335, No.2, pp. 99-107, ISSN 0028-4793 
DeLong, G. R., Stanbury, J. B., & Fierro-Benitez, R. (1985). Neurological signs in congenital 
iodine-deficiency disorder (endemic cretinism). Developmental medicine and child 
neurology, Vol.27, No.3, pp. 317-324, ISSN 0012-1622 
Elias, C. F., Lee, C., Kelly, J., Aschkenasi, C., Ahima, R. S., Couceyro, P. R., Kuhar, M. J., 
Saper, C. B., & Elmquist, J. K. (1998). Leptin activates hypothalamic CART neurons 
projecting to the spinal cord. Neuron, Vol.21, No.6, pp. 1375-1385, ISSN 0896-6273 
Emrich, T., Chang, S. Y., Karl, G., Panzinger, B., & Santini, C. (2002). Quantitative detection 
of telomerase components by real-time, online RT-PCR analysis with the 
LightCycler. Methods Mol Biol, Vol.191, pp. 99-108, ISSN  
Faglia, G., Bitensky, L., Pinchera, A., Ferrari, C., Paracchi, A., Beck-Peccoz, P., Ambrosi, B., & 
Spada, A. (1979). Thyrotropin secretion in patients with central hypothyroidism: 
 
Thyroid-Stimulating Hormone Regulation and Transcription in Hypothyroidism 
 
271 
evidence for reduced biological activity of immunoreactive thyrotropin. The Journal 
of clinical endocrinology and metabolism, Vol.48, No.6, pp. 989-998, ISSN 0021-972X 
Fatourechi, V. (2009). Subclinical hypothyroidism: an update for primary care physicians. 
Mayo Clinic proceedings. Mayo Clinic, Vol.84, No1, pp. 65-71, ISSN 1942-5546 
Fekete, C., Kelly, J., Mihaly, E., Sarkar, S., Rand, W. M., Legradi, G., Emerson, C. H., & 
Lechan, R. M. (2001). Neuropeptide Y has a central inhibitory action on the 
hypothalamic-pituitary-thyroid axis. Endocrinology, Vol.142, No.6, pp. 2606-2613, 
ISSN  
Fekete, C., & Lechan, R. M. (2007). Negative feedback regulation of hypophysiotropic 
thyrotropin-releasing hormone (TRH) synthesizing neurons: role of neuronal 
afferents and type 2 deiodinase. Frontiers in neuroendocrinology, Vol.28, No.2-3, pp. 
97-114, ISSN 0091-3022 
Fekete, C., Mihaly, E., Luo, L. G., Kelly, J., Clausen, J. T., Mao, Q., Rand, W. M., Moss, L. G., 
Kuhar, M., Emerson, C. H., Jackson, I. M., & Lechan, R. M. (2000). Association of 
cocaine- and amphetamine-regulated transcript-immunoreactive elements with 
thyrotropin-releasing hormone-synthesizing neurons in the hypothalamic 
paraventricular nucleus and its role in the regulation of the hypothalamic-pituitary-
thyroid axis during fasting. The Journal of neuroscience : the official journal of the 
Society for Neuroscience, Vol.20, No.24, pp. 9224-9234, ISSN 1529-2401 
Franklyn, J. A., Wood, D. F., Balfour, N. J., Ramsden, D. B., Docherty, K., Chin, W. W., & 
Sheppard, M. C. (1987). Effect of hypothyroidism and thyroid hormone 
replacement in vivo on pituitary cytoplasmic concentrations of thyrotropin-beta 
and alpha-subunit messenger ribonucleic acids. Endocrinology, Vol.120, No.6, pp. 
2279-2288, ISSN  
Fukushima, H., Tsunomori, Y., & Seki, R. (2003). Duplex real-time SYBR green PCR assays 
for detection of 17 species of food- or waterborne pathogens in stools. J Clin 
Microbiol, Vol.41, No.11, pp. 5134-5146, ISSN  
Ginsberg, A. B., Frank, M. G., Francis, A. B., Rubin, B. A., O'Connor, K. A., & Spencer, R. L. 
(2006). Specific and time-dependent effects of glucocorticoid receptor agonist 
RU28362 on stress-induced pro-opiomelanocortin hnRNA, c-fos mRNA and zif268 
mRNA in the pituitary. J Neuroendocrinol, Vol.18, No.2, pp. 129-138, ISSN  
Guadano-Ferraz, A., Obregon, M. J., St Germain, D. L., & Bernal, J. (1997). The type 2 
iodothyronine deiodinase is expressed primarily in glial cells in the neonatal rat 
brain. Proceedings of the National Academy of Sciences of the United States of America, 
Vol.94, No.19, pp. 10391-10396, ISSN 0027-8424 
Guevremont, E., Brassard, J., Houde, A., Simard, C., & Trottier, Y. L. (2006). Development of 
an extraction and concentration procedure and comparison of RT-PCR primer 
systems for the detection of hepatitis A virus and norovirus GII in green onions. J 
Virol Methods, Vol.134, pp. 130-135, ISSN  
Hahn, T. M., Breininger, J. F., Baskin, D. G., & Schwartz, M. W. (1998). Coexpression of Agrp 
and NPY in fasting-activated hypothalamic neurons. Nature neuroscience, Vol.1, 
No.4, pp. 271-272, ISSN 1097-6256 
Hashimoto, K., Zanger, K., Hollenberg, A. N., Cohen, L. E., Radovick, S., & Wondisford, F. 
E. (2000). cAMP response element-binding protein-binding protein mediates 
thyrotropin-releasing hormone signaling on thyrotropin subunit genes. The Journal 
of biological chemistry, Vol.275, No.43, pp. 33365-33372, ISSN 0021-9258 
 
Hypothyroidism – Influences and Treatments 
 
270 
Carr, F. E., Burnside, J., & Chin, W. W. (1989). Thyroid hormones regulate rat thyrotropin 
beta gene promoter activity expressed in GH3 cells. Molecular endocrinology, Vol.3, 
No.4, pp. 709-716, ISSN 0888-8809 
Carr, F. E., & Chin, W. W. (1988). Differential thyroid hormone-regulated rat thyrotropin 
beta gene expression detected by blot hybridization. Mol Endocrinol, Vol.2, No.8, 
pp. 667-673, ISSN  
Carr, F. E., Galloway, R. J., Reid, A. H., Kaseem, L. L., Dhillon, G., Fein, H. G., & Smallridge, 
R. C. (1991). Thyrotropin-releasing hormone regulation of thyrotropin beta-subunit 
gene expression involves intracellular calcium and protein kinase C. Biochemistry, 
Vol.30, No.15, pp. 3721-3728, ISSN 0006-2960 
Cheng, S. Y. (2005). Thyroid hormone receptor mutations and disease: beyond thyroid 
hormone resistance. Trends in endocrinology and metabolism: TEM, Vol.16, No.4, 
pp. 176-182, ISSN 1043-2760 
Cintra, A., Fuxe, K., Wikstrom, A. C., Visser, T., & Gustafsson, J. A. (1990). Evidence for 
thyrotropin-releasing hormone and glucocorticoid receptor-immunoreactive 
neurons in various preoptic and hypothalamic nuclei of the male rat. Brain research, 
Vol.506, No.1, pp. 139-144, ISSN 0006-8993 
Contini, C., Seraceni, S., Cultrera, R., Incorvaia, C., Sebastiani, A., & Picot, S. (2005). 
Evaluation of a Real-time PCR-based assay using the lightcycler system for 
detection of Toxoplasma gondii bradyzoite genes in blood specimens from patients 
with toxoplasmic retinochoroiditis. Int J Parasitol, Vol.35, No.3, pp. 275-283, ISSN  
Cooper, D. S. (1984). Antithyroid drugs. N Engl J Med, Vol.311, No.21, pp. 1353-1362, ISSN  
Cooper, D. S. (1986). Which anti-thyroid drug? Am J Med, Vol.80, No.6, pp. 1165-1168, ISSN  
Crantz, F. R., Silva, J. E., & Larsen, P. R. (1982). An analysis of the sources and quantity of 
3,5,3'-triiodothyronine specifically bound to nuclear receptors in rat cerebral cortex 
and cerebellum. Endocrinology, Vol.110, No.2, pp. 367-375, ISSN 0013-7227 
Crisanti, P., Omri, B., Hughes, E., Meduri, G., Hery, C., Clauser, E., Jacquemin, C., & 
Saunier, B. (2001). The expression of thyrotropin receptor in the brain. 
Endocrinology, Vol.142, No.2, pp. 812-822, ISSN 0013-7227 
Danzi, S., Dubon, P., & Klein, I. (2005). Effect of serum triiodothyronine on regulation of 
cardiac gene expression: role of histone acetylation. Am J Physiol Heart Circ Physiol, 
Vol.289, No.4, pp. H1506-1511, ISSN  
Darnell, J. E., Jr. (1983). The processing of RNA. Sci Am, Vol.249, No.4, pp. 90-100, ISSN  
Dayan, C. M., & Daniels, G. H. (1996). Chronic autoimmune thyroiditis. The New England 
journal of medicine, Vol.335, No.2, pp. 99-107, ISSN 0028-4793 
DeLong, G. R., Stanbury, J. B., & Fierro-Benitez, R. (1985). Neurological signs in congenital 
iodine-deficiency disorder (endemic cretinism). Developmental medicine and child 
neurology, Vol.27, No.3, pp. 317-324, ISSN 0012-1622 
Elias, C. F., Lee, C., Kelly, J., Aschkenasi, C., Ahima, R. S., Couceyro, P. R., Kuhar, M. J., 
Saper, C. B., & Elmquist, J. K. (1998). Leptin activates hypothalamic CART neurons 
projecting to the spinal cord. Neuron, Vol.21, No.6, pp. 1375-1385, ISSN 0896-6273 
Emrich, T., Chang, S. Y., Karl, G., Panzinger, B., & Santini, C. (2002). Quantitative detection 
of telomerase components by real-time, online RT-PCR analysis with the 
LightCycler. Methods Mol Biol, Vol.191, pp. 99-108, ISSN  
Faglia, G., Bitensky, L., Pinchera, A., Ferrari, C., Paracchi, A., Beck-Peccoz, P., Ambrosi, B., & 
Spada, A. (1979). Thyrotropin secretion in patients with central hypothyroidism: 
 
Thyroid-Stimulating Hormone Regulation and Transcription in Hypothyroidism 
 
271 
evidence for reduced biological activity of immunoreactive thyrotropin. The Journal 
of clinical endocrinology and metabolism, Vol.48, No.6, pp. 989-998, ISSN 0021-972X 
Fatourechi, V. (2009). Subclinical hypothyroidism: an update for primary care physicians. 
Mayo Clinic proceedings. Mayo Clinic, Vol.84, No1, pp. 65-71, ISSN 1942-5546 
Fekete, C., Kelly, J., Mihaly, E., Sarkar, S., Rand, W. M., Legradi, G., Emerson, C. H., & 
Lechan, R. M. (2001). Neuropeptide Y has a central inhibitory action on the 
hypothalamic-pituitary-thyroid axis. Endocrinology, Vol.142, No.6, pp. 2606-2613, 
ISSN  
Fekete, C., & Lechan, R. M. (2007). Negative feedback regulation of hypophysiotropic 
thyrotropin-releasing hormone (TRH) synthesizing neurons: role of neuronal 
afferents and type 2 deiodinase. Frontiers in neuroendocrinology, Vol.28, No.2-3, pp. 
97-114, ISSN 0091-3022 
Fekete, C., Mihaly, E., Luo, L. G., Kelly, J., Clausen, J. T., Mao, Q., Rand, W. M., Moss, L. G., 
Kuhar, M., Emerson, C. H., Jackson, I. M., & Lechan, R. M. (2000). Association of 
cocaine- and amphetamine-regulated transcript-immunoreactive elements with 
thyrotropin-releasing hormone-synthesizing neurons in the hypothalamic 
paraventricular nucleus and its role in the regulation of the hypothalamic-pituitary-
thyroid axis during fasting. The Journal of neuroscience : the official journal of the 
Society for Neuroscience, Vol.20, No.24, pp. 9224-9234, ISSN 1529-2401 
Franklyn, J. A., Wood, D. F., Balfour, N. J., Ramsden, D. B., Docherty, K., Chin, W. W., & 
Sheppard, M. C. (1987). Effect of hypothyroidism and thyroid hormone 
replacement in vivo on pituitary cytoplasmic concentrations of thyrotropin-beta 
and alpha-subunit messenger ribonucleic acids. Endocrinology, Vol.120, No.6, pp. 
2279-2288, ISSN  
Fukushima, H., Tsunomori, Y., & Seki, R. (2003). Duplex real-time SYBR green PCR assays 
for detection of 17 species of food- or waterborne pathogens in stools. J Clin 
Microbiol, Vol.41, No.11, pp. 5134-5146, ISSN  
Ginsberg, A. B., Frank, M. G., Francis, A. B., Rubin, B. A., O'Connor, K. A., & Spencer, R. L. 
(2006). Specific and time-dependent effects of glucocorticoid receptor agonist 
RU28362 on stress-induced pro-opiomelanocortin hnRNA, c-fos mRNA and zif268 
mRNA in the pituitary. J Neuroendocrinol, Vol.18, No.2, pp. 129-138, ISSN  
Guadano-Ferraz, A., Obregon, M. J., St Germain, D. L., & Bernal, J. (1997). The type 2 
iodothyronine deiodinase is expressed primarily in glial cells in the neonatal rat 
brain. Proceedings of the National Academy of Sciences of the United States of America, 
Vol.94, No.19, pp. 10391-10396, ISSN 0027-8424 
Guevremont, E., Brassard, J., Houde, A., Simard, C., & Trottier, Y. L. (2006). Development of 
an extraction and concentration procedure and comparison of RT-PCR primer 
systems for the detection of hepatitis A virus and norovirus GII in green onions. J 
Virol Methods, Vol.134, pp. 130-135, ISSN  
Hahn, T. M., Breininger, J. F., Baskin, D. G., & Schwartz, M. W. (1998). Coexpression of Agrp 
and NPY in fasting-activated hypothalamic neurons. Nature neuroscience, Vol.1, 
No.4, pp. 271-272, ISSN 1097-6256 
Hashimoto, K., Zanger, K., Hollenberg, A. N., Cohen, L. E., Radovick, S., & Wondisford, F. 
E. (2000). cAMP response element-binding protein-binding protein mediates 
thyrotropin-releasing hormone signaling on thyrotropin subunit genes. The Journal 
of biological chemistry, Vol.275, No.43, pp. 33365-33372, ISSN 0021-9258 
 
Hypothyroidism – Influences and Treatments 
 
272 
Heuer, H., & Visser, T. J. (2009). Minireview: Pathophysiological importance of thyroid 
hormone transporters. Endocrinology, Vol.150, No.3, pp. 1078-1083, ISSN 1945-7170 
Huang, S. A., Tu, H. M., Harney, J. W., Venihaki, M., Butte, A. J., Kozakewich, H. P., 
Fishman, S. J., & Larsen, P. R. (2000). Severe hypothyroidism caused by type 3 
iodothyronine deiodinase in infantile hemangiomas. The New England journal of 
medicine, Vol.343, No.3, pp. 185-189, ISSN 0028-4793 
Itagaki, Y., Yoshida, K., Ikeda, H., Kaise, K., Kaise, N., Yamamoto, M., Sakurada, T., & 
Yoshinaga, K. (1990). Thyroxine 5'-deiodinase in human anterior pituitary tumors. 
The Journal of clinical endocrinology and metabolism, Vol.71, No.2, pp. 340-344, ISSN 
0021-972X 
Johnson, R. F., Mitchell, C. M., Giles, W. B., Walters, W. A., & Zakar, T. (2002). The in vivo 
control of prostaglandin H synthase-2 messenger ribonucleic acid expression in the 
human amnion at parturition. J Clin Endocrinol Metab, Vol.87, No.6, pp. 2816-2823, 
ISSN  
Johnson, R. F., Mitchell, C. M., Giles, W. B., Walters, W. A., & Zakar, T. (2003). The control of 
prostaglandin endoperoxide H-Synthase-2 expression in the human chorion laeve 
at term. J Soc Gynecol Investig, Vol.10, No.4, pp. 222-230, ISSN  
Kelberman, D., Rizzoti, K., Lovell-Badge, R., Robinson, I. C., & Dattani, M. T. (2009). Genetic 
regulation of pituitary gland development in human and mouse. Endocr Rev, 
Vol.30, No.7, pp. 790-829, ISSN  
Kren, B. T., & Steer, C. J. (1996). Posttranscriptional regulation of gene expression in liver 
regeneration: role of mRNA stability. Faseb J, Vol.10, No.5, pp. 559-573, ISSN  
Kuroda, M., Oikawa, K., Yoshida, K., Takeuchi, A., Takeuchi, M., Usui, M., Umezawa, A., & 
Mukai, K. (2005). Effects of 3-methylcholanthrene on the transcriptional activity 
and mRNA accumulation of the oncogene hWAPL. Cancer Lett, Vol.221, No.1, pp. 
21-28, ISSN  
Ladenson, P. W., Singer, P. A., Ain, K. B., Bagchi, N., Bigos, S. T., Levy, E. G., Smith, S. A., 
Daniels, G. H., & Cohen, H. D. (2000). American Thyroid Association guidelines for 
detection of thyroid dysfunction. Archives of internal medicine, Vol.160, No.11, pp. 
1573-1575, ISSN 0003-9926 
Lamberts, S. W., Zuyderwijk, J., den Holder, F., van Koetsveld, P., & Hofland, L. (1989). 
Studies on the conditions determining the inhibitory effect of somatostatin on 
adrenocorticotropin, prolactin and thyrotropin release by cultured rat pituitary 
cells. Neuroendocrinology, Vol.50, No.1, pp. 44-50, ISSN 0028-3835 
Lania, A., Persani, L., & Beck-Peccoz, P. (2008). Central hypothyroidism. Pituitary, Vol.11, 
No.2, pp. 181-186, ISSN 1386-341X 
Lechan, R. M., & Fekete, C. (2006). The TRH neuron: a hypothalamic integrator of energy 
metabolism. Progress in brain research, Vol.153, pp. 209-235, ISSN 0079-6123. 
Legradi, G., Emerson, C. H., Ahima, R. S., Flier, J. S., & Lechan, R. M. (1997). Leptin prevents 
fasting-induced suppression of prothyrotropin-releasing hormone messenger 
ribonucleic acid in neurons of the hypothalamic paraventricular nucleus. 
Endocrinology, Vol.138, No.6, pp. 2569-2576, ISSN 0013-7227 
Lewis, B. M., Dieguez, C., Lewis, M. D., & Scanlon, M. F. (1987). Dopamine stimulates 
release of thyrotrophin-releasing hormone from perfused intact rat hypothalamus 
via hypothalamic D2-receptors. The Journal of endocrinology, Vol.115, No.3, pp. 419-
424, ISSN 0022-0795 
 
Thyroid-Stimulating Hormone Regulation and Transcription in Hypothyroidism 
 
273 
Li, G. J., Zhao, Q., & Zheng, W. (2005). Alteration at translational but not transcriptional 
level of transferrin receptor expression following manganese exposure at the blood-
CSF barrier in vitro. Toxicol Appl Pharmacol, Vol.205, No.2, pp. 188-200, ISSN  
Lyon, E. (2001). Mutation detection using fluorescent hybridization probes and melting 
curve analysis. Expert Rev Mol Diagn, Vol.1, No.1, pp. 92-101, ISSN  
Magner, J. A. (1990). Thyroid-stimulating hormone: biosynthesis, cell biology, and 
bioactivity. Endocrine reviews, Vol.11, No.2, pp. 354-385, ISSN 0163-769X 
Matsushita, A., Sasaki, S., Kashiwabara, Y., Nagayama, K., Ohba, K., Iwaki, H., Misawa, H., 
Ishizuka, K., & Nakamura, H. (2007). Essential role of GATA2 in the negative 
regulation of thyrotropin beta gene by thyroid hormone and its receptors. Molecular 
endocrinology, Vol.21, No.4, pp. 865-884, ISSN 0888-8809 
Menezes-Ferreira, M. M., Petrick, P. A., & Weintraub, B. D. (1986). Regulation of thyrotropin 
(TSH) bioactivity by TSH-releasing hormone and thyroid hormone. Endocrinology, 
Vol.118, No.5, pp. 2125-2130, ISSN 0013-7227 
Mihaly, E., Fekete, C., Legradi, G., & Lechan, R. M. (2001). Hypothalamic dorsomedial 
nucleus neurons innervate thyrotropin-releasing hormone-synthesizing neurons in 
the paraventricular nucleus. Brain research, Vol.891, No.1-2, pp. 20-31, ISSN 0006-
8993 
Mizuno, T. M., Kleopoulos, S. P., Bergen, H. T., Roberts, J. L., Priest, C. A., & Mobbs, C. V. 
(1998). Hypothalamic pro-opiomelanocortin mRNA is reduced by fasting and 
[corrected] in ob/ob and db/db mice, but is stimulated by leptin. Diabetes, Vol.47, 
No.2, pp. 294-297, ISSN 0012-1797 
Nakano, K., Matsushita, A., Sasaki, S., Misawa, H., Nishiyama, K., Kashiwabara, Y., & 
Nakamura, H. (2004). Thyroid-hormone-dependent negative regulation of 
thyrotropin beta gene by thyroid hormone receptors: study with a new 
experimental system using CV1 cells. The Biochemical journal, Vol.378, No.2, pp. 549-
557, ISSN 1470-8728 
Nicholson, J. L., & Altman, J. (1972). Synaptogenesis in the rat cerebellum: effects of early 
hypo- and hyperthyroidism. Science, Vol.176, No.34, pp. 530-532, ISSN  
Nikrodhanond, A. A., Ortiga-Carvalho, T. M., Shibusawa, N., Hashimoto, K., Liao, X. H., 
Refetoff, S., Yamada, M., Mori, M., & Wondisford, F. E. (2006). Dominant role of 
thyrotropin-releasing hormone in the hypothalamic-pituitary-thyroid axis. The 
Journal of biological chemistry, Vol.281, No.8, pp. 5000-5007, ISSN 0021-9258 
O'Shea, P. J., & Williams, G. R. (2002). Insight into the physiological actions of thyroid 
hormone receptors from genetically modified mice. J Endocrinol, Vol.175, No.3, pp. 
553-570, ISSN  
Obregon, M. J., Pascual, A., Mallol, J., Morreale de Escobar, G., & Escobar del Rey, F. (1980). 
Evidence against a major role of L-thyroxine at the pituitary level: studies in rats 
treated with iopanoic acid (telepaque). Endocrinology, Vol.106, No.6, pp. 1827-1836, 
ISSN 0013-7227 
Pang, X. P., Hershman, J. M., Mirell, C. J., & Pekary, A. E. (1989). Impairment of 
hypothalamic-pituitary-thyroid function in rats treated with human recombinant 
tumor necrosis factor-alpha (cachectin). Endocrinology, Vol.125, No.1, pp. 76-84, 
ISSN 0013-7227 
Petersen, V. B., McGregor, A. M., Belchetz, P. E., Elkeles, R. S., & Hall, R. (1978). The 
secretion of thyrotrophin with impaired biological activity in patients with 
 
Hypothyroidism – Influences and Treatments 
 
272 
Heuer, H., & Visser, T. J. (2009). Minireview: Pathophysiological importance of thyroid 
hormone transporters. Endocrinology, Vol.150, No.3, pp. 1078-1083, ISSN 1945-7170 
Huang, S. A., Tu, H. M., Harney, J. W., Venihaki, M., Butte, A. J., Kozakewich, H. P., 
Fishman, S. J., & Larsen, P. R. (2000). Severe hypothyroidism caused by type 3 
iodothyronine deiodinase in infantile hemangiomas. The New England journal of 
medicine, Vol.343, No.3, pp. 185-189, ISSN 0028-4793 
Itagaki, Y., Yoshida, K., Ikeda, H., Kaise, K., Kaise, N., Yamamoto, M., Sakurada, T., & 
Yoshinaga, K. (1990). Thyroxine 5'-deiodinase in human anterior pituitary tumors. 
The Journal of clinical endocrinology and metabolism, Vol.71, No.2, pp. 340-344, ISSN 
0021-972X 
Johnson, R. F., Mitchell, C. M., Giles, W. B., Walters, W. A., & Zakar, T. (2002). The in vivo 
control of prostaglandin H synthase-2 messenger ribonucleic acid expression in the 
human amnion at parturition. J Clin Endocrinol Metab, Vol.87, No.6, pp. 2816-2823, 
ISSN  
Johnson, R. F., Mitchell, C. M., Giles, W. B., Walters, W. A., & Zakar, T. (2003). The control of 
prostaglandin endoperoxide H-Synthase-2 expression in the human chorion laeve 
at term. J Soc Gynecol Investig, Vol.10, No.4, pp. 222-230, ISSN  
Kelberman, D., Rizzoti, K., Lovell-Badge, R., Robinson, I. C., & Dattani, M. T. (2009). Genetic 
regulation of pituitary gland development in human and mouse. Endocr Rev, 
Vol.30, No.7, pp. 790-829, ISSN  
Kren, B. T., & Steer, C. J. (1996). Posttranscriptional regulation of gene expression in liver 
regeneration: role of mRNA stability. Faseb J, Vol.10, No.5, pp. 559-573, ISSN  
Kuroda, M., Oikawa, K., Yoshida, K., Takeuchi, A., Takeuchi, M., Usui, M., Umezawa, A., & 
Mukai, K. (2005). Effects of 3-methylcholanthrene on the transcriptional activity 
and mRNA accumulation of the oncogene hWAPL. Cancer Lett, Vol.221, No.1, pp. 
21-28, ISSN  
Ladenson, P. W., Singer, P. A., Ain, K. B., Bagchi, N., Bigos, S. T., Levy, E. G., Smith, S. A., 
Daniels, G. H., & Cohen, H. D. (2000). American Thyroid Association guidelines for 
detection of thyroid dysfunction. Archives of internal medicine, Vol.160, No.11, pp. 
1573-1575, ISSN 0003-9926 
Lamberts, S. W., Zuyderwijk, J., den Holder, F., van Koetsveld, P., & Hofland, L. (1989). 
Studies on the conditions determining the inhibitory effect of somatostatin on 
adrenocorticotropin, prolactin and thyrotropin release by cultured rat pituitary 
cells. Neuroendocrinology, Vol.50, No.1, pp. 44-50, ISSN 0028-3835 
Lania, A., Persani, L., & Beck-Peccoz, P. (2008). Central hypothyroidism. Pituitary, Vol.11, 
No.2, pp. 181-186, ISSN 1386-341X 
Lechan, R. M., & Fekete, C. (2006). The TRH neuron: a hypothalamic integrator of energy 
metabolism. Progress in brain research, Vol.153, pp. 209-235, ISSN 0079-6123. 
Legradi, G., Emerson, C. H., Ahima, R. S., Flier, J. S., & Lechan, R. M. (1997). Leptin prevents 
fasting-induced suppression of prothyrotropin-releasing hormone messenger 
ribonucleic acid in neurons of the hypothalamic paraventricular nucleus. 
Endocrinology, Vol.138, No.6, pp. 2569-2576, ISSN 0013-7227 
Lewis, B. M., Dieguez, C., Lewis, M. D., & Scanlon, M. F. (1987). Dopamine stimulates 
release of thyrotrophin-releasing hormone from perfused intact rat hypothalamus 
via hypothalamic D2-receptors. The Journal of endocrinology, Vol.115, No.3, pp. 419-
424, ISSN 0022-0795 
 
Thyroid-Stimulating Hormone Regulation and Transcription in Hypothyroidism 
 
273 
Li, G. J., Zhao, Q., & Zheng, W. (2005). Alteration at translational but not transcriptional 
level of transferrin receptor expression following manganese exposure at the blood-
CSF barrier in vitro. Toxicol Appl Pharmacol, Vol.205, No.2, pp. 188-200, ISSN  
Lyon, E. (2001). Mutation detection using fluorescent hybridization probes and melting 
curve analysis. Expert Rev Mol Diagn, Vol.1, No.1, pp. 92-101, ISSN  
Magner, J. A. (1990). Thyroid-stimulating hormone: biosynthesis, cell biology, and 
bioactivity. Endocrine reviews, Vol.11, No.2, pp. 354-385, ISSN 0163-769X 
Matsushita, A., Sasaki, S., Kashiwabara, Y., Nagayama, K., Ohba, K., Iwaki, H., Misawa, H., 
Ishizuka, K., & Nakamura, H. (2007). Essential role of GATA2 in the negative 
regulation of thyrotropin beta gene by thyroid hormone and its receptors. Molecular 
endocrinology, Vol.21, No.4, pp. 865-884, ISSN 0888-8809 
Menezes-Ferreira, M. M., Petrick, P. A., & Weintraub, B. D. (1986). Regulation of thyrotropin 
(TSH) bioactivity by TSH-releasing hormone and thyroid hormone. Endocrinology, 
Vol.118, No.5, pp. 2125-2130, ISSN 0013-7227 
Mihaly, E., Fekete, C., Legradi, G., & Lechan, R. M. (2001). Hypothalamic dorsomedial 
nucleus neurons innervate thyrotropin-releasing hormone-synthesizing neurons in 
the paraventricular nucleus. Brain research, Vol.891, No.1-2, pp. 20-31, ISSN 0006-
8993 
Mizuno, T. M., Kleopoulos, S. P., Bergen, H. T., Roberts, J. L., Priest, C. A., & Mobbs, C. V. 
(1998). Hypothalamic pro-opiomelanocortin mRNA is reduced by fasting and 
[corrected] in ob/ob and db/db mice, but is stimulated by leptin. Diabetes, Vol.47, 
No.2, pp. 294-297, ISSN 0012-1797 
Nakano, K., Matsushita, A., Sasaki, S., Misawa, H., Nishiyama, K., Kashiwabara, Y., & 
Nakamura, H. (2004). Thyroid-hormone-dependent negative regulation of 
thyrotropin beta gene by thyroid hormone receptors: study with a new 
experimental system using CV1 cells. The Biochemical journal, Vol.378, No.2, pp. 549-
557, ISSN 1470-8728 
Nicholson, J. L., & Altman, J. (1972). Synaptogenesis in the rat cerebellum: effects of early 
hypo- and hyperthyroidism. Science, Vol.176, No.34, pp. 530-532, ISSN  
Nikrodhanond, A. A., Ortiga-Carvalho, T. M., Shibusawa, N., Hashimoto, K., Liao, X. H., 
Refetoff, S., Yamada, M., Mori, M., & Wondisford, F. E. (2006). Dominant role of 
thyrotropin-releasing hormone in the hypothalamic-pituitary-thyroid axis. The 
Journal of biological chemistry, Vol.281, No.8, pp. 5000-5007, ISSN 0021-9258 
O'Shea, P. J., & Williams, G. R. (2002). Insight into the physiological actions of thyroid 
hormone receptors from genetically modified mice. J Endocrinol, Vol.175, No.3, pp. 
553-570, ISSN  
Obregon, M. J., Pascual, A., Mallol, J., Morreale de Escobar, G., & Escobar del Rey, F. (1980). 
Evidence against a major role of L-thyroxine at the pituitary level: studies in rats 
treated with iopanoic acid (telepaque). Endocrinology, Vol.106, No.6, pp. 1827-1836, 
ISSN 0013-7227 
Pang, X. P., Hershman, J. M., Mirell, C. J., & Pekary, A. E. (1989). Impairment of 
hypothalamic-pituitary-thyroid function in rats treated with human recombinant 
tumor necrosis factor-alpha (cachectin). Endocrinology, Vol.125, No.1, pp. 76-84, 
ISSN 0013-7227 
Petersen, V. B., McGregor, A. M., Belchetz, P. E., Elkeles, R. S., & Hall, R. (1978). The 
secretion of thyrotrophin with impaired biological activity in patients with 
 
Hypothyroidism – Influences and Treatments 
 
274 
hypothalamic-pituitary disease. Clinical endocrinology, Vol.8, No.5, pp. 397-402, 
ISSN 0300-0664 
Porterfield, S. P., & Hendrich, C. E. (1993). The role of thyroid hormones in prenatal and 
neonatal neurological development--current perspectives. Endocrine reviews, Vol.14, 
No.1, pp. 94-106, ISSN 0163-769X 
Prummel, M. F., Brokken, L. J., Meduri, G., Misrahi, M., Bakker, O., & Wiersinga, W. M. 
(2000). Expression of the thyroid-stimulating hormone receptor in the folliculo-
stellate cells of the human anterior pituitary. The Journal of clinical endocrinology and 
metabolism, Vol.85, No.11, pp. 4347-4353, ISSN 0021-972X 
Prummel, M. F., Brokken, L. J., & Wiersinga, W. M. (2004). Ultra short-loop feedback control 
of thyrotropin secretion. Thyroid : official journal of the American Thyroid 
Association, Vol.14, No.10, pp. 825-829, ISSN 1050-7256 
Refetoff, S., Weiss, R. E., & Usala, S. J. (1993). The syndromes of resistance to thyroid 
hormone. Endocr Rev, Vol.14, No.3, pp. 348-399, ISSN 0163-769X 
Ridgway, E. C., Weintraub, B. D., & Maloof, F. (1974). Metabolic clearance and production 
rates of human thyrotropin. The Journal of clinical investigation, Vol.53, No.3, pp. 895-
903, ISSN 0021-9738 
Rose, S. R. (2001). Cranial irradiation and central hypothyroidism. Trends in endocrinology 
and metabolism: TEM, Vo.12, No.3, pp. 97-104, ISSN 1043-2760 
Samuels, M. H., Wierman, M. E., Wang, C., & Ridgway, E. C. (1989). The effect of altered 
thyroid status on pituitary hormone messenger ribonucleic acid concentrations in 
the rat. Endocrinology, Vol.124, No.5, pp. 2277-2282, ISSN  
Schuster, R., Max, N., Mann, B., Heufelder, K., Thilo, F., Grone, J., Rokos, F., Buhr, H. J., 
Thiel, E., & Keilholz, U. (2004). Quantitative real-time RT-PCR for detection of 
disseminated tumor cells in peripheral blood of patients with colorectal cancer 
using different mRNA markers. Int J Cancer, Vol.108, No.2, pp. 219-227, ISSN  
Shupnik, M. A., Greenspan, S. L., & Ridgway, E. C. (1986). Transcriptional regulation of 
thyrotropin subunit genes by thyrotropin-releasing hormone and dopamine in 
pituitary cell culture. The Journal of biological chemistry, Vol.261, No.27, pp. 12675-
12679, ISSN 0021-9258 
Shupnik, M. A., & Ridgway, E. C. (1987). Thyroid hormone control of thyrotropin gene 
expression in rat anterior pituitary cells. Endocrinology, Vol.121, No.2, pp. 619-624, 
ISSN  
Shupnik, M. A., Ridgway, E. C., & Chin, W. W. (1989). Molecular biology of thyrotropin. 
Endocrine reviews, Vol.10, No.4, pp. 459-475, ISSN 0163-769X 
Silva, J. E., & Larsen, P. R. (1978). Contributions of plasma triiodothyronine and local 
thyroxine monodeiodination to triiodothyronine to nuclear triiodothyronine 
receptor saturation in pituitary, liver, and kidney of hypothyroid rats. Further 
evidence relating saturation of pituitary nuclear triiodothyronine receptors and the 
acute inhibition of thyroid-stimulating hormone release. The Journal of clinical 
investigation, Vol.61, No.5, pp. 1247-1259, ISSN 0021-9738 
Steel, J. H., O'Halloran, D. J., Jones, P. M., Van Noorden, S., Chin, W. W., Bloom, S. R., & 
Polak, J. M. (1990). Combined use of immunocytochemistry and in situ 
hybridization to study beta thyroid-stimulating hormone gene expression in 
pituitaries of hypothyroid rats. Mol Cell Probes, Vol.4, No.5, pp. 385-396, ISSN  
 
Thyroid-Stimulating Hormone Regulation and Transcription in Hypothyroidism 
 
275 
Sugimoto, K., Mori, K., Uchida, K., Kobayashi, D., & Itoi, K. (2007). Quantitative analysis of 
thyroid-stimulating hormone messenger RNA and heterogeneous nuclear RNA in 
hypothyroid rats. Brain Res Bull, Vol.74, No.1-3, pp. 142-146, ISSN  
Tan, B. H., Lim, E. A., Liaw, J. C., Seah, S. G., & Yap, E. P. (2004). Diagnostic value of real-
time capillary thermal cycler in virus detection. Expert Rev Mol Diagn, Vol.4, No.2, 
pp. 219-230, ISSN  
Tang, K. T., Braverman, L. E., & DeVito, W. J. (1995). Tumor necrosis factor-alpha and 
interferon-gamma modulate gene expression of type I 5'-deiodinase, thyroid 
peroxidase, and thyroglobulin in FRTL-5 rat thyroid cells. Endocrinology, Vol.136, 
No.3, pp. 881-888, ISSN 0013-7227 
Taylor, T., & Weintraub, B. D. (1989). Altered thyrotropin (TSH) carbohydrate structures in 
hypothalamic hypothyroidism created by paraventricular nuclear lesions are 
corrected by in vivo TSH-releasing hormone administration. Endocrinology, Vol.125, 
No.4, pp. 2198-2203, ISSN 0013-7227 
Taylor, T., Wondisford, F. E., Blaine, T., & Weintraub, B. D. (1990). The paraventricular 
nucleus of the hypothalamus has a major role in thyroid hormone feedback 
regulation of thyrotropin synthesis and secretion. Endocrinology, Vol.126, No.1, pp. 
317-324, ISSN  
Thonberg, H., Fredriksson, J. M., Nedergaard, J., & Cannon, B. (2002). A novel pathway for 
adrenergic stimulation of cAMP-response-element-binding protein (CREB) 
phosphorylation: mediation via alpha1-adrenoceptors and protein kinase C 
activation. The Biochemical journal, Vol.364, No.1, pp. 73-79, ISSN 0264-6021 
Tu, H. M., Kim, S. W., Salvatore, D., Bartha, T., Legradi, G., Larsen, P. R., & Lechan, R. M. 
(1997). Regional distribution of type 2 thyroxine deiodinase messenger ribonucleic 
acid in rat hypothalamus and pituitary and its regulation by thyroid hormone. 
Endocrinology, Vol.138, No.8, pp. 3359-3368, ISSN 0013-7227 
Weiss, R. E., Forrest, D., Pohlenz, J., Cua, K., Curran, T., & Refetoff, S. (1997). Thyrotropin 
regulation by thyroid hormone in thyroid hormone receptor beta-deficient mice. 
Endocrinology, Vol.138, No.9, pp. 3624-3629, ISSN 0013-7227 
Wikstrom, L., Johansson, C., Salto, C., Barlow, C., Campos Barros, A., Baas, F., Forrest, D., 
Thoren, P., & Vennstrom, B. (1998). Abnormal heart rate and body temperature in 
mice lacking thyroid hormone receptor alpha 1. The EMBO journal, Vol.17, No.2, 
pp. 455-461, ISSN 0261-4189 
Wilber, J. F., & Utiger, R. D. (1969). The effect of glucocorticoids on thyrotropin secretion. 
The Journal of clinical investigation, Vol.48, No.11, pp. 2096-2103, ISSN 0021-9738. 
Wilber, J. F., & Xu, A. H. (1998). The thyrotropin-releasing hormone gene 1998: cloning, 
characterization, and transcriptional regulation in the central nervous system, 
heart, and testis. Thyroid : official journal of the American Thyroid Association, Vol.8, 
No.10, pp. 897-901, ISSN 1050-7256 
Wittmann, G., Liposits, Z., Lechan, R. M., & Fekete, C. (2002). Medullary adrenergic neurons 
contribute to the neuropeptide Y-ergic innervation of hypophysiotropic 
thyrotropin-releasing hormone-synthesizing neurons in the rat. Neuroscience letters, 
Vol.324, No.1, pp. 69-73, ISSN 0304-3940 
Wittmann, G., Liposits, Z., Lechan, R. M., & Fekete, C. (2004). Medullary adrenergic neurons 
contribute to the cocaine- and amphetamine-regulated transcript-immunoreactive 
innervation of thyrotropin-releasing hormone synthesizing neurons in the 
 
Hypothyroidism – Influences and Treatments 
 
274 
hypothalamic-pituitary disease. Clinical endocrinology, Vol.8, No.5, pp. 397-402, 
ISSN 0300-0664 
Porterfield, S. P., & Hendrich, C. E. (1993). The role of thyroid hormones in prenatal and 
neonatal neurological development--current perspectives. Endocrine reviews, Vol.14, 
No.1, pp. 94-106, ISSN 0163-769X 
Prummel, M. F., Brokken, L. J., Meduri, G., Misrahi, M., Bakker, O., & Wiersinga, W. M. 
(2000). Expression of the thyroid-stimulating hormone receptor in the folliculo-
stellate cells of the human anterior pituitary. The Journal of clinical endocrinology and 
metabolism, Vol.85, No.11, pp. 4347-4353, ISSN 0021-972X 
Prummel, M. F., Brokken, L. J., & Wiersinga, W. M. (2004). Ultra short-loop feedback control 
of thyrotropin secretion. Thyroid : official journal of the American Thyroid 
Association, Vol.14, No.10, pp. 825-829, ISSN 1050-7256 
Refetoff, S., Weiss, R. E., & Usala, S. J. (1993). The syndromes of resistance to thyroid 
hormone. Endocr Rev, Vol.14, No.3, pp. 348-399, ISSN 0163-769X 
Ridgway, E. C., Weintraub, B. D., & Maloof, F. (1974). Metabolic clearance and production 
rates of human thyrotropin. The Journal of clinical investigation, Vol.53, No.3, pp. 895-
903, ISSN 0021-9738 
Rose, S. R. (2001). Cranial irradiation and central hypothyroidism. Trends in endocrinology 
and metabolism: TEM, Vo.12, No.3, pp. 97-104, ISSN 1043-2760 
Samuels, M. H., Wierman, M. E., Wang, C., & Ridgway, E. C. (1989). The effect of altered 
thyroid status on pituitary hormone messenger ribonucleic acid concentrations in 
the rat. Endocrinology, Vol.124, No.5, pp. 2277-2282, ISSN  
Schuster, R., Max, N., Mann, B., Heufelder, K., Thilo, F., Grone, J., Rokos, F., Buhr, H. J., 
Thiel, E., & Keilholz, U. (2004). Quantitative real-time RT-PCR for detection of 
disseminated tumor cells in peripheral blood of patients with colorectal cancer 
using different mRNA markers. Int J Cancer, Vol.108, No.2, pp. 219-227, ISSN  
Shupnik, M. A., Greenspan, S. L., & Ridgway, E. C. (1986). Transcriptional regulation of 
thyrotropin subunit genes by thyrotropin-releasing hormone and dopamine in 
pituitary cell culture. The Journal of biological chemistry, Vol.261, No.27, pp. 12675-
12679, ISSN 0021-9258 
Shupnik, M. A., & Ridgway, E. C. (1987). Thyroid hormone control of thyrotropin gene 
expression in rat anterior pituitary cells. Endocrinology, Vol.121, No.2, pp. 619-624, 
ISSN  
Shupnik, M. A., Ridgway, E. C., & Chin, W. W. (1989). Molecular biology of thyrotropin. 
Endocrine reviews, Vol.10, No.4, pp. 459-475, ISSN 0163-769X 
Silva, J. E., & Larsen, P. R. (1978). Contributions of plasma triiodothyronine and local 
thyroxine monodeiodination to triiodothyronine to nuclear triiodothyronine 
receptor saturation in pituitary, liver, and kidney of hypothyroid rats. Further 
evidence relating saturation of pituitary nuclear triiodothyronine receptors and the 
acute inhibition of thyroid-stimulating hormone release. The Journal of clinical 
investigation, Vol.61, No.5, pp. 1247-1259, ISSN 0021-9738 
Steel, J. H., O'Halloran, D. J., Jones, P. M., Van Noorden, S., Chin, W. W., Bloom, S. R., & 
Polak, J. M. (1990). Combined use of immunocytochemistry and in situ 
hybridization to study beta thyroid-stimulating hormone gene expression in 
pituitaries of hypothyroid rats. Mol Cell Probes, Vol.4, No.5, pp. 385-396, ISSN  
 
Thyroid-Stimulating Hormone Regulation and Transcription in Hypothyroidism 
 
275 
Sugimoto, K., Mori, K., Uchida, K., Kobayashi, D., & Itoi, K. (2007). Quantitative analysis of 
thyroid-stimulating hormone messenger RNA and heterogeneous nuclear RNA in 
hypothyroid rats. Brain Res Bull, Vol.74, No.1-3, pp. 142-146, ISSN  
Tan, B. H., Lim, E. A., Liaw, J. C., Seah, S. G., & Yap, E. P. (2004). Diagnostic value of real-
time capillary thermal cycler in virus detection. Expert Rev Mol Diagn, Vol.4, No.2, 
pp. 219-230, ISSN  
Tang, K. T., Braverman, L. E., & DeVito, W. J. (1995). Tumor necrosis factor-alpha and 
interferon-gamma modulate gene expression of type I 5'-deiodinase, thyroid 
peroxidase, and thyroglobulin in FRTL-5 rat thyroid cells. Endocrinology, Vol.136, 
No.3, pp. 881-888, ISSN 0013-7227 
Taylor, T., & Weintraub, B. D. (1989). Altered thyrotropin (TSH) carbohydrate structures in 
hypothalamic hypothyroidism created by paraventricular nuclear lesions are 
corrected by in vivo TSH-releasing hormone administration. Endocrinology, Vol.125, 
No.4, pp. 2198-2203, ISSN 0013-7227 
Taylor, T., Wondisford, F. E., Blaine, T., & Weintraub, B. D. (1990). The paraventricular 
nucleus of the hypothalamus has a major role in thyroid hormone feedback 
regulation of thyrotropin synthesis and secretion. Endocrinology, Vol.126, No.1, pp. 
317-324, ISSN  
Thonberg, H., Fredriksson, J. M., Nedergaard, J., & Cannon, B. (2002). A novel pathway for 
adrenergic stimulation of cAMP-response-element-binding protein (CREB) 
phosphorylation: mediation via alpha1-adrenoceptors and protein kinase C 
activation. The Biochemical journal, Vol.364, No.1, pp. 73-79, ISSN 0264-6021 
Tu, H. M., Kim, S. W., Salvatore, D., Bartha, T., Legradi, G., Larsen, P. R., & Lechan, R. M. 
(1997). Regional distribution of type 2 thyroxine deiodinase messenger ribonucleic 
acid in rat hypothalamus and pituitary and its regulation by thyroid hormone. 
Endocrinology, Vol.138, No.8, pp. 3359-3368, ISSN 0013-7227 
Weiss, R. E., Forrest, D., Pohlenz, J., Cua, K., Curran, T., & Refetoff, S. (1997). Thyrotropin 
regulation by thyroid hormone in thyroid hormone receptor beta-deficient mice. 
Endocrinology, Vol.138, No.9, pp. 3624-3629, ISSN 0013-7227 
Wikstrom, L., Johansson, C., Salto, C., Barlow, C., Campos Barros, A., Baas, F., Forrest, D., 
Thoren, P., & Vennstrom, B. (1998). Abnormal heart rate and body temperature in 
mice lacking thyroid hormone receptor alpha 1. The EMBO journal, Vol.17, No.2, 
pp. 455-461, ISSN 0261-4189 
Wilber, J. F., & Utiger, R. D. (1969). The effect of glucocorticoids on thyrotropin secretion. 
The Journal of clinical investigation, Vol.48, No.11, pp. 2096-2103, ISSN 0021-9738. 
Wilber, J. F., & Xu, A. H. (1998). The thyrotropin-releasing hormone gene 1998: cloning, 
characterization, and transcriptional regulation in the central nervous system, 
heart, and testis. Thyroid : official journal of the American Thyroid Association, Vol.8, 
No.10, pp. 897-901, ISSN 1050-7256 
Wittmann, G., Liposits, Z., Lechan, R. M., & Fekete, C. (2002). Medullary adrenergic neurons 
contribute to the neuropeptide Y-ergic innervation of hypophysiotropic 
thyrotropin-releasing hormone-synthesizing neurons in the rat. Neuroscience letters, 
Vol.324, No.1, pp. 69-73, ISSN 0304-3940 
Wittmann, G., Liposits, Z., Lechan, R. M., & Fekete, C. (2004). Medullary adrenergic neurons 
contribute to the cocaine- and amphetamine-regulated transcript-immunoreactive 
innervation of thyrotropin-releasing hormone synthesizing neurons in the 
 
Hypothyroidism – Influences and Treatments 
 
276 
hypothalamic paraventricular nucleus. Brain research, Vol.1006, No.1, pp. 1-7, ISSN 
0006-8993 
Yamada, M., Saga, Y., Shibusawa, N., Hirato, J., Murakami, M., Iwasaki, T., Hashimoto, K., 
Satoh, T., Wakabayashi, K., Taketo, M. M., & Mori, M. (1997). Tertiary 
hypothyroidism and hyperglycemia in mice with targeted disruption of the 
thyrotropin-releasing hormone gene. Proceedings of the National Academy of Sciences 
of the United States of America, Vol.94, No.20, pp. 10862-10867, ISSN 0027-8424 
16 
Thyroid Hormones and  
Motoneurons Development 
Farzaneh Ganji 
Department of Biology, Faculty of Science,  
Golestan University, Gorgan 
Iran 
1. Introduction 
It is well known that postnatal maturation of the central nervous system is critically 
dependent on thyroid hormone levels (Thompson & Potter, 2000) and this might influence 
the neuromuscular system (Barakat-Walter et al., 2000). Previous neuroanatomical and 
biochemical investigations demonstrated that development of skeletal muscles including the 
masseter is affected by both neuronal and thyroid hormonal effects (Adams et al., 1999; d’ 
Albis et al., 1989, 1990; Butler-Browne et al. 1984; Gambke et al., 1983; Rubinstein et al., 
1988). Under normal condition the phenotypic properties of motoneurons and muscle fibers 
in the neuromuscular unit are matched (Copray & Kernell, 2000; Hughes & Salinas, 1999; 
Akihiko Ishihara, Kawano, Okiura, Morimatsu, & Ohira, 2005). 
A pronounced shift in oromotor behavior occurs with the transition from sucking to 
chewing in humans and other mammals (Green et al., 1997; Saito, Ohnuki, Yamane, & Saeki, 
2002). It has been reported that the transition from neonatal to adult fast MHC is however 
dependent on thyroid hormone (Soukup & Jirmanová, 2000). In the rat there is a significant 
rise to peak T4 serum levels at 15 days followed by a slight decline to mature values 
(Gambke et al., 1983). The diameter of muscle fibers enlarges progressively from slow to fast 
type in order to adapt to the rapid functional changes from weaning to chewing motion 
(Miyata et al., 1996). 
During development, hyporthyroidism results in an inhibition in the expression of adult fast 
MHC isoforms and a persistence of the slow isoforms in the masseter muscle (Agbulut et al., 
2003; Butler-Browne et al., 1987; Pette & Staron, 2000) which is also associated with a 
decrease in fiber diameter of the masseter muscle (Sugasawa & Mori, 1998). The increase in 
the circulating levels of thyroid hormone in suckling rats is involved in development of the 
masseter (Maeda et al., 1981a, 1981b). This effect is explained first as a result of an 
orthograde mechanism through the trophic factors secreted by different motoneuron types 
at the neuromuscular junction. The second explanation invokes a retrograde mechanism, so 
that, once muscle fibers are differentiated into slow or fast types they may modify properties 
of motoneurons via retrograde transport of substances (Barakat-Walter & Riederer, 1996; 
Munson et al., 1997). Based on these hypotheses, Sickles et al. (Sickles et al., 1987) and Bakels 
et al. (Bakels et al., 1998) reported considerable alteration in the adult rats' soleus 
motoneurons morphology due to hyper- and hypo-thyroidism respectively. In regard to the 
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masseter is affected by both neuronal and thyroid hormonal effects (Adams et al., 1999; d’ 
Albis et al., 1989, 1990; Butler-Browne et al. 1984; Gambke et al., 1983; Rubinstein et al., 
1988). Under normal condition the phenotypic properties of motoneurons and muscle fibers 
in the neuromuscular unit are matched (Copray & Kernell, 2000; Hughes & Salinas, 1999; 
Akihiko Ishihara, Kawano, Okiura, Morimatsu, & Ohira, 2005). 
A pronounced shift in oromotor behavior occurs with the transition from sucking to 
chewing in humans and other mammals (Green et al., 1997; Saito, Ohnuki, Yamane, & Saeki, 
2002). It has been reported that the transition from neonatal to adult fast MHC is however 
dependent on thyroid hormone (Soukup & Jirmanová, 2000). In the rat there is a significant 
rise to peak T4 serum levels at 15 days followed by a slight decline to mature values 
(Gambke et al., 1983). The diameter of muscle fibers enlarges progressively from slow to fast 
type in order to adapt to the rapid functional changes from weaning to chewing motion 
(Miyata et al., 1996). 
During development, hyporthyroidism results in an inhibition in the expression of adult fast 
MHC isoforms and a persistence of the slow isoforms in the masseter muscle (Agbulut et al., 
2003; Butler-Browne et al., 1987; Pette & Staron, 2000) which is also associated with a 
decrease in fiber diameter of the masseter muscle (Sugasawa & Mori, 1998). The increase in 
the circulating levels of thyroid hormone in suckling rats is involved in development of the 
masseter (Maeda et al., 1981a, 1981b). This effect is explained first as a result of an 
orthograde mechanism through the trophic factors secreted by different motoneuron types 
at the neuromuscular junction. The second explanation invokes a retrograde mechanism, so 
that, once muscle fibers are differentiated into slow or fast types they may modify properties 
of motoneurons via retrograde transport of substances (Barakat-Walter & Riederer, 1996; 
Munson et al., 1997). Based on these hypotheses, Sickles et al. (Sickles et al., 1987) and Bakels 
et al. (Bakels et al., 1998) reported considerable alteration in the adult rats' soleus 
motoneurons morphology due to hyper- and hypo-thyroidism respectively. In regard to the 
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masseter muscle, neuroanatomical evidence related to the mechanisms of shifting from 
sucking to biting was first reported by Kubota et al. in mice (Kubota et al., 1988). Upon their 
observation the differentiation of the trigeminal motoneurons related to biting is rapidly 
accelerated after birth. Miyata et al. have reported morphometric alteration of superficial 
masseter motoneurons from sucking to chewing in normal rats in a way that the diameter of 
the largest motoneurons increases rapidly from 5 to 21 postnatal days (Miyata et al., 1996).  
Calcitoin-gene related peptide (CGRP), a co-transmitter, along with acetylcholine in the 
neuromuscular system is released at motor end plates, where the muscle cells demonstrate 
binding sites for CGRP (Popper & P. E. Micevych, 1989; Terrado et al., 1997). In fact, CGRP 
is synthesized in the motoneuron cell bodies, transported down to the motor terminals, 
stored in dense-core vesicles and released upon nerve stimulation (Buffelli et al., 2001). This 
neuropeptide exerts a variety of effects on skeletal muscle such as spontaneous acetylcholine 
release from motor nerve terminals, enhancement of neurally evoked muscle contraction 
and regulation of the rate of the acetylcholine receptor (AChR) at the neuromuscular 
junction (Kimura, 1998; van Rossum, Hanisch, & Quirion, 1997). CGRP functions are 
mediated by cell membrane receptors that belong to the family of G-protein-coupled 
receptors (van Rossum et al., 1997). CGRP may thus serve as an anterograde trophic agent 
released by motoneurons that contributes to the maintenance of a high density of 
neuromuscular junctional AChRs (H L Fernandez, Chen, I Nadelhaft, & Durr, 2003; Roa & 
Changeux, 1991). Indeed, motoneuronal CGRP acts as a physiological transducer through its 
complex receptors in muscle motor endplates (Hugo L. Fernandez, Ross, & Irving 
Nadelhaft, 1999). It has been proposed that the levels of CGRP present in individual 
motoneurons are related to the type of muscle unit that is innervated by the respective 
motoneuron (Popper & P. E. Micevych, 1989). It has also been claimed that there is a 
relationship between the type of myosin composition of different rat muscles and the CGRP 
mRNA expression in conveying motoneurons (Blanco, Popper, & P. Micevych, 1997). 
Hypothyroid muscles show a nearly 50% reduction in AChRs density when compared to the 
control muscles (Kragie & Smiehorowski, 1993), therefore during weaning, when feeding 
behavior needs to transform from suckling to chewing (Saito et al., 2002), prenatal slow 
myosin persists, preventing faster muscular contraction due to severe decrease in the 
density of neuro- muscular junction AChRs (Miyata et al., 1996). According to the available 
target, motoneuronal CGRP levels alter in relation to the type of muscle fibers (Blanco et al., 
1997; Popper & P. E. Micevych, 1989).  
A review of literature regarding to motoneurons development shows that detailed 
morphometric data on the developing masseter innervation has been neglected in prenatal 
hypothyroid rats. Thus in this chapter the morphological features of the developing 
masseter motoneurons labeled by injection of HRP into the superficial masseter muscle were 
analyzed in normal and congenital hypothyroid rat's offspring. HRP retrograde reaction 
product is observed as dark blue intracellular granules varying in quantity from 
motoneuron to motoneuron even in the same trigeminal motor nucleus (Kawagishi et al., 
1992). As hypothyroidism reduces neuronal process growth, synaptogenesis, axonal 
transport velocity (Biesiada et al., 1996; Stein et al., 1991) and neurotransmitter synthesis 
(Barakat-Walter et al., 2000; Behzadi & Ganji, 2005), it was of especial interest to investigate 
the alteration in the morphological characteristics of masseter motoneurons as well as HRP 
uptake and transport from the neuromuscular junction. In this regard the labeling quality of 
HRP backfilled masseteric motoneurons along with their size distribution profile under 
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developmental hypothyroidism were evaluated. Furthermore the oro-facial motoneuronal 
CGRP immunoreactive responses under the congenital thyroid hypofunction were 
examined and also usig the Golgi staining method, the morphology of the masseteric 
motoneurons including their dendritic arborization pattern in normal and hypothyroid 
weaned rat pups was studied. These studies may lead to better understanding of the 
ontogenic changes in mastication. 
2. Materials and methods 
2.1 Animals 
Timed pregnant Sprauge-Dawley rats (Pasteur’s Institute, Tehran, Iran) were housed 
individually in plastic cages with free access to food and water. The animal room was 
maintained at constant 22-24º C temperature under a 12 hour light/ 12 hour dark cycle. The 
studies were performed according to the guidelines for laboratory animal use and care set 
forth by the research council at Shahid Beheshti University of Medical Sciences (Tehran- 
Iran). Neonatal hypothyroidism was induced by adding 50mg/liter PTU (Sigma) to the 
drinking water of pregnant dams beginning at gestational day 16 to postnatal day 23. It 
should be noted that this concentration represents the same amount of PTU which is 
received by the pups during suckling period (Blake & Henning, 1985). Control dams 
received tap water. Usually litters were culled to 8 pups on postnatal day 1 for each dam. 
2.2 Intramasseter HRP injection  
On the 1st, 5th, 13th and 21st days after birth several male pups in each age group were 
anesthetized by i.p. injection of Ketamine (100mg/Kg) and Xylazine (5mg/Kg). A small 
incision was made in the chick skin to expose the surface of the superficial masseter muscle. 
Then 1-5µlit of 40% HRP (type VI- Sigma) dissolved in sterile saline was injected slowly into 
the 2-5 loci above as well as under the parotid duct in the left masseter using a Hamilton 
syringe as demonstrated by Kawagishi et al. (Kawagishi et al., 1992). After each injection the 
needle was left in situ for 1 min to avoid backflow of the injected HRP, following which the 
needle was removed, the injection sites were cleaned with sterile saline, and the opening 
was sutured. 
2.2.1 Histochemical procedure 
After 24-48h of survival time, the pups were deeply anesthetized and perfused 
transcardially with 20-50 ml saline (37°C) followed by 50-100 ml of fixative ( 1.25% 
glutaraldehyde and 1% paraformaldehyde in 0.1 M phosphate buffer at pH 7.4, 4°C). 
Following perfusion and fixation the lower brainstems were removed and post fixed for 24h. 
The blocks of tissue were cut serially into 50μm thick coronal sections using a Vibratome. 
Then the sections were processed for HRP reaction using TMB method (Mesulam, 1982) and 
counterstained with 0.1% neutral red. 
2.2.2 Microscopic study 
In each experimental group, three pups with the most reliable labeling in their trigeminal 
motor nucleus (Mo5) were chosen for microscopic study. From rostral to caudal part of Mo5, 
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eight cross sections were selected per animal for each age group of normal and hypothyroid 
pups. The HRP labeled motoneurons showing a nucleolus or with visible primary dendrites 
were counted and upon their HRP labeling profile they were semi-quantitatively divided 
into strong (S) and weak (W) intensities. The cell body area of 500 HRP labeled neurons with 
both intensities were measured through the cross sections using a computer based image 
analysis system (Olympus BX60, DP12, Olysia soft imaging system, Japan). To measure the 
soma areas images of labeled cells were displayed on a monitor and their cell bodies 
perimeters in continuous with soma-dendritic transitional regions were outlined. 
Photomicrographs were arranged using CorelDRAW12. 
2.2.3 Statistics 
Differences between normal and hypothyroid groups were analyzed with two tailed 
student’s t-test. Two- way analysis of variance (ANOVA) was employed to assess the 
variation of soma size in relation to labeling intensity of masseteric motoneurons in different 
groups. The level of significance was set at P<0.05. Values are means ± SEM 
2.3 CGRP immunohistochemistry 
At the onset of weaning period (post natal day 23), 12 deeply anaesthetized (100 mg/kg 
ketamine and 5 mg/kg xylazine) male pups (6 hypothyroid and 6 controls) underwent 
transcardial perfusion with saline followed by 4% paraformaldehyde, 1.33% picric acid and 
0.1% glutaraldehyde in phosphate buffer, pH 7.4. The brainstems of all 12 rats were cut 
serially into 50 micron thick coronal sections with a Vibratome. Tissue sections were 
collected in phosphate buffered saline (PBS) containing 0.3% Triton X-100 (PBST) and 0.3% 
hydrogen peroxide. The sections were rinsed with bovine serum albumin (0.1% in PBST, for 
1 h) and then they were incubated in a rabbit polyclonal CGRP antibody solution (Sigma, 
USA, 1:2500 dilution) at 4 ◦C for 72 h. Thereafter, the sections were washed in PBST and 
incubated in biotinylated goat anti-rabbit IgG (Vector Laboratories, 1:2000 dilution) at 4 ◦C 
overnight with stirring. After two further rinses, the sections were placed in a 1:1000 
dilution of avidin–biotin complex (Vector Laboratories) for 2 h. The immunohistochemical 
reaction product was revealed with 0.05% 3, 3’-diaminobenzidine (DAB, Sigma) and 0.5% 
nickel in Tris–HCl buffer, pH 7.6, in the presence of 0.005% hydrogen peroxide. Finally, 
tissue sections were washed in Tris–HCl buffer, mounted on gelatinized slides and 
counterstained with neutral red before coverslipping 
2.3.1 Microscopic study  
Eight sections containing main and accessory trigeminal (Mo5 and Mo5-AC) and facial 
(Mo7) motor nuclei were selected per animal. A semiquantitative CGRP-like intensity of 
these motoneurons was unilaterally evaluated as strong, moderate, weak and negative 
staining. The mean soma diameter of the motoneurons showing a nucleus were obtained by 
taking the average of two diameters, measured at the maximal and minimal axes of soma 
(Honma et al. 2002; Ishihara et al. 1988), using a computer- based image analysis system 
(Olympus BX60, DP12, Olysia soft imaging system, Japan). Photomicrographs were 
arranged using CorelDRAW12. Statistical significance was analyzed by Student’s t-test. The 
level of significance was set at P < 0.05. 
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2.4 Golgi staining method 
Time pregnant female Wistar rats weighing 180 g were randomly divided into control and 
PTU-treated groups. PTU-treated group received 50ppm propylthiouracil (PTU) in their 
drinking water from 16th day of pregnancy, continued to 22nd day post-partum. Control 
group received tap water. After transcardial perfusion, brain stems of 6 male 23 day old 
pups in each experimental group were processed for Golgi-Hortega staining method. Using 
rotary microtome brain stem paraffin embedded blocks were cut to 70 micron slices. Mo5 
tissue sections were selected for photomicrography and morphological analysis. Using 
Image Analysis Starter software (Olympus, Japan) the cross section area of selected 
motoneurons in both experimental groups were measured and their primary and secondary 
dendrites were counted. Dendritic tree arborization pattern was analyzed with altered 
Sholl’s concentric circles method (Ristanović,et al. 2006) . Statistical analysis including 
Student’s t-test and ANOVA tests was done using SPSS software.  
3. Results 
3.1 Experimental hypothyroidism 
For induction of prenatal hypothyroidism, at first, a range of 0.050 and 0.075 % of PTU was 
tested, but the survival of the pups dropped sharply beyond the second postnatal week and 
and finally the 0.005% concentration of this drug was used which induced a mild 
hypothyroidism and allowed us to have hypothyroid pups with a moderate rate of mortality 
until the time of weaning. In accordance with previous observations (Blake & Henning, 1985; 
Sawin, Brodish, Carter, Stanton, & Lau, 1998), PTU treated pups displayed the skeletal and 
morphological deformities characteristic of hypothyroidism including blunt snouts, unfolded 
ears and rounded bodies compared to normal pups, eye opening was delayed for 2 days. In 
this study, PTU-treated pups were weighed at different times from birth to 23 days after birth 
(Fig 1). At the time of weaning hypothyroid pups weighed 50% under normal weight. 
 
 
Fig. 1. Body weight profile (mean ± S.E.M.) of hypothyroid offspring was significantly 
reduced compared to the controls by postnatal day 15 up to 23 (P < 0.001). 
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3.2 Masseter HRP labeled motoneurons  
In accordance to Mizuno et al., the masseteric labeled motoneurons were located in the 
dorsolateral part of the trigeminal motor nucleus (Mizuno et al. 1975). No contralateral 
neuronal labeling was observed. Unlabeled motoneurons were excluded from the study. 
The labeled motoneurons of normal and hypothyroid pups at days1, 7, 15 and 23 are shown 
in Fig 2. The number of labeled motoneurons in control pups was not significantly different 
from those found in their hypothyroid homologues (table 1). In addition, the total number of 
strongly labeled motoneurons (S) was higher than weakly labeled (W) ones in both normal 
and hypothyroid pups during postnatal development. Indeed, the most obvious 
morphological changes in hypothyroid masseter motoneurons could be detected from day 
15 to 23, in that the hypothyroid masseteric motoneurons showed less primary dendrites 
with shorter processes and slightly more weakly HRP labeled soma compared to normal 
pups (fig. 3).  
 
Pups day 1 day 7 day 15 day 23 
Normal 190±18.8 170±13.9 195±19.1 174±17.0 
Hypothyroid 182±24.0 182±22.7 199±13.5 176± 7.8 
Table 1. 
The correlative results between soma size and HRP labeling intensity of 500 measured 
motoneurons in each group were as follows: 
Day 1 
At day 1 after birth, a similar number of HRP-positive neurons was found in hypothyroid 
and in normal pups. The soma area of the labeled motoneurons ranged between 80-400µm². 
Among them, the number of smaller motoneurons (soma area < 200µm²) was about 2/3 of 
all the labeled cells (Fig 4A). In addition, about 60% of them were strongly labeled (table 2). 
Day 7 
One week after birth the masseter motoneurons grew rapidly and about 4/5 of total labeled 
cells reached a soma area of 200 up to 500µm² and the ratio of S /W neurons was about 2/1 
in both normal and hypothyroid pups (tables 2,3). 
Day 15 
The medium size motoneurons appeared at the 15th postnatal day with a significantly lower 
value in hypothyroid pups (P<0.001, table 2). In contrast their small sized weakly labeled 
motoneurons (<500µm2) were higher than normal (P<0.01, table 2,3). Regardless of the 
labeling intensity a higher frequency of smaller motoneurons (<300µm2) and a lower 
frequency of larger motoneurons were observed in hypothyroid pups when compared to 
normal pups (fig. 5A). Both the intense and weakly hypothyroid labeled neurons displayed 
quite shorter processes in comparison to normal animals (Figs 2, 3).  
Day 23 
The most pronounced changes in soma area and labeling intensity were observed at the time 
of weaning. Small motoneurons in normal pups comprised less than 20% of all labeled  
 




Fig. 2. Photomicrographs showing superficial masseter HRP labeled motoneurons from day 
1 to day 23 in normal and hypothyroid trigeminal motor nucleus. At day 23 initial parts of 
dendrites of normal labeled motoneurons exhibit a Golgi-like labeling appearance with 
visibly longer extension than those of their hypothyroid homologues. 
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3.2 Masseter HRP labeled motoneurons  
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Pups day 1 day 7 day 15 day 23 
Normal 190±18.8 170±13.9 195±19.1 174±17.0 
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Table 1. 
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motoneurons, whereas hypothyroid Mo5 contained 2 fold more of small motoneurons 
(P<0.001).The medium size motoneurons had almost an equal quantitative pattern (~ 45% 
and 50%) in both normal and hypothyroid pups respectively. While the number of large 
motoneurons reached to 40% of total number of labeled motoneurons in normal pups, the 
hypothyroid masseteric motor pool contained 15% of large cells (P<0.001), (See fig. 5B in 
details). The pattern of labeling intensity showed larger and strongly HRP labeled 
motoneurons in normal pups versus smaller and strong intensity of HRP labeled 
motoneurons in hypothyroid pups. In normal animals, the Golgi-like labeled motoneuron 
pool had numerous dedritic processes that extended in both ventral and transverse 
directions. However in hypothyroid motoneurons the primary dendritic processes were 
shortened remarkably in all any directions (Fig. 3, B, b). 
Peak frequency distributions of labeled motoneurons with different soma size revealed a 
trimodal pattern of masseter muscle innervation at the time of weaning in both groups: 
Small size motoneurons with soma area <500µm2, medium size motoneurons 500-700µm2 
and large motoneurons >700µm2 are presented in table 2. 
 
Fig. 3. Masseteric motoneurons labeled with HRP at 15 and 23 postnatal days in normal  
(A, B) and hypothyroid (a, b) pups. Insets illustrate high magnification of strong and weakly 
labeled motoneurons (asterisks). Examples of outlined motoneurons are shown in B (inset). 
Note that hypothyroid motoneurons possess remarkably shorter dendritic processes 
compared to those of normal pups. 
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 Strongly labeled cells Weakly labeled cells 
 small medium large small medium large 
 N H N H N H N H N H N H 
Day 1 96± 3.9 
96±
4.8 




0 0 0 0 
Day 7 117± 8.0 
106±
5.7 




0 0 0 0 







































N; normal, H; hypothyroid. * P<0.05, ** P<0.01, *** P<0.001 
Table 2.  
 
Fig. 4. Frequency distributions in soma area of labeled motoneurons innervating superficial 
masseter muscle in both normal and hypothyroid pups at 1 day of age (A) and 7 days of age 
(B).There was no significant difference between normal and hypothyroid pups in both age 
groups, although at 7 days of age in hypothyroid pups the number of smaller cells (up to 
300 μm2) was more and that of larger cells (300–500 μm2) was less than the normal pups. 
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Fig. 5. Frequency distributions in soma area in both normal and hypothyroid pups at 15 
days of age (A) and 23 days of age (B). At day 23, neurons in both control and hypothyroid 
pups were composed of three populations with lower quantity of small, large size and 
higher quantity of medium-sized motoneurons in peaks. Note that in normal pups there are 
significantly more larger and less smaller motoneurons than in hypothyroid pups. 
3.3 CGRP Histochemistry 
To analyze the effect of prenatal thyroid hypofunction on the CGRP immunoreactive 
intensity, distribution of CGRP containing motoneurons was quantified through Mo5, Mo5-
AC and Mo7 nuclei (Fig. 6). CGRP immunoreactivity is extensively and differentially 
expressed in oro-facial motoneurons somata and primary processes.  
 








Fig. 6. Low-power photomicrographs of frontal sections through brainstem showing the 
distribution of CGRP immunoreactive motoneurons through the trigeminal (Mo5), 
trigeminal accessory (Mo5-AC, outlined area) and facial (Mo7) motor nuclei in the normal 
(A–C) and in the hypothyroid (a–c) weaned pups. 
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Fig. 7. High-power photomicrographs showing different CGRP immunoreactive intensity in 
hypothyroid Mo5 nucleus with numerous weakly stained motoneurons (arrowheads, a), 
and with mostly strong CGRP immunolabeling in Mo5-AC (arrows, b) as well as in Mo7 
(white arrows, c). The presence of large immunopositive motoneurons (asterisks) is more 
detectable in normal motor nuclei compared to their hypothyroid homologues 
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3.3.1 Trigeminal motor nucleus (Mo5) 
Although, the number of positive CGRP neurons is gradually increased from strong to 
moderate and weak in both normal and hypothyroid Mo5 nucleus, the small 
immunopositive motoneurons had a large proportion (~70%) in hypothyroid pups 
compared to normal ones (less than 50%). This increase is especially significant for weakly 
labeled motoneurons (P < 0.05). In contrast, the number of the strong, moderate and weakly 
stained large motoneurons decreased considerably (P < 0.01, <0.001 and <0.01, respectively) 
in comparison with normal motoneurons (see Table 3 a,b and Fig. 7 A,a). 
(a) Small motoneurons with  diameter < 25µm and percentage of increase in hypothyroid pups  
Ø < 25 µm Mo5   Mo5-AC    Mo7  
CGRP-ir Normal Hypothyroid (%) Normal Hypothyroid (%)  Normal Hypothyroid (%) 
Strong 
Moderate 
304 ± 7.8 
848 ± 22.0 
354 ± 4.7 
878 ± 12.2 
14 
4 
12 ± 0.6 
61 ± 3.5 
65 ± 4.4 





488 ± 8.5 
019 ± 21.4
812 ± 25.5 
1161 ± 5.9 
40* 
13 
Weak 1015 ± 25.8 1467 ± 19.3 31* 68 ± 2.7 119 ± 3.2 43* 1 011 ± 20.6 1255 ± 5.9 20 
(b) Large motoneurons with diameter > 25µm and percentage of decrease in hypothyroid pups 
Ø > 25 µm Mo5   Mo5-AC    Mo7   
CGRP-ir Normal Hypothyroid (%) Normal Hypothyroid (%)  Normal Hypothyroid (%) 
Strong 333 ± 8.5 170 ± 2.3 49** 9 ± 0.6 9 ± .06 0  132 ± 17.5 118 ± 2.9 11 
Moderate 921 ± 16.1 422 ± 5.9 54** * 52 ± 1.5 15 ± 1.0 71**  294 ± 25.1 171 ± 3.8 42** 
Weak 1107 ± 28.2 661 ± 9.2 40** 59 ± 3.3 16 ± 1.2 73**  294 ± 27.5 184 ± 4.4 37** 
(c) Percentage of decrease in number of small and large motoneurons devoid of CGRP in hypothyroid 
pups 








Ø < 25 m 181 ± 3.90 131 ±1.33 28* 0 0 0 124 ± 2.9 72 ± 1.5 42** 
Ø > 25 m 195 ± 3.2 64 ± 2.6 67*** 0 0 0 33 ± 0.6 13 ± 0.3 64*** 
* P<0.05  ** P<0.01  *** P<0.001 
Table 3. Total number (±S.E.) of CGRP immunolabeled motoneurons with different intensity 
in each nucleus 
3.3.2 Trigeminal accessory nucleus (Mo5-AC) 
Normal trigeminal accessory motor nucleus showed almost the same pattern of 
immunolabeling intensity as Mo5 with a proportion of 55% for small motoneurons and 45% 
for large motoneurons. In the hypothyroid rats, this pattern contained 90% of small 
immunopositive motoneurons (strong P < 0.01, and moderate and weak P < 0.05) versus 
10% of large ones with a significant decrease in moderate and weak intensity (P < 0.01) 
(Table 3 a,b and Fig. 7 B,b).  
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3.3.3 Facial motor nucleus (Mo7) 
In comparison with the trigeminal motor nucleus, nor mal facial motor nucleus showed 
many more small CGRPcontaining motoneurons (>70%) mostly with moderate and weak 
immunoreactivity. This proportion reached 85% in hypothyroid rats with a significant 
increase (P < 0.05) in the number of small and strongly immunolabeled cells. The proportion 
of large motoneurons (~20%) in normal weaned pups dropped to ~12% in hypothyroid 
pups with significant reduction in moderate and weakly labeled motoneurons (P < 0.01) 
(Table 3 a,b and. Fig 7 C,c). 
Normal Hypothyroid 
 
Fig. 8. Golgi staining sections from normal and hypothyroid 23 day old rat pups. Low 
magnification photomigrographs from Mo5 in normal (A) and hypothyroid (B) pups. 
Primary (P) and secondary (S) dendrites are shown. 
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3.3.4 Unlabeled motoneurons 
In normal pups, about 7% of Mo5 motoneurons and about 5% of Mo7 motoneurons were 
devoid of CGRP immunos taining, while in the hypothyroid pups, this proportion shifted to 
5 and 2%, respectively. In the hypothyroid Mo5, the number of small and large unlabeled 
neurons was reduced significantly (P < 0.05 and <0.001); however, Mo7 nucleus had a lower 
proportion of large motoneurons (P < 0.001) than the small ones (P < 0.01). It should be 
noted that both normal and hypothyroid Mo5-AC nucleus were devoid of unlabeled 
motoneurons (Table 3c). Nevertheless, no significant difference was observed in the total 
number of motoneurons in all experimental groups. 
3.4 Golgi stained motoneurons 
The results of cell measuring and counting the primary and secondary dendrites revealed 
that in hypothyroid pups beside the significant decrease in soma size in trigeminal large 
motoneurons (a 50% reduction in the number of 900-1200µm2 motoneurons in PTU-treated 
group compared to controls, P<0.05), the number of secondary (3.8± 0.4 in PTU- treated 
compared to 4.3±0.5 in control group) - but not primary dendrites- showed a significant 
decrease comparing to normal group (4.1±0.3 vs 6.5±0.4 respectively, P<0.001).  
4. Conclusion 
In the present studies birth weights of hypothyroid animals were slightly lower than 
normal; this moderate retardation persisted until day 15, then hypothyroid animals 
stopped growing and clinically became cretinous. The premature profile of masseter 
muscle begins to appear around the pre-weaning time (day 15) in rats. To meet these 
muscle functional properties, 2 weeks after birth, the medium-sized labeled motoneurons 
appeared at the expense of a reduction in the number of small motoneurons. However, 
during the same period, the number of medium- sized motoneurons was more than 2-fold 
under the normal values and the quantity of small motoneurons was about 4- fold in 
hypothyroid pups.  
During development hypothyroidism alters the patterns of masseter motoneurons 
morphology such as soma size, dendritic orientation and arborization pattern and also 
induces a severe delay in the size transition, which may affect the development and 
plasticity of oral feeding behavior. On the other hand, immunohistochemical studies in 
normal animals have shown that motoneurons supplying fast-twitch muscles show a higher 
level CGRP staining than motoneurons innervating muscles of slow twitch fiber type 
(Homonko & Theriault, 2000). A severe delay in the appearance of large fast-twitch jaw 
closing and jaw opening motoneurons due to congenital hypothyroidism suggests an intact 
thyroid and CGRP state are obligatory for the attainment of normal preadult oro-fascial 
masticatory profile. 
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1. Introduction 
Resistance to thyrotropin (RTSH) is a condition in which thyroid cells show reduced 
sensitivity to TSH. This condition is characterized by elevated serum TSH concentration, a 
normal or hypoplastic thyroid gland and normal to very low levels of thyroid hormones. 
Loss-of-function mutations in the TSH receptor gene (TSHR) lead to RTSH syndrome, 
presenting with either congenital hypothyroidism (CH) or subclinical hypothyroidism 
(Beck-Peccoz et al., 2006; Refetoff, 2003). 
CH occurs in about 1 in 3500 live births. Thyroid dysgenesis is responsible for 75% of these 
cases, dyshormonogenesis for 15%, central hypothyroidism for 5%, and 5% are due to other 
causes (Grüters et al., 2003; Kratzsch & Pulzer, 2008). Most cases of CH due to thyroid 
dysgenesis occur sporadically, but 2% of the patients are familial (Castanet et al., 2000, 2001). 
Dyshormonogenesis is commonly recessively inherited (Park & Chatterjee, 2005). Genes 
associated with thyroid gland dysgenesis include TITF1, TITF2 and PAX8 (De Felice & Di 
Lauro, 2004; Gillam & Kopp, 2001(a); Park & Chatterjee, 2005). Thyroid dyshormonogenesis 
is caused by genes that are involved in thyroid hormone synthesis including 
thyroperoxidase (TPO), thyroglobulin (TG), sodium iodide symporter (NIS), pendrin (PDS), 
dual oxidase 2 (DUOX2) and its maturation factor (DUOXA2), and dehalogenase (DEHAL1) 
(Gillam & Kopp, 2001(b); Grasberger & Refetoff, 2010). Loss-of-function mutations in TSHR 
lead to a spectrum of phenotypes, depending on the mutation's location and severity 
(Biebermann et al., 2010; De Felice & Di Lauro, 2004). The first report in 1968 of RTSH was of 
an 8-year-old boy with cretinism in whom the thyroid gland was small in a 99mTC scan and 
radioiodine uptake was normal (Stanbury et al., 1968). It was only in 1995 that the cause for 
RTSH syndrome in that case was shown to be a mutation in TSHR (Sunthornthepvarakul et 
al., 1995). Since the first report of CH caused by a TSHR mutation, several cases of loss-of-
function mutations of TSHR have been reported: most are missense mutations, but deletions 
and insertions have been identified as well (see http: www.hgmd.cf.ac.uk/ac/ 
gene.php?gene=TSHR and OMIM#275200) (Abramowicz et al., 1997; Alberti et al., 2002; 
Biebermann et al., 1997, 2010; Bretones et al., 2001;  Camilot et al., 2005; Cangul et al., 2010; 
Clifton-Bligh et al., 1997; De Marco et al., 2009; de Roux et al., 1996; Fricke-Otto et al., 2005; 
Gagne et al., 1998; Grasberger et al., 2007; Jeziorowska et al., 2006; Jordan et al., 2003; Kanda 
et al., 2006; Nagashima et al., 2001; Narumi et al., 2009; Narumi et al., 2011; Park et al., 2004; 
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1. Introduction 
Resistance to thyrotropin (RTSH) is a condition in which thyroid cells show reduced 
sensitivity to TSH. This condition is characterized by elevated serum TSH concentration, a 
normal or hypoplastic thyroid gland and normal to very low levels of thyroid hormones. 
Loss-of-function mutations in the TSH receptor gene (TSHR) lead to RTSH syndrome, 
presenting with either congenital hypothyroidism (CH) or subclinical hypothyroidism 
(Beck-Peccoz et al., 2006; Refetoff, 2003). 
CH occurs in about 1 in 3500 live births. Thyroid dysgenesis is responsible for 75% of these 
cases, dyshormonogenesis for 15%, central hypothyroidism for 5%, and 5% are due to other 
causes (Grüters et al., 2003; Kratzsch & Pulzer, 2008). Most cases of CH due to thyroid 
dysgenesis occur sporadically, but 2% of the patients are familial (Castanet et al., 2000, 2001). 
Dyshormonogenesis is commonly recessively inherited (Park & Chatterjee, 2005). Genes 
associated with thyroid gland dysgenesis include TITF1, TITF2 and PAX8 (De Felice & Di 
Lauro, 2004; Gillam & Kopp, 2001(a); Park & Chatterjee, 2005). Thyroid dyshormonogenesis 
is caused by genes that are involved in thyroid hormone synthesis including 
thyroperoxidase (TPO), thyroglobulin (TG), sodium iodide symporter (NIS), pendrin (PDS), 
dual oxidase 2 (DUOX2) and its maturation factor (DUOXA2), and dehalogenase (DEHAL1) 
(Gillam & Kopp, 2001(b); Grasberger & Refetoff, 2010). Loss-of-function mutations in TSHR 
lead to a spectrum of phenotypes, depending on the mutation's location and severity 
(Biebermann et al., 2010; De Felice & Di Lauro, 2004). The first report in 1968 of RTSH was of 
an 8-year-old boy with cretinism in whom the thyroid gland was small in a 99mTC scan and 
radioiodine uptake was normal (Stanbury et al., 1968). It was only in 1995 that the cause for 
RTSH syndrome in that case was shown to be a mutation in TSHR (Sunthornthepvarakul et 
al., 1995). Since the first report of CH caused by a TSHR mutation, several cases of loss-of-
function mutations of TSHR have been reported: most are missense mutations, but deletions 
and insertions have been identified as well (see http: www.hgmd.cf.ac.uk/ac/ 
gene.php?gene=TSHR and OMIM#275200) (Abramowicz et al., 1997; Alberti et al., 2002; 
Biebermann et al., 1997, 2010; Bretones et al., 2001;  Camilot et al., 2005; Cangul et al., 2010; 
Clifton-Bligh et al., 1997; De Marco et al., 2009; de Roux et al., 1996; Fricke-Otto et al., 2005; 
Gagne et al., 1998; Grasberger et al., 2007; Jeziorowska et al., 2006; Jordan et al., 2003; Kanda 
et al., 2006; Nagashima et al., 2001; Narumi et al., 2009; Narumi et al., 2011; Park et al., 2004; 
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Richter-Unruh et al., 2004; Rubio et al., 2008; Russo et al., 2000;  Sriphrapradang et al., 2011; 
Sunthornthepvarakul et al., 1995; Sura-Trueba et al.,2009; Tenenbaum-Rakover et al., 2009; 
Tiosano et al., 1999; Tonacchera et al., 2000, 2001, 2004; Tsunekawa et al., 2006; Wonerow et 
al., 2001) (Table 1, Fig 1). 
2. TSHR: Structure and function 
TSH controls thyroid function upon its interaction with the G-protein-coupled TSHR. The 
family of G-protein-coupled receptors (GPCRs) shares seven transmembrane segments 
connected by three extracellular and three intracellular loops (ECL and ICL, respectively). 
Together with the receptors for glycoprotein hormones LH/HCG and FSH, TSHR has a long 
N-terminal domain that is involved in recognition and binding of the ligand. The TSHR 
gene located on chromosome 14q31 was cloned in 1989 (Libert et al., 1989). It encodes a 
protein with a large N-terminal ligand-binding extracellular domain, a hepta-helical 
transmembrane domain and an intracellular domain. The extracellular domain is encoded 
by the first nine exons and part of exon 10, whereas the transmembrane and intracellular 
domains are encoded entirely by exon 10. The protein consists of 744 amino acids and the N-
terminal ectodomain consists of 398 amino acids composed of eight leucine-rich repeat 
motifs (Szkudlinski et al., 2002; Van Durme et al., 2006). Similar to other GPCRs, TSHR 
shares a common mode of intracellular signaling, stimulating the exchange of GDP for GTP 
on the Gα subunit (Gsα) and phosphoinositol (IP) turnover through Gq coupling. TSH 
binding to TSHR on the basolateral membrane of the thyroid follicular cells leads to 
stimulation of secondary-messenger pathways involving these two main pathways: 
Gs/cAMP, which mediates hormone secretion, thyroid cell growth and differentiation and 
iodide uptake, and IP/Ca+2, which regulates thyroid hormone synthesis by stimulating 
iodide organification (Dumont et al., 1992; Vassart & Dumont, 1992; Wonerow et al., 2001). 
Mutations in TSHR result in either gain or loss of receptor function.  
3. Gain-of-function mutations in TSHR 
Germline gain-of-function mutations result in non-autoimmune hyperthyroidism, whereas 
somatic mutations that constitutively activate TSHR result in toxic thyroid nodules. 
Hyperthyroidism caused by germline mutations in TSHR exhibits autosomal dominant 
inheritance. The mutations are located mainly in exon 10, which encodes the transmembrane 
region and intracellular tail that constitutively activate TSHR. The phenotype of these 
patients is characterized by hyperthyroidism with the presence of goiter but the absence of 
ophtolmopathy, and a lack of thyroid autoantibodies as well as of lymphocytic infiltration in 
thyroid histology (Van Sande et al., 1995). The clinical spectrum of phenotypes is variable 
and onset can occur anywhere from birth to adulthood. The presence of either congenital or 
adulthood-onset hyperthyroidism, multinodular goiter (MNG) and follicular carcinoma has 
been reported in the same family (Karges et al., 2005). To date, more then 55 germline gain-
of-function mutations have been reported, about 14 of them sporadic and the others with 
familial occurrence (http: www.hgmd.cf.ac.uk/ac/gene.php?gene=TSHR) (Akcurin et al., 
2008; Davies et al., 2005; Farid et al., 2000; Führer et al., 1997(b);  Holzapfel et al., 1997; 
Karges et al., 2005; Khoo et al., 1999; Tonacchera et al., 1996; Van Sande et al., 1995). 
Hyperthyroidism in affected individuals is often resistant to the conventional treatment 
used in Graves’ disease, and either radiotherapy or total thyroidectomy is required. 
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Autonomous benign and malignant toxic thyroid nodules have been shown to result from a 
variety of somatic mutations leading to constitutive activation of TSHR and affecting cell 
proliferation and cell function. Somatic TSHR mutations commonly occur in the 
transmembrane and ECL domains, but hot spots are the sixth transmembrane domain and 
the third ICL where the receptor interacts with G-proteins. Toxic adenoma due to TSHR-
activating mutations may occur in infancy (Kohn et al., 2009) or even in utero (Kopp et al., 
1997) (OMIM#2603372) (Davies et al., 2005; Führer et al., 1997(a); Kohn et al., 2009). To date, 
about 25 different somatic TSHR-activating mutations have been reported manifesting with 
toxic adenoma, MNG and toxic thyroid carcinoma. 
4. Loss-of-function mutations in TSHR 
About 50 different loss-of-function mutations have been described in TSHR (Table 1). 
Affected individuals are either homozygous, compound heterozygous or heterozygous. The 
degree of insensitivity to TSH depends on the type and location of the TSHR mutation; more 
severe loss of TSHR function manifests as CH, whereas mild mutations present with 
euthyroid hyperthyrotropinemia or subclinical hypothyroidism. When both alleles carry 
mutated receptors with complete lack of function, the result is severe hypothyroidism, 
commonly presenting at birth, whereas carriers of a mutation on one allele present with 
compensated hyperthyrotropinemia. The thyroid gland is hypoplastic or invisible in a 99mTC 
scan; however, in ultasonographic imaging, the gland is shown to be in a normal position 
and commonly of small size. TSHR mutations are distributed all along the receptor. 
Mutations located in the binding domain result in reduced binding capacity or decreased 
membrane expression of the receptor. The third ECL and the seventh intracellular domain of 
TSHR are hot spots for gain-of-function mutations, but some inactivating mutations have 
been identified in this domain as well (Alberti et al., 2002; Grasberger et al., 2007; Tiosano et 
al., 1999) (Fig. 1).  
4.1 Prevalence of loss-of-function mutations 
The exact prevalence of inactivating TSHR mutations is not known. A prevalence of 4.3% 
biallelic TSHR mutations was found among 134 Japanese infants with CH (Narumi et al., 
2009). Among 38 children with non-autoimmune subclinical hypothyroidism, 11 (29%) were 
carriers of TSHR mutations (Nicoletti et al., 2009). A prevalence of 12% TSHR mutations was 
shown in 42 subjects with non-autoimmune isolated hyperthyrotropinemia in Italy; all were 
with familial occurrence (Tonacchera et al., 2004). Camilot et al. (2005) identified 13 patients 
with heterozygous mutations (11%) out of 116 pediatric patients with asymptomatic 
euthyroid hyperthyrotropinemia. A rate of 0.6% for carriers of W546X-mutated TSHR was 
identified in Welsh euthyroid individuals (Jordan et al., 2003). We found up to 2.4% carriers 
of two known mutations in a highly consanguineous population in the northern region of 
Israel (Tenebaum-Rakover et al., 2009). Moreover, the coexistence of two different novel 
mutations of TSHR in each of two separate clans has been shown (Sriphrapradang et al., 
2011). In view of these data, it may be speculated that the occurrence of inactivating TSHR 
mutations in certain populations is not so rare, and therefore screening for TSHR mutations 
is indicated in cases with non-autoimmune subclinical hypothyroidism in those 
populations.  
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Fig. 1. Scheme of TSHR with known loss-of–function mutations 
4.2 Clinical characteristics  
Loss-of-function mutations manifest with a variable clinical spectrum of phenotypes. Severe 
uncompensated RTSH presents with CH, partially compensated RTSH manifests with 
subclinical hypothyroidism, and fully compensated RTSH presents with euthyroid 
hyperthyrotropinemia or even normal thyroid function. The diagnosis of TSHR defect is 
based on the absence of thyroid antibodies, a lack of goiter, measurable serum 
thyroglobulin, and familial occurrence of hyperthyrotropinemia or hypothyroidism. CH is 
commonly detected by TSH-based neonatal screening but may missed by total T4 (TT4)-
based screening since, in many cases, TT4 levels are within the normal range at birth (Table 
1). The degree of CH is variable and depends on the genotype. Severe forms manifest as 
overt CH (Bretones et al., 2001; Gagne et al., 1998; Jeziorowska et al., 2006; Park et al., 2004; 
Tonacchera et al., 2000), moderate forms as hypothyroidism identified by neonatal screening 
without clinical symptoms of hypothyroidism (Abramowicz et al., 1997; Jordan et al., 2003), 
and mild forms present with hyperthyrotropinemia and normal thyroid hormones (de Roux 
et al., 1996; Nagashima et al., 2001; Narumi et al., 2009; Tenenbaum-Rakover et al., 2009). 
Gagne et al. (1998) described a case of CH with persistent neonatal jaundice, myxedematous 
facies, large fontanelle and absence of ossification centers of the knee on x-rays, indicating 
severe prenatal deficiency of thyroid hormone. Most of the described cases of CH are 
detected by neonatal screening with elevated TSH and normal TT4 levels, but without any 
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clinical symptoms or signs of hypothyroidism (de Roux et al., 1996; Tenenbaum-Rakover et 
al., 2009). Nevertheless, L-T4 therapy is initiated in most cases to prevent future 
consequences of untreated CH. At the age of 2 to 3 years, when L-T4 is withdrawn, thyroid 
hormones remain low in the severe mutations (Abramowicz et al., 1997; Biebermann et al., 
1997; Tonacchera et al., 2000); however in milder mutations, despite extremely elevated 
TSH, thyroid hormone levels are normal, indicating compensated hypothyroidism (Clifton-
Bligh et al., 1997; Tenenbaum-Rakover et al., 2009). 99mTC scan commonly reveals a normal 
or hypoplastic gland but in some cases, an absence of thyroid gland has been demonstrated, 
suggesting thyroid agenesis (Table 1). The presence of detectable thyroglobulin as well as 
the demonstration of a thyroid gland in the normal position in ultrasonographic imaging 
exclude thyroid agenesis and indicate a diagnosis of RTSH. In a few reports, an enlarged 
thyroid gland has been described (de Roux et al., 1996; Grasberger et al., 2007). Inactivating 
TSHR mutations at older ages present with either subclinical hypothyroidism or euthyroid 
hyperthyrotropinemia without thyroid autoantibodies. The affected patients are commonly 
identified by routine laboratory tests and are asymptomatic. Most of the described cases are 
heterozygous for TSHR mutations, but biallelic mutations have been reported as well 
(Kanda et al., 2006; Russo et al., 2000;  Sriphrapradang et al., 2011; Tenenbaum-Rakover et 
al., 2009; Tonacchera et al., 2001, 2007).  
4.3 Mechanism of loss-of-function mutations  
The mechanism leading to loss-of-function of TSHR includes abnormal binding affinity, 
abnormal receptor synthesis, accelerated degradation, defective receptor targeting to the cell 
membrane and abnormal signal transduction (Tao, 2006). Mutations may exert their activity 
by causing protein misfolding, misassembly or aberrant oligomerization. Loss-of-function 
mutations are located all along the TSHR (Biebermann et al., 2010) (Fig 1). The function of 
TSHR is assessed in vitro by cAMP response, IP accumulation, TSH binding and cell-surface 
expression of the mutated receptor. The analysis is performed with COS-7 cells transfected 
with the mutant receptor. Each mutation has a different effect on binding capacity, 
membrane expression and cAMP and IP accumulation, depending on its type and location 
along the TSHR. In in-vitro studies, it has been shown that TSHR mutations differ in their 
effect on the Gs and Gq pathways, which may lead to more severe loss of one pathway 
compared to the other (Claus et al., 2005). The third ECL represents an important domain for 
intermolecular TSHR signal transduction and single amino acids play different roles in 
receptor folding and cAMP and IP signaling (Claus et al., 2005). We identified a biallelic 
L653V mutation located in the third ECL in three sisters presenting with marked 
hyperthyrotropinemia and increased thyroid radioiodine uptake (Grasberger et al., 2007). 
Normal ligand binding, slightly reduced cell expression and mildly reduced basal and 
stimulated cAMP accumulation with markedly reduced IP formation were found in in-vitro 
studies using transfected COS-7 cells. These in-vitro findings explained the phenotype of the 
affected subjects manifesting compensated hyperthyrotropinemia concomitant with 
increased iodide uptake, and this was the first report to provide in-vivo evidence of the 
important role of the IP/Ca+2 pathway in the regulation of thyroid hormone synthesis. 
Narumi et al. (2011) recently reported two patients with CH and high iodide uptake 
harboring biallelic TSHR mutations (R450H+T145I in one and R450H+I166fs in the other), 
supporting our previous findings. They termed this apparently discrepant phenotype 
nonclassic TSH resistance. 
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4.4 Heterozygosity for loss-of-function mutations 
Heterozygous subjects carrying loss-of–function mutations in TSHR are commonly mildly 
affected, presenting with euthyroid hyperthyrotropinemia but with variable expressivity 
(Camilot et al., 2005; Sriphrapradang et al., 2011; Tenenbaum-Rakover et al., 2009). 
Heterozygotes are typically diagnosed with slightly increased TSH but normal free T4 (FT4) 
levels. At least one case of neonatal hypothyroidism has been reported as well (Camilot et 
al., 2005). In in-vitro models expressing the combination of wild-type and mutated TSHR, it 
has been shown that basal and TSH-stimulated cAMP production are reduced compared to 
cells transfected with wild-type receptor, albeit less severely than in biallelic mutations. 
These in-vitro studies are consistent with the dominant-negative effect of the mutated 
receptor on the activity of the wild type and explain the mild phenotype of the carriers 
(Calebiro et al., 2005; Tenenbaum-Rakover et al., 2009). The dominant-negative effect of the 
mutated receptor may result in reduction of cAMP accumulation, as well as reduced 
membrane cell-surface expression of the receptor and retention in intracellular 
compartments (Calebiro et al., 2005).  
5. Genotype-phenotype association 
The phenotype of the affected subjects correlates with the severity of the mutation, which 
is dependent on its location and type, and whether it is mono- or biallelic. Most of the 
described cases reveal a direct association between the severity of the mutation and the 
phenotype, which is reflected by the extent of increase in TSH and decrease in FT4 levels. 
The more severe mutations manifest in infancy with persistent CH, while the mild 
monoallelic mutations manifest as asymptomatic mild hyperthyrotropinemia. We 
identified 33 subjects carrying two novel TSHR gene mutations (P68S and L653V) in a 
large consanguineous kindred occurring as homozygous L653V (5 subjects), heterozygous 
P68S (4 subjects), heterozygous L653V (20 subjects), and compound heterozygous 
L653V/P68S (4 subjects). Our finding in a large cohort of affected members enabled us to 
assess the genotype-phenotype association. All homozygotes and compound 
heterozygotes presented with compensated RTSH, 9 out of 24 heterozygotes showed mild 
hyperthyrotropinemia and the others had normal TSH values. The clinical results were 
supported by in-vitro studies in which the L653V-mutated TSHR resulted in more severely 
impaired signal transduction than the other genotype combinations. However, large 
variability was found to exist between affected members. Among those with the 
homozygous L653V mutation, one child had CH and the other four, aged 3 to 20 years, 
had markedly elevated TSH, but FT4 levels were within the normal range; among the 
heterozygous members for the two different mutations, variable hyperthyrotropinemia 
was observed, with a few of the affected subjects showing normal thyroid function 
(Tenenbaum-Rakover et al., 2009). 
6. Outcome  
Despite several reports of patients affected with TSHR mutations, there are limited data 
on the long-term outcome of this condition. In subjects with TSHR mutations, it has been 
shown that TSH levels remain stable and they do not develop hypothyroidism; in 
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contrast, in autoimmune thyroid disease (AITD), overt hypothyroidism commonly 
develops over the years. In our abovementioned large cohort of affected family members, 
cross-sectional analysis showed neither a decrease nor an increase in TSH levels with age, 
suggesting stable compensated RTSH with an appropriately adjusted set point of 
pituitary-thyroid feedback (Tenenbaum-Rakover et al., 2009). In contrast to subclinical 
hypothyroidism in the context of AITD, the thyroidal compensation in mild to moderate 
RTSH is expected to be clinically stable with no progression toward true hypothyroidism 
or spontaneous regression toward normal TSH levels. Patients with homozygous or 
compound heterozygous mutations who are detected in infancy by neonatal screening to 
have CH may have normal FT4 levels despite elevated TSH levels after L-T4 withdrawal 
and in these patients, L-T4 replacement may not be needed. In contrast, development of 
overt hypothyroidism at the age of 15 years was shown in a patient homozygous for the 
R540H mutation who presented with compensated hypothyroidism in infancy (Mizuno et 
al., 2009), but not in an additional four subjects with the same genotype after long-term 
follow-up. Asymptomatic heterozygotes for TSHR mutations have normal or slightly 
elevated TSH levels with negative thyroid antibodies (Camilot et al., 2005). However, 
coexistence of thyroid autoantibodies has been reported in some cases of compensated 
RTSH, leading to overt hypothyroidism (Tonacchera et al., 2001). It is possible that 
carriers of TSHR mutations are at increased risk for AITD. TSHR is involved in AITD, 
TSH-stimulating autoantibodies in Graves’ disease and TSH-blocking antibodies in 
Hashimoto thyroiditis. Therefore, it has been speculated that modification of TSH 
structure by the mutated receptor may lead to AITD (Tonacchera et al., 2001). Fluctuation 
of TSH levels from slightly above normal to normal values have been observed in some 
cases by us and others (Tenenbaum-Rakover et al., 2009; Tonacchera et al., 2001). In view 
of the variability in outcome among affected individuals, careful long-term follow-up is 
recommended.  
7. Treatment 
The question of whether to treat patients with TSHR mutations with L-T4 is a matter of 
debate (Utiger, 1995). In cases with loss-of-function mutations in TSHR presenting with CH, 
early initiation of L-T4 therapy is recommended to prevent late-effect consequences of 
hypothyroidism as in other etiologies of CH. However, withdrawal of L-T4 at the age of 2 to 
3 years revealed transient hypothyroidism in some cases, putting the need for lifelong 
replacement therapy into question (Alberti et al., 2002; Tenenbaum-Rakover et al., 2009). 
Euthyroid hyperthyrotropinemia caused by TSHR mutations with mild to moderate loss of 
function maintains stable compensated RTSH and may not necessitate thyroid hormone 
replacement. Moreover, most patients with RTSH do not present with symptoms of 
hypothyroidism or with biochemical parameters of uncompensated hypothyroidism, such 
as elevated CPK and liver enzymes and hyperlipidemia (Tenenbaum-Rakover et al., 2009). 
The presence of normal FT4 levels argues against the need for replacement treatment, 
especially when inadvertent overtreatment, producing subclinical hyperthyroidism, can 
have undesirable effects (Samuels et al., 2008). In our long experience, no clinical benefit has 
been observed with L-T4 therapy. Contrasting with this approach, it has been shown that 
some subjects with RTSH have a slight decrease in FT4 levels compared to controls, although 
 
Hypothyroidism – Influences and Treatments 
 
302 
4.4 Heterozygosity for loss-of-function mutations 
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contrast, in autoimmune thyroid disease (AITD), overt hypothyroidism commonly 
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cases by us and others (Tenenbaum-Rakover et al., 2009; Tonacchera et al., 2001). In view 
of the variability in outcome among affected individuals, careful long-term follow-up is 
recommended.  
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debate (Utiger, 1995). In cases with loss-of-function mutations in TSHR presenting with CH, 
early initiation of L-T4 therapy is recommended to prevent late-effect consequences of 
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3 years revealed transient hypothyroidism in some cases, putting the need for lifelong 
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replacement. Moreover, most patients with RTSH do not present with symptoms of 
hypothyroidism or with biochemical parameters of uncompensated hypothyroidism, such 
as elevated CPK and liver enzymes and hyperlipidemia (Tenenbaum-Rakover et al., 2009). 
The presence of normal FT4 levels argues against the need for replacement treatment, 
especially when inadvertent overtreatment, producing subclinical hyperthyroidism, can 
have undesirable effects (Samuels et al., 2008). In our long experience, no clinical benefit has 
been observed with L-T4 therapy. Contrasting with this approach, it has been shown that 
some subjects with RTSH have a slight decrease in FT4 levels compared to controls, although 
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remaining within the normal range, which may point to subclinical hypothyroidism in these 
affected patients. In addition, the possibility of secondary pituitary enlargement in patients 
with extreme hyperthyrotropinemia may support L-T4 replacement therapy. In view of the 
variability of phenotypes in different types of mutations, as well as between individuals 
with the same genotypes, it is recommended that careful follow-up and cautious 
administration of L-T4 be considered based on individual thyroid hormone levels in the 
clinical context. 
8. Differential diagnosis 
The diagnostic work-up of RTSH should exclude PAX8 mutations, which are characterized 
by thyroid dysgenesis associated with kidney abnormalities (Grüters et al., 2003; Park & 
Chatterjee, 2005), and mutations in guanine nucleotide binding subunit 1 (GNAS1), which 
encodes Gsα subunit and causes pseudohypoparathyroidism (PHP) type Ia. The latter 
inactivating mutations in Gsα lead to a syndrome of resistance to multiple hormones, 
including TSH (Mantovani et al., 2002). Another form of RTSH is an autosomal dominantly 
inherited disease characterized by euthyroid hyperthyrotropinemia, for which the specific 
gene has not yet been identified. This condition has been linked to a locus on chromosome 
15q25.3-26.1 (Grasberger et al., 2005(b)). In many of the cases with clinical characteristics of 
RTSH, no mutations have been found in TSHR, suggesting that additional genes are 
involved in RTSH syndrome (Xie et al., 1997). Bigenic defects in thyroid-synthesis pathways 
have been recently described. Coexistence of mutations in TPO (Sriphrapradang et al., 2011) 
and GNAS (Lado-Abeal et al., 2011), in addition to mutations in TSHR, has been reported in 
the same individuals. In those reports, the coexistence of  mutated TPO and TSHR in the 
same individuals belonging to the same kindred did not aggravate the severity of the RTSH 
phenotype (Sriphrapradang et al., 2011); similar observations were made for the presence of 
a monoallelic TSHR mutation coexisting with a GNAS mutation (Lado-Abeal et al., 2011). It 
is therefore suggested that in cases where TSHR mutations do not explain the phenotype, 
additional genes that are involved in thyroid hormone synthesis be screened. RTSH must be 
differentiated from AITD (Ross, 2000), the most common cause of subclinical 
hypothyroidism in the adult population. The presence of autoantibodies as well as a typical 
hypoechogenic pattern of the thyroid in ultasonographic imaging support the diagnosis of 
AITD. This is important from a clinical standpoint since in RTSH, hyperthyrotropinemia is 
almost always stable while in AITD, hypothyroidism develops with time in about 30% of 
the cases.  
9. Conclusion 
To date, about 50 different TSHR mutations have been reported presenting with a spectrum 
of phenotypes ranging from overt CH to mild euthyroid hyperthyrotropinemia. Subjects 
with euthyroid hyperthyrotropinemia commonly have stable TSH levels and do not develop 
overt hypothyroidism with time. The phenotype correlates with the genotype as the latter is 
reflected by the severity of hyperthyrotropinemia and the decrease in FT4 levels. Screening 
for TSHR mutations should be considered in individuals with apparent non-autoimmune 
subclinical hypothyroidism. In view of the variability in phenotypes and in outcome among 
individuals in this condition, careful long-term follow-up is recommended and replacement 
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therapy should be considered on an individual basis according to thyroid hormone levels in 
the clinical context. 
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1. Introduction  
Hypothyroidism, thyroid gland hormone deficiency, is quite a common disease, affecting 
more women than men. Patients with an elevated risk of hypothyroidism comprise 
postpartum women, patients affected with autoimmune diseases as well as patients with 
autoimmune family history, primary pulmonary hypertension, Down’s and Turner’s 
syndromes. The main causes of congenital hypothyroidism are endemic iodine deficiency, 
agenesis or dysgenesis of the thyroid gland and impaired synthesis of the thyroid 
hormones. The causes of the primary hypothyroidism are autoimmune thyroiditis, injury by 
surgery, irradiation or drug side effects. Secondary hypothyroidism is caused by pituitary 
adenomas, adenoma treatment by surgery or radiotherapy, tumors of the suprasellar region, 
sarcoidosis or hemochromatosis.  
Hypothyroid patients complain of cold intolerance, weight gain, constipation, dry skin, 
bradycardia, hoarseness and dementia (Roberts & Ladenson, 2004). However, thyroid 
hypofunction, and a consequent lower level of thyroid hormones in the blood, has also been 
observed in heart disease patients. In patients with acute myocardial infarction, both total 
and free levels of triiodotyronine were seen to be lower. Moreover, a transient decrease of 
tyroxine has been observed while the level of TSH was unchanged (Franklyn et al., 1984). 
Similar data was obtained on children who had undergone open heart surgery. In this case, 
decreased levels of free and total triiodothyronine, total thyroxine and TSH were observed; 
all of which, except TSH, remained depressed until the 5th to 8th days after surgery. These 
results support the statement that the pituitary-thyroid axis is suppressed in patients with 
open heart surgery (Mainwaring et al., 1994). According to the above data, a vicious circle is 
postulated (Klein  &  Ojaama, 2001; a); heart disease induces suppression of the thyroid 
gland function, which in turn, may influence the structure and function of the heart. 
The heart is composed of several cell types: cardiomyocytes, fibroblasts / myofibroblasts, 
endothelial cells and smooth muscle cells of the blood vessels. Cardiomiocytes comprise 
more than 50% of the volume of the organ and exhibit contractile properties. Cardiac 
fibroblasts comprise as much as 67% of the cells in the heart of rats. The fibroblasts are 
responsible for the synthesis and catabolism of the extracellular matrix (collagen type I and 
III, elastin and laminin),  influence the electrophysiological properties of cardiomyocytes as 
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well as regulate myocyte growth and blood vessel formation in the heart (Krenning et al., 
2010).   
The cardiovascular system remains under the regulatory influence of thyroid hormones. 
Since dysfunction of the thyroid gland results in complex changes within the heart, the 
structure and function of the heart is disturbed in both hypothyroidism and 
hyperthyroidism. Hypothyroidism affects the electrophysiological, contractile and 
hemodynamic functions of the heart and is associated with disturbances of the heart’s 
connective tissue stroma.  
The effects of thyroid hormones on the circulatory system have both genomic and non-
genomic bases. T3, triiodothyronine (3, 5, 3’-triiodo-L-thyronine), the active thyroid 
hormone, is transported to the cardiomyocyte by a specific protein situated in the cell 
membrane (Everts et al. 1996) where it is then moved to the nucleus and bound by thyroid 
nuclear receptors: two  isoforms (TR1, TR2) and three  isoforms (TR1-TR3). Of these 
isoforms, TR1 and TRbind 40% of the T3 each, and the remaining 20% is bound by the 
TR2 receptor; TR2 is unable to bind triiodothyronine. (Schwartz et.al., 1994; Kahaly & 
Dilmann, 2005). The receptor-hormone complex is bound to thyroid responsive elements 
(TRE) and, acting as gene regulator, may influence target gene expression (Brent et al., 1994). 
Several genes are upregulated by T3: the  isoform of myosin heavy chains (Morkin et al., 
1993), calcium activated ATPase (Dillman et al., 1990), 1 adrenergic receptor (Fazio et 
al.2004). The expression of other genes is inhibited by T3:  isoform of myosin heavy chains 
or phospholamban (Fazio et al. 2004). 
2. Electrophysiological function of heart  
T3 has been demonstrated to have a general regulatory effect on heart rate; bradycardia, a 
typical symptom of the patient with hypothyroidism, is related to a lowered level of 
triiodothyronine (T3). In an isolated rat atrial neonatal myocyte model, T3 was shown to 
increase the pacemaker rate mainly by elevation of the slope of spontaneous depolarization. 
Several ionic currents that may determine the pacemaker activity were considered as 
potential targets for the action of the thyroid hormones. The electrogenic Na+-Ca2+ exchange 
current (INa/Ca) density was influenced by T3 application. Thus, INa/Ca alterations by thyroid 
hormone may change the slope of the spontaneous depolarization and modify the 
pacemaker rate (Sun et al., 2001).  
The If current is defined as the current determining spontaneous diastolic depolarization 
and influence the activity of the heart pacemaker (Er et al, 2003). In vertebrates, proteins 
deriving from HCN genes form pores of the If current; three HCN isoforms have been found 
in the human heart : HCN1, HCN2 and HCN4. The experiments performed on neonatal rat 
ventricular cardiac myocytes showed that triiodothyronine (T3) evoked a positive 
chronotropic effect on spontaneously beating myocytes. In myocytes with overexpression of 
the thyroid hormone receptor TR1, increased beating activity linked with accelerated 
depolarization velocity and shortened action potential duration, as well as increased If  
current density and increased HCN2 and HCN4 transcripts and proteins were observed. 
The effect of thyroid hormones on CHN2 subunit expression is thought to be responsible for 
a positive chronotropic effect. The changes in both HCN2 and HCN4 gene expression seem 
not to be influenced by direct binding of thyroid hormone to the TREs in the promoter 
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region of the two genes. On the other hand, in cells with TR1 overexpression, lower beating 
activities, inhibition of phase 4 depolarization and prolongation of the action potential were 
found. Reduced transcription of HCN4 was also obseved (Gassanow et al., 2009). Thus, the 
thyroid hormones would apper to be involved in regulation of the heart rate, and their low 
level could be responsible for bradycardia development. 
In patients affected by hypothyroidism, atrioventricular blocks are rarely described. A 
complete atrioventricular block has been observed in a patient with severe hypothyroidism, 
complaining of bradycardia (15 beats/min), fatigue, dizziness and syncope (Schoenmakers 
et al. 2008).  In another patient, bradycardia (44 beats/min) was caused by a 2:1 
atrioventricular block with subclinical hypothyroidism (Nakayama et al., 2006). The blocks 
in two described patients were resolved after thyroxin supplementation. The functional 
blocks have been diagnosed.  
Apart from bradycardia, the typical electrocardiographical changes in hypothyroid patients 
comprise prolongation of the PQ interval, reduced QRS complex voltage, elongation of the 
QT interval and flattening or inversion of the T wave. An acquired elongation of QT with a 
tendency toward ventricular arrhythmias has also been shown in many patients affected 
with hypothyroidism. The QT interval (Fig. 1) is the marker of ventricle repolarization. 
Prolongation of the QT is usually caused by prolongation of the action potential due to a 
reduction of repolarizing currents or elevation of the inward current (Antzelvitch, 2004). In 
patients with overt primary hypothyroidism, Galetta and coworkers (2008) highlighted the 
prolongation and increased dispersion of the QT interval, partial reduction of which was 
seen after replacement therapy. In addition, the reduction of heart rate variability 
parameters seen in the study suggests a sympato-vagal imbalance in hypothyroid patients. 
An increase of QT interval dispersion was also found in women with subclinical 
hypothyroidism. The differences of QTc (- QT dispersion corrected for heart rate) were 
normalized when TSH level (>10mIU/l) was lowered (Bakiner et al., 2008). The 
cardiomyocytes isolated from hypothyroid rats are characterized by a very long action 
potential duration compared with euthyroid cardiomyocytes, however application of T3 
reduces their action potential duration by 24% (Sun et al., 2000). The mechanism of QT 
prolongation in the hypothyroid subjects is not very well explained.  However, prolongation 
of ventricular repolarisation is thought to be due to fibrous tissue accumulation in the heart 
and swelling due to excessive deposition of the osmotic compounds in the heart wall 
(Galetta et al., 2008).  
Sun et al. (2000) postulate that both the genomic and non-genomic effects of the thyroid 
hormone (T3) could be involved in the prolongation of action potential in the ventricular 
myocytes of hypothyroid rats. The genomic effects are involved with modulation of T3-
specific cardiac gene expression. Ito transient outward current density (Fig. 1) was decreased 
in the ventricular cardiomyocytes of hypothyroid rats compared to euthyroid 
cardiomyocytes; this effect is connected with reduced expression of KCND2 genes, which 
encode proteins of the voltage-dependent K+ channel Kv4.2 (Nishiyama et al.,  1998). The 
Kv4.2 and Kv4.3 gene products are molecular components determining the Ito current. Ito 
current is responsible for early repolarisation (phase 1) of action potential and is composed 
of the rapid form Ito,f and slower form reffered as Ito,s. Le Bouter and coworkers (2003) found 
reduced transcription of several genes (KCNA5, KCNB1, KCND2 KCNK2) in hypothyroid 
mice while the expression of other genes was upregulated (KCNQ1, KCNE1); these genes 
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TR2 receptor; TR2 is unable to bind triiodothyronine. (Schwartz et.al., 1994; Kahaly & 
Dilmann, 2005). The receptor-hormone complex is bound to thyroid responsive elements 
(TRE) and, acting as gene regulator, may influence target gene expression (Brent et al., 1994). 
Several genes are upregulated by T3: the  isoform of myosin heavy chains (Morkin et al., 
1993), calcium activated ATPase (Dillman et al., 1990), 1 adrenergic receptor (Fazio et 
al.2004). The expression of other genes is inhibited by T3:  isoform of myosin heavy chains 
or phospholamban (Fazio et al. 2004). 
2. Electrophysiological function of heart  
T3 has been demonstrated to have a general regulatory effect on heart rate; bradycardia, a 
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region of the two genes. On the other hand, in cells with TR1 overexpression, lower beating 
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level could be responsible for bradycardia development. 
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(Galetta et al., 2008).  
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in the ventricular cardiomyocytes of hypothyroid rats compared to euthyroid 
cardiomyocytes; this effect is connected with reduced expression of KCND2 genes, which 
encode proteins of the voltage-dependent K+ channel Kv4.2 (Nishiyama et al.,  1998). The 
Kv4.2 and Kv4.3 gene products are molecular components determining the Ito current. Ito 
current is responsible for early repolarisation (phase 1) of action potential and is composed 
of the rapid form Ito,f and slower form reffered as Ito,s. Le Bouter and coworkers (2003) found 
reduced transcription of several genes (KCNA5, KCNB1, KCND2 KCNK2) in hypothyroid 
mice while the expression of other genes was upregulated (KCNQ1, KCNE1); these genes 
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encode the proteins of the voltage-gated K+ channel proteins. The results were confirmed on 
the protein level and were linked with reductions of Ito,f and delayed rectifying K+ current 
(Ikslow) densities and elevation of slowly activating delayed rectifier (Iks) density in 
cardiomyocytes isolated from hypothyroid mice. The thyroid hormone is thought to 
regulate the components of Ito on the transcriptional level (Shimoni & Severson, 1995). The 
reduction of Ito density could be partially responsible for prolongation of the action potential 
and QT interval elongation (Sun et al., 2000).  
 
Fig. 1. The action potential of the cardiomyocyte (lower part) and surface electrocardiogram 
(upper part). The cardiomyocyte action potential is consisted of phases 0-4 and is generated 
by following currents: INa sodium current, Ito transient outward K+ current, ICa-L voltage-
gated calcium current,  IKs slowly activating delayed rectifier current, IKr rapidly activating 
K+current, IK1 inward rectifier K+ current.  
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Ionic characteristics however are not rapidly influenced by addition of T3 to 
cardiomyocytes isolated from the hypothyroid rats, implying that changes in Ito current 
density are regulated at the transcriptional level (Sun et al., 2000). On the other hand, the 
rapid effect of T3 treatment on the Ik current, the effects being seen in only 5-15 min, 
suggests a non-genomic influence of the thyroid hormone; transcription and translation 
processes need more time (Sun et al., 2000).  Thus, different types of regulation have been 
noted for Ito and IK (delayed rectifier): transcriptional and non-genomic regulation 
respectively. Non-genomic regulation was demonstrated also for the sodium channel and 
the IK1 channel: The action potential duration was shortened by T3 application, which was 
linked with an increase of whole cell inward rectifier potassium current (IK1; Sakaguchi et 
al. 1996). Application of T3 elevated the burst activity of the sodium channel (Dudley & 
Baumgarten,1993).  
A novel genetic link between inherited long QT interval and hypothyroidism has been 
proposed by Putrell and coworkers (2010). Mutations of the KCNQ1 and KCNE2 genes are 
related to long QT interval. hERC and KCNQ1, complexed with KCNE are the subunits of 
the voltage-gated potassium channels. They generate repolarisation currents Ikr and Iks. Iks is 
the slowly activated potassium current (generated by KCNQ1,-KCNE1 subunits) and Ikr is 
the rapidly activated potassium channel (generated by hERG-KCNE2 subunits). KCNQ1 
mutations reduce ventricular muscle repolarisation capacity and prolong the QT interval. 
Furthermore, the KCNQ1-KCNE2 channel determines potassium influx to thyreocytes and 
correct accumulation of iodine ions. A mutation of KCNE could diminish the delivery of 
iodine ions to the thyreocytes, decreasing the substrate availability for thyroid hormone 
synthesis. Thus, two concomitant effects of KCNE dysfunction are observed: in the heart 
prolongation QT and possible arrhythmias, and in the thyroid gland inhibition of thyroid 
hormone synthesis and hypothyroidism formation. Hypothyroidism is associated by a 
molecular link with prolongation of QT (Purtell et al. 2010). 
Life-threatening ventricular ectopic arrhythmias are rarely seen in hypothyroid patients 
(Schenck et al. 2006); additional factors triggering sustained or life-threatening ventricular 
arrhythmias are postulated (Galetta et al., 2008). Very few reports document ventricular 
arrhythmias in the course of hypothyroidism. The “torsade de pointes’ (TdP) tachycardia 
was revealed in a few cases of women aged from 50 to 78 years affected with 
hypothyroidism with symptoms of hypometabolic crisis being commonly found. However, 
although different methods of treatment were applied, the authors stress that systematic 
therapy with thyroxine caused normalization of the electrocardiogram (Chojnowski et al. 
2007, Shojaie & Eshraghian 2008, Schenck et al. 2006). 
3. Heart contraction 
Hypothyroidism causes a reduction of heart contractility, lowers the speed of myocardial 
relaxation (Jakab et al. 1994), decreases stroke volume, ventricular feeling and cardiac 
output. In hypothyroidism, the cardiac output is decreased by 30-50%. Thus, the 
hypodynamic status of the circulatory system can be diagnosed. In a hypothyroid subject  
while the expression of  isoform of myosin heavy chains (MSH), sarcoplasmatic reticulum 
Ca2+ -ATPase (SERCa2) 1-adrenergic receptor genes is reduced due to a lowering of the 
triiodothyronine level (triiodothyronine is the factor which increases expression of these 
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the IK1 channel: The action potential duration was shortened by T3 application, which was 
linked with an increase of whole cell inward rectifier potassium current (IK1; Sakaguchi et 
al. 1996). Application of T3 elevated the burst activity of the sodium channel (Dudley & 
Baumgarten,1993).  
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synthesis. Thus, two concomitant effects of KCNE dysfunction are observed: in the heart 
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hormone synthesis and hypothyroidism formation. Hypothyroidism is associated by a 
molecular link with prolongation of QT (Purtell et al. 2010). 
Life-threatening ventricular ectopic arrhythmias are rarely seen in hypothyroid patients 
(Schenck et al. 2006); additional factors triggering sustained or life-threatening ventricular 
arrhythmias are postulated (Galetta et al., 2008). Very few reports document ventricular 
arrhythmias in the course of hypothyroidism. The “torsade de pointes’ (TdP) tachycardia 
was revealed in a few cases of women aged from 50 to 78 years affected with 
hypothyroidism with symptoms of hypometabolic crisis being commonly found. However, 
although different methods of treatment were applied, the authors stress that systematic 
therapy with thyroxine caused normalization of the electrocardiogram (Chojnowski et al. 
2007, Shojaie & Eshraghian 2008, Schenck et al. 2006). 
3. Heart contraction 
Hypothyroidism causes a reduction of heart contractility, lowers the speed of myocardial 
relaxation (Jakab et al. 1994), decreases stroke volume, ventricular feeling and cardiac 
output. In hypothyroidism, the cardiac output is decreased by 30-50%. Thus, the 
hypodynamic status of the circulatory system can be diagnosed. In a hypothyroid subject  
while the expression of  isoform of myosin heavy chains (MSH), sarcoplasmatic reticulum 
Ca2+ -ATPase (SERCa2) 1-adrenergic receptor genes is reduced due to a lowering of the 
triiodothyronine level (triiodothyronine is the factor which increases expression of these 
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genes), the expression of  isoform of myosin heavy chains (MSH) and phospholamban 
genes is increased.  
Both transcript and protein levels of MSH (known as slow myosin) are elevated in 
experimental animals with induced hypothyroidism (Haddad et al., 2003). MSH 
demonstrates low ATPase activity and works more economically (Harris et al., 1994). 
However, higher ATPase activity with a faster heart myofiber shortening velocity can be 
found in -MSH, known as fast myosin ( VanBuren et al., 1995). Domination of MSH in 
rodents impairs both diastolic and systolic heart functions. (Dillman et al., 1989, Morkin, 
1993). This phenomenon could be seen mainly in laboratory animals because the myosin 
heavy chain isoform comprises 95% of the myosin molecule in human (Gorza et al., 1984) 
and is not markedly influenced by changes of thyroid hormone level. In a hypothyroid 
patient with dilated cardiomyopathy, the cardiac output was reduced to 16% and the -
myosin heavy chain mRNA level was found to be low in biopsy samples. After 9-month 
therapy with thyroid hormone, not only was the cardiac output elevated to 37%, but the 
level of -myosin heavy chain mRNA was also increased (Ladenson et al., 1992). 
Myofibrillar ATPase activity in the heart of thyreoidectomized rats was found to be lower 
(Dowell et al., 1994) 
The adrenergic receptors in the heart remain under the positive regulatory influence of 
the thyroid hormone. In rats with experimentally-induced hypothyroidism, a decreased -
receptor number was found on cell membranes but the agonists’ affinity to the receptors 
was not changed. Isoproterenol-induced activation of adenylate cyclase was reduced 
(Dowell et al., 1994). Novotny and coworkers (1999) confirmed the reduced number of -
receptors in hypothyroid rats. Moreover, the positive inotropic effect of isoproterenol was 
reduced. These results were contrasted by Ariogla and coworkers (2009), who noted a 
reduced effect of isoproterenol and noradrenalin on heart contractility in hypothyroid 
animals, but saw increased expression of  2 and  3 receptors with no change in expression 
of  1 receptors. 
In animals with hypothyroidism, reduced pressure dvelopment (dP/dt) was linked with 
decreased phosphorylation of cardiac troponin I (cTnI) in the heart. Moreover, mRNA of 
cardiac troponin I was increased 3 fold in hearts of hypothyroid rats but mRNA of slow 
skeletal troponin I was initialy elevated but later was decreased to undedectable level in 
animals with hypothyroidism. (Averyhart-Fullard et al., 1994).  
The reduction of heart contractility due to overt hypothyroidism decreases stroke volume 
and ejection fraction. In hypothyroid patients, prolongation of the pre-ejection period and 
decrease of ventricular ejection period were observed, however these values were 
normalized after replacement therapy (Crowley 1977). Moreover, these phenomena, as well 
as bradycardia, decreases cardiac output in hypothyroid patients. 
The changes of calcium concentration in the heart are regulated by calcium activated 
ATPase and phospholamban during both systole and diastole periods. Calcium-activated 
ATPase is responsible for the calcium influx to the endoplasmatic reticulum and, in this 
way, influences the myocardial relaxation velocity (Dillman et al., 1990, Kiss et al., 1994). 
Phosholamban was found to inhibit the activity of the calcium-activated ATPase (Kiss et al. 
1994). Cardiac contractility was increased in phospholamban-deficient mice and the thyroid 
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hormone treatment was not found to increase myocardium contractility (Kiss et al. 1998). 
Triodothyronin may determine the relaxation of the heart via regulation of gene expression 
through upregulation of calcium activated ATPase and downregulation of phospholamban. 
Thus, in hypothyroidism, the gene for calcium-activated ATPase expression is decreased but 
phospholamban gene expression is increased, which will affect the systo-diastolic function 
of the heart (Fazio et al. 2004). Impairment of the diastolic function in hypothyroidism 
patients by slow myocardial relaxation of the heart results in reduction of ventricular 
feeling. Furthermore, a decreased rate of active diastolic relaxation has been found in 
hypothyroid patients (Wieshammer et al., 1989). Echocardiographic studies of hypothyroid 
patients show the modifications of the acoustic properties and myocardial fiber velocity as 
well as regional myocardial deformations. Decreased intramyocardial contractility and the 
impairment of both the active and passive diastole phases have been observed (Di Bello et 
al., 2009). In women with subclinical hypothyroidism, magnetic resonance imaging revealed 
decreased end diastolic volume – preload and increased afterload causing impaired cardiac 
performance (Ripoli et al., 2005).  
Exercise intolerance of the hypothyroid rats is related to decreased heart performance and 
increased total peripheral resistance. Lower blood flow to extensor muscles has been 
observed as well as reduced vasodilatator potential of isolated blood vessels (McAllister et 
al., 1995). Cardiac oxygen consumption measured by positron emission tomography is 
reduced in hypothyroid patients. This reduction is associated with decreased contractility 
and elevated total peripheral resistance (Bengel et al., 2000). Athea and coworkers (2007) 
investigated the effect of hypothyroidism on the cardiac energy metabolism. The maximal 
oxidative capacity of heart tissue was found to be markedly reduced, cytochrome oxidase 
and citrate synthase were inhibited  and mitochondrial cardiolipin content was lower. 
Cardiolipin influences the activity of many inner membrane proteins and its amount 
increases in mitochondria with elevated metabolic rates. Utilization of 3 phospho-glycerol, 
malate and octanoate decreased in hypothyroid animals. Additionally, while the content or 
activity of creatine kinase is not changed, it was observed to have decreased efficacy in 
hypothyroid animals, leading to impairment of mitochondrial function. However, the 
mechanism of these changes remains to be elucidated. Expression of adenine nucleotide 
transferase is reduced in hypothyroidism. This effect is linked with impairment of 
mitochondrial permeability (Paradies et al., 1997; Chavez et al., 2008). 
4. Connective tissue in the heart 
The connective tissue of the heart remains under the regulatory influence of the thyroid 
hormones. Triiodothyronine increases the intracellular transport of amino acids, sugars and 
calcium and increases protein synthesis. However, interstitial fibrosis with excessive 
glycosaminoglycan accumulation was found on histological examination of a hypothyroid 
heart (Mohr-Kahaly et al. 1996). Additoinally, echocardiography showed changes of the 
heart structure in hypothyroid patients. The alterations could be the result of excessive 
accumulation of collagen, water retention or changes of the muscle fiber orientation 
(Monzani et al., 2001).  
Ciulla and coworkers (2004) investigated the collagen content in the heart of hypothyroid 
patients with echocardiographical studies. The derived collagen volume fraction (dCVF% 
echocardiographical evaluation of the collagen content in the heart) was evaluated. Higher 
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genes), the expression of  isoform of myosin heavy chains (MSH) and phospholamban 
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values of dCFV% were found in hypothyroid hearts, but echoreflectivity was normalized 
after thyroid hormone treatment. Experiments performed on rats with induced 
hypothyroidism by thyroidectomy or 4-methyl-2-thiouracil application demonstrated 
increased accumulation of collagen and glycosaminoglycans in the hearts of two groups 
with experimental hypothyreosis (Drobnik et al., 2009). Moreover, an increased level of 
hialuronic acid was found in hypothyroid rats in the heart and the hindlimb muscle (Wiig et 
al., 2000). An elevated level of hyaluronan was also noted in human fibroblasts cultured in 
conditions without thyroid hormones (Shishiba et al., 1988). 
The mechanism of the observed changes remains a matter of debate. The elevation of the 
extracellular matrix in the hypothyroid heart is supposed to be related to a low level of 
thyroid hormones and reduced catabolism of extracellular compounds. Decreased 
hydroxyproline levels, the marker of collagen, were noticed in the urine and serum of 
hypothyroid subjects; these changes were normalized by replacement therapy. 
Additionally, decreased collagen degradation was confirmed in hypothyroid subjects by 
experiments with radiolabeled proline. Most importantly however, the final effect of the 
thyroid status would seem to be dependent on the target organ; increased collagen 
content was noted in both the skin and liver of the hypothyroid animals as well as a 
decreased collagen level in the bones (Kucharz, 1992). Previous results showed decreased 
collagen catabolism in hypothyroid animals, and this effect may explain the elevation of 
collagen level in the heart.  
However, in primary hypothyroidism, a low level of the thyroid hormone is accompanied 
with an elevation of TSH, which is thought to influence the regulation of the connective 
tissue matrix in the heart. Although an increased number of cells was found in 
myofibroblast cultures isolated from newborn rat heart after TSH application, the level of 
collagen or glycosaminoglycans in the culture was unchanged; this elevation of 
myofibroblast number in TSH-treated cultures raises the question of whether a TSH-
dependent effect could be responsible for connective tissue accumulation in the hypothyroid 
heart (Drobnik et al., 2009). Application of immunoglobulin from the sera of patients with 
Graves’ disease increases collagen biosynthesis, which is explained by immunoglobulin 
binding to the TSH receptors (Kohn & Winand, 1975). Experimental outcomes prove that the 
TSH receptor transcript is present in the human heart (Koshiyama et al., 1996). TSH receptor 
transcripts and receptor immunoreactivity were found in fibroblasts of different origins 
(Daumiere et al., 2002; Feliciello et al., 1993). Collagen accumulation in the heart is 
responsible for the increased stiffness of the heart wall and may contribute to diastolic heart 
failure development.  
Excessive glycosaminoglycan accumulation in the skin is linked with myxedema formation 
(Smith et al., 1989). Wiig and coworkers (2000) found increased interstitial fluid pressure in 
the skin and muscle in hypothyroid rats. Thus, accumulation of glycosaminoglycans and 
proteins in the interstitial space is supposed to increase the edema of the interstitium.  
While pleural or pericardial effusions are noted in 10% to 30% of the adult hypothyroidism 
patients, this complication is rare in children (Martinez-Soto et al., 2010). The main 
symptoms of cardiac tamponade in hypothyroid patients are increased or normal heart rate 
(after pericardiocentesis, the tempo is slowed) distant heart sounds, enlarged jugular veins, 
low P valves, T valves and QRS complex in the electrocardiogram and massive pericardial 
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effusion in echocardiography. The following mechanisms of the cardiac tamponade are 
possible: increased permeability in microcirculation, leakage of fluid with high protein 
concentration and disturbed lymphatic drainage. The cardiac tamponade is a rare 
complication of hypothyroidism because of the slow liquid accumulation and high 
distensibility of the pericardium (Lin et al., 2003). 
5. Blood vessel 
Low cardiac output and decreased blood pressure was noted in hypothyroid subjects 
however, increased total peripheral resistance was also noticed. On the other hand, diastolic 
hypertension was observed in 25% of the patients. Hypertension has been linked with 
increased systemic vascular resistance (Klein &  Ojama, 2001; b). However, experimental 
hypertension could be reversed by hypothyroidism (Vargas et al., 1988).  
The pressor response for vasoconstrictors and vasodilatators changes in the hypothyroid 
subject (Vargas et al., 2006). A reduced pressor response to noradrenalin has been proven in 
normotensive hypothyroid patients, suggesting a decreased sensitivity of blood vessels to 
noradrenalin, however, the response of blood vessels to noradrenalin become normal after 
thyroxin supplementation. Interestingly, in hypertensive hypothyroid patients, the 
sensitivity of blood vessel to noradrenalin was found to be normal (Bramnert et al., 1994). 
Similarly, aortic rings with an intact endothelium has been proven to demonstrate a reduced 
pressor response to phenylephrine (Pantes et al., 2006). The reduced sensitivity of blood 
vessels to 1 stimulators is thought to be due to a decreased number of 1-adrenoreceptors 
in tested samples (Vargas et al., 2006).  Reduced arteries sensitivity to nitric oxide donors 
(sodium nitroprusside) has also been reported. Infusion of nitroprusside caused lower 
elevation of forearm blood flow in hypothyroid patients comparing with healthy subjects 
(Napoli et al., 2009). Moreover, both acetylcholine or histamine-induced vasodilatation was 
seen to be lower in hypothyroid rats but nitric oxide independent vasodilatation remained 
unchanged  (Moreno et al., 2003).  
Inhibited vasodilatation by endothelium dependent factors is thought to be responsible for 
the increased total peripheral vascular resistance seen in hypothyroid subjects (Vargas et al., 
2006). Human smooth muscle cells are postulated to be targets for the thyroid hormones. 
The genomic and non-genomic mechanisms of thyroid hormones may well play a role in the 
regulation of smooth muscle cell contractility. However, the molecular targets are not 
known (Klein & Ojama, 2001; b). In hypothyroidism, a lower level of plasma renin 
concentration (Bouhnik et al., 1981) increased vasopressin level (Arnaout et al., 1992) and 
decreased concentration of atrial natriuretic peptide (Kohno et al., 1987) were observed.  
Reduced activity of the thyroid gland was observed in subjects affected by hypertension. 
The inhibition of thyroid activity is supposed to be related to the thyroid-depressing factor 
found in the liver, spleen, kidney and plasma, which was released during hypertension 
development in rats. This thyroid-depressing factor reduces thyroid activity mainly by 
inhibiting the binding of 131I and blocking thyrotropin-stimulated 131I binding (Fregly & 
Threatte 1982; Vargas et al., 2006).  
In hypothyroid patients elevation of total cholesterol, low-density lipoprotein (LDL) as well 
as the apo B levels was observed (Staub et al., 1992). These results could be explained by 
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decreased concentration of atrial natriuretic peptide (Kohno et al., 1987) were observed.  
Reduced activity of the thyroid gland was observed in subjects affected by hypertension. 
The inhibition of thyroid activity is supposed to be related to the thyroid-depressing factor 
found in the liver, spleen, kidney and plasma, which was released during hypertension 
development in rats. This thyroid-depressing factor reduces thyroid activity mainly by 
inhibiting the binding of 131I and blocking thyrotropin-stimulated 131I binding (Fregly & 
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as the apo B levels was observed (Staub et al., 1992). These results could be explained by 
 
Hypothyroidism – Influences and Treatments 
 
322 
lowered number of LDL receptors. Thus, decreased level of mRNA for LDL receptor in the 
liver of hypothyroid rats was found; however this effect was reversed by thyroxine 
treatment (Staels et al., 1990). In hypothyroid women the LDL catabolism was decreased 
(Thompson et al., 1981). The genomic effects of the thyroid hormones on LDL receptor 
expression were proved (Bakker et al., 1998). The gene coding of the LDL receptor is 
positively regulated by thyroid hormones.  
Patients affected with overt hypothyroidism are influenced by several risk factors of 
atherosclerosis: elevated levels of low-density lipoprotein, total cholesterol, diastolic 
hypertension and elevated coagulability. Higher prevalence of atherosclerotic changes in 
aorta and myocardial infarction in women with subclinical hypothyroidism was observed 
(Hak et al., 2000). On the other hand, the thyroid hormone supplementation could be 
responsible for exacerbation of the ischemic heart disease due to positive chronotropic and 
inotropic effects (Roberts and Ladenson 2004) 
6. Summary 
The paper shows that hypothyroidism is responsible for profound disturbances in the 
structure and function of the cardiovascular system. The symptoms of hypothyroidism 
comprise heart arrhythmias (bradycardia, atrioventricular block, tachycardia, torsade de 
points) and disturbances in myocardium contraction and relaxation, as well as decrease of 
oxygen consumption. Molecular mechanism of symptoms has been described. Decreased 
thyroid hormone content influences the mechanisms of the development of 
hypothyroidism symptoms through both genomic and non-genomic effects. Elevation of 
TSH is thought to be involved in some of the peripheral effects observed in rats with 
primary hypothyroidism. In patients with heart disease, hypothyroidism should be 
considered as a possible cause. 
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1. Introduction  
Hypothyroidism is defined as a clinical state resulting from insufficient secretion of thyroid 
hormone from thyroid gland due to some structural or/and functional impairments in 
thyroid hormone production (Kek PC et al., 2003, Dashe JS & Cunningham FG., 2001). 
Hypothyroidism effects all of the organ systems. Main clinical findings are fatigue, 
weakness, dryness and coarseness of the skin, cold intolerance, swelling of the extremities, 
hair loss, lack of concentration and memory,  constipation, weight gain without loss of 
appetite, dyspnea, hoarseness of speech, menorrhagia, paraesthesia, hearing disorders, 
diffuse alopecia, bradycardia, delayed relaxation of tendon reflexes, carpal tunnel syndrome 
and serous cavitary effusions (Kek PC et al., 2003). All of these signs and symptoms recover 
after replacement of thyroid hormone (Larsen PR & Davies TF, 2003, Fatourechi V., 2001).). 
Subclinical hypothyroidism reflects the earliest stage of thyroid dysfunction with subjects 
having normal or decreased fT4, normal fT3 and decreased TSH levels. Since diagnosis 
depends on laboratory values, theoretically, no symptoms or signs are expected but yet 
patients may suffer from somnolence, weakness and fatigue (Kek PC et al., 2003).    
In the English literature there exsists several studies revealing the effect of clinical 
hypothyroidism on respiratory and cardiovascular systems but we were not able to find any 
comparative effect of subclinical hypothyroidism on these systems. In this study we evaluated 
the respiratory function in subclinical hypothyroidism as well as comparing the results with 
clinical hypothyroidism and healthy control groups. Our aim was to determine if respiratory 
function was effected in subclinical hypothyroidism by using simple spirometry. 
2. Materials and methods 
Two hundred and sixty-seven subjects were enrolled in the study. None of the participants 
had a history of smoking, any respiratory illness or any other systemic pathology affecting 
the respiratory system. The patients did not suffer from goitre disturbing  the respiratory 
function. The body mass indices (BMI) of all  of the participants were under 30 kg/m2. 
Following the approval of the local ethics committee written informed consent was obtained 
from all of the participants.  
Serum fT3, fT4 levels were assessed by Chemiluminescent Competitive Enzyme 
Immunoassay method with Immulite 2000 of BIODPC. Serum TSH analysis was performed 
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by Enzyme Chemiluminescent Immunometric Assay method with the same analyser. 
Normal range for TSH was <4.0 uIU/ml, 1.57-4.71 ng/ml for fT3, and 0.8-1.8 ng/ml for fT4 . 
If the patients' serum fT3 level was between 1.57-4.71 ng/ml, fT4 was between 0.8-1.8 ng/ml 
and  TSH level was >4.0 uIU/ml, they were included in the subclinical hypothyroidism 
group. On the other hand, if their serum levels of  fT3 was <1.57 ng/ml, fT4<0.8 ng/ml and 
TSH was >4.0 uIU/ml; they were included in the clinical hypothyroidism group. The 
control group consisted of  subjects having normal fT3, fT4 and TSH values.  
Spirometric analysis was performed with Jaeger Master Scobe (version 4.5). All respiratory 
parameters including FVC, FVC %,  FEV1, FEV1 %,  FEV1/FVC, FEF25-75, FEF25-75 %, PEF, PEF 
% were assessed.  
The mean and standard deviation of parametric values were assessed with Students'-t test 
and ANOVA.  Chi-square test was used when assessing the percentages of the groups and 
Pearson correlation was used to compare the groups.  P<0.05 was considered as significant.  
3. Results 
Among 120 patients enrolled into the study with subclinical hypothroidism,  114 of them 
were women and 6 were men while there were 86 women and 3 male patients with clinical 
hypothyroidism. Control group consisted of 51 women and 9 men. The mean age of the 
patients was 43±13 years and 41±13 years with subclinical hypothyroidism and clinical 
hypothyroidism, respectively. The mean age was 41±12 years in the control group. There 










Age/years 43.68±13.31 41.97±13.22 41.45±11.98 
Gender F 114 84 51 
M 6 3 9 
Table 1. Demographic features of the participants  
Serum fT3, fT4  and TSH values and spirometric parameters of the groups are shown at Table 2 
and 3, respectively. Spirometric values were the lowest in the clinical hypothyroidism group 










fT3 (ng/ml) 2,82±0,76 1,65±0,85 3,12±1.01 
fT4(ng/dl) 1,06±0,16 0,52±0,22 1,17±0,23 
TSH(uIU/m) 10,19±6,22 74,17±140,78 1,60±1,07 
Table 2. Thyroid function values of the participants 
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The comparison between clinical hypothyroidism and control group demonstrated that all 
of the spirometric parameters were higher in control group;but only  the differences among 
FVC, FVC %, FEV1, FEF 25-75  reached statistical significance   
 (p<0.05); the others were not statistically significant.  
According to the comparison between subclinical hypothyroidism and control group, 
spirometric parameters were higher in the control group and lower in patients with 
subclinical hypothyroidism and there was a statistical significant difference regarding FVC, 
FVC %, FEV1 and FEF25-75 (p<0.05).   
Statistically significant positive correlation was found  between FT4  and FVC % in patients 










FVC(ml) 3284±574* 3218±767* 3565±806 
FVC % 109±18* 105±19* 115±15 
FEV1(ml) 2661±529* 2614±623* 2866±706 
FEV1 % 103±16 100±21 106±14 
FEV1/FVC 80±9 80±7 78±6 
FEF25-75(ml) 4716±1415* 4534±1470* 9034±13162 
FEF25-75 % 81±22 79±26 81±20 
PEF(ml) 4966±1413 4940±1337 5374±1932 
PEF % 77±20 77±21 80±21 
Table 3. Spirometry parameters of the participants 
There was a positive correlation between fT3 and FEF25-75 (r=0.484, p=0.0001), FEF25-75 % 
(r=0.490, p=0.0001), PEF (r=0.419, p=0.0001) and PEF% (r=0.432, p=0.0001) in the clinical 
hypothyroidism group. There was also a positive correlation between fT4 and FEF25-75 
(r=0.211, p=0.05), FVC (r=0.251, p=0.019) and FVC% (r=0.248, p=0.021). On the other hand, 
there was a negative correlation between TSH and FVC%  (r= -0.249, p=0.02). 
4. Conclusion 
Hypothyroidism and subclinical hypothyroidism is a clinical disorder  occuring frequently 
in community. Literature research reveals many studies regarding the effects of clinical 
hypothyroidism on respiratory and cardiovascular systems. But there exists no study 
concerning the effect of subclinical hypothyroidism on respiratory system nor there exists 
any study comparing healthy subjects to clinical hypothyroid patients in terms of 
respiratory function tests. Therefore we aimed to assess the respiratory function of patients 
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with subclinical hypothyroidism in comparison with clinical hypothyroidism and healthy 
subjects. 
The incidence of primary hypothyroidism is 2% in women and 0.2% in men. 
Hypothyroidism effects all of the organ systems (Kek PC et al., 2003, Larsen PR & Davies 
TF, 2003). The clinical presentation of thyroid hormone deficiency alters from one person to 
another depending on the duration, cause and the degree of deficiency. The decrease in both 
expiratory and inspiratory muscle strength (Siafakas NM et al., 1992), alveolar 
hypoventilation due to depression of hypoxic and hypercapnoeic ventilatory drives (Kahaly 
GJ, 2000) and decrease in maximal breathing and diffusing capacity (Zwillich CW et al., 
1975) are evident in patients with hypothyroidism. These impairments are reversible with 
hormone replacement therapy. Respiratory infections are more common than healthy 
people (Harrison RN & Tattersfield AE., 1984, Krishnan R et al., 1984). Obstructive sleep 
apnea syndrome is common in severe hypothyroidism but it is reversible with restoration of 
a euthyroid state (Larsen PR & Davies TF, 2003). The prominent features like somnolence, 
apathy and lethargy may also recover with replacement therapy (Krishnan R et al., 1984, 
Jameson JL & Weetman AP, 2001). Muscle strength measurement and sleep investigation is 
not routine analysis in these patients, so simple spirometric evaluation is preferred. Thus, 
we used only spirometric measurements in our study since this method is easier, more 
available and cheaper than other respiratory function tests.  
Siafakas et al. found a significant decrease in the strength of inspiratory and expiratory 
muscles in patients with clinical hypothyroidism. In the mentioned study, vital capacity 
(VC), forced vital capacity (FVC), forced vital capacity one second (FEV1), FEV1/FVC were 
significantly lower in patients with clinical hypothyroidism compared to healtly controls. In 
our study, the patients with clinical hypothyroidism had significantly lower spirometric 
parameters such as vital capacity (VC), forced vital capacity (FVC), forced vital capacity in 
one second (FEV1), FEV1/FVC, peak expiratory flow (PEF) and forced expiratory flow 25-75 
(FEF 25-75) than control group. 
Subclinical hypothyroidism reflects the earliest stage of thyroid dysfunction. Chronical 
autoimmune thyroiditis, subacute thyroiditis, thyroidectomy, radioactive iodine treatment, 
insufficient thyroid hormone replacement therapy may be the cause of  subclinical 
hypothyroidism. The rate of progression to clinical hypothyroidism from subclinical 
hypothyroidism is about  7,8 %-17,8 %. Initiating therapy doesn’t change the natural course 
of the illness, but it prevents the progression of clinical hypothyroidism (Biondi B et al., 
2002, Surks MI & Ocampo E., 1996). 
Subclinical hypothyroidism is a common phenomenon seen more often in women with 
increasing age. The prevalance in women is 6-8 % and 3 % in men (Kek PC et al., 2003, 
Surks MI & Ocampo E., 2004). In our study 114 female and  6 male patients had 
subclinical hypothyroidism. Theoretically no symptoms or findings are expected in 
subclinical hypothyroidism. On the contrary, almost all of our patients suffered from at 
least one or more of the  symptoms like fatigue, weakness and somnolence. This situation 
revealed that clinical findings also associated to spirometric abnormalities. Fatigue is 
observed in subclinical hypothyroidism because of muscle dysfunction. Diagnosis 
 
Spirometry in Patients with Clinical and Subclinical Hypothyroidism 
 
333 
depends on laboratory evaluation. (Kahaly GJ, 2000, Biondi B et al., 2002, Biondi B et al., 
2002).   
The effect of subclinical hypothyroidism on several organ systems are well known, whereas 
the effect on respiratory system is not fully understood (Col NF et al., 2004, Beyer IW et al., 
1998). The study we designed led us to the conclusion that the measurements of spirometric 
variables are higher in subclinical hypothyroidism than in clinical hypothyroidism but 
lower than healthy subjects reaching statistical significance.  
In conclusion it is possible to claim that respiratory system is effected in subclinical 
hypothyroidism. Since subclinical hypothyroidism is common in general population, the 
patients at high risk who had clinical signs and symptoms may be screened with simple 
spirometry. 
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1. Introduction 
Overt thyroid disease often involves mood disorders and cognitive impairment in adults. 
But at the subclinical level a relationship has been difficult to establish.  Some authors 
regard thyroid stimulant hormone small elevation in the elderly as part of aging. However, 
there is a body of studies that demonstrate the impact of SH in target tissues; vg, ejection 
fraction and lipid profile alterations; thus many experts recommend comprehensive 
treatment, adjusting it to the patient´s specific context, age, comorbidities etc. However, 
regarding cognitive and mood problems there is still controversy. There are studies 
concluding no association between SH, cognition or depression but these used insensitive 
instruments to measure cognition and depression, or they had some other methodological 
bias. There are also cross-sectional and case studies showing an association with newly-
developed more sensitive instruments. Subclinical hypothyroidism, cognitive impairment 
and depression occur more often in old age. Population aging increases SH, cognitive 
impairment, and depression prevalence and this will be a health burthen for patients, their 
families, and society; thus measures to minimize it is urgent in developing countries, where 
a high increase in the elderly population is expected. Indeed Heathcare polices everywhere 
must strive for mind and physical well-being. We will review instruments to screen and 
score different spheres of cognitive function in the geriatric or general practitioner´s office, 
and assess the available evidence, and aspects that need further investigation.  
2. Definitions  
1. Subclinical hypothyroidism (SH) is defined as an elevated serum thyroid stimulant 
hormone (TSH) level  4.0 mUI/L with free thyroxine (FT4) within normal range, with 
or without symptoms. 
2. Cognition impairment: refers to decrease ability in mental activities to acquire, store, 
retrieve and use information. People with mild cognitive impairment are able to 
perform basic everyday activities, but present mental decline (forgetfulness, confusion, 
inattention etc) noticeable by themselves, their relatives, or test. While in dementia the 
performing of everyday activities are also deteriorated. 
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3. Depression is a long lasting sadness accompanied by loss of interest in activities; even 
activities the subject finds enjoyable. It can affect mental activity, behavior, and general 
well-being. 
3. Subclinical hypothyroidism 
3.1 Prevalence and risk factors for SH 
 SH comprises the largest fraction of TSH elevation. SH predominates in women, and its 
prevalence increases with age. In the United States, the percent of individuals with TSH over 
4.5 mIU/L raises to 14% after 70 years of age [Hollowell et al 2002]. But a study [Hoogendoorn 
et al 2006] in Netherlands reported 4.4% of adult population with TSH over 4.0 mU/L; it also 
reported a decrease in the mean TSH by age (Figure 1). In Spain, a study reported a prevalence 
of hypothyroidism (TSH >6.7 mUI/L) of 11% in 60-69 age group population [Sender Palacios 
et al, 2004]. In Cuba, [Hernandez-Perera et al 2005] reported that 5.3% of population older than 
59 years had a serum TSH >5.6 mU/L. The prevalence estimates have varied depending on the 
population studied and the criteria used to define it. 
 
Fig. 1. TSH IU/L by Age Adapted from Hoogendoorn et al 2006 
Besides age and gender, genetics is among the population factors that inflict variation to 
prevalence estimates, accounting for almost 65% thyroidal phenotype [Samollow et al 2004, 
Peeters RP 2009]. Also, the amount of dietary iodine has to be considered. Its deficiency 
translates into endemic goiter, congenital hypothyroidism and other thyroidal dysfunction 
[Jameson & Weetman, 2005]. Sustained implementation of iodinated salt has been successful in 
abating simple goiter and cretinism [Basil S Hetzel 2004]. In Mexico City, Martinez et al [1999] 
reported 11% of subjects 55 and older with TSH higher than 5.6 IU/L; however, in Monterrey 
Mexico, a region formally known for endemic goiter, 27.3% of geriatric outpatients had TSH 
>4.5 IU/L [Cárdenas-Ibarra et al 2008]. The unexpectedly high frequency was confirmed by a 
population study [Cárdenas-Ibarra et al 2011a]. Another interesting observation of this study 
was a non significant difference of prevalence by gender, suggesting that advancing age 
decreases the gender gap of SH prevalence. The inhabitants of this region tend to ingest rather 
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large quantities of iodinated salt (the only one available for a half century now) owing to the 
very hot weather that characterized this region. According with iodine sufficiency is the region 
low goiter prevalence (Cárdenas-Ibarra et al 2011a) and that 93.4% of congenital 
hypothyroidism is due to thyroid dysgenesis  and 6% dyshormogenesis (Vela-Amieva et al 
2003). Albeit, urinary iodine excretion was not measured. NHANES III [Hollowell et al 2002] 
reported an increase in mean TSH with age (see Figure 2) and also  significantly higher TSH 
concentrations in persons with high iodine excretion (>500 g/g creatinine) than in persons 
with normal iodine excretion (50–500 g/g creatinine) (P < .02). Moreover, in a borderline 
sufficient iodine intake prevalence of overt hypothyroidism was 0.4% and subclinical 4.0%. In 
this study decreasing TSH serum levels with age were also observed [Hoogendoorn et al 2006] 
(Fig 1). Thyroid malfunction may come from an excess of iodine intake by a direct inhibitory 
effect to the thyroidal gland or by eliciting autoimmunity [Teng et al 2006]. Impairment in 
thyroid function changes directly with thyroid autoimmunity; but high urinary iodine 
excretion predicted an increase of TSH and antithyroperoxidase antibodies one month later 
[Karmisholt & Laurberg 2008]. Surveillance of dietary iodine is recommended. 
 
Fig. 2. TSH IU/L by Age Adapted from Hollowell et al 2002 
3.2 Clinical aspects of SH in the old 
Thyroxine regulates the metabolism of all cells, rendering multisystem unspecific symptoms. 
Diagnosis of hypothyroidism in the elderly is specially challenging, since it develops very 
insidiously and symptoms usually go unnoticed [VermaA & Hasan 2009]. Even when 
symptoms are noted, they are confused with other health problems or are disregarded because 
they are thought to be part of aging. A questionnaire assessing hypothyroidism somatic 
symptoms was not able to predict abnormal TSH levels [Cárdenas-Ibarra et al 2011a]. See 
Table 1. In general, in symptom comparison among groups [Canaris et al 2004], subclinical 
hypothyroidism versus euthyroidism can show significant differences. These researchers 
reported a positive but weak association between the proportion of symptoms reported by the 
patients and progression of thyroid failure. Single or grouped symptoms are of little value at 
the individual level in just one consultation; thus most often SH is regarded as asymptomatic. 
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It is not until the patient is on levothyroxine that he/she notices improvement, such as less 
body aches, and not running out of energy. However, other symptoms such as weight change, 
puffy eyes, or hoarse voice take longer too reverse, if they do. Other functions such as 
cognition and mood symptoms can be reliably measured through validated instruments, but 
memory and depression complaints can not discriminate SH from euthyroidism. Mental 
slowing and depression are among the early hypothyroidism symptoms. Screening thyroid 
function in the elderly can save a lot of time, permit the implementation of appropriate 
measures, and avoid anguish to the patients and their families.  
 
Symptom Sensitivity Especificity 
Doesn’t sweat 0.28 0.76 
Deep voice 0.31 0.70 
Paresthesia 0.64 0.47 
Dry skin 0.56 0.59 
Constipation 0.51 0.65 
Can’t lose weight 0.49 0.76 
Slow to move 0.36 0.76 
Rough skin 0.35 0.74 
Puffy eyes 0.47 0.78 
Cold intolerance 0.31 0.78 
Cárdenas-Ibarra et al 2011a 
Table 1. Symptoms on subjects with and without SH 
3.3 Brain and thyroidal hormones 
The availability of active thyroid hormone in adult brain results from the balance of its 
activation and inactivation [Kester et al 2004]. The selenoenzyme, type 2 iodothyronine 
deiodinase, removes an outer ring iodine atom from the thyroxine to generate 
thriiodothyronine, the active hormone. The type 3 iodothyronine deiodinase removes an 
iner ring iodine to inactivate the hormone. Brain protection from thriiodothyronine swings 
is attained by coordinating the expression of type 2 and 3 deiodinases.  This is, expression of 
type 2 increases while type 3 decreases in low thyroxine; the opposite occurs with excess 
thyroxine. The monocarboxylate transporter-8 is a thyroid hormone specific transporter 
protein that crosses the blood-brain barrier. It is expressed in all brain locations involved in 
negative thyrotrophic releasing hormone feedback.  
The hypothalamus-pituitary-thyroid axis is controlled by thyroid receptor beta 2 isoform, 
which is expressed solely in the hypothalamus and anterior pituitary, and is specific for 
thriiodothyronine [Abel et al 1999]. Low level of hypothalamic triiodothyronine elevates 
TSH. Thyroid hormone receptor studies on mutant mice report that the behavior of mice, 
lacking receptor beta, brings to mind the attention-deficit-hyperactivity disorder. The mice 
lacking TR alpha respond poorly to fear conditioning, showing poor memory, high anxiety, 
and inhibition of exploratory behavior. [Williams 2008] 
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Triiodothyronine deficiency prevents proper glucose uptake in neurons and decreases brain 
perfusion impairing processes of cognition and mood [Kinuya et al 1999].  Functional 
Magnetic resonance imaging revealed load effect of blood oxygen level dependent on the 
response in regions of interest in the frontal cortex (working memory), absent  in subjects with 
SH, but present after six months of levothyroxine and improved performance in n-back task 
[Zhu et al 2006]. Hage &Azar 2011 review concluded that thyroid hormone supplements 
might help in the clinical response to antidepressive drugs.  It seems sensible to screen for 
thyroidal problems in patients with depression that do not respond to treatment.    
3.4 Normal thyroidal aging changes 
Morphologic changes are reduction of follicle and colloidal content; but the individual 
remains clinical healthy. In iodine plentiful regions, age and thyroid stimulant hormone are 
positively related, while free thyroxine does not show a significant change with age. Anti-
thyroeroxidase antibodies increase with age 8.5% in the 20-29 year age group to 22.3% in the 
70-79 year age group; but antibodies are related to disease rather than senescence. 
[Hollowell et al 2002]. In borderline sufficient iodine, THS decreases while free thyroxine 
increases with age and antithyroperoxidase antibodies show insignificant changes. Atzmon 
et al [2009] reported that remarkably old individuals had high serum TSH levels, and that 
their offspring also had higher TSH values than age-matched controls, but this might not be 
extrapolable to other populations.  
There is decreased production and release of TSH which produces 25% less production of 
thyroxine, but the serum level of thyroxine does not decrease due to underactive peripheral 
diiodinase type 2 function; also, the level of rT3 is positively age-related [Marioti et al 1993]. 
Hence the level of free Triiodothyronine decreases, but free thyroxine remains unchanged 
[Latrofa & Pinchera 2005]. There is no data of hypothalamic Triiodothyronine turnover to 
mantain adequate glucose uptake and brain perfusion in old age. 
4. Cognition 
Cognition comes from the Latin word cognoscere, meaning “to know”. Cognition refers to 
mental activities to acquire, store, retrieve and use information. The mental processes most 
tested to evaluate cognition decline are: orientation (time, place, person), memory (code and 
retrieval), visuospatial (perception and memory), attention (speed and discrimination), 
language (denomination, fluency, comprehension, read &  write), and executive function 
(concept, association, praxis) [Albert et al 1988].  
4.1 Instruments to measure cognition and mood 
The screening instruments most used to measure one or more of the above cognitive 
processes in general or geriatric clinical settings are: 
 Mood: “Geriatric Depression Scale” (GDS) Yesavage validated for screening; it is 
widely use in English and Spanish-speaking population [Yesavage 1986]. The Hospital 
Anxiety and Depression Scale (HADS) is a self-assessment scale for English speaking 
educated outpatients. [Zigmond & Snaith 1983]; Beck Depression Inventory is a self -
administrated 21 close-ended questionnaire [Beck 1961 in  Jorde et al 2006]. 
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 Mini-Mental-State-Examination (MMSE); low sensitivity in mild cognitive impairment; 
low specificity in subjects with less than middle schooling [Crum et al 1993].  
  Katz’s “Activities of daily-living” (Katz) useful for detecting dependence [Katz et al 
1970].  
 Lawton’s “Instrumental activities of daily-living” (LW) tests subject’s functionality. It 
has been used to screen for dementia [Lawton et al 1969]. 
 Dementia Rating Scale (DRS). Its application requires specialized personnel [APA 1994]. 
 Brief Neuropsychological Batteries; best options for screening (a paramedic can be 
trained to apply them): 
 ADAS-COG, (Alzheimer's Disease Assessment Scale-Cognitive) developed in 
educated Anglo population. Assesses orientation, memory, language, praxis, and 
executive function [Kolibas E et al 2000]. 
 NEUROPSI: it assesses orientation, attention, memory: coding (verbal and 
visuospacial) dilayed memory (verbal and visuoespacial), language, and executive 
function. It was validated and standardized in Latin-American population; it is also 
useful in illiterate subjects [Ostrosky et al 1999].   
 Evaluation of just one mental process saves times but the partial information can be 
misleading and many still need specialized personnel to apply it. [Begin et al 2008] For 
attention: paced auditory serial addition task, Stroop test, concept shifting, digit spans 
backward; for memory: Wechsler memory scale, facial memory test, selective reminding 
test, word learning task. Praxis clock drawing, Rey_Osterrieth complex figure, etc. 
4.2 Cognitive function in elderly 
Advancing age is the first risk factor for dementia, although dementia is not part of 
normal aging. There is a cognitive continuum disease that can be differentiated from 
normal although mild cognitive impaiment overlaps with both normal and disease 
[Petersen 2004]. Mood disorders are also overrepresented in the elderly, mainly 
depression: a long lasting feeling of sadness, hopeless, helpless, worthless, and aversion. 
Depression can affect mental activity, behavior and physical well-being. Cognitive 
function is affected by depression through interference in attention, memory (coding and 
retrieval), and decision taking.  
In absence of overt disease, a decline of cognitive performance is seen in aging. The decline 
is associated to brain age changes: less glucose utilization, long-term potentiation and 
paired-pulse facilitation, protein expression, neurotransmitter levels and trophic changes.  
But it is not known if the above changes produce or are a product of alterations in the old 
brain. Freeman et al 2009 in a proteomic study in an animal model demostrated that changes 
in hippocampal proteom were related to cognitive performance. They also indicated the 
relevance of comparing old subjects sub grouped by cognitive level; they found that 9 
hippocampal proteins were related with cognitive status. Only one was detected when 
comparing old with young animals. 
A study [Cárdenas-Ibarra et al 2006] in a randomly selected sample of 142 geriatric 
outpatients to determine the frequency of impaired cognition by Mini-mental test 
examination found that 74.5% of subjects did not completed basic schooling, thus MMSE 
scores above 20 instead of 26 were considered normal. Still, impaired cognition was found in 
59% vs 20% of those with partial vs full basic schooling (X2=4.52, gl=1,p<0.05). The 
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proportion of subjects with normal cognition decreased by age; in the over 80 y/o than in 
the 60-69 y/o, 27.3% vs 66.6% respectively (X2=15.3, gl=6,p<0.05). Disadvantaged scores for 
GDS and LW were among CI and dementia (p<0.05, ANOVA); and Katz only to dementia 
(p<0.05, ANOVA) concluded that 31.7% were known dementia cases; another 24% had a 
new diagnosis of impaired cognition. 
Ostrosky et al [Ardila et al 2000] used NEUROPSI in elderly urban population to describe 
normal cognitive decline in relation to education. They measured cognition in 806 subjects, 
of these 56.8% were over 50 years old. They reported different relationship patterns among 
education and specific cognitive domain; for example parallelism for copying a figure task, 
protection for word recall, confluence upwards for digits backwards, confluence 
downwards for semantic verbal fluency. they also found that healthy illiterate subjects 
showed no significant age decline in the domains of orientation, digits backward, language 
(repetition, naming, comprehension), and motor functions (hand position imitation, and 
alternating movement). Age changes are affected by education. Among the illiterate, peak 
performance is reached at an older age than subjects with formal education. Performance by 
age group and schooling on orientation, attention, coding, language motor function and 
memory subscales are shown in figure 3.  
 
                          
Fig. 3. Mean scores of Six Mental Processes by Age and Schooling 
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proportion of subjects with normal cognition decreased by age; in the over 80 y/o than in 
the 60-69 y/o, 27.3% vs 66.6% respectively (X2=15.3, gl=6,p<0.05). Disadvantaged scores for 
GDS and LW were among CI and dementia (p<0.05, ANOVA); and Katz only to dementia 
(p<0.05, ANOVA) concluded that 31.7% were known dementia cases; another 24% had a 
new diagnosis of impaired cognition. 
Ostrosky et al [Ardila et al 2000] used NEUROPSI in elderly urban population to describe 
normal cognitive decline in relation to education. They measured cognition in 806 subjects, 
of these 56.8% were over 50 years old. They reported different relationship patterns among 
education and specific cognitive domain; for example parallelism for copying a figure task, 
protection for word recall, confluence upwards for digits backwards, confluence 
downwards for semantic verbal fluency. they also found that healthy illiterate subjects 
showed no significant age decline in the domains of orientation, digits backward, language 
(repetition, naming, comprehension), and motor functions (hand position imitation, and 
alternating movement). Age changes are affected by education. Among the illiterate, peak 
performance is reached at an older age than subjects with formal education. Performance by 
age group and schooling on orientation, attention, coding, language motor function and 
memory subscales are shown in figure 3.  
 
                          
Fig. 3. Mean scores of Six Mental Processes by Age and Schooling 
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In agreement with cognitive preservation notion, a study in open elderly rural population 
found that about 12% of the subjects scored higher than normal ranges for age and 
schooling supplied in the NEUROPSI manual (Figure 4), confirming that lucidity can be 
present in advancing age with little or no formal education [Cárdenas-Ibarra et al 2011]. 
 
 
Fig. 4. Distribution of Rural Eldery's Neuropsi Score 
5. Thyroidal status and cognitive function 
Elderly people have the highest risk for thyroidal dysfunction as well as cognitive and mood 
disorders. Depression and memory complaints are excessively often in old age. In fact, 
depression is among the early symptoms of hypothyroidism; and memory loss relates to the 
level and length of thyroidal deficiency. Overall intellect is irreversibly affected in the 
developing brain as seen in congenital hypothyroidism. 
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The importance of thyroxine in the developing brain is well documented; the inability to 
focus and mood disturbances in the hyperthyroidal sate. Also in overt hypothyroidism lack 
of concentration, slow thinking and depression are described. In fact, it has been identified 
among the reversible causes of dementia [Jamerson & Weetman 2005]. But, Roberts et al 
[Roberts et al 2006] did not find association; neither did Gussekloo et al [Gussekloo et al 
2004]] in a cohort of aging subjects. But the cognitive assessment instrument they used was 
the Mini-Mental-State-Examination, which is not sensible for mildly impaired cognitive 
function; including LW and Katz in the cognitive assessment did not increase sensitivity for 
dysfunction not reaching dementia. However, Gussekloo et al also reported that low free T3 
was associated with rapid cognitive decline. These conflicting results demand studies with 
adequate assessments and well defined study groups.  
A cross-sectional study [Cárdenas-Ibarra et al 2008] was set to compare the frequency of 
thyroid stimulating hormone (TSH) >4.5 mUI/L level in 33 randomly selected geriatric 
outpatients without dementia versus 101 dementia cases (DSM-IV-R). High TSH was found 
in nine (27.3%, CI: 12.1- 42.5%) and thirty (29.7%, CI: 20.8-38.6%), respectively. It is worth 
mentioning that 76.7% were subclinical hypothyroidism; i.e., free thyroxin was in normal 
range. However, average free thyroxine levels in patients with a high TSH were significantly 
lower than those with a normal TSH; the  free thyroxine level of most of the subclinical 
hypothyroidism cases were in the lower half in contrast with the Gaussian distribution of 
free thyroxine in those with TSH in normal range. McDermott et al [McDermott & Ridway 
2001] conclude that many of subclinical hypothyroidism cases require treatment. Monzani et 
al [Monzani et al 1993] and Lauberg et al [Laurberg et al 2005] point out that in the presence 
of depression and/or cognitive decline, thyroid supplementation will improve symptoms. 
From the perspective of quality of life and patient care; even a modest cognitive 
improvement is highly desirable [Steverson 1990]. 
Treatment is only being recommended for patients with low range thyroxin levels; while the 
presence of cognitive decline, not reaching level of dementia, in subclinical hypothyroidism 
must be addressed in other studies to assess it potential benefit.  
To circumvent MMSE sensibility, specificity, language and cultural bias, we turn to 
NEUROPSI, an abovementioned instrument. We found it easy to apply and calculated a 
Cronbach’s alpha of 0.86 denoting it as a reliable instrument [Cardenas-Ibarra et al  2011b 
and 2011c]. NEUROPSI was used to describe the cognitive function of the elderly in a rural 
open population study. These results are being submitted for publication. Our team is 
committed to a project with an open population to determine the local overt and subclinical 
hypothyroidism prevalence in urban elderly. To identify enough elderly subjects with SH, 
besides the population section, additionally a convenient sample of elderly visiting hospital 
patients with unknown thyroidal status were invited to be tested. Subjects with known 
thyroidal problems were excluded, subjects with known dementia, arrhythmia, kidney, 
lung, heart severe dysfunction or cancer were also excluded. Thus, subjects identified as 
having subclinical hypothyroidism were invited to a clinical trial [Cárdenas-Ibarra et al 
2008b] with parallel control random assignment to test thyroxine versus placebo; which has 
not ended yet. Meanwhile, with the baseline data comparison was made between 37 subjects 
with SH and 39 controls (normal thyroid function) who were age and schooling matched. 
Impaired cognition in subjects with SH was almost double of that found in controls, in who 
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the prevalence of impaired cognition was as expected. These results have only been 
discussed in a congress [Cárdenas-Ibarra et al 2011d] 
A lower global cognitive status has been reported in hypothyroidism, specifically: attention, 
memory, word fluency, and psychomotor and visuospatial processes. Mixed results are 
reported for specific domains even in those with positive association. Moreover, 
improvement of cognitive impairement after levothyroxine replacement in elderly with SH 
has been reproted. Bono et al [Bono et al 2004] reported better verbal fluency after 6 moths 
with levothyroxine treatment. Enhanced elevating memory was reported by Monzani et al 
[Monzani et al 1993]. Enhanced working memory was noted after six months of thyroxine 
supplementation [Zhu et al 2006]. Improved response to antidepressants with levothyroxine 
has been documented in subjects with SH [Hage&Azar 2011] 
Data on the extent of dysfunction reversibility for cognitive processes is lacking. Much work 
needs to be done to standardize cognitive results for comparison and uniform protocols to get 
homogenous groups on thyroidal function (including and excluding criteria). Long survival 
without cognitive enjoyment of being is pointless. The goal now is quality of life. Since the 
cognitive processes are central to well-being, its preservation is as important as a healthy body.  
Cognitive labeling must be avoided; nevertheless timely repeated cognitive evaluation must 
be pursued to detect early decline and risks. Along with protocols to overcome 
cardiovascular risk and other preventable health problems, cognitive assessment by trained 
personnel to apply a neuropsychologically validated, reliable, and culturally compatible 
instrument must be performed. Interpretation and recommendations should be made by 
neuropsychologist or gerontologist consultants.  
6. Acknowledgement 
Our thanks go to Sergio Lozano-Rodriguez, M.D. for his help in reviewing the chapter; to 
Javier Ramos-Cardenas MD, and Macarena del Rosario Sifuentes-Martinez MD for their 
help at the rural communities; to Psychologist Xochitl A Ortiz Jimenez for her advice in 
instruments to measure cognitive function. And finaly to the Endocrinology Laboratory 
team, QCB Gloria Alejandra Jasso de la Peña y QCB Ramón Valdez-Leal.  
7. References 
Abel ED, Boers ME, Pazos-Moura C, Moura E, Kaulbach H, Zakaria M, Lowell B, Radovick 
S, Liberman MC, & Wondisford F. Divergent roles for thyroid hormone receptor 
beta isoforms in the endocrine axis and auditory system. J Clin Invest 1999; 104: 
291–300. 
Albert MS & Heaton R 1988. Intelligence testing. In Albert MS & Moss MB (Eds), Geriatric 
neuropsychology New York. The Guildford Press. pp10-32. 
American Psychiatric Association, 1994. Diagnostic and Statistical Manual, 4th Ed APA 
Press, Washington DC. 
Ardila A, Ostrosky-Solis F, Rosselli M, & Gomez C. Age-related cognitive decline during 
normal aging: The complex effect of education. Archives of Clinical 
Neuropsychology 2000; 15:495-514. 
 
Cognitive Function in Elderly with Subclinical Hypothyroidism 
 
345 
Atzmon G, Barzilai N, Hollowell JG, Surks MI & Gabriely I. Extreme longevity is associated 
with increased serum thyrotropin. J Clin Endocrinol Metab 94:1251-1254. 
Begin ME, Langlois MF,Lorrain D, & Cunnane SC. Thyoid function and cognition during 
aging. Current gerontology and geriatrics research 2008; 2008:1-11. 
BonoG, Fancellu R, Blandini F, Santoro G, & Mauri M. Cognitive and affective startus in 
mild hypothyroidism and interactions with L-thyroxine treatment. 2004; 1 
Canaris GJ, Manowitz NR,  Mayor G & Ridgway ECh. The Colorado Thyroid Disease 
Prevalence Study. Arch Intern Med. 2000;160:526-534 
Cárdenas-Ibarra L, Villarreal-Perez JZ, & Salinas-Martinez R. Capacidad Cognitiva en 
Pacientes Ancianos de un Servicio Geriátrico Ambulatorio en Monterrey, México. 
Medicina Universitaria 2006; 8:84-87. 
Cárdenas-Ibarra L, Solano Velazquez JA, Salinas –Martinez R, Aspera-Ledezma TD, 
Sifuentes-Martinez MR, & Villarreal-Perez JZ. Cross-sectional Observations of 
thyroid function in Geriatric Mexican Outpatients with and without dementia. 
Arch Gerontol Geriatr 2008a, 46:173-180. 
Cárdenas-Ibarra L, Mellado-Urbina PA, Turner-Llaguno AL, Montemayor-Alatorre A, 
Ramos-Cárdenas J, Lira-Castillo JC, Gutierrez Herrera RF, & Villarreal-Pérez JZ. 
Prevalence and risk factors for Hypothyroidism in Elderly Urban Population. (to be 
published  2011a) 
Cárdenas-Ibarra L, Ramirez-Navarro A, Ramos-Cárdenas J, Sifuentes_Martínez MR, 
Vázquez-García AA, & Villarreal-Perez JZ. Cognitive score distribution among 
elders of a rural population. (to be publish 2011b). 
Cárdenas-Ibarra L, Ramos-Cárdenas J, Ramirez_Navarro EA, Nava-Aleman A, Sifuentes-
Martinez MR, Ortiz-Jimenez XA, Saucedo Martinez D, & Villarreal-Perez JZ.  
Semantic verbal fluency in rural Elderly at Northeastern Mexico. (2011c) 
Cardenas-Ibarra L, Sepulveda-Morelos H, Mellado-Urbina PA, Turner-Llaguno AL, 
Montemayor-Alatorre A, Ramos_Cardenas J, Lira-Castillo JC, Gutierrez-Herrera 
RF, & Villarreal-Perez JZ. Cognitive function of elderly subjects with and without 
subclinical hypothyroidism. Cell Symposia: Metabolism & Aging Conference 
March 27– 9, 2011d Cape code MA.  
Cárdenas-Ibarra L, Mellado-Urbina PA, Turner-Llaguno AL, Montemayor-Alatorre A, 
Ramos-Cárdenas J, Lira-Castillo JC, Gutierrez Herrera  RF, Vázquez-García AA, & 
Villarreal-Pérez JZ. Subclinical Hypothyroidism and Mind in the Elderly. 
ClinicalTrails.gov: NCT00921050, 2008b. 
Crum RM,  Anthony JC, Bassett SS, & Folstein MF. Population-based norms for the Mini-
Mental State Examination by age and educational level. JAMA 1993; 269(18): 2386–
2391. 
Freeman WM, VanGuilder HD,Bennett C, & Sonntag WE. Cognitive performance and age-
related changes in hippocampal proteome. Neuroscience 2009:159:183-195.  
Gussekloo, J, Van Exel E, de Craen AJM, Meinders AE, Frölich M, & Westendorp RGJ. 
Thyroid status, disability and cognitive function, and survival in old age. Jama, 
2004. 292:2591-9. 
Hage MP, & Azar ST, The link between thyroid function and depression. Journal of thyroid 
research accepted 26 sep 2011. 
 
Hypothyroidism – Influences and Treatments 
 
344 
the prevalence of impaired cognition was as expected. These results have only been 
discussed in a congress [Cárdenas-Ibarra et al 2011d] 
A lower global cognitive status has been reported in hypothyroidism, specifically: attention, 
memory, word fluency, and psychomotor and visuospatial processes. Mixed results are 
reported for specific domains even in those with positive association. Moreover, 
improvement of cognitive impairement after levothyroxine replacement in elderly with SH 
has been reproted. Bono et al [Bono et al 2004] reported better verbal fluency after 6 moths 
with levothyroxine treatment. Enhanced elevating memory was reported by Monzani et al 
[Monzani et al 1993]. Enhanced working memory was noted after six months of thyroxine 
supplementation [Zhu et al 2006]. Improved response to antidepressants with levothyroxine 
has been documented in subjects with SH [Hage&Azar 2011] 
Data on the extent of dysfunction reversibility for cognitive processes is lacking. Much work 
needs to be done to standardize cognitive results for comparison and uniform protocols to get 
homogenous groups on thyroidal function (including and excluding criteria). Long survival 
without cognitive enjoyment of being is pointless. The goal now is quality of life. Since the 
cognitive processes are central to well-being, its preservation is as important as a healthy body.  
Cognitive labeling must be avoided; nevertheless timely repeated cognitive evaluation must 
be pursued to detect early decline and risks. Along with protocols to overcome 
cardiovascular risk and other preventable health problems, cognitive assessment by trained 
personnel to apply a neuropsychologically validated, reliable, and culturally compatible 
instrument must be performed. Interpretation and recommendations should be made by 
neuropsychologist or gerontologist consultants.  
6. Acknowledgement 
Our thanks go to Sergio Lozano-Rodriguez, M.D. for his help in reviewing the chapter; to 
Javier Ramos-Cardenas MD, and Macarena del Rosario Sifuentes-Martinez MD for their 
help at the rural communities; to Psychologist Xochitl A Ortiz Jimenez for her advice in 
instruments to measure cognitive function. And finaly to the Endocrinology Laboratory 
team, QCB Gloria Alejandra Jasso de la Peña y QCB Ramón Valdez-Leal.  
7. References 
Abel ED, Boers ME, Pazos-Moura C, Moura E, Kaulbach H, Zakaria M, Lowell B, Radovick 
S, Liberman MC, & Wondisford F. Divergent roles for thyroid hormone receptor 
beta isoforms in the endocrine axis and auditory system. J Clin Invest 1999; 104: 
291–300. 
Albert MS & Heaton R 1988. Intelligence testing. In Albert MS & Moss MB (Eds), Geriatric 
neuropsychology New York. The Guildford Press. pp10-32. 
American Psychiatric Association, 1994. Diagnostic and Statistical Manual, 4th Ed APA 
Press, Washington DC. 
Ardila A, Ostrosky-Solis F, Rosselli M, & Gomez C. Age-related cognitive decline during 
normal aging: The complex effect of education. Archives of Clinical 
Neuropsychology 2000; 15:495-514. 
 
Cognitive Function in Elderly with Subclinical Hypothyroidism 
 
345 
Atzmon G, Barzilai N, Hollowell JG, Surks MI & Gabriely I. Extreme longevity is associated 
with increased serum thyrotropin. J Clin Endocrinol Metab 94:1251-1254. 
Begin ME, Langlois MF,Lorrain D, & Cunnane SC. Thyoid function and cognition during 
aging. Current gerontology and geriatrics research 2008; 2008:1-11. 
BonoG, Fancellu R, Blandini F, Santoro G, & Mauri M. Cognitive and affective startus in 
mild hypothyroidism and interactions with L-thyroxine treatment. 2004; 1 
Canaris GJ, Manowitz NR,  Mayor G & Ridgway ECh. The Colorado Thyroid Disease 
Prevalence Study. Arch Intern Med. 2000;160:526-534 
Cárdenas-Ibarra L, Villarreal-Perez JZ, & Salinas-Martinez R. Capacidad Cognitiva en 
Pacientes Ancianos de un Servicio Geriátrico Ambulatorio en Monterrey, México. 
Medicina Universitaria 2006; 8:84-87. 
Cárdenas-Ibarra L, Solano Velazquez JA, Salinas –Martinez R, Aspera-Ledezma TD, 
Sifuentes-Martinez MR, & Villarreal-Perez JZ. Cross-sectional Observations of 
thyroid function in Geriatric Mexican Outpatients with and without dementia. 
Arch Gerontol Geriatr 2008a, 46:173-180. 
Cárdenas-Ibarra L, Mellado-Urbina PA, Turner-Llaguno AL, Montemayor-Alatorre A, 
Ramos-Cárdenas J, Lira-Castillo JC, Gutierrez Herrera RF, & Villarreal-Pérez JZ. 
Prevalence and risk factors for Hypothyroidism in Elderly Urban Population. (to be 
published  2011a) 
Cárdenas-Ibarra L, Ramirez-Navarro A, Ramos-Cárdenas J, Sifuentes_Martínez MR, 
Vázquez-García AA, & Villarreal-Perez JZ. Cognitive score distribution among 
elders of a rural population. (to be publish 2011b). 
Cárdenas-Ibarra L, Ramos-Cárdenas J, Ramirez_Navarro EA, Nava-Aleman A, Sifuentes-
Martinez MR, Ortiz-Jimenez XA, Saucedo Martinez D, & Villarreal-Perez JZ.  
Semantic verbal fluency in rural Elderly at Northeastern Mexico. (2011c) 
Cardenas-Ibarra L, Sepulveda-Morelos H, Mellado-Urbina PA, Turner-Llaguno AL, 
Montemayor-Alatorre A, Ramos_Cardenas J, Lira-Castillo JC, Gutierrez-Herrera 
RF, & Villarreal-Perez JZ. Cognitive function of elderly subjects with and without 
subclinical hypothyroidism. Cell Symposia: Metabolism & Aging Conference 
March 27– 9, 2011d Cape code MA.  
Cárdenas-Ibarra L, Mellado-Urbina PA, Turner-Llaguno AL, Montemayor-Alatorre A, 
Ramos-Cárdenas J, Lira-Castillo JC, Gutierrez Herrera  RF, Vázquez-García AA, & 
Villarreal-Pérez JZ. Subclinical Hypothyroidism and Mind in the Elderly. 
ClinicalTrails.gov: NCT00921050, 2008b. 
Crum RM,  Anthony JC, Bassett SS, & Folstein MF. Population-based norms for the Mini-
Mental State Examination by age and educational level. JAMA 1993; 269(18): 2386–
2391. 
Freeman WM, VanGuilder HD,Bennett C, & Sonntag WE. Cognitive performance and age-
related changes in hippocampal proteome. Neuroscience 2009:159:183-195.  
Gussekloo, J, Van Exel E, de Craen AJM, Meinders AE, Frölich M, & Westendorp RGJ. 
Thyroid status, disability and cognitive function, and survival in old age. Jama, 
2004. 292:2591-9. 
Hage MP, & Azar ST, The link between thyroid function and depression. Journal of thyroid 
research accepted 26 sep 2011. 
 
Hypothyroidism – Influences and Treatments 
 
346 
Hatzel BS. The Nature and Magnitude of the Iodine Deficiency Disorders (IDD) In Towards 
the Global Elimination  Of Brain Damage Due to  Iodine Deficiency. Editors: Delange F., 
Dunn JT., Ling J., Mannar V. and  Pandav Ch. Delhi Oxford University Press 
CALCUTTA 2004 http://www.iccidd.org iccidd.server295.com/media/Hetzel% 
20book/hetzel-a-frontpage.pdf 
Hernández–Perera A, López–González LE, Hernández–Perera A, & Mesa–Santamarina A. 
Hipotiroidismo subclínico en el anciano ambulatorio. Rev Biomed 2007;18:162-166. 
Hollowell JG, Steahling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA & 
Braverman LE. Serum TSH, thyroxin and Thyroid Antibodies in the US Population 
(1988 to 1994): National Health and Nutrition Examination Survey. J Clin 
Endocrinol Metab, 2002; 87:489-499. 
Hoogendoorn EH, Hermus AR, Vegt FD, Ross HA, Verbeek ALM, Kiemeney LALM, 
Swinkels DW, Sweep FCG, & Heijer MD. Thyroid Function and Prevalence of Anti-
Thyroperoxidase antibodies in a population with borderline sufficient iodine 
intake: Influences of Age and sex.  Clinical Chemistry 2006, 52:104-111. 
Jameson JL & Weetman AP, 2005. Disorders of the thyroid gland. In Kasper, Braunwald, 
Fauci, Hauser, Longo and Jameson (Eds). Harrison’s Principles of Internal Medicine. 
New York: McGraw-Hill, pg 2104 – 2126. 
Jorde R, Waterloo K, Storhaug H, Nyrnes A, Sundsfjord J, &Jenssen TG. Neuropsychological 
function and symptoms in subjects with subclinical hypothyroidism and the effect 
of thyroxine treatment. J Clin Endocrinol Metab 2006;91:145-153. 
Karmisholt J & Laurberg P. Serum TSH and serum thyroidperoxidase antibody fluctuate in 
parallel and high urinary iodine excretion predicts subsequent thyroid failure in a 
1-year study of patients with untreated subclinical hypothyroidism. European 
Journal of Endocrinology 2008;158:209-215. 
Katz S. Downs TD, Cash HR, & Grotz RC. Progress in the development of the index of ADL, 
Gerontologist 1970; 10:20-30. 
Kester MH, Martinez de Mena R, Obregon MJ, Marinkovic D, Howatson A, Visser TJ, Hume 
R, & Morreale de Escobar G. Iodothyronine levels in the human developing brain: 
major regulatory roles of iodothyronine deiodinases in different areas. J Clin 
Endocrinol Metab 2004; 89: 3117–3128. 
Kinuya S, Michigishi T, Tonami N, Aburano T, Tsuji S, & Hashimoto T. Reversible cerebral 
hypoperfusion observed with Tc-99m HMPAO SPECT in reversible dementia 
caused by hypothyroidism. Clin Nucl Med. 1999 Sep;24(9):666-8 
Kolibas E, KorinkovaV,.Novotny V, Vajdickova K, & HunakovaD.  ADAS-cog (Alzheimer´s 
Disease Assessment Scale-cognitive-subscale) validation of the Slovak version. 
Bratisl Lek Listy 2000; 101:598-602. 
Latrofa F & Pinchera A. Aging and the thyroid. Hot Thyroidology 2005. 
www.hotthyroidology.com 
Laurberg P, Andersen S, Pedersen I B & Carlé A. Hypothyroidism in the elderly: 
pathophysiology, diagnosis and treatment. Drugs Aging 2005; 22:23-38. 
Lawton MP, & Brody EM. Assessment of older people: Self-maintaining and instrumental 
activities of daily living. The Gerontologist 1969; 9: 179-186. 
 
Cognitive Function in Elderly with Subclinical Hypothyroidism 
 
347 
Maritti S, Barbesino G, Caturegli P, Bartalena L, Sansoni P, Fagnoni F, Monti D, Fagiolo U, 
Franceschi C & Pinchera A. Complex Alterations of thyroid function in healthy 
centenarians. J Clin Endocrinol Metab 77:1130-1134. 
Martinez Lara E, Morales Yepez HA, Sandoval Pacheco R, & Lopez Hernandez CM. 
Prevalencia de hipotiroidismo en pacientes mayors de 55 años en la consulta de 
geriatria del Horpital Central Militar. Rev Sanid Milit Mex 1999; 53:105-108.   
McDermott MT & Ridgway EC. Subclinical hypothyroidism is mild failure and should be 
treated. J Clin Endocrinol Metab, 2001; 86:3585- 4590  
Monzani F, Del Guerra P, Caraccio N, Prunetti CA, Pucci E, Luisi M & Baschieri L. 
Subclinical hypothyroidism: neurobehavioral features and beneficial effect of l-
thyroxin treatment. Clin Investig, 1993; 71:367-71. 
Ostrosky F, Ardila A & Rosselli M. “Neuropsi”. A brief neuropsychological test battery in 
Spanish with norms by age and educational level. Journal of the International 
Neuropsychological Society. 1999; 5:413-433. 
Peeters RP. Thyroid function and longevity New insights into an old dilema. J Clin 
Endocrinol metab 2009, 94:4658-4660. 
Petersen RC. Mild cognitive impairment as diagnostic entity. Journal of Internal Medicine 
2004;256:183-194. 
Roberts LM, Pattison H, Roalfe A, Franklin J, Wilson S, Hobbs R, & Parle JV. Is subclinical 
thyroid dysfunction in the elderly associated with depression or cognitive 
dysfunction? Ann Intern Med 2006; 145:573-581. 
Samollow PB, Pérez G, Kammerer CM, Finegold D, Zwartjes PW, Havill LM, Comuzzie AG, 
Mahaney MC, Göring HH, Blangero J, Foley TP, & Barmada MM. Genetic and 
Environmental Influences of Thyroid Hormone Variation in Mexican Americans. J 
Clin Endocrinol Metab, 2004; 89:3276-84. 
Sender Palacios  MJ, Vernet Vernet M, Pérez López S, Faro Colomel M, Rojas Blanc M & 
Pallisa Gabriel L. Enfermedad funcional tiroidea en la población de edad avanzada. 
Atención primaria,  2004;34:192-7. 
Stevenson JP. Family stress related to home care of Alzheimer’s disease patients and 
implications for support. J Neurosci Nurs, 1990; 22:179-88 
Teng W, Shan Z, Teng X, Guan H, Li Y, Teng D, Jin Y, Yu X, Fan C, Chong W, Yang F, Dai 
H, Yu Y, Li J, Chen Y, Zhao D, Shi X, Hu F, Mao J, Gu X, Yang R, Tong Y,WangW, 
Gao T & Li C. Effect of iodine intake on thyroid diseases in China. New England 
Journal of Medicine 2006;354:2783–2793. 
Vela-Amieva M, Gamboa-Cardiel S, Pérez-Andrade ME, Ortiz-Cortés J, Gonzalez-Contreras 
CR, Ortega-Velazquez V. Epidemiología del hipotiroidismo congénito en México. 
Salud Publica Mex 2004;46:141-148. 
Verma A. & Hasan T. Clinical Geriatrics Thyroid disorders in older people. Reviews in 
Clinical Gerontology 2009;19: 193-206 
Williams GR. Neurodevelopmental and Neurophysiological Actions of Thyroid Hormone. 
Journal of Neuroendocrinology 20:784–794. 
Yesavage: The use of Rating Depression Series in the Elderly, en Poon (ed.):Clínical Memory 
Assessment of Older Adults, American Psychological Association, 1986 
 
Hypothyroidism – Influences and Treatments 
 
346 
Hatzel BS. The Nature and Magnitude of the Iodine Deficiency Disorders (IDD) In Towards 
the Global Elimination  Of Brain Damage Due to  Iodine Deficiency. Editors: Delange F., 
Dunn JT., Ling J., Mannar V. and  Pandav Ch. Delhi Oxford University Press 
CALCUTTA 2004 http://www.iccidd.org iccidd.server295.com/media/Hetzel% 
20book/hetzel-a-frontpage.pdf 
Hernández–Perera A, López–González LE, Hernández–Perera A, & Mesa–Santamarina A. 
Hipotiroidismo subclínico en el anciano ambulatorio. Rev Biomed 2007;18:162-166. 
Hollowell JG, Steahling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA & 
Braverman LE. Serum TSH, thyroxin and Thyroid Antibodies in the US Population 
(1988 to 1994): National Health and Nutrition Examination Survey. J Clin 
Endocrinol Metab, 2002; 87:489-499. 
Hoogendoorn EH, Hermus AR, Vegt FD, Ross HA, Verbeek ALM, Kiemeney LALM, 
Swinkels DW, Sweep FCG, & Heijer MD. Thyroid Function and Prevalence of Anti-
Thyroperoxidase antibodies in a population with borderline sufficient iodine 
intake: Influences of Age and sex.  Clinical Chemistry 2006, 52:104-111. 
Jameson JL & Weetman AP, 2005. Disorders of the thyroid gland. In Kasper, Braunwald, 
Fauci, Hauser, Longo and Jameson (Eds). Harrison’s Principles of Internal Medicine. 
New York: McGraw-Hill, pg 2104 – 2126. 
Jorde R, Waterloo K, Storhaug H, Nyrnes A, Sundsfjord J, &Jenssen TG. Neuropsychological 
function and symptoms in subjects with subclinical hypothyroidism and the effect 
of thyroxine treatment. J Clin Endocrinol Metab 2006;91:145-153. 
Karmisholt J & Laurberg P. Serum TSH and serum thyroidperoxidase antibody fluctuate in 
parallel and high urinary iodine excretion predicts subsequent thyroid failure in a 
1-year study of patients with untreated subclinical hypothyroidism. European 
Journal of Endocrinology 2008;158:209-215. 
Katz S. Downs TD, Cash HR, & Grotz RC. Progress in the development of the index of ADL, 
Gerontologist 1970; 10:20-30. 
Kester MH, Martinez de Mena R, Obregon MJ, Marinkovic D, Howatson A, Visser TJ, Hume 
R, & Morreale de Escobar G. Iodothyronine levels in the human developing brain: 
major regulatory roles of iodothyronine deiodinases in different areas. J Clin 
Endocrinol Metab 2004; 89: 3117–3128. 
Kinuya S, Michigishi T, Tonami N, Aburano T, Tsuji S, & Hashimoto T. Reversible cerebral 
hypoperfusion observed with Tc-99m HMPAO SPECT in reversible dementia 
caused by hypothyroidism. Clin Nucl Med. 1999 Sep;24(9):666-8 
Kolibas E, KorinkovaV,.Novotny V, Vajdickova K, & HunakovaD.  ADAS-cog (Alzheimer´s 
Disease Assessment Scale-cognitive-subscale) validation of the Slovak version. 
Bratisl Lek Listy 2000; 101:598-602. 
Latrofa F & Pinchera A. Aging and the thyroid. Hot Thyroidology 2005. 
www.hotthyroidology.com 
Laurberg P, Andersen S, Pedersen I B & Carlé A. Hypothyroidism in the elderly: 
pathophysiology, diagnosis and treatment. Drugs Aging 2005; 22:23-38. 
Lawton MP, & Brody EM. Assessment of older people: Self-maintaining and instrumental 
activities of daily living. The Gerontologist 1969; 9: 179-186. 
 
Cognitive Function in Elderly with Subclinical Hypothyroidism 
 
347 
Maritti S, Barbesino G, Caturegli P, Bartalena L, Sansoni P, Fagnoni F, Monti D, Fagiolo U, 
Franceschi C & Pinchera A. Complex Alterations of thyroid function in healthy 
centenarians. J Clin Endocrinol Metab 77:1130-1134. 
Martinez Lara E, Morales Yepez HA, Sandoval Pacheco R, & Lopez Hernandez CM. 
Prevalencia de hipotiroidismo en pacientes mayors de 55 años en la consulta de 
geriatria del Horpital Central Militar. Rev Sanid Milit Mex 1999; 53:105-108.   
McDermott MT & Ridgway EC. Subclinical hypothyroidism is mild failure and should be 
treated. J Clin Endocrinol Metab, 2001; 86:3585- 4590  
Monzani F, Del Guerra P, Caraccio N, Prunetti CA, Pucci E, Luisi M & Baschieri L. 
Subclinical hypothyroidism: neurobehavioral features and beneficial effect of l-
thyroxin treatment. Clin Investig, 1993; 71:367-71. 
Ostrosky F, Ardila A & Rosselli M. “Neuropsi”. A brief neuropsychological test battery in 
Spanish with norms by age and educational level. Journal of the International 
Neuropsychological Society. 1999; 5:413-433. 
Peeters RP. Thyroid function and longevity New insights into an old dilema. J Clin 
Endocrinol metab 2009, 94:4658-4660. 
Petersen RC. Mild cognitive impairment as diagnostic entity. Journal of Internal Medicine 
2004;256:183-194. 
Roberts LM, Pattison H, Roalfe A, Franklin J, Wilson S, Hobbs R, & Parle JV. Is subclinical 
thyroid dysfunction in the elderly associated with depression or cognitive 
dysfunction? Ann Intern Med 2006; 145:573-581. 
Samollow PB, Pérez G, Kammerer CM, Finegold D, Zwartjes PW, Havill LM, Comuzzie AG, 
Mahaney MC, Göring HH, Blangero J, Foley TP, & Barmada MM. Genetic and 
Environmental Influences of Thyroid Hormone Variation in Mexican Americans. J 
Clin Endocrinol Metab, 2004; 89:3276-84. 
Sender Palacios  MJ, Vernet Vernet M, Pérez López S, Faro Colomel M, Rojas Blanc M & 
Pallisa Gabriel L. Enfermedad funcional tiroidea en la población de edad avanzada. 
Atención primaria,  2004;34:192-7. 
Stevenson JP. Family stress related to home care of Alzheimer’s disease patients and 
implications for support. J Neurosci Nurs, 1990; 22:179-88 
Teng W, Shan Z, Teng X, Guan H, Li Y, Teng D, Jin Y, Yu X, Fan C, Chong W, Yang F, Dai 
H, Yu Y, Li J, Chen Y, Zhao D, Shi X, Hu F, Mao J, Gu X, Yang R, Tong Y,WangW, 
Gao T & Li C. Effect of iodine intake on thyroid diseases in China. New England 
Journal of Medicine 2006;354:2783–2793. 
Vela-Amieva M, Gamboa-Cardiel S, Pérez-Andrade ME, Ortiz-Cortés J, Gonzalez-Contreras 
CR, Ortega-Velazquez V. Epidemiología del hipotiroidismo congénito en México. 
Salud Publica Mex 2004;46:141-148. 
Verma A. & Hasan T. Clinical Geriatrics Thyroid disorders in older people. Reviews in 
Clinical Gerontology 2009;19: 193-206 
Williams GR. Neurodevelopmental and Neurophysiological Actions of Thyroid Hormone. 
Journal of Neuroendocrinology 20:784–794. 
Yesavage: The use of Rating Depression Series in the Elderly, en Poon (ed.):Clínical Memory 
Assessment of Older Adults, American Psychological Association, 1986 
 
Hypothyroidism – Influences and Treatments 
 
348 
Zhu DF, Wang ZX, Zhang DR, Pan ZL, He S, H eu XP, Chen XCh & Zhou JN. fMRI revealed 
neural substrate for reversible working memory dysfunction in subclinical 
hypothyroidism. Brain 2006;129:2923-2930. 
Zigmond AS & Snaith RP The hospital anxiety and depression scale . Acta Psychiatr Scand. 
1983;67:361-370. 
 
Hypothyroidism – Influences and Treatments 
 
348 
Zhu DF, Wang ZX, Zhang DR, Pan ZL, He S, H eu XP, Chen XCh & Zhou JN. fMRI revealed 
neural substrate for reversible working memory dysfunction in subclinical 
hypothyroidism. Brain 2006;129:2923-2930. 




Edited by Drahomira Springer
Edited by Drahomira Springer
Hypothyroidism is the most common thyroid disorder and it is significantly more 
frequent than presented - millions of people suffer from this disease without knowing 
it. People with this condition will have symptoms associated with slow metabolism. 
Estimates of subclinical hypothyroidism range between 3 to 8 %, increasing with 
age, whereas it more likely affects women than men. About 10% of women may 
have some degree of thyroid hormone deficiency. Hypothyroidism may affect lipid 
metabolism, neurological diseases or other clinical conditions. The book includes 
studies on advancements in diagnosis, regulation and replacement therapy, thyroid 
ultrasonography and radioiodine therapy for hypothyroidism. “Hypothyroidism 
- Influences and Treatments” contains many important specifications, results of 
scientific studies and innovations for endocrine practice.
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